{"docstore/data": {"19f55e17-8d97-4090-a7f3-6fb80fd650e5": {"__data__": {"id_": "19f55e17-8d97-4090-a7f3-6fb80fd650e5", "embedding": null, "metadata": {"window": " \nPage 1 of 31 \n \nQ4 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust  6th, 2020 8:30AM Eastern  \n \nOperator:  Good day and welcome to the Cardinal Health Incorporated Fourth Quarter Fiscal Year \n2020 Earnings Conference Call.  Today's conference is being recorded.  And at this time I'd like to turn \nthe conference over to Mr. ", "original_text": " \nPage 1 of 31 \n \nQ4 FY20 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64b608ebc3a7a1711b4d3b88a47b92bfbfccd30ea4487cd93f7e3df6139f14d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73c38dfc-475e-4b3a-97f5-631e8dc13d6d", "node_type": "1", "metadata": {"window": " \nPage 1 of 31 \n \nQ4 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust  6th, 2020 8:30AM Eastern  \n \nOperator:  Good day and welcome to the Cardinal Health Incorporated Fourth Quarter Fiscal Year \n2020 Earnings Conference Call.  Today's conference is being recorded.  And at this time I'd like to turn \nthe conference over to Mr.  Kevin Moran. ", "original_text": "Earnings \nConference Call  \nAugust  6th, 2020 8:30AM Eastern  \n \nOperator:  Good day and welcome to the Cardinal Health Incorporated Fourth Quarter Fiscal Year \n2020 Earnings Conference Call. "}, "hash": "76e38313143740b01cc86009c15f50309b9df6fe03532d4055d7bdd7a47d0834", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 1 of 31 \n \nQ4 FY20 Cardinal Health, Inc. ", "start_char_idx": 0, "end_char_idx": 48, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73c38dfc-475e-4b3a-97f5-631e8dc13d6d": {"__data__": {"id_": "73c38dfc-475e-4b3a-97f5-631e8dc13d6d", "embedding": null, "metadata": {"window": " \nPage 1 of 31 \n \nQ4 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust  6th, 2020 8:30AM Eastern  \n \nOperator:  Good day and welcome to the Cardinal Health Incorporated Fourth Quarter Fiscal Year \n2020 Earnings Conference Call.  Today's conference is being recorded.  And at this time I'd like to turn \nthe conference over to Mr.  Kevin Moran. ", "original_text": "Earnings \nConference Call  \nAugust  6th, 2020 8:30AM Eastern  \n \nOperator:  Good day and welcome to the Cardinal Health Incorporated Fourth Quarter Fiscal Year \n2020 Earnings Conference Call. ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64b608ebc3a7a1711b4d3b88a47b92bfbfccd30ea4487cd93f7e3df6139f14d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19f55e17-8d97-4090-a7f3-6fb80fd650e5", "node_type": "1", "metadata": {"window": " \nPage 1 of 31 \n \nQ4 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust  6th, 2020 8:30AM Eastern  \n \nOperator:  Good day and welcome to the Cardinal Health Incorporated Fourth Quarter Fiscal Year \n2020 Earnings Conference Call.  Today's conference is being recorded.  And at this time I'd like to turn \nthe conference over to Mr. ", "original_text": " \nPage 1 of 31 \n \nQ4 FY20 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c905390cfc23bd28d6fd7947b5d5e62d9913e149e6319c78a78d6eaa6b1c5446", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e559be4-935b-41e6-bf07-032759fef578", "node_type": "1", "metadata": {"window": " \nPage 1 of 31 \n \nQ4 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust  6th, 2020 8:30AM Eastern  \n \nOperator:  Good day and welcome to the Cardinal Health Incorporated Fourth Quarter Fiscal Year \n2020 Earnings Conference Call.  Today's conference is being recorded.  And at this time I'd like to turn \nthe conference over to Mr.  Kevin Moran.  Please go ahead, sir.  \n \n", "original_text": "Today's conference is being recorded. "}, "hash": "eea3b9bec9df38c669b377f012e3afc1c10280fa3d00a514e729d0fa16eea6b2", "class_name": "RelatedNodeInfo"}}, "text": "Earnings \nConference Call  \nAugust  6th, 2020 8:30AM Eastern  \n \nOperator:  Good day and welcome to the Cardinal Health Incorporated Fourth Quarter Fiscal Year \n2020 Earnings Conference Call. ", "start_char_idx": 48, "end_char_idx": 240, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e559be4-935b-41e6-bf07-032759fef578": {"__data__": {"id_": "0e559be4-935b-41e6-bf07-032759fef578", "embedding": null, "metadata": {"window": " \nPage 1 of 31 \n \nQ4 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust  6th, 2020 8:30AM Eastern  \n \nOperator:  Good day and welcome to the Cardinal Health Incorporated Fourth Quarter Fiscal Year \n2020 Earnings Conference Call.  Today's conference is being recorded.  And at this time I'd like to turn \nthe conference over to Mr.  Kevin Moran.  Please go ahead, sir.  \n \n", "original_text": "Today's conference is being recorded. ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64b608ebc3a7a1711b4d3b88a47b92bfbfccd30ea4487cd93f7e3df6139f14d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73c38dfc-475e-4b3a-97f5-631e8dc13d6d", "node_type": "1", "metadata": {"window": " \nPage 1 of 31 \n \nQ4 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust  6th, 2020 8:30AM Eastern  \n \nOperator:  Good day and welcome to the Cardinal Health Incorporated Fourth Quarter Fiscal Year \n2020 Earnings Conference Call.  Today's conference is being recorded.  And at this time I'd like to turn \nthe conference over to Mr.  Kevin Moran. ", "original_text": "Earnings \nConference Call  \nAugust  6th, 2020 8:30AM Eastern  \n \nOperator:  Good day and welcome to the Cardinal Health Incorporated Fourth Quarter Fiscal Year \n2020 Earnings Conference Call. ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "292f141ae1fde93281fb8d3dae9912096f8d835f60d6a90d5112eccd73adc41e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca094ce4-bddf-423d-91dc-62af0696fe5a", "node_type": "1", "metadata": {"window": " \nPage 1 of 31 \n \nQ4 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust  6th, 2020 8:30AM Eastern  \n \nOperator:  Good day and welcome to the Cardinal Health Incorporated Fourth Quarter Fiscal Year \n2020 Earnings Conference Call.  Today's conference is being recorded.  And at this time I'd like to turn \nthe conference over to Mr.  Kevin Moran.  Please go ahead, sir.  \n \n Kevin Moran:  Good morning. ", "original_text": "And at this time I'd like to turn \nthe conference over to Mr. "}, "hash": "01ae559efe0ceded0981d4a7be8edb783f7790c93ba75bb1e74d3c2089a0f404", "class_name": "RelatedNodeInfo"}}, "text": "Today's conference is being recorded. ", "start_char_idx": 240, "end_char_idx": 278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca094ce4-bddf-423d-91dc-62af0696fe5a": {"__data__": {"id_": "ca094ce4-bddf-423d-91dc-62af0696fe5a", "embedding": null, "metadata": {"window": " \nPage 1 of 31 \n \nQ4 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust  6th, 2020 8:30AM Eastern  \n \nOperator:  Good day and welcome to the Cardinal Health Incorporated Fourth Quarter Fiscal Year \n2020 Earnings Conference Call.  Today's conference is being recorded.  And at this time I'd like to turn \nthe conference over to Mr.  Kevin Moran.  Please go ahead, sir.  \n \n Kevin Moran:  Good morning. ", "original_text": "And at this time I'd like to turn \nthe conference over to Mr. ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64b608ebc3a7a1711b4d3b88a47b92bfbfccd30ea4487cd93f7e3df6139f14d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e559be4-935b-41e6-bf07-032759fef578", "node_type": "1", "metadata": {"window": " \nPage 1 of 31 \n \nQ4 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust  6th, 2020 8:30AM Eastern  \n \nOperator:  Good day and welcome to the Cardinal Health Incorporated Fourth Quarter Fiscal Year \n2020 Earnings Conference Call.  Today's conference is being recorded.  And at this time I'd like to turn \nthe conference over to Mr.  Kevin Moran.  Please go ahead, sir.  \n \n", "original_text": "Today's conference is being recorded. ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce62ccb5eb3db55368dc1f4cda1f474828bf03bb6d9aed114f52a1c6f3163fef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f4af5d4-3890-4c10-bbac-73ee8b8c291a", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nAugust  6th, 2020 8:30AM Eastern  \n \nOperator:  Good day and welcome to the Cardinal Health Incorporated Fourth Quarter Fiscal Year \n2020 Earnings Conference Call.  Today's conference is being recorded.  And at this time I'd like to turn \nthe conference over to Mr.  Kevin Moran.  Please go ahead, sir.  \n \n Kevin Moran:  Good morning.  This is Kevin Moran, Vice President of Investor Relations. ", "original_text": "Kevin Moran. "}, "hash": "3953cf79e05524b0df1ba79190e3e81721778255f9d067d7ac7221b40dd4a72b", "class_name": "RelatedNodeInfo"}}, "text": "And at this time I'd like to turn \nthe conference over to Mr. ", "start_char_idx": 278, "end_char_idx": 340, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f4af5d4-3890-4c10-bbac-73ee8b8c291a": {"__data__": {"id_": "9f4af5d4-3890-4c10-bbac-73ee8b8c291a", "embedding": null, "metadata": {"window": "Earnings \nConference Call  \nAugust  6th, 2020 8:30AM Eastern  \n \nOperator:  Good day and welcome to the Cardinal Health Incorporated Fourth Quarter Fiscal Year \n2020 Earnings Conference Call.  Today's conference is being recorded.  And at this time I'd like to turn \nthe conference over to Mr.  Kevin Moran.  Please go ahead, sir.  \n \n Kevin Moran:  Good morning.  This is Kevin Moran, Vice President of Investor Relations. ", "original_text": "Kevin Moran. ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64b608ebc3a7a1711b4d3b88a47b92bfbfccd30ea4487cd93f7e3df6139f14d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca094ce4-bddf-423d-91dc-62af0696fe5a", "node_type": "1", "metadata": {"window": " \nPage 1 of 31 \n \nQ4 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust  6th, 2020 8:30AM Eastern  \n \nOperator:  Good day and welcome to the Cardinal Health Incorporated Fourth Quarter Fiscal Year \n2020 Earnings Conference Call.  Today's conference is being recorded.  And at this time I'd like to turn \nthe conference over to Mr.  Kevin Moran.  Please go ahead, sir.  \n \n Kevin Moran:  Good morning. ", "original_text": "And at this time I'd like to turn \nthe conference over to Mr. ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e821f4fe978b259a90ac1cf2a4844bdee01ba4c20635d9b9acc948ed657aff0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a728ce5-9960-47ec-b0f0-d0e48f440e79", "node_type": "1", "metadata": {"window": "Today's conference is being recorded.  And at this time I'd like to turn \nthe conference over to Mr.  Kevin Moran.  Please go ahead, sir.  \n \n Kevin Moran:  Good morning.  This is Kevin Moran, Vice President of Investor Relations.  Thank you \nfor joining us today. ", "original_text": "Please go ahead, sir.  \n \n"}, "hash": "597b31cc648fdcdc59e6fac8d158d7eec60a339bdfb2350505b3f7145144ed52", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran. ", "start_char_idx": 340, "end_char_idx": 353, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a728ce5-9960-47ec-b0f0-d0e48f440e79": {"__data__": {"id_": "8a728ce5-9960-47ec-b0f0-d0e48f440e79", "embedding": null, "metadata": {"window": "Today's conference is being recorded.  And at this time I'd like to turn \nthe conference over to Mr.  Kevin Moran.  Please go ahead, sir.  \n \n Kevin Moran:  Good morning.  This is Kevin Moran, Vice President of Investor Relations.  Thank you \nfor joining us today. ", "original_text": "Please go ahead, sir.  \n \n", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64b608ebc3a7a1711b4d3b88a47b92bfbfccd30ea4487cd93f7e3df6139f14d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f4af5d4-3890-4c10-bbac-73ee8b8c291a", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nAugust  6th, 2020 8:30AM Eastern  \n \nOperator:  Good day and welcome to the Cardinal Health Incorporated Fourth Quarter Fiscal Year \n2020 Earnings Conference Call.  Today's conference is being recorded.  And at this time I'd like to turn \nthe conference over to Mr.  Kevin Moran.  Please go ahead, sir.  \n \n Kevin Moran:  Good morning.  This is Kevin Moran, Vice President of Investor Relations. ", "original_text": "Kevin Moran. ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a59ffffb5515f253399019d7c7c2310aa7887acf4fa4d97f8f025aa451b6e495", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d1c53c7-aa34-4ebf-b6d0-1928c8ad41b4", "node_type": "1", "metadata": {"window": "And at this time I'd like to turn \nthe conference over to Mr.  Kevin Moran.  Please go ahead, sir.  \n \n Kevin Moran:  Good morning.  This is Kevin Moran, Vice President of Investor Relations.  Thank you \nfor joining us today.  We hope yo u and your loved ones are healthy and safe.  \n \n ", "original_text": "Kevin Moran:  Good morning. "}, "hash": "e9b7ccc89db95935fa9b683b4f9b198ee9e6c8d567193ab1b7b45772e85a2003", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead, sir.  \n \n", "start_char_idx": 353, "end_char_idx": 379, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d1c53c7-aa34-4ebf-b6d0-1928c8ad41b4": {"__data__": {"id_": "3d1c53c7-aa34-4ebf-b6d0-1928c8ad41b4", "embedding": null, "metadata": {"window": "And at this time I'd like to turn \nthe conference over to Mr.  Kevin Moran.  Please go ahead, sir.  \n \n Kevin Moran:  Good morning.  This is Kevin Moran, Vice President of Investor Relations.  Thank you \nfor joining us today.  We hope yo u and your loved ones are healthy and safe.  \n \n ", "original_text": "Kevin Moran:  Good morning. ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64b608ebc3a7a1711b4d3b88a47b92bfbfccd30ea4487cd93f7e3df6139f14d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a728ce5-9960-47ec-b0f0-d0e48f440e79", "node_type": "1", "metadata": {"window": "Today's conference is being recorded.  And at this time I'd like to turn \nthe conference over to Mr.  Kevin Moran.  Please go ahead, sir.  \n \n Kevin Moran:  Good morning.  This is Kevin Moran, Vice President of Investor Relations.  Thank you \nfor joining us today. ", "original_text": "Please go ahead, sir.  \n \n", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7c96c2163dcb9d2ac3944fc4b63d21ddc91c510d0acf97b5bfdee446c5674f75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d561b67-c87f-4314-b6c7-b3d4ca36b6c7", "node_type": "1", "metadata": {"window": "Kevin Moran.  Please go ahead, sir.  \n \n Kevin Moran:  Good morning.  This is Kevin Moran, Vice President of Investor Relations.  Thank you \nfor joining us today.  We hope yo u and your loved ones are healthy and safe.  \n \n  During the call we will discuss Cardinal Health's Fourth Quarter and Fiscal 2020 Results, along \nwith guidance for fiscal year 2021. ", "original_text": "This is Kevin Moran, Vice President of Investor Relations. "}, "hash": "97f5674f8472976c5013a4ce2fc805ad0edaf985debeb1642ca3c664cb227fe1", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran:  Good morning. ", "start_char_idx": 379, "end_char_idx": 407, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d561b67-c87f-4314-b6c7-b3d4ca36b6c7": {"__data__": {"id_": "2d561b67-c87f-4314-b6c7-b3d4ca36b6c7", "embedding": null, "metadata": {"window": "Kevin Moran.  Please go ahead, sir.  \n \n Kevin Moran:  Good morning.  This is Kevin Moran, Vice President of Investor Relations.  Thank you \nfor joining us today.  We hope yo u and your loved ones are healthy and safe.  \n \n  During the call we will discuss Cardinal Health's Fourth Quarter and Fiscal 2020 Results, along \nwith guidance for fiscal year 2021. ", "original_text": "This is Kevin Moran, Vice President of Investor Relations. ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64b608ebc3a7a1711b4d3b88a47b92bfbfccd30ea4487cd93f7e3df6139f14d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d1c53c7-aa34-4ebf-b6d0-1928c8ad41b4", "node_type": "1", "metadata": {"window": "And at this time I'd like to turn \nthe conference over to Mr.  Kevin Moran.  Please go ahead, sir.  \n \n Kevin Moran:  Good morning.  This is Kevin Moran, Vice President of Investor Relations.  Thank you \nfor joining us today.  We hope yo u and your loved ones are healthy and safe.  \n \n ", "original_text": "Kevin Moran:  Good morning. ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "412b22965db08eac3d62ffe640995ff563ce7eefd289ea71ae46acfdb10da0e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50ba95e0-b4a4-4494-b3c6-cfcb819a160b", "node_type": "1", "metadata": {"window": "Please go ahead, sir.  \n \n Kevin Moran:  Good morning.  This is Kevin Moran, Vice President of Investor Relations.  Thank you \nfor joining us today.  We hope yo u and your loved ones are healthy and safe.  \n \n  During the call we will discuss Cardinal Health's Fourth Quarter and Fiscal 2020 Results, along \nwith guidance for fiscal year 2021.  Joining me are Mike Kauffman, Chief Executive Officer. ", "original_text": "Thank you \nfor joining us today. "}, "hash": "48ccbdf89722582f57cfed6a04413bd9c6f3a36ee26713919f07b463cf440d5b", "class_name": "RelatedNodeInfo"}}, "text": "This is Kevin Moran, Vice President of Investor Relations. ", "start_char_idx": 407, "end_char_idx": 466, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50ba95e0-b4a4-4494-b3c6-cfcb819a160b": {"__data__": {"id_": "50ba95e0-b4a4-4494-b3c6-cfcb819a160b", "embedding": null, "metadata": {"window": "Please go ahead, sir.  \n \n Kevin Moran:  Good morning.  This is Kevin Moran, Vice President of Investor Relations.  Thank you \nfor joining us today.  We hope yo u and your loved ones are healthy and safe.  \n \n  During the call we will discuss Cardinal Health's Fourth Quarter and Fiscal 2020 Results, along \nwith guidance for fiscal year 2021.  Joining me are Mike Kauffman, Chief Executive Officer. ", "original_text": "Thank you \nfor joining us today. ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64b608ebc3a7a1711b4d3b88a47b92bfbfccd30ea4487cd93f7e3df6139f14d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d561b67-c87f-4314-b6c7-b3d4ca36b6c7", "node_type": "1", "metadata": {"window": "Kevin Moran.  Please go ahead, sir.  \n \n Kevin Moran:  Good morning.  This is Kevin Moran, Vice President of Investor Relations.  Thank you \nfor joining us today.  We hope yo u and your loved ones are healthy and safe.  \n \n  During the call we will discuss Cardinal Health's Fourth Quarter and Fiscal 2020 Results, along \nwith guidance for fiscal year 2021. ", "original_text": "This is Kevin Moran, Vice President of Investor Relations. ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e60f55c07dbb81cdb181d170ca0a5eacd8ae74237cdb557695455c5fe0f9b3f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11a3dc75-2147-4e3e-ad03-4ae36ef0ee26", "node_type": "1", "metadata": {"window": "Kevin Moran:  Good morning.  This is Kevin Moran, Vice President of Investor Relations.  Thank you \nfor joining us today.  We hope yo u and your loved ones are healthy and safe.  \n \n  During the call we will discuss Cardinal Health's Fourth Quarter and Fiscal 2020 Results, along \nwith guidance for fiscal year 2021.  Joining me are Mike Kauffman, Chief Executive Officer.  And Jason \nHoller, Chief  Financial Officer. ", "original_text": "We hope yo u and your loved ones are healthy and safe.  \n \n "}, "hash": "ce804fc61cf905cb36387dc35cd08a4b7168ab56d4b92f94ab8bcd327edd940c", "class_name": "RelatedNodeInfo"}}, "text": "Thank you \nfor joining us today. ", "start_char_idx": 466, "end_char_idx": 499, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11a3dc75-2147-4e3e-ad03-4ae36ef0ee26": {"__data__": {"id_": "11a3dc75-2147-4e3e-ad03-4ae36ef0ee26", "embedding": null, "metadata": {"window": "Kevin Moran:  Good morning.  This is Kevin Moran, Vice President of Investor Relations.  Thank you \nfor joining us today.  We hope yo u and your loved ones are healthy and safe.  \n \n  During the call we will discuss Cardinal Health's Fourth Quarter and Fiscal 2020 Results, along \nwith guidance for fiscal year 2021.  Joining me are Mike Kauffman, Chief Executive Officer.  And Jason \nHoller, Chief  Financial Officer. ", "original_text": "We hope yo u and your loved ones are healthy and safe.  \n \n ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64b608ebc3a7a1711b4d3b88a47b92bfbfccd30ea4487cd93f7e3df6139f14d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50ba95e0-b4a4-4494-b3c6-cfcb819a160b", "node_type": "1", "metadata": {"window": "Please go ahead, sir.  \n \n Kevin Moran:  Good morning.  This is Kevin Moran, Vice President of Investor Relations.  Thank you \nfor joining us today.  We hope yo u and your loved ones are healthy and safe.  \n \n  During the call we will discuss Cardinal Health's Fourth Quarter and Fiscal 2020 Results, along \nwith guidance for fiscal year 2021.  Joining me are Mike Kauffman, Chief Executive Officer. ", "original_text": "Thank you \nfor joining us today. ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3854a6a323c33b8ddc487b0365389f3e31c0f873341d4e9ab442f6b7a6c6a10b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40019dd5-4273-4402-9edb-7c00e88eaad6", "node_type": "1", "metadata": {"window": "This is Kevin Moran, Vice President of Investor Relations.  Thank you \nfor joining us today.  We hope yo u and your loved ones are healthy and safe.  \n \n  During the call we will discuss Cardinal Health's Fourth Quarter and Fiscal 2020 Results, along \nwith guidance for fiscal year 2021.  Joining me are Mike Kauffman, Chief Executive Officer.  And Jason \nHoller, Chief  Financial Officer.  You can find today's press release and presentation on the IR section \nof our website. ", "original_text": "During the call we will discuss Cardinal Health's Fourth Quarter and Fiscal 2020 Results, along \nwith guidance for fiscal year 2021. "}, "hash": "b270a5fb304a04a3fd1fe229a4e366258107b1db73f328449ba8b838bf9c84d5", "class_name": "RelatedNodeInfo"}}, "text": "We hope yo u and your loved ones are healthy and safe.  \n \n ", "start_char_idx": 499, "end_char_idx": 559, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40019dd5-4273-4402-9edb-7c00e88eaad6": {"__data__": {"id_": "40019dd5-4273-4402-9edb-7c00e88eaad6", "embedding": null, "metadata": {"window": "This is Kevin Moran, Vice President of Investor Relations.  Thank you \nfor joining us today.  We hope yo u and your loved ones are healthy and safe.  \n \n  During the call we will discuss Cardinal Health's Fourth Quarter and Fiscal 2020 Results, along \nwith guidance for fiscal year 2021.  Joining me are Mike Kauffman, Chief Executive Officer.  And Jason \nHoller, Chief  Financial Officer.  You can find today's press release and presentation on the IR section \nof our website. ", "original_text": "During the call we will discuss Cardinal Health's Fourth Quarter and Fiscal 2020 Results, along \nwith guidance for fiscal year 2021. ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64b608ebc3a7a1711b4d3b88a47b92bfbfccd30ea4487cd93f7e3df6139f14d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11a3dc75-2147-4e3e-ad03-4ae36ef0ee26", "node_type": "1", "metadata": {"window": "Kevin Moran:  Good morning.  This is Kevin Moran, Vice President of Investor Relations.  Thank you \nfor joining us today.  We hope yo u and your loved ones are healthy and safe.  \n \n  During the call we will discuss Cardinal Health's Fourth Quarter and Fiscal 2020 Results, along \nwith guidance for fiscal year 2021.  Joining me are Mike Kauffman, Chief Executive Officer.  And Jason \nHoller, Chief  Financial Officer. ", "original_text": "We hope yo u and your loved ones are healthy and safe.  \n \n ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e718dedaf1d401e10e02a244bf216599482c73596ebc15fd01ff22d95785e2b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "518bc030-5f87-409e-9290-8fdb3b4b49c0", "node_type": "1", "metadata": {"window": "Thank you \nfor joining us today.  We hope yo u and your loved ones are healthy and safe.  \n \n  During the call we will discuss Cardinal Health's Fourth Quarter and Fiscal 2020 Results, along \nwith guidance for fiscal year 2021.  Joining me are Mike Kauffman, Chief Executive Officer.  And Jason \nHoller, Chief  Financial Officer.  You can find today's press release and presentation on the IR section \nof our website.  Or at ir.cardinalhealth.com.  \n \n ", "original_text": "Joining me are Mike Kauffman, Chief Executive Officer. "}, "hash": "c9162f3efdabfee005127c1828ead129b768f9b783867c10471004b5196c9e87", "class_name": "RelatedNodeInfo"}}, "text": "During the call we will discuss Cardinal Health's Fourth Quarter and Fiscal 2020 Results, along \nwith guidance for fiscal year 2021. ", "start_char_idx": 559, "end_char_idx": 692, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "518bc030-5f87-409e-9290-8fdb3b4b49c0": {"__data__": {"id_": "518bc030-5f87-409e-9290-8fdb3b4b49c0", "embedding": null, "metadata": {"window": "Thank you \nfor joining us today.  We hope yo u and your loved ones are healthy and safe.  \n \n  During the call we will discuss Cardinal Health's Fourth Quarter and Fiscal 2020 Results, along \nwith guidance for fiscal year 2021.  Joining me are Mike Kauffman, Chief Executive Officer.  And Jason \nHoller, Chief  Financial Officer.  You can find today's press release and presentation on the IR section \nof our website.  Or at ir.cardinalhealth.com.  \n \n ", "original_text": "Joining me are Mike Kauffman, Chief Executive Officer. ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64b608ebc3a7a1711b4d3b88a47b92bfbfccd30ea4487cd93f7e3df6139f14d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40019dd5-4273-4402-9edb-7c00e88eaad6", "node_type": "1", "metadata": {"window": "This is Kevin Moran, Vice President of Investor Relations.  Thank you \nfor joining us today.  We hope yo u and your loved ones are healthy and safe.  \n \n  During the call we will discuss Cardinal Health's Fourth Quarter and Fiscal 2020 Results, along \nwith guidance for fiscal year 2021.  Joining me are Mike Kauffman, Chief Executive Officer.  And Jason \nHoller, Chief  Financial Officer.  You can find today's press release and presentation on the IR section \nof our website. ", "original_text": "During the call we will discuss Cardinal Health's Fourth Quarter and Fiscal 2020 Results, along \nwith guidance for fiscal year 2021. ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "06f6f6c2d498a6a307bf0548d7ff735eccc3bb8ef7efb388c527a7c1f95ce3a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca646f7c-fb85-4e14-b9f1-a63f7bbdde5a", "node_type": "1", "metadata": {"window": "We hope yo u and your loved ones are healthy and safe.  \n \n  During the call we will discuss Cardinal Health's Fourth Quarter and Fiscal 2020 Results, along \nwith guidance for fiscal year 2021.  Joining me are Mike Kauffman, Chief Executive Officer.  And Jason \nHoller, Chief  Financial Officer.  You can find today's press release and presentation on the IR section \nof our website.  Or at ir.cardinalhealth.com.  \n \n  During the call we will be making forward -looking statements. ", "original_text": "And Jason \nHoller, Chief  Financial Officer. "}, "hash": "2fcf03f91fafac50f012eed96bb1f493ed81aa786da45d3286f906149a97f583", "class_name": "RelatedNodeInfo"}}, "text": "Joining me are Mike Kauffman, Chief Executive Officer. ", "start_char_idx": 692, "end_char_idx": 747, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca646f7c-fb85-4e14-b9f1-a63f7bbdde5a": {"__data__": {"id_": "ca646f7c-fb85-4e14-b9f1-a63f7bbdde5a", "embedding": null, "metadata": {"window": "We hope yo u and your loved ones are healthy and safe.  \n \n  During the call we will discuss Cardinal Health's Fourth Quarter and Fiscal 2020 Results, along \nwith guidance for fiscal year 2021.  Joining me are Mike Kauffman, Chief Executive Officer.  And Jason \nHoller, Chief  Financial Officer.  You can find today's press release and presentation on the IR section \nof our website.  Or at ir.cardinalhealth.com.  \n \n  During the call we will be making forward -looking statements. ", "original_text": "And Jason \nHoller, Chief  Financial Officer. ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64b608ebc3a7a1711b4d3b88a47b92bfbfccd30ea4487cd93f7e3df6139f14d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "518bc030-5f87-409e-9290-8fdb3b4b49c0", "node_type": "1", "metadata": {"window": "Thank you \nfor joining us today.  We hope yo u and your loved ones are healthy and safe.  \n \n  During the call we will discuss Cardinal Health's Fourth Quarter and Fiscal 2020 Results, along \nwith guidance for fiscal year 2021.  Joining me are Mike Kauffman, Chief Executive Officer.  And Jason \nHoller, Chief  Financial Officer.  You can find today's press release and presentation on the IR section \nof our website.  Or at ir.cardinalhealth.com.  \n \n ", "original_text": "Joining me are Mike Kauffman, Chief Executive Officer. ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "48c258dce4b2f800e11852d2091d28f6da4ff35cab57ea53b7fac6abf2e29c37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "666e084e-6941-4f68-8e39-96545a6f2236", "node_type": "1", "metadata": {"window": "During the call we will discuss Cardinal Health's Fourth Quarter and Fiscal 2020 Results, along \nwith guidance for fiscal year 2021.  Joining me are Mike Kauffman, Chief Executive Officer.  And Jason \nHoller, Chief  Financial Officer.  You can find today's press release and presentation on the IR section \nof our website.  Or at ir.cardinalhealth.com.  \n \n  During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to th e risks and uncertainty that could cause actual results to differ materially \nfrom those projected or implied. ", "original_text": "You can find today's press release and presentation on the IR section \nof our website. "}, "hash": "651022af335f4dd9214708538044799ae4085424336a79e8e14368805858812c", "class_name": "RelatedNodeInfo"}}, "text": "And Jason \nHoller, Chief  Financial Officer. ", "start_char_idx": 747, "end_char_idx": 792, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "666e084e-6941-4f68-8e39-96545a6f2236": {"__data__": {"id_": "666e084e-6941-4f68-8e39-96545a6f2236", "embedding": null, "metadata": {"window": "During the call we will discuss Cardinal Health's Fourth Quarter and Fiscal 2020 Results, along \nwith guidance for fiscal year 2021.  Joining me are Mike Kauffman, Chief Executive Officer.  And Jason \nHoller, Chief  Financial Officer.  You can find today's press release and presentation on the IR section \nof our website.  Or at ir.cardinalhealth.com.  \n \n  During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to th e risks and uncertainty that could cause actual results to differ materially \nfrom those projected or implied. ", "original_text": "You can find today's press release and presentation on the IR section \nof our website. ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64b608ebc3a7a1711b4d3b88a47b92bfbfccd30ea4487cd93f7e3df6139f14d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca646f7c-fb85-4e14-b9f1-a63f7bbdde5a", "node_type": "1", "metadata": {"window": "We hope yo u and your loved ones are healthy and safe.  \n \n  During the call we will discuss Cardinal Health's Fourth Quarter and Fiscal 2020 Results, along \nwith guidance for fiscal year 2021.  Joining me are Mike Kauffman, Chief Executive Officer.  And Jason \nHoller, Chief  Financial Officer.  You can find today's press release and presentation on the IR section \nof our website.  Or at ir.cardinalhealth.com.  \n \n  During the call we will be making forward -looking statements. ", "original_text": "And Jason \nHoller, Chief  Financial Officer. ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a65c2357e1a85e08d433ccaf3e699dd2990d7347c471465ab64fd5c7394b5787", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52a575a2-d405-4736-9876-286be08f836a", "node_type": "1", "metadata": {"window": "Joining me are Mike Kauffman, Chief Executive Officer.  And Jason \nHoller, Chief  Financial Officer.  You can find today's press release and presentation on the IR section \nof our website.  Or at ir.cardinalhealth.com.  \n \n  During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to th e risks and uncertainty that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filing and the forward -looking statement slide \nat the beginning of our presentation for a description of these risks and u ncertainties.  \n \n ", "original_text": "Or at ir.cardinalhealth.com.  \n \n "}, "hash": "21bcfa69a6d60192355fa354e3b22a8968028fa67255f9b0c112fb6b3017a393", "class_name": "RelatedNodeInfo"}}, "text": "You can find today's press release and presentation on the IR section \nof our website. ", "start_char_idx": 792, "end_char_idx": 879, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52a575a2-d405-4736-9876-286be08f836a": {"__data__": {"id_": "52a575a2-d405-4736-9876-286be08f836a", "embedding": null, "metadata": {"window": "Joining me are Mike Kauffman, Chief Executive Officer.  And Jason \nHoller, Chief  Financial Officer.  You can find today's press release and presentation on the IR section \nof our website.  Or at ir.cardinalhealth.com.  \n \n  During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to th e risks and uncertainty that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filing and the forward -looking statement slide \nat the beginning of our presentation for a description of these risks and u ncertainties.  \n \n ", "original_text": "Or at ir.cardinalhealth.com.  \n \n ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64b608ebc3a7a1711b4d3b88a47b92bfbfccd30ea4487cd93f7e3df6139f14d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "666e084e-6941-4f68-8e39-96545a6f2236", "node_type": "1", "metadata": {"window": "During the call we will discuss Cardinal Health's Fourth Quarter and Fiscal 2020 Results, along \nwith guidance for fiscal year 2021.  Joining me are Mike Kauffman, Chief Executive Officer.  And Jason \nHoller, Chief  Financial Officer.  You can find today's press release and presentation on the IR section \nof our website.  Or at ir.cardinalhealth.com.  \n \n  During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to th e risks and uncertainty that could cause actual results to differ materially \nfrom those projected or implied. ", "original_text": "You can find today's press release and presentation on the IR section \nof our website. ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07ae10a6686d063a7a1185b647e9b648d68795bf2f059f685ee503021c4b7eaa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d680f8b-bfc2-464d-b5b6-aa1d9b8120a1", "node_type": "1", "metadata": {"window": "And Jason \nHoller, Chief  Financial Officer.  You can find today's press release and presentation on the IR section \nof our website.  Or at ir.cardinalhealth.com.  \n \n  During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to th e risks and uncertainty that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filing and the forward -looking statement slide \nat the beginning of our presentation for a description of these risks and u ncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP. ", "original_text": "During the call we will be making forward -looking statements. "}, "hash": "ab67ea8c22e07ed903d840e8924464e3aaf6c230eb9daaca2a2b4c30f23b294b", "class_name": "RelatedNodeInfo"}}, "text": "Or at ir.cardinalhealth.com.  \n \n ", "start_char_idx": 879, "end_char_idx": 913, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d680f8b-bfc2-464d-b5b6-aa1d9b8120a1": {"__data__": {"id_": "6d680f8b-bfc2-464d-b5b6-aa1d9b8120a1", "embedding": null, "metadata": {"window": "And Jason \nHoller, Chief  Financial Officer.  You can find today's press release and presentation on the IR section \nof our website.  Or at ir.cardinalhealth.com.  \n \n  During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to th e risks and uncertainty that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filing and the forward -looking statement slide \nat the beginning of our presentation for a description of these risks and u ncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP. ", "original_text": "During the call we will be making forward -looking statements. ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64b608ebc3a7a1711b4d3b88a47b92bfbfccd30ea4487cd93f7e3df6139f14d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52a575a2-d405-4736-9876-286be08f836a", "node_type": "1", "metadata": {"window": "Joining me are Mike Kauffman, Chief Executive Officer.  And Jason \nHoller, Chief  Financial Officer.  You can find today's press release and presentation on the IR section \nof our website.  Or at ir.cardinalhealth.com.  \n \n  During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to th e risks and uncertainty that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filing and the forward -looking statement slide \nat the beginning of our presentation for a description of these risks and u ncertainties.  \n \n ", "original_text": "Or at ir.cardinalhealth.com.  \n \n ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4b53b90c1da6a89e48c41e3adbe08b87d57c95e7a620f766d1087bc1c04811c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5238ae64-9827-4595-bbf4-4f136bdbe20a", "node_type": "1", "metadata": {"window": "You can find today's press release and presentation on the IR section \nof our website.  Or at ir.cardinalhealth.com.  \n \n  During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to th e risks and uncertainty that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filing and the forward -looking statement slide \nat the beginning of our presentation for a description of these risks and u ncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP.  GAAP  to non -GAAP reconciliation for all relevant \nperiods can be found in the schedules attached in our p ress release.  \n ", "original_text": "The matters addressed in the \nstatements are subject to th e risks and uncertainty that could cause actual results to differ materially \nfrom those projected or implied. "}, "hash": "4782a3b8cdc713968b4f22e7b75e6e4b297d1da08346a5c6e8f3b605355967a2", "class_name": "RelatedNodeInfo"}}, "text": "During the call we will be making forward -looking statements. ", "start_char_idx": 913, "end_char_idx": 976, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5238ae64-9827-4595-bbf4-4f136bdbe20a": {"__data__": {"id_": "5238ae64-9827-4595-bbf4-4f136bdbe20a", "embedding": null, "metadata": {"window": "You can find today's press release and presentation on the IR section \nof our website.  Or at ir.cardinalhealth.com.  \n \n  During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to th e risks and uncertainty that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filing and the forward -looking statement slide \nat the beginning of our presentation for a description of these risks and u ncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP.  GAAP  to non -GAAP reconciliation for all relevant \nperiods can be found in the schedules attached in our p ress release.  \n ", "original_text": "The matters addressed in the \nstatements are subject to th e risks and uncertainty that could cause actual results to differ materially \nfrom those projected or implied. ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64b608ebc3a7a1711b4d3b88a47b92bfbfccd30ea4487cd93f7e3df6139f14d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d680f8b-bfc2-464d-b5b6-aa1d9b8120a1", "node_type": "1", "metadata": {"window": "And Jason \nHoller, Chief  Financial Officer.  You can find today's press release and presentation on the IR section \nof our website.  Or at ir.cardinalhealth.com.  \n \n  During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to th e risks and uncertainty that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filing and the forward -looking statement slide \nat the beginning of our presentation for a description of these risks and u ncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP. ", "original_text": "During the call we will be making forward -looking statements. ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "926781c929404837c5f4f0f7d981515f30cc89210b4eb70261ddf557cb3c03ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd3b245e-c22b-4fd8-a291-da486e07fceb", "node_type": "1", "metadata": {"window": "Or at ir.cardinalhealth.com.  \n \n  During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to th e risks and uncertainty that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filing and the forward -looking statement slide \nat the beginning of our presentation for a description of these risks and u ncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP.  GAAP  to non -GAAP reconciliation for all relevant \nperiods can be found in the schedules attached in our p ress release.  \n ", "original_text": "Please refer to our SEC filing and the forward -looking statement slide \nat the beginning of our presentation for a description of these risks and u ncertainties.  \n \n "}, "hash": "55f7defc124bec468145e3fcb6fd8d1c2cc196f76656b1b63fdb564765cfa053", "class_name": "RelatedNodeInfo"}}, "text": "The matters addressed in the \nstatements are subject to th e risks and uncertainty that could cause actual results to differ materially \nfrom those projected or implied. ", "start_char_idx": 976, "end_char_idx": 1146, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd3b245e-c22b-4fd8-a291-da486e07fceb": {"__data__": {"id_": "dd3b245e-c22b-4fd8-a291-da486e07fceb", "embedding": null, "metadata": {"window": "Or at ir.cardinalhealth.com.  \n \n  During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to th e risks and uncertainty that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filing and the forward -looking statement slide \nat the beginning of our presentation for a description of these risks and u ncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP.  GAAP  to non -GAAP reconciliation for all relevant \nperiods can be found in the schedules attached in our p ress release.  \n ", "original_text": "Please refer to our SEC filing and the forward -looking statement slide \nat the beginning of our presentation for a description of these risks and u ncertainties.  \n \n ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64b608ebc3a7a1711b4d3b88a47b92bfbfccd30ea4487cd93f7e3df6139f14d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5238ae64-9827-4595-bbf4-4f136bdbe20a", "node_type": "1", "metadata": {"window": "You can find today's press release and presentation on the IR section \nof our website.  Or at ir.cardinalhealth.com.  \n \n  During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to th e risks and uncertainty that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filing and the forward -looking statement slide \nat the beginning of our presentation for a description of these risks and u ncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP.  GAAP  to non -GAAP reconciliation for all relevant \nperiods can be found in the schedules attached in our p ress release.  \n ", "original_text": "The matters addressed in the \nstatements are subject to th e risks and uncertainty that could cause actual results to differ materially \nfrom those projected or implied. ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "46211e0aa63f1f56a1eddd791b84d2b9f51e474fbe6a318c4abddbe15cad235c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b62bede-39f9-4e4e-acd7-73a13a2199cc", "node_type": "1", "metadata": {"window": "During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to th e risks and uncertainty that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filing and the forward -looking statement slide \nat the beginning of our presentation for a description of these risks and u ncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP.  GAAP  to non -GAAP reconciliation for all relevant \nperiods can be found in the schedules attached in our p ress release.  \n ", "original_text": "Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP. "}, "hash": "762c7c59d9d6202b52a6b2d2c2dbce99e506945fb60d10b9cf941df4dce740cf", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to our SEC filing and the forward -looking statement slide \nat the beginning of our presentation for a description of these risks and u ncertainties.  \n \n ", "start_char_idx": 1146, "end_char_idx": 1314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b62bede-39f9-4e4e-acd7-73a13a2199cc": {"__data__": {"id_": "8b62bede-39f9-4e4e-acd7-73a13a2199cc", "embedding": null, "metadata": {"window": "During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to th e risks and uncertainty that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filing and the forward -looking statement slide \nat the beginning of our presentation for a description of these risks and u ncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP.  GAAP  to non -GAAP reconciliation for all relevant \nperiods can be found in the schedules attached in our p ress release.  \n ", "original_text": "Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP. ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64b608ebc3a7a1711b4d3b88a47b92bfbfccd30ea4487cd93f7e3df6139f14d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd3b245e-c22b-4fd8-a291-da486e07fceb", "node_type": "1", "metadata": {"window": "Or at ir.cardinalhealth.com.  \n \n  During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to th e risks and uncertainty that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filing and the forward -looking statement slide \nat the beginning of our presentation for a description of these risks and u ncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP.  GAAP  to non -GAAP reconciliation for all relevant \nperiods can be found in the schedules attached in our p ress release.  \n ", "original_text": "Please refer to our SEC filing and the forward -looking statement slide \nat the beginning of our presentation for a description of these risks and u ncertainties.  \n \n ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08c3d390247660202912a85b8850f7d465f3eec84b41511c66e84e7674b19019", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b86d48e-d582-4fc3-82f1-6d2931eb22bf", "node_type": "1", "metadata": {"window": "The matters addressed in the \nstatements are subject to th e risks and uncertainty that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filing and the forward -looking statement slide \nat the beginning of our presentation for a description of these risks and u ncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP.  GAAP  to non -GAAP reconciliation for all relevant \nperiods can be found in the schedules attached in our p ress release.  \n ", "original_text": "GAAP  to non -GAAP reconciliation for all relevant \nperiods can be found in the schedules attached in our p ress release.  \n "}, "hash": "407f09086211587c14c80d3f11f9b234aa10e2619193c90f590533c753c989b5", "class_name": "RelatedNodeInfo"}}, "text": "Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP. ", "start_char_idx": 1314, "end_char_idx": 1452, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b86d48e-d582-4fc3-82f1-6d2931eb22bf": {"__data__": {"id_": "1b86d48e-d582-4fc3-82f1-6d2931eb22bf", "embedding": null, "metadata": {"window": "The matters addressed in the \nstatements are subject to th e risks and uncertainty that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filing and the forward -looking statement slide \nat the beginning of our presentation for a description of these risks and u ncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP.  GAAP  to non -GAAP reconciliation for all relevant \nperiods can be found in the schedules attached in our p ress release.  \n ", "original_text": "GAAP  to non -GAAP reconciliation for all relevant \nperiods can be found in the schedules attached in our p ress release.  \n ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64b608ebc3a7a1711b4d3b88a47b92bfbfccd30ea4487cd93f7e3df6139f14d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b62bede-39f9-4e4e-acd7-73a13a2199cc", "node_type": "1", "metadata": {"window": "During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to th e risks and uncertainty that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filing and the forward -looking statement slide \nat the beginning of our presentation for a description of these risks and u ncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP.  GAAP  to non -GAAP reconciliation for all relevant \nperiods can be found in the schedules attached in our p ress release.  \n ", "original_text": "Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP. ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a21702e706839462c51e1e2b365192e07a657827263ed22040455f9e056a705b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24e03b24-6abd-4f09-afc5-1896a54cff29", "node_type": "1", "metadata": {"window": " \nPage 2 of 31 \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion, so that we can try and give everyone an opportunity.  With that, I will now turn the call over \nto Mike.  \n \n Mike Kauffman:  Thanks, Kevin.  And good morning to everyone joining us.  \n \n ", "original_text": " \nPage 2 of 31 \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion, so that we can try and give everyone an opportunity. "}, "hash": "d61062575a6501c5cf9205575e67d8237fa3ce4fff1565b709f0a4d66a1b3d48", "class_name": "RelatedNodeInfo"}}, "text": "GAAP  to non -GAAP reconciliation for all relevant \nperiods can be found in the schedules attached in our p ress release.  \n ", "start_char_idx": 1452, "end_char_idx": 1577, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24e03b24-6abd-4f09-afc5-1896a54cff29": {"__data__": {"id_": "24e03b24-6abd-4f09-afc5-1896a54cff29", "embedding": null, "metadata": {"window": " \nPage 2 of 31 \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion, so that we can try and give everyone an opportunity.  With that, I will now turn the call over \nto Mike.  \n \n Mike Kauffman:  Thanks, Kevin.  And good morning to everyone joining us.  \n \n ", "original_text": " \nPage 2 of 31 \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion, so that we can try and give everyone an opportunity. ", "page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c8a6b818-b294-4b3d-ae18-fbb665a79bdd", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12f2dca9c40a48d9ef693483a91095ee395bebbfbdb8e9653481e5f778bacbf2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b86d48e-d582-4fc3-82f1-6d2931eb22bf", "node_type": "1", "metadata": {"window": "The matters addressed in the \nstatements are subject to th e risks and uncertainty that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filing and the forward -looking statement slide \nat the beginning of our presentation for a description of these risks and u ncertainties.  \n \n  Please note that during the discussion today, our comments will be on a non -GAAP basis \nunless they are specifically called out as GAAP.  GAAP  to non -GAAP reconciliation for all relevant \nperiods can be found in the schedules attached in our p ress release.  \n ", "original_text": "GAAP  to non -GAAP reconciliation for all relevant \nperiods can be found in the schedules attached in our p ress release.  \n ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "25d5afd65a1bf942fe3982f8b05bc28c021b66704d4984ccf6334a0e325a33d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11bdb025-1ff1-48c1-af94-e3991b3969d8", "node_type": "1", "metadata": {"window": " \nPage 2 of 31 \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion, so that we can try and give everyone an opportunity.  With that, I will now turn the call over \nto Mike.  \n \n Mike Kauffman:  Thanks, Kevin.  And good morning to everyone joining us.  \n \n  Before Jason and I discuss our results and outlook, let me share a few reflections.  \n \n ", "original_text": "With that, I will now turn the call over \nto Mike.  \n \n"}, "hash": "b9be84e8dd1677453fd09e156bfa28068e72922c5c505f21f9131d86199e861b", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 2 of 31 \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion, so that we can try and give everyone an opportunity. ", "start_char_idx": 0, "end_char_idx": 176, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11bdb025-1ff1-48c1-af94-e3991b3969d8": {"__data__": {"id_": "11bdb025-1ff1-48c1-af94-e3991b3969d8", "embedding": null, "metadata": {"window": " \nPage 2 of 31 \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion, so that we can try and give everyone an opportunity.  With that, I will now turn the call over \nto Mike.  \n \n Mike Kauffman:  Thanks, Kevin.  And good morning to everyone joining us.  \n \n  Before Jason and I discuss our results and outlook, let me share a few reflections.  \n \n ", "original_text": "With that, I will now turn the call over \nto Mike.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c8a6b818-b294-4b3d-ae18-fbb665a79bdd", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12f2dca9c40a48d9ef693483a91095ee395bebbfbdb8e9653481e5f778bacbf2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24e03b24-6abd-4f09-afc5-1896a54cff29", "node_type": "1", "metadata": {"window": " \nPage 2 of 31 \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion, so that we can try and give everyone an opportunity.  With that, I will now turn the call over \nto Mike.  \n \n Mike Kauffman:  Thanks, Kevin.  And good morning to everyone joining us.  \n \n ", "original_text": " \nPage 2 of 31 \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion, so that we can try and give everyone an opportunity. ", "page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3aa759e51196b02a0d58a687d64c14474d82a8e1ae3f6364e443bba0180edc0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22ac2b64-e4a1-411c-a4d4-03fdb32f4219", "node_type": "1", "metadata": {"window": " \nPage 2 of 31 \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion, so that we can try and give everyone an opportunity.  With that, I will now turn the call over \nto Mike.  \n \n Mike Kauffman:  Thanks, Kevin.  And good morning to everyone joining us.  \n \n  Before Jason and I discuss our results and outlook, let me share a few reflections.  \n \n  In my nearly 30 years as part of the Cardinal Health family, I have seen this company and this \nindustry expand with new products, services, and markets \u2026evolve with technology, regulatory, and \nmodel changes \u2026and adapt when faced with external challenges.  \n \n ", "original_text": "Mike Kauffman:  Thanks, Kevin. "}, "hash": "dc7715596b67adb5edac5576e83fe307a38198de49562266654845102adbd373", "class_name": "RelatedNodeInfo"}}, "text": "With that, I will now turn the call over \nto Mike.  \n \n", "start_char_idx": 176, "end_char_idx": 231, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22ac2b64-e4a1-411c-a4d4-03fdb32f4219": {"__data__": {"id_": "22ac2b64-e4a1-411c-a4d4-03fdb32f4219", "embedding": null, "metadata": {"window": " \nPage 2 of 31 \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion, so that we can try and give everyone an opportunity.  With that, I will now turn the call over \nto Mike.  \n \n Mike Kauffman:  Thanks, Kevin.  And good morning to everyone joining us.  \n \n  Before Jason and I discuss our results and outlook, let me share a few reflections.  \n \n  In my nearly 30 years as part of the Cardinal Health family, I have seen this company and this \nindustry expand with new products, services, and markets \u2026evolve with technology, regulatory, and \nmodel changes \u2026and adapt when faced with external challenges.  \n \n ", "original_text": "Mike Kauffman:  Thanks, Kevin. ", "page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c8a6b818-b294-4b3d-ae18-fbb665a79bdd", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12f2dca9c40a48d9ef693483a91095ee395bebbfbdb8e9653481e5f778bacbf2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11bdb025-1ff1-48c1-af94-e3991b3969d8", "node_type": "1", "metadata": {"window": " \nPage 2 of 31 \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion, so that we can try and give everyone an opportunity.  With that, I will now turn the call over \nto Mike.  \n \n Mike Kauffman:  Thanks, Kevin.  And good morning to everyone joining us.  \n \n  Before Jason and I discuss our results and outlook, let me share a few reflections.  \n \n ", "original_text": "With that, I will now turn the call over \nto Mike.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a1ece334099a0707c01bf4e0e201a8c0660fe7bebb9450b80e5afa825cdf88a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f103894b-944d-4785-981d-b69b247ff497", "node_type": "1", "metadata": {"window": " \nPage 2 of 31 \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion, so that we can try and give everyone an opportunity.  With that, I will now turn the call over \nto Mike.  \n \n Mike Kauffman:  Thanks, Kevin.  And good morning to everyone joining us.  \n \n  Before Jason and I discuss our results and outlook, let me share a few reflections.  \n \n  In my nearly 30 years as part of the Cardinal Health family, I have seen this company and this \nindustry expand with new products, services, and markets \u2026evolve with technology, regulatory, and \nmodel changes \u2026and adapt when faced with external challenges.  \n \n  In each of these moments, we have demonstrated grit and agility. ", "original_text": "And good morning to everyone joining us.  \n \n "}, "hash": "ed0c2510e5f3219c0f6d614eb93b4fb41c1881ba679ac4f6852af7767130c940", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kauffman:  Thanks, Kevin. ", "start_char_idx": 231, "end_char_idx": 262, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f103894b-944d-4785-981d-b69b247ff497": {"__data__": {"id_": "f103894b-944d-4785-981d-b69b247ff497", "embedding": null, "metadata": {"window": " \nPage 2 of 31 \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion, so that we can try and give everyone an opportunity.  With that, I will now turn the call over \nto Mike.  \n \n Mike Kauffman:  Thanks, Kevin.  And good morning to everyone joining us.  \n \n  Before Jason and I discuss our results and outlook, let me share a few reflections.  \n \n  In my nearly 30 years as part of the Cardinal Health family, I have seen this company and this \nindustry expand with new products, services, and markets \u2026evolve with technology, regulatory, and \nmodel changes \u2026and adapt when faced with external challenges.  \n \n  In each of these moments, we have demonstrated grit and agility. ", "original_text": "And good morning to everyone joining us.  \n \n ", "page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c8a6b818-b294-4b3d-ae18-fbb665a79bdd", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12f2dca9c40a48d9ef693483a91095ee395bebbfbdb8e9653481e5f778bacbf2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22ac2b64-e4a1-411c-a4d4-03fdb32f4219", "node_type": "1", "metadata": {"window": " \nPage 2 of 31 \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion, so that we can try and give everyone an opportunity.  With that, I will now turn the call over \nto Mike.  \n \n Mike Kauffman:  Thanks, Kevin.  And good morning to everyone joining us.  \n \n  Before Jason and I discuss our results and outlook, let me share a few reflections.  \n \n  In my nearly 30 years as part of the Cardinal Health family, I have seen this company and this \nindustry expand with new products, services, and markets \u2026evolve with technology, regulatory, and \nmodel changes \u2026and adapt when faced with external challenges.  \n \n ", "original_text": "Mike Kauffman:  Thanks, Kevin. ", "page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3beb4853a177a20d6f32bb29201bb6997be671c010c5a7c577b3119843c8bc25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcb11cb0-f96c-44cb-b951-c59ba1eacbb3", "node_type": "1", "metadata": {"window": "With that, I will now turn the call over \nto Mike.  \n \n Mike Kauffman:  Thanks, Kevin.  And good morning to everyone joining us.  \n \n  Before Jason and I discuss our results and outlook, let me share a few reflections.  \n \n  In my nearly 30 years as part of the Cardinal Health family, I have seen this company and this \nindustry expand with new products, services, and markets \u2026evolve with technology, regulatory, and \nmodel changes \u2026and adapt when faced with external challenges.  \n \n  In each of these moments, we have demonstrated grit and agility.  Now more than ever we will \nlean on that legacy to naviga te current challenges and perform our critical role in healthcare.  \n \n ", "original_text": "Before Jason and I discuss our results and outlook, let me share a few reflections.  \n \n "}, "hash": "710189ed44782530c1373fbab4e541414d6c1df42de824583fd4d2ab1d07a4d0", "class_name": "RelatedNodeInfo"}}, "text": "And good morning to everyone joining us.  \n \n ", "start_char_idx": 262, "end_char_idx": 308, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcb11cb0-f96c-44cb-b951-c59ba1eacbb3": {"__data__": {"id_": "dcb11cb0-f96c-44cb-b951-c59ba1eacbb3", "embedding": null, "metadata": {"window": "With that, I will now turn the call over \nto Mike.  \n \n Mike Kauffman:  Thanks, Kevin.  And good morning to everyone joining us.  \n \n  Before Jason and I discuss our results and outlook, let me share a few reflections.  \n \n  In my nearly 30 years as part of the Cardinal Health family, I have seen this company and this \nindustry expand with new products, services, and markets \u2026evolve with technology, regulatory, and \nmodel changes \u2026and adapt when faced with external challenges.  \n \n  In each of these moments, we have demonstrated grit and agility.  Now more than ever we will \nlean on that legacy to naviga te current challenges and perform our critical role in healthcare.  \n \n ", "original_text": "Before Jason and I discuss our results and outlook, let me share a few reflections.  \n \n ", "page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c8a6b818-b294-4b3d-ae18-fbb665a79bdd", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12f2dca9c40a48d9ef693483a91095ee395bebbfbdb8e9653481e5f778bacbf2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f103894b-944d-4785-981d-b69b247ff497", "node_type": "1", "metadata": {"window": " \nPage 2 of 31 \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion, so that we can try and give everyone an opportunity.  With that, I will now turn the call over \nto Mike.  \n \n Mike Kauffman:  Thanks, Kevin.  And good morning to everyone joining us.  \n \n  Before Jason and I discuss our results and outlook, let me share a few reflections.  \n \n  In my nearly 30 years as part of the Cardinal Health family, I have seen this company and this \nindustry expand with new products, services, and markets \u2026evolve with technology, regulatory, and \nmodel changes \u2026and adapt when faced with external challenges.  \n \n  In each of these moments, we have demonstrated grit and agility. ", "original_text": "And good morning to everyone joining us.  \n \n ", "page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d9a2169b19ec822b8652eb3ff2b45d3e84c743c7fd09067ca3a9718fa939a9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "973cb6dd-ab58-45d6-b9e0-c2f135151533", "node_type": "1", "metadata": {"window": "Mike Kauffman:  Thanks, Kevin.  And good morning to everyone joining us.  \n \n  Before Jason and I discuss our results and outlook, let me share a few reflections.  \n \n  In my nearly 30 years as part of the Cardinal Health family, I have seen this company and this \nindustry expand with new products, services, and markets \u2026evolve with technology, regulatory, and \nmodel changes \u2026and adapt when faced with external challenges.  \n \n  In each of these moments, we have demonstrated grit and agility.  Now more than ever we will \nlean on that legacy to naviga te current challenges and perform our critical role in healthcare.  \n \n  In fiscal 20, we delivered on our commitments and demonstrated these traits. ", "original_text": "In my nearly 30 years as part of the Cardinal Health family, I have seen this company and this \nindustry expand with new products, services, and markets \u2026evolve with technology, regulatory, and \nmodel changes \u2026and adapt when faced with external challenges.  \n \n "}, "hash": "3eb179815ef924ea943c3594cde8bade529e0215f28bdd08181612e76caa3cc5", "class_name": "RelatedNodeInfo"}}, "text": "Before Jason and I discuss our results and outlook, let me share a few reflections.  \n \n ", "start_char_idx": 308, "end_char_idx": 397, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "973cb6dd-ab58-45d6-b9e0-c2f135151533": {"__data__": {"id_": "973cb6dd-ab58-45d6-b9e0-c2f135151533", "embedding": null, "metadata": {"window": "Mike Kauffman:  Thanks, Kevin.  And good morning to everyone joining us.  \n \n  Before Jason and I discuss our results and outlook, let me share a few reflections.  \n \n  In my nearly 30 years as part of the Cardinal Health family, I have seen this company and this \nindustry expand with new products, services, and markets \u2026evolve with technology, regulatory, and \nmodel changes \u2026and adapt when faced with external challenges.  \n \n  In each of these moments, we have demonstrated grit and agility.  Now more than ever we will \nlean on that legacy to naviga te current challenges and perform our critical role in healthcare.  \n \n  In fiscal 20, we delivered on our commitments and demonstrated these traits. ", "original_text": "In my nearly 30 years as part of the Cardinal Health family, I have seen this company and this \nindustry expand with new products, services, and markets \u2026evolve with technology, regulatory, and \nmodel changes \u2026and adapt when faced with external challenges.  \n \n ", "page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c8a6b818-b294-4b3d-ae18-fbb665a79bdd", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12f2dca9c40a48d9ef693483a91095ee395bebbfbdb8e9653481e5f778bacbf2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcb11cb0-f96c-44cb-b951-c59ba1eacbb3", "node_type": "1", "metadata": {"window": "With that, I will now turn the call over \nto Mike.  \n \n Mike Kauffman:  Thanks, Kevin.  And good morning to everyone joining us.  \n \n  Before Jason and I discuss our results and outlook, let me share a few reflections.  \n \n  In my nearly 30 years as part of the Cardinal Health family, I have seen this company and this \nindustry expand with new products, services, and markets \u2026evolve with technology, regulatory, and \nmodel changes \u2026and adapt when faced with external challenges.  \n \n  In each of these moments, we have demonstrated grit and agility.  Now more than ever we will \nlean on that legacy to naviga te current challenges and perform our critical role in healthcare.  \n \n ", "original_text": "Before Jason and I discuss our results and outlook, let me share a few reflections.  \n \n ", "page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0d4297928b6301c6be66811e1301de9549d4695ba34df72a1e0c94e28843a61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da4b35a0-4b3d-4f71-94b5-c3bbdbc72f03", "node_type": "1", "metadata": {"window": "And good morning to everyone joining us.  \n \n  Before Jason and I discuss our results and outlook, let me share a few reflections.  \n \n  In my nearly 30 years as part of the Cardinal Health family, I have seen this company and this \nindustry expand with new products, services, and markets \u2026evolve with technology, regulatory, and \nmodel changes \u2026and adapt when faced with external challenges.  \n \n  In each of these moments, we have demonstrated grit and agility.  Now more than ever we will \nlean on that legacy to naviga te current challenges and perform our critical role in healthcare.  \n \n  In fiscal 20, we delivered on our commitments and demonstrated these traits.  We grew \noperating earnings, exceeded our EPS guidance range, surpassed our enterprise cost savings target, \nand strengthened our balance sheet \u2026all while continuing to execute our long -term strategic priorities \nin a rapidly changing environment.  \n \n ", "original_text": "In each of these moments, we have demonstrated grit and agility. "}, "hash": "2e07a12ed91c387a50b71ad85d09c227ade261c17e0cb884b7fec2a52fdd387b", "class_name": "RelatedNodeInfo"}}, "text": "In my nearly 30 years as part of the Cardinal Health family, I have seen this company and this \nindustry expand with new products, services, and markets \u2026evolve with technology, regulatory, and \nmodel changes \u2026and adapt when faced with external challenges.  \n \n ", "start_char_idx": 397, "end_char_idx": 659, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da4b35a0-4b3d-4f71-94b5-c3bbdbc72f03": {"__data__": {"id_": "da4b35a0-4b3d-4f71-94b5-c3bbdbc72f03", "embedding": null, "metadata": {"window": "And good morning to everyone joining us.  \n \n  Before Jason and I discuss our results and outlook, let me share a few reflections.  \n \n  In my nearly 30 years as part of the Cardinal Health family, I have seen this company and this \nindustry expand with new products, services, and markets \u2026evolve with technology, regulatory, and \nmodel changes \u2026and adapt when faced with external challenges.  \n \n  In each of these moments, we have demonstrated grit and agility.  Now more than ever we will \nlean on that legacy to naviga te current challenges and perform our critical role in healthcare.  \n \n  In fiscal 20, we delivered on our commitments and demonstrated these traits.  We grew \noperating earnings, exceeded our EPS guidance range, surpassed our enterprise cost savings target, \nand strengthened our balance sheet \u2026all while continuing to execute our long -term strategic priorities \nin a rapidly changing environment.  \n \n ", "original_text": "In each of these moments, we have demonstrated grit and agility. ", "page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c8a6b818-b294-4b3d-ae18-fbb665a79bdd", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12f2dca9c40a48d9ef693483a91095ee395bebbfbdb8e9653481e5f778bacbf2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "973cb6dd-ab58-45d6-b9e0-c2f135151533", "node_type": "1", "metadata": {"window": "Mike Kauffman:  Thanks, Kevin.  And good morning to everyone joining us.  \n \n  Before Jason and I discuss our results and outlook, let me share a few reflections.  \n \n  In my nearly 30 years as part of the Cardinal Health family, I have seen this company and this \nindustry expand with new products, services, and markets \u2026evolve with technology, regulatory, and \nmodel changes \u2026and adapt when faced with external challenges.  \n \n  In each of these moments, we have demonstrated grit and agility.  Now more than ever we will \nlean on that legacy to naviga te current challenges and perform our critical role in healthcare.  \n \n  In fiscal 20, we delivered on our commitments and demonstrated these traits. ", "original_text": "In my nearly 30 years as part of the Cardinal Health family, I have seen this company and this \nindustry expand with new products, services, and markets \u2026evolve with technology, regulatory, and \nmodel changes \u2026and adapt when faced with external challenges.  \n \n ", "page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6357d738f2d823d6e138ee7fbb2501adf578d869cff6a8fab54a0dfc9991d854", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "376921ea-0913-4cc4-9b00-eb72ae78246c", "node_type": "1", "metadata": {"window": "Before Jason and I discuss our results and outlook, let me share a few reflections.  \n \n  In my nearly 30 years as part of the Cardinal Health family, I have seen this company and this \nindustry expand with new products, services, and markets \u2026evolve with technology, regulatory, and \nmodel changes \u2026and adapt when faced with external challenges.  \n \n  In each of these moments, we have demonstrated grit and agility.  Now more than ever we will \nlean on that legacy to naviga te current challenges and perform our critical role in healthcare.  \n \n  In fiscal 20, we delivered on our commitments and demonstrated these traits.  We grew \noperating earnings, exceeded our EPS guidance range, surpassed our enterprise cost savings target, \nand strengthened our balance sheet \u2026all while continuing to execute our long -term strategic priorities \nin a rapidly changing environment.  \n \n  We made strategic portfolio decisions including divesting our remaining equity interest in \nNaviHealth, as well as invest ing and partnering in the evolving growth areas of Specialty, at -Home, \nand Services.  \n ", "original_text": "Now more than ever we will \nlean on that legacy to naviga te current challenges and perform our critical role in healthcare.  \n \n "}, "hash": "c5255ad78d97cb19c00f7ad20308280b104942cd7679f9cf69fd35ebe6d75b83", "class_name": "RelatedNodeInfo"}}, "text": "In each of these moments, we have demonstrated grit and agility. ", "start_char_idx": 659, "end_char_idx": 724, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "376921ea-0913-4cc4-9b00-eb72ae78246c": {"__data__": {"id_": "376921ea-0913-4cc4-9b00-eb72ae78246c", "embedding": null, "metadata": {"window": "Before Jason and I discuss our results and outlook, let me share a few reflections.  \n \n  In my nearly 30 years as part of the Cardinal Health family, I have seen this company and this \nindustry expand with new products, services, and markets \u2026evolve with technology, regulatory, and \nmodel changes \u2026and adapt when faced with external challenges.  \n \n  In each of these moments, we have demonstrated grit and agility.  Now more than ever we will \nlean on that legacy to naviga te current challenges and perform our critical role in healthcare.  \n \n  In fiscal 20, we delivered on our commitments and demonstrated these traits.  We grew \noperating earnings, exceeded our EPS guidance range, surpassed our enterprise cost savings target, \nand strengthened our balance sheet \u2026all while continuing to execute our long -term strategic priorities \nin a rapidly changing environment.  \n \n  We made strategic portfolio decisions including divesting our remaining equity interest in \nNaviHealth, as well as invest ing and partnering in the evolving growth areas of Specialty, at -Home, \nand Services.  \n ", "original_text": "Now more than ever we will \nlean on that legacy to naviga te current challenges and perform our critical role in healthcare.  \n \n ", "page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c8a6b818-b294-4b3d-ae18-fbb665a79bdd", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12f2dca9c40a48d9ef693483a91095ee395bebbfbdb8e9653481e5f778bacbf2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da4b35a0-4b3d-4f71-94b5-c3bbdbc72f03", "node_type": "1", "metadata": {"window": "And good morning to everyone joining us.  \n \n  Before Jason and I discuss our results and outlook, let me share a few reflections.  \n \n  In my nearly 30 years as part of the Cardinal Health family, I have seen this company and this \nindustry expand with new products, services, and markets \u2026evolve with technology, regulatory, and \nmodel changes \u2026and adapt when faced with external challenges.  \n \n  In each of these moments, we have demonstrated grit and agility.  Now more than ever we will \nlean on that legacy to naviga te current challenges and perform our critical role in healthcare.  \n \n  In fiscal 20, we delivered on our commitments and demonstrated these traits.  We grew \noperating earnings, exceeded our EPS guidance range, surpassed our enterprise cost savings target, \nand strengthened our balance sheet \u2026all while continuing to execute our long -term strategic priorities \nin a rapidly changing environment.  \n \n ", "original_text": "In each of these moments, we have demonstrated grit and agility. ", "page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b608f981995d1aebafe83ef92a26a67acb18ccd00ba9e51084a0c266dc4ae169", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "010ec09f-6a66-431e-b60c-2144632c56ec", "node_type": "1", "metadata": {"window": "In my nearly 30 years as part of the Cardinal Health family, I have seen this company and this \nindustry expand with new products, services, and markets \u2026evolve with technology, regulatory, and \nmodel changes \u2026and adapt when faced with external challenges.  \n \n  In each of these moments, we have demonstrated grit and agility.  Now more than ever we will \nlean on that legacy to naviga te current challenges and perform our critical role in healthcare.  \n \n  In fiscal 20, we delivered on our commitments and demonstrated these traits.  We grew \noperating earnings, exceeded our EPS guidance range, surpassed our enterprise cost savings target, \nand strengthened our balance sheet \u2026all while continuing to execute our long -term strategic priorities \nin a rapidly changing environment.  \n \n  We made strategic portfolio decisions including divesting our remaining equity interest in \nNaviHealth, as well as invest ing and partnering in the evolving growth areas of Specialty, at -Home, \nand Services.  \n ", "original_text": "In fiscal 20, we delivered on our commitments and demonstrated these traits. "}, "hash": "ce48f6dc059f368755060bbf47f37ad39587a2be8f9c0c0f346bb13e0bd095cd", "class_name": "RelatedNodeInfo"}}, "text": "Now more than ever we will \nlean on that legacy to naviga te current challenges and perform our critical role in healthcare.  \n \n ", "start_char_idx": 724, "end_char_idx": 854, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "010ec09f-6a66-431e-b60c-2144632c56ec": {"__data__": {"id_": "010ec09f-6a66-431e-b60c-2144632c56ec", "embedding": null, "metadata": {"window": "In my nearly 30 years as part of the Cardinal Health family, I have seen this company and this \nindustry expand with new products, services, and markets \u2026evolve with technology, regulatory, and \nmodel changes \u2026and adapt when faced with external challenges.  \n \n  In each of these moments, we have demonstrated grit and agility.  Now more than ever we will \nlean on that legacy to naviga te current challenges and perform our critical role in healthcare.  \n \n  In fiscal 20, we delivered on our commitments and demonstrated these traits.  We grew \noperating earnings, exceeded our EPS guidance range, surpassed our enterprise cost savings target, \nand strengthened our balance sheet \u2026all while continuing to execute our long -term strategic priorities \nin a rapidly changing environment.  \n \n  We made strategic portfolio decisions including divesting our remaining equity interest in \nNaviHealth, as well as invest ing and partnering in the evolving growth areas of Specialty, at -Home, \nand Services.  \n ", "original_text": "In fiscal 20, we delivered on our commitments and demonstrated these traits. ", "page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c8a6b818-b294-4b3d-ae18-fbb665a79bdd", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12f2dca9c40a48d9ef693483a91095ee395bebbfbdb8e9653481e5f778bacbf2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "376921ea-0913-4cc4-9b00-eb72ae78246c", "node_type": "1", "metadata": {"window": "Before Jason and I discuss our results and outlook, let me share a few reflections.  \n \n  In my nearly 30 years as part of the Cardinal Health family, I have seen this company and this \nindustry expand with new products, services, and markets \u2026evolve with technology, regulatory, and \nmodel changes \u2026and adapt when faced with external challenges.  \n \n  In each of these moments, we have demonstrated grit and agility.  Now more than ever we will \nlean on that legacy to naviga te current challenges and perform our critical role in healthcare.  \n \n  In fiscal 20, we delivered on our commitments and demonstrated these traits.  We grew \noperating earnings, exceeded our EPS guidance range, surpassed our enterprise cost savings target, \nand strengthened our balance sheet \u2026all while continuing to execute our long -term strategic priorities \nin a rapidly changing environment.  \n \n  We made strategic portfolio decisions including divesting our remaining equity interest in \nNaviHealth, as well as invest ing and partnering in the evolving growth areas of Specialty, at -Home, \nand Services.  \n ", "original_text": "Now more than ever we will \nlean on that legacy to naviga te current challenges and perform our critical role in healthcare.  \n \n ", "page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc0ba7fede9cd4d12e9cb5faebbf576896dad3de316b4ed28db10a117446ec6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fcbc7966-1b00-4883-b3c3-0b439af1cf4a", "node_type": "1", "metadata": {"window": "In each of these moments, we have demonstrated grit and agility.  Now more than ever we will \nlean on that legacy to naviga te current challenges and perform our critical role in healthcare.  \n \n  In fiscal 20, we delivered on our commitments and demonstrated these traits.  We grew \noperating earnings, exceeded our EPS guidance range, surpassed our enterprise cost savings target, \nand strengthened our balance sheet \u2026all while continuing to execute our long -term strategic priorities \nin a rapidly changing environment.  \n \n  We made strategic portfolio decisions including divesting our remaining equity interest in \nNaviHealth, as well as invest ing and partnering in the evolving growth areas of Specialty, at -Home, \nand Services.  \n ", "original_text": "We grew \noperating earnings, exceeded our EPS guidance range, surpassed our enterprise cost savings target, \nand strengthened our balance sheet \u2026all while continuing to execute our long -term strategic priorities \nin a rapidly changing environment.  \n \n "}, "hash": "e9aa1f6a66e4725f54eafa9d34894305fa7ad9473e70079bf67be5146cff5d75", "class_name": "RelatedNodeInfo"}}, "text": "In fiscal 20, we delivered on our commitments and demonstrated these traits. ", "start_char_idx": 854, "end_char_idx": 931, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fcbc7966-1b00-4883-b3c3-0b439af1cf4a": {"__data__": {"id_": "fcbc7966-1b00-4883-b3c3-0b439af1cf4a", "embedding": null, "metadata": {"window": "In each of these moments, we have demonstrated grit and agility.  Now more than ever we will \nlean on that legacy to naviga te current challenges and perform our critical role in healthcare.  \n \n  In fiscal 20, we delivered on our commitments and demonstrated these traits.  We grew \noperating earnings, exceeded our EPS guidance range, surpassed our enterprise cost savings target, \nand strengthened our balance sheet \u2026all while continuing to execute our long -term strategic priorities \nin a rapidly changing environment.  \n \n  We made strategic portfolio decisions including divesting our remaining equity interest in \nNaviHealth, as well as invest ing and partnering in the evolving growth areas of Specialty, at -Home, \nand Services.  \n ", "original_text": "We grew \noperating earnings, exceeded our EPS guidance range, surpassed our enterprise cost savings target, \nand strengthened our balance sheet \u2026all while continuing to execute our long -term strategic priorities \nin a rapidly changing environment.  \n \n ", "page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c8a6b818-b294-4b3d-ae18-fbb665a79bdd", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12f2dca9c40a48d9ef693483a91095ee395bebbfbdb8e9653481e5f778bacbf2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "010ec09f-6a66-431e-b60c-2144632c56ec", "node_type": "1", "metadata": {"window": "In my nearly 30 years as part of the Cardinal Health family, I have seen this company and this \nindustry expand with new products, services, and markets \u2026evolve with technology, regulatory, and \nmodel changes \u2026and adapt when faced with external challenges.  \n \n  In each of these moments, we have demonstrated grit and agility.  Now more than ever we will \nlean on that legacy to naviga te current challenges and perform our critical role in healthcare.  \n \n  In fiscal 20, we delivered on our commitments and demonstrated these traits.  We grew \noperating earnings, exceeded our EPS guidance range, surpassed our enterprise cost savings target, \nand strengthened our balance sheet \u2026all while continuing to execute our long -term strategic priorities \nin a rapidly changing environment.  \n \n  We made strategic portfolio decisions including divesting our remaining equity interest in \nNaviHealth, as well as invest ing and partnering in the evolving growth areas of Specialty, at -Home, \nand Services.  \n ", "original_text": "In fiscal 20, we delivered on our commitments and demonstrated these traits. ", "page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9f63fb2dd43e0c2966f1200b3996259210c5c8656c0fc1b1b5d7c8d109c2f3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7e75312-9637-48e4-8690-1a13dca3e149", "node_type": "1", "metadata": {"window": "Now more than ever we will \nlean on that legacy to naviga te current challenges and perform our critical role in healthcare.  \n \n  In fiscal 20, we delivered on our commitments and demonstrated these traits.  We grew \noperating earnings, exceeded our EPS guidance range, surpassed our enterprise cost savings target, \nand strengthened our balance sheet \u2026all while continuing to execute our long -term strategic priorities \nin a rapidly changing environment.  \n \n  We made strategic portfolio decisions including divesting our remaining equity interest in \nNaviHealth, as well as invest ing and partnering in the evolving growth areas of Specialty, at -Home, \nand Services.  \n ", "original_text": "We made strategic portfolio decisions including divesting our remaining equity interest in \nNaviHealth, as well as invest ing and partnering in the evolving growth areas of Specialty, at -Home, \nand Services.  \n "}, "hash": "60d2709898bbae37666d9d6c568ea11055feb73b8ff11ef96915efc76a75c554", "class_name": "RelatedNodeInfo"}}, "text": "We grew \noperating earnings, exceeded our EPS guidance range, surpassed our enterprise cost savings target, \nand strengthened our balance sheet \u2026all while continuing to execute our long -term strategic priorities \nin a rapidly changing environment.  \n \n ", "start_char_idx": 931, "end_char_idx": 1185, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7e75312-9637-48e4-8690-1a13dca3e149": {"__data__": {"id_": "c7e75312-9637-48e4-8690-1a13dca3e149", "embedding": null, "metadata": {"window": "Now more than ever we will \nlean on that legacy to naviga te current challenges and perform our critical role in healthcare.  \n \n  In fiscal 20, we delivered on our commitments and demonstrated these traits.  We grew \noperating earnings, exceeded our EPS guidance range, surpassed our enterprise cost savings target, \nand strengthened our balance sheet \u2026all while continuing to execute our long -term strategic priorities \nin a rapidly changing environment.  \n \n  We made strategic portfolio decisions including divesting our remaining equity interest in \nNaviHealth, as well as invest ing and partnering in the evolving growth areas of Specialty, at -Home, \nand Services.  \n ", "original_text": "We made strategic portfolio decisions including divesting our remaining equity interest in \nNaviHealth, as well as invest ing and partnering in the evolving growth areas of Specialty, at -Home, \nand Services.  \n ", "page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c8a6b818-b294-4b3d-ae18-fbb665a79bdd", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12f2dca9c40a48d9ef693483a91095ee395bebbfbdb8e9653481e5f778bacbf2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fcbc7966-1b00-4883-b3c3-0b439af1cf4a", "node_type": "1", "metadata": {"window": "In each of these moments, we have demonstrated grit and agility.  Now more than ever we will \nlean on that legacy to naviga te current challenges and perform our critical role in healthcare.  \n \n  In fiscal 20, we delivered on our commitments and demonstrated these traits.  We grew \noperating earnings, exceeded our EPS guidance range, surpassed our enterprise cost savings target, \nand strengthened our balance sheet \u2026all while continuing to execute our long -term strategic priorities \nin a rapidly changing environment.  \n \n  We made strategic portfolio decisions including divesting our remaining equity interest in \nNaviHealth, as well as invest ing and partnering in the evolving growth areas of Specialty, at -Home, \nand Services.  \n ", "original_text": "We grew \noperating earnings, exceeded our EPS guidance range, surpassed our enterprise cost savings target, \nand strengthened our balance sheet \u2026all while continuing to execute our long -term strategic priorities \nin a rapidly changing environment.  \n \n ", "page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "93f6cbd97ab9b1c90e14a38c5d6387e83dcab972483e17fc34c3f920bea8c1eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "903607c5-7e2c-497f-a1f5-55848f59e898", "node_type": "1", "metadata": {"window": " \nPage 3 of 31 \n \n We achieved these results as we adapted our operations to address the unique challenges \npresented by COVID -19.  We successfully transitioned our office employees to a remote work model, \nand we continuously maintained operations in all of our distribution facilities, nuclear pharmacies, and \nglobal manufacturing plants.  \n \n  Through all of this, we kept our primary focus:  delivering critical products and services to our \ncustomers , and at the same time prioritizing the safety of our employees.  \n \n  As I look toward the coming year, I recognize that the global and industry dynamics, resulting \nfrom the pandemic will continue to challenge areas of our business. ", "original_text": " \nPage 3 of 31 \n \n We achieved these results as we adapted our operations to address the unique challenges \npresented by COVID -19. "}, "hash": "8084282da7632b12fa677ab85cfad9ae2ba0bf21ae431db289875b3c0f6d99de", "class_name": "RelatedNodeInfo"}}, "text": "We made strategic portfolio decisions including divesting our remaining equity interest in \nNaviHealth, as well as invest ing and partnering in the evolving growth areas of Specialty, at -Home, \nand Services.  \n ", "start_char_idx": 1185, "end_char_idx": 1397, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "903607c5-7e2c-497f-a1f5-55848f59e898": {"__data__": {"id_": "903607c5-7e2c-497f-a1f5-55848f59e898", "embedding": null, "metadata": {"window": " \nPage 3 of 31 \n \n We achieved these results as we adapted our operations to address the unique challenges \npresented by COVID -19.  We successfully transitioned our office employees to a remote work model, \nand we continuously maintained operations in all of our distribution facilities, nuclear pharmacies, and \nglobal manufacturing plants.  \n \n  Through all of this, we kept our primary focus:  delivering critical products and services to our \ncustomers , and at the same time prioritizing the safety of our employees.  \n \n  As I look toward the coming year, I recognize that the global and industry dynamics, resulting \nfrom the pandemic will continue to challenge areas of our business. ", "original_text": " \nPage 3 of 31 \n \n We achieved these results as we adapted our operations to address the unique challenges \npresented by COVID -19. ", "page_label": "3", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7e7a17a-8d74-4fa1-8a13-fb462afeb8b4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76338d70c68efaf987a409ed1a68400bd11b2e185e98a8a853621837266ad980", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7e75312-9637-48e4-8690-1a13dca3e149", "node_type": "1", "metadata": {"window": "Now more than ever we will \nlean on that legacy to naviga te current challenges and perform our critical role in healthcare.  \n \n  In fiscal 20, we delivered on our commitments and demonstrated these traits.  We grew \noperating earnings, exceeded our EPS guidance range, surpassed our enterprise cost savings target, \nand strengthened our balance sheet \u2026all while continuing to execute our long -term strategic priorities \nin a rapidly changing environment.  \n \n  We made strategic portfolio decisions including divesting our remaining equity interest in \nNaviHealth, as well as invest ing and partnering in the evolving growth areas of Specialty, at -Home, \nand Services.  \n ", "original_text": "We made strategic portfolio decisions including divesting our remaining equity interest in \nNaviHealth, as well as invest ing and partnering in the evolving growth areas of Specialty, at -Home, \nand Services.  \n ", "page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42f455ae4cf478337fee928caf7ef41f489d0ab2ae41cae9786716da480887e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d4e84ad-5901-4d9e-a39b-37849537a7ce", "node_type": "1", "metadata": {"window": " \nPage 3 of 31 \n \n We achieved these results as we adapted our operations to address the unique challenges \npresented by COVID -19.  We successfully transitioned our office employees to a remote work model, \nand we continuously maintained operations in all of our distribution facilities, nuclear pharmacies, and \nglobal manufacturing plants.  \n \n  Through all of this, we kept our primary focus:  delivering critical products and services to our \ncustomers , and at the same time prioritizing the safety of our employees.  \n \n  As I look toward the coming year, I recognize that the global and industry dynamics, resulting \nfrom the pandemic will continue to challenge areas of our business.  I am confident that our team will \ncontinue rising to these challenges as we drive our strategic priorities forward.  \n \n ", "original_text": "We successfully transitioned our office employees to a remote work model, \nand we continuously maintained operations in all of our distribution facilities, nuclear pharmacies, and \nglobal manufacturing plants.  \n \n "}, "hash": "7f69cedfe25fdd180162395405578e8dcb15411f93d67b987f30d40d6a67e043", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 3 of 31 \n \n We achieved these results as we adapted our operations to address the unique challenges \npresented by COVID -19. ", "start_char_idx": 0, "end_char_idx": 132, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d4e84ad-5901-4d9e-a39b-37849537a7ce": {"__data__": {"id_": "6d4e84ad-5901-4d9e-a39b-37849537a7ce", "embedding": null, "metadata": {"window": " \nPage 3 of 31 \n \n We achieved these results as we adapted our operations to address the unique challenges \npresented by COVID -19.  We successfully transitioned our office employees to a remote work model, \nand we continuously maintained operations in all of our distribution facilities, nuclear pharmacies, and \nglobal manufacturing plants.  \n \n  Through all of this, we kept our primary focus:  delivering critical products and services to our \ncustomers , and at the same time prioritizing the safety of our employees.  \n \n  As I look toward the coming year, I recognize that the global and industry dynamics, resulting \nfrom the pandemic will continue to challenge areas of our business.  I am confident that our team will \ncontinue rising to these challenges as we drive our strategic priorities forward.  \n \n ", "original_text": "We successfully transitioned our office employees to a remote work model, \nand we continuously maintained operations in all of our distribution facilities, nuclear pharmacies, and \nglobal manufacturing plants.  \n \n ", "page_label": "3", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7e7a17a-8d74-4fa1-8a13-fb462afeb8b4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76338d70c68efaf987a409ed1a68400bd11b2e185e98a8a853621837266ad980", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "903607c5-7e2c-497f-a1f5-55848f59e898", "node_type": "1", "metadata": {"window": " \nPage 3 of 31 \n \n We achieved these results as we adapted our operations to address the unique challenges \npresented by COVID -19.  We successfully transitioned our office employees to a remote work model, \nand we continuously maintained operations in all of our distribution facilities, nuclear pharmacies, and \nglobal manufacturing plants.  \n \n  Through all of this, we kept our primary focus:  delivering critical products and services to our \ncustomers , and at the same time prioritizing the safety of our employees.  \n \n  As I look toward the coming year, I recognize that the global and industry dynamics, resulting \nfrom the pandemic will continue to challenge areas of our business. ", "original_text": " \nPage 3 of 31 \n \n We achieved these results as we adapted our operations to address the unique challenges \npresented by COVID -19. ", "page_label": "3", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b78253315203690385113b92fa3c7ec4e7c09b414df156f04754eefc3ce5e65e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e675ee0-8f3c-4ede-8fb7-07b89a76730a", "node_type": "1", "metadata": {"window": " \nPage 3 of 31 \n \n We achieved these results as we adapted our operations to address the unique challenges \npresented by COVID -19.  We successfully transitioned our office employees to a remote work model, \nand we continuously maintained operations in all of our distribution facilities, nuclear pharmacies, and \nglobal manufacturing plants.  \n \n  Through all of this, we kept our primary focus:  delivering critical products and services to our \ncustomers , and at the same time prioritizing the safety of our employees.  \n \n  As I look toward the coming year, I recognize that the global and industry dynamics, resulting \nfrom the pandemic will continue to challenge areas of our business.  I am confident that our team will \ncontinue rising to these challenges as we drive our strategic priorities forward.  \n \n  I'll provide some comments later about how I see these priorities evolving in fiscal 21 and \nbeyond, but first I'll turn to Jason to discuss the fourth quarter , fiscal 20 and our outlook for fiscal 21.  \n \n", "original_text": "Through all of this, we kept our primary focus:  delivering critical products and services to our \ncustomers , and at the same time prioritizing the safety of our employees.  \n \n "}, "hash": "15f139cf46082805741275c99079bcc56dcc42f1f4e73d0a57fe1559195527b6", "class_name": "RelatedNodeInfo"}}, "text": "We successfully transitioned our office employees to a remote work model, \nand we continuously maintained operations in all of our distribution facilities, nuclear pharmacies, and \nglobal manufacturing plants.  \n \n ", "start_char_idx": 132, "end_char_idx": 347, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e675ee0-8f3c-4ede-8fb7-07b89a76730a": {"__data__": {"id_": "1e675ee0-8f3c-4ede-8fb7-07b89a76730a", "embedding": null, "metadata": {"window": " \nPage 3 of 31 \n \n We achieved these results as we adapted our operations to address the unique challenges \npresented by COVID -19.  We successfully transitioned our office employees to a remote work model, \nand we continuously maintained operations in all of our distribution facilities, nuclear pharmacies, and \nglobal manufacturing plants.  \n \n  Through all of this, we kept our primary focus:  delivering critical products and services to our \ncustomers , and at the same time prioritizing the safety of our employees.  \n \n  As I look toward the coming year, I recognize that the global and industry dynamics, resulting \nfrom the pandemic will continue to challenge areas of our business.  I am confident that our team will \ncontinue rising to these challenges as we drive our strategic priorities forward.  \n \n  I'll provide some comments later about how I see these priorities evolving in fiscal 21 and \nbeyond, but first I'll turn to Jason to discuss the fourth quarter , fiscal 20 and our outlook for fiscal 21.  \n \n", "original_text": "Through all of this, we kept our primary focus:  delivering critical products and services to our \ncustomers , and at the same time prioritizing the safety of our employees.  \n \n ", "page_label": "3", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7e7a17a-8d74-4fa1-8a13-fb462afeb8b4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76338d70c68efaf987a409ed1a68400bd11b2e185e98a8a853621837266ad980", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d4e84ad-5901-4d9e-a39b-37849537a7ce", "node_type": "1", "metadata": {"window": " \nPage 3 of 31 \n \n We achieved these results as we adapted our operations to address the unique challenges \npresented by COVID -19.  We successfully transitioned our office employees to a remote work model, \nand we continuously maintained operations in all of our distribution facilities, nuclear pharmacies, and \nglobal manufacturing plants.  \n \n  Through all of this, we kept our primary focus:  delivering critical products and services to our \ncustomers , and at the same time prioritizing the safety of our employees.  \n \n  As I look toward the coming year, I recognize that the global and industry dynamics, resulting \nfrom the pandemic will continue to challenge areas of our business.  I am confident that our team will \ncontinue rising to these challenges as we drive our strategic priorities forward.  \n \n ", "original_text": "We successfully transitioned our office employees to a remote work model, \nand we continuously maintained operations in all of our distribution facilities, nuclear pharmacies, and \nglobal manufacturing plants.  \n \n ", "page_label": "3", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3836aad33d4afd0f279fa55dbb7128cf7afd84b011015123db43b7dfa155cb91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "790a4a87-6d47-4b66-a6a1-762e84c73d48", "node_type": "1", "metadata": {"window": " \nPage 3 of 31 \n \n We achieved these results as we adapted our operations to address the unique challenges \npresented by COVID -19.  We successfully transitioned our office employees to a remote work model, \nand we continuously maintained operations in all of our distribution facilities, nuclear pharmacies, and \nglobal manufacturing plants.  \n \n  Through all of this, we kept our primary focus:  delivering critical products and services to our \ncustomers , and at the same time prioritizing the safety of our employees.  \n \n  As I look toward the coming year, I recognize that the global and industry dynamics, resulting \nfrom the pandemic will continue to challenge areas of our business.  I am confident that our team will \ncontinue rising to these challenges as we drive our strategic priorities forward.  \n \n  I'll provide some comments later about how I see these priorities evolving in fiscal 21 and \nbeyond, but first I'll turn to Jason to discuss the fourth quarter , fiscal 20 and our outlook for fiscal 21.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.  \n \n ", "original_text": "As I look toward the coming year, I recognize that the global and industry dynamics, resulting \nfrom the pandemic will continue to challenge areas of our business. "}, "hash": "55a8c8288c1dd304594675e513a616bca8a78d7f6eb17f686cc9feef97cbb864", "class_name": "RelatedNodeInfo"}}, "text": "Through all of this, we kept our primary focus:  delivering critical products and services to our \ncustomers , and at the same time prioritizing the safety of our employees.  \n \n ", "start_char_idx": 347, "end_char_idx": 526, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "790a4a87-6d47-4b66-a6a1-762e84c73d48": {"__data__": {"id_": "790a4a87-6d47-4b66-a6a1-762e84c73d48", "embedding": null, "metadata": {"window": " \nPage 3 of 31 \n \n We achieved these results as we adapted our operations to address the unique challenges \npresented by COVID -19.  We successfully transitioned our office employees to a remote work model, \nand we continuously maintained operations in all of our distribution facilities, nuclear pharmacies, and \nglobal manufacturing plants.  \n \n  Through all of this, we kept our primary focus:  delivering critical products and services to our \ncustomers , and at the same time prioritizing the safety of our employees.  \n \n  As I look toward the coming year, I recognize that the global and industry dynamics, resulting \nfrom the pandemic will continue to challenge areas of our business.  I am confident that our team will \ncontinue rising to these challenges as we drive our strategic priorities forward.  \n \n  I'll provide some comments later about how I see these priorities evolving in fiscal 21 and \nbeyond, but first I'll turn to Jason to discuss the fourth quarter , fiscal 20 and our outlook for fiscal 21.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.  \n \n ", "original_text": "As I look toward the coming year, I recognize that the global and industry dynamics, resulting \nfrom the pandemic will continue to challenge areas of our business. ", "page_label": "3", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7e7a17a-8d74-4fa1-8a13-fb462afeb8b4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76338d70c68efaf987a409ed1a68400bd11b2e185e98a8a853621837266ad980", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e675ee0-8f3c-4ede-8fb7-07b89a76730a", "node_type": "1", "metadata": {"window": " \nPage 3 of 31 \n \n We achieved these results as we adapted our operations to address the unique challenges \npresented by COVID -19.  We successfully transitioned our office employees to a remote work model, \nand we continuously maintained operations in all of our distribution facilities, nuclear pharmacies, and \nglobal manufacturing plants.  \n \n  Through all of this, we kept our primary focus:  delivering critical products and services to our \ncustomers , and at the same time prioritizing the safety of our employees.  \n \n  As I look toward the coming year, I recognize that the global and industry dynamics, resulting \nfrom the pandemic will continue to challenge areas of our business.  I am confident that our team will \ncontinue rising to these challenges as we drive our strategic priorities forward.  \n \n  I'll provide some comments later about how I see these priorities evolving in fiscal 21 and \nbeyond, but first I'll turn to Jason to discuss the fourth quarter , fiscal 20 and our outlook for fiscal 21.  \n \n", "original_text": "Through all of this, we kept our primary focus:  delivering critical products and services to our \ncustomers , and at the same time prioritizing the safety of our employees.  \n \n ", "page_label": "3", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b306506313d26b8b6415b28ab62d337895c187a021542c25d69ebe1b30254911", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a48bd4a6-93d9-4b21-aa72-927cf414607f", "node_type": "1", "metadata": {"window": "We successfully transitioned our office employees to a remote work model, \nand we continuously maintained operations in all of our distribution facilities, nuclear pharmacies, and \nglobal manufacturing plants.  \n \n  Through all of this, we kept our primary focus:  delivering critical products and services to our \ncustomers , and at the same time prioritizing the safety of our employees.  \n \n  As I look toward the coming year, I recognize that the global and industry dynamics, resulting \nfrom the pandemic will continue to challenge areas of our business.  I am confident that our team will \ncontinue rising to these challenges as we drive our strategic priorities forward.  \n \n  I'll provide some comments later about how I see these priorities evolving in fiscal 21 and \nbeyond, but first I'll turn to Jason to discuss the fourth quarter , fiscal 20 and our outlook for fiscal 21.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.  \n \n  I am pleased to join you this morning on my first call since assuming the CFO role , and I look \nforward to engaging with you more in the future.  \n \n ", "original_text": "I am confident that our team will \ncontinue rising to these challenges as we drive our strategic priorities forward.  \n \n "}, "hash": "a8aa387887bb3e26f6a65f61e30ce49b92d60c0b37fe266e90c2f5d233cda8e5", "class_name": "RelatedNodeInfo"}}, "text": "As I look toward the coming year, I recognize that the global and industry dynamics, resulting \nfrom the pandemic will continue to challenge areas of our business. ", "start_char_idx": 526, "end_char_idx": 690, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a48bd4a6-93d9-4b21-aa72-927cf414607f": {"__data__": {"id_": "a48bd4a6-93d9-4b21-aa72-927cf414607f", "embedding": null, "metadata": {"window": "We successfully transitioned our office employees to a remote work model, \nand we continuously maintained operations in all of our distribution facilities, nuclear pharmacies, and \nglobal manufacturing plants.  \n \n  Through all of this, we kept our primary focus:  delivering critical products and services to our \ncustomers , and at the same time prioritizing the safety of our employees.  \n \n  As I look toward the coming year, I recognize that the global and industry dynamics, resulting \nfrom the pandemic will continue to challenge areas of our business.  I am confident that our team will \ncontinue rising to these challenges as we drive our strategic priorities forward.  \n \n  I'll provide some comments later about how I see these priorities evolving in fiscal 21 and \nbeyond, but first I'll turn to Jason to discuss the fourth quarter , fiscal 20 and our outlook for fiscal 21.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.  \n \n  I am pleased to join you this morning on my first call since assuming the CFO role , and I look \nforward to engaging with you more in the future.  \n \n ", "original_text": "I am confident that our team will \ncontinue rising to these challenges as we drive our strategic priorities forward.  \n \n ", "page_label": "3", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7e7a17a-8d74-4fa1-8a13-fb462afeb8b4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76338d70c68efaf987a409ed1a68400bd11b2e185e98a8a853621837266ad980", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "790a4a87-6d47-4b66-a6a1-762e84c73d48", "node_type": "1", "metadata": {"window": " \nPage 3 of 31 \n \n We achieved these results as we adapted our operations to address the unique challenges \npresented by COVID -19.  We successfully transitioned our office employees to a remote work model, \nand we continuously maintained operations in all of our distribution facilities, nuclear pharmacies, and \nglobal manufacturing plants.  \n \n  Through all of this, we kept our primary focus:  delivering critical products and services to our \ncustomers , and at the same time prioritizing the safety of our employees.  \n \n  As I look toward the coming year, I recognize that the global and industry dynamics, resulting \nfrom the pandemic will continue to challenge areas of our business.  I am confident that our team will \ncontinue rising to these challenges as we drive our strategic priorities forward.  \n \n  I'll provide some comments later about how I see these priorities evolving in fiscal 21 and \nbeyond, but first I'll turn to Jason to discuss the fourth quarter , fiscal 20 and our outlook for fiscal 21.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.  \n \n ", "original_text": "As I look toward the coming year, I recognize that the global and industry dynamics, resulting \nfrom the pandemic will continue to challenge areas of our business. ", "page_label": "3", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f689c1ec35bf6d4139cc283e0480cff600c486c625d6720ff337a19af471a68e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6a4423f-a20d-48a9-87a2-78f0cab7f743", "node_type": "1", "metadata": {"window": "Through all of this, we kept our primary focus:  delivering critical products and services to our \ncustomers , and at the same time prioritizing the safety of our employees.  \n \n  As I look toward the coming year, I recognize that the global and industry dynamics, resulting \nfrom the pandemic will continue to challenge areas of our business.  I am confident that our team will \ncontinue rising to these challenges as we drive our strategic priorities forward.  \n \n  I'll provide some comments later about how I see these priorities evolving in fiscal 21 and \nbeyond, but first I'll turn to Jason to discuss the fourth quarter , fiscal 20 and our outlook for fiscal 21.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.  \n \n  I am pleased to join you this morning on my first call since assuming the CFO role , and I look \nforward to engaging with you more in the future.  \n \n  I will p rovide a few comments on the fourth quarter and detail our results for the year before \nturning our fiscal 21 guidance and key assumptions.  \n ", "original_text": "I'll provide some comments later about how I see these priorities evolving in fiscal 21 and \nbeyond, but first I'll turn to Jason to discuss the fourth quarter , fiscal 20 and our outlook for fiscal 21.  \n \n"}, "hash": "939581d8430fab0326f164748e2e0ddfa30894f99c2b43302c441e3a5abacb45", "class_name": "RelatedNodeInfo"}}, "text": "I am confident that our team will \ncontinue rising to these challenges as we drive our strategic priorities forward.  \n \n ", "start_char_idx": 690, "end_char_idx": 812, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6a4423f-a20d-48a9-87a2-78f0cab7f743": {"__data__": {"id_": "b6a4423f-a20d-48a9-87a2-78f0cab7f743", "embedding": null, "metadata": {"window": "Through all of this, we kept our primary focus:  delivering critical products and services to our \ncustomers , and at the same time prioritizing the safety of our employees.  \n \n  As I look toward the coming year, I recognize that the global and industry dynamics, resulting \nfrom the pandemic will continue to challenge areas of our business.  I am confident that our team will \ncontinue rising to these challenges as we drive our strategic priorities forward.  \n \n  I'll provide some comments later about how I see these priorities evolving in fiscal 21 and \nbeyond, but first I'll turn to Jason to discuss the fourth quarter , fiscal 20 and our outlook for fiscal 21.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.  \n \n  I am pleased to join you this morning on my first call since assuming the CFO role , and I look \nforward to engaging with you more in the future.  \n \n  I will p rovide a few comments on the fourth quarter and detail our results for the year before \nturning our fiscal 21 guidance and key assumptions.  \n ", "original_text": "I'll provide some comments later about how I see these priorities evolving in fiscal 21 and \nbeyond, but first I'll turn to Jason to discuss the fourth quarter , fiscal 20 and our outlook for fiscal 21.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7e7a17a-8d74-4fa1-8a13-fb462afeb8b4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76338d70c68efaf987a409ed1a68400bd11b2e185e98a8a853621837266ad980", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a48bd4a6-93d9-4b21-aa72-927cf414607f", "node_type": "1", "metadata": {"window": "We successfully transitioned our office employees to a remote work model, \nand we continuously maintained operations in all of our distribution facilities, nuclear pharmacies, and \nglobal manufacturing plants.  \n \n  Through all of this, we kept our primary focus:  delivering critical products and services to our \ncustomers , and at the same time prioritizing the safety of our employees.  \n \n  As I look toward the coming year, I recognize that the global and industry dynamics, resulting \nfrom the pandemic will continue to challenge areas of our business.  I am confident that our team will \ncontinue rising to these challenges as we drive our strategic priorities forward.  \n \n  I'll provide some comments later about how I see these priorities evolving in fiscal 21 and \nbeyond, but first I'll turn to Jason to discuss the fourth quarter , fiscal 20 and our outlook for fiscal 21.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.  \n \n  I am pleased to join you this morning on my first call since assuming the CFO role , and I look \nforward to engaging with you more in the future.  \n \n ", "original_text": "I am confident that our team will \ncontinue rising to these challenges as we drive our strategic priorities forward.  \n \n ", "page_label": "3", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34e503c0d57e38f3e19f697de6fe148727039822818226d12f0cfe6d96d5317c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29423008-e546-423b-ab49-b37d78004ebe", "node_type": "1", "metadata": {"window": "As I look toward the coming year, I recognize that the global and industry dynamics, resulting \nfrom the pandemic will continue to challenge areas of our business.  I am confident that our team will \ncontinue rising to these challenges as we drive our strategic priorities forward.  \n \n  I'll provide some comments later about how I see these priorities evolving in fiscal 21 and \nbeyond, but first I'll turn to Jason to discuss the fourth quarter , fiscal 20 and our outlook for fiscal 21.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.  \n \n  I am pleased to join you this morning on my first call since assuming the CFO role , and I look \nforward to engaging with you more in the future.  \n \n  I will p rovide a few comments on the fourth quarter and detail our results for the year before \nturning our fiscal 21 guidance and key assumptions.  \n ", "original_text": "Jason Hollar:  Thanks, Mike, and good morning everyone.  \n \n "}, "hash": "12c950ec31987d211bd43e39325f3355b6b9d0980f8b5ed9b78f46fc33450c72", "class_name": "RelatedNodeInfo"}}, "text": "I'll provide some comments later about how I see these priorities evolving in fiscal 21 and \nbeyond, but first I'll turn to Jason to discuss the fourth quarter , fiscal 20 and our outlook for fiscal 21.  \n \n", "start_char_idx": 812, "end_char_idx": 1019, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29423008-e546-423b-ab49-b37d78004ebe": {"__data__": {"id_": "29423008-e546-423b-ab49-b37d78004ebe", "embedding": null, "metadata": {"window": "As I look toward the coming year, I recognize that the global and industry dynamics, resulting \nfrom the pandemic will continue to challenge areas of our business.  I am confident that our team will \ncontinue rising to these challenges as we drive our strategic priorities forward.  \n \n  I'll provide some comments later about how I see these priorities evolving in fiscal 21 and \nbeyond, but first I'll turn to Jason to discuss the fourth quarter , fiscal 20 and our outlook for fiscal 21.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.  \n \n  I am pleased to join you this morning on my first call since assuming the CFO role , and I look \nforward to engaging with you more in the future.  \n \n  I will p rovide a few comments on the fourth quarter and detail our results for the year before \nturning our fiscal 21 guidance and key assumptions.  \n ", "original_text": "Jason Hollar:  Thanks, Mike, and good morning everyone.  \n \n ", "page_label": "3", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7e7a17a-8d74-4fa1-8a13-fb462afeb8b4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76338d70c68efaf987a409ed1a68400bd11b2e185e98a8a853621837266ad980", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6a4423f-a20d-48a9-87a2-78f0cab7f743", "node_type": "1", "metadata": {"window": "Through all of this, we kept our primary focus:  delivering critical products and services to our \ncustomers , and at the same time prioritizing the safety of our employees.  \n \n  As I look toward the coming year, I recognize that the global and industry dynamics, resulting \nfrom the pandemic will continue to challenge areas of our business.  I am confident that our team will \ncontinue rising to these challenges as we drive our strategic priorities forward.  \n \n  I'll provide some comments later about how I see these priorities evolving in fiscal 21 and \nbeyond, but first I'll turn to Jason to discuss the fourth quarter , fiscal 20 and our outlook for fiscal 21.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.  \n \n  I am pleased to join you this morning on my first call since assuming the CFO role , and I look \nforward to engaging with you more in the future.  \n \n  I will p rovide a few comments on the fourth quarter and detail our results for the year before \nturning our fiscal 21 guidance and key assumptions.  \n ", "original_text": "I'll provide some comments later about how I see these priorities evolving in fiscal 21 and \nbeyond, but first I'll turn to Jason to discuss the fourth quarter , fiscal 20 and our outlook for fiscal 21.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "128c61c30042365d3d39a8dac3160c2cefc289748eb89b0cd87c89d25607b60b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b69e81f1-7fb4-48ea-bef5-5fc4a8792aba", "node_type": "1", "metadata": {"window": "I am confident that our team will \ncontinue rising to these challenges as we drive our strategic priorities forward.  \n \n  I'll provide some comments later about how I see these priorities evolving in fiscal 21 and \nbeyond, but first I'll turn to Jason to discuss the fourth quarter , fiscal 20 and our outlook for fiscal 21.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.  \n \n  I am pleased to join you this morning on my first call since assuming the CFO role , and I look \nforward to engaging with you more in the future.  \n \n  I will p rovide a few comments on the fourth quarter and detail our results for the year before \nturning our fiscal 21 guidance and key assumptions.  \n ", "original_text": "I am pleased to join you this morning on my first call since assuming the CFO role , and I look \nforward to engaging with you more in the future.  \n \n "}, "hash": "dae9b0ac996307d12a6428d433e9f2918bb5b3668475dc36b987832c6c69b56b", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Thanks, Mike, and good morning everyone.  \n \n ", "start_char_idx": 1019, "end_char_idx": 1080, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b69e81f1-7fb4-48ea-bef5-5fc4a8792aba": {"__data__": {"id_": "b69e81f1-7fb4-48ea-bef5-5fc4a8792aba", "embedding": null, "metadata": {"window": "I am confident that our team will \ncontinue rising to these challenges as we drive our strategic priorities forward.  \n \n  I'll provide some comments later about how I see these priorities evolving in fiscal 21 and \nbeyond, but first I'll turn to Jason to discuss the fourth quarter , fiscal 20 and our outlook for fiscal 21.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.  \n \n  I am pleased to join you this morning on my first call since assuming the CFO role , and I look \nforward to engaging with you more in the future.  \n \n  I will p rovide a few comments on the fourth quarter and detail our results for the year before \nturning our fiscal 21 guidance and key assumptions.  \n ", "original_text": "I am pleased to join you this morning on my first call since assuming the CFO role , and I look \nforward to engaging with you more in the future.  \n \n ", "page_label": "3", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7e7a17a-8d74-4fa1-8a13-fb462afeb8b4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76338d70c68efaf987a409ed1a68400bd11b2e185e98a8a853621837266ad980", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29423008-e546-423b-ab49-b37d78004ebe", "node_type": "1", "metadata": {"window": "As I look toward the coming year, I recognize that the global and industry dynamics, resulting \nfrom the pandemic will continue to challenge areas of our business.  I am confident that our team will \ncontinue rising to these challenges as we drive our strategic priorities forward.  \n \n  I'll provide some comments later about how I see these priorities evolving in fiscal 21 and \nbeyond, but first I'll turn to Jason to discuss the fourth quarter , fiscal 20 and our outlook for fiscal 21.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.  \n \n  I am pleased to join you this morning on my first call since assuming the CFO role , and I look \nforward to engaging with you more in the future.  \n \n  I will p rovide a few comments on the fourth quarter and detail our results for the year before \nturning our fiscal 21 guidance and key assumptions.  \n ", "original_text": "Jason Hollar:  Thanks, Mike, and good morning everyone.  \n \n ", "page_label": "3", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bd02d628490a3728675a322b11b67aaccdb74bcfe4d63d9854f2e720a435f2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97031aea-85e3-4c3d-aa67-b8f32103148e", "node_type": "1", "metadata": {"window": "I'll provide some comments later about how I see these priorities evolving in fiscal 21 and \nbeyond, but first I'll turn to Jason to discuss the fourth quarter , fiscal 20 and our outlook for fiscal 21.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.  \n \n  I am pleased to join you this morning on my first call since assuming the CFO role , and I look \nforward to engaging with you more in the future.  \n \n  I will p rovide a few comments on the fourth quarter and detail our results for the year before \nturning our fiscal 21 guidance and key assumptions.  \n ", "original_text": "I will p rovide a few comments on the fourth quarter and detail our results for the year before \nturning our fiscal 21 guidance and key assumptions.  \n "}, "hash": "063e38eff0ad9f7a2b84b146e25218d441c7baf05d94b14ff7d7b2a546bea3ff", "class_name": "RelatedNodeInfo"}}, "text": "I am pleased to join you this morning on my first call since assuming the CFO role , and I look \nforward to engaging with you more in the future.  \n \n ", "start_char_idx": 1080, "end_char_idx": 1231, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97031aea-85e3-4c3d-aa67-b8f32103148e": {"__data__": {"id_": "97031aea-85e3-4c3d-aa67-b8f32103148e", "embedding": null, "metadata": {"window": "I'll provide some comments later about how I see these priorities evolving in fiscal 21 and \nbeyond, but first I'll turn to Jason to discuss the fourth quarter , fiscal 20 and our outlook for fiscal 21.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.  \n \n  I am pleased to join you this morning on my first call since assuming the CFO role , and I look \nforward to engaging with you more in the future.  \n \n  I will p rovide a few comments on the fourth quarter and detail our results for the year before \nturning our fiscal 21 guidance and key assumptions.  \n ", "original_text": "I will p rovide a few comments on the fourth quarter and detail our results for the year before \nturning our fiscal 21 guidance and key assumptions.  \n ", "page_label": "3", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7e7a17a-8d74-4fa1-8a13-fb462afeb8b4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76338d70c68efaf987a409ed1a68400bd11b2e185e98a8a853621837266ad980", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b69e81f1-7fb4-48ea-bef5-5fc4a8792aba", "node_type": "1", "metadata": {"window": "I am confident that our team will \ncontinue rising to these challenges as we drive our strategic priorities forward.  \n \n  I'll provide some comments later about how I see these priorities evolving in fiscal 21 and \nbeyond, but first I'll turn to Jason to discuss the fourth quarter , fiscal 20 and our outlook for fiscal 21.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.  \n \n  I am pleased to join you this morning on my first call since assuming the CFO role , and I look \nforward to engaging with you more in the future.  \n \n  I will p rovide a few comments on the fourth quarter and detail our results for the year before \nturning our fiscal 21 guidance and key assumptions.  \n ", "original_text": "I am pleased to join you this morning on my first call since assuming the CFO role , and I look \nforward to engaging with you more in the future.  \n \n ", "page_label": "3", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ade64349fad204de49df4f567e7d0bd7c7055bad1611acbb60d2ce57fe61583a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f516ff6-f510-417f-ad2c-b932ec840fc1", "node_type": "1", "metadata": {"window": " \nPage 4 of 31 \n \n Starting with the quarter, we delivered better than expected EPS of $1.04, driven by improved \noperating performance , as well as lower interest and other expense.  \n \n  Turning to the segments.  Beginning with pharma on slide six , revenue was flat for the quarter. \n As expected, in Q4 we saw reduced pharmaceutical demand as a result of the accelerated Q3 sales \nrelated to COVID -19. ", "original_text": " \nPage 4 of 31 \n \n Starting with the quarter, we delivered better than expected EPS of $1.04, driven by improved \noperating performance , as well as lower interest and other expense.  \n \n "}, "hash": "0e0249ec241c91106a65bd3d166be36eb82a69f3c5656e5a1896565db6ace908", "class_name": "RelatedNodeInfo"}}, "text": "I will p rovide a few comments on the fourth quarter and detail our results for the year before \nturning our fiscal 21 guidance and key assumptions.  \n ", "start_char_idx": 1231, "end_char_idx": 1383, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f516ff6-f510-417f-ad2c-b932ec840fc1": {"__data__": {"id_": "5f516ff6-f510-417f-ad2c-b932ec840fc1", "embedding": null, "metadata": {"window": " \nPage 4 of 31 \n \n Starting with the quarter, we delivered better than expected EPS of $1.04, driven by improved \noperating performance , as well as lower interest and other expense.  \n \n  Turning to the segments.  Beginning with pharma on slide six , revenue was flat for the quarter. \n As expected, in Q4 we saw reduced pharmaceutical demand as a result of the accelerated Q3 sales \nrelated to COVID -19. ", "original_text": " \nPage 4 of 31 \n \n Starting with the quarter, we delivered better than expected EPS of $1.04, driven by improved \noperating performance , as well as lower interest and other expense.  \n \n ", "page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3fe6ce10-fe5e-4d94-b32d-9477a82f8e03", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f643f84dd478cae40b2fb0afb5cf656fa34d0cc03296eeb268b9d0e2fa53145", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97031aea-85e3-4c3d-aa67-b8f32103148e", "node_type": "1", "metadata": {"window": "I'll provide some comments later about how I see these priorities evolving in fiscal 21 and \nbeyond, but first I'll turn to Jason to discuss the fourth quarter , fiscal 20 and our outlook for fiscal 21.  \n \n Jason Hollar:  Thanks, Mike, and good morning everyone.  \n \n  I am pleased to join you this morning on my first call since assuming the CFO role , and I look \nforward to engaging with you more in the future.  \n \n  I will p rovide a few comments on the fourth quarter and detail our results for the year before \nturning our fiscal 21 guidance and key assumptions.  \n ", "original_text": "I will p rovide a few comments on the fourth quarter and detail our results for the year before \nturning our fiscal 21 guidance and key assumptions.  \n ", "page_label": "3", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4aac1b5cfa312dc39c743f48437e0072675048364960773e14879f250d5d74c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad581678-9160-419d-8f23-1f035ff78104", "node_type": "1", "metadata": {"window": " \nPage 4 of 31 \n \n Starting with the quarter, we delivered better than expected EPS of $1.04, driven by improved \noperating performance , as well as lower interest and other expense.  \n \n  Turning to the segments.  Beginning with pharma on slide six , revenue was flat for the quarter. \n As expected, in Q4 we saw reduced pharmaceutical demand as a result of the accelerated Q3 sales \nrelated to COVID -19.  Pharma segment profit decreased 20% to $359 million.  \n \n ", "original_text": "Turning to the segments. "}, "hash": "34696caaeb493f4dda0572af9a65d9ae4a02e9f187d9d72f64f634d3b064a15a", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 4 of 31 \n \n Starting with the quarter, we delivered better than expected EPS of $1.04, driven by improved \noperating performance , as well as lower interest and other expense.  \n \n ", "start_char_idx": 0, "end_char_idx": 188, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad581678-9160-419d-8f23-1f035ff78104": {"__data__": {"id_": "ad581678-9160-419d-8f23-1f035ff78104", "embedding": null, "metadata": {"window": " \nPage 4 of 31 \n \n Starting with the quarter, we delivered better than expected EPS of $1.04, driven by improved \noperating performance , as well as lower interest and other expense.  \n \n  Turning to the segments.  Beginning with pharma on slide six , revenue was flat for the quarter. \n As expected, in Q4 we saw reduced pharmaceutical demand as a result of the accelerated Q3 sales \nrelated to COVID -19.  Pharma segment profit decreased 20% to $359 million.  \n \n ", "original_text": "Turning to the segments. ", "page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3fe6ce10-fe5e-4d94-b32d-9477a82f8e03", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f643f84dd478cae40b2fb0afb5cf656fa34d0cc03296eeb268b9d0e2fa53145", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f516ff6-f510-417f-ad2c-b932ec840fc1", "node_type": "1", "metadata": {"window": " \nPage 4 of 31 \n \n Starting with the quarter, we delivered better than expected EPS of $1.04, driven by improved \noperating performance , as well as lower interest and other expense.  \n \n  Turning to the segments.  Beginning with pharma on slide six , revenue was flat for the quarter. \n As expected, in Q4 we saw reduced pharmaceutical demand as a result of the accelerated Q3 sales \nrelated to COVID -19. ", "original_text": " \nPage 4 of 31 \n \n Starting with the quarter, we delivered better than expected EPS of $1.04, driven by improved \noperating performance , as well as lower interest and other expense.  \n \n ", "page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4b9ae6d24f8b0899036387960961028ee5bcfc06e447bd81d1521e2c1107ae07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4bfe0848-d577-4158-9c5b-c59058f75165", "node_type": "1", "metadata": {"window": " \nPage 4 of 31 \n \n Starting with the quarter, we delivered better than expected EPS of $1.04, driven by improved \noperating performance , as well as lower interest and other expense.  \n \n  Turning to the segments.  Beginning with pharma on slide six , revenue was flat for the quarter. \n As expected, in Q4 we saw reduced pharmaceutical demand as a result of the accelerated Q3 sales \nrelated to COVID -19.  Pharma segment profit decreased 20% to $359 million.  \n \n  As anticipated, challenges related to the pandemic caused volume declines in several areas, \nparticularly in our nuclear business and our generics program.  \n \n ", "original_text": "Beginning with pharma on slide six , revenue was flat for the quarter. \n"}, "hash": "9594270152d35f28f7c22616964821137707759058fac961ade689f49e1d938b", "class_name": "RelatedNodeInfo"}}, "text": "Turning to the segments. ", "start_char_idx": 188, "end_char_idx": 213, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4bfe0848-d577-4158-9c5b-c59058f75165": {"__data__": {"id_": "4bfe0848-d577-4158-9c5b-c59058f75165", "embedding": null, "metadata": {"window": " \nPage 4 of 31 \n \n Starting with the quarter, we delivered better than expected EPS of $1.04, driven by improved \noperating performance , as well as lower interest and other expense.  \n \n  Turning to the segments.  Beginning with pharma on slide six , revenue was flat for the quarter. \n As expected, in Q4 we saw reduced pharmaceutical demand as a result of the accelerated Q3 sales \nrelated to COVID -19.  Pharma segment profit decreased 20% to $359 million.  \n \n  As anticipated, challenges related to the pandemic caused volume declines in several areas, \nparticularly in our nuclear business and our generics program.  \n \n ", "original_text": "Beginning with pharma on slide six , revenue was flat for the quarter. \n", "page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3fe6ce10-fe5e-4d94-b32d-9477a82f8e03", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f643f84dd478cae40b2fb0afb5cf656fa34d0cc03296eeb268b9d0e2fa53145", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad581678-9160-419d-8f23-1f035ff78104", "node_type": "1", "metadata": {"window": " \nPage 4 of 31 \n \n Starting with the quarter, we delivered better than expected EPS of $1.04, driven by improved \noperating performance , as well as lower interest and other expense.  \n \n  Turning to the segments.  Beginning with pharma on slide six , revenue was flat for the quarter. \n As expected, in Q4 we saw reduced pharmaceutical demand as a result of the accelerated Q3 sales \nrelated to COVID -19.  Pharma segment profit decreased 20% to $359 million.  \n \n ", "original_text": "Turning to the segments. ", "page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c06f3c260033baa4e4c306b56e3c1b3b536ff7faebd6851008191a1c3c393cad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df84a6d8-e359-4e82-8784-5b863ac6691d", "node_type": "1", "metadata": {"window": " \nPage 4 of 31 \n \n Starting with the quarter, we delivered better than expected EPS of $1.04, driven by improved \noperating performance , as well as lower interest and other expense.  \n \n  Turning to the segments.  Beginning with pharma on slide six , revenue was flat for the quarter. \n As expected, in Q4 we saw reduced pharmaceutical demand as a result of the accelerated Q3 sales \nrelated to COVID -19.  Pharma segment profit decreased 20% to $359 million.  \n \n  As anticipated, challenges related to the pandemic caused volume declines in several areas, \nparticularly in our nuclear business and our generics program.  \n \n  Similar to prior quarters, segment  profit also reflected a headwind from Pharmaceutical \nDistribution customer contract renewals.  \n \n ", "original_text": "As expected, in Q4 we saw reduced pharmaceutical demand as a result of the accelerated Q3 sales \nrelated to COVID -19. "}, "hash": "a617363b19be491339cd9116277602fb12e5546a26f858d78dd12eb6a077db55", "class_name": "RelatedNodeInfo"}}, "text": "Beginning with pharma on slide six , revenue was flat for the quarter. \n", "start_char_idx": 213, "end_char_idx": 285, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df84a6d8-e359-4e82-8784-5b863ac6691d": {"__data__": {"id_": "df84a6d8-e359-4e82-8784-5b863ac6691d", "embedding": null, "metadata": {"window": " \nPage 4 of 31 \n \n Starting with the quarter, we delivered better than expected EPS of $1.04, driven by improved \noperating performance , as well as lower interest and other expense.  \n \n  Turning to the segments.  Beginning with pharma on slide six , revenue was flat for the quarter. \n As expected, in Q4 we saw reduced pharmaceutical demand as a result of the accelerated Q3 sales \nrelated to COVID -19.  Pharma segment profit decreased 20% to $359 million.  \n \n  As anticipated, challenges related to the pandemic caused volume declines in several areas, \nparticularly in our nuclear business and our generics program.  \n \n  Similar to prior quarters, segment  profit also reflected a headwind from Pharmaceutical \nDistribution customer contract renewals.  \n \n ", "original_text": "As expected, in Q4 we saw reduced pharmaceutical demand as a result of the accelerated Q3 sales \nrelated to COVID -19. ", "page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3fe6ce10-fe5e-4d94-b32d-9477a82f8e03", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f643f84dd478cae40b2fb0afb5cf656fa34d0cc03296eeb268b9d0e2fa53145", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4bfe0848-d577-4158-9c5b-c59058f75165", "node_type": "1", "metadata": {"window": " \nPage 4 of 31 \n \n Starting with the quarter, we delivered better than expected EPS of $1.04, driven by improved \noperating performance , as well as lower interest and other expense.  \n \n  Turning to the segments.  Beginning with pharma on slide six , revenue was flat for the quarter. \n As expected, in Q4 we saw reduced pharmaceutical demand as a result of the accelerated Q3 sales \nrelated to COVID -19.  Pharma segment profit decreased 20% to $359 million.  \n \n  As anticipated, challenges related to the pandemic caused volume declines in several areas, \nparticularly in our nuclear business and our generics program.  \n \n ", "original_text": "Beginning with pharma on slide six , revenue was flat for the quarter. \n", "page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "37fdf68f0a153a7aac6c9bd42c891a22ccc4b454672c3608c690c2b30ed9187b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3938704-1db9-4495-9aec-0102dc1ee48c", "node_type": "1", "metadata": {"window": "Turning to the segments.  Beginning with pharma on slide six , revenue was flat for the quarter. \n As expected, in Q4 we saw reduced pharmaceutical demand as a result of the accelerated Q3 sales \nrelated to COVID -19.  Pharma segment profit decreased 20% to $359 million.  \n \n  As anticipated, challenges related to the pandemic caused volume declines in several areas, \nparticularly in our nuclear business and our generics program.  \n \n  Similar to prior quarters, segment  profit also reflected a headwind from Pharmaceutical \nDistribution customer contract renewals.  \n \n  In Medical, Q4 revenue decreased 13% due to the adverse impact of COVID -19 related \ncancellation and deferral of elective procedures. ", "original_text": "Pharma segment profit decreased 20% to $359 million.  \n \n "}, "hash": "65ef571fb98d9f5c8c32dcf793714e0ad78d7b4bd7c2bf29918af51c3e309834", "class_name": "RelatedNodeInfo"}}, "text": "As expected, in Q4 we saw reduced pharmaceutical demand as a result of the accelerated Q3 sales \nrelated to COVID -19. ", "start_char_idx": 285, "end_char_idx": 404, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3938704-1db9-4495-9aec-0102dc1ee48c": {"__data__": {"id_": "a3938704-1db9-4495-9aec-0102dc1ee48c", "embedding": null, "metadata": {"window": "Turning to the segments.  Beginning with pharma on slide six , revenue was flat for the quarter. \n As expected, in Q4 we saw reduced pharmaceutical demand as a result of the accelerated Q3 sales \nrelated to COVID -19.  Pharma segment profit decreased 20% to $359 million.  \n \n  As anticipated, challenges related to the pandemic caused volume declines in several areas, \nparticularly in our nuclear business and our generics program.  \n \n  Similar to prior quarters, segment  profit also reflected a headwind from Pharmaceutical \nDistribution customer contract renewals.  \n \n  In Medical, Q4 revenue decreased 13% due to the adverse impact of COVID -19 related \ncancellation and deferral of elective procedures. ", "original_text": "Pharma segment profit decreased 20% to $359 million.  \n \n ", "page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3fe6ce10-fe5e-4d94-b32d-9477a82f8e03", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f643f84dd478cae40b2fb0afb5cf656fa34d0cc03296eeb268b9d0e2fa53145", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df84a6d8-e359-4e82-8784-5b863ac6691d", "node_type": "1", "metadata": {"window": " \nPage 4 of 31 \n \n Starting with the quarter, we delivered better than expected EPS of $1.04, driven by improved \noperating performance , as well as lower interest and other expense.  \n \n  Turning to the segments.  Beginning with pharma on slide six , revenue was flat for the quarter. \n As expected, in Q4 we saw reduced pharmaceutical demand as a result of the accelerated Q3 sales \nrelated to COVID -19.  Pharma segment profit decreased 20% to $359 million.  \n \n  As anticipated, challenges related to the pandemic caused volume declines in several areas, \nparticularly in our nuclear business and our generics program.  \n \n  Similar to prior quarters, segment  profit also reflected a headwind from Pharmaceutical \nDistribution customer contract renewals.  \n \n ", "original_text": "As expected, in Q4 we saw reduced pharmaceutical demand as a result of the accelerated Q3 sales \nrelated to COVID -19. ", "page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "de2f9aa8942ff4900519f2d0fc2359bf391e12d2f8ef8526b738e371787454c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4f308ff-4b77-47a0-b1b0-496510ff6554", "node_type": "1", "metadata": {"window": "Beginning with pharma on slide six , revenue was flat for the quarter. \n As expected, in Q4 we saw reduced pharmaceutical demand as a result of the accelerated Q3 sales \nrelated to COVID -19.  Pharma segment profit decreased 20% to $359 million.  \n \n  As anticipated, challenges related to the pandemic caused volume declines in several areas, \nparticularly in our nuclear business and our generics program.  \n \n  Similar to prior quarters, segment  profit also reflected a headwind from Pharmaceutical \nDistribution customer contract renewals.  \n \n  In Medical, Q4 revenue decreased 13% due to the adverse impact of COVID -19 related \ncancellation and deferral of elective procedures.  This impact is primarily w ithin products and \ndistribution.  \n \n ", "original_text": "As anticipated, challenges related to the pandemic caused volume declines in several areas, \nparticularly in our nuclear business and our generics program.  \n \n "}, "hash": "98a7657a2261f9c77a6b4b66eaa57108ce7771c2b523aa4c322dc2913be9b4f5", "class_name": "RelatedNodeInfo"}}, "text": "Pharma segment profit decreased 20% to $359 million.  \n \n ", "start_char_idx": 404, "end_char_idx": 462, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4f308ff-4b77-47a0-b1b0-496510ff6554": {"__data__": {"id_": "c4f308ff-4b77-47a0-b1b0-496510ff6554", "embedding": null, "metadata": {"window": "Beginning with pharma on slide six , revenue was flat for the quarter. \n As expected, in Q4 we saw reduced pharmaceutical demand as a result of the accelerated Q3 sales \nrelated to COVID -19.  Pharma segment profit decreased 20% to $359 million.  \n \n  As anticipated, challenges related to the pandemic caused volume declines in several areas, \nparticularly in our nuclear business and our generics program.  \n \n  Similar to prior quarters, segment  profit also reflected a headwind from Pharmaceutical \nDistribution customer contract renewals.  \n \n  In Medical, Q4 revenue decreased 13% due to the adverse impact of COVID -19 related \ncancellation and deferral of elective procedures.  This impact is primarily w ithin products and \ndistribution.  \n \n ", "original_text": "As anticipated, challenges related to the pandemic caused volume declines in several areas, \nparticularly in our nuclear business and our generics program.  \n \n ", "page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3fe6ce10-fe5e-4d94-b32d-9477a82f8e03", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f643f84dd478cae40b2fb0afb5cf656fa34d0cc03296eeb268b9d0e2fa53145", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3938704-1db9-4495-9aec-0102dc1ee48c", "node_type": "1", "metadata": {"window": "Turning to the segments.  Beginning with pharma on slide six , revenue was flat for the quarter. \n As expected, in Q4 we saw reduced pharmaceutical demand as a result of the accelerated Q3 sales \nrelated to COVID -19.  Pharma segment profit decreased 20% to $359 million.  \n \n  As anticipated, challenges related to the pandemic caused volume declines in several areas, \nparticularly in our nuclear business and our generics program.  \n \n  Similar to prior quarters, segment  profit also reflected a headwind from Pharmaceutical \nDistribution customer contract renewals.  \n \n  In Medical, Q4 revenue decreased 13% due to the adverse impact of COVID -19 related \ncancellation and deferral of elective procedures. ", "original_text": "Pharma segment profit decreased 20% to $359 million.  \n \n ", "page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc452babd9f7ba614a43b7d9402268bcde09fc481020a3b5e410e80f45092535", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "465ff21e-edb4-4dae-ac42-7d00c646c2a2", "node_type": "1", "metadata": {"window": "As expected, in Q4 we saw reduced pharmaceutical demand as a result of the accelerated Q3 sales \nrelated to COVID -19.  Pharma segment profit decreased 20% to $359 million.  \n \n  As anticipated, challenges related to the pandemic caused volume declines in several areas, \nparticularly in our nuclear business and our generics program.  \n \n  Similar to prior quarters, segment  profit also reflected a headwind from Pharmaceutical \nDistribution customer contract renewals.  \n \n  In Medical, Q4 revenue decreased 13% due to the adverse impact of COVID -19 related \ncancellation and deferral of elective procedures.  This impact is primarily w ithin products and \ndistribution.  \n \n  Medical segment profit increased 24% to $120 million in the quarter, driven by cost savings \ninitiatives and the beneficial comparison to a supplier -related charge in the prior year, partially offset \nby the adverse impact of COVID -19. \n \n ", "original_text": "Similar to prior quarters, segment  profit also reflected a headwind from Pharmaceutical \nDistribution customer contract renewals.  \n \n "}, "hash": "1808fe6a1abcf77ed09ea11b8788b03cf5964457a0a781a074beaf5a52b3bf69", "class_name": "RelatedNodeInfo"}}, "text": "As anticipated, challenges related to the pandemic caused volume declines in several areas, \nparticularly in our nuclear business and our generics program.  \n \n ", "start_char_idx": 462, "end_char_idx": 623, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "465ff21e-edb4-4dae-ac42-7d00c646c2a2": {"__data__": {"id_": "465ff21e-edb4-4dae-ac42-7d00c646c2a2", "embedding": null, "metadata": {"window": "As expected, in Q4 we saw reduced pharmaceutical demand as a result of the accelerated Q3 sales \nrelated to COVID -19.  Pharma segment profit decreased 20% to $359 million.  \n \n  As anticipated, challenges related to the pandemic caused volume declines in several areas, \nparticularly in our nuclear business and our generics program.  \n \n  Similar to prior quarters, segment  profit also reflected a headwind from Pharmaceutical \nDistribution customer contract renewals.  \n \n  In Medical, Q4 revenue decreased 13% due to the adverse impact of COVID -19 related \ncancellation and deferral of elective procedures.  This impact is primarily w ithin products and \ndistribution.  \n \n  Medical segment profit increased 24% to $120 million in the quarter, driven by cost savings \ninitiatives and the beneficial comparison to a supplier -related charge in the prior year, partially offset \nby the adverse impact of COVID -19. \n \n ", "original_text": "Similar to prior quarters, segment  profit also reflected a headwind from Pharmaceutical \nDistribution customer contract renewals.  \n \n ", "page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3fe6ce10-fe5e-4d94-b32d-9477a82f8e03", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f643f84dd478cae40b2fb0afb5cf656fa34d0cc03296eeb268b9d0e2fa53145", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4f308ff-4b77-47a0-b1b0-496510ff6554", "node_type": "1", "metadata": {"window": "Beginning with pharma on slide six , revenue was flat for the quarter. \n As expected, in Q4 we saw reduced pharmaceutical demand as a result of the accelerated Q3 sales \nrelated to COVID -19.  Pharma segment profit decreased 20% to $359 million.  \n \n  As anticipated, challenges related to the pandemic caused volume declines in several areas, \nparticularly in our nuclear business and our generics program.  \n \n  Similar to prior quarters, segment  profit also reflected a headwind from Pharmaceutical \nDistribution customer contract renewals.  \n \n  In Medical, Q4 revenue decreased 13% due to the adverse impact of COVID -19 related \ncancellation and deferral of elective procedures.  This impact is primarily w ithin products and \ndistribution.  \n \n ", "original_text": "As anticipated, challenges related to the pandemic caused volume declines in several areas, \nparticularly in our nuclear business and our generics program.  \n \n ", "page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1749885037ef4600a7557d7c5cce4eb05f8818360950bfd58dd488e624a518f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "239aac79-9dae-49ab-9c7b-1d530cc3076f", "node_type": "1", "metadata": {"window": "Pharma segment profit decreased 20% to $359 million.  \n \n  As anticipated, challenges related to the pandemic caused volume declines in several areas, \nparticularly in our nuclear business and our generics program.  \n \n  Similar to prior quarters, segment  profit also reflected a headwind from Pharmaceutical \nDistribution customer contract renewals.  \n \n  In Medical, Q4 revenue decreased 13% due to the adverse impact of COVID -19 related \ncancellation and deferral of elective procedures.  This impact is primarily w ithin products and \ndistribution.  \n \n  Medical segment profit increased 24% to $120 million in the quarter, driven by cost savings \ninitiatives and the beneficial comparison to a supplier -related charge in the prior year, partially offset \nby the adverse impact of COVID -19. \n \n  As expected, PPE volumes for the quarter were down sequential ly, but above pre -COVID -19 \nlevels. ", "original_text": "In Medical, Q4 revenue decreased 13% due to the adverse impact of COVID -19 related \ncancellation and deferral of elective procedures. "}, "hash": "e7699f8f06f90408f2ae9642ba24f889de89ab62a6953e31d1863503100267e6", "class_name": "RelatedNodeInfo"}}, "text": "Similar to prior quarters, segment  profit also reflected a headwind from Pharmaceutical \nDistribution customer contract renewals.  \n \n ", "start_char_idx": 623, "end_char_idx": 759, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "239aac79-9dae-49ab-9c7b-1d530cc3076f": {"__data__": {"id_": "239aac79-9dae-49ab-9c7b-1d530cc3076f", "embedding": null, "metadata": {"window": "Pharma segment profit decreased 20% to $359 million.  \n \n  As anticipated, challenges related to the pandemic caused volume declines in several areas, \nparticularly in our nuclear business and our generics program.  \n \n  Similar to prior quarters, segment  profit also reflected a headwind from Pharmaceutical \nDistribution customer contract renewals.  \n \n  In Medical, Q4 revenue decreased 13% due to the adverse impact of COVID -19 related \ncancellation and deferral of elective procedures.  This impact is primarily w ithin products and \ndistribution.  \n \n  Medical segment profit increased 24% to $120 million in the quarter, driven by cost savings \ninitiatives and the beneficial comparison to a supplier -related charge in the prior year, partially offset \nby the adverse impact of COVID -19. \n \n  As expected, PPE volumes for the quarter were down sequential ly, but above pre -COVID -19 \nlevels. ", "original_text": "In Medical, Q4 revenue decreased 13% due to the adverse impact of COVID -19 related \ncancellation and deferral of elective procedures. ", "page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3fe6ce10-fe5e-4d94-b32d-9477a82f8e03", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f643f84dd478cae40b2fb0afb5cf656fa34d0cc03296eeb268b9d0e2fa53145", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "465ff21e-edb4-4dae-ac42-7d00c646c2a2", "node_type": "1", "metadata": {"window": "As expected, in Q4 we saw reduced pharmaceutical demand as a result of the accelerated Q3 sales \nrelated to COVID -19.  Pharma segment profit decreased 20% to $359 million.  \n \n  As anticipated, challenges related to the pandemic caused volume declines in several areas, \nparticularly in our nuclear business and our generics program.  \n \n  Similar to prior quarters, segment  profit also reflected a headwind from Pharmaceutical \nDistribution customer contract renewals.  \n \n  In Medical, Q4 revenue decreased 13% due to the adverse impact of COVID -19 related \ncancellation and deferral of elective procedures.  This impact is primarily w ithin products and \ndistribution.  \n \n  Medical segment profit increased 24% to $120 million in the quarter, driven by cost savings \ninitiatives and the beneficial comparison to a supplier -related charge in the prior year, partially offset \nby the adverse impact of COVID -19. \n \n ", "original_text": "Similar to prior quarters, segment  profit also reflected a headwind from Pharmaceutical \nDistribution customer contract renewals.  \n \n ", "page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "39bc76de312e4137fb55d52a5a77f260eec22c7fe3d5ef90bf1b0d57c1c6f097", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "098d02ee-7b4f-40ae-8653-445a4730fc14", "node_type": "1", "metadata": {"window": "As anticipated, challenges related to the pandemic caused volume declines in several areas, \nparticularly in our nuclear business and our generics program.  \n \n  Similar to prior quarters, segment  profit also reflected a headwind from Pharmaceutical \nDistribution customer contract renewals.  \n \n  In Medical, Q4 revenue decreased 13% due to the adverse impact of COVID -19 related \ncancellation and deferral of elective procedures.  This impact is primarily w ithin products and \ndistribution.  \n \n  Medical segment profit increased 24% to $120 million in the quarter, driven by cost savings \ninitiatives and the beneficial comparison to a supplier -related charge in the prior year, partially offset \nby the adverse impact of COVID -19. \n \n  As expected, PPE volumes for the quarter were down sequential ly, but above pre -COVID -19 \nlevels.  This reflects the demand -driven sellout of safety stock in the third quarter , as well as sustained \nincreases in demand and associated global supp ly challenges, which we will discuss later in our \nremarks.  ", "original_text": "This impact is primarily w ithin products and \ndistribution.  \n \n "}, "hash": "132c43edadd03ea355fc33ec85bb25f0ac848cdb856632eedc7b5701f15df58f", "class_name": "RelatedNodeInfo"}}, "text": "In Medical, Q4 revenue decreased 13% due to the adverse impact of COVID -19 related \ncancellation and deferral of elective procedures. ", "start_char_idx": 759, "end_char_idx": 894, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "098d02ee-7b4f-40ae-8653-445a4730fc14": {"__data__": {"id_": "098d02ee-7b4f-40ae-8653-445a4730fc14", "embedding": null, "metadata": {"window": "As anticipated, challenges related to the pandemic caused volume declines in several areas, \nparticularly in our nuclear business and our generics program.  \n \n  Similar to prior quarters, segment  profit also reflected a headwind from Pharmaceutical \nDistribution customer contract renewals.  \n \n  In Medical, Q4 revenue decreased 13% due to the adverse impact of COVID -19 related \ncancellation and deferral of elective procedures.  This impact is primarily w ithin products and \ndistribution.  \n \n  Medical segment profit increased 24% to $120 million in the quarter, driven by cost savings \ninitiatives and the beneficial comparison to a supplier -related charge in the prior year, partially offset \nby the adverse impact of COVID -19. \n \n  As expected, PPE volumes for the quarter were down sequential ly, but above pre -COVID -19 \nlevels.  This reflects the demand -driven sellout of safety stock in the third quarter , as well as sustained \nincreases in demand and associated global supp ly challenges, which we will discuss later in our \nremarks.  ", "original_text": "This impact is primarily w ithin products and \ndistribution.  \n \n ", "page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3fe6ce10-fe5e-4d94-b32d-9477a82f8e03", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f643f84dd478cae40b2fb0afb5cf656fa34d0cc03296eeb268b9d0e2fa53145", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "239aac79-9dae-49ab-9c7b-1d530cc3076f", "node_type": "1", "metadata": {"window": "Pharma segment profit decreased 20% to $359 million.  \n \n  As anticipated, challenges related to the pandemic caused volume declines in several areas, \nparticularly in our nuclear business and our generics program.  \n \n  Similar to prior quarters, segment  profit also reflected a headwind from Pharmaceutical \nDistribution customer contract renewals.  \n \n  In Medical, Q4 revenue decreased 13% due to the adverse impact of COVID -19 related \ncancellation and deferral of elective procedures.  This impact is primarily w ithin products and \ndistribution.  \n \n  Medical segment profit increased 24% to $120 million in the quarter, driven by cost savings \ninitiatives and the beneficial comparison to a supplier -related charge in the prior year, partially offset \nby the adverse impact of COVID -19. \n \n  As expected, PPE volumes for the quarter were down sequential ly, but above pre -COVID -19 \nlevels. ", "original_text": "In Medical, Q4 revenue decreased 13% due to the adverse impact of COVID -19 related \ncancellation and deferral of elective procedures. ", "page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3432c67ae2487082fdd41684cd95e9650f970c59c5d4558b86fc26942a7e600d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3437bc37-3389-463e-8e3d-eb6c0a1a5958", "node_type": "1", "metadata": {"window": "Similar to prior quarters, segment  profit also reflected a headwind from Pharmaceutical \nDistribution customer contract renewals.  \n \n  In Medical, Q4 revenue decreased 13% due to the adverse impact of COVID -19 related \ncancellation and deferral of elective procedures.  This impact is primarily w ithin products and \ndistribution.  \n \n  Medical segment profit increased 24% to $120 million in the quarter, driven by cost savings \ninitiatives and the beneficial comparison to a supplier -related charge in the prior year, partially offset \nby the adverse impact of COVID -19. \n \n  As expected, PPE volumes for the quarter were down sequential ly, but above pre -COVID -19 \nlevels.  This reflects the demand -driven sellout of safety stock in the third quarter , as well as sustained \nincreases in demand and associated global supp ly challenges, which we will discuss later in our \nremarks.  ", "original_text": "Medical segment profit increased 24% to $120 million in the quarter, driven by cost savings \ninitiatives and the beneficial comparison to a supplier -related charge in the prior year, partially offset \nby the adverse impact of COVID -19. \n \n "}, "hash": "d469ea928ba07ebecfb13466cc16ecf18a49d881507cfb3d8623d1678397b5be", "class_name": "RelatedNodeInfo"}}, "text": "This impact is primarily w ithin products and \ndistribution.  \n \n ", "start_char_idx": 894, "end_char_idx": 960, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3437bc37-3389-463e-8e3d-eb6c0a1a5958": {"__data__": {"id_": "3437bc37-3389-463e-8e3d-eb6c0a1a5958", "embedding": null, "metadata": {"window": "Similar to prior quarters, segment  profit also reflected a headwind from Pharmaceutical \nDistribution customer contract renewals.  \n \n  In Medical, Q4 revenue decreased 13% due to the adverse impact of COVID -19 related \ncancellation and deferral of elective procedures.  This impact is primarily w ithin products and \ndistribution.  \n \n  Medical segment profit increased 24% to $120 million in the quarter, driven by cost savings \ninitiatives and the beneficial comparison to a supplier -related charge in the prior year, partially offset \nby the adverse impact of COVID -19. \n \n  As expected, PPE volumes for the quarter were down sequential ly, but above pre -COVID -19 \nlevels.  This reflects the demand -driven sellout of safety stock in the third quarter , as well as sustained \nincreases in demand and associated global supp ly challenges, which we will discuss later in our \nremarks.  ", "original_text": "Medical segment profit increased 24% to $120 million in the quarter, driven by cost savings \ninitiatives and the beneficial comparison to a supplier -related charge in the prior year, partially offset \nby the adverse impact of COVID -19. \n \n ", "page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3fe6ce10-fe5e-4d94-b32d-9477a82f8e03", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f643f84dd478cae40b2fb0afb5cf656fa34d0cc03296eeb268b9d0e2fa53145", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "098d02ee-7b4f-40ae-8653-445a4730fc14", "node_type": "1", "metadata": {"window": "As anticipated, challenges related to the pandemic caused volume declines in several areas, \nparticularly in our nuclear business and our generics program.  \n \n  Similar to prior quarters, segment  profit also reflected a headwind from Pharmaceutical \nDistribution customer contract renewals.  \n \n  In Medical, Q4 revenue decreased 13% due to the adverse impact of COVID -19 related \ncancellation and deferral of elective procedures.  This impact is primarily w ithin products and \ndistribution.  \n \n  Medical segment profit increased 24% to $120 million in the quarter, driven by cost savings \ninitiatives and the beneficial comparison to a supplier -related charge in the prior year, partially offset \nby the adverse impact of COVID -19. \n \n  As expected, PPE volumes for the quarter were down sequential ly, but above pre -COVID -19 \nlevels.  This reflects the demand -driven sellout of safety stock in the third quarter , as well as sustained \nincreases in demand and associated global supp ly challenges, which we will discuss later in our \nremarks.  ", "original_text": "This impact is primarily w ithin products and \ndistribution.  \n \n ", "page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b9f1b62cfc87b330ed277525c27d321d7ddae45a90dab0b5262f664db26795f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e44d6bb0-370e-4e7f-8c62-20f794ad80ad", "node_type": "1", "metadata": {"window": "In Medical, Q4 revenue decreased 13% due to the adverse impact of COVID -19 related \ncancellation and deferral of elective procedures.  This impact is primarily w ithin products and \ndistribution.  \n \n  Medical segment profit increased 24% to $120 million in the quarter, driven by cost savings \ninitiatives and the beneficial comparison to a supplier -related charge in the prior year, partially offset \nby the adverse impact of COVID -19. \n \n  As expected, PPE volumes for the quarter were down sequential ly, but above pre -COVID -19 \nlevels.  This reflects the demand -driven sellout of safety stock in the third quarter , as well as sustained \nincreases in demand and associated global supp ly challenges, which we will discuss later in our \nremarks.  ", "original_text": "As expected, PPE volumes for the quarter were down sequential ly, but above pre -COVID -19 \nlevels. "}, "hash": "4719b4fe098345fb1f7246531a1c9f7b2adb7d7761c070b8a0f11b421a32df46", "class_name": "RelatedNodeInfo"}}, "text": "Medical segment profit increased 24% to $120 million in the quarter, driven by cost savings \ninitiatives and the beneficial comparison to a supplier -related charge in the prior year, partially offset \nby the adverse impact of COVID -19. \n \n ", "start_char_idx": 960, "end_char_idx": 1202, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e44d6bb0-370e-4e7f-8c62-20f794ad80ad": {"__data__": {"id_": "e44d6bb0-370e-4e7f-8c62-20f794ad80ad", "embedding": null, "metadata": {"window": "In Medical, Q4 revenue decreased 13% due to the adverse impact of COVID -19 related \ncancellation and deferral of elective procedures.  This impact is primarily w ithin products and \ndistribution.  \n \n  Medical segment profit increased 24% to $120 million in the quarter, driven by cost savings \ninitiatives and the beneficial comparison to a supplier -related charge in the prior year, partially offset \nby the adverse impact of COVID -19. \n \n  As expected, PPE volumes for the quarter were down sequential ly, but above pre -COVID -19 \nlevels.  This reflects the demand -driven sellout of safety stock in the third quarter , as well as sustained \nincreases in demand and associated global supp ly challenges, which we will discuss later in our \nremarks.  ", "original_text": "As expected, PPE volumes for the quarter were down sequential ly, but above pre -COVID -19 \nlevels. ", "page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3fe6ce10-fe5e-4d94-b32d-9477a82f8e03", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f643f84dd478cae40b2fb0afb5cf656fa34d0cc03296eeb268b9d0e2fa53145", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3437bc37-3389-463e-8e3d-eb6c0a1a5958", "node_type": "1", "metadata": {"window": "Similar to prior quarters, segment  profit also reflected a headwind from Pharmaceutical \nDistribution customer contract renewals.  \n \n  In Medical, Q4 revenue decreased 13% due to the adverse impact of COVID -19 related \ncancellation and deferral of elective procedures.  This impact is primarily w ithin products and \ndistribution.  \n \n  Medical segment profit increased 24% to $120 million in the quarter, driven by cost savings \ninitiatives and the beneficial comparison to a supplier -related charge in the prior year, partially offset \nby the adverse impact of COVID -19. \n \n  As expected, PPE volumes for the quarter were down sequential ly, but above pre -COVID -19 \nlevels.  This reflects the demand -driven sellout of safety stock in the third quarter , as well as sustained \nincreases in demand and associated global supp ly challenges, which we will discuss later in our \nremarks.  ", "original_text": "Medical segment profit increased 24% to $120 million in the quarter, driven by cost savings \ninitiatives and the beneficial comparison to a supplier -related charge in the prior year, partially offset \nby the adverse impact of COVID -19. \n \n ", "page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e7e3135f5249381747e191861c20caed7a437d7943c7c83246d1a473b4be750", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ab2020d-e408-4ea9-8591-5e577a60dd31", "node_type": "1", "metadata": {"window": "This impact is primarily w ithin products and \ndistribution.  \n \n  Medical segment profit increased 24% to $120 million in the quarter, driven by cost savings \ninitiatives and the beneficial comparison to a supplier -related charge in the prior year, partially offset \nby the adverse impact of COVID -19. \n \n  As expected, PPE volumes for the quarter were down sequential ly, but above pre -COVID -19 \nlevels.  This reflects the demand -driven sellout of safety stock in the third quarter , as well as sustained \nincreases in demand and associated global supp ly challenges, which we will discuss later in our \nremarks.  ", "original_text": "This reflects the demand -driven sellout of safety stock in the third quarter , as well as sustained \nincreases in demand and associated global supp ly challenges, which we will discuss later in our \nremarks.  "}, "hash": "3540bfcbab780e9677e455fefeac846d5152cff354c036eb74ec080bad422b34", "class_name": "RelatedNodeInfo"}}, "text": "As expected, PPE volumes for the quarter were down sequential ly, but above pre -COVID -19 \nlevels. ", "start_char_idx": 1202, "end_char_idx": 1302, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ab2020d-e408-4ea9-8591-5e577a60dd31": {"__data__": {"id_": "6ab2020d-e408-4ea9-8591-5e577a60dd31", "embedding": null, "metadata": {"window": "This impact is primarily w ithin products and \ndistribution.  \n \n  Medical segment profit increased 24% to $120 million in the quarter, driven by cost savings \ninitiatives and the beneficial comparison to a supplier -related charge in the prior year, partially offset \nby the adverse impact of COVID -19. \n \n  As expected, PPE volumes for the quarter were down sequential ly, but above pre -COVID -19 \nlevels.  This reflects the demand -driven sellout of safety stock in the third quarter , as well as sustained \nincreases in demand and associated global supp ly challenges, which we will discuss later in our \nremarks.  ", "original_text": "This reflects the demand -driven sellout of safety stock in the third quarter , as well as sustained \nincreases in demand and associated global supp ly challenges, which we will discuss later in our \nremarks.  ", "page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3fe6ce10-fe5e-4d94-b32d-9477a82f8e03", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f643f84dd478cae40b2fb0afb5cf656fa34d0cc03296eeb268b9d0e2fa53145", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e44d6bb0-370e-4e7f-8c62-20f794ad80ad", "node_type": "1", "metadata": {"window": "In Medical, Q4 revenue decreased 13% due to the adverse impact of COVID -19 related \ncancellation and deferral of elective procedures.  This impact is primarily w ithin products and \ndistribution.  \n \n  Medical segment profit increased 24% to $120 million in the quarter, driven by cost savings \ninitiatives and the beneficial comparison to a supplier -related charge in the prior year, partially offset \nby the adverse impact of COVID -19. \n \n  As expected, PPE volumes for the quarter were down sequential ly, but above pre -COVID -19 \nlevels.  This reflects the demand -driven sellout of safety stock in the third quarter , as well as sustained \nincreases in demand and associated global supp ly challenges, which we will discuss later in our \nremarks.  ", "original_text": "As expected, PPE volumes for the quarter were down sequential ly, but above pre -COVID -19 \nlevels. ", "page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "621dda8133f3ed8e5390ab2f3d577c157e9dea23af3c050aaf2792906d47ab33", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b2d9524-2acb-4242-9aac-9b00d4a2d0dc", "node_type": "1", "metadata": {"window": " \nPage 5 of 31 \n \n \n Across both segments, COVID -19 was a significant headwind to our business in the fourth \nquarter.  \n \n  Although it's always difficult to approximate the impact of lost sales, we estimate COVID -19 \nnegatively affected operating earnings by approximately $130 million despite some improvement in \nelective procedures and physician office visits over the course of the quarter.  \n \n  In Q4 we generated $240 million of operating cash flow.  Reflecting our continued  commitment \nto maintaining a strong balance sheet, in June we redeemed $500 million of notes with December \n2020 maturities. ", "original_text": " \nPage 5 of 31 \n \n \n Across both segments, COVID -19 was a significant headwind to our business in the fourth \nquarter.  \n \n "}, "hash": "56211227c5ba889a97068934208f67caf542e8abff0c9426cc7fc959add0eb66", "class_name": "RelatedNodeInfo"}}, "text": "This reflects the demand -driven sellout of safety stock in the third quarter , as well as sustained \nincreases in demand and associated global supp ly challenges, which we will discuss later in our \nremarks.  ", "start_char_idx": 1302, "end_char_idx": 1512, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b2d9524-2acb-4242-9aac-9b00d4a2d0dc": {"__data__": {"id_": "7b2d9524-2acb-4242-9aac-9b00d4a2d0dc", "embedding": null, "metadata": {"window": " \nPage 5 of 31 \n \n \n Across both segments, COVID -19 was a significant headwind to our business in the fourth \nquarter.  \n \n  Although it's always difficult to approximate the impact of lost sales, we estimate COVID -19 \nnegatively affected operating earnings by approximately $130 million despite some improvement in \nelective procedures and physician office visits over the course of the quarter.  \n \n  In Q4 we generated $240 million of operating cash flow.  Reflecting our continued  commitment \nto maintaining a strong balance sheet, in June we redeemed $500 million of notes with December \n2020 maturities. ", "original_text": " \nPage 5 of 31 \n \n \n Across both segments, COVID -19 was a significant headwind to our business in the fourth \nquarter.  \n \n ", "page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "776af277-817b-4ec3-bb54-b0c50d9f341b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c587b24e0665d7f8b6bf87f4ab8e7b5794ced955be066904d6437e2771c4951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ab2020d-e408-4ea9-8591-5e577a60dd31", "node_type": "1", "metadata": {"window": "This impact is primarily w ithin products and \ndistribution.  \n \n  Medical segment profit increased 24% to $120 million in the quarter, driven by cost savings \ninitiatives and the beneficial comparison to a supplier -related charge in the prior year, partially offset \nby the adverse impact of COVID -19. \n \n  As expected, PPE volumes for the quarter were down sequential ly, but above pre -COVID -19 \nlevels.  This reflects the demand -driven sellout of safety stock in the third quarter , as well as sustained \nincreases in demand and associated global supp ly challenges, which we will discuss later in our \nremarks.  ", "original_text": "This reflects the demand -driven sellout of safety stock in the third quarter , as well as sustained \nincreases in demand and associated global supp ly challenges, which we will discuss later in our \nremarks.  ", "page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f789db7d0c0381a71f289ed4c55befd2193dfedbb88ff0f673b9dc9bcb9d15ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2e02f5f-3c27-4622-9557-da7fce123ba3", "node_type": "1", "metadata": {"window": " \nPage 5 of 31 \n \n \n Across both segments, COVID -19 was a significant headwind to our business in the fourth \nquarter.  \n \n  Although it's always difficult to approximate the impact of lost sales, we estimate COVID -19 \nnegatively affected operating earnings by approximately $130 million despite some improvement in \nelective procedures and physician office visits over the course of the quarter.  \n \n  In Q4 we generated $240 million of operating cash flow.  Reflecting our continued  commitment \nto maintaining a strong balance sheet, in June we redeemed $500 million of notes with December \n2020 maturities.  Additionally , we generated nearly $900 million in the quarter from the sale of \ninvestments.  \n \n ", "original_text": "Although it's always difficult to approximate the impact of lost sales, we estimate COVID -19 \nnegatively affected operating earnings by approximately $130 million despite some improvement in \nelective procedures and physician office visits over the course of the quarter.  \n \n "}, "hash": "92de429c9fb31572127fea6d6b57254b3c76d00e53d847f2db8b4645ec23ef18", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 5 of 31 \n \n \n Across both segments, COVID -19 was a significant headwind to our business in the fourth \nquarter.  \n \n ", "start_char_idx": 0, "end_char_idx": 125, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2e02f5f-3c27-4622-9557-da7fce123ba3": {"__data__": {"id_": "b2e02f5f-3c27-4622-9557-da7fce123ba3", "embedding": null, "metadata": {"window": " \nPage 5 of 31 \n \n \n Across both segments, COVID -19 was a significant headwind to our business in the fourth \nquarter.  \n \n  Although it's always difficult to approximate the impact of lost sales, we estimate COVID -19 \nnegatively affected operating earnings by approximately $130 million despite some improvement in \nelective procedures and physician office visits over the course of the quarter.  \n \n  In Q4 we generated $240 million of operating cash flow.  Reflecting our continued  commitment \nto maintaining a strong balance sheet, in June we redeemed $500 million of notes with December \n2020 maturities.  Additionally , we generated nearly $900 million in the quarter from the sale of \ninvestments.  \n \n ", "original_text": "Although it's always difficult to approximate the impact of lost sales, we estimate COVID -19 \nnegatively affected operating earnings by approximately $130 million despite some improvement in \nelective procedures and physician office visits over the course of the quarter.  \n \n ", "page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "776af277-817b-4ec3-bb54-b0c50d9f341b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c587b24e0665d7f8b6bf87f4ab8e7b5794ced955be066904d6437e2771c4951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b2d9524-2acb-4242-9aac-9b00d4a2d0dc", "node_type": "1", "metadata": {"window": " \nPage 5 of 31 \n \n \n Across both segments, COVID -19 was a significant headwind to our business in the fourth \nquarter.  \n \n  Although it's always difficult to approximate the impact of lost sales, we estimate COVID -19 \nnegatively affected operating earnings by approximately $130 million despite some improvement in \nelective procedures and physician office visits over the course of the quarter.  \n \n  In Q4 we generated $240 million of operating cash flow.  Reflecting our continued  commitment \nto maintaining a strong balance sheet, in June we redeemed $500 million of notes with December \n2020 maturities. ", "original_text": " \nPage 5 of 31 \n \n \n Across both segments, COVID -19 was a significant headwind to our business in the fourth \nquarter.  \n \n ", "page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a9953e83668a752bbc84051bf91fda74d886205ca9308b5169567105339aec1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee3eee87-e200-4f9f-acef-dabd0f46f229", "node_type": "1", "metadata": {"window": " \nPage 5 of 31 \n \n \n Across both segments, COVID -19 was a significant headwind to our business in the fourth \nquarter.  \n \n  Although it's always difficult to approximate the impact of lost sales, we estimate COVID -19 \nnegatively affected operating earnings by approximately $130 million despite some improvement in \nelective procedures and physician office visits over the course of the quarter.  \n \n  In Q4 we generated $240 million of operating cash flow.  Reflecting our continued  commitment \nto maintaining a strong balance sheet, in June we redeemed $500 million of notes with December \n2020 maturities.  Additionally , we generated nearly $900 million in the quarter from the sale of \ninvestments.  \n \n  Now, I'll transition to the full year consolidated results.  \n \n ", "original_text": "In Q4 we generated $240 million of operating cash flow. "}, "hash": "d351f56d3059a35c90d95c3f0e1c51cf00af5a106cc963cd4f32f800cfd292cc", "class_name": "RelatedNodeInfo"}}, "text": "Although it's always difficult to approximate the impact of lost sales, we estimate COVID -19 \nnegatively affected operating earnings by approximately $130 million despite some improvement in \nelective procedures and physician office visits over the course of the quarter.  \n \n ", "start_char_idx": 125, "end_char_idx": 403, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee3eee87-e200-4f9f-acef-dabd0f46f229": {"__data__": {"id_": "ee3eee87-e200-4f9f-acef-dabd0f46f229", "embedding": null, "metadata": {"window": " \nPage 5 of 31 \n \n \n Across both segments, COVID -19 was a significant headwind to our business in the fourth \nquarter.  \n \n  Although it's always difficult to approximate the impact of lost sales, we estimate COVID -19 \nnegatively affected operating earnings by approximately $130 million despite some improvement in \nelective procedures and physician office visits over the course of the quarter.  \n \n  In Q4 we generated $240 million of operating cash flow.  Reflecting our continued  commitment \nto maintaining a strong balance sheet, in June we redeemed $500 million of notes with December \n2020 maturities.  Additionally , we generated nearly $900 million in the quarter from the sale of \ninvestments.  \n \n  Now, I'll transition to the full year consolidated results.  \n \n ", "original_text": "In Q4 we generated $240 million of operating cash flow. ", "page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "776af277-817b-4ec3-bb54-b0c50d9f341b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c587b24e0665d7f8b6bf87f4ab8e7b5794ced955be066904d6437e2771c4951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2e02f5f-3c27-4622-9557-da7fce123ba3", "node_type": "1", "metadata": {"window": " \nPage 5 of 31 \n \n \n Across both segments, COVID -19 was a significant headwind to our business in the fourth \nquarter.  \n \n  Although it's always difficult to approximate the impact of lost sales, we estimate COVID -19 \nnegatively affected operating earnings by approximately $130 million despite some improvement in \nelective procedures and physician office visits over the course of the quarter.  \n \n  In Q4 we generated $240 million of operating cash flow.  Reflecting our continued  commitment \nto maintaining a strong balance sheet, in June we redeemed $500 million of notes with December \n2020 maturities.  Additionally , we generated nearly $900 million in the quarter from the sale of \ninvestments.  \n \n ", "original_text": "Although it's always difficult to approximate the impact of lost sales, we estimate COVID -19 \nnegatively affected operating earnings by approximately $130 million despite some improvement in \nelective procedures and physician office visits over the course of the quarter.  \n \n ", "page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1146be0ccda66e9ed4db72ceee5748afdb68805f08ffa19175e8ac1d860266f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c690610c-1ee5-4698-b33b-9c4350ca8fea", "node_type": "1", "metadata": {"window": " \nPage 5 of 31 \n \n \n Across both segments, COVID -19 was a significant headwind to our business in the fourth \nquarter.  \n \n  Although it's always difficult to approximate the impact of lost sales, we estimate COVID -19 \nnegatively affected operating earnings by approximately $130 million despite some improvement in \nelective procedures and physician office visits over the course of the quarter.  \n \n  In Q4 we generated $240 million of operating cash flow.  Reflecting our continued  commitment \nto maintaining a strong balance sheet, in June we redeemed $500 million of notes with December \n2020 maturities.  Additionally , we generated nearly $900 million in the quarter from the sale of \ninvestments.  \n \n  Now, I'll transition to the full year consolidated results.  \n \n  In the midst of a challenging environment, we saw strong topline growth with revenue \nincreasing 5% to $153 billion. ", "original_text": "Reflecting our continued  commitment \nto maintaining a strong balance sheet, in June we redeemed $500 million of notes with December \n2020 maturities. "}, "hash": "87674f452a66b5a60cae42f842a02bd42a4bfba9546e563ed220786b2e79674f", "class_name": "RelatedNodeInfo"}}, "text": "In Q4 we generated $240 million of operating cash flow. ", "start_char_idx": 403, "end_char_idx": 459, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c690610c-1ee5-4698-b33b-9c4350ca8fea": {"__data__": {"id_": "c690610c-1ee5-4698-b33b-9c4350ca8fea", "embedding": null, "metadata": {"window": " \nPage 5 of 31 \n \n \n Across both segments, COVID -19 was a significant headwind to our business in the fourth \nquarter.  \n \n  Although it's always difficult to approximate the impact of lost sales, we estimate COVID -19 \nnegatively affected operating earnings by approximately $130 million despite some improvement in \nelective procedures and physician office visits over the course of the quarter.  \n \n  In Q4 we generated $240 million of operating cash flow.  Reflecting our continued  commitment \nto maintaining a strong balance sheet, in June we redeemed $500 million of notes with December \n2020 maturities.  Additionally , we generated nearly $900 million in the quarter from the sale of \ninvestments.  \n \n  Now, I'll transition to the full year consolidated results.  \n \n  In the midst of a challenging environment, we saw strong topline growth with revenue \nincreasing 5% to $153 billion. ", "original_text": "Reflecting our continued  commitment \nto maintaining a strong balance sheet, in June we redeemed $500 million of notes with December \n2020 maturities. ", "page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "776af277-817b-4ec3-bb54-b0c50d9f341b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c587b24e0665d7f8b6bf87f4ab8e7b5794ced955be066904d6437e2771c4951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee3eee87-e200-4f9f-acef-dabd0f46f229", "node_type": "1", "metadata": {"window": " \nPage 5 of 31 \n \n \n Across both segments, COVID -19 was a significant headwind to our business in the fourth \nquarter.  \n \n  Although it's always difficult to approximate the impact of lost sales, we estimate COVID -19 \nnegatively affected operating earnings by approximately $130 million despite some improvement in \nelective procedures and physician office visits over the course of the quarter.  \n \n  In Q4 we generated $240 million of operating cash flow.  Reflecting our continued  commitment \nto maintaining a strong balance sheet, in June we redeemed $500 million of notes with December \n2020 maturities.  Additionally , we generated nearly $900 million in the quarter from the sale of \ninvestments.  \n \n  Now, I'll transition to the full year consolidated results.  \n \n ", "original_text": "In Q4 we generated $240 million of operating cash flow. ", "page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62ce38e993bc37de5afaf86ed6d8199abdc41f658ff796d5957f76ae6cd1a63d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b27d47a-f281-473e-aa0d-985399cea5a4", "node_type": "1", "metadata": {"window": "Although it's always difficult to approximate the impact of lost sales, we estimate COVID -19 \nnegatively affected operating earnings by approximately $130 million despite some improvement in \nelective procedures and physician office visits over the course of the quarter.  \n \n  In Q4 we generated $240 million of operating cash flow.  Reflecting our continued  commitment \nto maintaining a strong balance sheet, in June we redeemed $500 million of notes with December \n2020 maturities.  Additionally , we generated nearly $900 million in the quarter from the sale of \ninvestments.  \n \n  Now, I'll transition to the full year consolidated results.  \n \n  In the midst of a challenging environment, we saw strong topline growth with revenue \nincreasing 5% to $153 billion.  Total company gross margin grew 1% to $6.9 billion. ", "original_text": "Additionally , we generated nearly $900 million in the quarter from the sale of \ninvestments.  \n \n "}, "hash": "648676248e1ed286759819b9a25169ba0c83cacf9bfad316027ae0d1eed5f384", "class_name": "RelatedNodeInfo"}}, "text": "Reflecting our continued  commitment \nto maintaining a strong balance sheet, in June we redeemed $500 million of notes with December \n2020 maturities. ", "start_char_idx": 459, "end_char_idx": 610, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b27d47a-f281-473e-aa0d-985399cea5a4": {"__data__": {"id_": "6b27d47a-f281-473e-aa0d-985399cea5a4", "embedding": null, "metadata": {"window": "Although it's always difficult to approximate the impact of lost sales, we estimate COVID -19 \nnegatively affected operating earnings by approximately $130 million despite some improvement in \nelective procedures and physician office visits over the course of the quarter.  \n \n  In Q4 we generated $240 million of operating cash flow.  Reflecting our continued  commitment \nto maintaining a strong balance sheet, in June we redeemed $500 million of notes with December \n2020 maturities.  Additionally , we generated nearly $900 million in the quarter from the sale of \ninvestments.  \n \n  Now, I'll transition to the full year consolidated results.  \n \n  In the midst of a challenging environment, we saw strong topline growth with revenue \nincreasing 5% to $153 billion.  Total company gross margin grew 1% to $6.9 billion. ", "original_text": "Additionally , we generated nearly $900 million in the quarter from the sale of \ninvestments.  \n \n ", "page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "776af277-817b-4ec3-bb54-b0c50d9f341b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c587b24e0665d7f8b6bf87f4ab8e7b5794ced955be066904d6437e2771c4951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c690610c-1ee5-4698-b33b-9c4350ca8fea", "node_type": "1", "metadata": {"window": " \nPage 5 of 31 \n \n \n Across both segments, COVID -19 was a significant headwind to our business in the fourth \nquarter.  \n \n  Although it's always difficult to approximate the impact of lost sales, we estimate COVID -19 \nnegatively affected operating earnings by approximately $130 million despite some improvement in \nelective procedures and physician office visits over the course of the quarter.  \n \n  In Q4 we generated $240 million of operating cash flow.  Reflecting our continued  commitment \nto maintaining a strong balance sheet, in June we redeemed $500 million of notes with December \n2020 maturities.  Additionally , we generated nearly $900 million in the quarter from the sale of \ninvestments.  \n \n  Now, I'll transition to the full year consolidated results.  \n \n  In the midst of a challenging environment, we saw strong topline growth with revenue \nincreasing 5% to $153 billion. ", "original_text": "Reflecting our continued  commitment \nto maintaining a strong balance sheet, in June we redeemed $500 million of notes with December \n2020 maturities. ", "page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "09d7226231592a8677828bc90e316036de78910d7336c3d1185d0b3c2b1003c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3860c263-0a3c-40ec-b3ac-b729b9ff225d", "node_type": "1", "metadata": {"window": "In Q4 we generated $240 million of operating cash flow.  Reflecting our continued  commitment \nto maintaining a strong balance sheet, in June we redeemed $500 million of notes with December \n2020 maturities.  Additionally , we generated nearly $900 million in the quarter from the sale of \ninvestments.  \n \n  Now, I'll transition to the full year consolidated results.  \n \n  In the midst of a challenging environment, we saw strong topline growth with revenue \nincreasing 5% to $153 billion.  Total company gross margin grew 1% to $6.9 billion.  SG&A increased \n1%, reflecting higher costs to support sales grow th. \n \n ", "original_text": "Now, I'll transition to the full year consolidated results.  \n \n "}, "hash": "db81fdc4be03954412fc8e6dd094b0db85a0e4ec248853360a155fdbf296353f", "class_name": "RelatedNodeInfo"}}, "text": "Additionally , we generated nearly $900 million in the quarter from the sale of \ninvestments.  \n \n ", "start_char_idx": 610, "end_char_idx": 709, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3860c263-0a3c-40ec-b3ac-b729b9ff225d": {"__data__": {"id_": "3860c263-0a3c-40ec-b3ac-b729b9ff225d", "embedding": null, "metadata": {"window": "In Q4 we generated $240 million of operating cash flow.  Reflecting our continued  commitment \nto maintaining a strong balance sheet, in June we redeemed $500 million of notes with December \n2020 maturities.  Additionally , we generated nearly $900 million in the quarter from the sale of \ninvestments.  \n \n  Now, I'll transition to the full year consolidated results.  \n \n  In the midst of a challenging environment, we saw strong topline growth with revenue \nincreasing 5% to $153 billion.  Total company gross margin grew 1% to $6.9 billion.  SG&A increased \n1%, reflecting higher costs to support sales grow th. \n \n ", "original_text": "Now, I'll transition to the full year consolidated results.  \n \n ", "page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "776af277-817b-4ec3-bb54-b0c50d9f341b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c587b24e0665d7f8b6bf87f4ab8e7b5794ced955be066904d6437e2771c4951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b27d47a-f281-473e-aa0d-985399cea5a4", "node_type": "1", "metadata": {"window": "Although it's always difficult to approximate the impact of lost sales, we estimate COVID -19 \nnegatively affected operating earnings by approximately $130 million despite some improvement in \nelective procedures and physician office visits over the course of the quarter.  \n \n  In Q4 we generated $240 million of operating cash flow.  Reflecting our continued  commitment \nto maintaining a strong balance sheet, in June we redeemed $500 million of notes with December \n2020 maturities.  Additionally , we generated nearly $900 million in the quarter from the sale of \ninvestments.  \n \n  Now, I'll transition to the full year consolidated results.  \n \n  In the midst of a challenging environment, we saw strong topline growth with revenue \nincreasing 5% to $153 billion.  Total company gross margin grew 1% to $6.9 billion. ", "original_text": "Additionally , we generated nearly $900 million in the quarter from the sale of \ninvestments.  \n \n ", "page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2eb74857a486cfb68eefe184d16437d62af60c39f99af0908bc0174c18ad30de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f8c379f-ce6f-4ca3-b573-53ec91a81e7c", "node_type": "1", "metadata": {"window": "Reflecting our continued  commitment \nto maintaining a strong balance sheet, in June we redeemed $500 million of notes with December \n2020 maturities.  Additionally , we generated nearly $900 million in the quarter from the sale of \ninvestments.  \n \n  Now, I'll transition to the full year consolidated results.  \n \n  In the midst of a challenging environment, we saw strong topline growth with revenue \nincreasing 5% to $153 billion.  Total company gross margin grew 1% to $6.9 billion.  SG&A increased \n1%, reflecting higher costs to support sales grow th. \n \n  Operating earnings returned to growth in fiscal 20, finishing at $2.4 billion, despite a net \nheadwind related to COVID -19 of approximately $100 million on the full year.  \n \n ", "original_text": "In the midst of a challenging environment, we saw strong topline growth with revenue \nincreasing 5% to $153 billion. "}, "hash": "b2252cf9eb5f766bed44f925de47b54471b2caf60a6edb623e2eed7f511c9dfa", "class_name": "RelatedNodeInfo"}}, "text": "Now, I'll transition to the full year consolidated results.  \n \n ", "start_char_idx": 709, "end_char_idx": 774, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f8c379f-ce6f-4ca3-b573-53ec91a81e7c": {"__data__": {"id_": "8f8c379f-ce6f-4ca3-b573-53ec91a81e7c", "embedding": null, "metadata": {"window": "Reflecting our continued  commitment \nto maintaining a strong balance sheet, in June we redeemed $500 million of notes with December \n2020 maturities.  Additionally , we generated nearly $900 million in the quarter from the sale of \ninvestments.  \n \n  Now, I'll transition to the full year consolidated results.  \n \n  In the midst of a challenging environment, we saw strong topline growth with revenue \nincreasing 5% to $153 billion.  Total company gross margin grew 1% to $6.9 billion.  SG&A increased \n1%, reflecting higher costs to support sales grow th. \n \n  Operating earnings returned to growth in fiscal 20, finishing at $2.4 billion, despite a net \nheadwind related to COVID -19 of approximately $100 million on the full year.  \n \n ", "original_text": "In the midst of a challenging environment, we saw strong topline growth with revenue \nincreasing 5% to $153 billion. ", "page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "776af277-817b-4ec3-bb54-b0c50d9f341b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c587b24e0665d7f8b6bf87f4ab8e7b5794ced955be066904d6437e2771c4951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3860c263-0a3c-40ec-b3ac-b729b9ff225d", "node_type": "1", "metadata": {"window": "In Q4 we generated $240 million of operating cash flow.  Reflecting our continued  commitment \nto maintaining a strong balance sheet, in June we redeemed $500 million of notes with December \n2020 maturities.  Additionally , we generated nearly $900 million in the quarter from the sale of \ninvestments.  \n \n  Now, I'll transition to the full year consolidated results.  \n \n  In the midst of a challenging environment, we saw strong topline growth with revenue \nincreasing 5% to $153 billion.  Total company gross margin grew 1% to $6.9 billion.  SG&A increased \n1%, reflecting higher costs to support sales grow th. \n \n ", "original_text": "Now, I'll transition to the full year consolidated results.  \n \n ", "page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0110b1c8ec15fdd7e316f786c710528299c4eeead72cf49babf8d164dc91adba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb48c738-22d3-4f73-bff9-fce3276da250", "node_type": "1", "metadata": {"window": "Additionally , we generated nearly $900 million in the quarter from the sale of \ninvestments.  \n \n  Now, I'll transition to the full year consolidated results.  \n \n  In the midst of a challenging environment, we saw strong topline growth with revenue \nincreasing 5% to $153 billion.  Total company gross margin grew 1% to $6.9 billion.  SG&A increased \n1%, reflecting higher costs to support sales grow th. \n \n  Operating earnings returned to growth in fiscal 20, finishing at $2.4 billion, despite a net \nheadwind related to COVID -19 of approximately $100 million on the full year.  \n \n  Interest and other expense decreased 23%, primarily due to a lower debt balanc e and a net \nbenefit from lower interest rates.  ", "original_text": "Total company gross margin grew 1% to $6.9 billion. "}, "hash": "f0a4eedb0d77f1fb37c5b843318de62502c8623db50641a8389b6524d63b302a", "class_name": "RelatedNodeInfo"}}, "text": "In the midst of a challenging environment, we saw strong topline growth with revenue \nincreasing 5% to $153 billion. ", "start_char_idx": 774, "end_char_idx": 891, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb48c738-22d3-4f73-bff9-fce3276da250": {"__data__": {"id_": "eb48c738-22d3-4f73-bff9-fce3276da250", "embedding": null, "metadata": {"window": "Additionally , we generated nearly $900 million in the quarter from the sale of \ninvestments.  \n \n  Now, I'll transition to the full year consolidated results.  \n \n  In the midst of a challenging environment, we saw strong topline growth with revenue \nincreasing 5% to $153 billion.  Total company gross margin grew 1% to $6.9 billion.  SG&A increased \n1%, reflecting higher costs to support sales grow th. \n \n  Operating earnings returned to growth in fiscal 20, finishing at $2.4 billion, despite a net \nheadwind related to COVID -19 of approximately $100 million on the full year.  \n \n  Interest and other expense decreased 23%, primarily due to a lower debt balanc e and a net \nbenefit from lower interest rates.  ", "original_text": "Total company gross margin grew 1% to $6.9 billion. ", "page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "776af277-817b-4ec3-bb54-b0c50d9f341b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c587b24e0665d7f8b6bf87f4ab8e7b5794ced955be066904d6437e2771c4951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f8c379f-ce6f-4ca3-b573-53ec91a81e7c", "node_type": "1", "metadata": {"window": "Reflecting our continued  commitment \nto maintaining a strong balance sheet, in June we redeemed $500 million of notes with December \n2020 maturities.  Additionally , we generated nearly $900 million in the quarter from the sale of \ninvestments.  \n \n  Now, I'll transition to the full year consolidated results.  \n \n  In the midst of a challenging environment, we saw strong topline growth with revenue \nincreasing 5% to $153 billion.  Total company gross margin grew 1% to $6.9 billion.  SG&A increased \n1%, reflecting higher costs to support sales grow th. \n \n  Operating earnings returned to growth in fiscal 20, finishing at $2.4 billion, despite a net \nheadwind related to COVID -19 of approximately $100 million on the full year.  \n \n ", "original_text": "In the midst of a challenging environment, we saw strong topline growth with revenue \nincreasing 5% to $153 billion. ", "page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d89658cc50460687faa1d3d491f763ce773cb9db9c3d2599b6b78900dbafb7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "988003d2-f3c5-4460-ad37-be1a4e671626", "node_type": "1", "metadata": {"window": "Now, I'll transition to the full year consolidated results.  \n \n  In the midst of a challenging environment, we saw strong topline growth with revenue \nincreasing 5% to $153 billion.  Total company gross margin grew 1% to $6.9 billion.  SG&A increased \n1%, reflecting higher costs to support sales grow th. \n \n  Operating earnings returned to growth in fiscal 20, finishing at $2.4 billion, despite a net \nheadwind related to COVID -19 of approximately $100 million on the full year.  \n \n  Interest and other expense decreased 23%, primarily due to a lower debt balanc e and a net \nbenefit from lower interest rates.  ", "original_text": "SG&A increased \n1%, reflecting higher costs to support sales grow th. \n \n "}, "hash": "cff2b4d1406cb7316c3ca7c7bab84f56e1b947a604bbb08a3bd168cf7072f5b4", "class_name": "RelatedNodeInfo"}}, "text": "Total company gross margin grew 1% to $6.9 billion. ", "start_char_idx": 891, "end_char_idx": 943, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "988003d2-f3c5-4460-ad37-be1a4e671626": {"__data__": {"id_": "988003d2-f3c5-4460-ad37-be1a4e671626", "embedding": null, "metadata": {"window": "Now, I'll transition to the full year consolidated results.  \n \n  In the midst of a challenging environment, we saw strong topline growth with revenue \nincreasing 5% to $153 billion.  Total company gross margin grew 1% to $6.9 billion.  SG&A increased \n1%, reflecting higher costs to support sales grow th. \n \n  Operating earnings returned to growth in fiscal 20, finishing at $2.4 billion, despite a net \nheadwind related to COVID -19 of approximately $100 million on the full year.  \n \n  Interest and other expense decreased 23%, primarily due to a lower debt balanc e and a net \nbenefit from lower interest rates.  ", "original_text": "SG&A increased \n1%, reflecting higher costs to support sales grow th. \n \n ", "page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "776af277-817b-4ec3-bb54-b0c50d9f341b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c587b24e0665d7f8b6bf87f4ab8e7b5794ced955be066904d6437e2771c4951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb48c738-22d3-4f73-bff9-fce3276da250", "node_type": "1", "metadata": {"window": "Additionally , we generated nearly $900 million in the quarter from the sale of \ninvestments.  \n \n  Now, I'll transition to the full year consolidated results.  \n \n  In the midst of a challenging environment, we saw strong topline growth with revenue \nincreasing 5% to $153 billion.  Total company gross margin grew 1% to $6.9 billion.  SG&A increased \n1%, reflecting higher costs to support sales grow th. \n \n  Operating earnings returned to growth in fiscal 20, finishing at $2.4 billion, despite a net \nheadwind related to COVID -19 of approximately $100 million on the full year.  \n \n  Interest and other expense decreased 23%, primarily due to a lower debt balanc e and a net \nbenefit from lower interest rates.  ", "original_text": "Total company gross margin grew 1% to $6.9 billion. ", "page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a59eaee6fe223903526fbf1e339c197941cd842aa69d6b679956e599334dd7e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92932204-b327-4b44-bbc5-036aa0941f42", "node_type": "1", "metadata": {"window": "In the midst of a challenging environment, we saw strong topline growth with revenue \nincreasing 5% to $153 billion.  Total company gross margin grew 1% to $6.9 billion.  SG&A increased \n1%, reflecting higher costs to support sales grow th. \n \n  Operating earnings returned to growth in fiscal 20, finishing at $2.4 billion, despite a net \nheadwind related to COVID -19 of approximately $100 million on the full year.  \n \n  Interest and other expense decreased 23%, primarily due to a lower debt balanc e and a net \nbenefit from lower interest rates.  ", "original_text": "Operating earnings returned to growth in fiscal 20, finishing at $2.4 billion, despite a net \nheadwind related to COVID -19 of approximately $100 million on the full year.  \n \n "}, "hash": "09bc6cc5feb156195e6f37546071bc84e90a1d5dc7a7bee0b4b37e254b4b029b", "class_name": "RelatedNodeInfo"}}, "text": "SG&A increased \n1%, reflecting higher costs to support sales grow th. \n \n ", "start_char_idx": 943, "end_char_idx": 1017, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92932204-b327-4b44-bbc5-036aa0941f42": {"__data__": {"id_": "92932204-b327-4b44-bbc5-036aa0941f42", "embedding": null, "metadata": {"window": "In the midst of a challenging environment, we saw strong topline growth with revenue \nincreasing 5% to $153 billion.  Total company gross margin grew 1% to $6.9 billion.  SG&A increased \n1%, reflecting higher costs to support sales grow th. \n \n  Operating earnings returned to growth in fiscal 20, finishing at $2.4 billion, despite a net \nheadwind related to COVID -19 of approximately $100 million on the full year.  \n \n  Interest and other expense decreased 23%, primarily due to a lower debt balanc e and a net \nbenefit from lower interest rates.  ", "original_text": "Operating earnings returned to growth in fiscal 20, finishing at $2.4 billion, despite a net \nheadwind related to COVID -19 of approximately $100 million on the full year.  \n \n ", "page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "776af277-817b-4ec3-bb54-b0c50d9f341b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c587b24e0665d7f8b6bf87f4ab8e7b5794ced955be066904d6437e2771c4951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "988003d2-f3c5-4460-ad37-be1a4e671626", "node_type": "1", "metadata": {"window": "Now, I'll transition to the full year consolidated results.  \n \n  In the midst of a challenging environment, we saw strong topline growth with revenue \nincreasing 5% to $153 billion.  Total company gross margin grew 1% to $6.9 billion.  SG&A increased \n1%, reflecting higher costs to support sales grow th. \n \n  Operating earnings returned to growth in fiscal 20, finishing at $2.4 billion, despite a net \nheadwind related to COVID -19 of approximately $100 million on the full year.  \n \n  Interest and other expense decreased 23%, primarily due to a lower debt balanc e and a net \nbenefit from lower interest rates.  ", "original_text": "SG&A increased \n1%, reflecting higher costs to support sales grow th. \n \n ", "page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f302b62d7c23724acb4052d0b955b46f1f4607e32073d540a9d037bd3d9505c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89ae58e9-125e-45f2-bc4d-6e7f317cac5a", "node_type": "1", "metadata": {"window": "Total company gross margin grew 1% to $6.9 billion.  SG&A increased \n1%, reflecting higher costs to support sales grow th. \n \n  Operating earnings returned to growth in fiscal 20, finishing at $2.4 billion, despite a net \nheadwind related to COVID -19 of approximately $100 million on the full year.  \n \n  Interest and other expense decreased 23%, primarily due to a lower debt balanc e and a net \nbenefit from lower interest rates.  ", "original_text": "Interest and other expense decreased 23%, primarily due to a lower debt balanc e and a net \nbenefit from lower interest rates.  "}, "hash": "86dbb6e02c5f34fb49752fa01466273b46441b678d992874e26f4fb1487b5057", "class_name": "RelatedNodeInfo"}}, "text": "Operating earnings returned to growth in fiscal 20, finishing at $2.4 billion, despite a net \nheadwind related to COVID -19 of approximately $100 million on the full year.  \n \n ", "start_char_idx": 1017, "end_char_idx": 1194, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89ae58e9-125e-45f2-bc4d-6e7f317cac5a": {"__data__": {"id_": "89ae58e9-125e-45f2-bc4d-6e7f317cac5a", "embedding": null, "metadata": {"window": "Total company gross margin grew 1% to $6.9 billion.  SG&A increased \n1%, reflecting higher costs to support sales grow th. \n \n  Operating earnings returned to growth in fiscal 20, finishing at $2.4 billion, despite a net \nheadwind related to COVID -19 of approximately $100 million on the full year.  \n \n  Interest and other expense decreased 23%, primarily due to a lower debt balanc e and a net \nbenefit from lower interest rates.  ", "original_text": "Interest and other expense decreased 23%, primarily due to a lower debt balanc e and a net \nbenefit from lower interest rates.  ", "page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "776af277-817b-4ec3-bb54-b0c50d9f341b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c587b24e0665d7f8b6bf87f4ab8e7b5794ced955be066904d6437e2771c4951", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92932204-b327-4b44-bbc5-036aa0941f42", "node_type": "1", "metadata": {"window": "In the midst of a challenging environment, we saw strong topline growth with revenue \nincreasing 5% to $153 billion.  Total company gross margin grew 1% to $6.9 billion.  SG&A increased \n1%, reflecting higher costs to support sales grow th. \n \n  Operating earnings returned to growth in fiscal 20, finishing at $2.4 billion, despite a net \nheadwind related to COVID -19 of approximately $100 million on the full year.  \n \n  Interest and other expense decreased 23%, primarily due to a lower debt balanc e and a net \nbenefit from lower interest rates.  ", "original_text": "Operating earnings returned to growth in fiscal 20, finishing at $2.4 billion, despite a net \nheadwind related to COVID -19 of approximately $100 million on the full year.  \n \n ", "page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "097b38711973858591307c0ac3a5088fac3847b45d0424b44a6bcf7b9793f0ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61098b3f-06ed-400e-8ffd-44b0c7c4fb38", "node_type": "1", "metadata": {"window": " \nPage 6 of 31 \n \n \n We finished the year with $2 billion of operating cash flow.  As a reminder , the day of the week \nin which the quarter ends affects point -in-time of cash flows.  \n \n  We ended the year with a $2.8 billion cash balance, with roughly half a billion dollars held \noutside the US and nothing outstanding under our $3 billion credit facilities.  \n \n  From a capital allocation perspective, we took additional actions in fiscal 20 to strengthen our \nposition for long -term growt h. We invested $37 5 million of capex  back into the business, focusing on \nenhancing our IT infrastructure and fueling strategic growth opportunities. ", "original_text": " \nPage 6 of 31 \n \n \n We finished the year with $2 billion of operating cash flow. "}, "hash": "1355607ffba4b6a0c027d5b97a94f055551325a3bf7e80e368522abee504d547", "class_name": "RelatedNodeInfo"}}, "text": "Interest and other expense decreased 23%, primarily due to a lower debt balanc e and a net \nbenefit from lower interest rates.  ", "start_char_idx": 1194, "end_char_idx": 1322, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61098b3f-06ed-400e-8ffd-44b0c7c4fb38": {"__data__": {"id_": "61098b3f-06ed-400e-8ffd-44b0c7c4fb38", "embedding": null, "metadata": {"window": " \nPage 6 of 31 \n \n \n We finished the year with $2 billion of operating cash flow.  As a reminder , the day of the week \nin which the quarter ends affects point -in-time of cash flows.  \n \n  We ended the year with a $2.8 billion cash balance, with roughly half a billion dollars held \noutside the US and nothing outstanding under our $3 billion credit facilities.  \n \n  From a capital allocation perspective, we took additional actions in fiscal 20 to strengthen our \nposition for long -term growt h. We invested $37 5 million of capex  back into the business, focusing on \nenhancing our IT infrastructure and fueling strategic growth opportunities. ", "original_text": " \nPage 6 of 31 \n \n \n We finished the year with $2 billion of operating cash flow. ", "page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91d90699-bd7b-4281-a21c-c28f6658f0be", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d6a7eac736f3f690a357bde1e4b4667c2d4fc8e5c6b5de57ed0e8fcc1326e6b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89ae58e9-125e-45f2-bc4d-6e7f317cac5a", "node_type": "1", "metadata": {"window": "Total company gross margin grew 1% to $6.9 billion.  SG&A increased \n1%, reflecting higher costs to support sales grow th. \n \n  Operating earnings returned to growth in fiscal 20, finishing at $2.4 billion, despite a net \nheadwind related to COVID -19 of approximately $100 million on the full year.  \n \n  Interest and other expense decreased 23%, primarily due to a lower debt balanc e and a net \nbenefit from lower interest rates.  ", "original_text": "Interest and other expense decreased 23%, primarily due to a lower debt balanc e and a net \nbenefit from lower interest rates.  ", "page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "774408fc81cecbac47f23fc105f4118146893c760dc205f03d156a3b8a0065e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71a956af-3359-4bf2-b858-f45b2cb40d99", "node_type": "1", "metadata": {"window": " \nPage 6 of 31 \n \n \n We finished the year with $2 billion of operating cash flow.  As a reminder , the day of the week \nin which the quarter ends affects point -in-time of cash flows.  \n \n  We ended the year with a $2.8 billion cash balance, with roughly half a billion dollars held \noutside the US and nothing outstanding under our $3 billion credit facilities.  \n \n  From a capital allocation perspective, we took additional actions in fiscal 20 to strengthen our \nposition for long -term growt h. We invested $37 5 million of capex  back into the business, focusing on \nenhancing our IT infrastructure and fueling strategic growth opportunities.  We paid down $1.4 billion \nof debt, and we returned over $900 million to shareholders through dividends and share repurchases.  \n \n ", "original_text": "As a reminder , the day of the week \nin which the quarter ends affects point -in-time of cash flows.  \n \n "}, "hash": "3aee2f32a2c78db6a1efdbbc1c0cc5323a99a3e11fa214bb57f2c632da32f1ac", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 6 of 31 \n \n \n We finished the year with $2 billion of operating cash flow. ", "start_char_idx": 0, "end_char_idx": 82, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71a956af-3359-4bf2-b858-f45b2cb40d99": {"__data__": {"id_": "71a956af-3359-4bf2-b858-f45b2cb40d99", "embedding": null, "metadata": {"window": " \nPage 6 of 31 \n \n \n We finished the year with $2 billion of operating cash flow.  As a reminder , the day of the week \nin which the quarter ends affects point -in-time of cash flows.  \n \n  We ended the year with a $2.8 billion cash balance, with roughly half a billion dollars held \noutside the US and nothing outstanding under our $3 billion credit facilities.  \n \n  From a capital allocation perspective, we took additional actions in fiscal 20 to strengthen our \nposition for long -term growt h. We invested $37 5 million of capex  back into the business, focusing on \nenhancing our IT infrastructure and fueling strategic growth opportunities.  We paid down $1.4 billion \nof debt, and we returned over $900 million to shareholders through dividends and share repurchases.  \n \n ", "original_text": "As a reminder , the day of the week \nin which the quarter ends affects point -in-time of cash flows.  \n \n ", "page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91d90699-bd7b-4281-a21c-c28f6658f0be", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d6a7eac736f3f690a357bde1e4b4667c2d4fc8e5c6b5de57ed0e8fcc1326e6b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61098b3f-06ed-400e-8ffd-44b0c7c4fb38", "node_type": "1", "metadata": {"window": " \nPage 6 of 31 \n \n \n We finished the year with $2 billion of operating cash flow.  As a reminder , the day of the week \nin which the quarter ends affects point -in-time of cash flows.  \n \n  We ended the year with a $2.8 billion cash balance, with roughly half a billion dollars held \noutside the US and nothing outstanding under our $3 billion credit facilities.  \n \n  From a capital allocation perspective, we took additional actions in fiscal 20 to strengthen our \nposition for long -term growt h. We invested $37 5 million of capex  back into the business, focusing on \nenhancing our IT infrastructure and fueling strategic growth opportunities. ", "original_text": " \nPage 6 of 31 \n \n \n We finished the year with $2 billion of operating cash flow. ", "page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c5ac16944bb01ec95f64fc6ca976c9b598ad6caa3226d080e5c0a838c3635884", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a0bfb30-2cab-4586-b944-0c2bcba769d0", "node_type": "1", "metadata": {"window": " \nPage 6 of 31 \n \n \n We finished the year with $2 billion of operating cash flow.  As a reminder , the day of the week \nin which the quarter ends affects point -in-time of cash flows.  \n \n  We ended the year with a $2.8 billion cash balance, with roughly half a billion dollars held \noutside the US and nothing outstanding under our $3 billion credit facilities.  \n \n  From a capital allocation perspective, we took additional actions in fiscal 20 to strengthen our \nposition for long -term growt h. We invested $37 5 million of capex  back into the business, focusing on \nenhancing our IT infrastructure and fueling strategic growth opportunities.  We paid down $1.4 billion \nof debt, and we returned over $900 million to shareholders through dividends and share repurchases.  \n \n  Our effective t ax rate for the year was 25%. ", "original_text": "We ended the year with a $2.8 billion cash balance, with roughly half a billion dollars held \noutside the US and nothing outstanding under our $3 billion credit facilities.  \n \n "}, "hash": "f99b73c3e2daf327c6ecd13e317baad8d943430e40ff95fce5022b6cf62dedc8", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder , the day of the week \nin which the quarter ends affects point -in-time of cash flows.  \n \n ", "start_char_idx": 82, "end_char_idx": 188, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a0bfb30-2cab-4586-b944-0c2bcba769d0": {"__data__": {"id_": "8a0bfb30-2cab-4586-b944-0c2bcba769d0", "embedding": null, "metadata": {"window": " \nPage 6 of 31 \n \n \n We finished the year with $2 billion of operating cash flow.  As a reminder , the day of the week \nin which the quarter ends affects point -in-time of cash flows.  \n \n  We ended the year with a $2.8 billion cash balance, with roughly half a billion dollars held \noutside the US and nothing outstanding under our $3 billion credit facilities.  \n \n  From a capital allocation perspective, we took additional actions in fiscal 20 to strengthen our \nposition for long -term growt h. We invested $37 5 million of capex  back into the business, focusing on \nenhancing our IT infrastructure and fueling strategic growth opportunities.  We paid down $1.4 billion \nof debt, and we returned over $900 million to shareholders through dividends and share repurchases.  \n \n  Our effective t ax rate for the year was 25%. ", "original_text": "We ended the year with a $2.8 billion cash balance, with roughly half a billion dollars held \noutside the US and nothing outstanding under our $3 billion credit facilities.  \n \n ", "page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91d90699-bd7b-4281-a21c-c28f6658f0be", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d6a7eac736f3f690a357bde1e4b4667c2d4fc8e5c6b5de57ed0e8fcc1326e6b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71a956af-3359-4bf2-b858-f45b2cb40d99", "node_type": "1", "metadata": {"window": " \nPage 6 of 31 \n \n \n We finished the year with $2 billion of operating cash flow.  As a reminder , the day of the week \nin which the quarter ends affects point -in-time of cash flows.  \n \n  We ended the year with a $2.8 billion cash balance, with roughly half a billion dollars held \noutside the US and nothing outstanding under our $3 billion credit facilities.  \n \n  From a capital allocation perspective, we took additional actions in fiscal 20 to strengthen our \nposition for long -term growt h. We invested $37 5 million of capex  back into the business, focusing on \nenhancing our IT infrastructure and fueling strategic growth opportunities.  We paid down $1.4 billion \nof debt, and we returned over $900 million to shareholders through dividends and share repurchases.  \n \n ", "original_text": "As a reminder , the day of the week \nin which the quarter ends affects point -in-time of cash flows.  \n \n ", "page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76d122413c41139b69a833d0ff8d6b740ab62cad4322cbf3e43bd5f99bb321ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb55a3f6-523b-4acb-9a1f-77c83685f062", "node_type": "1", "metadata": {"window": " \nPage 6 of 31 \n \n \n We finished the year with $2 billion of operating cash flow.  As a reminder , the day of the week \nin which the quarter ends affects point -in-time of cash flows.  \n \n  We ended the year with a $2.8 billion cash balance, with roughly half a billion dollars held \noutside the US and nothing outstanding under our $3 billion credit facilities.  \n \n  From a capital allocation perspective, we took additional actions in fiscal 20 to strengthen our \nposition for long -term growt h. We invested $37 5 million of capex  back into the business, focusing on \nenhancing our IT infrastructure and fueling strategic growth opportunities.  We paid down $1.4 billion \nof debt, and we returned over $900 million to shareholders through dividends and share repurchases.  \n \n  Our effective t ax rate for the year was 25%.  We finished the year with earnings per share of \n$5.45, up more than 3% vs. ", "original_text": "From a capital allocation perspective, we took additional actions in fiscal 20 to strengthen our \nposition for long -term growt h. We invested $37 5 million of capex  back into the business, focusing on \nenhancing our IT infrastructure and fueling strategic growth opportunities. "}, "hash": "5c163d6e0273bf1179bf39590e8c85728659de7167e3743cbdfc58453631926a", "class_name": "RelatedNodeInfo"}}, "text": "We ended the year with a $2.8 billion cash balance, with roughly half a billion dollars held \noutside the US and nothing outstanding under our $3 billion credit facilities.  \n \n ", "start_char_idx": 188, "end_char_idx": 366, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb55a3f6-523b-4acb-9a1f-77c83685f062": {"__data__": {"id_": "fb55a3f6-523b-4acb-9a1f-77c83685f062", "embedding": null, "metadata": {"window": " \nPage 6 of 31 \n \n \n We finished the year with $2 billion of operating cash flow.  As a reminder , the day of the week \nin which the quarter ends affects point -in-time of cash flows.  \n \n  We ended the year with a $2.8 billion cash balance, with roughly half a billion dollars held \noutside the US and nothing outstanding under our $3 billion credit facilities.  \n \n  From a capital allocation perspective, we took additional actions in fiscal 20 to strengthen our \nposition for long -term growt h. We invested $37 5 million of capex  back into the business, focusing on \nenhancing our IT infrastructure and fueling strategic growth opportunities.  We paid down $1.4 billion \nof debt, and we returned over $900 million to shareholders through dividends and share repurchases.  \n \n  Our effective t ax rate for the year was 25%.  We finished the year with earnings per share of \n$5.45, up more than 3% vs. ", "original_text": "From a capital allocation perspective, we took additional actions in fiscal 20 to strengthen our \nposition for long -term growt h. We invested $37 5 million of capex  back into the business, focusing on \nenhancing our IT infrastructure and fueling strategic growth opportunities. ", "page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91d90699-bd7b-4281-a21c-c28f6658f0be", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d6a7eac736f3f690a357bde1e4b4667c2d4fc8e5c6b5de57ed0e8fcc1326e6b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a0bfb30-2cab-4586-b944-0c2bcba769d0", "node_type": "1", "metadata": {"window": " \nPage 6 of 31 \n \n \n We finished the year with $2 billion of operating cash flow.  As a reminder , the day of the week \nin which the quarter ends affects point -in-time of cash flows.  \n \n  We ended the year with a $2.8 billion cash balance, with roughly half a billion dollars held \noutside the US and nothing outstanding under our $3 billion credit facilities.  \n \n  From a capital allocation perspective, we took additional actions in fiscal 20 to strengthen our \nposition for long -term growt h. We invested $37 5 million of capex  back into the business, focusing on \nenhancing our IT infrastructure and fueling strategic growth opportunities.  We paid down $1.4 billion \nof debt, and we returned over $900 million to shareholders through dividends and share repurchases.  \n \n  Our effective t ax rate for the year was 25%. ", "original_text": "We ended the year with a $2.8 billion cash balance, with roughly half a billion dollars held \noutside the US and nothing outstanding under our $3 billion credit facilities.  \n \n ", "page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b53491953f6267fb21bc415195ec77b001f712588bb3428f4dc90ab28faea657", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f99d7e92-9a38-40a4-b071-9ae8c81277b2", "node_type": "1", "metadata": {"window": "As a reminder , the day of the week \nin which the quarter ends affects point -in-time of cash flows.  \n \n  We ended the year with a $2.8 billion cash balance, with roughly half a billion dollars held \noutside the US and nothing outstanding under our $3 billion credit facilities.  \n \n  From a capital allocation perspective, we took additional actions in fiscal 20 to strengthen our \nposition for long -term growt h. We invested $37 5 million of capex  back into the business, focusing on \nenhancing our IT infrastructure and fueling strategic growth opportunities.  We paid down $1.4 billion \nof debt, and we returned over $900 million to shareholders through dividends and share repurchases.  \n \n  Our effective t ax rate for the year was 25%.  We finished the year with earnings per share of \n$5.45, up more than 3% vs.  prior year, which exceeded our guidance range.  \n", "original_text": "We paid down $1.4 billion \nof debt, and we returned over $900 million to shareholders through dividends and share repurchases.  \n \n "}, "hash": "6b8329e349f8484828eabe0a48a97174a7acfb5f84e4b326ef4eadd547a0c504", "class_name": "RelatedNodeInfo"}}, "text": "From a capital allocation perspective, we took additional actions in fiscal 20 to strengthen our \nposition for long -term growt h. We invested $37 5 million of capex  back into the business, focusing on \nenhancing our IT infrastructure and fueling strategic growth opportunities. ", "start_char_idx": 366, "end_char_idx": 646, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f99d7e92-9a38-40a4-b071-9ae8c81277b2": {"__data__": {"id_": "f99d7e92-9a38-40a4-b071-9ae8c81277b2", "embedding": null, "metadata": {"window": "As a reminder , the day of the week \nin which the quarter ends affects point -in-time of cash flows.  \n \n  We ended the year with a $2.8 billion cash balance, with roughly half a billion dollars held \noutside the US and nothing outstanding under our $3 billion credit facilities.  \n \n  From a capital allocation perspective, we took additional actions in fiscal 20 to strengthen our \nposition for long -term growt h. We invested $37 5 million of capex  back into the business, focusing on \nenhancing our IT infrastructure and fueling strategic growth opportunities.  We paid down $1.4 billion \nof debt, and we returned over $900 million to shareholders through dividends and share repurchases.  \n \n  Our effective t ax rate for the year was 25%.  We finished the year with earnings per share of \n$5.45, up more than 3% vs.  prior year, which exceeded our guidance range.  \n", "original_text": "We paid down $1.4 billion \nof debt, and we returned over $900 million to shareholders through dividends and share repurchases.  \n \n ", "page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91d90699-bd7b-4281-a21c-c28f6658f0be", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d6a7eac736f3f690a357bde1e4b4667c2d4fc8e5c6b5de57ed0e8fcc1326e6b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb55a3f6-523b-4acb-9a1f-77c83685f062", "node_type": "1", "metadata": {"window": " \nPage 6 of 31 \n \n \n We finished the year with $2 billion of operating cash flow.  As a reminder , the day of the week \nin which the quarter ends affects point -in-time of cash flows.  \n \n  We ended the year with a $2.8 billion cash balance, with roughly half a billion dollars held \noutside the US and nothing outstanding under our $3 billion credit facilities.  \n \n  From a capital allocation perspective, we took additional actions in fiscal 20 to strengthen our \nposition for long -term growt h. We invested $37 5 million of capex  back into the business, focusing on \nenhancing our IT infrastructure and fueling strategic growth opportunities.  We paid down $1.4 billion \nof debt, and we returned over $900 million to shareholders through dividends and share repurchases.  \n \n  Our effective t ax rate for the year was 25%.  We finished the year with earnings per share of \n$5.45, up more than 3% vs. ", "original_text": "From a capital allocation perspective, we took additional actions in fiscal 20 to strengthen our \nposition for long -term growt h. We invested $37 5 million of capex  back into the business, focusing on \nenhancing our IT infrastructure and fueling strategic growth opportunities. ", "page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef0561a363cef322a8c91aab18b60a56f7c0557a332416c2725bc958ca7a6809", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77c5c322-efc7-44d9-a687-f457ab4149d3", "node_type": "1", "metadata": {"window": "We ended the year with a $2.8 billion cash balance, with roughly half a billion dollars held \noutside the US and nothing outstanding under our $3 billion credit facilities.  \n \n  From a capital allocation perspective, we took additional actions in fiscal 20 to strengthen our \nposition for long -term growt h. We invested $37 5 million of capex  back into the business, focusing on \nenhancing our IT infrastructure and fueling strategic growth opportunities.  We paid down $1.4 billion \nof debt, and we returned over $900 million to shareholders through dividends and share repurchases.  \n \n  Our effective t ax rate for the year was 25%.  We finished the year with earnings per share of \n$5.45, up more than 3% vs.  prior year, which exceeded our guidance range.  \n Transitioning to the segments on slide 10, Pharma performance exceeded our expectations for \nthe full ye ar. ", "original_text": "Our effective t ax rate for the year was 25%. "}, "hash": "13b92a227da1dc0aa865a03f2061c6b75abc0e1aeed708f161156eefe2c6bd53", "class_name": "RelatedNodeInfo"}}, "text": "We paid down $1.4 billion \nof debt, and we returned over $900 million to shareholders through dividends and share repurchases.  \n \n ", "start_char_idx": 646, "end_char_idx": 778, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77c5c322-efc7-44d9-a687-f457ab4149d3": {"__data__": {"id_": "77c5c322-efc7-44d9-a687-f457ab4149d3", "embedding": null, "metadata": {"window": "We ended the year with a $2.8 billion cash balance, with roughly half a billion dollars held \noutside the US and nothing outstanding under our $3 billion credit facilities.  \n \n  From a capital allocation perspective, we took additional actions in fiscal 20 to strengthen our \nposition for long -term growt h. We invested $37 5 million of capex  back into the business, focusing on \nenhancing our IT infrastructure and fueling strategic growth opportunities.  We paid down $1.4 billion \nof debt, and we returned over $900 million to shareholders through dividends and share repurchases.  \n \n  Our effective t ax rate for the year was 25%.  We finished the year with earnings per share of \n$5.45, up more than 3% vs.  prior year, which exceeded our guidance range.  \n Transitioning to the segments on slide 10, Pharma performance exceeded our expectations for \nthe full ye ar. ", "original_text": "Our effective t ax rate for the year was 25%. ", "page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91d90699-bd7b-4281-a21c-c28f6658f0be", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d6a7eac736f3f690a357bde1e4b4667c2d4fc8e5c6b5de57ed0e8fcc1326e6b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f99d7e92-9a38-40a4-b071-9ae8c81277b2", "node_type": "1", "metadata": {"window": "As a reminder , the day of the week \nin which the quarter ends affects point -in-time of cash flows.  \n \n  We ended the year with a $2.8 billion cash balance, with roughly half a billion dollars held \noutside the US and nothing outstanding under our $3 billion credit facilities.  \n \n  From a capital allocation perspective, we took additional actions in fiscal 20 to strengthen our \nposition for long -term growt h. We invested $37 5 million of capex  back into the business, focusing on \nenhancing our IT infrastructure and fueling strategic growth opportunities.  We paid down $1.4 billion \nof debt, and we returned over $900 million to shareholders through dividends and share repurchases.  \n \n  Our effective t ax rate for the year was 25%.  We finished the year with earnings per share of \n$5.45, up more than 3% vs.  prior year, which exceeded our guidance range.  \n", "original_text": "We paid down $1.4 billion \nof debt, and we returned over $900 million to shareholders through dividends and share repurchases.  \n \n ", "page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "27795cad4ebf3304eb858aa67c5f6468602becfad48c73e9196a1082ea336684", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25e88350-3498-47a5-acf0-6ca59964a255", "node_type": "1", "metadata": {"window": "From a capital allocation perspective, we took additional actions in fiscal 20 to strengthen our \nposition for long -term growt h. We invested $37 5 million of capex  back into the business, focusing on \nenhancing our IT infrastructure and fueling strategic growth opportunities.  We paid down $1.4 billion \nof debt, and we returned over $900 million to shareholders through dividends and share repurchases.  \n \n  Our effective t ax rate for the year was 25%.  We finished the year with earnings per share of \n$5.45, up more than 3% vs.  prior year, which exceeded our guidance range.  \n Transitioning to the segments on slide 10, Pharma performance exceeded our expectations for \nthe full ye ar.  Segment revenue grew 6% to $137 billion, driven by sales growth from Pharmaceutical \nDistribution customers, and to a lesser extent, Specialty Solutions customers.  \n \n ", "original_text": "We finished the year with earnings per share of \n$5.45, up more than 3% vs. "}, "hash": "0743b834a033db3bde6ffef6e5e5b60dcaeed336eeee150791a2e6d8787ce310", "class_name": "RelatedNodeInfo"}}, "text": "Our effective t ax rate for the year was 25%. ", "start_char_idx": 778, "end_char_idx": 824, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25e88350-3498-47a5-acf0-6ca59964a255": {"__data__": {"id_": "25e88350-3498-47a5-acf0-6ca59964a255", "embedding": null, "metadata": {"window": "From a capital allocation perspective, we took additional actions in fiscal 20 to strengthen our \nposition for long -term growt h. We invested $37 5 million of capex  back into the business, focusing on \nenhancing our IT infrastructure and fueling strategic growth opportunities.  We paid down $1.4 billion \nof debt, and we returned over $900 million to shareholders through dividends and share repurchases.  \n \n  Our effective t ax rate for the year was 25%.  We finished the year with earnings per share of \n$5.45, up more than 3% vs.  prior year, which exceeded our guidance range.  \n Transitioning to the segments on slide 10, Pharma performance exceeded our expectations for \nthe full ye ar.  Segment revenue grew 6% to $137 billion, driven by sales growth from Pharmaceutical \nDistribution customers, and to a lesser extent, Specialty Solutions customers.  \n \n ", "original_text": "We finished the year with earnings per share of \n$5.45, up more than 3% vs. ", "page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91d90699-bd7b-4281-a21c-c28f6658f0be", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d6a7eac736f3f690a357bde1e4b4667c2d4fc8e5c6b5de57ed0e8fcc1326e6b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77c5c322-efc7-44d9-a687-f457ab4149d3", "node_type": "1", "metadata": {"window": "We ended the year with a $2.8 billion cash balance, with roughly half a billion dollars held \noutside the US and nothing outstanding under our $3 billion credit facilities.  \n \n  From a capital allocation perspective, we took additional actions in fiscal 20 to strengthen our \nposition for long -term growt h. We invested $37 5 million of capex  back into the business, focusing on \nenhancing our IT infrastructure and fueling strategic growth opportunities.  We paid down $1.4 billion \nof debt, and we returned over $900 million to shareholders through dividends and share repurchases.  \n \n  Our effective t ax rate for the year was 25%.  We finished the year with earnings per share of \n$5.45, up more than 3% vs.  prior year, which exceeded our guidance range.  \n Transitioning to the segments on slide 10, Pharma performance exceeded our expectations for \nthe full ye ar. ", "original_text": "Our effective t ax rate for the year was 25%. ", "page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a0313f6e16b6a8bb7c96ce6025c758cc5b890336f046920d510507f9d20b85d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44f815de-eb18-443c-99ee-a6718d1c7135", "node_type": "1", "metadata": {"window": "We paid down $1.4 billion \nof debt, and we returned over $900 million to shareholders through dividends and share repurchases.  \n \n  Our effective t ax rate for the year was 25%.  We finished the year with earnings per share of \n$5.45, up more than 3% vs.  prior year, which exceeded our guidance range.  \n Transitioning to the segments on slide 10, Pharma performance exceeded our expectations for \nthe full ye ar.  Segment revenue grew 6% to $137 billion, driven by sales growth from Pharmaceutical \nDistribution customers, and to a lesser extent, Specialty Solutions customers.  \n \n  Segment profit decreased 4% to $1.8 billion, reflecting the adverse impact of Pharmaceu tical \nDistribution customer contract renewals, partially offset by a favorable mix of brand sales and \nSpecialty Solutions growth.  \n \n ", "original_text": "prior year, which exceeded our guidance range.  \n"}, "hash": "ad1b6918d7ee092f14cb555a465ccb1c929ed7b5bcaaa65a62ad80ee21039e5c", "class_name": "RelatedNodeInfo"}}, "text": "We finished the year with earnings per share of \n$5.45, up more than 3% vs. ", "start_char_idx": 824, "end_char_idx": 900, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44f815de-eb18-443c-99ee-a6718d1c7135": {"__data__": {"id_": "44f815de-eb18-443c-99ee-a6718d1c7135", "embedding": null, "metadata": {"window": "We paid down $1.4 billion \nof debt, and we returned over $900 million to shareholders through dividends and share repurchases.  \n \n  Our effective t ax rate for the year was 25%.  We finished the year with earnings per share of \n$5.45, up more than 3% vs.  prior year, which exceeded our guidance range.  \n Transitioning to the segments on slide 10, Pharma performance exceeded our expectations for \nthe full ye ar.  Segment revenue grew 6% to $137 billion, driven by sales growth from Pharmaceutical \nDistribution customers, and to a lesser extent, Specialty Solutions customers.  \n \n  Segment profit decreased 4% to $1.8 billion, reflecting the adverse impact of Pharmaceu tical \nDistribution customer contract renewals, partially offset by a favorable mix of brand sales and \nSpecialty Solutions growth.  \n \n ", "original_text": "prior year, which exceeded our guidance range.  \n", "page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91d90699-bd7b-4281-a21c-c28f6658f0be", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d6a7eac736f3f690a357bde1e4b4667c2d4fc8e5c6b5de57ed0e8fcc1326e6b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25e88350-3498-47a5-acf0-6ca59964a255", "node_type": "1", "metadata": {"window": "From a capital allocation perspective, we took additional actions in fiscal 20 to strengthen our \nposition for long -term growt h. We invested $37 5 million of capex  back into the business, focusing on \nenhancing our IT infrastructure and fueling strategic growth opportunities.  We paid down $1.4 billion \nof debt, and we returned over $900 million to shareholders through dividends and share repurchases.  \n \n  Our effective t ax rate for the year was 25%.  We finished the year with earnings per share of \n$5.45, up more than 3% vs.  prior year, which exceeded our guidance range.  \n Transitioning to the segments on slide 10, Pharma performance exceeded our expectations for \nthe full ye ar.  Segment revenue grew 6% to $137 billion, driven by sales growth from Pharmaceutical \nDistribution customers, and to a lesser extent, Specialty Solutions customers.  \n \n ", "original_text": "We finished the year with earnings per share of \n$5.45, up more than 3% vs. ", "page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd1c66620bc99e7c354412b6ed9486cec849854512f1ce540e986d91a5d74bc4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed9831fe-8ef3-4b56-a238-6e59a8e8270f", "node_type": "1", "metadata": {"window": "Our effective t ax rate for the year was 25%.  We finished the year with earnings per share of \n$5.45, up more than 3% vs.  prior year, which exceeded our guidance range.  \n Transitioning to the segments on slide 10, Pharma performance exceeded our expectations for \nthe full ye ar.  Segment revenue grew 6% to $137 billion, driven by sales growth from Pharmaceutical \nDistribution customers, and to a lesser extent, Specialty Solutions customers.  \n \n  Segment profit decreased 4% to $1.8 billion, reflecting the adverse impact of Pharmaceu tical \nDistribution customer contract renewals, partially offset by a favorable mix of brand sales and \nSpecialty Solutions growth.  \n \n  Importantly, although we saw lower volumes in the fourth quarter related to COVID -19, our \ngenerics program experienced overa ll consistent market dynamics during the year and was a net \ntailwind in fiscal 20.  ", "original_text": "Transitioning to the segments on slide 10, Pharma performance exceeded our expectations for \nthe full ye ar. "}, "hash": "572edee062efe880c91011d3f01822b5fb1403197a2cbd9b71866d2eab5d8736", "class_name": "RelatedNodeInfo"}}, "text": "prior year, which exceeded our guidance range.  \n", "start_char_idx": 900, "end_char_idx": 949, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed9831fe-8ef3-4b56-a238-6e59a8e8270f": {"__data__": {"id_": "ed9831fe-8ef3-4b56-a238-6e59a8e8270f", "embedding": null, "metadata": {"window": "Our effective t ax rate for the year was 25%.  We finished the year with earnings per share of \n$5.45, up more than 3% vs.  prior year, which exceeded our guidance range.  \n Transitioning to the segments on slide 10, Pharma performance exceeded our expectations for \nthe full ye ar.  Segment revenue grew 6% to $137 billion, driven by sales growth from Pharmaceutical \nDistribution customers, and to a lesser extent, Specialty Solutions customers.  \n \n  Segment profit decreased 4% to $1.8 billion, reflecting the adverse impact of Pharmaceu tical \nDistribution customer contract renewals, partially offset by a favorable mix of brand sales and \nSpecialty Solutions growth.  \n \n  Importantly, although we saw lower volumes in the fourth quarter related to COVID -19, our \ngenerics program experienced overa ll consistent market dynamics during the year and was a net \ntailwind in fiscal 20.  ", "original_text": "Transitioning to the segments on slide 10, Pharma performance exceeded our expectations for \nthe full ye ar. ", "page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91d90699-bd7b-4281-a21c-c28f6658f0be", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d6a7eac736f3f690a357bde1e4b4667c2d4fc8e5c6b5de57ed0e8fcc1326e6b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44f815de-eb18-443c-99ee-a6718d1c7135", "node_type": "1", "metadata": {"window": "We paid down $1.4 billion \nof debt, and we returned over $900 million to shareholders through dividends and share repurchases.  \n \n  Our effective t ax rate for the year was 25%.  We finished the year with earnings per share of \n$5.45, up more than 3% vs.  prior year, which exceeded our guidance range.  \n Transitioning to the segments on slide 10, Pharma performance exceeded our expectations for \nthe full ye ar.  Segment revenue grew 6% to $137 billion, driven by sales growth from Pharmaceutical \nDistribution customers, and to a lesser extent, Specialty Solutions customers.  \n \n  Segment profit decreased 4% to $1.8 billion, reflecting the adverse impact of Pharmaceu tical \nDistribution customer contract renewals, partially offset by a favorable mix of brand sales and \nSpecialty Solutions growth.  \n \n ", "original_text": "prior year, which exceeded our guidance range.  \n", "page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "47061143a6cb5409f9ac8f95d369c093ce43806b5599246f2040f4f5135535fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29bd0de8-a244-44b3-8dcf-eb82f425f522", "node_type": "1", "metadata": {"window": "We finished the year with earnings per share of \n$5.45, up more than 3% vs.  prior year, which exceeded our guidance range.  \n Transitioning to the segments on slide 10, Pharma performance exceeded our expectations for \nthe full ye ar.  Segment revenue grew 6% to $137 billion, driven by sales growth from Pharmaceutical \nDistribution customers, and to a lesser extent, Specialty Solutions customers.  \n \n  Segment profit decreased 4% to $1.8 billion, reflecting the adverse impact of Pharmaceu tical \nDistribution customer contract renewals, partially offset by a favorable mix of brand sales and \nSpecialty Solutions growth.  \n \n  Importantly, although we saw lower volumes in the fourth quarter related to COVID -19, our \ngenerics program experienced overa ll consistent market dynamics during the year and was a net \ntailwind in fiscal 20.  ", "original_text": "Segment revenue grew 6% to $137 billion, driven by sales growth from Pharmaceutical \nDistribution customers, and to a lesser extent, Specialty Solutions customers.  \n \n "}, "hash": "e5ebe998f92b7bcf70f430e9d029d628b044446e001ea1300c6dbf552b8d9690", "class_name": "RelatedNodeInfo"}}, "text": "Transitioning to the segments on slide 10, Pharma performance exceeded our expectations for \nthe full ye ar. ", "start_char_idx": 949, "end_char_idx": 1058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29bd0de8-a244-44b3-8dcf-eb82f425f522": {"__data__": {"id_": "29bd0de8-a244-44b3-8dcf-eb82f425f522", "embedding": null, "metadata": {"window": "We finished the year with earnings per share of \n$5.45, up more than 3% vs.  prior year, which exceeded our guidance range.  \n Transitioning to the segments on slide 10, Pharma performance exceeded our expectations for \nthe full ye ar.  Segment revenue grew 6% to $137 billion, driven by sales growth from Pharmaceutical \nDistribution customers, and to a lesser extent, Specialty Solutions customers.  \n \n  Segment profit decreased 4% to $1.8 billion, reflecting the adverse impact of Pharmaceu tical \nDistribution customer contract renewals, partially offset by a favorable mix of brand sales and \nSpecialty Solutions growth.  \n \n  Importantly, although we saw lower volumes in the fourth quarter related to COVID -19, our \ngenerics program experienced overa ll consistent market dynamics during the year and was a net \ntailwind in fiscal 20.  ", "original_text": "Segment revenue grew 6% to $137 billion, driven by sales growth from Pharmaceutical \nDistribution customers, and to a lesser extent, Specialty Solutions customers.  \n \n ", "page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91d90699-bd7b-4281-a21c-c28f6658f0be", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d6a7eac736f3f690a357bde1e4b4667c2d4fc8e5c6b5de57ed0e8fcc1326e6b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed9831fe-8ef3-4b56-a238-6e59a8e8270f", "node_type": "1", "metadata": {"window": "Our effective t ax rate for the year was 25%.  We finished the year with earnings per share of \n$5.45, up more than 3% vs.  prior year, which exceeded our guidance range.  \n Transitioning to the segments on slide 10, Pharma performance exceeded our expectations for \nthe full ye ar.  Segment revenue grew 6% to $137 billion, driven by sales growth from Pharmaceutical \nDistribution customers, and to a lesser extent, Specialty Solutions customers.  \n \n  Segment profit decreased 4% to $1.8 billion, reflecting the adverse impact of Pharmaceu tical \nDistribution customer contract renewals, partially offset by a favorable mix of brand sales and \nSpecialty Solutions growth.  \n \n  Importantly, although we saw lower volumes in the fourth quarter related to COVID -19, our \ngenerics program experienced overa ll consistent market dynamics during the year and was a net \ntailwind in fiscal 20.  ", "original_text": "Transitioning to the segments on slide 10, Pharma performance exceeded our expectations for \nthe full ye ar. ", "page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bbe3741cb1d7e3037d7db4aa784cc46b37eccfa12660b64f80841f1e88f27cc7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c733ec25-46d9-4bd9-9e3a-eae5e86205e0", "node_type": "1", "metadata": {"window": "prior year, which exceeded our guidance range.  \n Transitioning to the segments on slide 10, Pharma performance exceeded our expectations for \nthe full ye ar.  Segment revenue grew 6% to $137 billion, driven by sales growth from Pharmaceutical \nDistribution customers, and to a lesser extent, Specialty Solutions customers.  \n \n  Segment profit decreased 4% to $1.8 billion, reflecting the adverse impact of Pharmaceu tical \nDistribution customer contract renewals, partially offset by a favorable mix of brand sales and \nSpecialty Solutions growth.  \n \n  Importantly, although we saw lower volumes in the fourth quarter related to COVID -19, our \ngenerics program experienced overa ll consistent market dynamics during the year and was a net \ntailwind in fiscal 20.  ", "original_text": "Segment profit decreased 4% to $1.8 billion, reflecting the adverse impact of Pharmaceu tical \nDistribution customer contract renewals, partially offset by a favorable mix of brand sales and \nSpecialty Solutions growth.  \n \n "}, "hash": "abf6978b130ab7885c2d59fe89d1cade07932fb6b0552d9e146907e6a25457d7", "class_name": "RelatedNodeInfo"}}, "text": "Segment revenue grew 6% to $137 billion, driven by sales growth from Pharmaceutical \nDistribution customers, and to a lesser extent, Specialty Solutions customers.  \n \n ", "start_char_idx": 1058, "end_char_idx": 1227, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c733ec25-46d9-4bd9-9e3a-eae5e86205e0": {"__data__": {"id_": "c733ec25-46d9-4bd9-9e3a-eae5e86205e0", "embedding": null, "metadata": {"window": "prior year, which exceeded our guidance range.  \n Transitioning to the segments on slide 10, Pharma performance exceeded our expectations for \nthe full ye ar.  Segment revenue grew 6% to $137 billion, driven by sales growth from Pharmaceutical \nDistribution customers, and to a lesser extent, Specialty Solutions customers.  \n \n  Segment profit decreased 4% to $1.8 billion, reflecting the adverse impact of Pharmaceu tical \nDistribution customer contract renewals, partially offset by a favorable mix of brand sales and \nSpecialty Solutions growth.  \n \n  Importantly, although we saw lower volumes in the fourth quarter related to COVID -19, our \ngenerics program experienced overa ll consistent market dynamics during the year and was a net \ntailwind in fiscal 20.  ", "original_text": "Segment profit decreased 4% to $1.8 billion, reflecting the adverse impact of Pharmaceu tical \nDistribution customer contract renewals, partially offset by a favorable mix of brand sales and \nSpecialty Solutions growth.  \n \n ", "page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91d90699-bd7b-4281-a21c-c28f6658f0be", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d6a7eac736f3f690a357bde1e4b4667c2d4fc8e5c6b5de57ed0e8fcc1326e6b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29bd0de8-a244-44b3-8dcf-eb82f425f522", "node_type": "1", "metadata": {"window": "We finished the year with earnings per share of \n$5.45, up more than 3% vs.  prior year, which exceeded our guidance range.  \n Transitioning to the segments on slide 10, Pharma performance exceeded our expectations for \nthe full ye ar.  Segment revenue grew 6% to $137 billion, driven by sales growth from Pharmaceutical \nDistribution customers, and to a lesser extent, Specialty Solutions customers.  \n \n  Segment profit decreased 4% to $1.8 billion, reflecting the adverse impact of Pharmaceu tical \nDistribution customer contract renewals, partially offset by a favorable mix of brand sales and \nSpecialty Solutions growth.  \n \n  Importantly, although we saw lower volumes in the fourth quarter related to COVID -19, our \ngenerics program experienced overa ll consistent market dynamics during the year and was a net \ntailwind in fiscal 20.  ", "original_text": "Segment revenue grew 6% to $137 billion, driven by sales growth from Pharmaceutical \nDistribution customers, and to a lesser extent, Specialty Solutions customers.  \n \n ", "page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "006a7f5784afaa179a9b14bac37d8f3a9b75a78813c44842fe59b92a9b78932a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c979cb4d-50a7-4a61-a741-5057e7ec2ff1", "node_type": "1", "metadata": {"window": "Transitioning to the segments on slide 10, Pharma performance exceeded our expectations for \nthe full ye ar.  Segment revenue grew 6% to $137 billion, driven by sales growth from Pharmaceutical \nDistribution customers, and to a lesser extent, Specialty Solutions customers.  \n \n  Segment profit decreased 4% to $1.8 billion, reflecting the adverse impact of Pharmaceu tical \nDistribution customer contract renewals, partially offset by a favorable mix of brand sales and \nSpecialty Solutions growth.  \n \n  Importantly, although we saw lower volumes in the fourth quarter related to COVID -19, our \ngenerics program experienced overa ll consistent market dynamics during the year and was a net \ntailwind in fiscal 20.  ", "original_text": "Importantly, although we saw lower volumes in the fourth quarter related to COVID -19, our \ngenerics program experienced overa ll consistent market dynamics during the year and was a net \ntailwind in fiscal 20.  "}, "hash": "fc0359fcad0a541691f14cacbbe417292b741b9fcff34f030462f7c34cf7de61", "class_name": "RelatedNodeInfo"}}, "text": "Segment profit decreased 4% to $1.8 billion, reflecting the adverse impact of Pharmaceu tical \nDistribution customer contract renewals, partially offset by a favorable mix of brand sales and \nSpecialty Solutions growth.  \n \n ", "start_char_idx": 1227, "end_char_idx": 1452, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c979cb4d-50a7-4a61-a741-5057e7ec2ff1": {"__data__": {"id_": "c979cb4d-50a7-4a61-a741-5057e7ec2ff1", "embedding": null, "metadata": {"window": "Transitioning to the segments on slide 10, Pharma performance exceeded our expectations for \nthe full ye ar.  Segment revenue grew 6% to $137 billion, driven by sales growth from Pharmaceutical \nDistribution customers, and to a lesser extent, Specialty Solutions customers.  \n \n  Segment profit decreased 4% to $1.8 billion, reflecting the adverse impact of Pharmaceu tical \nDistribution customer contract renewals, partially offset by a favorable mix of brand sales and \nSpecialty Solutions growth.  \n \n  Importantly, although we saw lower volumes in the fourth quarter related to COVID -19, our \ngenerics program experienced overa ll consistent market dynamics during the year and was a net \ntailwind in fiscal 20.  ", "original_text": "Importantly, although we saw lower volumes in the fourth quarter related to COVID -19, our \ngenerics program experienced overa ll consistent market dynamics during the year and was a net \ntailwind in fiscal 20.  ", "page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "91d90699-bd7b-4281-a21c-c28f6658f0be", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d6a7eac736f3f690a357bde1e4b4667c2d4fc8e5c6b5de57ed0e8fcc1326e6b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c733ec25-46d9-4bd9-9e3a-eae5e86205e0", "node_type": "1", "metadata": {"window": "prior year, which exceeded our guidance range.  \n Transitioning to the segments on slide 10, Pharma performance exceeded our expectations for \nthe full ye ar.  Segment revenue grew 6% to $137 billion, driven by sales growth from Pharmaceutical \nDistribution customers, and to a lesser extent, Specialty Solutions customers.  \n \n  Segment profit decreased 4% to $1.8 billion, reflecting the adverse impact of Pharmaceu tical \nDistribution customer contract renewals, partially offset by a favorable mix of brand sales and \nSpecialty Solutions growth.  \n \n  Importantly, although we saw lower volumes in the fourth quarter related to COVID -19, our \ngenerics program experienced overa ll consistent market dynamics during the year and was a net \ntailwind in fiscal 20.  ", "original_text": "Segment profit decreased 4% to $1.8 billion, reflecting the adverse impact of Pharmaceu tical \nDistribution customer contract renewals, partially offset by a favorable mix of brand sales and \nSpecialty Solutions growth.  \n \n ", "page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa49e5d02891b64d199fc46c07b6e43bfa6ea8167d57731845a22a736cba30fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f58158c-b83e-4781-98e4-9306d205f347", "node_type": "1", "metadata": {"window": " \nPage 7 of 31 \n \n \n In Medical, performance was strong.  Although revenue decreased 1% to $15.4 billion due to \nthe adverse impact from COVID -19, segment profit increased 15% to $663 million.  T his was driven by \ncost savings initiatives, particularly within our global manufacturing and supply chain , and the \nbeneficial comparison to a supplier -related charge in the prior year, partially offset by the impact of \nCOVID -19. \n \n  Across the company in fis cal 20 we demonstrated positive performance despite significant \nglobal challenges. ", "original_text": " \nPage 7 of 31 \n \n \n In Medical, performance was strong. "}, "hash": "6cfa477172bf2c1b376beac44b2908e3c93fc73db4c9d009f72c04664b4564e0", "class_name": "RelatedNodeInfo"}}, "text": "Importantly, although we saw lower volumes in the fourth quarter related to COVID -19, our \ngenerics program experienced overa ll consistent market dynamics during the year and was a net \ntailwind in fiscal 20.  ", "start_char_idx": 1452, "end_char_idx": 1664, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f58158c-b83e-4781-98e4-9306d205f347": {"__data__": {"id_": "3f58158c-b83e-4781-98e4-9306d205f347", "embedding": null, "metadata": {"window": " \nPage 7 of 31 \n \n \n In Medical, performance was strong.  Although revenue decreased 1% to $15.4 billion due to \nthe adverse impact from COVID -19, segment profit increased 15% to $663 million.  T his was driven by \ncost savings initiatives, particularly within our global manufacturing and supply chain , and the \nbeneficial comparison to a supplier -related charge in the prior year, partially offset by the impact of \nCOVID -19. \n \n  Across the company in fis cal 20 we demonstrated positive performance despite significant \nglobal challenges. ", "original_text": " \nPage 7 of 31 \n \n \n In Medical, performance was strong. ", "page_label": "7", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cb67424-de13-43db-b082-558d37f75ec2", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aefdd1f3ca14ef4352884295c77f9b63e8139c37eaa737b3a40c27660f8ae029", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c979cb4d-50a7-4a61-a741-5057e7ec2ff1", "node_type": "1", "metadata": {"window": "Transitioning to the segments on slide 10, Pharma performance exceeded our expectations for \nthe full ye ar.  Segment revenue grew 6% to $137 billion, driven by sales growth from Pharmaceutical \nDistribution customers, and to a lesser extent, Specialty Solutions customers.  \n \n  Segment profit decreased 4% to $1.8 billion, reflecting the adverse impact of Pharmaceu tical \nDistribution customer contract renewals, partially offset by a favorable mix of brand sales and \nSpecialty Solutions growth.  \n \n  Importantly, although we saw lower volumes in the fourth quarter related to COVID -19, our \ngenerics program experienced overa ll consistent market dynamics during the year and was a net \ntailwind in fiscal 20.  ", "original_text": "Importantly, although we saw lower volumes in the fourth quarter related to COVID -19, our \ngenerics program experienced overa ll consistent market dynamics during the year and was a net \ntailwind in fiscal 20.  ", "page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d4700c85d276b26370eb9e08aa06ce32b3b3f72f2126bc3212dddeada329dd6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24134567-87a3-4524-95e3-eefdb4c51361", "node_type": "1", "metadata": {"window": " \nPage 7 of 31 \n \n \n In Medical, performance was strong.  Although revenue decreased 1% to $15.4 billion due to \nthe adverse impact from COVID -19, segment profit increased 15% to $663 million.  T his was driven by \ncost savings initiatives, particularly within our global manufacturing and supply chain , and the \nbeneficial comparison to a supplier -related charge in the prior year, partially offset by the impact of \nCOVID -19. \n \n  Across the company in fis cal 20 we demonstrated positive performance despite significant \nglobal challenges.  As these dynamics continue into fiscal 21, we are focused on building upon our \noperational momentum  through the underlying strength and resilience of our business.  \n \n ", "original_text": "Although revenue decreased 1% to $15.4 billion due to \nthe adverse impact from COVID -19, segment profit increased 15% to $663 million. "}, "hash": "826bf89d3ff3ef77e05d9f5eb80045568b5be6d102824f1c8333347270958979", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 7 of 31 \n \n \n In Medical, performance was strong. ", "start_char_idx": 0, "end_char_idx": 57, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24134567-87a3-4524-95e3-eefdb4c51361": {"__data__": {"id_": "24134567-87a3-4524-95e3-eefdb4c51361", "embedding": null, "metadata": {"window": " \nPage 7 of 31 \n \n \n In Medical, performance was strong.  Although revenue decreased 1% to $15.4 billion due to \nthe adverse impact from COVID -19, segment profit increased 15% to $663 million.  T his was driven by \ncost savings initiatives, particularly within our global manufacturing and supply chain , and the \nbeneficial comparison to a supplier -related charge in the prior year, partially offset by the impact of \nCOVID -19. \n \n  Across the company in fis cal 20 we demonstrated positive performance despite significant \nglobal challenges.  As these dynamics continue into fiscal 21, we are focused on building upon our \noperational momentum  through the underlying strength and resilience of our business.  \n \n ", "original_text": "Although revenue decreased 1% to $15.4 billion due to \nthe adverse impact from COVID -19, segment profit increased 15% to $663 million. ", "page_label": "7", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cb67424-de13-43db-b082-558d37f75ec2", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aefdd1f3ca14ef4352884295c77f9b63e8139c37eaa737b3a40c27660f8ae029", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f58158c-b83e-4781-98e4-9306d205f347", "node_type": "1", "metadata": {"window": " \nPage 7 of 31 \n \n \n In Medical, performance was strong.  Although revenue decreased 1% to $15.4 billion due to \nthe adverse impact from COVID -19, segment profit increased 15% to $663 million.  T his was driven by \ncost savings initiatives, particularly within our global manufacturing and supply chain , and the \nbeneficial comparison to a supplier -related charge in the prior year, partially offset by the impact of \nCOVID -19. \n \n  Across the company in fis cal 20 we demonstrated positive performance despite significant \nglobal challenges. ", "original_text": " \nPage 7 of 31 \n \n \n In Medical, performance was strong. ", "page_label": "7", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4d5cd00357819c67ab29673e413505af65a6bbb664ab2d7cb15caa571865249", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6639e552-b50e-4c85-a10d-bc71ee227887", "node_type": "1", "metadata": {"window": " \nPage 7 of 31 \n \n \n In Medical, performance was strong.  Although revenue decreased 1% to $15.4 billion due to \nthe adverse impact from COVID -19, segment profit increased 15% to $663 million.  T his was driven by \ncost savings initiatives, particularly within our global manufacturing and supply chain , and the \nbeneficial comparison to a supplier -related charge in the prior year, partially offset by the impact of \nCOVID -19. \n \n  Across the company in fis cal 20 we demonstrated positive performance despite significant \nglobal challenges.  As these dynamics continue into fiscal 21, we are focused on building upon our \noperational momentum  through the underlying strength and resilience of our business.  \n \n  Before I share our outlook for fiscal 21, let me first provide a few updates regarding the \nassumed COVID -19 trajectory going forward.  \n \n ", "original_text": "T his was driven by \ncost savings initiatives, particularly within our global manufacturing and supply chain , and the \nbeneficial comparison to a supplier -related charge in the prior year, partially offset by the impact of \nCOVID -19. \n \n "}, "hash": "c60c5eae70630692b7b3762d9c2f0fdae66e7c741b8ea3fcc26290e35c8866ad", "class_name": "RelatedNodeInfo"}}, "text": "Although revenue decreased 1% to $15.4 billion due to \nthe adverse impact from COVID -19, segment profit increased 15% to $663 million. ", "start_char_idx": 57, "end_char_idx": 193, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6639e552-b50e-4c85-a10d-bc71ee227887": {"__data__": {"id_": "6639e552-b50e-4c85-a10d-bc71ee227887", "embedding": null, "metadata": {"window": " \nPage 7 of 31 \n \n \n In Medical, performance was strong.  Although revenue decreased 1% to $15.4 billion due to \nthe adverse impact from COVID -19, segment profit increased 15% to $663 million.  T his was driven by \ncost savings initiatives, particularly within our global manufacturing and supply chain , and the \nbeneficial comparison to a supplier -related charge in the prior year, partially offset by the impact of \nCOVID -19. \n \n  Across the company in fis cal 20 we demonstrated positive performance despite significant \nglobal challenges.  As these dynamics continue into fiscal 21, we are focused on building upon our \noperational momentum  through the underlying strength and resilience of our business.  \n \n  Before I share our outlook for fiscal 21, let me first provide a few updates regarding the \nassumed COVID -19 trajectory going forward.  \n \n ", "original_text": "T his was driven by \ncost savings initiatives, particularly within our global manufacturing and supply chain , and the \nbeneficial comparison to a supplier -related charge in the prior year, partially offset by the impact of \nCOVID -19. \n \n ", "page_label": "7", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cb67424-de13-43db-b082-558d37f75ec2", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aefdd1f3ca14ef4352884295c77f9b63e8139c37eaa737b3a40c27660f8ae029", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24134567-87a3-4524-95e3-eefdb4c51361", "node_type": "1", "metadata": {"window": " \nPage 7 of 31 \n \n \n In Medical, performance was strong.  Although revenue decreased 1% to $15.4 billion due to \nthe adverse impact from COVID -19, segment profit increased 15% to $663 million.  T his was driven by \ncost savings initiatives, particularly within our global manufacturing and supply chain , and the \nbeneficial comparison to a supplier -related charge in the prior year, partially offset by the impact of \nCOVID -19. \n \n  Across the company in fis cal 20 we demonstrated positive performance despite significant \nglobal challenges.  As these dynamics continue into fiscal 21, we are focused on building upon our \noperational momentum  through the underlying strength and resilience of our business.  \n \n ", "original_text": "Although revenue decreased 1% to $15.4 billion due to \nthe adverse impact from COVID -19, segment profit increased 15% to $663 million. ", "page_label": "7", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e8420bc423f8ad70744386b3caf60f31b651c7073a3428509d75ad55b78400c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4368969-aa9c-4567-bee5-51b78b66ade4", "node_type": "1", "metadata": {"window": " \nPage 7 of 31 \n \n \n In Medical, performance was strong.  Although revenue decreased 1% to $15.4 billion due to \nthe adverse impact from COVID -19, segment profit increased 15% to $663 million.  T his was driven by \ncost savings initiatives, particularly within our global manufacturing and supply chain , and the \nbeneficial comparison to a supplier -related charge in the prior year, partially offset by the impact of \nCOVID -19. \n \n  Across the company in fis cal 20 we demonstrated positive performance despite significant \nglobal challenges.  As these dynamics continue into fiscal 21, we are focused on building upon our \noperational momentum  through the underlying strength and resilience of our business.  \n \n  Before I share our outlook for fiscal 21, let me first provide a few updates regarding the \nassumed COVID -19 trajectory going forward.  \n \n  This can be found on slide 13.  \n \n ", "original_text": "Across the company in fis cal 20 we demonstrated positive performance despite significant \nglobal challenges. "}, "hash": "631a455de3bdb41fe30ba3bd501de85c1a816f120d81bc845f57733642a0d17b", "class_name": "RelatedNodeInfo"}}, "text": "T his was driven by \ncost savings initiatives, particularly within our global manufacturing and supply chain , and the \nbeneficial comparison to a supplier -related charge in the prior year, partially offset by the impact of \nCOVID -19. \n \n ", "start_char_idx": 193, "end_char_idx": 434, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4368969-aa9c-4567-bee5-51b78b66ade4": {"__data__": {"id_": "b4368969-aa9c-4567-bee5-51b78b66ade4", "embedding": null, "metadata": {"window": " \nPage 7 of 31 \n \n \n In Medical, performance was strong.  Although revenue decreased 1% to $15.4 billion due to \nthe adverse impact from COVID -19, segment profit increased 15% to $663 million.  T his was driven by \ncost savings initiatives, particularly within our global manufacturing and supply chain , and the \nbeneficial comparison to a supplier -related charge in the prior year, partially offset by the impact of \nCOVID -19. \n \n  Across the company in fis cal 20 we demonstrated positive performance despite significant \nglobal challenges.  As these dynamics continue into fiscal 21, we are focused on building upon our \noperational momentum  through the underlying strength and resilience of our business.  \n \n  Before I share our outlook for fiscal 21, let me first provide a few updates regarding the \nassumed COVID -19 trajectory going forward.  \n \n  This can be found on slide 13.  \n \n ", "original_text": "Across the company in fis cal 20 we demonstrated positive performance despite significant \nglobal challenges. ", "page_label": "7", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cb67424-de13-43db-b082-558d37f75ec2", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aefdd1f3ca14ef4352884295c77f9b63e8139c37eaa737b3a40c27660f8ae029", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6639e552-b50e-4c85-a10d-bc71ee227887", "node_type": "1", "metadata": {"window": " \nPage 7 of 31 \n \n \n In Medical, performance was strong.  Although revenue decreased 1% to $15.4 billion due to \nthe adverse impact from COVID -19, segment profit increased 15% to $663 million.  T his was driven by \ncost savings initiatives, particularly within our global manufacturing and supply chain , and the \nbeneficial comparison to a supplier -related charge in the prior year, partially offset by the impact of \nCOVID -19. \n \n  Across the company in fis cal 20 we demonstrated positive performance despite significant \nglobal challenges.  As these dynamics continue into fiscal 21, we are focused on building upon our \noperational momentum  through the underlying strength and resilience of our business.  \n \n  Before I share our outlook for fiscal 21, let me first provide a few updates regarding the \nassumed COVID -19 trajectory going forward.  \n \n ", "original_text": "T his was driven by \ncost savings initiatives, particularly within our global manufacturing and supply chain , and the \nbeneficial comparison to a supplier -related charge in the prior year, partially offset by the impact of \nCOVID -19. \n \n ", "page_label": "7", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "964d343288807aa909f04aa6c1599499c4a666651c6ebe8273b06d3adf4a815c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93e55058-6cbb-48a0-bc95-3ae8d6411b67", "node_type": "1", "metadata": {"window": "Although revenue decreased 1% to $15.4 billion due to \nthe adverse impact from COVID -19, segment profit increased 15% to $663 million.  T his was driven by \ncost savings initiatives, particularly within our global manufacturing and supply chain , and the \nbeneficial comparison to a supplier -related charge in the prior year, partially offset by the impact of \nCOVID -19. \n \n  Across the company in fis cal 20 we demonstrated positive performance despite significant \nglobal challenges.  As these dynamics continue into fiscal 21, we are focused on building upon our \noperational momentum  through the underlying strength and resilience of our business.  \n \n  Before I share our outlook for fiscal 21, let me first provide a few updates regarding the \nassumed COVID -19 trajectory going forward.  \n \n  This can be found on slide 13.  \n \n  After significant dialogue both with external and internal thought leaders, as well as with ou r \nupstream and downstream partners, we now believe the general recovery regarding COVID -19 will \nbe a flatter , more elongated curve than initially anticipated.  \n \n ", "original_text": "As these dynamics continue into fiscal 21, we are focused on building upon our \noperational momentum  through the underlying strength and resilience of our business.  \n \n "}, "hash": "59ac8a21dc084c9117df165f750a8a83c413074d24ccc605ae0c4d1f94aa8f42", "class_name": "RelatedNodeInfo"}}, "text": "Across the company in fis cal 20 we demonstrated positive performance despite significant \nglobal challenges. ", "start_char_idx": 434, "end_char_idx": 544, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93e55058-6cbb-48a0-bc95-3ae8d6411b67": {"__data__": {"id_": "93e55058-6cbb-48a0-bc95-3ae8d6411b67", "embedding": null, "metadata": {"window": "Although revenue decreased 1% to $15.4 billion due to \nthe adverse impact from COVID -19, segment profit increased 15% to $663 million.  T his was driven by \ncost savings initiatives, particularly within our global manufacturing and supply chain , and the \nbeneficial comparison to a supplier -related charge in the prior year, partially offset by the impact of \nCOVID -19. \n \n  Across the company in fis cal 20 we demonstrated positive performance despite significant \nglobal challenges.  As these dynamics continue into fiscal 21, we are focused on building upon our \noperational momentum  through the underlying strength and resilience of our business.  \n \n  Before I share our outlook for fiscal 21, let me first provide a few updates regarding the \nassumed COVID -19 trajectory going forward.  \n \n  This can be found on slide 13.  \n \n  After significant dialogue both with external and internal thought leaders, as well as with ou r \nupstream and downstream partners, we now believe the general recovery regarding COVID -19 will \nbe a flatter , more elongated curve than initially anticipated.  \n \n ", "original_text": "As these dynamics continue into fiscal 21, we are focused on building upon our \noperational momentum  through the underlying strength and resilience of our business.  \n \n ", "page_label": "7", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cb67424-de13-43db-b082-558d37f75ec2", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aefdd1f3ca14ef4352884295c77f9b63e8139c37eaa737b3a40c27660f8ae029", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4368969-aa9c-4567-bee5-51b78b66ade4", "node_type": "1", "metadata": {"window": " \nPage 7 of 31 \n \n \n In Medical, performance was strong.  Although revenue decreased 1% to $15.4 billion due to \nthe adverse impact from COVID -19, segment profit increased 15% to $663 million.  T his was driven by \ncost savings initiatives, particularly within our global manufacturing and supply chain , and the \nbeneficial comparison to a supplier -related charge in the prior year, partially offset by the impact of \nCOVID -19. \n \n  Across the company in fis cal 20 we demonstrated positive performance despite significant \nglobal challenges.  As these dynamics continue into fiscal 21, we are focused on building upon our \noperational momentum  through the underlying strength and resilience of our business.  \n \n  Before I share our outlook for fiscal 21, let me first provide a few updates regarding the \nassumed COVID -19 trajectory going forward.  \n \n  This can be found on slide 13.  \n \n ", "original_text": "Across the company in fis cal 20 we demonstrated positive performance despite significant \nglobal challenges. ", "page_label": "7", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "498c3137f75d6c776172dd497b843b3442609b508d66384dafe0de13af4dc84d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1cbd26c-add5-4709-93c4-a5f1167202de", "node_type": "1", "metadata": {"window": "T his was driven by \ncost savings initiatives, particularly within our global manufacturing and supply chain , and the \nbeneficial comparison to a supplier -related charge in the prior year, partially offset by the impact of \nCOVID -19. \n \n  Across the company in fis cal 20 we demonstrated positive performance despite significant \nglobal challenges.  As these dynamics continue into fiscal 21, we are focused on building upon our \noperational momentum  through the underlying strength and resilience of our business.  \n \n  Before I share our outlook for fiscal 21, let me first provide a few updates regarding the \nassumed COVID -19 trajectory going forward.  \n \n  This can be found on slide 13.  \n \n  After significant dialogue both with external and internal thought leaders, as well as with ou r \nupstream and downstream partners, we now believe the general recovery regarding COVID -19 will \nbe a flatter , more elongated curve than initially anticipated.  \n \n  We are assuming a more significant impact from the ongoing deferral and cancellation of \nelectiv e procedures and physician office visits in the first half of the fiscal year, with an eventual \nrecovery to pre -COVID -19 levels as we exit fiscal 21.  \n ", "original_text": "Before I share our outlook for fiscal 21, let me first provide a few updates regarding the \nassumed COVID -19 trajectory going forward.  \n \n "}, "hash": "29527730cb5aa62b5b5cfd8a6437eba600bcf9f22ac23007a5cd9c94995c6648", "class_name": "RelatedNodeInfo"}}, "text": "As these dynamics continue into fiscal 21, we are focused on building upon our \noperational momentum  through the underlying strength and resilience of our business.  \n \n ", "start_char_idx": 544, "end_char_idx": 715, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1cbd26c-add5-4709-93c4-a5f1167202de": {"__data__": {"id_": "f1cbd26c-add5-4709-93c4-a5f1167202de", "embedding": null, "metadata": {"window": "T his was driven by \ncost savings initiatives, particularly within our global manufacturing and supply chain , and the \nbeneficial comparison to a supplier -related charge in the prior year, partially offset by the impact of \nCOVID -19. \n \n  Across the company in fis cal 20 we demonstrated positive performance despite significant \nglobal challenges.  As these dynamics continue into fiscal 21, we are focused on building upon our \noperational momentum  through the underlying strength and resilience of our business.  \n \n  Before I share our outlook for fiscal 21, let me first provide a few updates regarding the \nassumed COVID -19 trajectory going forward.  \n \n  This can be found on slide 13.  \n \n  After significant dialogue both with external and internal thought leaders, as well as with ou r \nupstream and downstream partners, we now believe the general recovery regarding COVID -19 will \nbe a flatter , more elongated curve than initially anticipated.  \n \n  We are assuming a more significant impact from the ongoing deferral and cancellation of \nelectiv e procedures and physician office visits in the first half of the fiscal year, with an eventual \nrecovery to pre -COVID -19 levels as we exit fiscal 21.  \n ", "original_text": "Before I share our outlook for fiscal 21, let me first provide a few updates regarding the \nassumed COVID -19 trajectory going forward.  \n \n ", "page_label": "7", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cb67424-de13-43db-b082-558d37f75ec2", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aefdd1f3ca14ef4352884295c77f9b63e8139c37eaa737b3a40c27660f8ae029", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93e55058-6cbb-48a0-bc95-3ae8d6411b67", "node_type": "1", "metadata": {"window": "Although revenue decreased 1% to $15.4 billion due to \nthe adverse impact from COVID -19, segment profit increased 15% to $663 million.  T his was driven by \ncost savings initiatives, particularly within our global manufacturing and supply chain , and the \nbeneficial comparison to a supplier -related charge in the prior year, partially offset by the impact of \nCOVID -19. \n \n  Across the company in fis cal 20 we demonstrated positive performance despite significant \nglobal challenges.  As these dynamics continue into fiscal 21, we are focused on building upon our \noperational momentum  through the underlying strength and resilience of our business.  \n \n  Before I share our outlook for fiscal 21, let me first provide a few updates regarding the \nassumed COVID -19 trajectory going forward.  \n \n  This can be found on slide 13.  \n \n  After significant dialogue both with external and internal thought leaders, as well as with ou r \nupstream and downstream partners, we now believe the general recovery regarding COVID -19 will \nbe a flatter , more elongated curve than initially anticipated.  \n \n ", "original_text": "As these dynamics continue into fiscal 21, we are focused on building upon our \noperational momentum  through the underlying strength and resilience of our business.  \n \n ", "page_label": "7", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4bee5dfc0e8ce20c8235527b1dcb39617cbe2b72b3d6702641b590803ee45793", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56a56827-ded7-445a-ad49-0ede13e4209e", "node_type": "1", "metadata": {"window": "Across the company in fis cal 20 we demonstrated positive performance despite significant \nglobal challenges.  As these dynamics continue into fiscal 21, we are focused on building upon our \noperational momentum  through the underlying strength and resilience of our business.  \n \n  Before I share our outlook for fiscal 21, let me first provide a few updates regarding the \nassumed COVID -19 trajectory going forward.  \n \n  This can be found on slide 13.  \n \n  After significant dialogue both with external and internal thought leaders, as well as with ou r \nupstream and downstream partners, we now believe the general recovery regarding COVID -19 will \nbe a flatter , more elongated curve than initially anticipated.  \n \n  We are assuming a more significant impact from the ongoing deferral and cancellation of \nelectiv e procedures and physician office visits in the first half of the fiscal year, with an eventual \nrecovery to pre -COVID -19 levels as we exit fiscal 21.  \n ", "original_text": "This can be found on slide 13.  \n \n "}, "hash": "2dc02576bd9b12d46e4f062f99f72c963fdbfae34352deb998f20b66dca61e49", "class_name": "RelatedNodeInfo"}}, "text": "Before I share our outlook for fiscal 21, let me first provide a few updates regarding the \nassumed COVID -19 trajectory going forward.  \n \n ", "start_char_idx": 715, "end_char_idx": 856, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56a56827-ded7-445a-ad49-0ede13e4209e": {"__data__": {"id_": "56a56827-ded7-445a-ad49-0ede13e4209e", "embedding": null, "metadata": {"window": "Across the company in fis cal 20 we demonstrated positive performance despite significant \nglobal challenges.  As these dynamics continue into fiscal 21, we are focused on building upon our \noperational momentum  through the underlying strength and resilience of our business.  \n \n  Before I share our outlook for fiscal 21, let me first provide a few updates regarding the \nassumed COVID -19 trajectory going forward.  \n \n  This can be found on slide 13.  \n \n  After significant dialogue both with external and internal thought leaders, as well as with ou r \nupstream and downstream partners, we now believe the general recovery regarding COVID -19 will \nbe a flatter , more elongated curve than initially anticipated.  \n \n  We are assuming a more significant impact from the ongoing deferral and cancellation of \nelectiv e procedures and physician office visits in the first half of the fiscal year, with an eventual \nrecovery to pre -COVID -19 levels as we exit fiscal 21.  \n ", "original_text": "This can be found on slide 13.  \n \n ", "page_label": "7", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cb67424-de13-43db-b082-558d37f75ec2", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aefdd1f3ca14ef4352884295c77f9b63e8139c37eaa737b3a40c27660f8ae029", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1cbd26c-add5-4709-93c4-a5f1167202de", "node_type": "1", "metadata": {"window": "T his was driven by \ncost savings initiatives, particularly within our global manufacturing and supply chain , and the \nbeneficial comparison to a supplier -related charge in the prior year, partially offset by the impact of \nCOVID -19. \n \n  Across the company in fis cal 20 we demonstrated positive performance despite significant \nglobal challenges.  As these dynamics continue into fiscal 21, we are focused on building upon our \noperational momentum  through the underlying strength and resilience of our business.  \n \n  Before I share our outlook for fiscal 21, let me first provide a few updates regarding the \nassumed COVID -19 trajectory going forward.  \n \n  This can be found on slide 13.  \n \n  After significant dialogue both with external and internal thought leaders, as well as with ou r \nupstream and downstream partners, we now believe the general recovery regarding COVID -19 will \nbe a flatter , more elongated curve than initially anticipated.  \n \n  We are assuming a more significant impact from the ongoing deferral and cancellation of \nelectiv e procedures and physician office visits in the first half of the fiscal year, with an eventual \nrecovery to pre -COVID -19 levels as we exit fiscal 21.  \n ", "original_text": "Before I share our outlook for fiscal 21, let me first provide a few updates regarding the \nassumed COVID -19 trajectory going forward.  \n \n ", "page_label": "7", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "69a2c1effe1358024a094e815a7db07a1fc80c86b926b3bf628a543143ae24a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a49809cc-0f98-4b68-95f7-2d7c2886a8a4", "node_type": "1", "metadata": {"window": "As these dynamics continue into fiscal 21, we are focused on building upon our \noperational momentum  through the underlying strength and resilience of our business.  \n \n  Before I share our outlook for fiscal 21, let me first provide a few updates regarding the \nassumed COVID -19 trajectory going forward.  \n \n  This can be found on slide 13.  \n \n  After significant dialogue both with external and internal thought leaders, as well as with ou r \nupstream and downstream partners, we now believe the general recovery regarding COVID -19 will \nbe a flatter , more elongated curve than initially anticipated.  \n \n  We are assuming a more significant impact from the ongoing deferral and cancellation of \nelectiv e procedures and physician office visits in the first half of the fiscal year, with an eventual \nrecovery to pre -COVID -19 levels as we exit fiscal 21.  \n ", "original_text": "After significant dialogue both with external and internal thought leaders, as well as with ou r \nupstream and downstream partners, we now believe the general recovery regarding COVID -19 will \nbe a flatter , more elongated curve than initially anticipated.  \n \n "}, "hash": "b8eb89d2aa36045db371440d22e0a4019d2cfecdcb4b4c0dcaeca3db158bb5ca", "class_name": "RelatedNodeInfo"}}, "text": "This can be found on slide 13.  \n \n ", "start_char_idx": 856, "end_char_idx": 892, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a49809cc-0f98-4b68-95f7-2d7c2886a8a4": {"__data__": {"id_": "a49809cc-0f98-4b68-95f7-2d7c2886a8a4", "embedding": null, "metadata": {"window": "As these dynamics continue into fiscal 21, we are focused on building upon our \noperational momentum  through the underlying strength and resilience of our business.  \n \n  Before I share our outlook for fiscal 21, let me first provide a few updates regarding the \nassumed COVID -19 trajectory going forward.  \n \n  This can be found on slide 13.  \n \n  After significant dialogue both with external and internal thought leaders, as well as with ou r \nupstream and downstream partners, we now believe the general recovery regarding COVID -19 will \nbe a flatter , more elongated curve than initially anticipated.  \n \n  We are assuming a more significant impact from the ongoing deferral and cancellation of \nelectiv e procedures and physician office visits in the first half of the fiscal year, with an eventual \nrecovery to pre -COVID -19 levels as we exit fiscal 21.  \n ", "original_text": "After significant dialogue both with external and internal thought leaders, as well as with ou r \nupstream and downstream partners, we now believe the general recovery regarding COVID -19 will \nbe a flatter , more elongated curve than initially anticipated.  \n \n ", "page_label": "7", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cb67424-de13-43db-b082-558d37f75ec2", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aefdd1f3ca14ef4352884295c77f9b63e8139c37eaa737b3a40c27660f8ae029", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56a56827-ded7-445a-ad49-0ede13e4209e", "node_type": "1", "metadata": {"window": "Across the company in fis cal 20 we demonstrated positive performance despite significant \nglobal challenges.  As these dynamics continue into fiscal 21, we are focused on building upon our \noperational momentum  through the underlying strength and resilience of our business.  \n \n  Before I share our outlook for fiscal 21, let me first provide a few updates regarding the \nassumed COVID -19 trajectory going forward.  \n \n  This can be found on slide 13.  \n \n  After significant dialogue both with external and internal thought leaders, as well as with ou r \nupstream and downstream partners, we now believe the general recovery regarding COVID -19 will \nbe a flatter , more elongated curve than initially anticipated.  \n \n  We are assuming a more significant impact from the ongoing deferral and cancellation of \nelectiv e procedures and physician office visits in the first half of the fiscal year, with an eventual \nrecovery to pre -COVID -19 levels as we exit fiscal 21.  \n ", "original_text": "This can be found on slide 13.  \n \n ", "page_label": "7", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db87044ccbbdb9ede276c309d4c69aca1567a56494c44ad49b5f7f8490be80cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "871ac8d4-d387-4e60-9bb8-fc11f683bac8", "node_type": "1", "metadata": {"window": "Before I share our outlook for fiscal 21, let me first provide a few updates regarding the \nassumed COVID -19 trajectory going forward.  \n \n  This can be found on slide 13.  \n \n  After significant dialogue both with external and internal thought leaders, as well as with ou r \nupstream and downstream partners, we now believe the general recovery regarding COVID -19 will \nbe a flatter , more elongated curve than initially anticipated.  \n \n  We are assuming a more significant impact from the ongoing deferral and cancellation of \nelectiv e procedures and physician office visits in the first half of the fiscal year, with an eventual \nrecovery to pre -COVID -19 levels as we exit fiscal 21.  \n ", "original_text": "We are assuming a more significant impact from the ongoing deferral and cancellation of \nelectiv e procedures and physician office visits in the first half of the fiscal year, with an eventual \nrecovery to pre -COVID -19 levels as we exit fiscal 21.  \n "}, "hash": "2f1bb8bcff26b425952458068541e57b2e1a87a680cc2179b2714293e5ba902e", "class_name": "RelatedNodeInfo"}}, "text": "After significant dialogue both with external and internal thought leaders, as well as with ou r \nupstream and downstream partners, we now believe the general recovery regarding COVID -19 will \nbe a flatter , more elongated curve than initially anticipated.  \n \n ", "start_char_idx": 892, "end_char_idx": 1155, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "871ac8d4-d387-4e60-9bb8-fc11f683bac8": {"__data__": {"id_": "871ac8d4-d387-4e60-9bb8-fc11f683bac8", "embedding": null, "metadata": {"window": "Before I share our outlook for fiscal 21, let me first provide a few updates regarding the \nassumed COVID -19 trajectory going forward.  \n \n  This can be found on slide 13.  \n \n  After significant dialogue both with external and internal thought leaders, as well as with ou r \nupstream and downstream partners, we now believe the general recovery regarding COVID -19 will \nbe a flatter , more elongated curve than initially anticipated.  \n \n  We are assuming a more significant impact from the ongoing deferral and cancellation of \nelectiv e procedures and physician office visits in the first half of the fiscal year, with an eventual \nrecovery to pre -COVID -19 levels as we exit fiscal 21.  \n ", "original_text": "We are assuming a more significant impact from the ongoing deferral and cancellation of \nelectiv e procedures and physician office visits in the first half of the fiscal year, with an eventual \nrecovery to pre -COVID -19 levels as we exit fiscal 21.  \n ", "page_label": "7", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3cb67424-de13-43db-b082-558d37f75ec2", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aefdd1f3ca14ef4352884295c77f9b63e8139c37eaa737b3a40c27660f8ae029", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a49809cc-0f98-4b68-95f7-2d7c2886a8a4", "node_type": "1", "metadata": {"window": "As these dynamics continue into fiscal 21, we are focused on building upon our \noperational momentum  through the underlying strength and resilience of our business.  \n \n  Before I share our outlook for fiscal 21, let me first provide a few updates regarding the \nassumed COVID -19 trajectory going forward.  \n \n  This can be found on slide 13.  \n \n  After significant dialogue both with external and internal thought leaders, as well as with ou r \nupstream and downstream partners, we now believe the general recovery regarding COVID -19 will \nbe a flatter , more elongated curve than initially anticipated.  \n \n  We are assuming a more significant impact from the ongoing deferral and cancellation of \nelectiv e procedures and physician office visits in the first half of the fiscal year, with an eventual \nrecovery to pre -COVID -19 levels as we exit fiscal 21.  \n ", "original_text": "After significant dialogue both with external and internal thought leaders, as well as with ou r \nupstream and downstream partners, we now believe the general recovery regarding COVID -19 will \nbe a flatter , more elongated curve than initially anticipated.  \n \n ", "page_label": "7", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1371e15d2487a793885609ff91c718a8bd5bedbcf467b81315e1832693c25fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbd7a769-5861-4493-9822-32d73cad7800", "node_type": "1", "metadata": {"window": " \nPage 8 of 31 \n \n On average, we believe elective procedures will be down relative to pre -pandemic levels in the \nhigh-single digit range, and physician office visits will be down in the mid -single digit range for the full \nyear.  \n \n  Additionally, while we are working diligently to address global PPE supply challenges, we are \nassuming demand will continue to outpace available sup ply for the balance of fiscal 21.   We are \nincurring higher cost procuring certain PPE products for our customers during the pandemic , and this \nwill be a headwind for us in fiscal 21, especially in the first half of the year.  Keep in mind, our outlook \nis sub ject to considerable uncertainty and at this time does not assume additional widespread \nshutdowns like we saw in the spring.  \n \n ", "original_text": " \nPage 8 of 31 \n \n On average, we believe elective procedures will be down relative to pre -pandemic levels in the \nhigh-single digit range, and physician office visits will be down in the mid -single digit range for the full \nyear.  \n \n "}, "hash": "f924548d6299a7d82d22913e5bff100b33d8685a2baadfa23896447ceb36ca87", "class_name": "RelatedNodeInfo"}}, "text": "We are assuming a more significant impact from the ongoing deferral and cancellation of \nelectiv e procedures and physician office visits in the first half of the fiscal year, with an eventual \nrecovery to pre -COVID -19 levels as we exit fiscal 21.  \n ", "start_char_idx": 1155, "end_char_idx": 1408, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbd7a769-5861-4493-9822-32d73cad7800": {"__data__": {"id_": "cbd7a769-5861-4493-9822-32d73cad7800", "embedding": null, "metadata": {"window": " \nPage 8 of 31 \n \n On average, we believe elective procedures will be down relative to pre -pandemic levels in the \nhigh-single digit range, and physician office visits will be down in the mid -single digit range for the full \nyear.  \n \n  Additionally, while we are working diligently to address global PPE supply challenges, we are \nassuming demand will continue to outpace available sup ply for the balance of fiscal 21.   We are \nincurring higher cost procuring certain PPE products for our customers during the pandemic , and this \nwill be a headwind for us in fiscal 21, especially in the first half of the year.  Keep in mind, our outlook \nis sub ject to considerable uncertainty and at this time does not assume additional widespread \nshutdowns like we saw in the spring.  \n \n ", "original_text": " \nPage 8 of 31 \n \n On average, we believe elective procedures will be down relative to pre -pandemic levels in the \nhigh-single digit range, and physician office visits will be down in the mid -single digit range for the full \nyear.  \n \n ", "page_label": "8", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b55f1c03-037f-4ed6-b32c-0f51cdce7cf3", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a511e02a15a8feac18fadb128a838e869d892f7d04f57a5c538ed013d85d371", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "871ac8d4-d387-4e60-9bb8-fc11f683bac8", "node_type": "1", "metadata": {"window": "Before I share our outlook for fiscal 21, let me first provide a few updates regarding the \nassumed COVID -19 trajectory going forward.  \n \n  This can be found on slide 13.  \n \n  After significant dialogue both with external and internal thought leaders, as well as with ou r \nupstream and downstream partners, we now believe the general recovery regarding COVID -19 will \nbe a flatter , more elongated curve than initially anticipated.  \n \n  We are assuming a more significant impact from the ongoing deferral and cancellation of \nelectiv e procedures and physician office visits in the first half of the fiscal year, with an eventual \nrecovery to pre -COVID -19 levels as we exit fiscal 21.  \n ", "original_text": "We are assuming a more significant impact from the ongoing deferral and cancellation of \nelectiv e procedures and physician office visits in the first half of the fiscal year, with an eventual \nrecovery to pre -COVID -19 levels as we exit fiscal 21.  \n ", "page_label": "7", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16b60f48121f0faf9cc3c6ed44e7252a6eeb0b006ec8c9defcf6999f6c4226c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6bb30662-ef72-4c81-b429-799a163664a7", "node_type": "1", "metadata": {"window": " \nPage 8 of 31 \n \n On average, we believe elective procedures will be down relative to pre -pandemic levels in the \nhigh-single digit range, and physician office visits will be down in the mid -single digit range for the full \nyear.  \n \n  Additionally, while we are working diligently to address global PPE supply challenges, we are \nassuming demand will continue to outpace available sup ply for the balance of fiscal 21.   We are \nincurring higher cost procuring certain PPE products for our customers during the pandemic , and this \nwill be a headwind for us in fiscal 21, especially in the first half of the year.  Keep in mind, our outlook \nis sub ject to considerable uncertainty and at this time does not assume additional widespread \nshutdowns like we saw in the spring.  \n \n  We are closely monitoring key variables such as the trajectory of the virus itself, patient \npsychology in returning to sites of care, our customers \u2019 capacity, and the overall health of the \neconomy. ", "original_text": "Additionally, while we are working diligently to address global PPE supply challenges, we are \nassuming demand will continue to outpace available sup ply for the balance of fiscal 21.  "}, "hash": "86096aced50556c4e6ec977fe99135367607028d4edf68066ae4fc6cf1910ce4", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 8 of 31 \n \n On average, we believe elective procedures will be down relative to pre -pandemic levels in the \nhigh-single digit range, and physician office visits will be down in the mid -single digit range for the full \nyear.  \n \n ", "start_char_idx": 0, "end_char_idx": 238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6bb30662-ef72-4c81-b429-799a163664a7": {"__data__": {"id_": "6bb30662-ef72-4c81-b429-799a163664a7", "embedding": null, "metadata": {"window": " \nPage 8 of 31 \n \n On average, we believe elective procedures will be down relative to pre -pandemic levels in the \nhigh-single digit range, and physician office visits will be down in the mid -single digit range for the full \nyear.  \n \n  Additionally, while we are working diligently to address global PPE supply challenges, we are \nassuming demand will continue to outpace available sup ply for the balance of fiscal 21.   We are \nincurring higher cost procuring certain PPE products for our customers during the pandemic , and this \nwill be a headwind for us in fiscal 21, especially in the first half of the year.  Keep in mind, our outlook \nis sub ject to considerable uncertainty and at this time does not assume additional widespread \nshutdowns like we saw in the spring.  \n \n  We are closely monitoring key variables such as the trajectory of the virus itself, patient \npsychology in returning to sites of care, our customers \u2019 capacity, and the overall health of the \neconomy. ", "original_text": "Additionally, while we are working diligently to address global PPE supply challenges, we are \nassuming demand will continue to outpace available sup ply for the balance of fiscal 21.  ", "page_label": "8", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b55f1c03-037f-4ed6-b32c-0f51cdce7cf3", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a511e02a15a8feac18fadb128a838e869d892f7d04f57a5c538ed013d85d371", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbd7a769-5861-4493-9822-32d73cad7800", "node_type": "1", "metadata": {"window": " \nPage 8 of 31 \n \n On average, we believe elective procedures will be down relative to pre -pandemic levels in the \nhigh-single digit range, and physician office visits will be down in the mid -single digit range for the full \nyear.  \n \n  Additionally, while we are working diligently to address global PPE supply challenges, we are \nassuming demand will continue to outpace available sup ply for the balance of fiscal 21.   We are \nincurring higher cost procuring certain PPE products for our customers during the pandemic , and this \nwill be a headwind for us in fiscal 21, especially in the first half of the year.  Keep in mind, our outlook \nis sub ject to considerable uncertainty and at this time does not assume additional widespread \nshutdowns like we saw in the spring.  \n \n ", "original_text": " \nPage 8 of 31 \n \n On average, we believe elective procedures will be down relative to pre -pandemic levels in the \nhigh-single digit range, and physician office visits will be down in the mid -single digit range for the full \nyear.  \n \n ", "page_label": "8", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "926a47f19b3b74116addf6a231d64fa6dcbef9e6517456418bd86ac51aee7cc7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e84e8799-b0d1-4cc5-a861-8a6b20ab8740", "node_type": "1", "metadata": {"window": " \nPage 8 of 31 \n \n On average, we believe elective procedures will be down relative to pre -pandemic levels in the \nhigh-single digit range, and physician office visits will be down in the mid -single digit range for the full \nyear.  \n \n  Additionally, while we are working diligently to address global PPE supply challenges, we are \nassuming demand will continue to outpace available sup ply for the balance of fiscal 21.   We are \nincurring higher cost procuring certain PPE products for our customers during the pandemic , and this \nwill be a headwind for us in fiscal 21, especially in the first half of the year.  Keep in mind, our outlook \nis sub ject to considerable uncertainty and at this time does not assume additional widespread \nshutdowns like we saw in the spring.  \n \n  We are closely monitoring key variables such as the trajectory of the virus itself, patient \npsychology in returning to sites of care, our customers \u2019 capacity, and the overall health of the \neconomy.  Using these assumptions as our backdrop, we anticipate earnings per share in the range of \n$5.25 to $5.65 for fiscal 21.  ", "original_text": "We are \nincurring higher cost procuring certain PPE products for our customers during the pandemic , and this \nwill be a headwind for us in fiscal 21, especially in the first half of the year. "}, "hash": "455df9cba1068a3e06ba3c7e750335b793ac28aba857e5e1a287e5943cc22fbd", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, while we are working diligently to address global PPE supply challenges, we are \nassuming demand will continue to outpace available sup ply for the balance of fiscal 21.  ", "start_char_idx": 238, "end_char_idx": 423, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e84e8799-b0d1-4cc5-a861-8a6b20ab8740": {"__data__": {"id_": "e84e8799-b0d1-4cc5-a861-8a6b20ab8740", "embedding": null, "metadata": {"window": " \nPage 8 of 31 \n \n On average, we believe elective procedures will be down relative to pre -pandemic levels in the \nhigh-single digit range, and physician office visits will be down in the mid -single digit range for the full \nyear.  \n \n  Additionally, while we are working diligently to address global PPE supply challenges, we are \nassuming demand will continue to outpace available sup ply for the balance of fiscal 21.   We are \nincurring higher cost procuring certain PPE products for our customers during the pandemic , and this \nwill be a headwind for us in fiscal 21, especially in the first half of the year.  Keep in mind, our outlook \nis sub ject to considerable uncertainty and at this time does not assume additional widespread \nshutdowns like we saw in the spring.  \n \n  We are closely monitoring key variables such as the trajectory of the virus itself, patient \npsychology in returning to sites of care, our customers \u2019 capacity, and the overall health of the \neconomy.  Using these assumptions as our backdrop, we anticipate earnings per share in the range of \n$5.25 to $5.65 for fiscal 21.  ", "original_text": "We are \nincurring higher cost procuring certain PPE products for our customers during the pandemic , and this \nwill be a headwind for us in fiscal 21, especially in the first half of the year. ", "page_label": "8", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b55f1c03-037f-4ed6-b32c-0f51cdce7cf3", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a511e02a15a8feac18fadb128a838e869d892f7d04f57a5c538ed013d85d371", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6bb30662-ef72-4c81-b429-799a163664a7", "node_type": "1", "metadata": {"window": " \nPage 8 of 31 \n \n On average, we believe elective procedures will be down relative to pre -pandemic levels in the \nhigh-single digit range, and physician office visits will be down in the mid -single digit range for the full \nyear.  \n \n  Additionally, while we are working diligently to address global PPE supply challenges, we are \nassuming demand will continue to outpace available sup ply for the balance of fiscal 21.   We are \nincurring higher cost procuring certain PPE products for our customers during the pandemic , and this \nwill be a headwind for us in fiscal 21, especially in the first half of the year.  Keep in mind, our outlook \nis sub ject to considerable uncertainty and at this time does not assume additional widespread \nshutdowns like we saw in the spring.  \n \n  We are closely monitoring key variables such as the trajectory of the virus itself, patient \npsychology in returning to sites of care, our customers \u2019 capacity, and the overall health of the \neconomy. ", "original_text": "Additionally, while we are working diligently to address global PPE supply challenges, we are \nassuming demand will continue to outpace available sup ply for the balance of fiscal 21.  ", "page_label": "8", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1bd42458b87a9b05d5a22194f9debbc014821cef39ba52e4d46c0315c52f116", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3dde167d-9554-4b30-8b54-058aa0d9027d", "node_type": "1", "metadata": {"window": " \nPage 8 of 31 \n \n On average, we believe elective procedures will be down relative to pre -pandemic levels in the \nhigh-single digit range, and physician office visits will be down in the mid -single digit range for the full \nyear.  \n \n  Additionally, while we are working diligently to address global PPE supply challenges, we are \nassuming demand will continue to outpace available sup ply for the balance of fiscal 21.   We are \nincurring higher cost procuring certain PPE products for our customers during the pandemic , and this \nwill be a headwind for us in fiscal 21, especially in the first half of the year.  Keep in mind, our outlook \nis sub ject to considerable uncertainty and at this time does not assume additional widespread \nshutdowns like we saw in the spring.  \n \n  We are closely monitoring key variables such as the trajectory of the virus itself, patient \npsychology in returning to sites of care, our customers \u2019 capacity, and the overall health of the \neconomy.  Using these assumptions as our backdrop, we anticipate earnings per share in the range of \n$5.25 to $5.65 for fiscal 21.   This range assumes an estimated incremental net headwind related t o \nCOVID -19 of a similar year -over-year magnitude as experienced in fiscal 20.  \n \n ", "original_text": "Keep in mind, our outlook \nis sub ject to considerable uncertainty and at this time does not assume additional widespread \nshutdowns like we saw in the spring.  \n \n "}, "hash": "4ec158df62831b8b731d53f1e54660f01b530610a1122ef11ca9e68b39f45bc5", "class_name": "RelatedNodeInfo"}}, "text": "We are \nincurring higher cost procuring certain PPE products for our customers during the pandemic , and this \nwill be a headwind for us in fiscal 21, especially in the first half of the year. ", "start_char_idx": 423, "end_char_idx": 616, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3dde167d-9554-4b30-8b54-058aa0d9027d": {"__data__": {"id_": "3dde167d-9554-4b30-8b54-058aa0d9027d", "embedding": null, "metadata": {"window": " \nPage 8 of 31 \n \n On average, we believe elective procedures will be down relative to pre -pandemic levels in the \nhigh-single digit range, and physician office visits will be down in the mid -single digit range for the full \nyear.  \n \n  Additionally, while we are working diligently to address global PPE supply challenges, we are \nassuming demand will continue to outpace available sup ply for the balance of fiscal 21.   We are \nincurring higher cost procuring certain PPE products for our customers during the pandemic , and this \nwill be a headwind for us in fiscal 21, especially in the first half of the year.  Keep in mind, our outlook \nis sub ject to considerable uncertainty and at this time does not assume additional widespread \nshutdowns like we saw in the spring.  \n \n  We are closely monitoring key variables such as the trajectory of the virus itself, patient \npsychology in returning to sites of care, our customers \u2019 capacity, and the overall health of the \neconomy.  Using these assumptions as our backdrop, we anticipate earnings per share in the range of \n$5.25 to $5.65 for fiscal 21.   This range assumes an estimated incremental net headwind related t o \nCOVID -19 of a similar year -over-year magnitude as experienced in fiscal 20.  \n \n ", "original_text": "Keep in mind, our outlook \nis sub ject to considerable uncertainty and at this time does not assume additional widespread \nshutdowns like we saw in the spring.  \n \n ", "page_label": "8", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b55f1c03-037f-4ed6-b32c-0f51cdce7cf3", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a511e02a15a8feac18fadb128a838e869d892f7d04f57a5c538ed013d85d371", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e84e8799-b0d1-4cc5-a861-8a6b20ab8740", "node_type": "1", "metadata": {"window": " \nPage 8 of 31 \n \n On average, we believe elective procedures will be down relative to pre -pandemic levels in the \nhigh-single digit range, and physician office visits will be down in the mid -single digit range for the full \nyear.  \n \n  Additionally, while we are working diligently to address global PPE supply challenges, we are \nassuming demand will continue to outpace available sup ply for the balance of fiscal 21.   We are \nincurring higher cost procuring certain PPE products for our customers during the pandemic , and this \nwill be a headwind for us in fiscal 21, especially in the first half of the year.  Keep in mind, our outlook \nis sub ject to considerable uncertainty and at this time does not assume additional widespread \nshutdowns like we saw in the spring.  \n \n  We are closely monitoring key variables such as the trajectory of the virus itself, patient \npsychology in returning to sites of care, our customers \u2019 capacity, and the overall health of the \neconomy.  Using these assumptions as our backdrop, we anticipate earnings per share in the range of \n$5.25 to $5.65 for fiscal 21.  ", "original_text": "We are \nincurring higher cost procuring certain PPE products for our customers during the pandemic , and this \nwill be a headwind for us in fiscal 21, especially in the first half of the year. ", "page_label": "8", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1d3d41327f1dd75801035dcb293dbda2c06f89add3975319e33b01353167976", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42814d00-34b6-4e4e-bd11-63125562b94b", "node_type": "1", "metadata": {"window": "Additionally, while we are working diligently to address global PPE supply challenges, we are \nassuming demand will continue to outpace available sup ply for the balance of fiscal 21.   We are \nincurring higher cost procuring certain PPE products for our customers during the pandemic , and this \nwill be a headwind for us in fiscal 21, especially in the first half of the year.  Keep in mind, our outlook \nis sub ject to considerable uncertainty and at this time does not assume additional widespread \nshutdowns like we saw in the spring.  \n \n  We are closely monitoring key variables such as the trajectory of the virus itself, patient \npsychology in returning to sites of care, our customers \u2019 capacity, and the overall health of the \neconomy.  Using these assumptions as our backdrop, we anticipate earnings per share in the range of \n$5.25 to $5.65 for fiscal 21.   This range assumes an estimated incremental net headwind related t o \nCOVID -19 of a similar year -over-year magnitude as experienced in fiscal 20.  \n \n  We expect interest and other expense in the range of 190 to $215 million, which reflects \ninterest expense savings from fiscal 20 debt pay down, as well as anticipated debt pay down in fiscal \n21 of at least $500 million.  \n \n ", "original_text": "We are closely monitoring key variables such as the trajectory of the virus itself, patient \npsychology in returning to sites of care, our customers \u2019 capacity, and the overall health of the \neconomy. "}, "hash": "b943c11bfe1b138a93d443afa9d37a0f469ada98f243301b6a4d63a4a4f3deee", "class_name": "RelatedNodeInfo"}}, "text": "Keep in mind, our outlook \nis sub ject to considerable uncertainty and at this time does not assume additional widespread \nshutdowns like we saw in the spring.  \n \n ", "start_char_idx": 616, "end_char_idx": 781, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42814d00-34b6-4e4e-bd11-63125562b94b": {"__data__": {"id_": "42814d00-34b6-4e4e-bd11-63125562b94b", "embedding": null, "metadata": {"window": "Additionally, while we are working diligently to address global PPE supply challenges, we are \nassuming demand will continue to outpace available sup ply for the balance of fiscal 21.   We are \nincurring higher cost procuring certain PPE products for our customers during the pandemic , and this \nwill be a headwind for us in fiscal 21, especially in the first half of the year.  Keep in mind, our outlook \nis sub ject to considerable uncertainty and at this time does not assume additional widespread \nshutdowns like we saw in the spring.  \n \n  We are closely monitoring key variables such as the trajectory of the virus itself, patient \npsychology in returning to sites of care, our customers \u2019 capacity, and the overall health of the \neconomy.  Using these assumptions as our backdrop, we anticipate earnings per share in the range of \n$5.25 to $5.65 for fiscal 21.   This range assumes an estimated incremental net headwind related t o \nCOVID -19 of a similar year -over-year magnitude as experienced in fiscal 20.  \n \n  We expect interest and other expense in the range of 190 to $215 million, which reflects \ninterest expense savings from fiscal 20 debt pay down, as well as anticipated debt pay down in fiscal \n21 of at least $500 million.  \n \n ", "original_text": "We are closely monitoring key variables such as the trajectory of the virus itself, patient \npsychology in returning to sites of care, our customers \u2019 capacity, and the overall health of the \neconomy. ", "page_label": "8", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b55f1c03-037f-4ed6-b32c-0f51cdce7cf3", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a511e02a15a8feac18fadb128a838e869d892f7d04f57a5c538ed013d85d371", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3dde167d-9554-4b30-8b54-058aa0d9027d", "node_type": "1", "metadata": {"window": " \nPage 8 of 31 \n \n On average, we believe elective procedures will be down relative to pre -pandemic levels in the \nhigh-single digit range, and physician office visits will be down in the mid -single digit range for the full \nyear.  \n \n  Additionally, while we are working diligently to address global PPE supply challenges, we are \nassuming demand will continue to outpace available sup ply for the balance of fiscal 21.   We are \nincurring higher cost procuring certain PPE products for our customers during the pandemic , and this \nwill be a headwind for us in fiscal 21, especially in the first half of the year.  Keep in mind, our outlook \nis sub ject to considerable uncertainty and at this time does not assume additional widespread \nshutdowns like we saw in the spring.  \n \n  We are closely monitoring key variables such as the trajectory of the virus itself, patient \npsychology in returning to sites of care, our customers \u2019 capacity, and the overall health of the \neconomy.  Using these assumptions as our backdrop, we anticipate earnings per share in the range of \n$5.25 to $5.65 for fiscal 21.   This range assumes an estimated incremental net headwind related t o \nCOVID -19 of a similar year -over-year magnitude as experienced in fiscal 20.  \n \n ", "original_text": "Keep in mind, our outlook \nis sub ject to considerable uncertainty and at this time does not assume additional widespread \nshutdowns like we saw in the spring.  \n \n ", "page_label": "8", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e98fa26a67aab2e1432d5960a2bc092f9bfb3371781b2468d0679856ca2443c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88da3a2e-7618-48ad-aab8-91d4cc40a479", "node_type": "1", "metadata": {"window": "We are \nincurring higher cost procuring certain PPE products for our customers during the pandemic , and this \nwill be a headwind for us in fiscal 21, especially in the first half of the year.  Keep in mind, our outlook \nis sub ject to considerable uncertainty and at this time does not assume additional widespread \nshutdowns like we saw in the spring.  \n \n  We are closely monitoring key variables such as the trajectory of the virus itself, patient \npsychology in returning to sites of care, our customers \u2019 capacity, and the overall health of the \neconomy.  Using these assumptions as our backdrop, we anticipate earnings per share in the range of \n$5.25 to $5.65 for fiscal 21.   This range assumes an estimated incremental net headwind related t o \nCOVID -19 of a similar year -over-year magnitude as experienced in fiscal 20.  \n \n  We expect interest and other expense in the range of 190 to $215 million, which reflects \ninterest expense savings from fiscal 20 debt pay down, as well as anticipated debt pay down in fiscal \n21 of at least $500 million.  \n \n  We are assuming a full year non -GAAP effective tax rate in the range of 24% to 26%. ", "original_text": "Using these assumptions as our backdrop, we anticipate earnings per share in the range of \n$5.25 to $5.65 for fiscal 21.  "}, "hash": "41571eb9f7fdb0b90d67d8f78c37e2f0e3147d379dd4a4e4239fe48416793361", "class_name": "RelatedNodeInfo"}}, "text": "We are closely monitoring key variables such as the trajectory of the virus itself, patient \npsychology in returning to sites of care, our customers \u2019 capacity, and the overall health of the \neconomy. ", "start_char_idx": 781, "end_char_idx": 982, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88da3a2e-7618-48ad-aab8-91d4cc40a479": {"__data__": {"id_": "88da3a2e-7618-48ad-aab8-91d4cc40a479", "embedding": null, "metadata": {"window": "We are \nincurring higher cost procuring certain PPE products for our customers during the pandemic , and this \nwill be a headwind for us in fiscal 21, especially in the first half of the year.  Keep in mind, our outlook \nis sub ject to considerable uncertainty and at this time does not assume additional widespread \nshutdowns like we saw in the spring.  \n \n  We are closely monitoring key variables such as the trajectory of the virus itself, patient \npsychology in returning to sites of care, our customers \u2019 capacity, and the overall health of the \neconomy.  Using these assumptions as our backdrop, we anticipate earnings per share in the range of \n$5.25 to $5.65 for fiscal 21.   This range assumes an estimated incremental net headwind related t o \nCOVID -19 of a similar year -over-year magnitude as experienced in fiscal 20.  \n \n  We expect interest and other expense in the range of 190 to $215 million, which reflects \ninterest expense savings from fiscal 20 debt pay down, as well as anticipated debt pay down in fiscal \n21 of at least $500 million.  \n \n  We are assuming a full year non -GAAP effective tax rate in the range of 24% to 26%. ", "original_text": "Using these assumptions as our backdrop, we anticipate earnings per share in the range of \n$5.25 to $5.65 for fiscal 21.  ", "page_label": "8", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b55f1c03-037f-4ed6-b32c-0f51cdce7cf3", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a511e02a15a8feac18fadb128a838e869d892f7d04f57a5c538ed013d85d371", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42814d00-34b6-4e4e-bd11-63125562b94b", "node_type": "1", "metadata": {"window": "Additionally, while we are working diligently to address global PPE supply challenges, we are \nassuming demand will continue to outpace available sup ply for the balance of fiscal 21.   We are \nincurring higher cost procuring certain PPE products for our customers during the pandemic , and this \nwill be a headwind for us in fiscal 21, especially in the first half of the year.  Keep in mind, our outlook \nis sub ject to considerable uncertainty and at this time does not assume additional widespread \nshutdowns like we saw in the spring.  \n \n  We are closely monitoring key variables such as the trajectory of the virus itself, patient \npsychology in returning to sites of care, our customers \u2019 capacity, and the overall health of the \neconomy.  Using these assumptions as our backdrop, we anticipate earnings per share in the range of \n$5.25 to $5.65 for fiscal 21.   This range assumes an estimated incremental net headwind related t o \nCOVID -19 of a similar year -over-year magnitude as experienced in fiscal 20.  \n \n  We expect interest and other expense in the range of 190 to $215 million, which reflects \ninterest expense savings from fiscal 20 debt pay down, as well as anticipated debt pay down in fiscal \n21 of at least $500 million.  \n \n ", "original_text": "We are closely monitoring key variables such as the trajectory of the virus itself, patient \npsychology in returning to sites of care, our customers \u2019 capacity, and the overall health of the \neconomy. ", "page_label": "8", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4a072342558b86b09714d3894517dc278239d8d344b8591d2da59bcdd4e2da6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6cb7ff4d-bab8-40a9-9572-7e642c0ef388", "node_type": "1", "metadata": {"window": "Keep in mind, our outlook \nis sub ject to considerable uncertainty and at this time does not assume additional widespread \nshutdowns like we saw in the spring.  \n \n  We are closely monitoring key variables such as the trajectory of the virus itself, patient \npsychology in returning to sites of care, our customers \u2019 capacity, and the overall health of the \neconomy.  Using these assumptions as our backdrop, we anticipate earnings per share in the range of \n$5.25 to $5.65 for fiscal 21.   This range assumes an estimated incremental net headwind related t o \nCOVID -19 of a similar year -over-year magnitude as experienced in fiscal 20.  \n \n  We expect interest and other expense in the range of 190 to $215 million, which reflects \ninterest expense savings from fiscal 20 debt pay down, as well as anticipated debt pay down in fiscal \n21 of at least $500 million.  \n \n  We are assuming a full year non -GAAP effective tax rate in the range of 24% to 26%.  As a \nreminder, this assumption does not contemplate the potential effects of any unusual or open year \naudit adjustments, favor able or unfavorable, which we have historically included in our non -GAAP tax \nrate. \n ", "original_text": "This range assumes an estimated incremental net headwind related t o \nCOVID -19 of a similar year -over-year magnitude as experienced in fiscal 20.  \n \n "}, "hash": "c6955cdb948b3710c8ecf84b300c3cdf8dc05f4c8823902bd8f0ad10be6528db", "class_name": "RelatedNodeInfo"}}, "text": "Using these assumptions as our backdrop, we anticipate earnings per share in the range of \n$5.25 to $5.65 for fiscal 21.  ", "start_char_idx": 982, "end_char_idx": 1104, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6cb7ff4d-bab8-40a9-9572-7e642c0ef388": {"__data__": {"id_": "6cb7ff4d-bab8-40a9-9572-7e642c0ef388", "embedding": null, "metadata": {"window": "Keep in mind, our outlook \nis sub ject to considerable uncertainty and at this time does not assume additional widespread \nshutdowns like we saw in the spring.  \n \n  We are closely monitoring key variables such as the trajectory of the virus itself, patient \npsychology in returning to sites of care, our customers \u2019 capacity, and the overall health of the \neconomy.  Using these assumptions as our backdrop, we anticipate earnings per share in the range of \n$5.25 to $5.65 for fiscal 21.   This range assumes an estimated incremental net headwind related t o \nCOVID -19 of a similar year -over-year magnitude as experienced in fiscal 20.  \n \n  We expect interest and other expense in the range of 190 to $215 million, which reflects \ninterest expense savings from fiscal 20 debt pay down, as well as anticipated debt pay down in fiscal \n21 of at least $500 million.  \n \n  We are assuming a full year non -GAAP effective tax rate in the range of 24% to 26%.  As a \nreminder, this assumption does not contemplate the potential effects of any unusual or open year \naudit adjustments, favor able or unfavorable, which we have historically included in our non -GAAP tax \nrate. \n ", "original_text": "This range assumes an estimated incremental net headwind related t o \nCOVID -19 of a similar year -over-year magnitude as experienced in fiscal 20.  \n \n ", "page_label": "8", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b55f1c03-037f-4ed6-b32c-0f51cdce7cf3", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a511e02a15a8feac18fadb128a838e869d892f7d04f57a5c538ed013d85d371", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88da3a2e-7618-48ad-aab8-91d4cc40a479", "node_type": "1", "metadata": {"window": "We are \nincurring higher cost procuring certain PPE products for our customers during the pandemic , and this \nwill be a headwind for us in fiscal 21, especially in the first half of the year.  Keep in mind, our outlook \nis sub ject to considerable uncertainty and at this time does not assume additional widespread \nshutdowns like we saw in the spring.  \n \n  We are closely monitoring key variables such as the trajectory of the virus itself, patient \npsychology in returning to sites of care, our customers \u2019 capacity, and the overall health of the \neconomy.  Using these assumptions as our backdrop, we anticipate earnings per share in the range of \n$5.25 to $5.65 for fiscal 21.   This range assumes an estimated incremental net headwind related t o \nCOVID -19 of a similar year -over-year magnitude as experienced in fiscal 20.  \n \n  We expect interest and other expense in the range of 190 to $215 million, which reflects \ninterest expense savings from fiscal 20 debt pay down, as well as anticipated debt pay down in fiscal \n21 of at least $500 million.  \n \n  We are assuming a full year non -GAAP effective tax rate in the range of 24% to 26%. ", "original_text": "Using these assumptions as our backdrop, we anticipate earnings per share in the range of \n$5.25 to $5.65 for fiscal 21.  ", "page_label": "8", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f65cce9924bd961b096987766d02560208f7f7ba94d4b69d1cffef84c410f5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc326d9d-2b3b-4a73-a271-d0ee1dfaad24", "node_type": "1", "metadata": {"window": "We are closely monitoring key variables such as the trajectory of the virus itself, patient \npsychology in returning to sites of care, our customers \u2019 capacity, and the overall health of the \neconomy.  Using these assumptions as our backdrop, we anticipate earnings per share in the range of \n$5.25 to $5.65 for fiscal 21.   This range assumes an estimated incremental net headwind related t o \nCOVID -19 of a similar year -over-year magnitude as experienced in fiscal 20.  \n \n  We expect interest and other expense in the range of 190 to $215 million, which reflects \ninterest expense savings from fiscal 20 debt pay down, as well as anticipated debt pay down in fiscal \n21 of at least $500 million.  \n \n  We are assuming a full year non -GAAP effective tax rate in the range of 24% to 26%.  As a \nreminder, this assumption does not contemplate the potential effects of any unusual or open year \naudit adjustments, favor able or unfavorable, which we have historically included in our non -GAAP tax \nrate. \n ", "original_text": "We expect interest and other expense in the range of 190 to $215 million, which reflects \ninterest expense savings from fiscal 20 debt pay down, as well as anticipated debt pay down in fiscal \n21 of at least $500 million.  \n \n "}, "hash": "6e4de6a0bf347af63bccc21cc2456fb8faa3fbc609927abc1b000ab775e5052f", "class_name": "RelatedNodeInfo"}}, "text": "This range assumes an estimated incremental net headwind related t o \nCOVID -19 of a similar year -over-year magnitude as experienced in fiscal 20.  \n \n ", "start_char_idx": 1104, "end_char_idx": 1257, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc326d9d-2b3b-4a73-a271-d0ee1dfaad24": {"__data__": {"id_": "cc326d9d-2b3b-4a73-a271-d0ee1dfaad24", "embedding": null, "metadata": {"window": "We are closely monitoring key variables such as the trajectory of the virus itself, patient \npsychology in returning to sites of care, our customers \u2019 capacity, and the overall health of the \neconomy.  Using these assumptions as our backdrop, we anticipate earnings per share in the range of \n$5.25 to $5.65 for fiscal 21.   This range assumes an estimated incremental net headwind related t o \nCOVID -19 of a similar year -over-year magnitude as experienced in fiscal 20.  \n \n  We expect interest and other expense in the range of 190 to $215 million, which reflects \ninterest expense savings from fiscal 20 debt pay down, as well as anticipated debt pay down in fiscal \n21 of at least $500 million.  \n \n  We are assuming a full year non -GAAP effective tax rate in the range of 24% to 26%.  As a \nreminder, this assumption does not contemplate the potential effects of any unusual or open year \naudit adjustments, favor able or unfavorable, which we have historically included in our non -GAAP tax \nrate. \n ", "original_text": "We expect interest and other expense in the range of 190 to $215 million, which reflects \ninterest expense savings from fiscal 20 debt pay down, as well as anticipated debt pay down in fiscal \n21 of at least $500 million.  \n \n ", "page_label": "8", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b55f1c03-037f-4ed6-b32c-0f51cdce7cf3", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a511e02a15a8feac18fadb128a838e869d892f7d04f57a5c538ed013d85d371", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6cb7ff4d-bab8-40a9-9572-7e642c0ef388", "node_type": "1", "metadata": {"window": "Keep in mind, our outlook \nis sub ject to considerable uncertainty and at this time does not assume additional widespread \nshutdowns like we saw in the spring.  \n \n  We are closely monitoring key variables such as the trajectory of the virus itself, patient \npsychology in returning to sites of care, our customers \u2019 capacity, and the overall health of the \neconomy.  Using these assumptions as our backdrop, we anticipate earnings per share in the range of \n$5.25 to $5.65 for fiscal 21.   This range assumes an estimated incremental net headwind related t o \nCOVID -19 of a similar year -over-year magnitude as experienced in fiscal 20.  \n \n  We expect interest and other expense in the range of 190 to $215 million, which reflects \ninterest expense savings from fiscal 20 debt pay down, as well as anticipated debt pay down in fiscal \n21 of at least $500 million.  \n \n  We are assuming a full year non -GAAP effective tax rate in the range of 24% to 26%.  As a \nreminder, this assumption does not contemplate the potential effects of any unusual or open year \naudit adjustments, favor able or unfavorable, which we have historically included in our non -GAAP tax \nrate. \n ", "original_text": "This range assumes an estimated incremental net headwind related t o \nCOVID -19 of a similar year -over-year magnitude as experienced in fiscal 20.  \n \n ", "page_label": "8", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "56e7bcb4a16474ccba0971264e541258da38fcccb7d7ed09275c19db0a8b8b4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2e34d1c-1fd5-4f8c-97de-41a8b5bf194f", "node_type": "1", "metadata": {"window": "Using these assumptions as our backdrop, we anticipate earnings per share in the range of \n$5.25 to $5.65 for fiscal 21.   This range assumes an estimated incremental net headwind related t o \nCOVID -19 of a similar year -over-year magnitude as experienced in fiscal 20.  \n \n  We expect interest and other expense in the range of 190 to $215 million, which reflects \ninterest expense savings from fiscal 20 debt pay down, as well as anticipated debt pay down in fiscal \n21 of at least $500 million.  \n \n  We are assuming a full year non -GAAP effective tax rate in the range of 24% to 26%.  As a \nreminder, this assumption does not contemplate the potential effects of any unusual or open year \naudit adjustments, favor able or unfavorable, which we have historically included in our non -GAAP tax \nrate. \n ", "original_text": "We are assuming a full year non -GAAP effective tax rate in the range of 24% to 26%. "}, "hash": "f2faec8a03fde9ecc8e1bd234bea75df9709e57165a637552633ca6be109bb57", "class_name": "RelatedNodeInfo"}}, "text": "We expect interest and other expense in the range of 190 to $215 million, which reflects \ninterest expense savings from fiscal 20 debt pay down, as well as anticipated debt pay down in fiscal \n21 of at least $500 million.  \n \n ", "start_char_idx": 1257, "end_char_idx": 1484, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2e34d1c-1fd5-4f8c-97de-41a8b5bf194f": {"__data__": {"id_": "c2e34d1c-1fd5-4f8c-97de-41a8b5bf194f", "embedding": null, "metadata": {"window": "Using these assumptions as our backdrop, we anticipate earnings per share in the range of \n$5.25 to $5.65 for fiscal 21.   This range assumes an estimated incremental net headwind related t o \nCOVID -19 of a similar year -over-year magnitude as experienced in fiscal 20.  \n \n  We expect interest and other expense in the range of 190 to $215 million, which reflects \ninterest expense savings from fiscal 20 debt pay down, as well as anticipated debt pay down in fiscal \n21 of at least $500 million.  \n \n  We are assuming a full year non -GAAP effective tax rate in the range of 24% to 26%.  As a \nreminder, this assumption does not contemplate the potential effects of any unusual or open year \naudit adjustments, favor able or unfavorable, which we have historically included in our non -GAAP tax \nrate. \n ", "original_text": "We are assuming a full year non -GAAP effective tax rate in the range of 24% to 26%. ", "page_label": "8", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b55f1c03-037f-4ed6-b32c-0f51cdce7cf3", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a511e02a15a8feac18fadb128a838e869d892f7d04f57a5c538ed013d85d371", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc326d9d-2b3b-4a73-a271-d0ee1dfaad24", "node_type": "1", "metadata": {"window": "We are closely monitoring key variables such as the trajectory of the virus itself, patient \npsychology in returning to sites of care, our customers \u2019 capacity, and the overall health of the \neconomy.  Using these assumptions as our backdrop, we anticipate earnings per share in the range of \n$5.25 to $5.65 for fiscal 21.   This range assumes an estimated incremental net headwind related t o \nCOVID -19 of a similar year -over-year magnitude as experienced in fiscal 20.  \n \n  We expect interest and other expense in the range of 190 to $215 million, which reflects \ninterest expense savings from fiscal 20 debt pay down, as well as anticipated debt pay down in fiscal \n21 of at least $500 million.  \n \n  We are assuming a full year non -GAAP effective tax rate in the range of 24% to 26%.  As a \nreminder, this assumption does not contemplate the potential effects of any unusual or open year \naudit adjustments, favor able or unfavorable, which we have historically included in our non -GAAP tax \nrate. \n ", "original_text": "We expect interest and other expense in the range of 190 to $215 million, which reflects \ninterest expense savings from fiscal 20 debt pay down, as well as anticipated debt pay down in fiscal \n21 of at least $500 million.  \n \n ", "page_label": "8", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e6e3e53f30fcb7f9d40f679b4f5281b18c339a965539857f32623aee59ace1d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aad782db-0ade-4ede-a289-5bfc6b0f1934", "node_type": "1", "metadata": {"window": "This range assumes an estimated incremental net headwind related t o \nCOVID -19 of a similar year -over-year magnitude as experienced in fiscal 20.  \n \n  We expect interest and other expense in the range of 190 to $215 million, which reflects \ninterest expense savings from fiscal 20 debt pay down, as well as anticipated debt pay down in fiscal \n21 of at least $500 million.  \n \n  We are assuming a full year non -GAAP effective tax rate in the range of 24% to 26%.  As a \nreminder, this assumption does not contemplate the potential effects of any unusual or open year \naudit adjustments, favor able or unfavorable, which we have historically included in our non -GAAP tax \nrate. \n ", "original_text": "As a \nreminder, this assumption does not contemplate the potential effects of any unusual or open year \naudit adjustments, favor able or unfavorable, which we have historically included in our non -GAAP tax \nrate. \n "}, "hash": "0b272eb47448c2bc37b4669382102501f5dbc7e2997b1420375761bc4d2774f2", "class_name": "RelatedNodeInfo"}}, "text": "We are assuming a full year non -GAAP effective tax rate in the range of 24% to 26%. ", "start_char_idx": 1484, "end_char_idx": 1569, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aad782db-0ade-4ede-a289-5bfc6b0f1934": {"__data__": {"id_": "aad782db-0ade-4ede-a289-5bfc6b0f1934", "embedding": null, "metadata": {"window": "This range assumes an estimated incremental net headwind related t o \nCOVID -19 of a similar year -over-year magnitude as experienced in fiscal 20.  \n \n  We expect interest and other expense in the range of 190 to $215 million, which reflects \ninterest expense savings from fiscal 20 debt pay down, as well as anticipated debt pay down in fiscal \n21 of at least $500 million.  \n \n  We are assuming a full year non -GAAP effective tax rate in the range of 24% to 26%.  As a \nreminder, this assumption does not contemplate the potential effects of any unusual or open year \naudit adjustments, favor able or unfavorable, which we have historically included in our non -GAAP tax \nrate. \n ", "original_text": "As a \nreminder, this assumption does not contemplate the potential effects of any unusual or open year \naudit adjustments, favor able or unfavorable, which we have historically included in our non -GAAP tax \nrate. \n ", "page_label": "8", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b55f1c03-037f-4ed6-b32c-0f51cdce7cf3", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a511e02a15a8feac18fadb128a838e869d892f7d04f57a5c538ed013d85d371", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2e34d1c-1fd5-4f8c-97de-41a8b5bf194f", "node_type": "1", "metadata": {"window": "Using these assumptions as our backdrop, we anticipate earnings per share in the range of \n$5.25 to $5.65 for fiscal 21.   This range assumes an estimated incremental net headwind related t o \nCOVID -19 of a similar year -over-year magnitude as experienced in fiscal 20.  \n \n  We expect interest and other expense in the range of 190 to $215 million, which reflects \ninterest expense savings from fiscal 20 debt pay down, as well as anticipated debt pay down in fiscal \n21 of at least $500 million.  \n \n  We are assuming a full year non -GAAP effective tax rate in the range of 24% to 26%.  As a \nreminder, this assumption does not contemplate the potential effects of any unusual or open year \naudit adjustments, favor able or unfavorable, which we have historically included in our non -GAAP tax \nrate. \n ", "original_text": "We are assuming a full year non -GAAP effective tax rate in the range of 24% to 26%. ", "page_label": "8", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71843370ccfc1b1bebd1319c40f0d6b97fb7469526757bf5669ddacda38c04d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "913b95ef-6264-4484-9c7a-6694d1b28d64", "node_type": "1", "metadata": {"window": " \nPage 9 of 31 \n \n Given we have multiple years of US tax audits open, we could expect greater than usual \nvariability in our effective tax rate in the near to medium term.  \n \n  We anticipate dilut ive shares in the range of 292 to 296 million , and finally , we expect capital \nexpenditures of 400 to $450 million.  \n \n  For the segments, beginning with Pharma on slide 15, we expect mid -single digits segment \nrevenue growth, and segment profit  growth in the low single digits.  We are anticipating consistent \nmarket dynamics within our generics program and a similar contingent brand inflation rate in fiscal 21 \nas in fiscal 20.  \n \n ", "original_text": " \nPage 9 of 31 \n \n Given we have multiple years of US tax audits open, we could expect greater than usual \nvariability in our effective tax rate in the near to medium term.  \n \n "}, "hash": "73de44a7fe29ed83b682c9aea72f52ab8a50e94bf1b8544a75b0a0e786dd2904", "class_name": "RelatedNodeInfo"}}, "text": "As a \nreminder, this assumption does not contemplate the potential effects of any unusual or open year \naudit adjustments, favor able or unfavorable, which we have historically included in our non -GAAP tax \nrate. \n ", "start_char_idx": 1569, "end_char_idx": 1785, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "913b95ef-6264-4484-9c7a-6694d1b28d64": {"__data__": {"id_": "913b95ef-6264-4484-9c7a-6694d1b28d64", "embedding": null, "metadata": {"window": " \nPage 9 of 31 \n \n Given we have multiple years of US tax audits open, we could expect greater than usual \nvariability in our effective tax rate in the near to medium term.  \n \n  We anticipate dilut ive shares in the range of 292 to 296 million , and finally , we expect capital \nexpenditures of 400 to $450 million.  \n \n  For the segments, beginning with Pharma on slide 15, we expect mid -single digits segment \nrevenue growth, and segment profit  growth in the low single digits.  We are anticipating consistent \nmarket dynamics within our generics program and a similar contingent brand inflation rate in fiscal 21 \nas in fiscal 20.  \n \n ", "original_text": " \nPage 9 of 31 \n \n Given we have multiple years of US tax audits open, we could expect greater than usual \nvariability in our effective tax rate in the near to medium term.  \n \n ", "page_label": "9", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43360e11-0ef7-4bb3-9af2-c2b08bba0418", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "518fd80661091d83d2183e29636e78a080b130e4dbf90d0594b240d9db74751b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aad782db-0ade-4ede-a289-5bfc6b0f1934", "node_type": "1", "metadata": {"window": "This range assumes an estimated incremental net headwind related t o \nCOVID -19 of a similar year -over-year magnitude as experienced in fiscal 20.  \n \n  We expect interest and other expense in the range of 190 to $215 million, which reflects \ninterest expense savings from fiscal 20 debt pay down, as well as anticipated debt pay down in fiscal \n21 of at least $500 million.  \n \n  We are assuming a full year non -GAAP effective tax rate in the range of 24% to 26%.  As a \nreminder, this assumption does not contemplate the potential effects of any unusual or open year \naudit adjustments, favor able or unfavorable, which we have historically included in our non -GAAP tax \nrate. \n ", "original_text": "As a \nreminder, this assumption does not contemplate the potential effects of any unusual or open year \naudit adjustments, favor able or unfavorable, which we have historically included in our non -GAAP tax \nrate. \n ", "page_label": "8", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "17e605818d6f77e4c8f9123f7aa59e4c986635c3366f43d72a1c5b1b7d7f5821", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9014ceb6-b9c1-43cd-baa1-a3c1f1efac57", "node_type": "1", "metadata": {"window": " \nPage 9 of 31 \n \n Given we have multiple years of US tax audits open, we could expect greater than usual \nvariability in our effective tax rate in the near to medium term.  \n \n  We anticipate dilut ive shares in the range of 292 to 296 million , and finally , we expect capital \nexpenditures of 400 to $450 million.  \n \n  For the segments, beginning with Pharma on slide 15, we expect mid -single digits segment \nrevenue growth, and segment profit  growth in the low single digits.  We are anticipating consistent \nmarket dynamics within our generics program and a similar contingent brand inflation rate in fiscal 21 \nas in fiscal 20.  \n \n  We also expect opioid legal costs of approximately $100 million, cons istent with the prior year. \n", "original_text": "We anticipate dilut ive shares in the range of 292 to 296 million , and finally , we expect capital \nexpenditures of 400 to $450 million.  \n \n "}, "hash": "b3f47a0f1c284fb62aa07c287f3306eb9910148f271939c3dc73c79e8de2a471", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 9 of 31 \n \n Given we have multiple years of US tax audits open, we could expect greater than usual \nvariability in our effective tax rate in the near to medium term.  \n \n ", "start_char_idx": 0, "end_char_idx": 178, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9014ceb6-b9c1-43cd-baa1-a3c1f1efac57": {"__data__": {"id_": "9014ceb6-b9c1-43cd-baa1-a3c1f1efac57", "embedding": null, "metadata": {"window": " \nPage 9 of 31 \n \n Given we have multiple years of US tax audits open, we could expect greater than usual \nvariability in our effective tax rate in the near to medium term.  \n \n  We anticipate dilut ive shares in the range of 292 to 296 million , and finally , we expect capital \nexpenditures of 400 to $450 million.  \n \n  For the segments, beginning with Pharma on slide 15, we expect mid -single digits segment \nrevenue growth, and segment profit  growth in the low single digits.  We are anticipating consistent \nmarket dynamics within our generics program and a similar contingent brand inflation rate in fiscal 21 \nas in fiscal 20.  \n \n  We also expect opioid legal costs of approximately $100 million, cons istent with the prior year. \n", "original_text": "We anticipate dilut ive shares in the range of 292 to 296 million , and finally , we expect capital \nexpenditures of 400 to $450 million.  \n \n ", "page_label": "9", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43360e11-0ef7-4bb3-9af2-c2b08bba0418", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "518fd80661091d83d2183e29636e78a080b130e4dbf90d0594b240d9db74751b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "913b95ef-6264-4484-9c7a-6694d1b28d64", "node_type": "1", "metadata": {"window": " \nPage 9 of 31 \n \n Given we have multiple years of US tax audits open, we could expect greater than usual \nvariability in our effective tax rate in the near to medium term.  \n \n  We anticipate dilut ive shares in the range of 292 to 296 million , and finally , we expect capital \nexpenditures of 400 to $450 million.  \n \n  For the segments, beginning with Pharma on slide 15, we expect mid -single digits segment \nrevenue growth, and segment profit  growth in the low single digits.  We are anticipating consistent \nmarket dynamics within our generics program and a similar contingent brand inflation rate in fiscal 21 \nas in fiscal 20.  \n \n ", "original_text": " \nPage 9 of 31 \n \n Given we have multiple years of US tax audits open, we could expect greater than usual \nvariability in our effective tax rate in the near to medium term.  \n \n ", "page_label": "9", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "134ae2832ea79814bd054d9606b91af9e4898044b262208734b5947847516ca3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f92afadd-0c9d-4c73-adf7-772a5509765a", "node_type": "1", "metadata": {"window": " \nPage 9 of 31 \n \n Given we have multiple years of US tax audits open, we could expect greater than usual \nvariability in our effective tax rate in the near to medium term.  \n \n  We anticipate dilut ive shares in the range of 292 to 296 million , and finally , we expect capital \nexpenditures of 400 to $450 million.  \n \n  For the segments, beginning with Pharma on slide 15, we expect mid -single digits segment \nrevenue growth, and segment profit  growth in the low single digits.  We are anticipating consistent \nmarket dynamics within our generics program and a similar contingent brand inflation rate in fiscal 21 \nas in fiscal 20.  \n \n  We also expect opioid legal costs of approximately $100 million, cons istent with the prior year. \n In Medical, although we expect low -single digit revenue growth, we expect high -single digit profit \ndecline, due to higher costs associated with procuring PPE for our customers and the impact of less \nelective procedures.  \n \n ", "original_text": "For the segments, beginning with Pharma on slide 15, we expect mid -single digits segment \nrevenue growth, and segment profit  growth in the low single digits. "}, "hash": "313320ad554ad76520ae51bf3c050e83d1839beb8778dbf3df0fd46dd9be3ff7", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate dilut ive shares in the range of 292 to 296 million , and finally , we expect capital \nexpenditures of 400 to $450 million.  \n \n ", "start_char_idx": 178, "end_char_idx": 321, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f92afadd-0c9d-4c73-adf7-772a5509765a": {"__data__": {"id_": "f92afadd-0c9d-4c73-adf7-772a5509765a", "embedding": null, "metadata": {"window": " \nPage 9 of 31 \n \n Given we have multiple years of US tax audits open, we could expect greater than usual \nvariability in our effective tax rate in the near to medium term.  \n \n  We anticipate dilut ive shares in the range of 292 to 296 million , and finally , we expect capital \nexpenditures of 400 to $450 million.  \n \n  For the segments, beginning with Pharma on slide 15, we expect mid -single digits segment \nrevenue growth, and segment profit  growth in the low single digits.  We are anticipating consistent \nmarket dynamics within our generics program and a similar contingent brand inflation rate in fiscal 21 \nas in fiscal 20.  \n \n  We also expect opioid legal costs of approximately $100 million, cons istent with the prior year. \n In Medical, although we expect low -single digit revenue growth, we expect high -single digit profit \ndecline, due to higher costs associated with procuring PPE for our customers and the impact of less \nelective procedures.  \n \n ", "original_text": "For the segments, beginning with Pharma on slide 15, we expect mid -single digits segment \nrevenue growth, and segment profit  growth in the low single digits. ", "page_label": "9", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43360e11-0ef7-4bb3-9af2-c2b08bba0418", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "518fd80661091d83d2183e29636e78a080b130e4dbf90d0594b240d9db74751b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9014ceb6-b9c1-43cd-baa1-a3c1f1efac57", "node_type": "1", "metadata": {"window": " \nPage 9 of 31 \n \n Given we have multiple years of US tax audits open, we could expect greater than usual \nvariability in our effective tax rate in the near to medium term.  \n \n  We anticipate dilut ive shares in the range of 292 to 296 million , and finally , we expect capital \nexpenditures of 400 to $450 million.  \n \n  For the segments, beginning with Pharma on slide 15, we expect mid -single digits segment \nrevenue growth, and segment profit  growth in the low single digits.  We are anticipating consistent \nmarket dynamics within our generics program and a similar contingent brand inflation rate in fiscal 21 \nas in fiscal 20.  \n \n  We also expect opioid legal costs of approximately $100 million, cons istent with the prior year. \n", "original_text": "We anticipate dilut ive shares in the range of 292 to 296 million , and finally , we expect capital \nexpenditures of 400 to $450 million.  \n \n ", "page_label": "9", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d8aa208117ed1fbd4e4f551b5fc0f7de6a65336fdf262f7b8389242cce73442a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4fab729-fcf4-4396-aec2-6d6b160b9f98", "node_type": "1", "metadata": {"window": " \nPage 9 of 31 \n \n Given we have multiple years of US tax audits open, we could expect greater than usual \nvariability in our effective tax rate in the near to medium term.  \n \n  We anticipate dilut ive shares in the range of 292 to 296 million , and finally , we expect capital \nexpenditures of 400 to $450 million.  \n \n  For the segments, beginning with Pharma on slide 15, we expect mid -single digits segment \nrevenue growth, and segment profit  growth in the low single digits.  We are anticipating consistent \nmarket dynamics within our generics program and a similar contingent brand inflation rate in fiscal 21 \nas in fiscal 20.  \n \n  We also expect opioid legal costs of approximately $100 million, cons istent with the prior year. \n In Medical, although we expect low -single digit revenue growth, we expect high -single digit profit \ndecline, due to higher costs associated with procuring PPE for our customers and the impact of less \nelective procedures.  \n \n  Exclud ing the adverse impacts of COVID -19, we would expect Medical segment profit growth \nto be in the mid -single digits. ", "original_text": "We are anticipating consistent \nmarket dynamics within our generics program and a similar contingent brand inflation rate in fiscal 21 \nas in fiscal 20.  \n \n "}, "hash": "dfc099475fd8c7a995dc172678e78852615a63cb336e3c753ba14b967ee54763", "class_name": "RelatedNodeInfo"}}, "text": "For the segments, beginning with Pharma on slide 15, we expect mid -single digits segment \nrevenue growth, and segment profit  growth in the low single digits. ", "start_char_idx": 321, "end_char_idx": 481, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4fab729-fcf4-4396-aec2-6d6b160b9f98": {"__data__": {"id_": "c4fab729-fcf4-4396-aec2-6d6b160b9f98", "embedding": null, "metadata": {"window": " \nPage 9 of 31 \n \n Given we have multiple years of US tax audits open, we could expect greater than usual \nvariability in our effective tax rate in the near to medium term.  \n \n  We anticipate dilut ive shares in the range of 292 to 296 million , and finally , we expect capital \nexpenditures of 400 to $450 million.  \n \n  For the segments, beginning with Pharma on slide 15, we expect mid -single digits segment \nrevenue growth, and segment profit  growth in the low single digits.  We are anticipating consistent \nmarket dynamics within our generics program and a similar contingent brand inflation rate in fiscal 21 \nas in fiscal 20.  \n \n  We also expect opioid legal costs of approximately $100 million, cons istent with the prior year. \n In Medical, although we expect low -single digit revenue growth, we expect high -single digit profit \ndecline, due to higher costs associated with procuring PPE for our customers and the impact of less \nelective procedures.  \n \n  Exclud ing the adverse impacts of COVID -19, we would expect Medical segment profit growth \nto be in the mid -single digits. ", "original_text": "We are anticipating consistent \nmarket dynamics within our generics program and a similar contingent brand inflation rate in fiscal 21 \nas in fiscal 20.  \n \n ", "page_label": "9", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43360e11-0ef7-4bb3-9af2-c2b08bba0418", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "518fd80661091d83d2183e29636e78a080b130e4dbf90d0594b240d9db74751b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f92afadd-0c9d-4c73-adf7-772a5509765a", "node_type": "1", "metadata": {"window": " \nPage 9 of 31 \n \n Given we have multiple years of US tax audits open, we could expect greater than usual \nvariability in our effective tax rate in the near to medium term.  \n \n  We anticipate dilut ive shares in the range of 292 to 296 million , and finally , we expect capital \nexpenditures of 400 to $450 million.  \n \n  For the segments, beginning with Pharma on slide 15, we expect mid -single digits segment \nrevenue growth, and segment profit  growth in the low single digits.  We are anticipating consistent \nmarket dynamics within our generics program and a similar contingent brand inflation rate in fiscal 21 \nas in fiscal 20.  \n \n  We also expect opioid legal costs of approximately $100 million, cons istent with the prior year. \n In Medical, although we expect low -single digit revenue growth, we expect high -single digit profit \ndecline, due to higher costs associated with procuring PPE for our customers and the impact of less \nelective procedures.  \n \n ", "original_text": "For the segments, beginning with Pharma on slide 15, we expect mid -single digits segment \nrevenue growth, and segment profit  growth in the low single digits. ", "page_label": "9", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da38b9d73e771674c7984863da72e089b341c8a2fad3f5f2748162efb2e4ece7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c2952e7-4338-4482-848b-34a7447ae710", "node_type": "1", "metadata": {"window": "We anticipate dilut ive shares in the range of 292 to 296 million , and finally , we expect capital \nexpenditures of 400 to $450 million.  \n \n  For the segments, beginning with Pharma on slide 15, we expect mid -single digits segment \nrevenue growth, and segment profit  growth in the low single digits.  We are anticipating consistent \nmarket dynamics within our generics program and a similar contingent brand inflation rate in fiscal 21 \nas in fiscal 20.  \n \n  We also expect opioid legal costs of approximately $100 million, cons istent with the prior year. \n In Medical, although we expect low -single digit revenue growth, we expect high -single digit profit \ndecline, due to higher costs associated with procuring PPE for our customers and the impact of less \nelective procedures.  \n \n  Exclud ing the adverse impacts of COVID -19, we would expect Medical segment profit growth \nto be in the mid -single digits.  Mike will elaborate on our strategies to address the challenges facing \nthe segment related to COVID -19, and our plans to continue to improve the segment's underlying \nperformance.  \n \n ", "original_text": "We also expect opioid legal costs of approximately $100 million, cons istent with the prior year. \n"}, "hash": "321ab32e11fab448ae1644e42afdc371b25933d13850ee6dc228a77d9774b93e", "class_name": "RelatedNodeInfo"}}, "text": "We are anticipating consistent \nmarket dynamics within our generics program and a similar contingent brand inflation rate in fiscal 21 \nas in fiscal 20.  \n \n ", "start_char_idx": 481, "end_char_idx": 639, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c2952e7-4338-4482-848b-34a7447ae710": {"__data__": {"id_": "8c2952e7-4338-4482-848b-34a7447ae710", "embedding": null, "metadata": {"window": "We anticipate dilut ive shares in the range of 292 to 296 million , and finally , we expect capital \nexpenditures of 400 to $450 million.  \n \n  For the segments, beginning with Pharma on slide 15, we expect mid -single digits segment \nrevenue growth, and segment profit  growth in the low single digits.  We are anticipating consistent \nmarket dynamics within our generics program and a similar contingent brand inflation rate in fiscal 21 \nas in fiscal 20.  \n \n  We also expect opioid legal costs of approximately $100 million, cons istent with the prior year. \n In Medical, although we expect low -single digit revenue growth, we expect high -single digit profit \ndecline, due to higher costs associated with procuring PPE for our customers and the impact of less \nelective procedures.  \n \n  Exclud ing the adverse impacts of COVID -19, we would expect Medical segment profit growth \nto be in the mid -single digits.  Mike will elaborate on our strategies to address the challenges facing \nthe segment related to COVID -19, and our plans to continue to improve the segment's underlying \nperformance.  \n \n ", "original_text": "We also expect opioid legal costs of approximately $100 million, cons istent with the prior year. \n", "page_label": "9", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43360e11-0ef7-4bb3-9af2-c2b08bba0418", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "518fd80661091d83d2183e29636e78a080b130e4dbf90d0594b240d9db74751b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4fab729-fcf4-4396-aec2-6d6b160b9f98", "node_type": "1", "metadata": {"window": " \nPage 9 of 31 \n \n Given we have multiple years of US tax audits open, we could expect greater than usual \nvariability in our effective tax rate in the near to medium term.  \n \n  We anticipate dilut ive shares in the range of 292 to 296 million , and finally , we expect capital \nexpenditures of 400 to $450 million.  \n \n  For the segments, beginning with Pharma on slide 15, we expect mid -single digits segment \nrevenue growth, and segment profit  growth in the low single digits.  We are anticipating consistent \nmarket dynamics within our generics program and a similar contingent brand inflation rate in fiscal 21 \nas in fiscal 20.  \n \n  We also expect opioid legal costs of approximately $100 million, cons istent with the prior year. \n In Medical, although we expect low -single digit revenue growth, we expect high -single digit profit \ndecline, due to higher costs associated with procuring PPE for our customers and the impact of less \nelective procedures.  \n \n  Exclud ing the adverse impacts of COVID -19, we would expect Medical segment profit growth \nto be in the mid -single digits. ", "original_text": "We are anticipating consistent \nmarket dynamics within our generics program and a similar contingent brand inflation rate in fiscal 21 \nas in fiscal 20.  \n \n ", "page_label": "9", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f265e6009a134af07751a149b02b215958702bb506108fa269b38fa0abccc026", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1992716-3dd4-4e33-a914-63226daba0cf", "node_type": "1", "metadata": {"window": "For the segments, beginning with Pharma on slide 15, we expect mid -single digits segment \nrevenue growth, and segment profit  growth in the low single digits.  We are anticipating consistent \nmarket dynamics within our generics program and a similar contingent brand inflation rate in fiscal 21 \nas in fiscal 20.  \n \n  We also expect opioid legal costs of approximately $100 million, cons istent with the prior year. \n In Medical, although we expect low -single digit revenue growth, we expect high -single digit profit \ndecline, due to higher costs associated with procuring PPE for our customers and the impact of less \nelective procedures.  \n \n  Exclud ing the adverse impacts of COVID -19, we would expect Medical segment profit growth \nto be in the mid -single digits.  Mike will elaborate on our strategies to address the challenges facing \nthe segment related to COVID -19, and our plans to continue to improve the segment's underlying \nperformance.  \n \n  Before I turn the call back over the Mike, in my brief remarks last quarter, I expressed my \nexcitement about the team, our mission, and the tremendous opportunities in front of us.  \n ", "original_text": "In Medical, although we expect low -single digit revenue growth, we expect high -single digit profit \ndecline, due to higher costs associated with procuring PPE for our customers and the impact of less \nelective procedures.  \n \n "}, "hash": "555a53dbe124349f87762636215c2131b683b1348aab51be0e450b44bdc2e323", "class_name": "RelatedNodeInfo"}}, "text": "We also expect opioid legal costs of approximately $100 million, cons istent with the prior year. \n", "start_char_idx": 639, "end_char_idx": 738, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1992716-3dd4-4e33-a914-63226daba0cf": {"__data__": {"id_": "a1992716-3dd4-4e33-a914-63226daba0cf", "embedding": null, "metadata": {"window": "For the segments, beginning with Pharma on slide 15, we expect mid -single digits segment \nrevenue growth, and segment profit  growth in the low single digits.  We are anticipating consistent \nmarket dynamics within our generics program and a similar contingent brand inflation rate in fiscal 21 \nas in fiscal 20.  \n \n  We also expect opioid legal costs of approximately $100 million, cons istent with the prior year. \n In Medical, although we expect low -single digit revenue growth, we expect high -single digit profit \ndecline, due to higher costs associated with procuring PPE for our customers and the impact of less \nelective procedures.  \n \n  Exclud ing the adverse impacts of COVID -19, we would expect Medical segment profit growth \nto be in the mid -single digits.  Mike will elaborate on our strategies to address the challenges facing \nthe segment related to COVID -19, and our plans to continue to improve the segment's underlying \nperformance.  \n \n  Before I turn the call back over the Mike, in my brief remarks last quarter, I expressed my \nexcitement about the team, our mission, and the tremendous opportunities in front of us.  \n ", "original_text": "In Medical, although we expect low -single digit revenue growth, we expect high -single digit profit \ndecline, due to higher costs associated with procuring PPE for our customers and the impact of less \nelective procedures.  \n \n ", "page_label": "9", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43360e11-0ef7-4bb3-9af2-c2b08bba0418", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "518fd80661091d83d2183e29636e78a080b130e4dbf90d0594b240d9db74751b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c2952e7-4338-4482-848b-34a7447ae710", "node_type": "1", "metadata": {"window": "We anticipate dilut ive shares in the range of 292 to 296 million , and finally , we expect capital \nexpenditures of 400 to $450 million.  \n \n  For the segments, beginning with Pharma on slide 15, we expect mid -single digits segment \nrevenue growth, and segment profit  growth in the low single digits.  We are anticipating consistent \nmarket dynamics within our generics program and a similar contingent brand inflation rate in fiscal 21 \nas in fiscal 20.  \n \n  We also expect opioid legal costs of approximately $100 million, cons istent with the prior year. \n In Medical, although we expect low -single digit revenue growth, we expect high -single digit profit \ndecline, due to higher costs associated with procuring PPE for our customers and the impact of less \nelective procedures.  \n \n  Exclud ing the adverse impacts of COVID -19, we would expect Medical segment profit growth \nto be in the mid -single digits.  Mike will elaborate on our strategies to address the challenges facing \nthe segment related to COVID -19, and our plans to continue to improve the segment's underlying \nperformance.  \n \n ", "original_text": "We also expect opioid legal costs of approximately $100 million, cons istent with the prior year. \n", "page_label": "9", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "622a3117fdc1c41d4655748b6dd50c156ec39854cf6364b8f3fbcd86986835ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57c4a5ba-6292-4b07-b53e-6b96514d6c8c", "node_type": "1", "metadata": {"window": "We are anticipating consistent \nmarket dynamics within our generics program and a similar contingent brand inflation rate in fiscal 21 \nas in fiscal 20.  \n \n  We also expect opioid legal costs of approximately $100 million, cons istent with the prior year. \n In Medical, although we expect low -single digit revenue growth, we expect high -single digit profit \ndecline, due to higher costs associated with procuring PPE for our customers and the impact of less \nelective procedures.  \n \n  Exclud ing the adverse impacts of COVID -19, we would expect Medical segment profit growth \nto be in the mid -single digits.  Mike will elaborate on our strategies to address the challenges facing \nthe segment related to COVID -19, and our plans to continue to improve the segment's underlying \nperformance.  \n \n  Before I turn the call back over the Mike, in my brief remarks last quarter, I expressed my \nexcitement about the team, our mission, and the tremendous opportunities in front of us.  \n ", "original_text": "Exclud ing the adverse impacts of COVID -19, we would expect Medical segment profit growth \nto be in the mid -single digits. "}, "hash": "7dd4ddc04076943a315f4b52908449a9be945724f841949281ce787c12e0f80b", "class_name": "RelatedNodeInfo"}}, "text": "In Medical, although we expect low -single digit revenue growth, we expect high -single digit profit \ndecline, due to higher costs associated with procuring PPE for our customers and the impact of less \nelective procedures.  \n \n ", "start_char_idx": 738, "end_char_idx": 967, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57c4a5ba-6292-4b07-b53e-6b96514d6c8c": {"__data__": {"id_": "57c4a5ba-6292-4b07-b53e-6b96514d6c8c", "embedding": null, "metadata": {"window": "We are anticipating consistent \nmarket dynamics within our generics program and a similar contingent brand inflation rate in fiscal 21 \nas in fiscal 20.  \n \n  We also expect opioid legal costs of approximately $100 million, cons istent with the prior year. \n In Medical, although we expect low -single digit revenue growth, we expect high -single digit profit \ndecline, due to higher costs associated with procuring PPE for our customers and the impact of less \nelective procedures.  \n \n  Exclud ing the adverse impacts of COVID -19, we would expect Medical segment profit growth \nto be in the mid -single digits.  Mike will elaborate on our strategies to address the challenges facing \nthe segment related to COVID -19, and our plans to continue to improve the segment's underlying \nperformance.  \n \n  Before I turn the call back over the Mike, in my brief remarks last quarter, I expressed my \nexcitement about the team, our mission, and the tremendous opportunities in front of us.  \n ", "original_text": "Exclud ing the adverse impacts of COVID -19, we would expect Medical segment profit growth \nto be in the mid -single digits. ", "page_label": "9", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43360e11-0ef7-4bb3-9af2-c2b08bba0418", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "518fd80661091d83d2183e29636e78a080b130e4dbf90d0594b240d9db74751b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1992716-3dd4-4e33-a914-63226daba0cf", "node_type": "1", "metadata": {"window": "For the segments, beginning with Pharma on slide 15, we expect mid -single digits segment \nrevenue growth, and segment profit  growth in the low single digits.  We are anticipating consistent \nmarket dynamics within our generics program and a similar contingent brand inflation rate in fiscal 21 \nas in fiscal 20.  \n \n  We also expect opioid legal costs of approximately $100 million, cons istent with the prior year. \n In Medical, although we expect low -single digit revenue growth, we expect high -single digit profit \ndecline, due to higher costs associated with procuring PPE for our customers and the impact of less \nelective procedures.  \n \n  Exclud ing the adverse impacts of COVID -19, we would expect Medical segment profit growth \nto be in the mid -single digits.  Mike will elaborate on our strategies to address the challenges facing \nthe segment related to COVID -19, and our plans to continue to improve the segment's underlying \nperformance.  \n \n  Before I turn the call back over the Mike, in my brief remarks last quarter, I expressed my \nexcitement about the team, our mission, and the tremendous opportunities in front of us.  \n ", "original_text": "In Medical, although we expect low -single digit revenue growth, we expect high -single digit profit \ndecline, due to higher costs associated with procuring PPE for our customers and the impact of less \nelective procedures.  \n \n ", "page_label": "9", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61806bbe68ea9fde9a3530beb94887060a637114d31321c6c2c673ca3417b71b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36b72c4d-ba05-4809-9e39-2094da70e421", "node_type": "1", "metadata": {"window": "We also expect opioid legal costs of approximately $100 million, cons istent with the prior year. \n In Medical, although we expect low -single digit revenue growth, we expect high -single digit profit \ndecline, due to higher costs associated with procuring PPE for our customers and the impact of less \nelective procedures.  \n \n  Exclud ing the adverse impacts of COVID -19, we would expect Medical segment profit growth \nto be in the mid -single digits.  Mike will elaborate on our strategies to address the challenges facing \nthe segment related to COVID -19, and our plans to continue to improve the segment's underlying \nperformance.  \n \n  Before I turn the call back over the Mike, in my brief remarks last quarter, I expressed my \nexcitement about the team, our mission, and the tremendous opportunities in front of us.  \n ", "original_text": "Mike will elaborate on our strategies to address the challenges facing \nthe segment related to COVID -19, and our plans to continue to improve the segment's underlying \nperformance.  \n \n "}, "hash": "2f391d9afba32019b41e8fc14e33416cd9bfb4a76b378075faea571aa3fa7a7f", "class_name": "RelatedNodeInfo"}}, "text": "Exclud ing the adverse impacts of COVID -19, we would expect Medical segment profit growth \nto be in the mid -single digits. ", "start_char_idx": 967, "end_char_idx": 1092, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36b72c4d-ba05-4809-9e39-2094da70e421": {"__data__": {"id_": "36b72c4d-ba05-4809-9e39-2094da70e421", "embedding": null, "metadata": {"window": "We also expect opioid legal costs of approximately $100 million, cons istent with the prior year. \n In Medical, although we expect low -single digit revenue growth, we expect high -single digit profit \ndecline, due to higher costs associated with procuring PPE for our customers and the impact of less \nelective procedures.  \n \n  Exclud ing the adverse impacts of COVID -19, we would expect Medical segment profit growth \nto be in the mid -single digits.  Mike will elaborate on our strategies to address the challenges facing \nthe segment related to COVID -19, and our plans to continue to improve the segment's underlying \nperformance.  \n \n  Before I turn the call back over the Mike, in my brief remarks last quarter, I expressed my \nexcitement about the team, our mission, and the tremendous opportunities in front of us.  \n ", "original_text": "Mike will elaborate on our strategies to address the challenges facing \nthe segment related to COVID -19, and our plans to continue to improve the segment's underlying \nperformance.  \n \n ", "page_label": "9", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43360e11-0ef7-4bb3-9af2-c2b08bba0418", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "518fd80661091d83d2183e29636e78a080b130e4dbf90d0594b240d9db74751b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57c4a5ba-6292-4b07-b53e-6b96514d6c8c", "node_type": "1", "metadata": {"window": "We are anticipating consistent \nmarket dynamics within our generics program and a similar contingent brand inflation rate in fiscal 21 \nas in fiscal 20.  \n \n  We also expect opioid legal costs of approximately $100 million, cons istent with the prior year. \n In Medical, although we expect low -single digit revenue growth, we expect high -single digit profit \ndecline, due to higher costs associated with procuring PPE for our customers and the impact of less \nelective procedures.  \n \n  Exclud ing the adverse impacts of COVID -19, we would expect Medical segment profit growth \nto be in the mid -single digits.  Mike will elaborate on our strategies to address the challenges facing \nthe segment related to COVID -19, and our plans to continue to improve the segment's underlying \nperformance.  \n \n  Before I turn the call back over the Mike, in my brief remarks last quarter, I expressed my \nexcitement about the team, our mission, and the tremendous opportunities in front of us.  \n ", "original_text": "Exclud ing the adverse impacts of COVID -19, we would expect Medical segment profit growth \nto be in the mid -single digits. ", "page_label": "9", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9881c7c3e42a08e58a0e57adc95eb5695fb64b491a1cc00b7c93d5b43353f13e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e1f4c5f-5310-46ee-9b14-8bf762677c07", "node_type": "1", "metadata": {"window": "In Medical, although we expect low -single digit revenue growth, we expect high -single digit profit \ndecline, due to higher costs associated with procuring PPE for our customers and the impact of less \nelective procedures.  \n \n  Exclud ing the adverse impacts of COVID -19, we would expect Medical segment profit growth \nto be in the mid -single digits.  Mike will elaborate on our strategies to address the challenges facing \nthe segment related to COVID -19, and our plans to continue to improve the segment's underlying \nperformance.  \n \n  Before I turn the call back over the Mike, in my brief remarks last quarter, I expressed my \nexcitement about the team, our mission, and the tremendous opportunities in front of us.  \n ", "original_text": "Before I turn the call back over the Mike, in my brief remarks last quarter, I expressed my \nexcitement about the team, our mission, and the tremendous opportunities in front of us.  \n "}, "hash": "5cd2490cdd7d1b51bf17175a3cdfa9a708cb677806213269fde6b2f6ad170752", "class_name": "RelatedNodeInfo"}}, "text": "Mike will elaborate on our strategies to address the challenges facing \nthe segment related to COVID -19, and our plans to continue to improve the segment's underlying \nperformance.  \n \n ", "start_char_idx": 1092, "end_char_idx": 1279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e1f4c5f-5310-46ee-9b14-8bf762677c07": {"__data__": {"id_": "9e1f4c5f-5310-46ee-9b14-8bf762677c07", "embedding": null, "metadata": {"window": "In Medical, although we expect low -single digit revenue growth, we expect high -single digit profit \ndecline, due to higher costs associated with procuring PPE for our customers and the impact of less \nelective procedures.  \n \n  Exclud ing the adverse impacts of COVID -19, we would expect Medical segment profit growth \nto be in the mid -single digits.  Mike will elaborate on our strategies to address the challenges facing \nthe segment related to COVID -19, and our plans to continue to improve the segment's underlying \nperformance.  \n \n  Before I turn the call back over the Mike, in my brief remarks last quarter, I expressed my \nexcitement about the team, our mission, and the tremendous opportunities in front of us.  \n ", "original_text": "Before I turn the call back over the Mike, in my brief remarks last quarter, I expressed my \nexcitement about the team, our mission, and the tremendous opportunities in front of us.  \n ", "page_label": "9", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "43360e11-0ef7-4bb3-9af2-c2b08bba0418", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "518fd80661091d83d2183e29636e78a080b130e4dbf90d0594b240d9db74751b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36b72c4d-ba05-4809-9e39-2094da70e421", "node_type": "1", "metadata": {"window": "We also expect opioid legal costs of approximately $100 million, cons istent with the prior year. \n In Medical, although we expect low -single digit revenue growth, we expect high -single digit profit \ndecline, due to higher costs associated with procuring PPE for our customers and the impact of less \nelective procedures.  \n \n  Exclud ing the adverse impacts of COVID -19, we would expect Medical segment profit growth \nto be in the mid -single digits.  Mike will elaborate on our strategies to address the challenges facing \nthe segment related to COVID -19, and our plans to continue to improve the segment's underlying \nperformance.  \n \n  Before I turn the call back over the Mike, in my brief remarks last quarter, I expressed my \nexcitement about the team, our mission, and the tremendous opportunities in front of us.  \n ", "original_text": "Mike will elaborate on our strategies to address the challenges facing \nthe segment related to COVID -19, and our plans to continue to improve the segment's underlying \nperformance.  \n \n ", "page_label": "9", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3bce7111ec805b25f2409004d00b0d266cc31d280132c2635effc2f791f57827", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c788baed-0daa-40ab-ae74-05e24461a9ed", "node_type": "1", "metadata": {"window": " \nPage 10 of 31 \n \n Those initial impressions have be en further confirmed in my first few months.  I am confident \nwe can collectively navigate current and future complexities to perform our essential role in \nhealthcare and realize our future opportunities.  \n \n  With that, let me turn it back over to Mike.  \n \n Mike Kaufmann:  Jason has quickly learned our business, our strategy, and our ongoing \ntransformations across the enterprise and on behalf of our full leadership team, we are grateful for his \nearly contributions and partnership.  \n \n ", "original_text": " \nPage 10 of 31 \n \n Those initial impressions have be en further confirmed in my first few months. "}, "hash": "249cffafb9d24361a53d47f3f50a73fabd871e85d582076b765e7359ec77ef02", "class_name": "RelatedNodeInfo"}}, "text": "Before I turn the call back over the Mike, in my brief remarks last quarter, I expressed my \nexcitement about the team, our mission, and the tremendous opportunities in front of us.  \n ", "start_char_idx": 1279, "end_char_idx": 1464, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c788baed-0daa-40ab-ae74-05e24461a9ed": {"__data__": {"id_": "c788baed-0daa-40ab-ae74-05e24461a9ed", "embedding": null, "metadata": {"window": " \nPage 10 of 31 \n \n Those initial impressions have be en further confirmed in my first few months.  I am confident \nwe can collectively navigate current and future complexities to perform our essential role in \nhealthcare and realize our future opportunities.  \n \n  With that, let me turn it back over to Mike.  \n \n Mike Kaufmann:  Jason has quickly learned our business, our strategy, and our ongoing \ntransformations across the enterprise and on behalf of our full leadership team, we are grateful for his \nearly contributions and partnership.  \n \n ", "original_text": " \nPage 10 of 31 \n \n Those initial impressions have be en further confirmed in my first few months. ", "page_label": "10", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f206d3e4-a985-4e1c-9a04-4bbaf8aaebb1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1895c9d527046f751d73085c2b0ad523761336c9f40f7bbda5c907e0a9e01148", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e1f4c5f-5310-46ee-9b14-8bf762677c07", "node_type": "1", "metadata": {"window": "In Medical, although we expect low -single digit revenue growth, we expect high -single digit profit \ndecline, due to higher costs associated with procuring PPE for our customers and the impact of less \nelective procedures.  \n \n  Exclud ing the adverse impacts of COVID -19, we would expect Medical segment profit growth \nto be in the mid -single digits.  Mike will elaborate on our strategies to address the challenges facing \nthe segment related to COVID -19, and our plans to continue to improve the segment's underlying \nperformance.  \n \n  Before I turn the call back over the Mike, in my brief remarks last quarter, I expressed my \nexcitement about the team, our mission, and the tremendous opportunities in front of us.  \n ", "original_text": "Before I turn the call back over the Mike, in my brief remarks last quarter, I expressed my \nexcitement about the team, our mission, and the tremendous opportunities in front of us.  \n ", "page_label": "9", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "122a8191327ae56fbbdb70d15692ecab5f696166953e197921b7ae56cade8100", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a14d0ee-c0c0-4852-9334-8dba8e682646", "node_type": "1", "metadata": {"window": " \nPage 10 of 31 \n \n Those initial impressions have be en further confirmed in my first few months.  I am confident \nwe can collectively navigate current and future complexities to perform our essential role in \nhealthcare and realize our future opportunities.  \n \n  With that, let me turn it back over to Mike.  \n \n Mike Kaufmann:  Jason has quickly learned our business, our strategy, and our ongoing \ntransformations across the enterprise and on behalf of our full leadership team, we are grateful for his \nearly contributions and partnership.  \n \n  Turning to our future, in fisca l 21 and beyond, we are focused on optimizing our core \nbusinesses and investing for growth. ", "original_text": "I am confident \nwe can collectively navigate current and future complexities to perform our essential role in \nhealthcare and realize our future opportunities.  \n \n "}, "hash": "fd2c3e3c730ee1f72bd021d81fb61d4cded6d6cc06d4afaf556cc4f18c1e7d48", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 10 of 31 \n \n Those initial impressions have be en further confirmed in my first few months. ", "start_char_idx": 0, "end_char_idx": 99, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a14d0ee-c0c0-4852-9334-8dba8e682646": {"__data__": {"id_": "0a14d0ee-c0c0-4852-9334-8dba8e682646", "embedding": null, "metadata": {"window": " \nPage 10 of 31 \n \n Those initial impressions have be en further confirmed in my first few months.  I am confident \nwe can collectively navigate current and future complexities to perform our essential role in \nhealthcare and realize our future opportunities.  \n \n  With that, let me turn it back over to Mike.  \n \n Mike Kaufmann:  Jason has quickly learned our business, our strategy, and our ongoing \ntransformations across the enterprise and on behalf of our full leadership team, we are grateful for his \nearly contributions and partnership.  \n \n  Turning to our future, in fisca l 21 and beyond, we are focused on optimizing our core \nbusinesses and investing for growth. ", "original_text": "I am confident \nwe can collectively navigate current and future complexities to perform our essential role in \nhealthcare and realize our future opportunities.  \n \n ", "page_label": "10", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f206d3e4-a985-4e1c-9a04-4bbaf8aaebb1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1895c9d527046f751d73085c2b0ad523761336c9f40f7bbda5c907e0a9e01148", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c788baed-0daa-40ab-ae74-05e24461a9ed", "node_type": "1", "metadata": {"window": " \nPage 10 of 31 \n \n Those initial impressions have be en further confirmed in my first few months.  I am confident \nwe can collectively navigate current and future complexities to perform our essential role in \nhealthcare and realize our future opportunities.  \n \n  With that, let me turn it back over to Mike.  \n \n Mike Kaufmann:  Jason has quickly learned our business, our strategy, and our ongoing \ntransformations across the enterprise and on behalf of our full leadership team, we are grateful for his \nearly contributions and partnership.  \n \n ", "original_text": " \nPage 10 of 31 \n \n Those initial impressions have be en further confirmed in my first few months. ", "page_label": "10", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a3762ddc82a682fb115b020877e4859f6272d706368339ef7c4b8c684ed0a68", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "922d9bcb-193f-421e-b7de-efc61a836cac", "node_type": "1", "metadata": {"window": " \nPage 10 of 31 \n \n Those initial impressions have be en further confirmed in my first few months.  I am confident \nwe can collectively navigate current and future complexities to perform our essential role in \nhealthcare and realize our future opportunities.  \n \n  With that, let me turn it back over to Mike.  \n \n Mike Kaufmann:  Jason has quickly learned our business, our strategy, and our ongoing \ntransformations across the enterprise and on behalf of our full leadership team, we are grateful for his \nearly contributions and partnership.  \n \n  Turning to our future, in fisca l 21 and beyond, we are focused on optimizing our core \nbusinesses and investing for growth.  I will share how we are doing both across the segments.  \n \n ", "original_text": "With that, let me turn it back over to Mike.  \n \n"}, "hash": "e8f69c08c17c95d0fae6a347f2aca7d63f0a3a2a73718054080954df558f2d15", "class_name": "RelatedNodeInfo"}}, "text": "I am confident \nwe can collectively navigate current and future complexities to perform our essential role in \nhealthcare and realize our future opportunities.  \n \n ", "start_char_idx": 99, "end_char_idx": 264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "922d9bcb-193f-421e-b7de-efc61a836cac": {"__data__": {"id_": "922d9bcb-193f-421e-b7de-efc61a836cac", "embedding": null, "metadata": {"window": " \nPage 10 of 31 \n \n Those initial impressions have be en further confirmed in my first few months.  I am confident \nwe can collectively navigate current and future complexities to perform our essential role in \nhealthcare and realize our future opportunities.  \n \n  With that, let me turn it back over to Mike.  \n \n Mike Kaufmann:  Jason has quickly learned our business, our strategy, and our ongoing \ntransformations across the enterprise and on behalf of our full leadership team, we are grateful for his \nearly contributions and partnership.  \n \n  Turning to our future, in fisca l 21 and beyond, we are focused on optimizing our core \nbusinesses and investing for growth.  I will share how we are doing both across the segments.  \n \n ", "original_text": "With that, let me turn it back over to Mike.  \n \n", "page_label": "10", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f206d3e4-a985-4e1c-9a04-4bbaf8aaebb1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1895c9d527046f751d73085c2b0ad523761336c9f40f7bbda5c907e0a9e01148", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a14d0ee-c0c0-4852-9334-8dba8e682646", "node_type": "1", "metadata": {"window": " \nPage 10 of 31 \n \n Those initial impressions have be en further confirmed in my first few months.  I am confident \nwe can collectively navigate current and future complexities to perform our essential role in \nhealthcare and realize our future opportunities.  \n \n  With that, let me turn it back over to Mike.  \n \n Mike Kaufmann:  Jason has quickly learned our business, our strategy, and our ongoing \ntransformations across the enterprise and on behalf of our full leadership team, we are grateful for his \nearly contributions and partnership.  \n \n  Turning to our future, in fisca l 21 and beyond, we are focused on optimizing our core \nbusinesses and investing for growth. ", "original_text": "I am confident \nwe can collectively navigate current and future complexities to perform our essential role in \nhealthcare and realize our future opportunities.  \n \n ", "page_label": "10", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80ad174c414b33ea00563031e66e69e369423fa168059842c6b37026bc418dd9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "316f9175-08d1-4ea2-b4ce-6cf248416e66", "node_type": "1", "metadata": {"window": " \nPage 10 of 31 \n \n Those initial impressions have be en further confirmed in my first few months.  I am confident \nwe can collectively navigate current and future complexities to perform our essential role in \nhealthcare and realize our future opportunities.  \n \n  With that, let me turn it back over to Mike.  \n \n Mike Kaufmann:  Jason has quickly learned our business, our strategy, and our ongoing \ntransformations across the enterprise and on behalf of our full leadership team, we are grateful for his \nearly contributions and partnership.  \n \n  Turning to our future, in fisca l 21 and beyond, we are focused on optimizing our core \nbusinesses and investing for growth.  I will share how we are doing both across the segments.  \n \n  First, in Pharma, we're building momentum on a solid growth trajectory. ", "original_text": "Mike Kaufmann:  Jason has quickly learned our business, our strategy, and our ongoing \ntransformations across the enterprise and on behalf of our full leadership team, we are grateful for his \nearly contributions and partnership.  \n \n "}, "hash": "0d9098c4302019583f9a93a7deb9e041a35ecc468337251188af367c8a908b7e", "class_name": "RelatedNodeInfo"}}, "text": "With that, let me turn it back over to Mike.  \n \n", "start_char_idx": 264, "end_char_idx": 313, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "316f9175-08d1-4ea2-b4ce-6cf248416e66": {"__data__": {"id_": "316f9175-08d1-4ea2-b4ce-6cf248416e66", "embedding": null, "metadata": {"window": " \nPage 10 of 31 \n \n Those initial impressions have be en further confirmed in my first few months.  I am confident \nwe can collectively navigate current and future complexities to perform our essential role in \nhealthcare and realize our future opportunities.  \n \n  With that, let me turn it back over to Mike.  \n \n Mike Kaufmann:  Jason has quickly learned our business, our strategy, and our ongoing \ntransformations across the enterprise and on behalf of our full leadership team, we are grateful for his \nearly contributions and partnership.  \n \n  Turning to our future, in fisca l 21 and beyond, we are focused on optimizing our core \nbusinesses and investing for growth.  I will share how we are doing both across the segments.  \n \n  First, in Pharma, we're building momentum on a solid growth trajectory. ", "original_text": "Mike Kaufmann:  Jason has quickly learned our business, our strategy, and our ongoing \ntransformations across the enterprise and on behalf of our full leadership team, we are grateful for his \nearly contributions and partnership.  \n \n ", "page_label": "10", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f206d3e4-a985-4e1c-9a04-4bbaf8aaebb1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1895c9d527046f751d73085c2b0ad523761336c9f40f7bbda5c907e0a9e01148", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "922d9bcb-193f-421e-b7de-efc61a836cac", "node_type": "1", "metadata": {"window": " \nPage 10 of 31 \n \n Those initial impressions have be en further confirmed in my first few months.  I am confident \nwe can collectively navigate current and future complexities to perform our essential role in \nhealthcare and realize our future opportunities.  \n \n  With that, let me turn it back over to Mike.  \n \n Mike Kaufmann:  Jason has quickly learned our business, our strategy, and our ongoing \ntransformations across the enterprise and on behalf of our full leadership team, we are grateful for his \nearly contributions and partnership.  \n \n  Turning to our future, in fisca l 21 and beyond, we are focused on optimizing our core \nbusinesses and investing for growth.  I will share how we are doing both across the segments.  \n \n ", "original_text": "With that, let me turn it back over to Mike.  \n \n", "page_label": "10", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ee516a46c318eb02381dbeb6281721cee07160119b6c267800324994c7c314a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0bad7abd-a093-4392-b598-233440078953", "node_type": "1", "metadata": {"window": "I am confident \nwe can collectively navigate current and future complexities to perform our essential role in \nhealthcare and realize our future opportunities.  \n \n  With that, let me turn it back over to Mike.  \n \n Mike Kaufmann:  Jason has quickly learned our business, our strategy, and our ongoing \ntransformations across the enterprise and on behalf of our full leadership team, we are grateful for his \nearly contributions and partnership.  \n \n  Turning to our future, in fisca l 21 and beyond, we are focused on optimizing our core \nbusinesses and investing for growth.  I will share how we are doing both across the segments.  \n \n  First, in Pharma, we're building momentum on a solid growth trajectory.  We continue to \nenhance our infrast ructure, deploying technologies across the segment to streamline our operations, \nimprove our processes, and strengthen our e -commerce platforms.  \n \n ", "original_text": "Turning to our future, in fisca l 21 and beyond, we are focused on optimizing our core \nbusinesses and investing for growth. "}, "hash": "a3f19cc1a2b62e8efef52803dea1382a26ccb90dbcff7e5860d463c24e757eae", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Jason has quickly learned our business, our strategy, and our ongoing \ntransformations across the enterprise and on behalf of our full leadership team, we are grateful for his \nearly contributions and partnership.  \n \n ", "start_char_idx": 313, "end_char_idx": 548, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0bad7abd-a093-4392-b598-233440078953": {"__data__": {"id_": "0bad7abd-a093-4392-b598-233440078953", "embedding": null, "metadata": {"window": "I am confident \nwe can collectively navigate current and future complexities to perform our essential role in \nhealthcare and realize our future opportunities.  \n \n  With that, let me turn it back over to Mike.  \n \n Mike Kaufmann:  Jason has quickly learned our business, our strategy, and our ongoing \ntransformations across the enterprise and on behalf of our full leadership team, we are grateful for his \nearly contributions and partnership.  \n \n  Turning to our future, in fisca l 21 and beyond, we are focused on optimizing our core \nbusinesses and investing for growth.  I will share how we are doing both across the segments.  \n \n  First, in Pharma, we're building momentum on a solid growth trajectory.  We continue to \nenhance our infrast ructure, deploying technologies across the segment to streamline our operations, \nimprove our processes, and strengthen our e -commerce platforms.  \n \n ", "original_text": "Turning to our future, in fisca l 21 and beyond, we are focused on optimizing our core \nbusinesses and investing for growth. ", "page_label": "10", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f206d3e4-a985-4e1c-9a04-4bbaf8aaebb1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1895c9d527046f751d73085c2b0ad523761336c9f40f7bbda5c907e0a9e01148", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "316f9175-08d1-4ea2-b4ce-6cf248416e66", "node_type": "1", "metadata": {"window": " \nPage 10 of 31 \n \n Those initial impressions have be en further confirmed in my first few months.  I am confident \nwe can collectively navigate current and future complexities to perform our essential role in \nhealthcare and realize our future opportunities.  \n \n  With that, let me turn it back over to Mike.  \n \n Mike Kaufmann:  Jason has quickly learned our business, our strategy, and our ongoing \ntransformations across the enterprise and on behalf of our full leadership team, we are grateful for his \nearly contributions and partnership.  \n \n  Turning to our future, in fisca l 21 and beyond, we are focused on optimizing our core \nbusinesses and investing for growth.  I will share how we are doing both across the segments.  \n \n  First, in Pharma, we're building momentum on a solid growth trajectory. ", "original_text": "Mike Kaufmann:  Jason has quickly learned our business, our strategy, and our ongoing \ntransformations across the enterprise and on behalf of our full leadership team, we are grateful for his \nearly contributions and partnership.  \n \n ", "page_label": "10", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7d02ea02c7360a2c3f7c4db194a28fb1c1770c998076c55b4b0222c697a3e61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7a752f3-33ad-4608-8d18-7ed803874077", "node_type": "1", "metadata": {"window": "With that, let me turn it back over to Mike.  \n \n Mike Kaufmann:  Jason has quickly learned our business, our strategy, and our ongoing \ntransformations across the enterprise and on behalf of our full leadership team, we are grateful for his \nearly contributions and partnership.  \n \n  Turning to our future, in fisca l 21 and beyond, we are focused on optimizing our core \nbusinesses and investing for growth.  I will share how we are doing both across the segments.  \n \n  First, in Pharma, we're building momentum on a solid growth trajectory.  We continue to \nenhance our infrast ructure, deploying technologies across the segment to streamline our operations, \nimprove our processes, and strengthen our e -commerce platforms.  \n \n  We also continue to invest in generics, including our best -in-class sourcing capabilities through \nRed Oak as we drive all aspects of the program for sustained momentum and performance.  \n \n ", "original_text": "I will share how we are doing both across the segments.  \n \n "}, "hash": "2072f1b27fc05b809c59a50ee6380dfc9ec0c38a964aeddf3c26e0008b15dbb7", "class_name": "RelatedNodeInfo"}}, "text": "Turning to our future, in fisca l 21 and beyond, we are focused on optimizing our core \nbusinesses and investing for growth. ", "start_char_idx": 548, "end_char_idx": 673, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7a752f3-33ad-4608-8d18-7ed803874077": {"__data__": {"id_": "d7a752f3-33ad-4608-8d18-7ed803874077", "embedding": null, "metadata": {"window": "With that, let me turn it back over to Mike.  \n \n Mike Kaufmann:  Jason has quickly learned our business, our strategy, and our ongoing \ntransformations across the enterprise and on behalf of our full leadership team, we are grateful for his \nearly contributions and partnership.  \n \n  Turning to our future, in fisca l 21 and beyond, we are focused on optimizing our core \nbusinesses and investing for growth.  I will share how we are doing both across the segments.  \n \n  First, in Pharma, we're building momentum on a solid growth trajectory.  We continue to \nenhance our infrast ructure, deploying technologies across the segment to streamline our operations, \nimprove our processes, and strengthen our e -commerce platforms.  \n \n  We also continue to invest in generics, including our best -in-class sourcing capabilities through \nRed Oak as we drive all aspects of the program for sustained momentum and performance.  \n \n ", "original_text": "I will share how we are doing both across the segments.  \n \n ", "page_label": "10", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f206d3e4-a985-4e1c-9a04-4bbaf8aaebb1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1895c9d527046f751d73085c2b0ad523761336c9f40f7bbda5c907e0a9e01148", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0bad7abd-a093-4392-b598-233440078953", "node_type": "1", "metadata": {"window": "I am confident \nwe can collectively navigate current and future complexities to perform our essential role in \nhealthcare and realize our future opportunities.  \n \n  With that, let me turn it back over to Mike.  \n \n Mike Kaufmann:  Jason has quickly learned our business, our strategy, and our ongoing \ntransformations across the enterprise and on behalf of our full leadership team, we are grateful for his \nearly contributions and partnership.  \n \n  Turning to our future, in fisca l 21 and beyond, we are focused on optimizing our core \nbusinesses and investing for growth.  I will share how we are doing both across the segments.  \n \n  First, in Pharma, we're building momentum on a solid growth trajectory.  We continue to \nenhance our infrast ructure, deploying technologies across the segment to streamline our operations, \nimprove our processes, and strengthen our e -commerce platforms.  \n \n ", "original_text": "Turning to our future, in fisca l 21 and beyond, we are focused on optimizing our core \nbusinesses and investing for growth. ", "page_label": "10", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88e5d475af2afa0a1ceedb224d2cd42137074efb55e91f6c24e6096743e6db48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9d5ffa4-6af6-47c4-a647-aa044d79366d", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Jason has quickly learned our business, our strategy, and our ongoing \ntransformations across the enterprise and on behalf of our full leadership team, we are grateful for his \nearly contributions and partnership.  \n \n  Turning to our future, in fisca l 21 and beyond, we are focused on optimizing our core \nbusinesses and investing for growth.  I will share how we are doing both across the segments.  \n \n  First, in Pharma, we're building momentum on a solid growth trajectory.  We continue to \nenhance our infrast ructure, deploying technologies across the segment to streamline our operations, \nimprove our processes, and strengthen our e -commerce platforms.  \n \n  We also continue to invest in generics, including our best -in-class sourcing capabilities through \nRed Oak as we drive all aspects of the program for sustained momentum and performance.  \n \n  Along with these workstreams, we are fueling growth in key areas of the segment, through \nstrategic investments to diversify our capabilities and enhance the customer experienc e. \n ", "original_text": "First, in Pharma, we're building momentum on a solid growth trajectory. "}, "hash": "0169a2122797a59e6913c7da7f4f8a412dd36e83f9bb122b32de3d29f9e3c499", "class_name": "RelatedNodeInfo"}}, "text": "I will share how we are doing both across the segments.  \n \n ", "start_char_idx": 673, "end_char_idx": 734, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9d5ffa4-6af6-47c4-a647-aa044d79366d": {"__data__": {"id_": "a9d5ffa4-6af6-47c4-a647-aa044d79366d", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Jason has quickly learned our business, our strategy, and our ongoing \ntransformations across the enterprise and on behalf of our full leadership team, we are grateful for his \nearly contributions and partnership.  \n \n  Turning to our future, in fisca l 21 and beyond, we are focused on optimizing our core \nbusinesses and investing for growth.  I will share how we are doing both across the segments.  \n \n  First, in Pharma, we're building momentum on a solid growth trajectory.  We continue to \nenhance our infrast ructure, deploying technologies across the segment to streamline our operations, \nimprove our processes, and strengthen our e -commerce platforms.  \n \n  We also continue to invest in generics, including our best -in-class sourcing capabilities through \nRed Oak as we drive all aspects of the program for sustained momentum and performance.  \n \n  Along with these workstreams, we are fueling growth in key areas of the segment, through \nstrategic investments to diversify our capabilities and enhance the customer experienc e. \n ", "original_text": "First, in Pharma, we're building momentum on a solid growth trajectory. ", "page_label": "10", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f206d3e4-a985-4e1c-9a04-4bbaf8aaebb1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1895c9d527046f751d73085c2b0ad523761336c9f40f7bbda5c907e0a9e01148", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7a752f3-33ad-4608-8d18-7ed803874077", "node_type": "1", "metadata": {"window": "With that, let me turn it back over to Mike.  \n \n Mike Kaufmann:  Jason has quickly learned our business, our strategy, and our ongoing \ntransformations across the enterprise and on behalf of our full leadership team, we are grateful for his \nearly contributions and partnership.  \n \n  Turning to our future, in fisca l 21 and beyond, we are focused on optimizing our core \nbusinesses and investing for growth.  I will share how we are doing both across the segments.  \n \n  First, in Pharma, we're building momentum on a solid growth trajectory.  We continue to \nenhance our infrast ructure, deploying technologies across the segment to streamline our operations, \nimprove our processes, and strengthen our e -commerce platforms.  \n \n  We also continue to invest in generics, including our best -in-class sourcing capabilities through \nRed Oak as we drive all aspects of the program for sustained momentum and performance.  \n \n ", "original_text": "I will share how we are doing both across the segments.  \n \n ", "page_label": "10", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cac0129c6666d4a6f2d47ba191ab5ba3b75b755be5a84181cb23caf780943eec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "473821da-71e0-4e9f-9eee-c4837d779214", "node_type": "1", "metadata": {"window": "Turning to our future, in fisca l 21 and beyond, we are focused on optimizing our core \nbusinesses and investing for growth.  I will share how we are doing both across the segments.  \n \n  First, in Pharma, we're building momentum on a solid growth trajectory.  We continue to \nenhance our infrast ructure, deploying technologies across the segment to streamline our operations, \nimprove our processes, and strengthen our e -commerce platforms.  \n \n  We also continue to invest in generics, including our best -in-class sourcing capabilities through \nRed Oak as we drive all aspects of the program for sustained momentum and performance.  \n \n  Along with these workstreams, we are fueling growth in key areas of the segment, through \nstrategic investments to diversify our capabilities and enhance the customer experienc e. \n ", "original_text": "We continue to \nenhance our infrast ructure, deploying technologies across the segment to streamline our operations, \nimprove our processes, and strengthen our e -commerce platforms.  \n \n "}, "hash": "938e84481c2a6a53848c3b8ef3473334ce55265a7e5d928cc915b973126e9556", "class_name": "RelatedNodeInfo"}}, "text": "First, in Pharma, we're building momentum on a solid growth trajectory. ", "start_char_idx": 734, "end_char_idx": 806, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "473821da-71e0-4e9f-9eee-c4837d779214": {"__data__": {"id_": "473821da-71e0-4e9f-9eee-c4837d779214", "embedding": null, "metadata": {"window": "Turning to our future, in fisca l 21 and beyond, we are focused on optimizing our core \nbusinesses and investing for growth.  I will share how we are doing both across the segments.  \n \n  First, in Pharma, we're building momentum on a solid growth trajectory.  We continue to \nenhance our infrast ructure, deploying technologies across the segment to streamline our operations, \nimprove our processes, and strengthen our e -commerce platforms.  \n \n  We also continue to invest in generics, including our best -in-class sourcing capabilities through \nRed Oak as we drive all aspects of the program for sustained momentum and performance.  \n \n  Along with these workstreams, we are fueling growth in key areas of the segment, through \nstrategic investments to diversify our capabilities and enhance the customer experienc e. \n ", "original_text": "We continue to \nenhance our infrast ructure, deploying technologies across the segment to streamline our operations, \nimprove our processes, and strengthen our e -commerce platforms.  \n \n ", "page_label": "10", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f206d3e4-a985-4e1c-9a04-4bbaf8aaebb1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1895c9d527046f751d73085c2b0ad523761336c9f40f7bbda5c907e0a9e01148", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9d5ffa4-6af6-47c4-a647-aa044d79366d", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Jason has quickly learned our business, our strategy, and our ongoing \ntransformations across the enterprise and on behalf of our full leadership team, we are grateful for his \nearly contributions and partnership.  \n \n  Turning to our future, in fisca l 21 and beyond, we are focused on optimizing our core \nbusinesses and investing for growth.  I will share how we are doing both across the segments.  \n \n  First, in Pharma, we're building momentum on a solid growth trajectory.  We continue to \nenhance our infrast ructure, deploying technologies across the segment to streamline our operations, \nimprove our processes, and strengthen our e -commerce platforms.  \n \n  We also continue to invest in generics, including our best -in-class sourcing capabilities through \nRed Oak as we drive all aspects of the program for sustained momentum and performance.  \n \n  Along with these workstreams, we are fueling growth in key areas of the segment, through \nstrategic investments to diversify our capabilities and enhance the customer experienc e. \n ", "original_text": "First, in Pharma, we're building momentum on a solid growth trajectory. ", "page_label": "10", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dd636cc1ee7b04a22f1689927ad1adc674980cd840f9aec4c4cd684daa8fd2c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3eab3dcb-5b2f-496b-a4ff-9d555144bbc7", "node_type": "1", "metadata": {"window": "I will share how we are doing both across the segments.  \n \n  First, in Pharma, we're building momentum on a solid growth trajectory.  We continue to \nenhance our infrast ructure, deploying technologies across the segment to streamline our operations, \nimprove our processes, and strengthen our e -commerce platforms.  \n \n  We also continue to invest in generics, including our best -in-class sourcing capabilities through \nRed Oak as we drive all aspects of the program for sustained momentum and performance.  \n \n  Along with these workstreams, we are fueling growth in key areas of the segment, through \nstrategic investments to diversify our capabilities and enhance the customer experienc e. \n ", "original_text": "We also continue to invest in generics, including our best -in-class sourcing capabilities through \nRed Oak as we drive all aspects of the program for sustained momentum and performance.  \n \n "}, "hash": "57cd85c997c62b5274f288c8e117a0551f4db6152c13b7262d5eb49ad4ba54d3", "class_name": "RelatedNodeInfo"}}, "text": "We continue to \nenhance our infrast ructure, deploying technologies across the segment to streamline our operations, \nimprove our processes, and strengthen our e -commerce platforms.  \n \n ", "start_char_idx": 806, "end_char_idx": 994, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3eab3dcb-5b2f-496b-a4ff-9d555144bbc7": {"__data__": {"id_": "3eab3dcb-5b2f-496b-a4ff-9d555144bbc7", "embedding": null, "metadata": {"window": "I will share how we are doing both across the segments.  \n \n  First, in Pharma, we're building momentum on a solid growth trajectory.  We continue to \nenhance our infrast ructure, deploying technologies across the segment to streamline our operations, \nimprove our processes, and strengthen our e -commerce platforms.  \n \n  We also continue to invest in generics, including our best -in-class sourcing capabilities through \nRed Oak as we drive all aspects of the program for sustained momentum and performance.  \n \n  Along with these workstreams, we are fueling growth in key areas of the segment, through \nstrategic investments to diversify our capabilities and enhance the customer experienc e. \n ", "original_text": "We also continue to invest in generics, including our best -in-class sourcing capabilities through \nRed Oak as we drive all aspects of the program for sustained momentum and performance.  \n \n ", "page_label": "10", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f206d3e4-a985-4e1c-9a04-4bbaf8aaebb1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1895c9d527046f751d73085c2b0ad523761336c9f40f7bbda5c907e0a9e01148", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "473821da-71e0-4e9f-9eee-c4837d779214", "node_type": "1", "metadata": {"window": "Turning to our future, in fisca l 21 and beyond, we are focused on optimizing our core \nbusinesses and investing for growth.  I will share how we are doing both across the segments.  \n \n  First, in Pharma, we're building momentum on a solid growth trajectory.  We continue to \nenhance our infrast ructure, deploying technologies across the segment to streamline our operations, \nimprove our processes, and strengthen our e -commerce platforms.  \n \n  We also continue to invest in generics, including our best -in-class sourcing capabilities through \nRed Oak as we drive all aspects of the program for sustained momentum and performance.  \n \n  Along with these workstreams, we are fueling growth in key areas of the segment, through \nstrategic investments to diversify our capabilities and enhance the customer experienc e. \n ", "original_text": "We continue to \nenhance our infrast ructure, deploying technologies across the segment to streamline our operations, \nimprove our processes, and strengthen our e -commerce platforms.  \n \n ", "page_label": "10", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eecdf12ead114b44f88079876d752e1c72a940cdb35073c1e323bdc852120a1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b892c5c1-2378-4d71-a656-527e241159a2", "node_type": "1", "metadata": {"window": "First, in Pharma, we're building momentum on a solid growth trajectory.  We continue to \nenhance our infrast ructure, deploying technologies across the segment to streamline our operations, \nimprove our processes, and strengthen our e -commerce platforms.  \n \n  We also continue to invest in generics, including our best -in-class sourcing capabilities through \nRed Oak as we drive all aspects of the program for sustained momentum and performance.  \n \n  Along with these workstreams, we are fueling growth in key areas of the segment, through \nstrategic investments to diversify our capabilities and enhance the customer experienc e. \n ", "original_text": "Along with these workstreams, we are fueling growth in key areas of the segment, through \nstrategic investments to diversify our capabilities and enhance the customer experienc e. \n "}, "hash": "a572cc3b127fdd2637789e280aad5503590b142e3ec4cc0db0dd516b21e72dec", "class_name": "RelatedNodeInfo"}}, "text": "We also continue to invest in generics, including our best -in-class sourcing capabilities through \nRed Oak as we drive all aspects of the program for sustained momentum and performance.  \n \n ", "start_char_idx": 994, "end_char_idx": 1186, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b892c5c1-2378-4d71-a656-527e241159a2": {"__data__": {"id_": "b892c5c1-2378-4d71-a656-527e241159a2", "embedding": null, "metadata": {"window": "First, in Pharma, we're building momentum on a solid growth trajectory.  We continue to \nenhance our infrast ructure, deploying technologies across the segment to streamline our operations, \nimprove our processes, and strengthen our e -commerce platforms.  \n \n  We also continue to invest in generics, including our best -in-class sourcing capabilities through \nRed Oak as we drive all aspects of the program for sustained momentum and performance.  \n \n  Along with these workstreams, we are fueling growth in key areas of the segment, through \nstrategic investments to diversify our capabilities and enhance the customer experienc e. \n ", "original_text": "Along with these workstreams, we are fueling growth in key areas of the segment, through \nstrategic investments to diversify our capabilities and enhance the customer experienc e. \n ", "page_label": "10", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f206d3e4-a985-4e1c-9a04-4bbaf8aaebb1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1895c9d527046f751d73085c2b0ad523761336c9f40f7bbda5c907e0a9e01148", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3eab3dcb-5b2f-496b-a4ff-9d555144bbc7", "node_type": "1", "metadata": {"window": "I will share how we are doing both across the segments.  \n \n  First, in Pharma, we're building momentum on a solid growth trajectory.  We continue to \nenhance our infrast ructure, deploying technologies across the segment to streamline our operations, \nimprove our processes, and strengthen our e -commerce platforms.  \n \n  We also continue to invest in generics, including our best -in-class sourcing capabilities through \nRed Oak as we drive all aspects of the program for sustained momentum and performance.  \n \n  Along with these workstreams, we are fueling growth in key areas of the segment, through \nstrategic investments to diversify our capabilities and enhance the customer experienc e. \n ", "original_text": "We also continue to invest in generics, including our best -in-class sourcing capabilities through \nRed Oak as we drive all aspects of the program for sustained momentum and performance.  \n \n ", "page_label": "10", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a044c2768b96f60be80bfbf851e32120d5bbdd4c040e452fde69e1d0ef69e80a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e872649b-5634-476c-b818-ca6605cd04e2", "node_type": "1", "metadata": {"window": " \nPage 11 of 31 \n \n In Specialty, we are beginning to operationalize the investment we mentioned in Q1 to \nestablish a new distribution center outside of Nashville, Tennessee.  \n \n  This facility includes a state -of-the-art cold chain complex with deep -frozen technology, and it \nenables us to drive operational efficiencies , as well as support further growth in this area of the \nindustry.  \n \n  In Connected Care, we're identifying and investing in innovative digital capabilities that will \nimprove interactions with patients, payers, p harmacies, and providers.  \n \n  We are also investing in an expanded innovations center for theranostics opportunities in our \nNuclear business, which will drive longer -term profitable growth.  \n \n ", "original_text": " \nPage 11 of 31 \n \n In Specialty, we are beginning to operationalize the investment we mentioned in Q1 to \nestablish a new distribution center outside of Nashville, Tennessee.  \n \n "}, "hash": "e65debf44ecceab97f85d568ba8ff3117913b2d1bc795ebfcb12d6efda58c6ef", "class_name": "RelatedNodeInfo"}}, "text": "Along with these workstreams, we are fueling growth in key areas of the segment, through \nstrategic investments to diversify our capabilities and enhance the customer experienc e. \n ", "start_char_idx": 1186, "end_char_idx": 1368, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e872649b-5634-476c-b818-ca6605cd04e2": {"__data__": {"id_": "e872649b-5634-476c-b818-ca6605cd04e2", "embedding": null, "metadata": {"window": " \nPage 11 of 31 \n \n In Specialty, we are beginning to operationalize the investment we mentioned in Q1 to \nestablish a new distribution center outside of Nashville, Tennessee.  \n \n  This facility includes a state -of-the-art cold chain complex with deep -frozen technology, and it \nenables us to drive operational efficiencies , as well as support further growth in this area of the \nindustry.  \n \n  In Connected Care, we're identifying and investing in innovative digital capabilities that will \nimprove interactions with patients, payers, p harmacies, and providers.  \n \n  We are also investing in an expanded innovations center for theranostics opportunities in our \nNuclear business, which will drive longer -term profitable growth.  \n \n ", "original_text": " \nPage 11 of 31 \n \n In Specialty, we are beginning to operationalize the investment we mentioned in Q1 to \nestablish a new distribution center outside of Nashville, Tennessee.  \n \n ", "page_label": "11", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f6fea48-a7c1-4810-bfee-5e9fbc802a26", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a82102a93614f9fc80f8d94f46ddf6f0fa04d312f7203a04d38e8035bd2cb10d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b892c5c1-2378-4d71-a656-527e241159a2", "node_type": "1", "metadata": {"window": "First, in Pharma, we're building momentum on a solid growth trajectory.  We continue to \nenhance our infrast ructure, deploying technologies across the segment to streamline our operations, \nimprove our processes, and strengthen our e -commerce platforms.  \n \n  We also continue to invest in generics, including our best -in-class sourcing capabilities through \nRed Oak as we drive all aspects of the program for sustained momentum and performance.  \n \n  Along with these workstreams, we are fueling growth in key areas of the segment, through \nstrategic investments to diversify our capabilities and enhance the customer experienc e. \n ", "original_text": "Along with these workstreams, we are fueling growth in key areas of the segment, through \nstrategic investments to diversify our capabilities and enhance the customer experienc e. \n ", "page_label": "10", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "558fe7224df7db68cb5d035e8abd6f1b6f6325c0088e3366df71eb14cbe55355", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25713efc-5b14-42a7-8fe6-3d601d8c846e", "node_type": "1", "metadata": {"window": " \nPage 11 of 31 \n \n In Specialty, we are beginning to operationalize the investment we mentioned in Q1 to \nestablish a new distribution center outside of Nashville, Tennessee.  \n \n  This facility includes a state -of-the-art cold chain complex with deep -frozen technology, and it \nenables us to drive operational efficiencies , as well as support further growth in this area of the \nindustry.  \n \n  In Connected Care, we're identifying and investing in innovative digital capabilities that will \nimprove interactions with patients, payers, p harmacies, and providers.  \n \n  We are also investing in an expanded innovations center for theranostics opportunities in our \nNuclear business, which will drive longer -term profitable growth.  \n \n  Turning now to Medical. ", "original_text": "This facility includes a state -of-the-art cold chain complex with deep -frozen technology, and it \nenables us to drive operational efficiencies , as well as support further growth in this area of the \nindustry.  \n \n "}, "hash": "20bf0921565f6c3b35da6d2bd6edffb2dd05e7a98abbb9c477bab2584b66ac85", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 11 of 31 \n \n In Specialty, we are beginning to operationalize the investment we mentioned in Q1 to \nestablish a new distribution center outside of Nashville, Tennessee.  \n \n ", "start_char_idx": 0, "end_char_idx": 181, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25713efc-5b14-42a7-8fe6-3d601d8c846e": {"__data__": {"id_": "25713efc-5b14-42a7-8fe6-3d601d8c846e", "embedding": null, "metadata": {"window": " \nPage 11 of 31 \n \n In Specialty, we are beginning to operationalize the investment we mentioned in Q1 to \nestablish a new distribution center outside of Nashville, Tennessee.  \n \n  This facility includes a state -of-the-art cold chain complex with deep -frozen technology, and it \nenables us to drive operational efficiencies , as well as support further growth in this area of the \nindustry.  \n \n  In Connected Care, we're identifying and investing in innovative digital capabilities that will \nimprove interactions with patients, payers, p harmacies, and providers.  \n \n  We are also investing in an expanded innovations center for theranostics opportunities in our \nNuclear business, which will drive longer -term profitable growth.  \n \n  Turning now to Medical. ", "original_text": "This facility includes a state -of-the-art cold chain complex with deep -frozen technology, and it \nenables us to drive operational efficiencies , as well as support further growth in this area of the \nindustry.  \n \n ", "page_label": "11", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f6fea48-a7c1-4810-bfee-5e9fbc802a26", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a82102a93614f9fc80f8d94f46ddf6f0fa04d312f7203a04d38e8035bd2cb10d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e872649b-5634-476c-b818-ca6605cd04e2", "node_type": "1", "metadata": {"window": " \nPage 11 of 31 \n \n In Specialty, we are beginning to operationalize the investment we mentioned in Q1 to \nestablish a new distribution center outside of Nashville, Tennessee.  \n \n  This facility includes a state -of-the-art cold chain complex with deep -frozen technology, and it \nenables us to drive operational efficiencies , as well as support further growth in this area of the \nindustry.  \n \n  In Connected Care, we're identifying and investing in innovative digital capabilities that will \nimprove interactions with patients, payers, p harmacies, and providers.  \n \n  We are also investing in an expanded innovations center for theranostics opportunities in our \nNuclear business, which will drive longer -term profitable growth.  \n \n ", "original_text": " \nPage 11 of 31 \n \n In Specialty, we are beginning to operationalize the investment we mentioned in Q1 to \nestablish a new distribution center outside of Nashville, Tennessee.  \n \n ", "page_label": "11", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cdf2381ec4bb8629d2ca86a97c51ec674afbcd40396c045ea6abbd6414843203", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82c99bf1-5d29-4938-9296-e0e878bbba5b", "node_type": "1", "metadata": {"window": " \nPage 11 of 31 \n \n In Specialty, we are beginning to operationalize the investment we mentioned in Q1 to \nestablish a new distribution center outside of Nashville, Tennessee.  \n \n  This facility includes a state -of-the-art cold chain complex with deep -frozen technology, and it \nenables us to drive operational efficiencies , as well as support further growth in this area of the \nindustry.  \n \n  In Connected Care, we're identifying and investing in innovative digital capabilities that will \nimprove interactions with patients, payers, p harmacies, and providers.  \n \n  We are also investing in an expanded innovations center for theranostics opportunities in our \nNuclear business, which will drive longer -term profitable growth.  \n \n  Turning now to Medical.  We have multiple initiatives underway to d rive longer -term growth in \nthis segment, but first and foremost, we continue to prioritize our response to customers and their \npatients as we navigate the pandemic.  \n \n ", "original_text": "In Connected Care, we're identifying and investing in innovative digital capabilities that will \nimprove interactions with patients, payers, p harmacies, and providers.  \n \n "}, "hash": "d9716fe52e5cab96a42745fc1f0cec768a08e52fe24a672459870c523eb2eff7", "class_name": "RelatedNodeInfo"}}, "text": "This facility includes a state -of-the-art cold chain complex with deep -frozen technology, and it \nenables us to drive operational efficiencies , as well as support further growth in this area of the \nindustry.  \n \n ", "start_char_idx": 181, "end_char_idx": 398, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82c99bf1-5d29-4938-9296-e0e878bbba5b": {"__data__": {"id_": "82c99bf1-5d29-4938-9296-e0e878bbba5b", "embedding": null, "metadata": {"window": " \nPage 11 of 31 \n \n In Specialty, we are beginning to operationalize the investment we mentioned in Q1 to \nestablish a new distribution center outside of Nashville, Tennessee.  \n \n  This facility includes a state -of-the-art cold chain complex with deep -frozen technology, and it \nenables us to drive operational efficiencies , as well as support further growth in this area of the \nindustry.  \n \n  In Connected Care, we're identifying and investing in innovative digital capabilities that will \nimprove interactions with patients, payers, p harmacies, and providers.  \n \n  We are also investing in an expanded innovations center for theranostics opportunities in our \nNuclear business, which will drive longer -term profitable growth.  \n \n  Turning now to Medical.  We have multiple initiatives underway to d rive longer -term growth in \nthis segment, but first and foremost, we continue to prioritize our response to customers and their \npatients as we navigate the pandemic.  \n \n ", "original_text": "In Connected Care, we're identifying and investing in innovative digital capabilities that will \nimprove interactions with patients, payers, p harmacies, and providers.  \n \n ", "page_label": "11", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f6fea48-a7c1-4810-bfee-5e9fbc802a26", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a82102a93614f9fc80f8d94f46ddf6f0fa04d312f7203a04d38e8035bd2cb10d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25713efc-5b14-42a7-8fe6-3d601d8c846e", "node_type": "1", "metadata": {"window": " \nPage 11 of 31 \n \n In Specialty, we are beginning to operationalize the investment we mentioned in Q1 to \nestablish a new distribution center outside of Nashville, Tennessee.  \n \n  This facility includes a state -of-the-art cold chain complex with deep -frozen technology, and it \nenables us to drive operational efficiencies , as well as support further growth in this area of the \nindustry.  \n \n  In Connected Care, we're identifying and investing in innovative digital capabilities that will \nimprove interactions with patients, payers, p harmacies, and providers.  \n \n  We are also investing in an expanded innovations center for theranostics opportunities in our \nNuclear business, which will drive longer -term profitable growth.  \n \n  Turning now to Medical. ", "original_text": "This facility includes a state -of-the-art cold chain complex with deep -frozen technology, and it \nenables us to drive operational efficiencies , as well as support further growth in this area of the \nindustry.  \n \n ", "page_label": "11", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "66ad1cbdae985df17a335e483cfe4ae7cadfbd36b89c27a96cd9bfdd2e6475c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2897a40d-2757-466c-8f68-5a8d642603ed", "node_type": "1", "metadata": {"window": " \nPage 11 of 31 \n \n In Specialty, we are beginning to operationalize the investment we mentioned in Q1 to \nestablish a new distribution center outside of Nashville, Tennessee.  \n \n  This facility includes a state -of-the-art cold chain complex with deep -frozen technology, and it \nenables us to drive operational efficiencies , as well as support further growth in this area of the \nindustry.  \n \n  In Connected Care, we're identifying and investing in innovative digital capabilities that will \nimprove interactions with patients, payers, p harmacies, and providers.  \n \n  We are also investing in an expanded innovations center for theranostics opportunities in our \nNuclear business, which will drive longer -term profitable growth.  \n \n  Turning now to Medical.  We have multiple initiatives underway to d rive longer -term growth in \nthis segment, but first and foremost, we continue to prioritize our response to customers and their \npatients as we navigate the pandemic.  \n \n  The unprecedented and sustained increases in demand for certain product categories are \ncreating supply challenges and cost pressures for us and for our customers that will likely negatively \naffect our results.  \n \n ", "original_text": "We are also investing in an expanded innovations center for theranostics opportunities in our \nNuclear business, which will drive longer -term profitable growth.  \n \n "}, "hash": "c34c948e9cf41fc09b929f55113c6076cabbdb3e45af06e2f921d124273c83f0", "class_name": "RelatedNodeInfo"}}, "text": "In Connected Care, we're identifying and investing in innovative digital capabilities that will \nimprove interactions with patients, payers, p harmacies, and providers.  \n \n ", "start_char_idx": 398, "end_char_idx": 572, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2897a40d-2757-466c-8f68-5a8d642603ed": {"__data__": {"id_": "2897a40d-2757-466c-8f68-5a8d642603ed", "embedding": null, "metadata": {"window": " \nPage 11 of 31 \n \n In Specialty, we are beginning to operationalize the investment we mentioned in Q1 to \nestablish a new distribution center outside of Nashville, Tennessee.  \n \n  This facility includes a state -of-the-art cold chain complex with deep -frozen technology, and it \nenables us to drive operational efficiencies , as well as support further growth in this area of the \nindustry.  \n \n  In Connected Care, we're identifying and investing in innovative digital capabilities that will \nimprove interactions with patients, payers, p harmacies, and providers.  \n \n  We are also investing in an expanded innovations center for theranostics opportunities in our \nNuclear business, which will drive longer -term profitable growth.  \n \n  Turning now to Medical.  We have multiple initiatives underway to d rive longer -term growth in \nthis segment, but first and foremost, we continue to prioritize our response to customers and their \npatients as we navigate the pandemic.  \n \n  The unprecedented and sustained increases in demand for certain product categories are \ncreating supply challenges and cost pressures for us and for our customers that will likely negatively \naffect our results.  \n \n ", "original_text": "We are also investing in an expanded innovations center for theranostics opportunities in our \nNuclear business, which will drive longer -term profitable growth.  \n \n ", "page_label": "11", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f6fea48-a7c1-4810-bfee-5e9fbc802a26", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a82102a93614f9fc80f8d94f46ddf6f0fa04d312f7203a04d38e8035bd2cb10d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82c99bf1-5d29-4938-9296-e0e878bbba5b", "node_type": "1", "metadata": {"window": " \nPage 11 of 31 \n \n In Specialty, we are beginning to operationalize the investment we mentioned in Q1 to \nestablish a new distribution center outside of Nashville, Tennessee.  \n \n  This facility includes a state -of-the-art cold chain complex with deep -frozen technology, and it \nenables us to drive operational efficiencies , as well as support further growth in this area of the \nindustry.  \n \n  In Connected Care, we're identifying and investing in innovative digital capabilities that will \nimprove interactions with patients, payers, p harmacies, and providers.  \n \n  We are also investing in an expanded innovations center for theranostics opportunities in our \nNuclear business, which will drive longer -term profitable growth.  \n \n  Turning now to Medical.  We have multiple initiatives underway to d rive longer -term growth in \nthis segment, but first and foremost, we continue to prioritize our response to customers and their \npatients as we navigate the pandemic.  \n \n ", "original_text": "In Connected Care, we're identifying and investing in innovative digital capabilities that will \nimprove interactions with patients, payers, p harmacies, and providers.  \n \n ", "page_label": "11", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "efdb60e5184324970f80fd1ccd58bfe34e1658168481b06780796b01ee3af07e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90ee906f-3628-4f75-9c42-05eb784da364", "node_type": "1", "metadata": {"window": "This facility includes a state -of-the-art cold chain complex with deep -frozen technology, and it \nenables us to drive operational efficiencies , as well as support further growth in this area of the \nindustry.  \n \n  In Connected Care, we're identifying and investing in innovative digital capabilities that will \nimprove interactions with patients, payers, p harmacies, and providers.  \n \n  We are also investing in an expanded innovations center for theranostics opportunities in our \nNuclear business, which will drive longer -term profitable growth.  \n \n  Turning now to Medical.  We have multiple initiatives underway to d rive longer -term growth in \nthis segment, but first and foremost, we continue to prioritize our response to customers and their \npatients as we navigate the pandemic.  \n \n  The unprecedented and sustained increases in demand for certain product categories are \ncreating supply challenges and cost pressures for us and for our customers that will likely negatively \naffect our results.  \n \n  In response, we have and will continue to expand our self -manufacturing capacity and \nsourcing capabilities. ", "original_text": "Turning now to Medical. "}, "hash": "d860f85517f6c6b99d64c51ff09219d0a9263f01a81281b6097629fcc995127c", "class_name": "RelatedNodeInfo"}}, "text": "We are also investing in an expanded innovations center for theranostics opportunities in our \nNuclear business, which will drive longer -term profitable growth.  \n \n ", "start_char_idx": 572, "end_char_idx": 739, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90ee906f-3628-4f75-9c42-05eb784da364": {"__data__": {"id_": "90ee906f-3628-4f75-9c42-05eb784da364", "embedding": null, "metadata": {"window": "This facility includes a state -of-the-art cold chain complex with deep -frozen technology, and it \nenables us to drive operational efficiencies , as well as support further growth in this area of the \nindustry.  \n \n  In Connected Care, we're identifying and investing in innovative digital capabilities that will \nimprove interactions with patients, payers, p harmacies, and providers.  \n \n  We are also investing in an expanded innovations center for theranostics opportunities in our \nNuclear business, which will drive longer -term profitable growth.  \n \n  Turning now to Medical.  We have multiple initiatives underway to d rive longer -term growth in \nthis segment, but first and foremost, we continue to prioritize our response to customers and their \npatients as we navigate the pandemic.  \n \n  The unprecedented and sustained increases in demand for certain product categories are \ncreating supply challenges and cost pressures for us and for our customers that will likely negatively \naffect our results.  \n \n  In response, we have and will continue to expand our self -manufacturing capacity and \nsourcing capabilities. ", "original_text": "Turning now to Medical. ", "page_label": "11", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f6fea48-a7c1-4810-bfee-5e9fbc802a26", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a82102a93614f9fc80f8d94f46ddf6f0fa04d312f7203a04d38e8035bd2cb10d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2897a40d-2757-466c-8f68-5a8d642603ed", "node_type": "1", "metadata": {"window": " \nPage 11 of 31 \n \n In Specialty, we are beginning to operationalize the investment we mentioned in Q1 to \nestablish a new distribution center outside of Nashville, Tennessee.  \n \n  This facility includes a state -of-the-art cold chain complex with deep -frozen technology, and it \nenables us to drive operational efficiencies , as well as support further growth in this area of the \nindustry.  \n \n  In Connected Care, we're identifying and investing in innovative digital capabilities that will \nimprove interactions with patients, payers, p harmacies, and providers.  \n \n  We are also investing in an expanded innovations center for theranostics opportunities in our \nNuclear business, which will drive longer -term profitable growth.  \n \n  Turning now to Medical.  We have multiple initiatives underway to d rive longer -term growth in \nthis segment, but first and foremost, we continue to prioritize our response to customers and their \npatients as we navigate the pandemic.  \n \n  The unprecedented and sustained increases in demand for certain product categories are \ncreating supply challenges and cost pressures for us and for our customers that will likely negatively \naffect our results.  \n \n ", "original_text": "We are also investing in an expanded innovations center for theranostics opportunities in our \nNuclear business, which will drive longer -term profitable growth.  \n \n ", "page_label": "11", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eeee0bddaabdfbc91146af2f1568e7274fed3a637e67d6241322bfcda5d1b218", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2475a12d-06b7-4150-bdeb-810ca20ec9ee", "node_type": "1", "metadata": {"window": "In Connected Care, we're identifying and investing in innovative digital capabilities that will \nimprove interactions with patients, payers, p harmacies, and providers.  \n \n  We are also investing in an expanded innovations center for theranostics opportunities in our \nNuclear business, which will drive longer -term profitable growth.  \n \n  Turning now to Medical.  We have multiple initiatives underway to d rive longer -term growth in \nthis segment, but first and foremost, we continue to prioritize our response to customers and their \npatients as we navigate the pandemic.  \n \n  The unprecedented and sustained increases in demand for certain product categories are \ncreating supply challenges and cost pressures for us and for our customers that will likely negatively \naffect our results.  \n \n  In response, we have and will continue to expand our self -manufacturing capacity and \nsourcing capabilities.  Our sourcing and marketing teams have reviewed more than 700 leads for \nalternative sources of PPE supply. ", "original_text": "We have multiple initiatives underway to d rive longer -term growth in \nthis segment, but first and foremost, we continue to prioritize our response to customers and their \npatients as we navigate the pandemic.  \n \n "}, "hash": "32048b215aa3ab9105bcba806698352d04ec06330097af19cc2a1a8459a36934", "class_name": "RelatedNodeInfo"}}, "text": "Turning now to Medical. ", "start_char_idx": 739, "end_char_idx": 763, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2475a12d-06b7-4150-bdeb-810ca20ec9ee": {"__data__": {"id_": "2475a12d-06b7-4150-bdeb-810ca20ec9ee", "embedding": null, "metadata": {"window": "In Connected Care, we're identifying and investing in innovative digital capabilities that will \nimprove interactions with patients, payers, p harmacies, and providers.  \n \n  We are also investing in an expanded innovations center for theranostics opportunities in our \nNuclear business, which will drive longer -term profitable growth.  \n \n  Turning now to Medical.  We have multiple initiatives underway to d rive longer -term growth in \nthis segment, but first and foremost, we continue to prioritize our response to customers and their \npatients as we navigate the pandemic.  \n \n  The unprecedented and sustained increases in demand for certain product categories are \ncreating supply challenges and cost pressures for us and for our customers that will likely negatively \naffect our results.  \n \n  In response, we have and will continue to expand our self -manufacturing capacity and \nsourcing capabilities.  Our sourcing and marketing teams have reviewed more than 700 leads for \nalternative sources of PPE supply. ", "original_text": "We have multiple initiatives underway to d rive longer -term growth in \nthis segment, but first and foremost, we continue to prioritize our response to customers and their \npatients as we navigate the pandemic.  \n \n ", "page_label": "11", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f6fea48-a7c1-4810-bfee-5e9fbc802a26", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a82102a93614f9fc80f8d94f46ddf6f0fa04d312f7203a04d38e8035bd2cb10d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90ee906f-3628-4f75-9c42-05eb784da364", "node_type": "1", "metadata": {"window": "This facility includes a state -of-the-art cold chain complex with deep -frozen technology, and it \nenables us to drive operational efficiencies , as well as support further growth in this area of the \nindustry.  \n \n  In Connected Care, we're identifying and investing in innovative digital capabilities that will \nimprove interactions with patients, payers, p harmacies, and providers.  \n \n  We are also investing in an expanded innovations center for theranostics opportunities in our \nNuclear business, which will drive longer -term profitable growth.  \n \n  Turning now to Medical.  We have multiple initiatives underway to d rive longer -term growth in \nthis segment, but first and foremost, we continue to prioritize our response to customers and their \npatients as we navigate the pandemic.  \n \n  The unprecedented and sustained increases in demand for certain product categories are \ncreating supply challenges and cost pressures for us and for our customers that will likely negatively \naffect our results.  \n \n  In response, we have and will continue to expand our self -manufacturing capacity and \nsourcing capabilities. ", "original_text": "Turning now to Medical. ", "page_label": "11", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0961205e10b01ed6c898dcd999f421792acae9e9a11278f877f00ab8b9559a1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e09e745f-8297-43d0-9d76-ba995c39f1e9", "node_type": "1", "metadata": {"window": "We are also investing in an expanded innovations center for theranostics opportunities in our \nNuclear business, which will drive longer -term profitable growth.  \n \n  Turning now to Medical.  We have multiple initiatives underway to d rive longer -term growth in \nthis segment, but first and foremost, we continue to prioritize our response to customers and their \npatients as we navigate the pandemic.  \n \n  The unprecedented and sustained increases in demand for certain product categories are \ncreating supply challenges and cost pressures for us and for our customers that will likely negatively \naffect our results.  \n \n  In response, we have and will continue to expand our self -manufacturing capacity and \nsourcing capabilities.  Our sourcing and marketing teams have reviewed more than 700 leads for \nalternative sources of PPE supply.  However, only a small number of these leads have satisfied our \nrigorous vetting process , and we are developing sourcing relationships where economically feasible.  ", "original_text": "The unprecedented and sustained increases in demand for certain product categories are \ncreating supply challenges and cost pressures for us and for our customers that will likely negatively \naffect our results.  \n \n "}, "hash": "4b62182c06b42f6e9efa5d928678cab42cd97218f2d07d91bbb493efafabf09c", "class_name": "RelatedNodeInfo"}}, "text": "We have multiple initiatives underway to d rive longer -term growth in \nthis segment, but first and foremost, we continue to prioritize our response to customers and their \npatients as we navigate the pandemic.  \n \n ", "start_char_idx": 763, "end_char_idx": 979, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e09e745f-8297-43d0-9d76-ba995c39f1e9": {"__data__": {"id_": "e09e745f-8297-43d0-9d76-ba995c39f1e9", "embedding": null, "metadata": {"window": "We are also investing in an expanded innovations center for theranostics opportunities in our \nNuclear business, which will drive longer -term profitable growth.  \n \n  Turning now to Medical.  We have multiple initiatives underway to d rive longer -term growth in \nthis segment, but first and foremost, we continue to prioritize our response to customers and their \npatients as we navigate the pandemic.  \n \n  The unprecedented and sustained increases in demand for certain product categories are \ncreating supply challenges and cost pressures for us and for our customers that will likely negatively \naffect our results.  \n \n  In response, we have and will continue to expand our self -manufacturing capacity and \nsourcing capabilities.  Our sourcing and marketing teams have reviewed more than 700 leads for \nalternative sources of PPE supply.  However, only a small number of these leads have satisfied our \nrigorous vetting process , and we are developing sourcing relationships where economically feasible.  ", "original_text": "The unprecedented and sustained increases in demand for certain product categories are \ncreating supply challenges and cost pressures for us and for our customers that will likely negatively \naffect our results.  \n \n ", "page_label": "11", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f6fea48-a7c1-4810-bfee-5e9fbc802a26", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a82102a93614f9fc80f8d94f46ddf6f0fa04d312f7203a04d38e8035bd2cb10d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2475a12d-06b7-4150-bdeb-810ca20ec9ee", "node_type": "1", "metadata": {"window": "In Connected Care, we're identifying and investing in innovative digital capabilities that will \nimprove interactions with patients, payers, p harmacies, and providers.  \n \n  We are also investing in an expanded innovations center for theranostics opportunities in our \nNuclear business, which will drive longer -term profitable growth.  \n \n  Turning now to Medical.  We have multiple initiatives underway to d rive longer -term growth in \nthis segment, but first and foremost, we continue to prioritize our response to customers and their \npatients as we navigate the pandemic.  \n \n  The unprecedented and sustained increases in demand for certain product categories are \ncreating supply challenges and cost pressures for us and for our customers that will likely negatively \naffect our results.  \n \n  In response, we have and will continue to expand our self -manufacturing capacity and \nsourcing capabilities.  Our sourcing and marketing teams have reviewed more than 700 leads for \nalternative sources of PPE supply. ", "original_text": "We have multiple initiatives underway to d rive longer -term growth in \nthis segment, but first and foremost, we continue to prioritize our response to customers and their \npatients as we navigate the pandemic.  \n \n ", "page_label": "11", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5e0cc9aa412a695811e1041f374d6b5cf981229c15b0735680bf6bb43f4400d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2789efde-d324-4660-8758-4615a35dd864", "node_type": "1", "metadata": {"window": "Turning now to Medical.  We have multiple initiatives underway to d rive longer -term growth in \nthis segment, but first and foremost, we continue to prioritize our response to customers and their \npatients as we navigate the pandemic.  \n \n  The unprecedented and sustained increases in demand for certain product categories are \ncreating supply challenges and cost pressures for us and for our customers that will likely negatively \naffect our results.  \n \n  In response, we have and will continue to expand our self -manufacturing capacity and \nsourcing capabilities.  Our sourcing and marketing teams have reviewed more than 700 leads for \nalternative sources of PPE supply.  However, only a small number of these leads have satisfied our \nrigorous vetting process , and we are developing sourcing relationships where economically feasible.  ", "original_text": "In response, we have and will continue to expand our self -manufacturing capacity and \nsourcing capabilities. "}, "hash": "85be29ecf29da403837e9735644aba1b53ffff6ddff1b0f07c763748b84c741f", "class_name": "RelatedNodeInfo"}}, "text": "The unprecedented and sustained increases in demand for certain product categories are \ncreating supply challenges and cost pressures for us and for our customers that will likely negatively \naffect our results.  \n \n ", "start_char_idx": 979, "end_char_idx": 1196, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2789efde-d324-4660-8758-4615a35dd864": {"__data__": {"id_": "2789efde-d324-4660-8758-4615a35dd864", "embedding": null, "metadata": {"window": "Turning now to Medical.  We have multiple initiatives underway to d rive longer -term growth in \nthis segment, but first and foremost, we continue to prioritize our response to customers and their \npatients as we navigate the pandemic.  \n \n  The unprecedented and sustained increases in demand for certain product categories are \ncreating supply challenges and cost pressures for us and for our customers that will likely negatively \naffect our results.  \n \n  In response, we have and will continue to expand our self -manufacturing capacity and \nsourcing capabilities.  Our sourcing and marketing teams have reviewed more than 700 leads for \nalternative sources of PPE supply.  However, only a small number of these leads have satisfied our \nrigorous vetting process , and we are developing sourcing relationships where economically feasible.  ", "original_text": "In response, we have and will continue to expand our self -manufacturing capacity and \nsourcing capabilities. ", "page_label": "11", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f6fea48-a7c1-4810-bfee-5e9fbc802a26", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a82102a93614f9fc80f8d94f46ddf6f0fa04d312f7203a04d38e8035bd2cb10d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e09e745f-8297-43d0-9d76-ba995c39f1e9", "node_type": "1", "metadata": {"window": "We are also investing in an expanded innovations center for theranostics opportunities in our \nNuclear business, which will drive longer -term profitable growth.  \n \n  Turning now to Medical.  We have multiple initiatives underway to d rive longer -term growth in \nthis segment, but first and foremost, we continue to prioritize our response to customers and their \npatients as we navigate the pandemic.  \n \n  The unprecedented and sustained increases in demand for certain product categories are \ncreating supply challenges and cost pressures for us and for our customers that will likely negatively \naffect our results.  \n \n  In response, we have and will continue to expand our self -manufacturing capacity and \nsourcing capabilities.  Our sourcing and marketing teams have reviewed more than 700 leads for \nalternative sources of PPE supply.  However, only a small number of these leads have satisfied our \nrigorous vetting process , and we are developing sourcing relationships where economically feasible.  ", "original_text": "The unprecedented and sustained increases in demand for certain product categories are \ncreating supply challenges and cost pressures for us and for our customers that will likely negatively \naffect our results.  \n \n ", "page_label": "11", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f187028fe3daf4de13227c1b7a873fc2f969ff9a3be5976c58690cf2c8747e43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e48181b5-2b1a-41e4-a612-78d1ccccc38e", "node_type": "1", "metadata": {"window": "We have multiple initiatives underway to d rive longer -term growth in \nthis segment, but first and foremost, we continue to prioritize our response to customers and their \npatients as we navigate the pandemic.  \n \n  The unprecedented and sustained increases in demand for certain product categories are \ncreating supply challenges and cost pressures for us and for our customers that will likely negatively \naffect our results.  \n \n  In response, we have and will continue to expand our self -manufacturing capacity and \nsourcing capabilities.  Our sourcing and marketing teams have reviewed more than 700 leads for \nalternative sources of PPE supply.  However, only a small number of these leads have satisfied our \nrigorous vetting process , and we are developing sourcing relationships where economically feasible.  ", "original_text": "Our sourcing and marketing teams have reviewed more than 700 leads for \nalternative sources of PPE supply. "}, "hash": "cc31908623b71e1d67972ee75e28a61c640cdfc963a4746e251059b2f01daecd", "class_name": "RelatedNodeInfo"}}, "text": "In response, we have and will continue to expand our self -manufacturing capacity and \nsourcing capabilities. ", "start_char_idx": 1196, "end_char_idx": 1306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e48181b5-2b1a-41e4-a612-78d1ccccc38e": {"__data__": {"id_": "e48181b5-2b1a-41e4-a612-78d1ccccc38e", "embedding": null, "metadata": {"window": "We have multiple initiatives underway to d rive longer -term growth in \nthis segment, but first and foremost, we continue to prioritize our response to customers and their \npatients as we navigate the pandemic.  \n \n  The unprecedented and sustained increases in demand for certain product categories are \ncreating supply challenges and cost pressures for us and for our customers that will likely negatively \naffect our results.  \n \n  In response, we have and will continue to expand our self -manufacturing capacity and \nsourcing capabilities.  Our sourcing and marketing teams have reviewed more than 700 leads for \nalternative sources of PPE supply.  However, only a small number of these leads have satisfied our \nrigorous vetting process , and we are developing sourcing relationships where economically feasible.  ", "original_text": "Our sourcing and marketing teams have reviewed more than 700 leads for \nalternative sources of PPE supply. ", "page_label": "11", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f6fea48-a7c1-4810-bfee-5e9fbc802a26", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a82102a93614f9fc80f8d94f46ddf6f0fa04d312f7203a04d38e8035bd2cb10d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2789efde-d324-4660-8758-4615a35dd864", "node_type": "1", "metadata": {"window": "Turning now to Medical.  We have multiple initiatives underway to d rive longer -term growth in \nthis segment, but first and foremost, we continue to prioritize our response to customers and their \npatients as we navigate the pandemic.  \n \n  The unprecedented and sustained increases in demand for certain product categories are \ncreating supply challenges and cost pressures for us and for our customers that will likely negatively \naffect our results.  \n \n  In response, we have and will continue to expand our self -manufacturing capacity and \nsourcing capabilities.  Our sourcing and marketing teams have reviewed more than 700 leads for \nalternative sources of PPE supply.  However, only a small number of these leads have satisfied our \nrigorous vetting process , and we are developing sourcing relationships where economically feasible.  ", "original_text": "In response, we have and will continue to expand our self -manufacturing capacity and \nsourcing capabilities. ", "page_label": "11", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dca256ac31fdbba15f5fc05f0626a16479f8e400c1e05412b2b7f1f15695cd76", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da92bdab-2f8c-4e85-ab11-29988a60d370", "node_type": "1", "metadata": {"window": "The unprecedented and sustained increases in demand for certain product categories are \ncreating supply challenges and cost pressures for us and for our customers that will likely negatively \naffect our results.  \n \n  In response, we have and will continue to expand our self -manufacturing capacity and \nsourcing capabilities.  Our sourcing and marketing teams have reviewed more than 700 leads for \nalternative sources of PPE supply.  However, only a small number of these leads have satisfied our \nrigorous vetting process , and we are developing sourcing relationships where economically feasible.  ", "original_text": "However, only a small number of these leads have satisfied our \nrigorous vetting process , and we are developing sourcing relationships where economically feasible.  "}, "hash": "36c49cd04268842e0bb3ac3d7c0bc7a9ce4eea3d0881b601ac998fc329bde91c", "class_name": "RelatedNodeInfo"}}, "text": "Our sourcing and marketing teams have reviewed more than 700 leads for \nalternative sources of PPE supply. ", "start_char_idx": 1306, "end_char_idx": 1413, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da92bdab-2f8c-4e85-ab11-29988a60d370": {"__data__": {"id_": "da92bdab-2f8c-4e85-ab11-29988a60d370", "embedding": null, "metadata": {"window": "The unprecedented and sustained increases in demand for certain product categories are \ncreating supply challenges and cost pressures for us and for our customers that will likely negatively \naffect our results.  \n \n  In response, we have and will continue to expand our self -manufacturing capacity and \nsourcing capabilities.  Our sourcing and marketing teams have reviewed more than 700 leads for \nalternative sources of PPE supply.  However, only a small number of these leads have satisfied our \nrigorous vetting process , and we are developing sourcing relationships where economically feasible.  ", "original_text": "However, only a small number of these leads have satisfied our \nrigorous vetting process , and we are developing sourcing relationships where economically feasible.  ", "page_label": "11", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f6fea48-a7c1-4810-bfee-5e9fbc802a26", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a82102a93614f9fc80f8d94f46ddf6f0fa04d312f7203a04d38e8035bd2cb10d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e48181b5-2b1a-41e4-a612-78d1ccccc38e", "node_type": "1", "metadata": {"window": "We have multiple initiatives underway to d rive longer -term growth in \nthis segment, but first and foremost, we continue to prioritize our response to customers and their \npatients as we navigate the pandemic.  \n \n  The unprecedented and sustained increases in demand for certain product categories are \ncreating supply challenges and cost pressures for us and for our customers that will likely negatively \naffect our results.  \n \n  In response, we have and will continue to expand our self -manufacturing capacity and \nsourcing capabilities.  Our sourcing and marketing teams have reviewed more than 700 leads for \nalternative sources of PPE supply.  However, only a small number of these leads have satisfied our \nrigorous vetting process , and we are developing sourcing relationships where economically feasible.  ", "original_text": "Our sourcing and marketing teams have reviewed more than 700 leads for \nalternative sources of PPE supply. ", "page_label": "11", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74048eda51c6fda2c21a3f0eefb5b5a14c61d7439e09fae1f444aaf77b5bd9fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65bebd47-205f-467e-9609-83982046f48b", "node_type": "1", "metadata": {"window": " \nPage 12 of 31 \n \n \n In addition to short -term pricing actions to mitigate increasing costs, our teams are also \nbuilding a longer -term strategy for supply assurance.  \n \n  Regarding our commercial strategy, although our pace has been and will continue to be \naffected by COVID -19, we are confident in our talent and ability to execute this important workstream.  \n We are moving forward with an enhanced focus on supporting the needs of our diverse customer \nbase.   We believe this workstream will ramp up with the gradual increase in elective p rocedures , as its \nprogress is dependent upon our customers \u2019 readiness to engage in incremental product and services \ndiscussions.  \n \n ", "original_text": " \nPage 12 of 31 \n \n \n In addition to short -term pricing actions to mitigate increasing costs, our teams are also \nbuilding a longer -term strategy for supply assurance.  \n \n "}, "hash": "a462a8818e81186e3cb4a81abf0fad4af4875316b7a05f0b60bb2a88618e247f", "class_name": "RelatedNodeInfo"}}, "text": "However, only a small number of these leads have satisfied our \nrigorous vetting process , and we are developing sourcing relationships where economically feasible.  ", "start_char_idx": 1413, "end_char_idx": 1579, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65bebd47-205f-467e-9609-83982046f48b": {"__data__": {"id_": "65bebd47-205f-467e-9609-83982046f48b", "embedding": null, "metadata": {"window": " \nPage 12 of 31 \n \n \n In addition to short -term pricing actions to mitigate increasing costs, our teams are also \nbuilding a longer -term strategy for supply assurance.  \n \n  Regarding our commercial strategy, although our pace has been and will continue to be \naffected by COVID -19, we are confident in our talent and ability to execute this important workstream.  \n We are moving forward with an enhanced focus on supporting the needs of our diverse customer \nbase.   We believe this workstream will ramp up with the gradual increase in elective p rocedures , as its \nprogress is dependent upon our customers \u2019 readiness to engage in incremental product and services \ndiscussions.  \n \n ", "original_text": " \nPage 12 of 31 \n \n \n In addition to short -term pricing actions to mitigate increasing costs, our teams are also \nbuilding a longer -term strategy for supply assurance.  \n \n ", "page_label": "12", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b803411d-7757-4a56-8ae1-333719409f76", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10987d29c804727d54195698d0c3dbca6775f134adcdd1cefb9af65d95d7f3e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da92bdab-2f8c-4e85-ab11-29988a60d370", "node_type": "1", "metadata": {"window": "The unprecedented and sustained increases in demand for certain product categories are \ncreating supply challenges and cost pressures for us and for our customers that will likely negatively \naffect our results.  \n \n  In response, we have and will continue to expand our self -manufacturing capacity and \nsourcing capabilities.  Our sourcing and marketing teams have reviewed more than 700 leads for \nalternative sources of PPE supply.  However, only a small number of these leads have satisfied our \nrigorous vetting process , and we are developing sourcing relationships where economically feasible.  ", "original_text": "However, only a small number of these leads have satisfied our \nrigorous vetting process , and we are developing sourcing relationships where economically feasible.  ", "page_label": "11", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f44b78c0a83adcd537a99116ca0b676bd88ca33f631dc6760b1591dd78fd813f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9526225-f598-4ae9-8d09-aedf27fc8bab", "node_type": "1", "metadata": {"window": " \nPage 12 of 31 \n \n \n In addition to short -term pricing actions to mitigate increasing costs, our teams are also \nbuilding a longer -term strategy for supply assurance.  \n \n  Regarding our commercial strategy, although our pace has been and will continue to be \naffected by COVID -19, we are confident in our talent and ability to execute this important workstream.  \n We are moving forward with an enhanced focus on supporting the needs of our diverse customer \nbase.   We believe this workstream will ramp up with the gradual increase in elective p rocedures , as its \nprogress is dependent upon our customers \u2019 readiness to engage in incremental product and services \ndiscussions.  \n \n  At the same time, we continue to optimize our end -to-end global supply chain. ", "original_text": "Regarding our commercial strategy, although our pace has been and will continue to be \naffected by COVID -19, we are confident in our talent and ability to execute this important workstream.  \n"}, "hash": "c41b6339c6b8a31a15bb03d14579e3cc4c5300145ed7b1a16b67e34e6107f1c7", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 12 of 31 \n \n \n In addition to short -term pricing actions to mitigate increasing costs, our teams are also \nbuilding a longer -term strategy for supply assurance.  \n \n ", "start_char_idx": 0, "end_char_idx": 175, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9526225-f598-4ae9-8d09-aedf27fc8bab": {"__data__": {"id_": "b9526225-f598-4ae9-8d09-aedf27fc8bab", "embedding": null, "metadata": {"window": " \nPage 12 of 31 \n \n \n In addition to short -term pricing actions to mitigate increasing costs, our teams are also \nbuilding a longer -term strategy for supply assurance.  \n \n  Regarding our commercial strategy, although our pace has been and will continue to be \naffected by COVID -19, we are confident in our talent and ability to execute this important workstream.  \n We are moving forward with an enhanced focus on supporting the needs of our diverse customer \nbase.   We believe this workstream will ramp up with the gradual increase in elective p rocedures , as its \nprogress is dependent upon our customers \u2019 readiness to engage in incremental product and services \ndiscussions.  \n \n  At the same time, we continue to optimize our end -to-end global supply chain. ", "original_text": "Regarding our commercial strategy, although our pace has been and will continue to be \naffected by COVID -19, we are confident in our talent and ability to execute this important workstream.  \n", "page_label": "12", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b803411d-7757-4a56-8ae1-333719409f76", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10987d29c804727d54195698d0c3dbca6775f134adcdd1cefb9af65d95d7f3e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65bebd47-205f-467e-9609-83982046f48b", "node_type": "1", "metadata": {"window": " \nPage 12 of 31 \n \n \n In addition to short -term pricing actions to mitigate increasing costs, our teams are also \nbuilding a longer -term strategy for supply assurance.  \n \n  Regarding our commercial strategy, although our pace has been and will continue to be \naffected by COVID -19, we are confident in our talent and ability to execute this important workstream.  \n We are moving forward with an enhanced focus on supporting the needs of our diverse customer \nbase.   We believe this workstream will ramp up with the gradual increase in elective p rocedures , as its \nprogress is dependent upon our customers \u2019 readiness to engage in incremental product and services \ndiscussions.  \n \n ", "original_text": " \nPage 12 of 31 \n \n \n In addition to short -term pricing actions to mitigate increasing costs, our teams are also \nbuilding a longer -term strategy for supply assurance.  \n \n ", "page_label": "12", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae9c95c5e6b88222cb05b55ae6f5cb588c7ed53ea6deb20424e451655573018f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75679fe9-0c65-4075-87cf-aa27715f428b", "node_type": "1", "metadata": {"window": " \nPage 12 of 31 \n \n \n In addition to short -term pricing actions to mitigate increasing costs, our teams are also \nbuilding a longer -term strategy for supply assurance.  \n \n  Regarding our commercial strategy, although our pace has been and will continue to be \naffected by COVID -19, we are confident in our talent and ability to execute this important workstream.  \n We are moving forward with an enhanced focus on supporting the needs of our diverse customer \nbase.   We believe this workstream will ramp up with the gradual increase in elective p rocedures , as its \nprogress is dependent upon our customers \u2019 readiness to engage in incremental product and services \ndiscussions.  \n \n  At the same time, we continue to optimize our end -to-end global supply chain.  We are making \nthoughtful modifications to our l ogistics, planning, manufacturing, and procurement initiatives, and this \nwork is on track to deliver significant efficiencies.  ", "original_text": "We are moving forward with an enhanced focus on supporting the needs of our diverse customer \nbase.  "}, "hash": "73b13a710fb968876333595211d50bc4e4ac83c81cdc1155fe218234d7b3589d", "class_name": "RelatedNodeInfo"}}, "text": "Regarding our commercial strategy, although our pace has been and will continue to be \naffected by COVID -19, we are confident in our talent and ability to execute this important workstream.  \n", "start_char_idx": 175, "end_char_idx": 368, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75679fe9-0c65-4075-87cf-aa27715f428b": {"__data__": {"id_": "75679fe9-0c65-4075-87cf-aa27715f428b", "embedding": null, "metadata": {"window": " \nPage 12 of 31 \n \n \n In addition to short -term pricing actions to mitigate increasing costs, our teams are also \nbuilding a longer -term strategy for supply assurance.  \n \n  Regarding our commercial strategy, although our pace has been and will continue to be \naffected by COVID -19, we are confident in our talent and ability to execute this important workstream.  \n We are moving forward with an enhanced focus on supporting the needs of our diverse customer \nbase.   We believe this workstream will ramp up with the gradual increase in elective p rocedures , as its \nprogress is dependent upon our customers \u2019 readiness to engage in incremental product and services \ndiscussions.  \n \n  At the same time, we continue to optimize our end -to-end global supply chain.  We are making \nthoughtful modifications to our l ogistics, planning, manufacturing, and procurement initiatives, and this \nwork is on track to deliver significant efficiencies.  ", "original_text": "We are moving forward with an enhanced focus on supporting the needs of our diverse customer \nbase.  ", "page_label": "12", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b803411d-7757-4a56-8ae1-333719409f76", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10987d29c804727d54195698d0c3dbca6775f134adcdd1cefb9af65d95d7f3e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9526225-f598-4ae9-8d09-aedf27fc8bab", "node_type": "1", "metadata": {"window": " \nPage 12 of 31 \n \n \n In addition to short -term pricing actions to mitigate increasing costs, our teams are also \nbuilding a longer -term strategy for supply assurance.  \n \n  Regarding our commercial strategy, although our pace has been and will continue to be \naffected by COVID -19, we are confident in our talent and ability to execute this important workstream.  \n We are moving forward with an enhanced focus on supporting the needs of our diverse customer \nbase.   We believe this workstream will ramp up with the gradual increase in elective p rocedures , as its \nprogress is dependent upon our customers \u2019 readiness to engage in incremental product and services \ndiscussions.  \n \n  At the same time, we continue to optimize our end -to-end global supply chain. ", "original_text": "Regarding our commercial strategy, although our pace has been and will continue to be \naffected by COVID -19, we are confident in our talent and ability to execute this important workstream.  \n", "page_label": "12", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fca108057d63c63719c9751082038da612de58f1eb491abf2f249fd12fabdae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b140aca-ed69-4412-9c38-73972ce1cac1", "node_type": "1", "metadata": {"window": " \nPage 12 of 31 \n \n \n In addition to short -term pricing actions to mitigate increasing costs, our teams are also \nbuilding a longer -term strategy for supply assurance.  \n \n  Regarding our commercial strategy, although our pace has been and will continue to be \naffected by COVID -19, we are confident in our talent and ability to execute this important workstream.  \n We are moving forward with an enhanced focus on supporting the needs of our diverse customer \nbase.   We believe this workstream will ramp up with the gradual increase in elective p rocedures , as its \nprogress is dependent upon our customers \u2019 readiness to engage in incremental product and services \ndiscussions.  \n \n  At the same time, we continue to optimize our end -to-end global supply chain.  We are making \nthoughtful modifications to our l ogistics, planning, manufacturing, and procurement initiatives, and this \nwork is on track to deliver significant efficiencies.   Also, we continue to evaluate our footprint and \nmake selective investments in our capabilities and infrastructure.  \n \n", "original_text": "We believe this workstream will ramp up with the gradual increase in elective p rocedures , as its \nprogress is dependent upon our customers \u2019 readiness to engage in incremental product and services \ndiscussions.  \n \n "}, "hash": "07224fdd5c593d5db4075aa4bd55c6534323361019dfd36078f108c8d0e503c4", "class_name": "RelatedNodeInfo"}}, "text": "We are moving forward with an enhanced focus on supporting the needs of our diverse customer \nbase.  ", "start_char_idx": 368, "end_char_idx": 469, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b140aca-ed69-4412-9c38-73972ce1cac1": {"__data__": {"id_": "5b140aca-ed69-4412-9c38-73972ce1cac1", "embedding": null, "metadata": {"window": " \nPage 12 of 31 \n \n \n In addition to short -term pricing actions to mitigate increasing costs, our teams are also \nbuilding a longer -term strategy for supply assurance.  \n \n  Regarding our commercial strategy, although our pace has been and will continue to be \naffected by COVID -19, we are confident in our talent and ability to execute this important workstream.  \n We are moving forward with an enhanced focus on supporting the needs of our diverse customer \nbase.   We believe this workstream will ramp up with the gradual increase in elective p rocedures , as its \nprogress is dependent upon our customers \u2019 readiness to engage in incremental product and services \ndiscussions.  \n \n  At the same time, we continue to optimize our end -to-end global supply chain.  We are making \nthoughtful modifications to our l ogistics, planning, manufacturing, and procurement initiatives, and this \nwork is on track to deliver significant efficiencies.   Also, we continue to evaluate our footprint and \nmake selective investments in our capabilities and infrastructure.  \n \n", "original_text": "We believe this workstream will ramp up with the gradual increase in elective p rocedures , as its \nprogress is dependent upon our customers \u2019 readiness to engage in incremental product and services \ndiscussions.  \n \n ", "page_label": "12", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b803411d-7757-4a56-8ae1-333719409f76", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10987d29c804727d54195698d0c3dbca6775f134adcdd1cefb9af65d95d7f3e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75679fe9-0c65-4075-87cf-aa27715f428b", "node_type": "1", "metadata": {"window": " \nPage 12 of 31 \n \n \n In addition to short -term pricing actions to mitigate increasing costs, our teams are also \nbuilding a longer -term strategy for supply assurance.  \n \n  Regarding our commercial strategy, although our pace has been and will continue to be \naffected by COVID -19, we are confident in our talent and ability to execute this important workstream.  \n We are moving forward with an enhanced focus on supporting the needs of our diverse customer \nbase.   We believe this workstream will ramp up with the gradual increase in elective p rocedures , as its \nprogress is dependent upon our customers \u2019 readiness to engage in incremental product and services \ndiscussions.  \n \n  At the same time, we continue to optimize our end -to-end global supply chain.  We are making \nthoughtful modifications to our l ogistics, planning, manufacturing, and procurement initiatives, and this \nwork is on track to deliver significant efficiencies.  ", "original_text": "We are moving forward with an enhanced focus on supporting the needs of our diverse customer \nbase.  ", "page_label": "12", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "615795e3f52d851f443121c9dabbc9bd0abf73a1342418e73153bff4f8220f8e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eaa128fb-ce58-4457-bc51-e08ad83b3a2e", "node_type": "1", "metadata": {"window": "Regarding our commercial strategy, although our pace has been and will continue to be \naffected by COVID -19, we are confident in our talent and ability to execute this important workstream.  \n We are moving forward with an enhanced focus on supporting the needs of our diverse customer \nbase.   We believe this workstream will ramp up with the gradual increase in elective p rocedures , as its \nprogress is dependent upon our customers \u2019 readiness to engage in incremental product and services \ndiscussions.  \n \n  At the same time, we continue to optimize our end -to-end global supply chain.  We are making \nthoughtful modifications to our l ogistics, planning, manufacturing, and procurement initiatives, and this \nwork is on track to deliver significant efficiencies.   Also, we continue to evaluate our footprint and \nmake selective investments in our capabilities and infrastructure.  \n \n Additionally  we are continuing to grow in evolving areas like our at -Home and Services \nbusinesses through investments that further enhance our strong strategic positions.  ", "original_text": "At the same time, we continue to optimize our end -to-end global supply chain. "}, "hash": "eb0bffd761e6364710eeb161ea60cb4aed33e5dc124b5b5f96a827a8b2e1c8b3", "class_name": "RelatedNodeInfo"}}, "text": "We believe this workstream will ramp up with the gradual increase in elective p rocedures , as its \nprogress is dependent upon our customers \u2019 readiness to engage in incremental product and services \ndiscussions.  \n \n ", "start_char_idx": 469, "end_char_idx": 687, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eaa128fb-ce58-4457-bc51-e08ad83b3a2e": {"__data__": {"id_": "eaa128fb-ce58-4457-bc51-e08ad83b3a2e", "embedding": null, "metadata": {"window": "Regarding our commercial strategy, although our pace has been and will continue to be \naffected by COVID -19, we are confident in our talent and ability to execute this important workstream.  \n We are moving forward with an enhanced focus on supporting the needs of our diverse customer \nbase.   We believe this workstream will ramp up with the gradual increase in elective p rocedures , as its \nprogress is dependent upon our customers \u2019 readiness to engage in incremental product and services \ndiscussions.  \n \n  At the same time, we continue to optimize our end -to-end global supply chain.  We are making \nthoughtful modifications to our l ogistics, planning, manufacturing, and procurement initiatives, and this \nwork is on track to deliver significant efficiencies.   Also, we continue to evaluate our footprint and \nmake selective investments in our capabilities and infrastructure.  \n \n Additionally  we are continuing to grow in evolving areas like our at -Home and Services \nbusinesses through investments that further enhance our strong strategic positions.  ", "original_text": "At the same time, we continue to optimize our end -to-end global supply chain. ", "page_label": "12", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b803411d-7757-4a56-8ae1-333719409f76", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10987d29c804727d54195698d0c3dbca6775f134adcdd1cefb9af65d95d7f3e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b140aca-ed69-4412-9c38-73972ce1cac1", "node_type": "1", "metadata": {"window": " \nPage 12 of 31 \n \n \n In addition to short -term pricing actions to mitigate increasing costs, our teams are also \nbuilding a longer -term strategy for supply assurance.  \n \n  Regarding our commercial strategy, although our pace has been and will continue to be \naffected by COVID -19, we are confident in our talent and ability to execute this important workstream.  \n We are moving forward with an enhanced focus on supporting the needs of our diverse customer \nbase.   We believe this workstream will ramp up with the gradual increase in elective p rocedures , as its \nprogress is dependent upon our customers \u2019 readiness to engage in incremental product and services \ndiscussions.  \n \n  At the same time, we continue to optimize our end -to-end global supply chain.  We are making \nthoughtful modifications to our l ogistics, planning, manufacturing, and procurement initiatives, and this \nwork is on track to deliver significant efficiencies.   Also, we continue to evaluate our footprint and \nmake selective investments in our capabilities and infrastructure.  \n \n", "original_text": "We believe this workstream will ramp up with the gradual increase in elective p rocedures , as its \nprogress is dependent upon our customers \u2019 readiness to engage in incremental product and services \ndiscussions.  \n \n ", "page_label": "12", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d12f1089c1876c48473bc2cc9bdc43e9c2f1ce0d1a9b5a6f5ebc9a259fd7d089", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a826c9d3-e2d3-4999-97e4-bcf7d917f83e", "node_type": "1", "metadata": {"window": "We are moving forward with an enhanced focus on supporting the needs of our diverse customer \nbase.   We believe this workstream will ramp up with the gradual increase in elective p rocedures , as its \nprogress is dependent upon our customers \u2019 readiness to engage in incremental product and services \ndiscussions.  \n \n  At the same time, we continue to optimize our end -to-end global supply chain.  We are making \nthoughtful modifications to our l ogistics, planning, manufacturing, and procurement initiatives, and this \nwork is on track to deliver significant efficiencies.   Also, we continue to evaluate our footprint and \nmake selective investments in our capabilities and infrastructure.  \n \n Additionally  we are continuing to grow in evolving areas like our at -Home and Services \nbusinesses through investments that further enhance our strong strategic positions.   For example, in \nat-Home, we are investing in technology that improves our interactions with the p atient, and drives \nefficiencies to create significant value in future years.  \n \n ", "original_text": "We are making \nthoughtful modifications to our l ogistics, planning, manufacturing, and procurement initiatives, and this \nwork is on track to deliver significant efficiencies.  "}, "hash": "282fb27d4b12eba02004ae4f8a1c684e2015caec17610015e595755122909516", "class_name": "RelatedNodeInfo"}}, "text": "At the same time, we continue to optimize our end -to-end global supply chain. ", "start_char_idx": 687, "end_char_idx": 766, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a826c9d3-e2d3-4999-97e4-bcf7d917f83e": {"__data__": {"id_": "a826c9d3-e2d3-4999-97e4-bcf7d917f83e", "embedding": null, "metadata": {"window": "We are moving forward with an enhanced focus on supporting the needs of our diverse customer \nbase.   We believe this workstream will ramp up with the gradual increase in elective p rocedures , as its \nprogress is dependent upon our customers \u2019 readiness to engage in incremental product and services \ndiscussions.  \n \n  At the same time, we continue to optimize our end -to-end global supply chain.  We are making \nthoughtful modifications to our l ogistics, planning, manufacturing, and procurement initiatives, and this \nwork is on track to deliver significant efficiencies.   Also, we continue to evaluate our footprint and \nmake selective investments in our capabilities and infrastructure.  \n \n Additionally  we are continuing to grow in evolving areas like our at -Home and Services \nbusinesses through investments that further enhance our strong strategic positions.   For example, in \nat-Home, we are investing in technology that improves our interactions with the p atient, and drives \nefficiencies to create significant value in future years.  \n \n ", "original_text": "We are making \nthoughtful modifications to our l ogistics, planning, manufacturing, and procurement initiatives, and this \nwork is on track to deliver significant efficiencies.  ", "page_label": "12", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b803411d-7757-4a56-8ae1-333719409f76", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10987d29c804727d54195698d0c3dbca6775f134adcdd1cefb9af65d95d7f3e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eaa128fb-ce58-4457-bc51-e08ad83b3a2e", "node_type": "1", "metadata": {"window": "Regarding our commercial strategy, although our pace has been and will continue to be \naffected by COVID -19, we are confident in our talent and ability to execute this important workstream.  \n We are moving forward with an enhanced focus on supporting the needs of our diverse customer \nbase.   We believe this workstream will ramp up with the gradual increase in elective p rocedures , as its \nprogress is dependent upon our customers \u2019 readiness to engage in incremental product and services \ndiscussions.  \n \n  At the same time, we continue to optimize our end -to-end global supply chain.  We are making \nthoughtful modifications to our l ogistics, planning, manufacturing, and procurement initiatives, and this \nwork is on track to deliver significant efficiencies.   Also, we continue to evaluate our footprint and \nmake selective investments in our capabilities and infrastructure.  \n \n Additionally  we are continuing to grow in evolving areas like our at -Home and Services \nbusinesses through investments that further enhance our strong strategic positions.  ", "original_text": "At the same time, we continue to optimize our end -to-end global supply chain. ", "page_label": "12", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf43bc23681554722e37f73ccc1ada8c789d0ebf382b58dbfb865e384900c115", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f35a1739-ea3c-41a2-a6b3-5ca2e83b75da", "node_type": "1", "metadata": {"window": "We believe this workstream will ramp up with the gradual increase in elective p rocedures , as its \nprogress is dependent upon our customers \u2019 readiness to engage in incremental product and services \ndiscussions.  \n \n  At the same time, we continue to optimize our end -to-end global supply chain.  We are making \nthoughtful modifications to our l ogistics, planning, manufacturing, and procurement initiatives, and this \nwork is on track to deliver significant efficiencies.   Also, we continue to evaluate our footprint and \nmake selective investments in our capabilities and infrastructure.  \n \n Additionally  we are continuing to grow in evolving areas like our at -Home and Services \nbusinesses through investments that further enhance our strong strategic positions.   For example, in \nat-Home, we are investing in technology that improves our interactions with the p atient, and drives \nefficiencies to create significant value in future years.  \n \n  Let me now turn to the enterprise.  \n ", "original_text": "Also, we continue to evaluate our footprint and \nmake selective investments in our capabilities and infrastructure.  \n \n"}, "hash": "d63914c2445d79962ede6b9838a461c7de0f8ac22f97a8cac72febbc815853b0", "class_name": "RelatedNodeInfo"}}, "text": "We are making \nthoughtful modifications to our l ogistics, planning, manufacturing, and procurement initiatives, and this \nwork is on track to deliver significant efficiencies.  ", "start_char_idx": 766, "end_char_idx": 944, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f35a1739-ea3c-41a2-a6b3-5ca2e83b75da": {"__data__": {"id_": "f35a1739-ea3c-41a2-a6b3-5ca2e83b75da", "embedding": null, "metadata": {"window": "We believe this workstream will ramp up with the gradual increase in elective p rocedures , as its \nprogress is dependent upon our customers \u2019 readiness to engage in incremental product and services \ndiscussions.  \n \n  At the same time, we continue to optimize our end -to-end global supply chain.  We are making \nthoughtful modifications to our l ogistics, planning, manufacturing, and procurement initiatives, and this \nwork is on track to deliver significant efficiencies.   Also, we continue to evaluate our footprint and \nmake selective investments in our capabilities and infrastructure.  \n \n Additionally  we are continuing to grow in evolving areas like our at -Home and Services \nbusinesses through investments that further enhance our strong strategic positions.   For example, in \nat-Home, we are investing in technology that improves our interactions with the p atient, and drives \nefficiencies to create significant value in future years.  \n \n  Let me now turn to the enterprise.  \n ", "original_text": "Also, we continue to evaluate our footprint and \nmake selective investments in our capabilities and infrastructure.  \n \n", "page_label": "12", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b803411d-7757-4a56-8ae1-333719409f76", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10987d29c804727d54195698d0c3dbca6775f134adcdd1cefb9af65d95d7f3e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a826c9d3-e2d3-4999-97e4-bcf7d917f83e", "node_type": "1", "metadata": {"window": "We are moving forward with an enhanced focus on supporting the needs of our diverse customer \nbase.   We believe this workstream will ramp up with the gradual increase in elective p rocedures , as its \nprogress is dependent upon our customers \u2019 readiness to engage in incremental product and services \ndiscussions.  \n \n  At the same time, we continue to optimize our end -to-end global supply chain.  We are making \nthoughtful modifications to our l ogistics, planning, manufacturing, and procurement initiatives, and this \nwork is on track to deliver significant efficiencies.   Also, we continue to evaluate our footprint and \nmake selective investments in our capabilities and infrastructure.  \n \n Additionally  we are continuing to grow in evolving areas like our at -Home and Services \nbusinesses through investments that further enhance our strong strategic positions.   For example, in \nat-Home, we are investing in technology that improves our interactions with the p atient, and drives \nefficiencies to create significant value in future years.  \n \n ", "original_text": "We are making \nthoughtful modifications to our l ogistics, planning, manufacturing, and procurement initiatives, and this \nwork is on track to deliver significant efficiencies.  ", "page_label": "12", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ceb904c276a84e920ede6b0acc68f3115667c232a2d5e5d5614719fbedc32bbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c946f4c1-c54e-44f5-8ed0-2126adea8b8f", "node_type": "1", "metadata": {"window": "At the same time, we continue to optimize our end -to-end global supply chain.  We are making \nthoughtful modifications to our l ogistics, planning, manufacturing, and procurement initiatives, and this \nwork is on track to deliver significant efficiencies.   Also, we continue to evaluate our footprint and \nmake selective investments in our capabilities and infrastructure.  \n \n Additionally  we are continuing to grow in evolving areas like our at -Home and Services \nbusinesses through investments that further enhance our strong strategic positions.   For example, in \nat-Home, we are investing in technology that improves our interactions with the p atient, and drives \nefficiencies to create significant value in future years.  \n \n  Let me now turn to the enterprise.  \n ", "original_text": "Additionally  we are continuing to grow in evolving areas like our at -Home and Services \nbusinesses through investments that further enhance our strong strategic positions.  "}, "hash": "4dd0e246390b9d08dbdc864ed47c29e86cb3d52603887dd338ae355594e1d568", "class_name": "RelatedNodeInfo"}}, "text": "Also, we continue to evaluate our footprint and \nmake selective investments in our capabilities and infrastructure.  \n \n", "start_char_idx": 944, "end_char_idx": 1064, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c946f4c1-c54e-44f5-8ed0-2126adea8b8f": {"__data__": {"id_": "c946f4c1-c54e-44f5-8ed0-2126adea8b8f", "embedding": null, "metadata": {"window": "At the same time, we continue to optimize our end -to-end global supply chain.  We are making \nthoughtful modifications to our l ogistics, planning, manufacturing, and procurement initiatives, and this \nwork is on track to deliver significant efficiencies.   Also, we continue to evaluate our footprint and \nmake selective investments in our capabilities and infrastructure.  \n \n Additionally  we are continuing to grow in evolving areas like our at -Home and Services \nbusinesses through investments that further enhance our strong strategic positions.   For example, in \nat-Home, we are investing in technology that improves our interactions with the p atient, and drives \nefficiencies to create significant value in future years.  \n \n  Let me now turn to the enterprise.  \n ", "original_text": "Additionally  we are continuing to grow in evolving areas like our at -Home and Services \nbusinesses through investments that further enhance our strong strategic positions.  ", "page_label": "12", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b803411d-7757-4a56-8ae1-333719409f76", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10987d29c804727d54195698d0c3dbca6775f134adcdd1cefb9af65d95d7f3e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f35a1739-ea3c-41a2-a6b3-5ca2e83b75da", "node_type": "1", "metadata": {"window": "We believe this workstream will ramp up with the gradual increase in elective p rocedures , as its \nprogress is dependent upon our customers \u2019 readiness to engage in incremental product and services \ndiscussions.  \n \n  At the same time, we continue to optimize our end -to-end global supply chain.  We are making \nthoughtful modifications to our l ogistics, planning, manufacturing, and procurement initiatives, and this \nwork is on track to deliver significant efficiencies.   Also, we continue to evaluate our footprint and \nmake selective investments in our capabilities and infrastructure.  \n \n Additionally  we are continuing to grow in evolving areas like our at -Home and Services \nbusinesses through investments that further enhance our strong strategic positions.   For example, in \nat-Home, we are investing in technology that improves our interactions with the p atient, and drives \nefficiencies to create significant value in future years.  \n \n  Let me now turn to the enterprise.  \n ", "original_text": "Also, we continue to evaluate our footprint and \nmake selective investments in our capabilities and infrastructure.  \n \n", "page_label": "12", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c18d68ffdf36054058688159b6f5b7ed83870500458eb3f7908552c0954f63", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db57f8ba-7fcf-494a-a91e-249e711f3bb4", "node_type": "1", "metadata": {"window": "We are making \nthoughtful modifications to our l ogistics, planning, manufacturing, and procurement initiatives, and this \nwork is on track to deliver significant efficiencies.   Also, we continue to evaluate our footprint and \nmake selective investments in our capabilities and infrastructure.  \n \n Additionally  we are continuing to grow in evolving areas like our at -Home and Services \nbusinesses through investments that further enhance our strong strategic positions.   For example, in \nat-Home, we are investing in technology that improves our interactions with the p atient, and drives \nefficiencies to create significant value in future years.  \n \n  Let me now turn to the enterprise.  \n ", "original_text": "For example, in \nat-Home, we are investing in technology that improves our interactions with the p atient, and drives \nefficiencies to create significant value in future years.  \n \n "}, "hash": "076529810eac5dcd8e652f4ab1e0ee0fa74b749da8f217d33d16bb5e0b9d87dc", "class_name": "RelatedNodeInfo"}}, "text": "Additionally  we are continuing to grow in evolving areas like our at -Home and Services \nbusinesses through investments that further enhance our strong strategic positions.  ", "start_char_idx": 1064, "end_char_idx": 1239, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db57f8ba-7fcf-494a-a91e-249e711f3bb4": {"__data__": {"id_": "db57f8ba-7fcf-494a-a91e-249e711f3bb4", "embedding": null, "metadata": {"window": "We are making \nthoughtful modifications to our l ogistics, planning, manufacturing, and procurement initiatives, and this \nwork is on track to deliver significant efficiencies.   Also, we continue to evaluate our footprint and \nmake selective investments in our capabilities and infrastructure.  \n \n Additionally  we are continuing to grow in evolving areas like our at -Home and Services \nbusinesses through investments that further enhance our strong strategic positions.   For example, in \nat-Home, we are investing in technology that improves our interactions with the p atient, and drives \nefficiencies to create significant value in future years.  \n \n  Let me now turn to the enterprise.  \n ", "original_text": "For example, in \nat-Home, we are investing in technology that improves our interactions with the p atient, and drives \nefficiencies to create significant value in future years.  \n \n ", "page_label": "12", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b803411d-7757-4a56-8ae1-333719409f76", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10987d29c804727d54195698d0c3dbca6775f134adcdd1cefb9af65d95d7f3e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c946f4c1-c54e-44f5-8ed0-2126adea8b8f", "node_type": "1", "metadata": {"window": "At the same time, we continue to optimize our end -to-end global supply chain.  We are making \nthoughtful modifications to our l ogistics, planning, manufacturing, and procurement initiatives, and this \nwork is on track to deliver significant efficiencies.   Also, we continue to evaluate our footprint and \nmake selective investments in our capabilities and infrastructure.  \n \n Additionally  we are continuing to grow in evolving areas like our at -Home and Services \nbusinesses through investments that further enhance our strong strategic positions.   For example, in \nat-Home, we are investing in technology that improves our interactions with the p atient, and drives \nefficiencies to create significant value in future years.  \n \n  Let me now turn to the enterprise.  \n ", "original_text": "Additionally  we are continuing to grow in evolving areas like our at -Home and Services \nbusinesses through investments that further enhance our strong strategic positions.  ", "page_label": "12", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b168035053420397acdaf0919e5254e52c65a1955aeab5e78cd80f1c10f4aa0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af5b9ed0-fcc2-4eb8-868b-4d5c0c46ccd5", "node_type": "1", "metadata": {"window": "Also, we continue to evaluate our footprint and \nmake selective investments in our capabilities and infrastructure.  \n \n Additionally  we are continuing to grow in evolving areas like our at -Home and Services \nbusinesses through investments that further enhance our strong strategic positions.   For example, in \nat-Home, we are investing in technology that improves our interactions with the p atient, and drives \nefficiencies to create significant value in future years.  \n \n  Let me now turn to the enterprise.  \n ", "original_text": "Let me now turn to the enterprise.  \n "}, "hash": "6559db90248135d0e9441879866e85f33f183e44897a4f7b22015407bd9e5f76", "class_name": "RelatedNodeInfo"}}, "text": "For example, in \nat-Home, we are investing in technology that improves our interactions with the p atient, and drives \nefficiencies to create significant value in future years.  \n \n ", "start_char_idx": 1239, "end_char_idx": 1421, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af5b9ed0-fcc2-4eb8-868b-4d5c0c46ccd5": {"__data__": {"id_": "af5b9ed0-fcc2-4eb8-868b-4d5c0c46ccd5", "embedding": null, "metadata": {"window": "Also, we continue to evaluate our footprint and \nmake selective investments in our capabilities and infrastructure.  \n \n Additionally  we are continuing to grow in evolving areas like our at -Home and Services \nbusinesses through investments that further enhance our strong strategic positions.   For example, in \nat-Home, we are investing in technology that improves our interactions with the p atient, and drives \nefficiencies to create significant value in future years.  \n \n  Let me now turn to the enterprise.  \n ", "original_text": "Let me now turn to the enterprise.  \n ", "page_label": "12", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b803411d-7757-4a56-8ae1-333719409f76", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10987d29c804727d54195698d0c3dbca6775f134adcdd1cefb9af65d95d7f3e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db57f8ba-7fcf-494a-a91e-249e711f3bb4", "node_type": "1", "metadata": {"window": "We are making \nthoughtful modifications to our l ogistics, planning, manufacturing, and procurement initiatives, and this \nwork is on track to deliver significant efficiencies.   Also, we continue to evaluate our footprint and \nmake selective investments in our capabilities and infrastructure.  \n \n Additionally  we are continuing to grow in evolving areas like our at -Home and Services \nbusinesses through investments that further enhance our strong strategic positions.   For example, in \nat-Home, we are investing in technology that improves our interactions with the p atient, and drives \nefficiencies to create significant value in future years.  \n \n  Let me now turn to the enterprise.  \n ", "original_text": "For example, in \nat-Home, we are investing in technology that improves our interactions with the p atient, and drives \nefficiencies to create significant value in future years.  \n \n ", "page_label": "12", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5250727a0b11dd8f6492d43ae26ee3ae37e6301a4f51c98e15abfa6d973d17a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "839e2d38-bded-4834-8d4a-fb14672698b8", "node_type": "1", "metadata": {"window": " \nPage 13 of 31 \n \n Our commitment to efficient operations will enable us to optimize and invest.  To that end, we \nhave multiple initiatives in flight that will deliver savings in excess of our multi -year, $500 million target \nas well as technology and process improvements that drive future growth.  \n \n  Turning briefly to capital allocation , our priorities of investing in the business, strengthening our \nbalance s heet through debt pay down, and returning cash to shareholders through our differentiated \ndividend remain unchanged.  \n \n  To close, al though  fiscal 20 presented significant global and industry challenges, we delivered \non our commitments, and our team responde d with the grit that I've seen time and time again at \nCardinal Health.  \n \n ", "original_text": " \nPage 13 of 31 \n \n Our commitment to efficient operations will enable us to optimize and invest. "}, "hash": "d4913735a609500ec739f5b82c09899232dd737c0b16193f5746272a054e52e4", "class_name": "RelatedNodeInfo"}}, "text": "Let me now turn to the enterprise.  \n ", "start_char_idx": 1421, "end_char_idx": 1459, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "839e2d38-bded-4834-8d4a-fb14672698b8": {"__data__": {"id_": "839e2d38-bded-4834-8d4a-fb14672698b8", "embedding": null, "metadata": {"window": " \nPage 13 of 31 \n \n Our commitment to efficient operations will enable us to optimize and invest.  To that end, we \nhave multiple initiatives in flight that will deliver savings in excess of our multi -year, $500 million target \nas well as technology and process improvements that drive future growth.  \n \n  Turning briefly to capital allocation , our priorities of investing in the business, strengthening our \nbalance s heet through debt pay down, and returning cash to shareholders through our differentiated \ndividend remain unchanged.  \n \n  To close, al though  fiscal 20 presented significant global and industry challenges, we delivered \non our commitments, and our team responde d with the grit that I've seen time and time again at \nCardinal Health.  \n \n ", "original_text": " \nPage 13 of 31 \n \n Our commitment to efficient operations will enable us to optimize and invest. ", "page_label": "13", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86caa692-41f3-414c-9fbc-154c8c6d5001", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cabc6f0c978c75f3f44cf38e494f587cbb24f07766af7048942ded06d9322537", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af5b9ed0-fcc2-4eb8-868b-4d5c0c46ccd5", "node_type": "1", "metadata": {"window": "Also, we continue to evaluate our footprint and \nmake selective investments in our capabilities and infrastructure.  \n \n Additionally  we are continuing to grow in evolving areas like our at -Home and Services \nbusinesses through investments that further enhance our strong strategic positions.   For example, in \nat-Home, we are investing in technology that improves our interactions with the p atient, and drives \nefficiencies to create significant value in future years.  \n \n  Let me now turn to the enterprise.  \n ", "original_text": "Let me now turn to the enterprise.  \n ", "page_label": "12", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8953683d7a31ebda538e8bc20a02231d60a83a5cc4dc10ebd7c14f7a3a5b3cb8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ab00943-3cc9-4e74-8e64-6a9935c1fcf4", "node_type": "1", "metadata": {"window": " \nPage 13 of 31 \n \n Our commitment to efficient operations will enable us to optimize and invest.  To that end, we \nhave multiple initiatives in flight that will deliver savings in excess of our multi -year, $500 million target \nas well as technology and process improvements that drive future growth.  \n \n  Turning briefly to capital allocation , our priorities of investing in the business, strengthening our \nbalance s heet through debt pay down, and returning cash to shareholders through our differentiated \ndividend remain unchanged.  \n \n  To close, al though  fiscal 20 presented significant global and industry challenges, we delivered \non our commitments, and our team responde d with the grit that I've seen time and time again at \nCardinal Health.  \n \n  I'd like to thank our employees, especially our frontline teams, for their dedication to our \nmission. ", "original_text": "To that end, we \nhave multiple initiatives in flight that will deliver savings in excess of our multi -year, $500 million target \nas well as technology and process improvements that drive future growth.  \n \n "}, "hash": "2238c30706d181c97f4bae6b0ade79fb7798dcd2f0817fb4db7f734466b59970", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 13 of 31 \n \n Our commitment to efficient operations will enable us to optimize and invest. ", "start_char_idx": 0, "end_char_idx": 98, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ab00943-3cc9-4e74-8e64-6a9935c1fcf4": {"__data__": {"id_": "1ab00943-3cc9-4e74-8e64-6a9935c1fcf4", "embedding": null, "metadata": {"window": " \nPage 13 of 31 \n \n Our commitment to efficient operations will enable us to optimize and invest.  To that end, we \nhave multiple initiatives in flight that will deliver savings in excess of our multi -year, $500 million target \nas well as technology and process improvements that drive future growth.  \n \n  Turning briefly to capital allocation , our priorities of investing in the business, strengthening our \nbalance s heet through debt pay down, and returning cash to shareholders through our differentiated \ndividend remain unchanged.  \n \n  To close, al though  fiscal 20 presented significant global and industry challenges, we delivered \non our commitments, and our team responde d with the grit that I've seen time and time again at \nCardinal Health.  \n \n  I'd like to thank our employees, especially our frontline teams, for their dedication to our \nmission. ", "original_text": "To that end, we \nhave multiple initiatives in flight that will deliver savings in excess of our multi -year, $500 million target \nas well as technology and process improvements that drive future growth.  \n \n ", "page_label": "13", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86caa692-41f3-414c-9fbc-154c8c6d5001", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cabc6f0c978c75f3f44cf38e494f587cbb24f07766af7048942ded06d9322537", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "839e2d38-bded-4834-8d4a-fb14672698b8", "node_type": "1", "metadata": {"window": " \nPage 13 of 31 \n \n Our commitment to efficient operations will enable us to optimize and invest.  To that end, we \nhave multiple initiatives in flight that will deliver savings in excess of our multi -year, $500 million target \nas well as technology and process improvements that drive future growth.  \n \n  Turning briefly to capital allocation , our priorities of investing in the business, strengthening our \nbalance s heet through debt pay down, and returning cash to shareholders through our differentiated \ndividend remain unchanged.  \n \n  To close, al though  fiscal 20 presented significant global and industry challenges, we delivered \non our commitments, and our team responde d with the grit that I've seen time and time again at \nCardinal Health.  \n \n ", "original_text": " \nPage 13 of 31 \n \n Our commitment to efficient operations will enable us to optimize and invest. ", "page_label": "13", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "035deda1ddac2276d40a6758da4efb29b06313566d453c16917cce1d22236dae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc4db64f-9476-4318-9ef3-8fc70164b3a6", "node_type": "1", "metadata": {"window": " \nPage 13 of 31 \n \n Our commitment to efficient operations will enable us to optimize and invest.  To that end, we \nhave multiple initiatives in flight that will deliver savings in excess of our multi -year, $500 million target \nas well as technology and process improvements that drive future growth.  \n \n  Turning briefly to capital allocation , our priorities of investing in the business, strengthening our \nbalance s heet through debt pay down, and returning cash to shareholders through our differentiated \ndividend remain unchanged.  \n \n  To close, al though  fiscal 20 presented significant global and industry challenges, we delivered \non our commitments, and our team responde d with the grit that I've seen time and time again at \nCardinal Health.  \n \n  I'd like to thank our employees, especially our frontline teams, for their dedication to our \nmission.  What we do matters, and together we will manage the complexities ahead, continue to \ndeliver products and solutions to our customers and their patients, and drive growth, so we can \nperform our essential role in healthcare, now and into the future.  \n \n ", "original_text": "Turning briefly to capital allocation , our priorities of investing in the business, strengthening our \nbalance s heet through debt pay down, and returning cash to shareholders through our differentiated \ndividend remain unchanged.  \n \n "}, "hash": "281bed18cea1945b1654f9baeb1be058d331c760ed667411fce864abcf838f39", "class_name": "RelatedNodeInfo"}}, "text": "To that end, we \nhave multiple initiatives in flight that will deliver savings in excess of our multi -year, $500 million target \nas well as technology and process improvements that drive future growth.  \n \n ", "start_char_idx": 98, "end_char_idx": 306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc4db64f-9476-4318-9ef3-8fc70164b3a6": {"__data__": {"id_": "bc4db64f-9476-4318-9ef3-8fc70164b3a6", "embedding": null, "metadata": {"window": " \nPage 13 of 31 \n \n Our commitment to efficient operations will enable us to optimize and invest.  To that end, we \nhave multiple initiatives in flight that will deliver savings in excess of our multi -year, $500 million target \nas well as technology and process improvements that drive future growth.  \n \n  Turning briefly to capital allocation , our priorities of investing in the business, strengthening our \nbalance s heet through debt pay down, and returning cash to shareholders through our differentiated \ndividend remain unchanged.  \n \n  To close, al though  fiscal 20 presented significant global and industry challenges, we delivered \non our commitments, and our team responde d with the grit that I've seen time and time again at \nCardinal Health.  \n \n  I'd like to thank our employees, especially our frontline teams, for their dedication to our \nmission.  What we do matters, and together we will manage the complexities ahead, continue to \ndeliver products and solutions to our customers and their patients, and drive growth, so we can \nperform our essential role in healthcare, now and into the future.  \n \n ", "original_text": "Turning briefly to capital allocation , our priorities of investing in the business, strengthening our \nbalance s heet through debt pay down, and returning cash to shareholders through our differentiated \ndividend remain unchanged.  \n \n ", "page_label": "13", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86caa692-41f3-414c-9fbc-154c8c6d5001", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cabc6f0c978c75f3f44cf38e494f587cbb24f07766af7048942ded06d9322537", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ab00943-3cc9-4e74-8e64-6a9935c1fcf4", "node_type": "1", "metadata": {"window": " \nPage 13 of 31 \n \n Our commitment to efficient operations will enable us to optimize and invest.  To that end, we \nhave multiple initiatives in flight that will deliver savings in excess of our multi -year, $500 million target \nas well as technology and process improvements that drive future growth.  \n \n  Turning briefly to capital allocation , our priorities of investing in the business, strengthening our \nbalance s heet through debt pay down, and returning cash to shareholders through our differentiated \ndividend remain unchanged.  \n \n  To close, al though  fiscal 20 presented significant global and industry challenges, we delivered \non our commitments, and our team responde d with the grit that I've seen time and time again at \nCardinal Health.  \n \n  I'd like to thank our employees, especially our frontline teams, for their dedication to our \nmission. ", "original_text": "To that end, we \nhave multiple initiatives in flight that will deliver savings in excess of our multi -year, $500 million target \nas well as technology and process improvements that drive future growth.  \n \n ", "page_label": "13", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5c81d9aa5c94b104551020ea1196949d4ce07ab8a6c3f2d696b51eeb4407f31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f68b0e7-876d-43b1-ac19-0ce8b550111e", "node_type": "1", "metadata": {"window": " \nPage 13 of 31 \n \n Our commitment to efficient operations will enable us to optimize and invest.  To that end, we \nhave multiple initiatives in flight that will deliver savings in excess of our multi -year, $500 million target \nas well as technology and process improvements that drive future growth.  \n \n  Turning briefly to capital allocation , our priorities of investing in the business, strengthening our \nbalance s heet through debt pay down, and returning cash to shareholders through our differentiated \ndividend remain unchanged.  \n \n  To close, al though  fiscal 20 presented significant global and industry challenges, we delivered \non our commitments, and our team responde d with the grit that I've seen time and time again at \nCardinal Health.  \n \n  I'd like to thank our employees, especially our frontline teams, for their dedication to our \nmission.  What we do matters, and together we will manage the complexities ahead, continue to \ndeliver products and solutions to our customers and their patients, and drive growth, so we can \nperform our essential role in healthcare, now and into the future.  \n \n  With that I'll pause to open it up for questions.  \n \n", "original_text": "To close, al though  fiscal 20 presented significant global and industry challenges, we delivered \non our commitments, and our team responde d with the grit that I've seen time and time again at \nCardinal Health.  \n \n "}, "hash": "838594a30f56c925055b3b4204093884da48944b8461e91a7306678d9347544a", "class_name": "RelatedNodeInfo"}}, "text": "Turning briefly to capital allocation , our priorities of investing in the business, strengthening our \nbalance s heet through debt pay down, and returning cash to shareholders through our differentiated \ndividend remain unchanged.  \n \n ", "start_char_idx": 306, "end_char_idx": 543, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f68b0e7-876d-43b1-ac19-0ce8b550111e": {"__data__": {"id_": "8f68b0e7-876d-43b1-ac19-0ce8b550111e", "embedding": null, "metadata": {"window": " \nPage 13 of 31 \n \n Our commitment to efficient operations will enable us to optimize and invest.  To that end, we \nhave multiple initiatives in flight that will deliver savings in excess of our multi -year, $500 million target \nas well as technology and process improvements that drive future growth.  \n \n  Turning briefly to capital allocation , our priorities of investing in the business, strengthening our \nbalance s heet through debt pay down, and returning cash to shareholders through our differentiated \ndividend remain unchanged.  \n \n  To close, al though  fiscal 20 presented significant global and industry challenges, we delivered \non our commitments, and our team responde d with the grit that I've seen time and time again at \nCardinal Health.  \n \n  I'd like to thank our employees, especially our frontline teams, for their dedication to our \nmission.  What we do matters, and together we will manage the complexities ahead, continue to \ndeliver products and solutions to our customers and their patients, and drive growth, so we can \nperform our essential role in healthcare, now and into the future.  \n \n  With that I'll pause to open it up for questions.  \n \n", "original_text": "To close, al though  fiscal 20 presented significant global and industry challenges, we delivered \non our commitments, and our team responde d with the grit that I've seen time and time again at \nCardinal Health.  \n \n ", "page_label": "13", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86caa692-41f3-414c-9fbc-154c8c6d5001", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cabc6f0c978c75f3f44cf38e494f587cbb24f07766af7048942ded06d9322537", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc4db64f-9476-4318-9ef3-8fc70164b3a6", "node_type": "1", "metadata": {"window": " \nPage 13 of 31 \n \n Our commitment to efficient operations will enable us to optimize and invest.  To that end, we \nhave multiple initiatives in flight that will deliver savings in excess of our multi -year, $500 million target \nas well as technology and process improvements that drive future growth.  \n \n  Turning briefly to capital allocation , our priorities of investing in the business, strengthening our \nbalance s heet through debt pay down, and returning cash to shareholders through our differentiated \ndividend remain unchanged.  \n \n  To close, al though  fiscal 20 presented significant global and industry challenges, we delivered \non our commitments, and our team responde d with the grit that I've seen time and time again at \nCardinal Health.  \n \n  I'd like to thank our employees, especially our frontline teams, for their dedication to our \nmission.  What we do matters, and together we will manage the complexities ahead, continue to \ndeliver products and solutions to our customers and their patients, and drive growth, so we can \nperform our essential role in healthcare, now and into the future.  \n \n ", "original_text": "Turning briefly to capital allocation , our priorities of investing in the business, strengthening our \nbalance s heet through debt pay down, and returning cash to shareholders through our differentiated \ndividend remain unchanged.  \n \n ", "page_label": "13", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f1c382da8b5e9000d7e660e802f6f40782cf57523cacc933ba89dc6d5f43933", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0abc12cc-d8ce-4e7c-9909-62d77afb41bc", "node_type": "1", "metadata": {"window": "To that end, we \nhave multiple initiatives in flight that will deliver savings in excess of our multi -year, $500 million target \nas well as technology and process improvements that drive future growth.  \n \n  Turning briefly to capital allocation , our priorities of investing in the business, strengthening our \nbalance s heet through debt pay down, and returning cash to shareholders through our differentiated \ndividend remain unchanged.  \n \n  To close, al though  fiscal 20 presented significant global and industry challenges, we delivered \non our commitments, and our team responde d with the grit that I've seen time and time again at \nCardinal Health.  \n \n  I'd like to thank our employees, especially our frontline teams, for their dedication to our \nmission.  What we do matters, and together we will manage the complexities ahead, continue to \ndeliver products and solutions to our customers and their patients, and drive growth, so we can \nperform our essential role in healthcare, now and into the future.  \n \n  With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMichael Cherny:  Good morning and thanks so much for the question. ", "original_text": "I'd like to thank our employees, especially our frontline teams, for their dedication to our \nmission. "}, "hash": "e58125a1de88b0d257d86b1f9c2661512d723766a6d6c08e89c189fed06be7de", "class_name": "RelatedNodeInfo"}}, "text": "To close, al though  fiscal 20 presented significant global and industry challenges, we delivered \non our commitments, and our team responde d with the grit that I've seen time and time again at \nCardinal Health.  \n \n ", "start_char_idx": 543, "end_char_idx": 761, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0abc12cc-d8ce-4e7c-9909-62d77afb41bc": {"__data__": {"id_": "0abc12cc-d8ce-4e7c-9909-62d77afb41bc", "embedding": null, "metadata": {"window": "To that end, we \nhave multiple initiatives in flight that will deliver savings in excess of our multi -year, $500 million target \nas well as technology and process improvements that drive future growth.  \n \n  Turning briefly to capital allocation , our priorities of investing in the business, strengthening our \nbalance s heet through debt pay down, and returning cash to shareholders through our differentiated \ndividend remain unchanged.  \n \n  To close, al though  fiscal 20 presented significant global and industry challenges, we delivered \non our commitments, and our team responde d with the grit that I've seen time and time again at \nCardinal Health.  \n \n  I'd like to thank our employees, especially our frontline teams, for their dedication to our \nmission.  What we do matters, and together we will manage the complexities ahead, continue to \ndeliver products and solutions to our customers and their patients, and drive growth, so we can \nperform our essential role in healthcare, now and into the future.  \n \n  With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMichael Cherny:  Good morning and thanks so much for the question. ", "original_text": "I'd like to thank our employees, especially our frontline teams, for their dedication to our \nmission. ", "page_label": "13", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86caa692-41f3-414c-9fbc-154c8c6d5001", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cabc6f0c978c75f3f44cf38e494f587cbb24f07766af7048942ded06d9322537", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f68b0e7-876d-43b1-ac19-0ce8b550111e", "node_type": "1", "metadata": {"window": " \nPage 13 of 31 \n \n Our commitment to efficient operations will enable us to optimize and invest.  To that end, we \nhave multiple initiatives in flight that will deliver savings in excess of our multi -year, $500 million target \nas well as technology and process improvements that drive future growth.  \n \n  Turning briefly to capital allocation , our priorities of investing in the business, strengthening our \nbalance s heet through debt pay down, and returning cash to shareholders through our differentiated \ndividend remain unchanged.  \n \n  To close, al though  fiscal 20 presented significant global and industry challenges, we delivered \non our commitments, and our team responde d with the grit that I've seen time and time again at \nCardinal Health.  \n \n  I'd like to thank our employees, especially our frontline teams, for their dedication to our \nmission.  What we do matters, and together we will manage the complexities ahead, continue to \ndeliver products and solutions to our customers and their patients, and drive growth, so we can \nperform our essential role in healthcare, now and into the future.  \n \n  With that I'll pause to open it up for questions.  \n \n", "original_text": "To close, al though  fiscal 20 presented significant global and industry challenges, we delivered \non our commitments, and our team responde d with the grit that I've seen time and time again at \nCardinal Health.  \n \n ", "page_label": "13", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e3c88f503c3e5bac6e6ef112dd7c417e19d9317b9127ba6180d8293fbba53420", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb264bb1-c94e-45dc-9934-17d46f0d0c46", "node_type": "1", "metadata": {"window": "Turning briefly to capital allocation , our priorities of investing in the business, strengthening our \nbalance s heet through debt pay down, and returning cash to shareholders through our differentiated \ndividend remain unchanged.  \n \n  To close, al though  fiscal 20 presented significant global and industry challenges, we delivered \non our commitments, and our team responde d with the grit that I've seen time and time again at \nCardinal Health.  \n \n  I'd like to thank our employees, especially our frontline teams, for their dedication to our \nmission.  What we do matters, and together we will manage the complexities ahead, continue to \ndeliver products and solutions to our customers and their patients, and drive growth, so we can \nperform our essential role in healthcare, now and into the future.  \n \n  With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMichael Cherny:  Good morning and thanks so much for the question.  So, I just want to dive a little bit \nmore into Medical - you know, Mike, as you think about the pathway forward on the Medical side, \nclearly I think everyone on this call is probably piecing t ogether the various different data points we're \ngetting across a whole host of utilization driven companies.  ", "original_text": "What we do matters, and together we will manage the complexities ahead, continue to \ndeliver products and solutions to our customers and their patients, and drive growth, so we can \nperform our essential role in healthcare, now and into the future.  \n \n "}, "hash": "6a1a817a547f2ebf058198272f6d7c8c60a4f4778c86f9254fe7f49f9cd0b29b", "class_name": "RelatedNodeInfo"}}, "text": "I'd like to thank our employees, especially our frontline teams, for their dedication to our \nmission. ", "start_char_idx": 761, "end_char_idx": 864, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb264bb1-c94e-45dc-9934-17d46f0d0c46": {"__data__": {"id_": "fb264bb1-c94e-45dc-9934-17d46f0d0c46", "embedding": null, "metadata": {"window": "Turning briefly to capital allocation , our priorities of investing in the business, strengthening our \nbalance s heet through debt pay down, and returning cash to shareholders through our differentiated \ndividend remain unchanged.  \n \n  To close, al though  fiscal 20 presented significant global and industry challenges, we delivered \non our commitments, and our team responde d with the grit that I've seen time and time again at \nCardinal Health.  \n \n  I'd like to thank our employees, especially our frontline teams, for their dedication to our \nmission.  What we do matters, and together we will manage the complexities ahead, continue to \ndeliver products and solutions to our customers and their patients, and drive growth, so we can \nperform our essential role in healthcare, now and into the future.  \n \n  With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMichael Cherny:  Good morning and thanks so much for the question.  So, I just want to dive a little bit \nmore into Medical - you know, Mike, as you think about the pathway forward on the Medical side, \nclearly I think everyone on this call is probably piecing t ogether the various different data points we're \ngetting across a whole host of utilization driven companies.  ", "original_text": "What we do matters, and together we will manage the complexities ahead, continue to \ndeliver products and solutions to our customers and their patients, and drive growth, so we can \nperform our essential role in healthcare, now and into the future.  \n \n ", "page_label": "13", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86caa692-41f3-414c-9fbc-154c8c6d5001", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cabc6f0c978c75f3f44cf38e494f587cbb24f07766af7048942ded06d9322537", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0abc12cc-d8ce-4e7c-9909-62d77afb41bc", "node_type": "1", "metadata": {"window": "To that end, we \nhave multiple initiatives in flight that will deliver savings in excess of our multi -year, $500 million target \nas well as technology and process improvements that drive future growth.  \n \n  Turning briefly to capital allocation , our priorities of investing in the business, strengthening our \nbalance s heet through debt pay down, and returning cash to shareholders through our differentiated \ndividend remain unchanged.  \n \n  To close, al though  fiscal 20 presented significant global and industry challenges, we delivered \non our commitments, and our team responde d with the grit that I've seen time and time again at \nCardinal Health.  \n \n  I'd like to thank our employees, especially our frontline teams, for their dedication to our \nmission.  What we do matters, and together we will manage the complexities ahead, continue to \ndeliver products and solutions to our customers and their patients, and drive growth, so we can \nperform our essential role in healthcare, now and into the future.  \n \n  With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMichael Cherny:  Good morning and thanks so much for the question. ", "original_text": "I'd like to thank our employees, especially our frontline teams, for their dedication to our \nmission. ", "page_label": "13", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16c1f46a663ed12101796571dcae07b3a7982b35bde04e46269cb8413c07af59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2334ca60-2c04-4be1-a1fb-7fa7b414b2db", "node_type": "1", "metadata": {"window": "To close, al though  fiscal 20 presented significant global and industry challenges, we delivered \non our commitments, and our team responde d with the grit that I've seen time and time again at \nCardinal Health.  \n \n  I'd like to thank our employees, especially our frontline teams, for their dedication to our \nmission.  What we do matters, and together we will manage the complexities ahead, continue to \ndeliver products and solutions to our customers and their patients, and drive growth, so we can \nperform our essential role in healthcare, now and into the future.  \n \n  With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMichael Cherny:  Good morning and thanks so much for the question.  So, I just want to dive a little bit \nmore into Medical - you know, Mike, as you think about the pathway forward on the Medical side, \nclearly I think everyone on this call is probably piecing t ogether the various different data points we're \ngetting across a whole host of utilization driven companies.  ", "original_text": "With that I'll pause to open it up for questions.  \n \n"}, "hash": "72ed31e129fdc50a59e3b8bf55f354b0be72909d7af77e87dc353ac87b7b32cc", "class_name": "RelatedNodeInfo"}}, "text": "What we do matters, and together we will manage the complexities ahead, continue to \ndeliver products and solutions to our customers and their patients, and drive growth, so we can \nperform our essential role in healthcare, now and into the future.  \n \n ", "start_char_idx": 864, "end_char_idx": 1118, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2334ca60-2c04-4be1-a1fb-7fa7b414b2db": {"__data__": {"id_": "2334ca60-2c04-4be1-a1fb-7fa7b414b2db", "embedding": null, "metadata": {"window": "To close, al though  fiscal 20 presented significant global and industry challenges, we delivered \non our commitments, and our team responde d with the grit that I've seen time and time again at \nCardinal Health.  \n \n  I'd like to thank our employees, especially our frontline teams, for their dedication to our \nmission.  What we do matters, and together we will manage the complexities ahead, continue to \ndeliver products and solutions to our customers and their patients, and drive growth, so we can \nperform our essential role in healthcare, now and into the future.  \n \n  With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMichael Cherny:  Good morning and thanks so much for the question.  So, I just want to dive a little bit \nmore into Medical - you know, Mike, as you think about the pathway forward on the Medical side, \nclearly I think everyone on this call is probably piecing t ogether the various different data points we're \ngetting across a whole host of utilization driven companies.  ", "original_text": "With that I'll pause to open it up for questions.  \n \n", "page_label": "13", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86caa692-41f3-414c-9fbc-154c8c6d5001", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cabc6f0c978c75f3f44cf38e494f587cbb24f07766af7048942ded06d9322537", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb264bb1-c94e-45dc-9934-17d46f0d0c46", "node_type": "1", "metadata": {"window": "Turning briefly to capital allocation , our priorities of investing in the business, strengthening our \nbalance s heet through debt pay down, and returning cash to shareholders through our differentiated \ndividend remain unchanged.  \n \n  To close, al though  fiscal 20 presented significant global and industry challenges, we delivered \non our commitments, and our team responde d with the grit that I've seen time and time again at \nCardinal Health.  \n \n  I'd like to thank our employees, especially our frontline teams, for their dedication to our \nmission.  What we do matters, and together we will manage the complexities ahead, continue to \ndeliver products and solutions to our customers and their patients, and drive growth, so we can \nperform our essential role in healthcare, now and into the future.  \n \n  With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMichael Cherny:  Good morning and thanks so much for the question.  So, I just want to dive a little bit \nmore into Medical - you know, Mike, as you think about the pathway forward on the Medical side, \nclearly I think everyone on this call is probably piecing t ogether the various different data points we're \ngetting across a whole host of utilization driven companies.  ", "original_text": "What we do matters, and together we will manage the complexities ahead, continue to \ndeliver products and solutions to our customers and their patients, and drive growth, so we can \nperform our essential role in healthcare, now and into the future.  \n \n ", "page_label": "13", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a4b4eb5a8a689d2ba74545ae11a67ba866965af1194f4c7741cc121a630b19dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "997e480c-27da-4c4f-bab5-2ea0b973f755", "node_type": "1", "metadata": {"window": "I'd like to thank our employees, especially our frontline teams, for their dedication to our \nmission.  What we do matters, and together we will manage the complexities ahead, continue to \ndeliver products and solutions to our customers and their patients, and drive growth, so we can \nperform our essential role in healthcare, now and into the future.  \n \n  With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMichael Cherny:  Good morning and thanks so much for the question.  So, I just want to dive a little bit \nmore into Medical - you know, Mike, as you think about the pathway forward on the Medical side, \nclearly I think everyone on this call is probably piecing t ogether the various different data points we're \ngetting across a whole host of utilization driven companies.  ", "original_text": "Operator:  Operator Instructions  \n \nMichael Cherny:  Good morning and thanks so much for the question. "}, "hash": "151606064c97773f70541351f518fb5f1b1d6e8c7fc4bbdb1c9ba80af98248a5", "class_name": "RelatedNodeInfo"}}, "text": "With that I'll pause to open it up for questions.  \n \n", "start_char_idx": 1118, "end_char_idx": 1172, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "997e480c-27da-4c4f-bab5-2ea0b973f755": {"__data__": {"id_": "997e480c-27da-4c4f-bab5-2ea0b973f755", "embedding": null, "metadata": {"window": "I'd like to thank our employees, especially our frontline teams, for their dedication to our \nmission.  What we do matters, and together we will manage the complexities ahead, continue to \ndeliver products and solutions to our customers and their patients, and drive growth, so we can \nperform our essential role in healthcare, now and into the future.  \n \n  With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMichael Cherny:  Good morning and thanks so much for the question.  So, I just want to dive a little bit \nmore into Medical - you know, Mike, as you think about the pathway forward on the Medical side, \nclearly I think everyone on this call is probably piecing t ogether the various different data points we're \ngetting across a whole host of utilization driven companies.  ", "original_text": "Operator:  Operator Instructions  \n \nMichael Cherny:  Good morning and thanks so much for the question. ", "page_label": "13", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86caa692-41f3-414c-9fbc-154c8c6d5001", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cabc6f0c978c75f3f44cf38e494f587cbb24f07766af7048942ded06d9322537", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2334ca60-2c04-4be1-a1fb-7fa7b414b2db", "node_type": "1", "metadata": {"window": "To close, al though  fiscal 20 presented significant global and industry challenges, we delivered \non our commitments, and our team responde d with the grit that I've seen time and time again at \nCardinal Health.  \n \n  I'd like to thank our employees, especially our frontline teams, for their dedication to our \nmission.  What we do matters, and together we will manage the complexities ahead, continue to \ndeliver products and solutions to our customers and their patients, and drive growth, so we can \nperform our essential role in healthcare, now and into the future.  \n \n  With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMichael Cherny:  Good morning and thanks so much for the question.  So, I just want to dive a little bit \nmore into Medical - you know, Mike, as you think about the pathway forward on the Medical side, \nclearly I think everyone on this call is probably piecing t ogether the various different data points we're \ngetting across a whole host of utilization driven companies.  ", "original_text": "With that I'll pause to open it up for questions.  \n \n", "page_label": "13", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f11d9db5775714d7208378d855ef71fd0b38d76221d645d53a558c3c0410a14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d8c6e06-5c13-4f38-880f-83322485fdfb", "node_type": "1", "metadata": {"window": "What we do matters, and together we will manage the complexities ahead, continue to \ndeliver products and solutions to our customers and their patients, and drive growth, so we can \nperform our essential role in healthcare, now and into the future.  \n \n  With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMichael Cherny:  Good morning and thanks so much for the question.  So, I just want to dive a little bit \nmore into Medical - you know, Mike, as you think about the pathway forward on the Medical side, \nclearly I think everyone on this call is probably piecing t ogether the various different data points we're \ngetting across a whole host of utilization driven companies.  ", "original_text": "So, I just want to dive a little bit \nmore into Medical - you know, Mike, as you think about the pathway forward on the Medical side, \nclearly I think everyone on this call is probably piecing t ogether the various different data points we're \ngetting across a whole host of utilization driven companies.  "}, "hash": "85424e6922a5e75a4d391673a984d7f077fd00c969839442571d6bcbf3c1cb95", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Operator Instructions  \n \nMichael Cherny:  Good morning and thanks so much for the question. ", "start_char_idx": 1172, "end_char_idx": 1276, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d8c6e06-5c13-4f38-880f-83322485fdfb": {"__data__": {"id_": "8d8c6e06-5c13-4f38-880f-83322485fdfb", "embedding": null, "metadata": {"window": "What we do matters, and together we will manage the complexities ahead, continue to \ndeliver products and solutions to our customers and their patients, and drive growth, so we can \nperform our essential role in healthcare, now and into the future.  \n \n  With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMichael Cherny:  Good morning and thanks so much for the question.  So, I just want to dive a little bit \nmore into Medical - you know, Mike, as you think about the pathway forward on the Medical side, \nclearly I think everyone on this call is probably piecing t ogether the various different data points we're \ngetting across a whole host of utilization driven companies.  ", "original_text": "So, I just want to dive a little bit \nmore into Medical - you know, Mike, as you think about the pathway forward on the Medical side, \nclearly I think everyone on this call is probably piecing t ogether the various different data points we're \ngetting across a whole host of utilization driven companies.  ", "page_label": "13", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86caa692-41f3-414c-9fbc-154c8c6d5001", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cabc6f0c978c75f3f44cf38e494f587cbb24f07766af7048942ded06d9322537", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "997e480c-27da-4c4f-bab5-2ea0b973f755", "node_type": "1", "metadata": {"window": "I'd like to thank our employees, especially our frontline teams, for their dedication to our \nmission.  What we do matters, and together we will manage the complexities ahead, continue to \ndeliver products and solutions to our customers and their patients, and drive growth, so we can \nperform our essential role in healthcare, now and into the future.  \n \n  With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMichael Cherny:  Good morning and thanks so much for the question.  So, I just want to dive a little bit \nmore into Medical - you know, Mike, as you think about the pathway forward on the Medical side, \nclearly I think everyone on this call is probably piecing t ogether the various different data points we're \ngetting across a whole host of utilization driven companies.  ", "original_text": "Operator:  Operator Instructions  \n \nMichael Cherny:  Good morning and thanks so much for the question. ", "page_label": "13", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d07cf5459a3c39bf77feb10a5bb1c8339f4204ee28ada0534dee9b8e085fe84d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46268da2-1da7-41d9-83ee-1692439ea447", "node_type": "1", "metadata": {"window": " \nPage 14 of 31 \n \n \n How do you think about the swing factors that would lead to upside or downside in terms of \nyour current outlook and how this could factor through  into the potential for upside downsides to the \nprofit growth outlook that you have?  \n \n Mike Kaufmann:  Yes, thanks for the question Michael.  First of all we're really excited that we were \nable to see Med grow this year and if you, you know, you adjust for C OVID next year we're excited \nthat we have Med growing in the mid -single digits next year, too.  So we feel really good about the \ntrajectory.  \n \n ", "original_text": " \nPage 14 of 31 \n \n \n How do you think about the swing factors that would lead to upside or downside in terms of \nyour current outlook and how this could factor through  into the potential for upside downsides to the \nprofit growth outlook that you have?  \n \n"}, "hash": "1eaa0b02b70ed95713791784b8e0abf21563f38db142cfbd0828ae3e96f5a40f", "class_name": "RelatedNodeInfo"}}, "text": "So, I just want to dive a little bit \nmore into Medical - you know, Mike, as you think about the pathway forward on the Medical side, \nclearly I think everyone on this call is probably piecing t ogether the various different data points we're \ngetting across a whole host of utilization driven companies.  ", "start_char_idx": 1276, "end_char_idx": 1582, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46268da2-1da7-41d9-83ee-1692439ea447": {"__data__": {"id_": "46268da2-1da7-41d9-83ee-1692439ea447", "embedding": null, "metadata": {"window": " \nPage 14 of 31 \n \n \n How do you think about the swing factors that would lead to upside or downside in terms of \nyour current outlook and how this could factor through  into the potential for upside downsides to the \nprofit growth outlook that you have?  \n \n Mike Kaufmann:  Yes, thanks for the question Michael.  First of all we're really excited that we were \nable to see Med grow this year and if you, you know, you adjust for C OVID next year we're excited \nthat we have Med growing in the mid -single digits next year, too.  So we feel really good about the \ntrajectory.  \n \n ", "original_text": " \nPage 14 of 31 \n \n \n How do you think about the swing factors that would lead to upside or downside in terms of \nyour current outlook and how this could factor through  into the potential for upside downsides to the \nprofit growth outlook that you have?  \n \n", "page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bda01840-44a8-4a6f-9d92-3b10e2b59e06", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01d48f5eda2e182baf35ef936efd8d49ffe466cd91054a95946b6d87432eb134", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d8c6e06-5c13-4f38-880f-83322485fdfb", "node_type": "1", "metadata": {"window": "What we do matters, and together we will manage the complexities ahead, continue to \ndeliver products and solutions to our customers and their patients, and drive growth, so we can \nperform our essential role in healthcare, now and into the future.  \n \n  With that I'll pause to open it up for questions.  \n \n Operator:  Operator Instructions  \n \nMichael Cherny:  Good morning and thanks so much for the question.  So, I just want to dive a little bit \nmore into Medical - you know, Mike, as you think about the pathway forward on the Medical side, \nclearly I think everyone on this call is probably piecing t ogether the various different data points we're \ngetting across a whole host of utilization driven companies.  ", "original_text": "So, I just want to dive a little bit \nmore into Medical - you know, Mike, as you think about the pathway forward on the Medical side, \nclearly I think everyone on this call is probably piecing t ogether the various different data points we're \ngetting across a whole host of utilization driven companies.  ", "page_label": "13", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75ec1bcabf2feaf01962115a53024fc5d67825b231c38512c5921c9ef6251bc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fca19427-fae5-46de-8fe8-2f0e64ed383d", "node_type": "1", "metadata": {"window": " \nPage 14 of 31 \n \n \n How do you think about the swing factors that would lead to upside or downside in terms of \nyour current outlook and how this could factor through  into the potential for upside downsides to the \nprofit growth outlook that you have?  \n \n Mike Kaufmann:  Yes, thanks for the question Michael.  First of all we're really excited that we were \nable to see Med grow this year and if you, you know, you adjust for C OVID next year we're excited \nthat we have Med growing in the mid -single digits next year, too.  So we feel really good about the \ntrajectory.  \n \n  I would say the main driver of being better or worse than where we expected is probably \nCOVID -19 itself and the va rious impacts it could have on our business.  \n \n ", "original_text": "Mike Kaufmann:  Yes, thanks for the question Michael. "}, "hash": "ab004d9353f6bf44359080c47784dbca4c69f31b071d4014a3249b0b0e4fd525", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 14 of 31 \n \n \n How do you think about the swing factors that would lead to upside or downside in terms of \nyour current outlook and how this could factor through  into the potential for upside downsides to the \nprofit growth outlook that you have?  \n \n", "start_char_idx": 0, "end_char_idx": 259, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fca19427-fae5-46de-8fe8-2f0e64ed383d": {"__data__": {"id_": "fca19427-fae5-46de-8fe8-2f0e64ed383d", "embedding": null, "metadata": {"window": " \nPage 14 of 31 \n \n \n How do you think about the swing factors that would lead to upside or downside in terms of \nyour current outlook and how this could factor through  into the potential for upside downsides to the \nprofit growth outlook that you have?  \n \n Mike Kaufmann:  Yes, thanks for the question Michael.  First of all we're really excited that we were \nable to see Med grow this year and if you, you know, you adjust for C OVID next year we're excited \nthat we have Med growing in the mid -single digits next year, too.  So we feel really good about the \ntrajectory.  \n \n  I would say the main driver of being better or worse than where we expected is probably \nCOVID -19 itself and the va rious impacts it could have on our business.  \n \n ", "original_text": "Mike Kaufmann:  Yes, thanks for the question Michael. ", "page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bda01840-44a8-4a6f-9d92-3b10e2b59e06", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01d48f5eda2e182baf35ef936efd8d49ffe466cd91054a95946b6d87432eb134", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46268da2-1da7-41d9-83ee-1692439ea447", "node_type": "1", "metadata": {"window": " \nPage 14 of 31 \n \n \n How do you think about the swing factors that would lead to upside or downside in terms of \nyour current outlook and how this could factor through  into the potential for upside downsides to the \nprofit growth outlook that you have?  \n \n Mike Kaufmann:  Yes, thanks for the question Michael.  First of all we're really excited that we were \nable to see Med grow this year and if you, you know, you adjust for C OVID next year we're excited \nthat we have Med growing in the mid -single digits next year, too.  So we feel really good about the \ntrajectory.  \n \n ", "original_text": " \nPage 14 of 31 \n \n \n How do you think about the swing factors that would lead to upside or downside in terms of \nyour current outlook and how this could factor through  into the potential for upside downsides to the \nprofit growth outlook that you have?  \n \n", "page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13f79057c5a182716bac63318907caeb084e9bd558c7b906e313dea59ca4628f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be9feac5-b2b3-4c98-b034-92309d23b1ce", "node_type": "1", "metadata": {"window": " \nPage 14 of 31 \n \n \n How do you think about the swing factors that would lead to upside or downside in terms of \nyour current outlook and how this could factor through  into the potential for upside downsides to the \nprofit growth outlook that you have?  \n \n Mike Kaufmann:  Yes, thanks for the question Michael.  First of all we're really excited that we were \nable to see Med grow this year and if you, you know, you adjust for C OVID next year we're excited \nthat we have Med growing in the mid -single digits next year, too.  So we feel really good about the \ntrajectory.  \n \n  I would say the main driver of being better or worse than where we expected is probably \nCOVID -19 itself and the va rious impacts it could have on our business.  \n \n  First of all , if there's either major regional or an overall large shut downs again of elective \nprocedures. ", "original_text": "First of all we're really excited that we were \nable to see Med grow this year and if you, you know, you adjust for C OVID next year we're excited \nthat we have Med growing in the mid -single digits next year, too. "}, "hash": "3038826ba1f91c54234f445217e7d4e18f9a7570d322001db3c6d4029c1f8be2", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes, thanks for the question Michael. ", "start_char_idx": 259, "end_char_idx": 313, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be9feac5-b2b3-4c98-b034-92309d23b1ce": {"__data__": {"id_": "be9feac5-b2b3-4c98-b034-92309d23b1ce", "embedding": null, "metadata": {"window": " \nPage 14 of 31 \n \n \n How do you think about the swing factors that would lead to upside or downside in terms of \nyour current outlook and how this could factor through  into the potential for upside downsides to the \nprofit growth outlook that you have?  \n \n Mike Kaufmann:  Yes, thanks for the question Michael.  First of all we're really excited that we were \nable to see Med grow this year and if you, you know, you adjust for C OVID next year we're excited \nthat we have Med growing in the mid -single digits next year, too.  So we feel really good about the \ntrajectory.  \n \n  I would say the main driver of being better or worse than where we expected is probably \nCOVID -19 itself and the va rious impacts it could have on our business.  \n \n  First of all , if there's either major regional or an overall large shut downs again of elective \nprocedures. ", "original_text": "First of all we're really excited that we were \nable to see Med grow this year and if you, you know, you adjust for C OVID next year we're excited \nthat we have Med growing in the mid -single digits next year, too. ", "page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bda01840-44a8-4a6f-9d92-3b10e2b59e06", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01d48f5eda2e182baf35ef936efd8d49ffe466cd91054a95946b6d87432eb134", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fca19427-fae5-46de-8fe8-2f0e64ed383d", "node_type": "1", "metadata": {"window": " \nPage 14 of 31 \n \n \n How do you think about the swing factors that would lead to upside or downside in terms of \nyour current outlook and how this could factor through  into the potential for upside downsides to the \nprofit growth outlook that you have?  \n \n Mike Kaufmann:  Yes, thanks for the question Michael.  First of all we're really excited that we were \nable to see Med grow this year and if you, you know, you adjust for C OVID next year we're excited \nthat we have Med growing in the mid -single digits next year, too.  So we feel really good about the \ntrajectory.  \n \n  I would say the main driver of being better or worse than where we expected is probably \nCOVID -19 itself and the va rious impacts it could have on our business.  \n \n ", "original_text": "Mike Kaufmann:  Yes, thanks for the question Michael. ", "page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7678a1eb40d8e6ffddf421826297834d93b62b87f5ee8e5a96c44f0b50f8e0a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6dd2b8f-e169-4a5f-829a-355ffcaaee94", "node_type": "1", "metadata": {"window": " \nPage 14 of 31 \n \n \n How do you think about the swing factors that would lead to upside or downside in terms of \nyour current outlook and how this could factor through  into the potential for upside downsides to the \nprofit growth outlook that you have?  \n \n Mike Kaufmann:  Yes, thanks for the question Michael.  First of all we're really excited that we were \nable to see Med grow this year and if you, you know, you adjust for C OVID next year we're excited \nthat we have Med growing in the mid -single digits next year, too.  So we feel really good about the \ntrajectory.  \n \n  I would say the main driver of being better or worse than where we expected is probably \nCOVID -19 itself and the va rious impacts it could have on our business.  \n \n  First of all , if there's either major regional or an overall large shut downs again of elective \nprocedures.  That's going to have a very negative impact on us.  \n \n ", "original_text": "So we feel really good about the \ntrajectory.  \n \n "}, "hash": "4faf97c438e5570b3d55735520d7fcc8504b514d4f812cd96401980dca2d8d48", "class_name": "RelatedNodeInfo"}}, "text": "First of all we're really excited that we were \nable to see Med grow this year and if you, you know, you adjust for C OVID next year we're excited \nthat we have Med growing in the mid -single digits next year, too. ", "start_char_idx": 313, "end_char_idx": 528, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6dd2b8f-e169-4a5f-829a-355ffcaaee94": {"__data__": {"id_": "a6dd2b8f-e169-4a5f-829a-355ffcaaee94", "embedding": null, "metadata": {"window": " \nPage 14 of 31 \n \n \n How do you think about the swing factors that would lead to upside or downside in terms of \nyour current outlook and how this could factor through  into the potential for upside downsides to the \nprofit growth outlook that you have?  \n \n Mike Kaufmann:  Yes, thanks for the question Michael.  First of all we're really excited that we were \nable to see Med grow this year and if you, you know, you adjust for C OVID next year we're excited \nthat we have Med growing in the mid -single digits next year, too.  So we feel really good about the \ntrajectory.  \n \n  I would say the main driver of being better or worse than where we expected is probably \nCOVID -19 itself and the va rious impacts it could have on our business.  \n \n  First of all , if there's either major regional or an overall large shut downs again of elective \nprocedures.  That's going to have a very negative impact on us.  \n \n ", "original_text": "So we feel really good about the \ntrajectory.  \n \n ", "page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bda01840-44a8-4a6f-9d92-3b10e2b59e06", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01d48f5eda2e182baf35ef936efd8d49ffe466cd91054a95946b6d87432eb134", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be9feac5-b2b3-4c98-b034-92309d23b1ce", "node_type": "1", "metadata": {"window": " \nPage 14 of 31 \n \n \n How do you think about the swing factors that would lead to upside or downside in terms of \nyour current outlook and how this could factor through  into the potential for upside downsides to the \nprofit growth outlook that you have?  \n \n Mike Kaufmann:  Yes, thanks for the question Michael.  First of all we're really excited that we were \nable to see Med grow this year and if you, you know, you adjust for C OVID next year we're excited \nthat we have Med growing in the mid -single digits next year, too.  So we feel really good about the \ntrajectory.  \n \n  I would say the main driver of being better or worse than where we expected is probably \nCOVID -19 itself and the va rious impacts it could have on our business.  \n \n  First of all , if there's either major regional or an overall large shut downs again of elective \nprocedures. ", "original_text": "First of all we're really excited that we were \nable to see Med grow this year and if you, you know, you adjust for C OVID next year we're excited \nthat we have Med growing in the mid -single digits next year, too. ", "page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4612567c8312ce7c77d2bf931f309e957ba04bf98ae0f479504bcb2a1f6dc46a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a8fb50e-7b86-42db-b813-190b599fa853", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes, thanks for the question Michael.  First of all we're really excited that we were \nable to see Med grow this year and if you, you know, you adjust for C OVID next year we're excited \nthat we have Med growing in the mid -single digits next year, too.  So we feel really good about the \ntrajectory.  \n \n  I would say the main driver of being better or worse than where we expected is probably \nCOVID -19 itself and the va rious impacts it could have on our business.  \n \n  First of all , if there's either major regional or an overall large shut downs again of elective \nprocedures.  That's going to have a very negative impact on us.  \n \n  Or, if it actually recovers faster, or if we swi ng back to some pent -up demand, which - that's not \nwhat we're projecting. ", "original_text": "I would say the main driver of being better or worse than where we expected is probably \nCOVID -19 itself and the va rious impacts it could have on our business.  \n \n "}, "hash": "f5fcf6d478f6ea177f7008af4f45779f4e07163bf8a1115c488d6bbf1bc47a41", "class_name": "RelatedNodeInfo"}}, "text": "So we feel really good about the \ntrajectory.  \n \n ", "start_char_idx": 528, "end_char_idx": 579, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a8fb50e-7b86-42db-b813-190b599fa853": {"__data__": {"id_": "4a8fb50e-7b86-42db-b813-190b599fa853", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes, thanks for the question Michael.  First of all we're really excited that we were \nable to see Med grow this year and if you, you know, you adjust for C OVID next year we're excited \nthat we have Med growing in the mid -single digits next year, too.  So we feel really good about the \ntrajectory.  \n \n  I would say the main driver of being better or worse than where we expected is probably \nCOVID -19 itself and the va rious impacts it could have on our business.  \n \n  First of all , if there's either major regional or an overall large shut downs again of elective \nprocedures.  That's going to have a very negative impact on us.  \n \n  Or, if it actually recovers faster, or if we swi ng back to some pent -up demand, which - that's not \nwhat we're projecting. ", "original_text": "I would say the main driver of being better or worse than where we expected is probably \nCOVID -19 itself and the va rious impacts it could have on our business.  \n \n ", "page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bda01840-44a8-4a6f-9d92-3b10e2b59e06", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01d48f5eda2e182baf35ef936efd8d49ffe466cd91054a95946b6d87432eb134", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6dd2b8f-e169-4a5f-829a-355ffcaaee94", "node_type": "1", "metadata": {"window": " \nPage 14 of 31 \n \n \n How do you think about the swing factors that would lead to upside or downside in terms of \nyour current outlook and how this could factor through  into the potential for upside downsides to the \nprofit growth outlook that you have?  \n \n Mike Kaufmann:  Yes, thanks for the question Michael.  First of all we're really excited that we were \nable to see Med grow this year and if you, you know, you adjust for C OVID next year we're excited \nthat we have Med growing in the mid -single digits next year, too.  So we feel really good about the \ntrajectory.  \n \n  I would say the main driver of being better or worse than where we expected is probably \nCOVID -19 itself and the va rious impacts it could have on our business.  \n \n  First of all , if there's either major regional or an overall large shut downs again of elective \nprocedures.  That's going to have a very negative impact on us.  \n \n ", "original_text": "So we feel really good about the \ntrajectory.  \n \n ", "page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "de5ce472f8789f3a3fbf76e551a557580b3546f1ced0a4729e558409bae3965f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16bb59f2-fa6d-4444-9803-60907e0a798d", "node_type": "1", "metadata": {"window": "First of all we're really excited that we were \nable to see Med grow this year and if you, you know, you adjust for C OVID next year we're excited \nthat we have Med growing in the mid -single digits next year, too.  So we feel really good about the \ntrajectory.  \n \n  I would say the main driver of being better or worse than where we expected is probably \nCOVID -19 itself and the va rious impacts it could have on our business.  \n \n  First of all , if there's either major regional or an overall large shut downs again of elective \nprocedures.  That's going to have a very negative impact on us.  \n \n  Or, if it actually recovers faster, or if we swi ng back to some pent -up demand, which - that's not \nwhat we're projecting.  That could be some upside for us.  \n \n ", "original_text": "First of all , if there's either major regional or an overall large shut downs again of elective \nprocedures. "}, "hash": "35849f126acb411ffab2f44de7080b86b0e12499454f4d9e8a34959ded971afa", "class_name": "RelatedNodeInfo"}}, "text": "I would say the main driver of being better or worse than where we expected is probably \nCOVID -19 itself and the va rious impacts it could have on our business.  \n \n ", "start_char_idx": 579, "end_char_idx": 746, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16bb59f2-fa6d-4444-9803-60907e0a798d": {"__data__": {"id_": "16bb59f2-fa6d-4444-9803-60907e0a798d", "embedding": null, "metadata": {"window": "First of all we're really excited that we were \nable to see Med grow this year and if you, you know, you adjust for C OVID next year we're excited \nthat we have Med growing in the mid -single digits next year, too.  So we feel really good about the \ntrajectory.  \n \n  I would say the main driver of being better or worse than where we expected is probably \nCOVID -19 itself and the va rious impacts it could have on our business.  \n \n  First of all , if there's either major regional or an overall large shut downs again of elective \nprocedures.  That's going to have a very negative impact on us.  \n \n  Or, if it actually recovers faster, or if we swi ng back to some pent -up demand, which - that's not \nwhat we're projecting.  That could be some upside for us.  \n \n ", "original_text": "First of all , if there's either major regional or an overall large shut downs again of elective \nprocedures. ", "page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bda01840-44a8-4a6f-9d92-3b10e2b59e06", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01d48f5eda2e182baf35ef936efd8d49ffe466cd91054a95946b6d87432eb134", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a8fb50e-7b86-42db-b813-190b599fa853", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes, thanks for the question Michael.  First of all we're really excited that we were \nable to see Med grow this year and if you, you know, you adjust for C OVID next year we're excited \nthat we have Med growing in the mid -single digits next year, too.  So we feel really good about the \ntrajectory.  \n \n  I would say the main driver of being better or worse than where we expected is probably \nCOVID -19 itself and the va rious impacts it could have on our business.  \n \n  First of all , if there's either major regional or an overall large shut downs again of elective \nprocedures.  That's going to have a very negative impact on us.  \n \n  Or, if it actually recovers faster, or if we swi ng back to some pent -up demand, which - that's not \nwhat we're projecting. ", "original_text": "I would say the main driver of being better or worse than where we expected is probably \nCOVID -19 itself and the va rious impacts it could have on our business.  \n \n ", "page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1bdfee2e68acd27e73d9efc8f653c9d93774e300e8e2b24d27b96429afd891ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a51de891-dd53-45b9-8151-52a4beb4b7ba", "node_type": "1", "metadata": {"window": "So we feel really good about the \ntrajectory.  \n \n  I would say the main driver of being better or worse than where we expected is probably \nCOVID -19 itself and the va rious impacts it could have on our business.  \n \n  First of all , if there's either major regional or an overall large shut downs again of elective \nprocedures.  That's going to have a very negative impact on us.  \n \n  Or, if it actually recovers faster, or if we swi ng back to some pent -up demand, which - that's not \nwhat we're projecting.  That could be some upside for us.  \n \n  So as Jason mentioned in his - we're really expecting to average high single digits across the \nyear in elective procedures being down for the year  - high single digits.  \n \n ", "original_text": "That's going to have a very negative impact on us.  \n \n "}, "hash": "9158f9a7d10f7a2ab54efe281ac0190378f1f93f208ca26bd13c6c9cd4b8486f", "class_name": "RelatedNodeInfo"}}, "text": "First of all , if there's either major regional or an overall large shut downs again of elective \nprocedures. ", "start_char_idx": 746, "end_char_idx": 856, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a51de891-dd53-45b9-8151-52a4beb4b7ba": {"__data__": {"id_": "a51de891-dd53-45b9-8151-52a4beb4b7ba", "embedding": null, "metadata": {"window": "So we feel really good about the \ntrajectory.  \n \n  I would say the main driver of being better or worse than where we expected is probably \nCOVID -19 itself and the va rious impacts it could have on our business.  \n \n  First of all , if there's either major regional or an overall large shut downs again of elective \nprocedures.  That's going to have a very negative impact on us.  \n \n  Or, if it actually recovers faster, or if we swi ng back to some pent -up demand, which - that's not \nwhat we're projecting.  That could be some upside for us.  \n \n  So as Jason mentioned in his - we're really expecting to average high single digits across the \nyear in elective procedures being down for the year  - high single digits.  \n \n ", "original_text": "That's going to have a very negative impact on us.  \n \n ", "page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bda01840-44a8-4a6f-9d92-3b10e2b59e06", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01d48f5eda2e182baf35ef936efd8d49ffe466cd91054a95946b6d87432eb134", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16bb59f2-fa6d-4444-9803-60907e0a798d", "node_type": "1", "metadata": {"window": "First of all we're really excited that we were \nable to see Med grow this year and if you, you know, you adjust for C OVID next year we're excited \nthat we have Med growing in the mid -single digits next year, too.  So we feel really good about the \ntrajectory.  \n \n  I would say the main driver of being better or worse than where we expected is probably \nCOVID -19 itself and the va rious impacts it could have on our business.  \n \n  First of all , if there's either major regional or an overall large shut downs again of elective \nprocedures.  That's going to have a very negative impact on us.  \n \n  Or, if it actually recovers faster, or if we swi ng back to some pent -up demand, which - that's not \nwhat we're projecting.  That could be some upside for us.  \n \n ", "original_text": "First of all , if there's either major regional or an overall large shut downs again of elective \nprocedures. ", "page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a990786d1334aef0745270a5fc71c4957446dac4d0a5214a3fdc27ec55157bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8bf371a7-a762-48d8-a7a2-93bc7e8998e4", "node_type": "1", "metadata": {"window": "I would say the main driver of being better or worse than where we expected is probably \nCOVID -19 itself and the va rious impacts it could have on our business.  \n \n  First of all , if there's either major regional or an overall large shut downs again of elective \nprocedures.  That's going to have a very negative impact on us.  \n \n  Or, if it actually recovers faster, or if we swi ng back to some pent -up demand, which - that's not \nwhat we're projecting.  That could be some upside for us.  \n \n  So as Jason mentioned in his - we're really expecting to average high single digits across the \nyear in elective procedures being down for the year  - high single digits.  \n \n  We expect it to start higher. ", "original_text": "Or, if it actually recovers faster, or if we swi ng back to some pent -up demand, which - that's not \nwhat we're projecting. "}, "hash": "2ca2aa1ff74619fee6992e581c27316836b2b196103b14a76310925e204f4437", "class_name": "RelatedNodeInfo"}}, "text": "That's going to have a very negative impact on us.  \n \n ", "start_char_idx": 856, "end_char_idx": 912, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8bf371a7-a762-48d8-a7a2-93bc7e8998e4": {"__data__": {"id_": "8bf371a7-a762-48d8-a7a2-93bc7e8998e4", "embedding": null, "metadata": {"window": "I would say the main driver of being better or worse than where we expected is probably \nCOVID -19 itself and the va rious impacts it could have on our business.  \n \n  First of all , if there's either major regional or an overall large shut downs again of elective \nprocedures.  That's going to have a very negative impact on us.  \n \n  Or, if it actually recovers faster, or if we swi ng back to some pent -up demand, which - that's not \nwhat we're projecting.  That could be some upside for us.  \n \n  So as Jason mentioned in his - we're really expecting to average high single digits across the \nyear in elective procedures being down for the year  - high single digits.  \n \n  We expect it to start higher. ", "original_text": "Or, if it actually recovers faster, or if we swi ng back to some pent -up demand, which - that's not \nwhat we're projecting. ", "page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bda01840-44a8-4a6f-9d92-3b10e2b59e06", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01d48f5eda2e182baf35ef936efd8d49ffe466cd91054a95946b6d87432eb134", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a51de891-dd53-45b9-8151-52a4beb4b7ba", "node_type": "1", "metadata": {"window": "So we feel really good about the \ntrajectory.  \n \n  I would say the main driver of being better or worse than where we expected is probably \nCOVID -19 itself and the va rious impacts it could have on our business.  \n \n  First of all , if there's either major regional or an overall large shut downs again of elective \nprocedures.  That's going to have a very negative impact on us.  \n \n  Or, if it actually recovers faster, or if we swi ng back to some pent -up demand, which - that's not \nwhat we're projecting.  That could be some upside for us.  \n \n  So as Jason mentioned in his - we're really expecting to average high single digits across the \nyear in elective procedures being down for the year  - high single digits.  \n \n ", "original_text": "That's going to have a very negative impact on us.  \n \n ", "page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "673580984691d1ed1ea20ecffa4728f18429a9198d8d1837ae1a992d53c13911", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0eefee8-7c90-4bd0-ba4f-91a588d1a4e1", "node_type": "1", "metadata": {"window": "First of all , if there's either major regional or an overall large shut downs again of elective \nprocedures.  That's going to have a very negative impact on us.  \n \n  Or, if it actually recovers faster, or if we swi ng back to some pent -up demand, which - that's not \nwhat we're projecting.  That could be some upside for us.  \n \n  So as Jason mentioned in his - we're really expecting to average high single digits across the \nyear in elective procedures being down for the year  - high single digits.  \n \n  We expect it to start higher.  Obviously we're exiting, we think, from our external information \nand looking at ours somewhere in the mid -teens, the high teens, exiting Q4 with elective procedures ", "original_text": "That could be some upside for us.  \n \n "}, "hash": "e2cde0335b65512e9d47257caef9a97c9bf78cc0202484b224b7bbc30d3a8879", "class_name": "RelatedNodeInfo"}}, "text": "Or, if it actually recovers faster, or if we swi ng back to some pent -up demand, which - that's not \nwhat we're projecting. ", "start_char_idx": 912, "end_char_idx": 1037, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0eefee8-7c90-4bd0-ba4f-91a588d1a4e1": {"__data__": {"id_": "d0eefee8-7c90-4bd0-ba4f-91a588d1a4e1", "embedding": null, "metadata": {"window": "First of all , if there's either major regional or an overall large shut downs again of elective \nprocedures.  That's going to have a very negative impact on us.  \n \n  Or, if it actually recovers faster, or if we swi ng back to some pent -up demand, which - that's not \nwhat we're projecting.  That could be some upside for us.  \n \n  So as Jason mentioned in his - we're really expecting to average high single digits across the \nyear in elective procedures being down for the year  - high single digits.  \n \n  We expect it to start higher.  Obviously we're exiting, we think, from our external information \nand looking at ours somewhere in the mid -teens, the high teens, exiting Q4 with elective procedures ", "original_text": "That could be some upside for us.  \n \n ", "page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bda01840-44a8-4a6f-9d92-3b10e2b59e06", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01d48f5eda2e182baf35ef936efd8d49ffe466cd91054a95946b6d87432eb134", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8bf371a7-a762-48d8-a7a2-93bc7e8998e4", "node_type": "1", "metadata": {"window": "I would say the main driver of being better or worse than where we expected is probably \nCOVID -19 itself and the va rious impacts it could have on our business.  \n \n  First of all , if there's either major regional or an overall large shut downs again of elective \nprocedures.  That's going to have a very negative impact on us.  \n \n  Or, if it actually recovers faster, or if we swi ng back to some pent -up demand, which - that's not \nwhat we're projecting.  That could be some upside for us.  \n \n  So as Jason mentioned in his - we're really expecting to average high single digits across the \nyear in elective procedures being down for the year  - high single digits.  \n \n  We expect it to start higher. ", "original_text": "Or, if it actually recovers faster, or if we swi ng back to some pent -up demand, which - that's not \nwhat we're projecting. ", "page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5176f55dbfbf3fdb6b4cecfc85b0354fd20fa02d80a798fb8891ced039058e67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f83eb034-6e57-42cf-b25b-0d6ebfa5d161", "node_type": "1", "metadata": {"window": "That's going to have a very negative impact on us.  \n \n  Or, if it actually recovers faster, or if we swi ng back to some pent -up demand, which - that's not \nwhat we're projecting.  That could be some upside for us.  \n \n  So as Jason mentioned in his - we're really expecting to average high single digits across the \nyear in elective procedures being down for the year  - high single digits.  \n \n  We expect it to start higher.  Obviously we're exiting, we think, from our external information \nand looking at ours somewhere in the mid -teens, the high teens, exiting Q4 with elective procedures ", "original_text": "So as Jason mentioned in his - we're really expecting to average high single digits across the \nyear in elective procedures being down for the year  - high single digits.  \n \n "}, "hash": "11fe3b85e949f781d60881c83f5593004064f055b2b957dc5997d75141012534", "class_name": "RelatedNodeInfo"}}, "text": "That could be some upside for us.  \n \n ", "start_char_idx": 1037, "end_char_idx": 1076, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f83eb034-6e57-42cf-b25b-0d6ebfa5d161": {"__data__": {"id_": "f83eb034-6e57-42cf-b25b-0d6ebfa5d161", "embedding": null, "metadata": {"window": "That's going to have a very negative impact on us.  \n \n  Or, if it actually recovers faster, or if we swi ng back to some pent -up demand, which - that's not \nwhat we're projecting.  That could be some upside for us.  \n \n  So as Jason mentioned in his - we're really expecting to average high single digits across the \nyear in elective procedures being down for the year  - high single digits.  \n \n  We expect it to start higher.  Obviously we're exiting, we think, from our external information \nand looking at ours somewhere in the mid -teens, the high teens, exiting Q4 with elective procedures ", "original_text": "So as Jason mentioned in his - we're really expecting to average high single digits across the \nyear in elective procedures being down for the year  - high single digits.  \n \n ", "page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bda01840-44a8-4a6f-9d92-3b10e2b59e06", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01d48f5eda2e182baf35ef936efd8d49ffe466cd91054a95946b6d87432eb134", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0eefee8-7c90-4bd0-ba4f-91a588d1a4e1", "node_type": "1", "metadata": {"window": "First of all , if there's either major regional or an overall large shut downs again of elective \nprocedures.  That's going to have a very negative impact on us.  \n \n  Or, if it actually recovers faster, or if we swi ng back to some pent -up demand, which - that's not \nwhat we're projecting.  That could be some upside for us.  \n \n  So as Jason mentioned in his - we're really expecting to average high single digits across the \nyear in elective procedures being down for the year  - high single digits.  \n \n  We expect it to start higher.  Obviously we're exiting, we think, from our external information \nand looking at ours somewhere in the mid -teens, the high teens, exiting Q4 with elective procedures ", "original_text": "That could be some upside for us.  \n \n ", "page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ab4c82e78c8bdd0536ec39eb2136da5041a3f55eb2d77407c89dc6b7e51ff82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17fb75e0-2dee-4de1-994b-eb9bf36af7a0", "node_type": "1", "metadata": {"window": "Or, if it actually recovers faster, or if we swi ng back to some pent -up demand, which - that's not \nwhat we're projecting.  That could be some upside for us.  \n \n  So as Jason mentioned in his - we're really expecting to average high single digits across the \nyear in elective procedures being down for the year  - high single digits.  \n \n  We expect it to start higher.  Obviously we're exiting, we think, from our external information \nand looking at ours somewhere in the mid -teens, the high teens, exiting Q4 with elective procedures ", "original_text": "We expect it to start higher. "}, "hash": "61aa60da4bb0ee489fe999449af4243b2da3556418a666770e2ec79b171bdfa8", "class_name": "RelatedNodeInfo"}}, "text": "So as Jason mentioned in his - we're really expecting to average high single digits across the \nyear in elective procedures being down for the year  - high single digits.  \n \n ", "start_char_idx": 1076, "end_char_idx": 1252, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17fb75e0-2dee-4de1-994b-eb9bf36af7a0": {"__data__": {"id_": "17fb75e0-2dee-4de1-994b-eb9bf36af7a0", "embedding": null, "metadata": {"window": "Or, if it actually recovers faster, or if we swi ng back to some pent -up demand, which - that's not \nwhat we're projecting.  That could be some upside for us.  \n \n  So as Jason mentioned in his - we're really expecting to average high single digits across the \nyear in elective procedures being down for the year  - high single digits.  \n \n  We expect it to start higher.  Obviously we're exiting, we think, from our external information \nand looking at ours somewhere in the mid -teens, the high teens, exiting Q4 with elective procedures ", "original_text": "We expect it to start higher. ", "page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bda01840-44a8-4a6f-9d92-3b10e2b59e06", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01d48f5eda2e182baf35ef936efd8d49ffe466cd91054a95946b6d87432eb134", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f83eb034-6e57-42cf-b25b-0d6ebfa5d161", "node_type": "1", "metadata": {"window": "That's going to have a very negative impact on us.  \n \n  Or, if it actually recovers faster, or if we swi ng back to some pent -up demand, which - that's not \nwhat we're projecting.  That could be some upside for us.  \n \n  So as Jason mentioned in his - we're really expecting to average high single digits across the \nyear in elective procedures being down for the year  - high single digits.  \n \n  We expect it to start higher.  Obviously we're exiting, we think, from our external information \nand looking at ours somewhere in the mid -teens, the high teens, exiting Q4 with elective procedures ", "original_text": "So as Jason mentioned in his - we're really expecting to average high single digits across the \nyear in elective procedures being down for the year  - high single digits.  \n \n ", "page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff6ce744da9d1cb95aa2617161321fdef793843a1ffef4a1f1e2acead891a51f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8133afb5-82b2-4e3c-b6c8-19846d06ff42", "node_type": "1", "metadata": {"window": "That could be some upside for us.  \n \n  So as Jason mentioned in his - we're really expecting to average high single digits across the \nyear in elective procedures being down for the year  - high single digits.  \n \n  We expect it to start higher.  Obviously we're exiting, we think, from our external information \nand looking at ours somewhere in the mid -teens, the high teens, exiting Q4 with elective procedures ", "original_text": "Obviously we're exiting, we think, from our external information \nand looking at ours somewhere in the mid -teens, the high teens, exiting Q4 with elective procedures "}, "hash": "744b196bce37ee22c3905bf4b7f096ddafac4ba0e53b9f4181e5c4cb1b6fea6f", "class_name": "RelatedNodeInfo"}}, "text": "We expect it to start higher. ", "start_char_idx": 1252, "end_char_idx": 1282, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8133afb5-82b2-4e3c-b6c8-19846d06ff42": {"__data__": {"id_": "8133afb5-82b2-4e3c-b6c8-19846d06ff42", "embedding": null, "metadata": {"window": "That could be some upside for us.  \n \n  So as Jason mentioned in his - we're really expecting to average high single digits across the \nyear in elective procedures being down for the year  - high single digits.  \n \n  We expect it to start higher.  Obviously we're exiting, we think, from our external information \nand looking at ours somewhere in the mid -teens, the high teens, exiting Q4 with elective procedures ", "original_text": "Obviously we're exiting, we think, from our external information \nand looking at ours somewhere in the mid -teens, the high teens, exiting Q4 with elective procedures ", "page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bda01840-44a8-4a6f-9d92-3b10e2b59e06", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01d48f5eda2e182baf35ef936efd8d49ffe466cd91054a95946b6d87432eb134", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17fb75e0-2dee-4de1-994b-eb9bf36af7a0", "node_type": "1", "metadata": {"window": "Or, if it actually recovers faster, or if we swi ng back to some pent -up demand, which - that's not \nwhat we're projecting.  That could be some upside for us.  \n \n  So as Jason mentioned in his - we're really expecting to average high single digits across the \nyear in elective procedures being down for the year  - high single digits.  \n \n  We expect it to start higher.  Obviously we're exiting, we think, from our external information \nand looking at ours somewhere in the mid -teens, the high teens, exiting Q4 with elective procedures ", "original_text": "We expect it to start higher. ", "page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7efa34076f185fe90b3e6c10a04fcb91145c105f9e2968fce4bc03a33bfd99a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7293f0f6-006f-456f-a2fe-13bbaf27c2c6", "node_type": "1", "metadata": {"window": " \nPage 15 of 31 \n \nbeing down and so we would expect to enter this year that way  and then exit FY21 at close to pre -\nCOVID levels.  \n \n  So that's kind of the trajectory that we see.  But again, different than that.  That would be the \nbiggest potential driver.  \n \n ", "original_text": " \nPage 15 of 31 \n \nbeing down and so we would expect to enter this year that way  and then exit FY21 at close to pre -\nCOVID levels.  \n \n "}, "hash": "a686c40bd659406fe2f68417a7180d0f31a3e617a01f0e58a18ec5d8f70f9c71", "class_name": "RelatedNodeInfo"}}, "text": "Obviously we're exiting, we think, from our external information \nand looking at ours somewhere in the mid -teens, the high teens, exiting Q4 with elective procedures ", "start_char_idx": 1282, "end_char_idx": 1449, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7293f0f6-006f-456f-a2fe-13bbaf27c2c6": {"__data__": {"id_": "7293f0f6-006f-456f-a2fe-13bbaf27c2c6", "embedding": null, "metadata": {"window": " \nPage 15 of 31 \n \nbeing down and so we would expect to enter this year that way  and then exit FY21 at close to pre -\nCOVID levels.  \n \n  So that's kind of the trajectory that we see.  But again, different than that.  That would be the \nbiggest potential driver.  \n \n ", "original_text": " \nPage 15 of 31 \n \nbeing down and so we would expect to enter this year that way  and then exit FY21 at close to pre -\nCOVID levels.  \n \n ", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d48d411-660e-4844-a192-428ac1781c55", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45d34c87a19feb70878c1cd8aa9d34a011438b413ad9c933f412d4c9b5d36074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8133afb5-82b2-4e3c-b6c8-19846d06ff42", "node_type": "1", "metadata": {"window": "That could be some upside for us.  \n \n  So as Jason mentioned in his - we're really expecting to average high single digits across the \nyear in elective procedures being down for the year  - high single digits.  \n \n  We expect it to start higher.  Obviously we're exiting, we think, from our external information \nand looking at ours somewhere in the mid -teens, the high teens, exiting Q4 with elective procedures ", "original_text": "Obviously we're exiting, we think, from our external information \nand looking at ours somewhere in the mid -teens, the high teens, exiting Q4 with elective procedures ", "page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2ebcd97dda379a4cebb085cb60a718257a85778e8d47be17355d53fbbe1d79c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e635cb31-d972-4124-8895-eef0a38f1a01", "node_type": "1", "metadata": {"window": " \nPage 15 of 31 \n \nbeing down and so we would expect to enter this year that way  and then exit FY21 at close to pre -\nCOVID levels.  \n \n  So that's kind of the trajectory that we see.  But again, different than that.  That would be the \nbiggest potential driver.  \n \n  In Medical, you'll always have the potential driver of tariffs, FX, and commodities. ", "original_text": "So that's kind of the trajectory that we see. "}, "hash": "731ca4998f13f79d14409423876bb938ee37b07c9eec4416b8ce6d594ecd3730", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 15 of 31 \n \nbeing down and so we would expect to enter this year that way  and then exit FY21 at close to pre -\nCOVID levels.  \n \n ", "start_char_idx": 0, "end_char_idx": 138, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e635cb31-d972-4124-8895-eef0a38f1a01": {"__data__": {"id_": "e635cb31-d972-4124-8895-eef0a38f1a01", "embedding": null, "metadata": {"window": " \nPage 15 of 31 \n \nbeing down and so we would expect to enter this year that way  and then exit FY21 at close to pre -\nCOVID levels.  \n \n  So that's kind of the trajectory that we see.  But again, different than that.  That would be the \nbiggest potential driver.  \n \n  In Medical, you'll always have the potential driver of tariffs, FX, and commodities. ", "original_text": "So that's kind of the trajectory that we see. ", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d48d411-660e-4844-a192-428ac1781c55", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45d34c87a19feb70878c1cd8aa9d34a011438b413ad9c933f412d4c9b5d36074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7293f0f6-006f-456f-a2fe-13bbaf27c2c6", "node_type": "1", "metadata": {"window": " \nPage 15 of 31 \n \nbeing down and so we would expect to enter this year that way  and then exit FY21 at close to pre -\nCOVID levels.  \n \n  So that's kind of the trajectory that we see.  But again, different than that.  That would be the \nbiggest potential driver.  \n \n ", "original_text": " \nPage 15 of 31 \n \nbeing down and so we would expect to enter this year that way  and then exit FY21 at close to pre -\nCOVID levels.  \n \n ", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "277f58740711d21fa1c12ea79b257cdbf3a4e82d11402f76a35dd0d8e92946cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc2b2b37-c369-4f91-a4b3-082f3b435d25", "node_type": "1", "metadata": {"window": " \nPage 15 of 31 \n \nbeing down and so we would expect to enter this year that way  and then exit FY21 at close to pre -\nCOVID levels.  \n \n  So that's kind of the trajectory that we see.  But again, different than that.  That would be the \nbiggest potential driver.  \n \n  In Medical, you'll always have the potential driver of tariffs, FX, and commodities.  We're not \nexpecting anything big on those, but as you've seen in past years, any one of those could swing one \nway or the other and create upside or downside.  \n \n ", "original_text": "But again, different than that. "}, "hash": "7f7056894cf708d7431a3ee924a14c91b4d2641502abe0cc9eb463f76a4838bb", "class_name": "RelatedNodeInfo"}}, "text": "So that's kind of the trajectory that we see. ", "start_char_idx": 138, "end_char_idx": 184, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc2b2b37-c369-4f91-a4b3-082f3b435d25": {"__data__": {"id_": "cc2b2b37-c369-4f91-a4b3-082f3b435d25", "embedding": null, "metadata": {"window": " \nPage 15 of 31 \n \nbeing down and so we would expect to enter this year that way  and then exit FY21 at close to pre -\nCOVID levels.  \n \n  So that's kind of the trajectory that we see.  But again, different than that.  That would be the \nbiggest potential driver.  \n \n  In Medical, you'll always have the potential driver of tariffs, FX, and commodities.  We're not \nexpecting anything big on those, but as you've seen in past years, any one of those could swing one \nway or the other and create upside or downside.  \n \n ", "original_text": "But again, different than that. ", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d48d411-660e-4844-a192-428ac1781c55", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45d34c87a19feb70878c1cd8aa9d34a011438b413ad9c933f412d4c9b5d36074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e635cb31-d972-4124-8895-eef0a38f1a01", "node_type": "1", "metadata": {"window": " \nPage 15 of 31 \n \nbeing down and so we would expect to enter this year that way  and then exit FY21 at close to pre -\nCOVID levels.  \n \n  So that's kind of the trajectory that we see.  But again, different than that.  That would be the \nbiggest potential driver.  \n \n  In Medical, you'll always have the potential driver of tariffs, FX, and commodities. ", "original_text": "So that's kind of the trajectory that we see. ", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d0d57a5a202b37d67bcc7eb854f30dcf555925a280d383acf045e4d7a9f2325", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62ae12e5-b03e-4ac2-8a6f-9ab16d4c3fba", "node_type": "1", "metadata": {"window": " \nPage 15 of 31 \n \nbeing down and so we would expect to enter this year that way  and then exit FY21 at close to pre -\nCOVID levels.  \n \n  So that's kind of the trajectory that we see.  But again, different than that.  That would be the \nbiggest potential driver.  \n \n  In Medical, you'll always have the potential driver of tariffs, FX, and commodities.  We're not \nexpecting anything big on those, but as you've seen in past years, any one of those could swing one \nway or the other and create upside or downside.  \n \n  So that's probably what I would say would be the biggest potential drivers of varia bility in \nMedical.  \n \n ", "original_text": "That would be the \nbiggest potential driver.  \n \n "}, "hash": "5c9f95e803fe26f46508a60efded09fd9ca12a14d67af61775d01d9af062e25d", "class_name": "RelatedNodeInfo"}}, "text": "But again, different than that. ", "start_char_idx": 184, "end_char_idx": 216, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62ae12e5-b03e-4ac2-8a6f-9ab16d4c3fba": {"__data__": {"id_": "62ae12e5-b03e-4ac2-8a6f-9ab16d4c3fba", "embedding": null, "metadata": {"window": " \nPage 15 of 31 \n \nbeing down and so we would expect to enter this year that way  and then exit FY21 at close to pre -\nCOVID levels.  \n \n  So that's kind of the trajectory that we see.  But again, different than that.  That would be the \nbiggest potential driver.  \n \n  In Medical, you'll always have the potential driver of tariffs, FX, and commodities.  We're not \nexpecting anything big on those, but as you've seen in past years, any one of those could swing one \nway or the other and create upside or downside.  \n \n  So that's probably what I would say would be the biggest potential drivers of varia bility in \nMedical.  \n \n ", "original_text": "That would be the \nbiggest potential driver.  \n \n ", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d48d411-660e-4844-a192-428ac1781c55", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45d34c87a19feb70878c1cd8aa9d34a011438b413ad9c933f412d4c9b5d36074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc2b2b37-c369-4f91-a4b3-082f3b435d25", "node_type": "1", "metadata": {"window": " \nPage 15 of 31 \n \nbeing down and so we would expect to enter this year that way  and then exit FY21 at close to pre -\nCOVID levels.  \n \n  So that's kind of the trajectory that we see.  But again, different than that.  That would be the \nbiggest potential driver.  \n \n  In Medical, you'll always have the potential driver of tariffs, FX, and commodities.  We're not \nexpecting anything big on those, but as you've seen in past years, any one of those could swing one \nway or the other and create upside or downside.  \n \n ", "original_text": "But again, different than that. ", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a9b4ade20039a3ae5fa987a379ee08d46795634cace5e9a00c60f159977815e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d2f3e57-844b-4219-a1d0-ace80908d2b2", "node_type": "1", "metadata": {"window": "So that's kind of the trajectory that we see.  But again, different than that.  That would be the \nbiggest potential driver.  \n \n  In Medical, you'll always have the potential driver of tariffs, FX, and commodities.  We're not \nexpecting anything big on those, but as you've seen in past years, any one of those could swing one \nway or the other and create upside or downside.  \n \n  So that's probably what I would say would be the biggest potential drivers of varia bility in \nMedical.  \n \n  Next question?  \n \n", "original_text": "In Medical, you'll always have the potential driver of tariffs, FX, and commodities. "}, "hash": "17d6dcb9ec40a9a22e6a390fcacf2ea6c61099c76bf81d244e23868d79b8f5c0", "class_name": "RelatedNodeInfo"}}, "text": "That would be the \nbiggest potential driver.  \n \n ", "start_char_idx": 216, "end_char_idx": 266, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d2f3e57-844b-4219-a1d0-ace80908d2b2": {"__data__": {"id_": "0d2f3e57-844b-4219-a1d0-ace80908d2b2", "embedding": null, "metadata": {"window": "So that's kind of the trajectory that we see.  But again, different than that.  That would be the \nbiggest potential driver.  \n \n  In Medical, you'll always have the potential driver of tariffs, FX, and commodities.  We're not \nexpecting anything big on those, but as you've seen in past years, any one of those could swing one \nway or the other and create upside or downside.  \n \n  So that's probably what I would say would be the biggest potential drivers of varia bility in \nMedical.  \n \n  Next question?  \n \n", "original_text": "In Medical, you'll always have the potential driver of tariffs, FX, and commodities. ", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d48d411-660e-4844-a192-428ac1781c55", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45d34c87a19feb70878c1cd8aa9d34a011438b413ad9c933f412d4c9b5d36074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62ae12e5-b03e-4ac2-8a6f-9ab16d4c3fba", "node_type": "1", "metadata": {"window": " \nPage 15 of 31 \n \nbeing down and so we would expect to enter this year that way  and then exit FY21 at close to pre -\nCOVID levels.  \n \n  So that's kind of the trajectory that we see.  But again, different than that.  That would be the \nbiggest potential driver.  \n \n  In Medical, you'll always have the potential driver of tariffs, FX, and commodities.  We're not \nexpecting anything big on those, but as you've seen in past years, any one of those could swing one \nway or the other and create upside or downside.  \n \n  So that's probably what I would say would be the biggest potential drivers of varia bility in \nMedical.  \n \n ", "original_text": "That would be the \nbiggest potential driver.  \n \n ", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75199e262e478c33a37fb9e6154ef9e433a4f60132befe7944e374312e11bb0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61c31698-c2ff-41fa-a007-a94466bbd5bb", "node_type": "1", "metadata": {"window": "But again, different than that.  That would be the \nbiggest potential driver.  \n \n  In Medical, you'll always have the potential driver of tariffs, FX, and commodities.  We're not \nexpecting anything big on those, but as you've seen in past years, any one of those could swing one \nway or the other and create upside or downside.  \n \n  So that's probably what I would say would be the biggest potential drivers of varia bility in \nMedical.  \n \n  Next question?  \n \n Operator:  Thank you. ", "original_text": "We're not \nexpecting anything big on those, but as you've seen in past years, any one of those could swing one \nway or the other and create upside or downside.  \n \n "}, "hash": "a3e6bde5b8b46d7a7d0fca1c8007aa152cbb05e09c8b8ebf8d4d065d835764b9", "class_name": "RelatedNodeInfo"}}, "text": "In Medical, you'll always have the potential driver of tariffs, FX, and commodities. ", "start_char_idx": 266, "end_char_idx": 351, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61c31698-c2ff-41fa-a007-a94466bbd5bb": {"__data__": {"id_": "61c31698-c2ff-41fa-a007-a94466bbd5bb", "embedding": null, "metadata": {"window": "But again, different than that.  That would be the \nbiggest potential driver.  \n \n  In Medical, you'll always have the potential driver of tariffs, FX, and commodities.  We're not \nexpecting anything big on those, but as you've seen in past years, any one of those could swing one \nway or the other and create upside or downside.  \n \n  So that's probably what I would say would be the biggest potential drivers of varia bility in \nMedical.  \n \n  Next question?  \n \n Operator:  Thank you. ", "original_text": "We're not \nexpecting anything big on those, but as you've seen in past years, any one of those could swing one \nway or the other and create upside or downside.  \n \n ", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d48d411-660e-4844-a192-428ac1781c55", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45d34c87a19feb70878c1cd8aa9d34a011438b413ad9c933f412d4c9b5d36074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d2f3e57-844b-4219-a1d0-ace80908d2b2", "node_type": "1", "metadata": {"window": "So that's kind of the trajectory that we see.  But again, different than that.  That would be the \nbiggest potential driver.  \n \n  In Medical, you'll always have the potential driver of tariffs, FX, and commodities.  We're not \nexpecting anything big on those, but as you've seen in past years, any one of those could swing one \nway or the other and create upside or downside.  \n \n  So that's probably what I would say would be the biggest potential drivers of varia bility in \nMedical.  \n \n  Next question?  \n \n", "original_text": "In Medical, you'll always have the potential driver of tariffs, FX, and commodities. ", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8815510daf75fd785adcd2d9f955bc78ebf472a822d3d6710ccb8cf47fcfe7ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07260682-3a82-4e2c-b8a5-44d3abf6b89b", "node_type": "1", "metadata": {"window": "That would be the \nbiggest potential driver.  \n \n  In Medical, you'll always have the potential driver of tariffs, FX, and commodities.  We're not \nexpecting anything big on those, but as you've seen in past years, any one of those could swing one \nway or the other and create upside or downside.  \n \n  So that's probably what I would say would be the biggest potential drivers of varia bility in \nMedical.  \n \n  Next question?  \n \n Operator:  Thank you.  We'll next go to Glen Santangelo with Guggenheim. ", "original_text": "So that's probably what I would say would be the biggest potential drivers of varia bility in \nMedical.  \n \n "}, "hash": "fff849f04fb15142dcc5113fd3fa76edab8d7f1e6993fe113ce4bc2e82c332a5", "class_name": "RelatedNodeInfo"}}, "text": "We're not \nexpecting anything big on those, but as you've seen in past years, any one of those could swing one \nway or the other and create upside or downside.  \n \n ", "start_char_idx": 351, "end_char_idx": 516, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07260682-3a82-4e2c-b8a5-44d3abf6b89b": {"__data__": {"id_": "07260682-3a82-4e2c-b8a5-44d3abf6b89b", "embedding": null, "metadata": {"window": "That would be the \nbiggest potential driver.  \n \n  In Medical, you'll always have the potential driver of tariffs, FX, and commodities.  We're not \nexpecting anything big on those, but as you've seen in past years, any one of those could swing one \nway or the other and create upside or downside.  \n \n  So that's probably what I would say would be the biggest potential drivers of varia bility in \nMedical.  \n \n  Next question?  \n \n Operator:  Thank you.  We'll next go to Glen Santangelo with Guggenheim. ", "original_text": "So that's probably what I would say would be the biggest potential drivers of varia bility in \nMedical.  \n \n ", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d48d411-660e-4844-a192-428ac1781c55", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45d34c87a19feb70878c1cd8aa9d34a011438b413ad9c933f412d4c9b5d36074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61c31698-c2ff-41fa-a007-a94466bbd5bb", "node_type": "1", "metadata": {"window": "But again, different than that.  That would be the \nbiggest potential driver.  \n \n  In Medical, you'll always have the potential driver of tariffs, FX, and commodities.  We're not \nexpecting anything big on those, but as you've seen in past years, any one of those could swing one \nway or the other and create upside or downside.  \n \n  So that's probably what I would say would be the biggest potential drivers of varia bility in \nMedical.  \n \n  Next question?  \n \n Operator:  Thank you. ", "original_text": "We're not \nexpecting anything big on those, but as you've seen in past years, any one of those could swing one \nway or the other and create upside or downside.  \n \n ", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dac719c8c1968910b177e6285b46104f670048ff0c0bdfee53735e36fd905fce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "675ef5c2-b707-4828-9c71-d5fc0e5eaac9", "node_type": "1", "metadata": {"window": "In Medical, you'll always have the potential driver of tariffs, FX, and commodities.  We're not \nexpecting anything big on those, but as you've seen in past years, any one of those could swing one \nway or the other and create upside or downside.  \n \n  So that's probably what I would say would be the biggest potential drivers of varia bility in \nMedical.  \n \n  Next question?  \n \n Operator:  Thank you.  We'll next go to Glen Santangelo with Guggenheim.  Please go ahead.  \n \n", "original_text": "Next question?  \n \n"}, "hash": "6bb4048d99bbc1f3f53e693af36d75b0e551e4749d5bd55018a8ccaf7846ed36", "class_name": "RelatedNodeInfo"}}, "text": "So that's probably what I would say would be the biggest potential drivers of varia bility in \nMedical.  \n \n ", "start_char_idx": 516, "end_char_idx": 625, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "675ef5c2-b707-4828-9c71-d5fc0e5eaac9": {"__data__": {"id_": "675ef5c2-b707-4828-9c71-d5fc0e5eaac9", "embedding": null, "metadata": {"window": "In Medical, you'll always have the potential driver of tariffs, FX, and commodities.  We're not \nexpecting anything big on those, but as you've seen in past years, any one of those could swing one \nway or the other and create upside or downside.  \n \n  So that's probably what I would say would be the biggest potential drivers of varia bility in \nMedical.  \n \n  Next question?  \n \n Operator:  Thank you.  We'll next go to Glen Santangelo with Guggenheim.  Please go ahead.  \n \n", "original_text": "Next question?  \n \n", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d48d411-660e-4844-a192-428ac1781c55", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45d34c87a19feb70878c1cd8aa9d34a011438b413ad9c933f412d4c9b5d36074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07260682-3a82-4e2c-b8a5-44d3abf6b89b", "node_type": "1", "metadata": {"window": "That would be the \nbiggest potential driver.  \n \n  In Medical, you'll always have the potential driver of tariffs, FX, and commodities.  We're not \nexpecting anything big on those, but as you've seen in past years, any one of those could swing one \nway or the other and create upside or downside.  \n \n  So that's probably what I would say would be the biggest potential drivers of varia bility in \nMedical.  \n \n  Next question?  \n \n Operator:  Thank you.  We'll next go to Glen Santangelo with Guggenheim. ", "original_text": "So that's probably what I would say would be the biggest potential drivers of varia bility in \nMedical.  \n \n ", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ed5dc12092afdaf185789fd7a5bbb184cf234c35d9418f59d04b9049b9ff4e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5231930f-c1bf-4238-80bc-e918e52ffb7b", "node_type": "1", "metadata": {"window": "We're not \nexpecting anything big on those, but as you've seen in past years, any one of those could swing one \nway or the other and create upside or downside.  \n \n  So that's probably what I would say would be the biggest potential drivers of varia bility in \nMedical.  \n \n  Next question?  \n \n Operator:  Thank you.  We'll next go to Glen Santangelo with Guggenheim.  Please go ahead.  \n \n Glen Santangelo:  Oh, yes. ", "original_text": "Operator:  Thank you. "}, "hash": "31af003118a32feb71a766b60a6113863abdc7ff53601c96b068c22b71f570ca", "class_name": "RelatedNodeInfo"}}, "text": "Next question?  \n \n", "start_char_idx": 625, "end_char_idx": 644, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5231930f-c1bf-4238-80bc-e918e52ffb7b": {"__data__": {"id_": "5231930f-c1bf-4238-80bc-e918e52ffb7b", "embedding": null, "metadata": {"window": "We're not \nexpecting anything big on those, but as you've seen in past years, any one of those could swing one \nway or the other and create upside or downside.  \n \n  So that's probably what I would say would be the biggest potential drivers of varia bility in \nMedical.  \n \n  Next question?  \n \n Operator:  Thank you.  We'll next go to Glen Santangelo with Guggenheim.  Please go ahead.  \n \n Glen Santangelo:  Oh, yes. ", "original_text": "Operator:  Thank you. ", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d48d411-660e-4844-a192-428ac1781c55", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45d34c87a19feb70878c1cd8aa9d34a011438b413ad9c933f412d4c9b5d36074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "675ef5c2-b707-4828-9c71-d5fc0e5eaac9", "node_type": "1", "metadata": {"window": "In Medical, you'll always have the potential driver of tariffs, FX, and commodities.  We're not \nexpecting anything big on those, but as you've seen in past years, any one of those could swing one \nway or the other and create upside or downside.  \n \n  So that's probably what I would say would be the biggest potential drivers of varia bility in \nMedical.  \n \n  Next question?  \n \n Operator:  Thank you.  We'll next go to Glen Santangelo with Guggenheim.  Please go ahead.  \n \n", "original_text": "Next question?  \n \n", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a856e10c2912b9765ee6bfa1c72371276adc61406c3efe4c3c04f066e36faf24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4b022a5-fa77-42c3-a35b-74630777daea", "node_type": "1", "metadata": {"window": "So that's probably what I would say would be the biggest potential drivers of varia bility in \nMedical.  \n \n  Next question?  \n \n Operator:  Thank you.  We'll next go to Glen Santangelo with Guggenheim.  Please go ahead.  \n \n Glen Santangelo:  Oh, yes.  Thanks for taking my question. ", "original_text": "We'll next go to Glen Santangelo with Guggenheim. "}, "hash": "27351c2656a2932bdcbb4a3c2effbf57b30c3fa4f4aa2d1fb75b5daec0d2b5a4", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you. ", "start_char_idx": 644, "end_char_idx": 666, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4b022a5-fa77-42c3-a35b-74630777daea": {"__data__": {"id_": "e4b022a5-fa77-42c3-a35b-74630777daea", "embedding": null, "metadata": {"window": "So that's probably what I would say would be the biggest potential drivers of varia bility in \nMedical.  \n \n  Next question?  \n \n Operator:  Thank you.  We'll next go to Glen Santangelo with Guggenheim.  Please go ahead.  \n \n Glen Santangelo:  Oh, yes.  Thanks for taking my question. ", "original_text": "We'll next go to Glen Santangelo with Guggenheim. ", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d48d411-660e-4844-a192-428ac1781c55", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45d34c87a19feb70878c1cd8aa9d34a011438b413ad9c933f412d4c9b5d36074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5231930f-c1bf-4238-80bc-e918e52ffb7b", "node_type": "1", "metadata": {"window": "We're not \nexpecting anything big on those, but as you've seen in past years, any one of those could swing one \nway or the other and create upside or downside.  \n \n  So that's probably what I would say would be the biggest potential drivers of varia bility in \nMedical.  \n \n  Next question?  \n \n Operator:  Thank you.  We'll next go to Glen Santangelo with Guggenheim.  Please go ahead.  \n \n Glen Santangelo:  Oh, yes. ", "original_text": "Operator:  Thank you. ", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0e3a895ddd23a21068bd715ddbb991a0232c74ed418146746be427ae2ce174b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24e149cf-2cb5-49c5-9032-8a64b287efdd", "node_type": "1", "metadata": {"window": "Next question?  \n \n Operator:  Thank you.  We'll next go to Glen Santangelo with Guggenheim.  Please go ahead.  \n \n Glen Santangelo:  Oh, yes.  Thanks for taking my question.  Jason, I just wanted to follow -up on some \nof the comments you made with  respect to the COVID impact on the fiscal 21 guidance. ", "original_text": "Please go ahead.  \n \n"}, "hash": "44d6e0bf20c07569288346915541240314ae6663ac7a728a4488e5e8c3be3f32", "class_name": "RelatedNodeInfo"}}, "text": "We'll next go to Glen Santangelo with Guggenheim. ", "start_char_idx": 666, "end_char_idx": 716, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24e149cf-2cb5-49c5-9032-8a64b287efdd": {"__data__": {"id_": "24e149cf-2cb5-49c5-9032-8a64b287efdd", "embedding": null, "metadata": {"window": "Next question?  \n \n Operator:  Thank you.  We'll next go to Glen Santangelo with Guggenheim.  Please go ahead.  \n \n Glen Santangelo:  Oh, yes.  Thanks for taking my question.  Jason, I just wanted to follow -up on some \nof the comments you made with  respect to the COVID impact on the fiscal 21 guidance. ", "original_text": "Please go ahead.  \n \n", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d48d411-660e-4844-a192-428ac1781c55", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45d34c87a19feb70878c1cd8aa9d34a011438b413ad9c933f412d4c9b5d36074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4b022a5-fa77-42c3-a35b-74630777daea", "node_type": "1", "metadata": {"window": "So that's probably what I would say would be the biggest potential drivers of varia bility in \nMedical.  \n \n  Next question?  \n \n Operator:  Thank you.  We'll next go to Glen Santangelo with Guggenheim.  Please go ahead.  \n \n Glen Santangelo:  Oh, yes.  Thanks for taking my question. ", "original_text": "We'll next go to Glen Santangelo with Guggenheim. ", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ceb4eaafe375d66ba3cccbfa9c273480cdd4e85209922b464b4f57f9240fbc85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e92ccb7-3c96-4930-98d8-7b3ec07308d7", "node_type": "1", "metadata": {"window": "Operator:  Thank you.  We'll next go to Glen Santangelo with Guggenheim.  Please go ahead.  \n \n Glen Santangelo:  Oh, yes.  Thanks for taking my question.  Jason, I just wanted to follow -up on some \nof the comments you made with  respect to the COVID impact on the fiscal 21 guidance.  I think you \nsaid you expect another 100 million of a headwind in fiscal 21 consistent with fiscal 20 -- is that \nanother 100 million or is that an incremental 100 million above? ", "original_text": "Glen Santangelo:  Oh, yes. "}, "hash": "e42a94d1621605cb458f8e6fdd3621a6cdb3f32761db70d0f9ef88b5c6fbf51b", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 716, "end_char_idx": 737, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e92ccb7-3c96-4930-98d8-7b3ec07308d7": {"__data__": {"id_": "2e92ccb7-3c96-4930-98d8-7b3ec07308d7", "embedding": null, "metadata": {"window": "Operator:  Thank you.  We'll next go to Glen Santangelo with Guggenheim.  Please go ahead.  \n \n Glen Santangelo:  Oh, yes.  Thanks for taking my question.  Jason, I just wanted to follow -up on some \nof the comments you made with  respect to the COVID impact on the fiscal 21 guidance.  I think you \nsaid you expect another 100 million of a headwind in fiscal 21 consistent with fiscal 20 -- is that \nanother 100 million or is that an incremental 100 million above? ", "original_text": "Glen Santangelo:  Oh, yes. ", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d48d411-660e-4844-a192-428ac1781c55", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45d34c87a19feb70878c1cd8aa9d34a011438b413ad9c933f412d4c9b5d36074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24e149cf-2cb5-49c5-9032-8a64b287efdd", "node_type": "1", "metadata": {"window": "Next question?  \n \n Operator:  Thank you.  We'll next go to Glen Santangelo with Guggenheim.  Please go ahead.  \n \n Glen Santangelo:  Oh, yes.  Thanks for taking my question.  Jason, I just wanted to follow -up on some \nof the comments you made with  respect to the COVID impact on the fiscal 21 guidance. ", "original_text": "Please go ahead.  \n \n", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ee44dbcf29d90776c4e532c0e5113e98405a6176dc5c7f9ae8f7dc6b3f137527", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "907b1ef8-2ee4-4e6c-899b-158f63a19e2e", "node_type": "1", "metadata": {"window": "We'll next go to Glen Santangelo with Guggenheim.  Please go ahead.  \n \n Glen Santangelo:  Oh, yes.  Thanks for taking my question.  Jason, I just wanted to follow -up on some \nof the comments you made with  respect to the COVID impact on the fiscal 21 guidance.  I think you \nsaid you expect another 100 million of a headwind in fiscal 21 consistent with fiscal 20 -- is that \nanother 100 million or is that an incremental 100 million above?  I'm just trying to figu re out if that's a, \nyou know, a roughly 25 cent impact you're calling out or a 50 cent impact you're calling out. ", "original_text": "Thanks for taking my question. "}, "hash": "051ffdc9176254b9f26df407f6da982083b0c0a31f089a3b43ba6b08475916ec", "class_name": "RelatedNodeInfo"}}, "text": "Glen Santangelo:  Oh, yes. ", "start_char_idx": 737, "end_char_idx": 764, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "907b1ef8-2ee4-4e6c-899b-158f63a19e2e": {"__data__": {"id_": "907b1ef8-2ee4-4e6c-899b-158f63a19e2e", "embedding": null, "metadata": {"window": "We'll next go to Glen Santangelo with Guggenheim.  Please go ahead.  \n \n Glen Santangelo:  Oh, yes.  Thanks for taking my question.  Jason, I just wanted to follow -up on some \nof the comments you made with  respect to the COVID impact on the fiscal 21 guidance.  I think you \nsaid you expect another 100 million of a headwind in fiscal 21 consistent with fiscal 20 -- is that \nanother 100 million or is that an incremental 100 million above?  I'm just trying to figu re out if that's a, \nyou know, a roughly 25 cent impact you're calling out or a 50 cent impact you're calling out. ", "original_text": "Thanks for taking my question. ", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d48d411-660e-4844-a192-428ac1781c55", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45d34c87a19feb70878c1cd8aa9d34a011438b413ad9c933f412d4c9b5d36074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e92ccb7-3c96-4930-98d8-7b3ec07308d7", "node_type": "1", "metadata": {"window": "Operator:  Thank you.  We'll next go to Glen Santangelo with Guggenheim.  Please go ahead.  \n \n Glen Santangelo:  Oh, yes.  Thanks for taking my question.  Jason, I just wanted to follow -up on some \nof the comments you made with  respect to the COVID impact on the fiscal 21 guidance.  I think you \nsaid you expect another 100 million of a headwind in fiscal 21 consistent with fiscal 20 -- is that \nanother 100 million or is that an incremental 100 million above? ", "original_text": "Glen Santangelo:  Oh, yes. ", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6ff2a396c8c8c7c1eac4bda097790dbdc30a91e27dee899d776965ea395da841", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e03567a3-26ba-4130-bf32-01f16c46528f", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Glen Santangelo:  Oh, yes.  Thanks for taking my question.  Jason, I just wanted to follow -up on some \nof the comments you made with  respect to the COVID impact on the fiscal 21 guidance.  I think you \nsaid you expect another 100 million of a headwind in fiscal 21 consistent with fiscal 20 -- is that \nanother 100 million or is that an incremental 100 million above?  I'm just trying to figu re out if that's a, \nyou know, a roughly 25 cent impact you're calling out or a 50 cent impact you're calling out.  Thank \nyou. \n ", "original_text": "Jason, I just wanted to follow -up on some \nof the comments you made with  respect to the COVID impact on the fiscal 21 guidance. "}, "hash": "6e2eb6599fe01d0f87f052c7eb6083b047a58839d93388e5f676b068d72ad9c0", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking my question. ", "start_char_idx": 764, "end_char_idx": 795, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e03567a3-26ba-4130-bf32-01f16c46528f": {"__data__": {"id_": "e03567a3-26ba-4130-bf32-01f16c46528f", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Glen Santangelo:  Oh, yes.  Thanks for taking my question.  Jason, I just wanted to follow -up on some \nof the comments you made with  respect to the COVID impact on the fiscal 21 guidance.  I think you \nsaid you expect another 100 million of a headwind in fiscal 21 consistent with fiscal 20 -- is that \nanother 100 million or is that an incremental 100 million above?  I'm just trying to figu re out if that's a, \nyou know, a roughly 25 cent impact you're calling out or a 50 cent impact you're calling out.  Thank \nyou. \n ", "original_text": "Jason, I just wanted to follow -up on some \nof the comments you made with  respect to the COVID impact on the fiscal 21 guidance. ", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d48d411-660e-4844-a192-428ac1781c55", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45d34c87a19feb70878c1cd8aa9d34a011438b413ad9c933f412d4c9b5d36074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "907b1ef8-2ee4-4e6c-899b-158f63a19e2e", "node_type": "1", "metadata": {"window": "We'll next go to Glen Santangelo with Guggenheim.  Please go ahead.  \n \n Glen Santangelo:  Oh, yes.  Thanks for taking my question.  Jason, I just wanted to follow -up on some \nof the comments you made with  respect to the COVID impact on the fiscal 21 guidance.  I think you \nsaid you expect another 100 million of a headwind in fiscal 21 consistent with fiscal 20 -- is that \nanother 100 million or is that an incremental 100 million above?  I'm just trying to figu re out if that's a, \nyou know, a roughly 25 cent impact you're calling out or a 50 cent impact you're calling out. ", "original_text": "Thanks for taking my question. ", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "acc69a4903d72a32811fb1e263b4bd8aab4898e0b333b257b3fb3bf380c892df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bdfa4baa-65ea-4e8f-bc84-7e4faac40cf5", "node_type": "1", "metadata": {"window": "Glen Santangelo:  Oh, yes.  Thanks for taking my question.  Jason, I just wanted to follow -up on some \nof the comments you made with  respect to the COVID impact on the fiscal 21 guidance.  I think you \nsaid you expect another 100 million of a headwind in fiscal 21 consistent with fiscal 20 -- is that \nanother 100 million or is that an incremental 100 million above?  I'm just trying to figu re out if that's a, \nyou know, a roughly 25 cent impact you're calling out or a 50 cent impact you're calling out.  Thank \nyou. \n ", "original_text": "I think you \nsaid you expect another 100 million of a headwind in fiscal 21 consistent with fiscal 20 -- is that \nanother 100 million or is that an incremental 100 million above? "}, "hash": "dcb366f7437a3a1615e90ab57fcc985a7e0fb6db4945531469fa4d602afec6c3", "class_name": "RelatedNodeInfo"}}, "text": "Jason, I just wanted to follow -up on some \nof the comments you made with  respect to the COVID impact on the fiscal 21 guidance. ", "start_char_idx": 795, "end_char_idx": 925, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bdfa4baa-65ea-4e8f-bc84-7e4faac40cf5": {"__data__": {"id_": "bdfa4baa-65ea-4e8f-bc84-7e4faac40cf5", "embedding": null, "metadata": {"window": "Glen Santangelo:  Oh, yes.  Thanks for taking my question.  Jason, I just wanted to follow -up on some \nof the comments you made with  respect to the COVID impact on the fiscal 21 guidance.  I think you \nsaid you expect another 100 million of a headwind in fiscal 21 consistent with fiscal 20 -- is that \nanother 100 million or is that an incremental 100 million above?  I'm just trying to figu re out if that's a, \nyou know, a roughly 25 cent impact you're calling out or a 50 cent impact you're calling out.  Thank \nyou. \n ", "original_text": "I think you \nsaid you expect another 100 million of a headwind in fiscal 21 consistent with fiscal 20 -- is that \nanother 100 million or is that an incremental 100 million above? ", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d48d411-660e-4844-a192-428ac1781c55", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45d34c87a19feb70878c1cd8aa9d34a011438b413ad9c933f412d4c9b5d36074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e03567a3-26ba-4130-bf32-01f16c46528f", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Glen Santangelo:  Oh, yes.  Thanks for taking my question.  Jason, I just wanted to follow -up on some \nof the comments you made with  respect to the COVID impact on the fiscal 21 guidance.  I think you \nsaid you expect another 100 million of a headwind in fiscal 21 consistent with fiscal 20 -- is that \nanother 100 million or is that an incremental 100 million above?  I'm just trying to figu re out if that's a, \nyou know, a roughly 25 cent impact you're calling out or a 50 cent impact you're calling out.  Thank \nyou. \n ", "original_text": "Jason, I just wanted to follow -up on some \nof the comments you made with  respect to the COVID impact on the fiscal 21 guidance. ", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca0006cc8d086628350b0a51ba130626011ca851aaae142755a65dbfb4d02e83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "006ba99f-645b-44be-8fd1-db2e4117b617", "node_type": "1", "metadata": {"window": "Thanks for taking my question.  Jason, I just wanted to follow -up on some \nof the comments you made with  respect to the COVID impact on the fiscal 21 guidance.  I think you \nsaid you expect another 100 million of a headwind in fiscal 21 consistent with fiscal 20 -- is that \nanother 100 million or is that an incremental 100 million above?  I'm just trying to figu re out if that's a, \nyou know, a roughly 25 cent impact you're calling out or a 50 cent impact you're calling out.  Thank \nyou. \n ", "original_text": "I'm just trying to figu re out if that's a, \nyou know, a roughly 25 cent impact you're calling out or a 50 cent impact you're calling out. "}, "hash": "57ac6bd4c043faca9f2a5bfaff07d4c5028fd17171a611fb42966dc3b1684911", "class_name": "RelatedNodeInfo"}}, "text": "I think you \nsaid you expect another 100 million of a headwind in fiscal 21 consistent with fiscal 20 -- is that \nanother 100 million or is that an incremental 100 million above? ", "start_char_idx": 925, "end_char_idx": 1104, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "006ba99f-645b-44be-8fd1-db2e4117b617": {"__data__": {"id_": "006ba99f-645b-44be-8fd1-db2e4117b617", "embedding": null, "metadata": {"window": "Thanks for taking my question.  Jason, I just wanted to follow -up on some \nof the comments you made with  respect to the COVID impact on the fiscal 21 guidance.  I think you \nsaid you expect another 100 million of a headwind in fiscal 21 consistent with fiscal 20 -- is that \nanother 100 million or is that an incremental 100 million above?  I'm just trying to figu re out if that's a, \nyou know, a roughly 25 cent impact you're calling out or a 50 cent impact you're calling out.  Thank \nyou. \n ", "original_text": "I'm just trying to figu re out if that's a, \nyou know, a roughly 25 cent impact you're calling out or a 50 cent impact you're calling out. ", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d48d411-660e-4844-a192-428ac1781c55", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45d34c87a19feb70878c1cd8aa9d34a011438b413ad9c933f412d4c9b5d36074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bdfa4baa-65ea-4e8f-bc84-7e4faac40cf5", "node_type": "1", "metadata": {"window": "Glen Santangelo:  Oh, yes.  Thanks for taking my question.  Jason, I just wanted to follow -up on some \nof the comments you made with  respect to the COVID impact on the fiscal 21 guidance.  I think you \nsaid you expect another 100 million of a headwind in fiscal 21 consistent with fiscal 20 -- is that \nanother 100 million or is that an incremental 100 million above?  I'm just trying to figu re out if that's a, \nyou know, a roughly 25 cent impact you're calling out or a 50 cent impact you're calling out.  Thank \nyou. \n ", "original_text": "I think you \nsaid you expect another 100 million of a headwind in fiscal 21 consistent with fiscal 20 -- is that \nanother 100 million or is that an incremental 100 million above? ", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08c3e04a5e40a57c35b4f46c0300c4c3b2f410373d65bac814bc3d8d7921c75a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63135c5b-aece-4b14-b625-49f80fedd5e2", "node_type": "1", "metadata": {"window": "Jason, I just wanted to follow -up on some \nof the comments you made with  respect to the COVID impact on the fiscal 21 guidance.  I think you \nsaid you expect another 100 million of a headwind in fiscal 21 consistent with fiscal 20 -- is that \nanother 100 million or is that an incremental 100 million above?  I'm just trying to figu re out if that's a, \nyou know, a roughly 25 cent impact you're calling out or a 50 cent impact you're calling out.  Thank \nyou. \n ", "original_text": "Thank \nyou. \n "}, "hash": "8884ed03de4aca279dd74bfa9e18766337b5ab5ee4d1e1c1481d80184baf45b7", "class_name": "RelatedNodeInfo"}}, "text": "I'm just trying to figu re out if that's a, \nyou know, a roughly 25 cent impact you're calling out or a 50 cent impact you're calling out. ", "start_char_idx": 1104, "end_char_idx": 1243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63135c5b-aece-4b14-b625-49f80fedd5e2": {"__data__": {"id_": "63135c5b-aece-4b14-b625-49f80fedd5e2", "embedding": null, "metadata": {"window": "Jason, I just wanted to follow -up on some \nof the comments you made with  respect to the COVID impact on the fiscal 21 guidance.  I think you \nsaid you expect another 100 million of a headwind in fiscal 21 consistent with fiscal 20 -- is that \nanother 100 million or is that an incremental 100 million above?  I'm just trying to figu re out if that's a, \nyou know, a roughly 25 cent impact you're calling out or a 50 cent impact you're calling out.  Thank \nyou. \n ", "original_text": "Thank \nyou. \n ", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d48d411-660e-4844-a192-428ac1781c55", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45d34c87a19feb70878c1cd8aa9d34a011438b413ad9c933f412d4c9b5d36074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "006ba99f-645b-44be-8fd1-db2e4117b617", "node_type": "1", "metadata": {"window": "Thanks for taking my question.  Jason, I just wanted to follow -up on some \nof the comments you made with  respect to the COVID impact on the fiscal 21 guidance.  I think you \nsaid you expect another 100 million of a headwind in fiscal 21 consistent with fiscal 20 -- is that \nanother 100 million or is that an incremental 100 million above?  I'm just trying to figu re out if that's a, \nyou know, a roughly 25 cent impact you're calling out or a 50 cent impact you're calling out.  Thank \nyou. \n ", "original_text": "I'm just trying to figu re out if that's a, \nyou know, a roughly 25 cent impact you're calling out or a 50 cent impact you're calling out. ", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5430aa535058e9739f12eec716418766fa2d1ab6287dca799d4f7ba84414ab51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "961ff273-9706-4913-af13-309cfacedb2d", "node_type": "1", "metadata": {"window": " \nPage 16 of 31 \n \nJason Hollar:  Yes, it's an - yes, thank you for the question.  It is an additional incremental headwind of \na similar magnitude of what we saw in 20.  \n \n  And just to give you a little bit more perspective, in 20 we saw that fairly well -balanced \nbetween the two different segments, between Med and Pharma, in 21, because of some of the \nreasons Mike just talked about that were a little bit more impactful for Medical.  We would expect there \nto be a bit of an overweighting of the impact on Medical vs. ", "original_text": " \nPage 16 of 31 \n \nJason Hollar:  Yes, it's an - yes, thank you for the question. "}, "hash": "59e7f39618d8b9f379406bd2ddc5945d44fc038fdf93fa6ba97827b382683c3c", "class_name": "RelatedNodeInfo"}}, "text": "Thank \nyou. \n ", "start_char_idx": 1243, "end_char_idx": 1257, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "961ff273-9706-4913-af13-309cfacedb2d": {"__data__": {"id_": "961ff273-9706-4913-af13-309cfacedb2d", "embedding": null, "metadata": {"window": " \nPage 16 of 31 \n \nJason Hollar:  Yes, it's an - yes, thank you for the question.  It is an additional incremental headwind of \na similar magnitude of what we saw in 20.  \n \n  And just to give you a little bit more perspective, in 20 we saw that fairly well -balanced \nbetween the two different segments, between Med and Pharma, in 21, because of some of the \nreasons Mike just talked about that were a little bit more impactful for Medical.  We would expect there \nto be a bit of an overweighting of the impact on Medical vs. ", "original_text": " \nPage 16 of 31 \n \nJason Hollar:  Yes, it's an - yes, thank you for the question. ", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35c2ff74e448a1dbc2796e512848899f9dbb32e3c8ea9505ece1df5c9fb5959a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63135c5b-aece-4b14-b625-49f80fedd5e2", "node_type": "1", "metadata": {"window": "Jason, I just wanted to follow -up on some \nof the comments you made with  respect to the COVID impact on the fiscal 21 guidance.  I think you \nsaid you expect another 100 million of a headwind in fiscal 21 consistent with fiscal 20 -- is that \nanother 100 million or is that an incremental 100 million above?  I'm just trying to figu re out if that's a, \nyou know, a roughly 25 cent impact you're calling out or a 50 cent impact you're calling out.  Thank \nyou. \n ", "original_text": "Thank \nyou. \n ", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0932c543856ed97b651a65f9df154f3341a06be53726e8d4ba64b6229af45e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "810ec6fb-4482-443c-875e-7e0158325da9", "node_type": "1", "metadata": {"window": " \nPage 16 of 31 \n \nJason Hollar:  Yes, it's an - yes, thank you for the question.  It is an additional incremental headwind of \na similar magnitude of what we saw in 20.  \n \n  And just to give you a little bit more perspective, in 20 we saw that fairly well -balanced \nbetween the two different segments, between Med and Pharma, in 21, because of some of the \nreasons Mike just talked about that were a little bit more impactful for Medical.  We would expect there \nto be a bit of an overweighting of the impact on Medical vs.  Pharma.  \n \n", "original_text": "It is an additional incremental headwind of \na similar magnitude of what we saw in 20.  \n \n "}, "hash": "c95a3ac7dee398c7626a5eb0ab0b578bc751c3a88591d6a77c652ab969a564d0", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 16 of 31 \n \nJason Hollar:  Yes, it's an - yes, thank you for the question. ", "start_char_idx": 0, "end_char_idx": 82, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "810ec6fb-4482-443c-875e-7e0158325da9": {"__data__": {"id_": "810ec6fb-4482-443c-875e-7e0158325da9", "embedding": null, "metadata": {"window": " \nPage 16 of 31 \n \nJason Hollar:  Yes, it's an - yes, thank you for the question.  It is an additional incremental headwind of \na similar magnitude of what we saw in 20.  \n \n  And just to give you a little bit more perspective, in 20 we saw that fairly well -balanced \nbetween the two different segments, between Med and Pharma, in 21, because of some of the \nreasons Mike just talked about that were a little bit more impactful for Medical.  We would expect there \nto be a bit of an overweighting of the impact on Medical vs.  Pharma.  \n \n", "original_text": "It is an additional incremental headwind of \na similar magnitude of what we saw in 20.  \n \n ", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35c2ff74e448a1dbc2796e512848899f9dbb32e3c8ea9505ece1df5c9fb5959a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "961ff273-9706-4913-af13-309cfacedb2d", "node_type": "1", "metadata": {"window": " \nPage 16 of 31 \n \nJason Hollar:  Yes, it's an - yes, thank you for the question.  It is an additional incremental headwind of \na similar magnitude of what we saw in 20.  \n \n  And just to give you a little bit more perspective, in 20 we saw that fairly well -balanced \nbetween the two different segments, between Med and Pharma, in 21, because of some of the \nreasons Mike just talked about that were a little bit more impactful for Medical.  We would expect there \nto be a bit of an overweighting of the impact on Medical vs. ", "original_text": " \nPage 16 of 31 \n \nJason Hollar:  Yes, it's an - yes, thank you for the question. ", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cbdf72611da604b17d2efc64c477420e2abb094fbbfb2addb6305d318b7214c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b79b9ef2-d8b4-4891-b6c5-60c22598f751", "node_type": "1", "metadata": {"window": " \nPage 16 of 31 \n \nJason Hollar:  Yes, it's an - yes, thank you for the question.  It is an additional incremental headwind of \na similar magnitude of what we saw in 20.  \n \n  And just to give you a little bit more perspective, in 20 we saw that fairly well -balanced \nbetween the two different segments, between Med and Pharma, in 21, because of some of the \nreasons Mike just talked about that were a little bit more impactful for Medical.  We would expect there \nto be a bit of an overweighting of the impact on Medical vs.  Pharma.  \n \n Mike Kauffman: Thank you for the question. ", "original_text": "And just to give you a little bit more perspective, in 20 we saw that fairly well -balanced \nbetween the two different segments, between Med and Pharma, in 21, because of some of the \nreasons Mike just talked about that were a little bit more impactful for Medical. "}, "hash": "35a9e1d378ccaf0bf21fc56fd37ac8cf44cfb1ff05c1855599d802e5ea29e32c", "class_name": "RelatedNodeInfo"}}, "text": "It is an additional incremental headwind of \na similar magnitude of what we saw in 20.  \n \n ", "start_char_idx": 82, "end_char_idx": 174, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b79b9ef2-d8b4-4891-b6c5-60c22598f751": {"__data__": {"id_": "b79b9ef2-d8b4-4891-b6c5-60c22598f751", "embedding": null, "metadata": {"window": " \nPage 16 of 31 \n \nJason Hollar:  Yes, it's an - yes, thank you for the question.  It is an additional incremental headwind of \na similar magnitude of what we saw in 20.  \n \n  And just to give you a little bit more perspective, in 20 we saw that fairly well -balanced \nbetween the two different segments, between Med and Pharma, in 21, because of some of the \nreasons Mike just talked about that were a little bit more impactful for Medical.  We would expect there \nto be a bit of an overweighting of the impact on Medical vs.  Pharma.  \n \n Mike Kauffman: Thank you for the question. ", "original_text": "And just to give you a little bit more perspective, in 20 we saw that fairly well -balanced \nbetween the two different segments, between Med and Pharma, in 21, because of some of the \nreasons Mike just talked about that were a little bit more impactful for Medical. ", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35c2ff74e448a1dbc2796e512848899f9dbb32e3c8ea9505ece1df5c9fb5959a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "810ec6fb-4482-443c-875e-7e0158325da9", "node_type": "1", "metadata": {"window": " \nPage 16 of 31 \n \nJason Hollar:  Yes, it's an - yes, thank you for the question.  It is an additional incremental headwind of \na similar magnitude of what we saw in 20.  \n \n  And just to give you a little bit more perspective, in 20 we saw that fairly well -balanced \nbetween the two different segments, between Med and Pharma, in 21, because of some of the \nreasons Mike just talked about that were a little bit more impactful for Medical.  We would expect there \nto be a bit of an overweighting of the impact on Medical vs.  Pharma.  \n \n", "original_text": "It is an additional incremental headwind of \na similar magnitude of what we saw in 20.  \n \n ", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d1225a0ccc03f874e2347b23a268fd523e4334536c613a7f854fc11c8eb3051", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2ab5e62-852c-4f83-94f0-29661f6c1e7c", "node_type": "1", "metadata": {"window": " \nPage 16 of 31 \n \nJason Hollar:  Yes, it's an - yes, thank you for the question.  It is an additional incremental headwind of \na similar magnitude of what we saw in 20.  \n \n  And just to give you a little bit more perspective, in 20 we saw that fairly well -balanced \nbetween the two different segments, between Med and Pharma, in 21, because of some of the \nreasons Mike just talked about that were a little bit more impactful for Medical.  We would expect there \nto be a bit of an overweighting of the impact on Medical vs.  Pharma.  \n \n Mike Kauffman: Thank you for the question.  Next question.  \n \n", "original_text": "We would expect there \nto be a bit of an overweighting of the impact on Medical vs. "}, "hash": "633883141e807bf09e2d75f715e2f000b01ac6f833177267223b62593db6eab0", "class_name": "RelatedNodeInfo"}}, "text": "And just to give you a little bit more perspective, in 20 we saw that fairly well -balanced \nbetween the two different segments, between Med and Pharma, in 21, because of some of the \nreasons Mike just talked about that were a little bit more impactful for Medical. ", "start_char_idx": 174, "end_char_idx": 440, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2ab5e62-852c-4f83-94f0-29661f6c1e7c": {"__data__": {"id_": "f2ab5e62-852c-4f83-94f0-29661f6c1e7c", "embedding": null, "metadata": {"window": " \nPage 16 of 31 \n \nJason Hollar:  Yes, it's an - yes, thank you for the question.  It is an additional incremental headwind of \na similar magnitude of what we saw in 20.  \n \n  And just to give you a little bit more perspective, in 20 we saw that fairly well -balanced \nbetween the two different segments, between Med and Pharma, in 21, because of some of the \nreasons Mike just talked about that were a little bit more impactful for Medical.  We would expect there \nto be a bit of an overweighting of the impact on Medical vs.  Pharma.  \n \n Mike Kauffman: Thank you for the question.  Next question.  \n \n", "original_text": "We would expect there \nto be a bit of an overweighting of the impact on Medical vs. ", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35c2ff74e448a1dbc2796e512848899f9dbb32e3c8ea9505ece1df5c9fb5959a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b79b9ef2-d8b4-4891-b6c5-60c22598f751", "node_type": "1", "metadata": {"window": " \nPage 16 of 31 \n \nJason Hollar:  Yes, it's an - yes, thank you for the question.  It is an additional incremental headwind of \na similar magnitude of what we saw in 20.  \n \n  And just to give you a little bit more perspective, in 20 we saw that fairly well -balanced \nbetween the two different segments, between Med and Pharma, in 21, because of some of the \nreasons Mike just talked about that were a little bit more impactful for Medical.  We would expect there \nto be a bit of an overweighting of the impact on Medical vs.  Pharma.  \n \n Mike Kauffman: Thank you for the question. ", "original_text": "And just to give you a little bit more perspective, in 20 we saw that fairly well -balanced \nbetween the two different segments, between Med and Pharma, in 21, because of some of the \nreasons Mike just talked about that were a little bit more impactful for Medical. ", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e5d9e8cc935c30354d71a4c3659014b914b685eb733acce063de2dcec4a0105", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fdf7b348-96e9-4915-8fea-4e9db5febf8a", "node_type": "1", "metadata": {"window": "It is an additional incremental headwind of \na similar magnitude of what we saw in 20.  \n \n  And just to give you a little bit more perspective, in 20 we saw that fairly well -balanced \nbetween the two different segments, between Med and Pharma, in 21, because of some of the \nreasons Mike just talked about that were a little bit more impactful for Medical.  We would expect there \nto be a bit of an overweighting of the impact on Medical vs.  Pharma.  \n \n Mike Kauffman: Thank you for the question.  Next question.  \n \n Operator:  Thank you. ", "original_text": "Pharma.  \n \n"}, "hash": "e44ac004c158dc117999eaa6b55c5ac694f6b328bc188cc3a8f82c01fbf94c94", "class_name": "RelatedNodeInfo"}}, "text": "We would expect there \nto be a bit of an overweighting of the impact on Medical vs. ", "start_char_idx": 440, "end_char_idx": 524, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fdf7b348-96e9-4915-8fea-4e9db5febf8a": {"__data__": {"id_": "fdf7b348-96e9-4915-8fea-4e9db5febf8a", "embedding": null, "metadata": {"window": "It is an additional incremental headwind of \na similar magnitude of what we saw in 20.  \n \n  And just to give you a little bit more perspective, in 20 we saw that fairly well -balanced \nbetween the two different segments, between Med and Pharma, in 21, because of some of the \nreasons Mike just talked about that were a little bit more impactful for Medical.  We would expect there \nto be a bit of an overweighting of the impact on Medical vs.  Pharma.  \n \n Mike Kauffman: Thank you for the question.  Next question.  \n \n Operator:  Thank you. ", "original_text": "Pharma.  \n \n", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35c2ff74e448a1dbc2796e512848899f9dbb32e3c8ea9505ece1df5c9fb5959a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2ab5e62-852c-4f83-94f0-29661f6c1e7c", "node_type": "1", "metadata": {"window": " \nPage 16 of 31 \n \nJason Hollar:  Yes, it's an - yes, thank you for the question.  It is an additional incremental headwind of \na similar magnitude of what we saw in 20.  \n \n  And just to give you a little bit more perspective, in 20 we saw that fairly well -balanced \nbetween the two different segments, between Med and Pharma, in 21, because of some of the \nreasons Mike just talked about that were a little bit more impactful for Medical.  We would expect there \nto be a bit of an overweighting of the impact on Medical vs.  Pharma.  \n \n Mike Kauffman: Thank you for the question.  Next question.  \n \n", "original_text": "We would expect there \nto be a bit of an overweighting of the impact on Medical vs. ", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a655ec1554e9e293040426a585d25b2b954e3d265aabe0383fd624266886e28d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a62aa45-38b3-4ae1-b681-23006967f893", "node_type": "1", "metadata": {"window": "And just to give you a little bit more perspective, in 20 we saw that fairly well -balanced \nbetween the two different segments, between Med and Pharma, in 21, because of some of the \nreasons Mike just talked about that were a little bit more impactful for Medical.  We would expect there \nto be a bit of an overweighting of the impact on Medical vs.  Pharma.  \n \n Mike Kauffman: Thank you for the question.  Next question.  \n \n Operator:  Thank you.  We'll next go to Elizabeth Anderson, with Evercore.  \n \n", "original_text": "Mike Kauffman: Thank you for the question. "}, "hash": "d0fe3f8b2cac0c406de8f893938e47e231c076ac81381c54ad2f07476f322c3b", "class_name": "RelatedNodeInfo"}}, "text": "Pharma.  \n \n", "start_char_idx": 524, "end_char_idx": 536, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a62aa45-38b3-4ae1-b681-23006967f893": {"__data__": {"id_": "8a62aa45-38b3-4ae1-b681-23006967f893", "embedding": null, "metadata": {"window": "And just to give you a little bit more perspective, in 20 we saw that fairly well -balanced \nbetween the two different segments, between Med and Pharma, in 21, because of some of the \nreasons Mike just talked about that were a little bit more impactful for Medical.  We would expect there \nto be a bit of an overweighting of the impact on Medical vs.  Pharma.  \n \n Mike Kauffman: Thank you for the question.  Next question.  \n \n Operator:  Thank you.  We'll next go to Elizabeth Anderson, with Evercore.  \n \n", "original_text": "Mike Kauffman: Thank you for the question. ", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35c2ff74e448a1dbc2796e512848899f9dbb32e3c8ea9505ece1df5c9fb5959a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fdf7b348-96e9-4915-8fea-4e9db5febf8a", "node_type": "1", "metadata": {"window": "It is an additional incremental headwind of \na similar magnitude of what we saw in 20.  \n \n  And just to give you a little bit more perspective, in 20 we saw that fairly well -balanced \nbetween the two different segments, between Med and Pharma, in 21, because of some of the \nreasons Mike just talked about that were a little bit more impactful for Medical.  We would expect there \nto be a bit of an overweighting of the impact on Medical vs.  Pharma.  \n \n Mike Kauffman: Thank you for the question.  Next question.  \n \n Operator:  Thank you. ", "original_text": "Pharma.  \n \n", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "391b10b27c65fce218cd5d8f246544ef2213515eac771d90395e7bdef404b74f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57b93a0b-bf70-42d9-998d-1a5c2e3ee73b", "node_type": "1", "metadata": {"window": "We would expect there \nto be a bit of an overweighting of the impact on Medical vs.  Pharma.  \n \n Mike Kauffman: Thank you for the question.  Next question.  \n \n Operator:  Thank you.  We'll next go to Elizabeth Anderson, with Evercore.  \n \n Joe Amato:  Hi, this is Joe Amato, on for Elizabeth. ", "original_text": "Next question.  \n \n"}, "hash": "61367df21fd275bb511f3c70bf44918edb3981bded0f2818f6a4e01ed328e005", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kauffman: Thank you for the question. ", "start_char_idx": 536, "end_char_idx": 579, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57b93a0b-bf70-42d9-998d-1a5c2e3ee73b": {"__data__": {"id_": "57b93a0b-bf70-42d9-998d-1a5c2e3ee73b", "embedding": null, "metadata": {"window": "We would expect there \nto be a bit of an overweighting of the impact on Medical vs.  Pharma.  \n \n Mike Kauffman: Thank you for the question.  Next question.  \n \n Operator:  Thank you.  We'll next go to Elizabeth Anderson, with Evercore.  \n \n Joe Amato:  Hi, this is Joe Amato, on for Elizabeth. ", "original_text": "Next question.  \n \n", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35c2ff74e448a1dbc2796e512848899f9dbb32e3c8ea9505ece1df5c9fb5959a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a62aa45-38b3-4ae1-b681-23006967f893", "node_type": "1", "metadata": {"window": "And just to give you a little bit more perspective, in 20 we saw that fairly well -balanced \nbetween the two different segments, between Med and Pharma, in 21, because of some of the \nreasons Mike just talked about that were a little bit more impactful for Medical.  We would expect there \nto be a bit of an overweighting of the impact on Medical vs.  Pharma.  \n \n Mike Kauffman: Thank you for the question.  Next question.  \n \n Operator:  Thank you.  We'll next go to Elizabeth Anderson, with Evercore.  \n \n", "original_text": "Mike Kauffman: Thank you for the question. ", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fc1db9203c07782bdd30990fa5113a2a3abe96de07ab0e1dc1d148c284dbe1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c7ad0f7-33e0-4da6-be43-87d32cd4276e", "node_type": "1", "metadata": {"window": "Pharma.  \n \n Mike Kauffman: Thank you for the question.  Next question.  \n \n Operator:  Thank you.  We'll next go to Elizabeth Anderson, with Evercore.  \n \n Joe Amato:  Hi, this is Joe Amato, on for Elizabeth.  I just have another question on the Medical side.  \n \n ", "original_text": "Operator:  Thank you. "}, "hash": "2d5fac63bad6aee1c0341caeeff2cc2909832a36b784f8979878fe19589ca274", "class_name": "RelatedNodeInfo"}}, "text": "Next question.  \n \n", "start_char_idx": 579, "end_char_idx": 598, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c7ad0f7-33e0-4da6-be43-87d32cd4276e": {"__data__": {"id_": "1c7ad0f7-33e0-4da6-be43-87d32cd4276e", "embedding": null, "metadata": {"window": "Pharma.  \n \n Mike Kauffman: Thank you for the question.  Next question.  \n \n Operator:  Thank you.  We'll next go to Elizabeth Anderson, with Evercore.  \n \n Joe Amato:  Hi, this is Joe Amato, on for Elizabeth.  I just have another question on the Medical side.  \n \n ", "original_text": "Operator:  Thank you. ", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35c2ff74e448a1dbc2796e512848899f9dbb32e3c8ea9505ece1df5c9fb5959a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57b93a0b-bf70-42d9-998d-1a5c2e3ee73b", "node_type": "1", "metadata": {"window": "We would expect there \nto be a bit of an overweighting of the impact on Medical vs.  Pharma.  \n \n Mike Kauffman: Thank you for the question.  Next question.  \n \n Operator:  Thank you.  We'll next go to Elizabeth Anderson, with Evercore.  \n \n Joe Amato:  Hi, this is Joe Amato, on for Elizabeth. ", "original_text": "Next question.  \n \n", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c751294cdd2ba9d9ee870b431c50bcb2e71181d04ad2180b3ef5211e2ff0cca0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e4f140f-d5f9-45a3-960b-f04569cda6f5", "node_type": "1", "metadata": {"window": "Mike Kauffman: Thank you for the question.  Next question.  \n \n Operator:  Thank you.  We'll next go to Elizabeth Anderson, with Evercore.  \n \n Joe Amato:  Hi, this is Joe Amato, on for Elizabeth.  I just have another question on the Medical side.  \n \n  Just is there anything you've been seeing in terms of volumes on the alternate site and acute \ncare settings? ", "original_text": "We'll next go to Elizabeth Anderson, with Evercore.  \n \n"}, "hash": "74f7b7b1d053bfc4204b4859e25e981f5d41cdcf17f9205556ad8af29df693bf", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you. ", "start_char_idx": 598, "end_char_idx": 620, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e4f140f-d5f9-45a3-960b-f04569cda6f5": {"__data__": {"id_": "9e4f140f-d5f9-45a3-960b-f04569cda6f5", "embedding": null, "metadata": {"window": "Mike Kauffman: Thank you for the question.  Next question.  \n \n Operator:  Thank you.  We'll next go to Elizabeth Anderson, with Evercore.  \n \n Joe Amato:  Hi, this is Joe Amato, on for Elizabeth.  I just have another question on the Medical side.  \n \n  Just is there anything you've been seeing in terms of volumes on the alternate site and acute \ncare settings? ", "original_text": "We'll next go to Elizabeth Anderson, with Evercore.  \n \n", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35c2ff74e448a1dbc2796e512848899f9dbb32e3c8ea9505ece1df5c9fb5959a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c7ad0f7-33e0-4da6-be43-87d32cd4276e", "node_type": "1", "metadata": {"window": "Pharma.  \n \n Mike Kauffman: Thank you for the question.  Next question.  \n \n Operator:  Thank you.  We'll next go to Elizabeth Anderson, with Evercore.  \n \n Joe Amato:  Hi, this is Joe Amato, on for Elizabeth.  I just have another question on the Medical side.  \n \n ", "original_text": "Operator:  Thank you. ", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0de0c21578f31df6ec0a7fb872f15cd41d29ea197a45bec38d7bb25dd0d49d56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a13ed5c-7224-43ed-a7cb-d467fde8cc02", "node_type": "1", "metadata": {"window": "Next question.  \n \n Operator:  Thank you.  We'll next go to Elizabeth Anderson, with Evercore.  \n \n Joe Amato:  Hi, this is Joe Amato, on for Elizabeth.  I just have another question on the Medical side.  \n \n  Just is there anything you've been seeing in terms of volumes on the alternate site and acute \ncare settings?  Sort of as doctor visits and elective proced ures start to resume a bit? ", "original_text": "Joe Amato:  Hi, this is Joe Amato, on for Elizabeth. "}, "hash": "7ffc0f041e6979e535ecab74c4422475cfc95ab27b1b7c5fd86ff75e98bb8a1a", "class_name": "RelatedNodeInfo"}}, "text": "We'll next go to Elizabeth Anderson, with Evercore.  \n \n", "start_char_idx": 620, "end_char_idx": 676, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a13ed5c-7224-43ed-a7cb-d467fde8cc02": {"__data__": {"id_": "8a13ed5c-7224-43ed-a7cb-d467fde8cc02", "embedding": null, "metadata": {"window": "Next question.  \n \n Operator:  Thank you.  We'll next go to Elizabeth Anderson, with Evercore.  \n \n Joe Amato:  Hi, this is Joe Amato, on for Elizabeth.  I just have another question on the Medical side.  \n \n  Just is there anything you've been seeing in terms of volumes on the alternate site and acute \ncare settings?  Sort of as doctor visits and elective proced ures start to resume a bit? ", "original_text": "Joe Amato:  Hi, this is Joe Amato, on for Elizabeth. ", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35c2ff74e448a1dbc2796e512848899f9dbb32e3c8ea9505ece1df5c9fb5959a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e4f140f-d5f9-45a3-960b-f04569cda6f5", "node_type": "1", "metadata": {"window": "Mike Kauffman: Thank you for the question.  Next question.  \n \n Operator:  Thank you.  We'll next go to Elizabeth Anderson, with Evercore.  \n \n Joe Amato:  Hi, this is Joe Amato, on for Elizabeth.  I just have another question on the Medical side.  \n \n  Just is there anything you've been seeing in terms of volumes on the alternate site and acute \ncare settings? ", "original_text": "We'll next go to Elizabeth Anderson, with Evercore.  \n \n", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be3b1a3283ac0a0878ef1c37c2ce809e5d4b3e592167cac30f731208a61e9acc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4bc29345-26de-4925-a3c0-6cc56ed81b94", "node_type": "1", "metadata": {"window": "Operator:  Thank you.  We'll next go to Elizabeth Anderson, with Evercore.  \n \n Joe Amato:  Hi, this is Joe Amato, on for Elizabeth.  I just have another question on the Medical side.  \n \n  Just is there anything you've been seeing in terms of volumes on the alternate site and acute \ncare settings?  Sort of as doctor visits and elective proced ures start to resume a bit?  Thanks.  \n \n", "original_text": "I just have another question on the Medical side.  \n \n "}, "hash": "3aaa1d560b1d5d991b93e86d7f9f5ca753945718b3cbe27623c4002957a4d54c", "class_name": "RelatedNodeInfo"}}, "text": "Joe Amato:  Hi, this is Joe Amato, on for Elizabeth. ", "start_char_idx": 676, "end_char_idx": 729, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4bc29345-26de-4925-a3c0-6cc56ed81b94": {"__data__": {"id_": "4bc29345-26de-4925-a3c0-6cc56ed81b94", "embedding": null, "metadata": {"window": "Operator:  Thank you.  We'll next go to Elizabeth Anderson, with Evercore.  \n \n Joe Amato:  Hi, this is Joe Amato, on for Elizabeth.  I just have another question on the Medical side.  \n \n  Just is there anything you've been seeing in terms of volumes on the alternate site and acute \ncare settings?  Sort of as doctor visits and elective proced ures start to resume a bit?  Thanks.  \n \n", "original_text": "I just have another question on the Medical side.  \n \n ", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35c2ff74e448a1dbc2796e512848899f9dbb32e3c8ea9505ece1df5c9fb5959a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a13ed5c-7224-43ed-a7cb-d467fde8cc02", "node_type": "1", "metadata": {"window": "Next question.  \n \n Operator:  Thank you.  We'll next go to Elizabeth Anderson, with Evercore.  \n \n Joe Amato:  Hi, this is Joe Amato, on for Elizabeth.  I just have another question on the Medical side.  \n \n  Just is there anything you've been seeing in terms of volumes on the alternate site and acute \ncare settings?  Sort of as doctor visits and elective proced ures start to resume a bit? ", "original_text": "Joe Amato:  Hi, this is Joe Amato, on for Elizabeth. ", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3258b11be73a0a0bbb1add741d187459398bb3ff63881bcc77f6f948381b40f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "081b2a83-b4a9-4037-b579-e7ea6e25c542", "node_type": "1", "metadata": {"window": "We'll next go to Elizabeth Anderson, with Evercore.  \n \n Joe Amato:  Hi, this is Joe Amato, on for Elizabeth.  I just have another question on the Medical side.  \n \n  Just is there anything you've been seeing in terms of volumes on the alternate site and acute \ncare settings?  Sort of as doctor visits and elective proced ures start to resume a bit?  Thanks.  \n \n Mike Kauffman:  Yes, again. ", "original_text": "Just is there anything you've been seeing in terms of volumes on the alternate site and acute \ncare settings? "}, "hash": "5e1ce31d0cbf7dbe07df38a9532435dd4d6a48d2b9dcf4bd61718b1fcc1d1228", "class_name": "RelatedNodeInfo"}}, "text": "I just have another question on the Medical side.  \n \n ", "start_char_idx": 729, "end_char_idx": 784, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "081b2a83-b4a9-4037-b579-e7ea6e25c542": {"__data__": {"id_": "081b2a83-b4a9-4037-b579-e7ea6e25c542", "embedding": null, "metadata": {"window": "We'll next go to Elizabeth Anderson, with Evercore.  \n \n Joe Amato:  Hi, this is Joe Amato, on for Elizabeth.  I just have another question on the Medical side.  \n \n  Just is there anything you've been seeing in terms of volumes on the alternate site and acute \ncare settings?  Sort of as doctor visits and elective proced ures start to resume a bit?  Thanks.  \n \n Mike Kauffman:  Yes, again. ", "original_text": "Just is there anything you've been seeing in terms of volumes on the alternate site and acute \ncare settings? ", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35c2ff74e448a1dbc2796e512848899f9dbb32e3c8ea9505ece1df5c9fb5959a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4bc29345-26de-4925-a3c0-6cc56ed81b94", "node_type": "1", "metadata": {"window": "Operator:  Thank you.  We'll next go to Elizabeth Anderson, with Evercore.  \n \n Joe Amato:  Hi, this is Joe Amato, on for Elizabeth.  I just have another question on the Medical side.  \n \n  Just is there anything you've been seeing in terms of volumes on the alternate site and acute \ncare settings?  Sort of as doctor visits and elective proced ures start to resume a bit?  Thanks.  \n \n", "original_text": "I just have another question on the Medical side.  \n \n ", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5367c4b83a6508bf1f880fa0cd3a91de5ba0afb292d60ad995727851ce567a0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd6e5011-44bf-49b0-90f4-ec43c4346d4d", "node_type": "1", "metadata": {"window": "Joe Amato:  Hi, this is Joe Amato, on for Elizabeth.  I just have another question on the Medical side.  \n \n  Just is there anything you've been seeing in terms of volumes on the alternate site and acute \ncare settings?  Sort of as doctor visits and elective proced ures start to resume a bit?  Thanks.  \n \n Mike Kauffman:  Yes, again.  I'll just emphasize what we've said here. ", "original_text": "Sort of as doctor visits and elective proced ures start to resume a bit? "}, "hash": "182cd1f4891f711e51ce3299b543d08f4ce20ed05a3e52b578757f8c0e92c798", "class_name": "RelatedNodeInfo"}}, "text": "Just is there anything you've been seeing in terms of volumes on the alternate site and acute \ncare settings? ", "start_char_idx": 784, "end_char_idx": 894, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd6e5011-44bf-49b0-90f4-ec43c4346d4d": {"__data__": {"id_": "dd6e5011-44bf-49b0-90f4-ec43c4346d4d", "embedding": null, "metadata": {"window": "Joe Amato:  Hi, this is Joe Amato, on for Elizabeth.  I just have another question on the Medical side.  \n \n  Just is there anything you've been seeing in terms of volumes on the alternate site and acute \ncare settings?  Sort of as doctor visits and elective proced ures start to resume a bit?  Thanks.  \n \n Mike Kauffman:  Yes, again.  I'll just emphasize what we've said here. ", "original_text": "Sort of as doctor visits and elective proced ures start to resume a bit? ", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35c2ff74e448a1dbc2796e512848899f9dbb32e3c8ea9505ece1df5c9fb5959a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "081b2a83-b4a9-4037-b579-e7ea6e25c542", "node_type": "1", "metadata": {"window": "We'll next go to Elizabeth Anderson, with Evercore.  \n \n Joe Amato:  Hi, this is Joe Amato, on for Elizabeth.  I just have another question on the Medical side.  \n \n  Just is there anything you've been seeing in terms of volumes on the alternate site and acute \ncare settings?  Sort of as doctor visits and elective proced ures start to resume a bit?  Thanks.  \n \n Mike Kauffman:  Yes, again. ", "original_text": "Just is there anything you've been seeing in terms of volumes on the alternate site and acute \ncare settings? ", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "19929d0e034c8112097d40df8196e4962ddb8e3f13b1dd29d1c9cbbcfe369074", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a1f8b23-176a-476b-ae8a-35aa4e226ffa", "node_type": "1", "metadata": {"window": "I just have another question on the Medical side.  \n \n  Just is there anything you've been seeing in terms of volumes on the alternate site and acute \ncare settings?  Sort of as doctor visits and elective proced ures start to resume a bit?  Thanks.  \n \n Mike Kauffman:  Yes, again.  I'll just emphasize what we've said here.  We do expect to enter this year \nsomewhere in the mid to high teens down on elective procedures - that's really more focused on \nacute than alternate s ites. \n \n ", "original_text": "Thanks.  \n \n"}, "hash": "cf9d9a3ab26a025a405d2b6230bca144429d47905b462fb0fded4c4ce71aa1d4", "class_name": "RelatedNodeInfo"}}, "text": "Sort of as doctor visits and elective proced ures start to resume a bit? ", "start_char_idx": 894, "end_char_idx": 967, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a1f8b23-176a-476b-ae8a-35aa4e226ffa": {"__data__": {"id_": "5a1f8b23-176a-476b-ae8a-35aa4e226ffa", "embedding": null, "metadata": {"window": "I just have another question on the Medical side.  \n \n  Just is there anything you've been seeing in terms of volumes on the alternate site and acute \ncare settings?  Sort of as doctor visits and elective proced ures start to resume a bit?  Thanks.  \n \n Mike Kauffman:  Yes, again.  I'll just emphasize what we've said here.  We do expect to enter this year \nsomewhere in the mid to high teens down on elective procedures - that's really more focused on \nacute than alternate s ites. \n \n ", "original_text": "Thanks.  \n \n", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35c2ff74e448a1dbc2796e512848899f9dbb32e3c8ea9505ece1df5c9fb5959a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd6e5011-44bf-49b0-90f4-ec43c4346d4d", "node_type": "1", "metadata": {"window": "Joe Amato:  Hi, this is Joe Amato, on for Elizabeth.  I just have another question on the Medical side.  \n \n  Just is there anything you've been seeing in terms of volumes on the alternate site and acute \ncare settings?  Sort of as doctor visits and elective proced ures start to resume a bit?  Thanks.  \n \n Mike Kauffman:  Yes, again.  I'll just emphasize what we've said here. ", "original_text": "Sort of as doctor visits and elective proced ures start to resume a bit? ", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80c53e7ef1b4b1b4d30ca1408c46e230417d0bc944559612cd36458c8ac713cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26a8b431-d646-4478-b0cd-2d70eec3dbd6", "node_type": "1", "metadata": {"window": "Just is there anything you've been seeing in terms of volumes on the alternate site and acute \ncare settings?  Sort of as doctor visits and elective proced ures start to resume a bit?  Thanks.  \n \n Mike Kauffman:  Yes, again.  I'll just emphasize what we've said here.  We do expect to enter this year \nsomewhere in the mid to high teens down on elective procedures - that's really more focused on \nacute than alternate s ites. \n \n  You know, when we look at alternate sites we don't have as good a data and information quite \non where that's at and it's not as big of a driver for us in Medical as the acute business is so we ", "original_text": "Mike Kauffman:  Yes, again. "}, "hash": "60ef1c50d37843723a98fb098168cff766498429b8e45897f4b31fe71d369752", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 967, "end_char_idx": 979, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26a8b431-d646-4478-b0cd-2d70eec3dbd6": {"__data__": {"id_": "26a8b431-d646-4478-b0cd-2d70eec3dbd6", "embedding": null, "metadata": {"window": "Just is there anything you've been seeing in terms of volumes on the alternate site and acute \ncare settings?  Sort of as doctor visits and elective proced ures start to resume a bit?  Thanks.  \n \n Mike Kauffman:  Yes, again.  I'll just emphasize what we've said here.  We do expect to enter this year \nsomewhere in the mid to high teens down on elective procedures - that's really more focused on \nacute than alternate s ites. \n \n  You know, when we look at alternate sites we don't have as good a data and information quite \non where that's at and it's not as big of a driver for us in Medical as the acute business is so we ", "original_text": "Mike Kauffman:  Yes, again. ", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35c2ff74e448a1dbc2796e512848899f9dbb32e3c8ea9505ece1df5c9fb5959a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a1f8b23-176a-476b-ae8a-35aa4e226ffa", "node_type": "1", "metadata": {"window": "I just have another question on the Medical side.  \n \n  Just is there anything you've been seeing in terms of volumes on the alternate site and acute \ncare settings?  Sort of as doctor visits and elective proced ures start to resume a bit?  Thanks.  \n \n Mike Kauffman:  Yes, again.  I'll just emphasize what we've said here.  We do expect to enter this year \nsomewhere in the mid to high teens down on elective procedures - that's really more focused on \nacute than alternate s ites. \n \n ", "original_text": "Thanks.  \n \n", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0567e724b7b1097911b42e2f326025efe1e3dfba419301a31ea4eeb2fae63dff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5795ee25-5eed-4e9b-8cec-0d751be37457", "node_type": "1", "metadata": {"window": "Sort of as doctor visits and elective proced ures start to resume a bit?  Thanks.  \n \n Mike Kauffman:  Yes, again.  I'll just emphasize what we've said here.  We do expect to enter this year \nsomewhere in the mid to high teens down on elective procedures - that's really more focused on \nacute than alternate s ites. \n \n  You know, when we look at alternate sites we don't have as good a data and information quite \non where that's at and it's not as big of a driver for us in Medical as the acute business is so we ", "original_text": "I'll just emphasize what we've said here. "}, "hash": "f244679cdab63efee77755beeff767c69d1dc94ff246b4896b70ecffbf633f72", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kauffman:  Yes, again. ", "start_char_idx": 979, "end_char_idx": 1007, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5795ee25-5eed-4e9b-8cec-0d751be37457": {"__data__": {"id_": "5795ee25-5eed-4e9b-8cec-0d751be37457", "embedding": null, "metadata": {"window": "Sort of as doctor visits and elective proced ures start to resume a bit?  Thanks.  \n \n Mike Kauffman:  Yes, again.  I'll just emphasize what we've said here.  We do expect to enter this year \nsomewhere in the mid to high teens down on elective procedures - that's really more focused on \nacute than alternate s ites. \n \n  You know, when we look at alternate sites we don't have as good a data and information quite \non where that's at and it's not as big of a driver for us in Medical as the acute business is so we ", "original_text": "I'll just emphasize what we've said here. ", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35c2ff74e448a1dbc2796e512848899f9dbb32e3c8ea9505ece1df5c9fb5959a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26a8b431-d646-4478-b0cd-2d70eec3dbd6", "node_type": "1", "metadata": {"window": "Just is there anything you've been seeing in terms of volumes on the alternate site and acute \ncare settings?  Sort of as doctor visits and elective proced ures start to resume a bit?  Thanks.  \n \n Mike Kauffman:  Yes, again.  I'll just emphasize what we've said here.  We do expect to enter this year \nsomewhere in the mid to high teens down on elective procedures - that's really more focused on \nacute than alternate s ites. \n \n  You know, when we look at alternate sites we don't have as good a data and information quite \non where that's at and it's not as big of a driver for us in Medical as the acute business is so we ", "original_text": "Mike Kauffman:  Yes, again. ", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9777715c64f643966de1fc1bdc3568e90c249c8f52b0cf9f087482a55287f613", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9e92c66-2cc3-43dc-917c-5d3653ce395b", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Mike Kauffman:  Yes, again.  I'll just emphasize what we've said here.  We do expect to enter this year \nsomewhere in the mid to high teens down on elective procedures - that's really more focused on \nacute than alternate s ites. \n \n  You know, when we look at alternate sites we don't have as good a data and information quite \non where that's at and it's not as big of a driver for us in Medical as the acute business is so we ", "original_text": "We do expect to enter this year \nsomewhere in the mid to high teens down on elective procedures - that's really more focused on \nacute than alternate s ites. \n \n "}, "hash": "dbf9a61c82e3a8e03aa6fd0ae548b53b138319de66484b6353a6a4481594270a", "class_name": "RelatedNodeInfo"}}, "text": "I'll just emphasize what we've said here. ", "start_char_idx": 1007, "end_char_idx": 1049, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9e92c66-2cc3-43dc-917c-5d3653ce395b": {"__data__": {"id_": "b9e92c66-2cc3-43dc-917c-5d3653ce395b", "embedding": null, "metadata": {"window": "Thanks.  \n \n Mike Kauffman:  Yes, again.  I'll just emphasize what we've said here.  We do expect to enter this year \nsomewhere in the mid to high teens down on elective procedures - that's really more focused on \nacute than alternate s ites. \n \n  You know, when we look at alternate sites we don't have as good a data and information quite \non where that's at and it's not as big of a driver for us in Medical as the acute business is so we ", "original_text": "We do expect to enter this year \nsomewhere in the mid to high teens down on elective procedures - that's really more focused on \nacute than alternate s ites. \n \n ", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35c2ff74e448a1dbc2796e512848899f9dbb32e3c8ea9505ece1df5c9fb5959a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5795ee25-5eed-4e9b-8cec-0d751be37457", "node_type": "1", "metadata": {"window": "Sort of as doctor visits and elective proced ures start to resume a bit?  Thanks.  \n \n Mike Kauffman:  Yes, again.  I'll just emphasize what we've said here.  We do expect to enter this year \nsomewhere in the mid to high teens down on elective procedures - that's really more focused on \nacute than alternate s ites. \n \n  You know, when we look at alternate sites we don't have as good a data and information quite \non where that's at and it's not as big of a driver for us in Medical as the acute business is so we ", "original_text": "I'll just emphasize what we've said here. ", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00286e44e788bf402f440286b8c98cc5dc71ab6f6cee83fd71f6434aa2474b6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "132b0ee1-e439-4344-b578-3edbf27605d5", "node_type": "1", "metadata": {"window": "Mike Kauffman:  Yes, again.  I'll just emphasize what we've said here.  We do expect to enter this year \nsomewhere in the mid to high teens down on elective procedures - that's really more focused on \nacute than alternate s ites. \n \n  You know, when we look at alternate sites we don't have as good a data and information quite \non where that's at and it's not as big of a driver for us in Medical as the acute business is so we ", "original_text": "You know, when we look at alternate sites we don't have as good a data and information quite \non where that's at and it's not as big of a driver for us in Medical as the acute business is so we "}, "hash": "e4b0a3cbf11c80090239380e3d965803e958d30ec515d265263c7f30fddcd675", "class_name": "RelatedNodeInfo"}}, "text": "We do expect to enter this year \nsomewhere in the mid to high teens down on elective procedures - that's really more focused on \nacute than alternate s ites. \n \n ", "start_char_idx": 1049, "end_char_idx": 1211, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "132b0ee1-e439-4344-b578-3edbf27605d5": {"__data__": {"id_": "132b0ee1-e439-4344-b578-3edbf27605d5", "embedding": null, "metadata": {"window": "Mike Kauffman:  Yes, again.  I'll just emphasize what we've said here.  We do expect to enter this year \nsomewhere in the mid to high teens down on elective procedures - that's really more focused on \nacute than alternate s ites. \n \n  You know, when we look at alternate sites we don't have as good a data and information quite \non where that's at and it's not as big of a driver for us in Medical as the acute business is so we ", "original_text": "You know, when we look at alternate sites we don't have as good a data and information quite \non where that's at and it's not as big of a driver for us in Medical as the acute business is so we ", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35c2ff74e448a1dbc2796e512848899f9dbb32e3c8ea9505ece1df5c9fb5959a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9e92c66-2cc3-43dc-917c-5d3653ce395b", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Mike Kauffman:  Yes, again.  I'll just emphasize what we've said here.  We do expect to enter this year \nsomewhere in the mid to high teens down on elective procedures - that's really more focused on \nacute than alternate s ites. \n \n  You know, when we look at alternate sites we don't have as good a data and information quite \non where that's at and it's not as big of a driver for us in Medical as the acute business is so we ", "original_text": "We do expect to enter this year \nsomewhere in the mid to high teens down on elective procedures - that's really more focused on \nacute than alternate s ites. \n \n ", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1010938e5b5ae65993f37d16cc4644ad1ebac9bc536ccf757ee162c49808d02a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38f202d9-ad37-40fe-80c8-d775c10fee49", "node_type": "1", "metadata": {"window": " \nPage 17 of 31 \n \nexpect to enter somewhere in that mid to high teens, negative v s. prior year, but exit the year at pre -\nCOVID levels with it obviously then improving during the year.  \n \n Kevin Moran:  Next question, please?  \n \n Operator:  Thank you, we'll next go to Charles R hyee with Cowen.  Please go ahead.  \n \n", "original_text": " \nPage 17 of 31 \n \nexpect to enter somewhere in that mid to high teens, negative v s. prior year, but exit the year at pre -\nCOVID levels with it obviously then improving during the year.  \n \n"}, "hash": "8ae4d130a961966597222e1bbe910d44c6a966329f6e6056979af6e6b5705e88", "class_name": "RelatedNodeInfo"}}, "text": "You know, when we look at alternate sites we don't have as good a data and information quite \non where that's at and it's not as big of a driver for us in Medical as the acute business is so we ", "start_char_idx": 1211, "end_char_idx": 1405, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38f202d9-ad37-40fe-80c8-d775c10fee49": {"__data__": {"id_": "38f202d9-ad37-40fe-80c8-d775c10fee49", "embedding": null, "metadata": {"window": " \nPage 17 of 31 \n \nexpect to enter somewhere in that mid to high teens, negative v s. prior year, but exit the year at pre -\nCOVID levels with it obviously then improving during the year.  \n \n Kevin Moran:  Next question, please?  \n \n Operator:  Thank you, we'll next go to Charles R hyee with Cowen.  Please go ahead.  \n \n", "original_text": " \nPage 17 of 31 \n \nexpect to enter somewhere in that mid to high teens, negative v s. prior year, but exit the year at pre -\nCOVID levels with it obviously then improving during the year.  \n \n", "page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1203bfd5-ad97-415c-8620-a142c7e42944", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c55b8d20862f53a38766e258737ea7fc3c0a4f56e9bd7c9c3fbb7de9c7441bc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "132b0ee1-e439-4344-b578-3edbf27605d5", "node_type": "1", "metadata": {"window": "Mike Kauffman:  Yes, again.  I'll just emphasize what we've said here.  We do expect to enter this year \nsomewhere in the mid to high teens down on elective procedures - that's really more focused on \nacute than alternate s ites. \n \n  You know, when we look at alternate sites we don't have as good a data and information quite \non where that's at and it's not as big of a driver for us in Medical as the acute business is so we ", "original_text": "You know, when we look at alternate sites we don't have as good a data and information quite \non where that's at and it's not as big of a driver for us in Medical as the acute business is so we ", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6452ab6816f6d07f227af224439a146a316ef911aef43185360c8821fdd6a001", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e003587a-9f6e-4752-991d-2bb0b84f6705", "node_type": "1", "metadata": {"window": " \nPage 17 of 31 \n \nexpect to enter somewhere in that mid to high teens, negative v s. prior year, but exit the year at pre -\nCOVID levels with it obviously then improving during the year.  \n \n Kevin Moran:  Next question, please?  \n \n Operator:  Thank you, we'll next go to Charles R hyee with Cowen.  Please go ahead.  \n \n Charles R hyee:  Hi, yes. ", "original_text": "Kevin Moran:  Next question, please?  \n \n"}, "hash": "ec4e751dc0403485b498d1772f5ee2cb09bee02a28a71d4b37a767168acf61a4", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 17 of 31 \n \nexpect to enter somewhere in that mid to high teens, negative v s. prior year, but exit the year at pre -\nCOVID levels with it obviously then improving during the year.  \n \n", "start_char_idx": 0, "end_char_idx": 192, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e003587a-9f6e-4752-991d-2bb0b84f6705": {"__data__": {"id_": "e003587a-9f6e-4752-991d-2bb0b84f6705", "embedding": null, "metadata": {"window": " \nPage 17 of 31 \n \nexpect to enter somewhere in that mid to high teens, negative v s. prior year, but exit the year at pre -\nCOVID levels with it obviously then improving during the year.  \n \n Kevin Moran:  Next question, please?  \n \n Operator:  Thank you, we'll next go to Charles R hyee with Cowen.  Please go ahead.  \n \n Charles R hyee:  Hi, yes. ", "original_text": "Kevin Moran:  Next question, please?  \n \n", "page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1203bfd5-ad97-415c-8620-a142c7e42944", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c55b8d20862f53a38766e258737ea7fc3c0a4f56e9bd7c9c3fbb7de9c7441bc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38f202d9-ad37-40fe-80c8-d775c10fee49", "node_type": "1", "metadata": {"window": " \nPage 17 of 31 \n \nexpect to enter somewhere in that mid to high teens, negative v s. prior year, but exit the year at pre -\nCOVID levels with it obviously then improving during the year.  \n \n Kevin Moran:  Next question, please?  \n \n Operator:  Thank you, we'll next go to Charles R hyee with Cowen.  Please go ahead.  \n \n", "original_text": " \nPage 17 of 31 \n \nexpect to enter somewhere in that mid to high teens, negative v s. prior year, but exit the year at pre -\nCOVID levels with it obviously then improving during the year.  \n \n", "page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "31d4cd78fe7c8dc2bdbd505f6ed636932f2768ba73e44e33fae6a731bf066cbe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "391edb10-ea92-4d7d-8f53-d38100392265", "node_type": "1", "metadata": {"window": " \nPage 17 of 31 \n \nexpect to enter somewhere in that mid to high teens, negative v s. prior year, but exit the year at pre -\nCOVID levels with it obviously then improving during the year.  \n \n Kevin Moran:  Next question, please?  \n \n Operator:  Thank you, we'll next go to Charles R hyee with Cowen.  Please go ahead.  \n \n Charles R hyee:  Hi, yes.  Thanks  for taking the question. ", "original_text": "Operator:  Thank you, we'll next go to Charles R hyee with Cowen. "}, "hash": "0841e976729015367c5f46082b10b8b949c9f0e33457b8eb64f97365af8775b1", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran:  Next question, please?  \n \n", "start_char_idx": 192, "end_char_idx": 233, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "391edb10-ea92-4d7d-8f53-d38100392265": {"__data__": {"id_": "391edb10-ea92-4d7d-8f53-d38100392265", "embedding": null, "metadata": {"window": " \nPage 17 of 31 \n \nexpect to enter somewhere in that mid to high teens, negative v s. prior year, but exit the year at pre -\nCOVID levels with it obviously then improving during the year.  \n \n Kevin Moran:  Next question, please?  \n \n Operator:  Thank you, we'll next go to Charles R hyee with Cowen.  Please go ahead.  \n \n Charles R hyee:  Hi, yes.  Thanks  for taking the question. ", "original_text": "Operator:  Thank you, we'll next go to Charles R hyee with Cowen. ", "page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1203bfd5-ad97-415c-8620-a142c7e42944", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c55b8d20862f53a38766e258737ea7fc3c0a4f56e9bd7c9c3fbb7de9c7441bc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e003587a-9f6e-4752-991d-2bb0b84f6705", "node_type": "1", "metadata": {"window": " \nPage 17 of 31 \n \nexpect to enter somewhere in that mid to high teens, negative v s. prior year, but exit the year at pre -\nCOVID levels with it obviously then improving during the year.  \n \n Kevin Moran:  Next question, please?  \n \n Operator:  Thank you, we'll next go to Charles R hyee with Cowen.  Please go ahead.  \n \n Charles R hyee:  Hi, yes. ", "original_text": "Kevin Moran:  Next question, please?  \n \n", "page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4cae385cee31065f1ad618f4c1a28103a0e614ca9ba9a749b5e3ed3dfea40d5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc3f9e25-66fa-4cdc-93be-c1fcf34f6450", "node_type": "1", "metadata": {"window": " \nPage 17 of 31 \n \nexpect to enter somewhere in that mid to high teens, negative v s. prior year, but exit the year at pre -\nCOVID levels with it obviously then improving during the year.  \n \n Kevin Moran:  Next question, please?  \n \n Operator:  Thank you, we'll next go to Charles R hyee with Cowen.  Please go ahead.  \n \n Charles R hyee:  Hi, yes.  Thanks  for taking the question.  Hey, guys. ", "original_text": "Please go ahead.  \n \n"}, "hash": "2daa2615b627b92a30686f95208b87b776c8e9cdf186b74d42fce6871ce73c1a", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you, we'll next go to Charles R hyee with Cowen. ", "start_char_idx": 233, "end_char_idx": 299, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc3f9e25-66fa-4cdc-93be-c1fcf34f6450": {"__data__": {"id_": "fc3f9e25-66fa-4cdc-93be-c1fcf34f6450", "embedding": null, "metadata": {"window": " \nPage 17 of 31 \n \nexpect to enter somewhere in that mid to high teens, negative v s. prior year, but exit the year at pre -\nCOVID levels with it obviously then improving during the year.  \n \n Kevin Moran:  Next question, please?  \n \n Operator:  Thank you, we'll next go to Charles R hyee with Cowen.  Please go ahead.  \n \n Charles R hyee:  Hi, yes.  Thanks  for taking the question.  Hey, guys. ", "original_text": "Please go ahead.  \n \n", "page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1203bfd5-ad97-415c-8620-a142c7e42944", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c55b8d20862f53a38766e258737ea7fc3c0a4f56e9bd7c9c3fbb7de9c7441bc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "391edb10-ea92-4d7d-8f53-d38100392265", "node_type": "1", "metadata": {"window": " \nPage 17 of 31 \n \nexpect to enter somewhere in that mid to high teens, negative v s. prior year, but exit the year at pre -\nCOVID levels with it obviously then improving during the year.  \n \n Kevin Moran:  Next question, please?  \n \n Operator:  Thank you, we'll next go to Charles R hyee with Cowen.  Please go ahead.  \n \n Charles R hyee:  Hi, yes.  Thanks  for taking the question. ", "original_text": "Operator:  Thank you, we'll next go to Charles R hyee with Cowen. ", "page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "317c60bf8a430df8f400389164a649af54dcd0886d677191eec7339680ddaadf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "524d566d-d76c-485b-a6a6-782c2a5311a2", "node_type": "1", "metadata": {"window": "Kevin Moran:  Next question, please?  \n \n Operator:  Thank you, we'll next go to Charles R hyee with Cowen.  Please go ahead.  \n \n Charles R hyee:  Hi, yes.  Thanks  for taking the question.  Hey, guys.  Just wanted to ask actually still a \nlittle bit more on Medical but - we really want to focus on the at -Home business and, you know, \nobviously this is a business you guys got into several years ago and at times you've sp oken about it \nclearly with COVID - I would imagine that the home business has really accelerated, you kind of hear \nthat in the home health sector as well.  \n \n ", "original_text": "Charles R hyee:  Hi, yes. "}, "hash": "e8c8b420fc6cf8d5f4e9f265e5150fa7e48c26f5ff7d5586b2f6af12da909318", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 299, "end_char_idx": 320, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "524d566d-d76c-485b-a6a6-782c2a5311a2": {"__data__": {"id_": "524d566d-d76c-485b-a6a6-782c2a5311a2", "embedding": null, "metadata": {"window": "Kevin Moran:  Next question, please?  \n \n Operator:  Thank you, we'll next go to Charles R hyee with Cowen.  Please go ahead.  \n \n Charles R hyee:  Hi, yes.  Thanks  for taking the question.  Hey, guys.  Just wanted to ask actually still a \nlittle bit more on Medical but - we really want to focus on the at -Home business and, you know, \nobviously this is a business you guys got into several years ago and at times you've sp oken about it \nclearly with COVID - I would imagine that the home business has really accelerated, you kind of hear \nthat in the home health sector as well.  \n \n ", "original_text": "Charles R hyee:  Hi, yes. ", "page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1203bfd5-ad97-415c-8620-a142c7e42944", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c55b8d20862f53a38766e258737ea7fc3c0a4f56e9bd7c9c3fbb7de9c7441bc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc3f9e25-66fa-4cdc-93be-c1fcf34f6450", "node_type": "1", "metadata": {"window": " \nPage 17 of 31 \n \nexpect to enter somewhere in that mid to high teens, negative v s. prior year, but exit the year at pre -\nCOVID levels with it obviously then improving during the year.  \n \n Kevin Moran:  Next question, please?  \n \n Operator:  Thank you, we'll next go to Charles R hyee with Cowen.  Please go ahead.  \n \n Charles R hyee:  Hi, yes.  Thanks  for taking the question.  Hey, guys. ", "original_text": "Please go ahead.  \n \n", "page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe1961bf26e6936a89029a9e00f27300cb21a98ffcb80ffa4b90641786bebcec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c8deb33-82e5-4117-98fb-b59c3f8aeccf", "node_type": "1", "metadata": {"window": "Operator:  Thank you, we'll next go to Charles R hyee with Cowen.  Please go ahead.  \n \n Charles R hyee:  Hi, yes.  Thanks  for taking the question.  Hey, guys.  Just wanted to ask actually still a \nlittle bit more on Medical but - we really want to focus on the at -Home business and, you know, \nobviously this is a business you guys got into several years ago and at times you've sp oken about it \nclearly with COVID - I would imagine that the home business has really accelerated, you kind of hear \nthat in the home health sector as well.  \n \n  Can you give us a sense more of, you know, what the make -up of this business is, you know, \nany kind  of metrics around the size of this business now within medical, sort of the growth rates \nrelative to the overall business and some of the dynamics that are impacting this that might be more \npositive or, you know, or more of a headwind because of the pande mic relative to the rest of the \nbusiness - I'd imagine that maybe this has PPE requirements that are hindering you or maybe not.  \n \n ", "original_text": "Thanks  for taking the question. "}, "hash": "0bdb4925eea35fe1fee6bd7fa4983649006e0cd9006e85a3f072aa01b138e0b1", "class_name": "RelatedNodeInfo"}}, "text": "Charles R hyee:  Hi, yes. ", "start_char_idx": 320, "end_char_idx": 346, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c8deb33-82e5-4117-98fb-b59c3f8aeccf": {"__data__": {"id_": "5c8deb33-82e5-4117-98fb-b59c3f8aeccf", "embedding": null, "metadata": {"window": "Operator:  Thank you, we'll next go to Charles R hyee with Cowen.  Please go ahead.  \n \n Charles R hyee:  Hi, yes.  Thanks  for taking the question.  Hey, guys.  Just wanted to ask actually still a \nlittle bit more on Medical but - we really want to focus on the at -Home business and, you know, \nobviously this is a business you guys got into several years ago and at times you've sp oken about it \nclearly with COVID - I would imagine that the home business has really accelerated, you kind of hear \nthat in the home health sector as well.  \n \n  Can you give us a sense more of, you know, what the make -up of this business is, you know, \nany kind  of metrics around the size of this business now within medical, sort of the growth rates \nrelative to the overall business and some of the dynamics that are impacting this that might be more \npositive or, you know, or more of a headwind because of the pande mic relative to the rest of the \nbusiness - I'd imagine that maybe this has PPE requirements that are hindering you or maybe not.  \n \n ", "original_text": "Thanks  for taking the question. ", "page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1203bfd5-ad97-415c-8620-a142c7e42944", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c55b8d20862f53a38766e258737ea7fc3c0a4f56e9bd7c9c3fbb7de9c7441bc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "524d566d-d76c-485b-a6a6-782c2a5311a2", "node_type": "1", "metadata": {"window": "Kevin Moran:  Next question, please?  \n \n Operator:  Thank you, we'll next go to Charles R hyee with Cowen.  Please go ahead.  \n \n Charles R hyee:  Hi, yes.  Thanks  for taking the question.  Hey, guys.  Just wanted to ask actually still a \nlittle bit more on Medical but - we really want to focus on the at -Home business and, you know, \nobviously this is a business you guys got into several years ago and at times you've sp oken about it \nclearly with COVID - I would imagine that the home business has really accelerated, you kind of hear \nthat in the home health sector as well.  \n \n ", "original_text": "Charles R hyee:  Hi, yes. ", "page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6469194da030cd6426a7a9e8a6de9f911ecf3088270d21234d12390e92bd3cca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69ba23d2-0dc2-4836-a49c-76d1dd4e4cc7", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Charles R hyee:  Hi, yes.  Thanks  for taking the question.  Hey, guys.  Just wanted to ask actually still a \nlittle bit more on Medical but - we really want to focus on the at -Home business and, you know, \nobviously this is a business you guys got into several years ago and at times you've sp oken about it \nclearly with COVID - I would imagine that the home business has really accelerated, you kind of hear \nthat in the home health sector as well.  \n \n  Can you give us a sense more of, you know, what the make -up of this business is, you know, \nany kind  of metrics around the size of this business now within medical, sort of the growth rates \nrelative to the overall business and some of the dynamics that are impacting this that might be more \npositive or, you know, or more of a headwind because of the pande mic relative to the rest of the \nbusiness - I'd imagine that maybe this has PPE requirements that are hindering you or maybe not.  \n \n  Just wanted to get more sense on this segment is like - it could be a bigger contributor going \nforward, thanks.  \n \n", "original_text": "Hey, guys. "}, "hash": "73f4407547503c52adeafe9e4ea4ca11cf8af208e7cff73154465a4bf0f67152", "class_name": "RelatedNodeInfo"}}, "text": "Thanks  for taking the question. ", "start_char_idx": 346, "end_char_idx": 379, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69ba23d2-0dc2-4836-a49c-76d1dd4e4cc7": {"__data__": {"id_": "69ba23d2-0dc2-4836-a49c-76d1dd4e4cc7", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Charles R hyee:  Hi, yes.  Thanks  for taking the question.  Hey, guys.  Just wanted to ask actually still a \nlittle bit more on Medical but - we really want to focus on the at -Home business and, you know, \nobviously this is a business you guys got into several years ago and at times you've sp oken about it \nclearly with COVID - I would imagine that the home business has really accelerated, you kind of hear \nthat in the home health sector as well.  \n \n  Can you give us a sense more of, you know, what the make -up of this business is, you know, \nany kind  of metrics around the size of this business now within medical, sort of the growth rates \nrelative to the overall business and some of the dynamics that are impacting this that might be more \npositive or, you know, or more of a headwind because of the pande mic relative to the rest of the \nbusiness - I'd imagine that maybe this has PPE requirements that are hindering you or maybe not.  \n \n  Just wanted to get more sense on this segment is like - it could be a bigger contributor going \nforward, thanks.  \n \n", "original_text": "Hey, guys. ", "page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1203bfd5-ad97-415c-8620-a142c7e42944", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c55b8d20862f53a38766e258737ea7fc3c0a4f56e9bd7c9c3fbb7de9c7441bc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c8deb33-82e5-4117-98fb-b59c3f8aeccf", "node_type": "1", "metadata": {"window": "Operator:  Thank you, we'll next go to Charles R hyee with Cowen.  Please go ahead.  \n \n Charles R hyee:  Hi, yes.  Thanks  for taking the question.  Hey, guys.  Just wanted to ask actually still a \nlittle bit more on Medical but - we really want to focus on the at -Home business and, you know, \nobviously this is a business you guys got into several years ago and at times you've sp oken about it \nclearly with COVID - I would imagine that the home business has really accelerated, you kind of hear \nthat in the home health sector as well.  \n \n  Can you give us a sense more of, you know, what the make -up of this business is, you know, \nany kind  of metrics around the size of this business now within medical, sort of the growth rates \nrelative to the overall business and some of the dynamics that are impacting this that might be more \npositive or, you know, or more of a headwind because of the pande mic relative to the rest of the \nbusiness - I'd imagine that maybe this has PPE requirements that are hindering you or maybe not.  \n \n ", "original_text": "Thanks  for taking the question. ", "page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34d96010959501355533c31d7e2189194e757e24695049d5bcbaffcef8f1ea71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d88e425a-eedf-448e-a34d-fcc663cab646", "node_type": "1", "metadata": {"window": "Charles R hyee:  Hi, yes.  Thanks  for taking the question.  Hey, guys.  Just wanted to ask actually still a \nlittle bit more on Medical but - we really want to focus on the at -Home business and, you know, \nobviously this is a business you guys got into several years ago and at times you've sp oken about it \nclearly with COVID - I would imagine that the home business has really accelerated, you kind of hear \nthat in the home health sector as well.  \n \n  Can you give us a sense more of, you know, what the make -up of this business is, you know, \nany kind  of metrics around the size of this business now within medical, sort of the growth rates \nrelative to the overall business and some of the dynamics that are impacting this that might be more \npositive or, you know, or more of a headwind because of the pande mic relative to the rest of the \nbusiness - I'd imagine that maybe this has PPE requirements that are hindering you or maybe not.  \n \n  Just wanted to get more sense on this segment is like - it could be a bigger contributor going \nforward, thanks.  \n \n Mike Kaufman n:  Yes, thanks for the question.  \n ", "original_text": "Just wanted to ask actually still a \nlittle bit more on Medical but - we really want to focus on the at -Home business and, you know, \nobviously this is a business you guys got into several years ago and at times you've sp oken about it \nclearly with COVID - I would imagine that the home business has really accelerated, you kind of hear \nthat in the home health sector as well.  \n \n "}, "hash": "501312978d354df352e1db0cbcc80b36f5d4dd1eb643e541112e54ebb219169c", "class_name": "RelatedNodeInfo"}}, "text": "Hey, guys. ", "start_char_idx": 379, "end_char_idx": 390, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d88e425a-eedf-448e-a34d-fcc663cab646": {"__data__": {"id_": "d88e425a-eedf-448e-a34d-fcc663cab646", "embedding": null, "metadata": {"window": "Charles R hyee:  Hi, yes.  Thanks  for taking the question.  Hey, guys.  Just wanted to ask actually still a \nlittle bit more on Medical but - we really want to focus on the at -Home business and, you know, \nobviously this is a business you guys got into several years ago and at times you've sp oken about it \nclearly with COVID - I would imagine that the home business has really accelerated, you kind of hear \nthat in the home health sector as well.  \n \n  Can you give us a sense more of, you know, what the make -up of this business is, you know, \nany kind  of metrics around the size of this business now within medical, sort of the growth rates \nrelative to the overall business and some of the dynamics that are impacting this that might be more \npositive or, you know, or more of a headwind because of the pande mic relative to the rest of the \nbusiness - I'd imagine that maybe this has PPE requirements that are hindering you or maybe not.  \n \n  Just wanted to get more sense on this segment is like - it could be a bigger contributor going \nforward, thanks.  \n \n Mike Kaufman n:  Yes, thanks for the question.  \n ", "original_text": "Just wanted to ask actually still a \nlittle bit more on Medical but - we really want to focus on the at -Home business and, you know, \nobviously this is a business you guys got into several years ago and at times you've sp oken about it \nclearly with COVID - I would imagine that the home business has really accelerated, you kind of hear \nthat in the home health sector as well.  \n \n ", "page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1203bfd5-ad97-415c-8620-a142c7e42944", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c55b8d20862f53a38766e258737ea7fc3c0a4f56e9bd7c9c3fbb7de9c7441bc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69ba23d2-0dc2-4836-a49c-76d1dd4e4cc7", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Charles R hyee:  Hi, yes.  Thanks  for taking the question.  Hey, guys.  Just wanted to ask actually still a \nlittle bit more on Medical but - we really want to focus on the at -Home business and, you know, \nobviously this is a business you guys got into several years ago and at times you've sp oken about it \nclearly with COVID - I would imagine that the home business has really accelerated, you kind of hear \nthat in the home health sector as well.  \n \n  Can you give us a sense more of, you know, what the make -up of this business is, you know, \nany kind  of metrics around the size of this business now within medical, sort of the growth rates \nrelative to the overall business and some of the dynamics that are impacting this that might be more \npositive or, you know, or more of a headwind because of the pande mic relative to the rest of the \nbusiness - I'd imagine that maybe this has PPE requirements that are hindering you or maybe not.  \n \n  Just wanted to get more sense on this segment is like - it could be a bigger contributor going \nforward, thanks.  \n \n", "original_text": "Hey, guys. ", "page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "47f2304de9bb730c17acf4f45b318bbbcdb047f478e0aca723b9c566bb09d1cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e106f78-491c-4f18-8e0a-b143d6d2ca5c", "node_type": "1", "metadata": {"window": "Thanks  for taking the question.  Hey, guys.  Just wanted to ask actually still a \nlittle bit more on Medical but - we really want to focus on the at -Home business and, you know, \nobviously this is a business you guys got into several years ago and at times you've sp oken about it \nclearly with COVID - I would imagine that the home business has really accelerated, you kind of hear \nthat in the home health sector as well.  \n \n  Can you give us a sense more of, you know, what the make -up of this business is, you know, \nany kind  of metrics around the size of this business now within medical, sort of the growth rates \nrelative to the overall business and some of the dynamics that are impacting this that might be more \npositive or, you know, or more of a headwind because of the pande mic relative to the rest of the \nbusiness - I'd imagine that maybe this has PPE requirements that are hindering you or maybe not.  \n \n  Just wanted to get more sense on this segment is like - it could be a bigger contributor going \nforward, thanks.  \n \n Mike Kaufman n:  Yes, thanks for the question.  \n ", "original_text": "Can you give us a sense more of, you know, what the make -up of this business is, you know, \nany kind  of metrics around the size of this business now within medical, sort of the growth rates \nrelative to the overall business and some of the dynamics that are impacting this that might be more \npositive or, you know, or more of a headwind because of the pande mic relative to the rest of the \nbusiness - I'd imagine that maybe this has PPE requirements that are hindering you or maybe not.  \n \n "}, "hash": "0f94287ee92aede8c3610bf374126264726452cf61103fa3a1b3472ffa9923c2", "class_name": "RelatedNodeInfo"}}, "text": "Just wanted to ask actually still a \nlittle bit more on Medical but - we really want to focus on the at -Home business and, you know, \nobviously this is a business you guys got into several years ago and at times you've sp oken about it \nclearly with COVID - I would imagine that the home business has really accelerated, you kind of hear \nthat in the home health sector as well.  \n \n ", "start_char_idx": 390, "end_char_idx": 775, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e106f78-491c-4f18-8e0a-b143d6d2ca5c": {"__data__": {"id_": "5e106f78-491c-4f18-8e0a-b143d6d2ca5c", "embedding": null, "metadata": {"window": "Thanks  for taking the question.  Hey, guys.  Just wanted to ask actually still a \nlittle bit more on Medical but - we really want to focus on the at -Home business and, you know, \nobviously this is a business you guys got into several years ago and at times you've sp oken about it \nclearly with COVID - I would imagine that the home business has really accelerated, you kind of hear \nthat in the home health sector as well.  \n \n  Can you give us a sense more of, you know, what the make -up of this business is, you know, \nany kind  of metrics around the size of this business now within medical, sort of the growth rates \nrelative to the overall business and some of the dynamics that are impacting this that might be more \npositive or, you know, or more of a headwind because of the pande mic relative to the rest of the \nbusiness - I'd imagine that maybe this has PPE requirements that are hindering you or maybe not.  \n \n  Just wanted to get more sense on this segment is like - it could be a bigger contributor going \nforward, thanks.  \n \n Mike Kaufman n:  Yes, thanks for the question.  \n ", "original_text": "Can you give us a sense more of, you know, what the make -up of this business is, you know, \nany kind  of metrics around the size of this business now within medical, sort of the growth rates \nrelative to the overall business and some of the dynamics that are impacting this that might be more \npositive or, you know, or more of a headwind because of the pande mic relative to the rest of the \nbusiness - I'd imagine that maybe this has PPE requirements that are hindering you or maybe not.  \n \n ", "page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1203bfd5-ad97-415c-8620-a142c7e42944", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c55b8d20862f53a38766e258737ea7fc3c0a4f56e9bd7c9c3fbb7de9c7441bc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d88e425a-eedf-448e-a34d-fcc663cab646", "node_type": "1", "metadata": {"window": "Charles R hyee:  Hi, yes.  Thanks  for taking the question.  Hey, guys.  Just wanted to ask actually still a \nlittle bit more on Medical but - we really want to focus on the at -Home business and, you know, \nobviously this is a business you guys got into several years ago and at times you've sp oken about it \nclearly with COVID - I would imagine that the home business has really accelerated, you kind of hear \nthat in the home health sector as well.  \n \n  Can you give us a sense more of, you know, what the make -up of this business is, you know, \nany kind  of metrics around the size of this business now within medical, sort of the growth rates \nrelative to the overall business and some of the dynamics that are impacting this that might be more \npositive or, you know, or more of a headwind because of the pande mic relative to the rest of the \nbusiness - I'd imagine that maybe this has PPE requirements that are hindering you or maybe not.  \n \n  Just wanted to get more sense on this segment is like - it could be a bigger contributor going \nforward, thanks.  \n \n Mike Kaufman n:  Yes, thanks for the question.  \n ", "original_text": "Just wanted to ask actually still a \nlittle bit more on Medical but - we really want to focus on the at -Home business and, you know, \nobviously this is a business you guys got into several years ago and at times you've sp oken about it \nclearly with COVID - I would imagine that the home business has really accelerated, you kind of hear \nthat in the home health sector as well.  \n \n ", "page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe2f81028b8513689e365e710b2d3cbe495548a9268df930efd9919178030742", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71c950e8-6cff-445b-89dc-a309b7a69cbd", "node_type": "1", "metadata": {"window": "Hey, guys.  Just wanted to ask actually still a \nlittle bit more on Medical but - we really want to focus on the at -Home business and, you know, \nobviously this is a business you guys got into several years ago and at times you've sp oken about it \nclearly with COVID - I would imagine that the home business has really accelerated, you kind of hear \nthat in the home health sector as well.  \n \n  Can you give us a sense more of, you know, what the make -up of this business is, you know, \nany kind  of metrics around the size of this business now within medical, sort of the growth rates \nrelative to the overall business and some of the dynamics that are impacting this that might be more \npositive or, you know, or more of a headwind because of the pande mic relative to the rest of the \nbusiness - I'd imagine that maybe this has PPE requirements that are hindering you or maybe not.  \n \n  Just wanted to get more sense on this segment is like - it could be a bigger contributor going \nforward, thanks.  \n \n Mike Kaufman n:  Yes, thanks for the question.  \n ", "original_text": "Just wanted to get more sense on this segment is like - it could be a bigger contributor going \nforward, thanks.  \n \n"}, "hash": "01585b29d24adab04fc8e2d140a5e5dd9da09eb02133ec777a3e6b9c1767cfca", "class_name": "RelatedNodeInfo"}}, "text": "Can you give us a sense more of, you know, what the make -up of this business is, you know, \nany kind  of metrics around the size of this business now within medical, sort of the growth rates \nrelative to the overall business and some of the dynamics that are impacting this that might be more \npositive or, you know, or more of a headwind because of the pande mic relative to the rest of the \nbusiness - I'd imagine that maybe this has PPE requirements that are hindering you or maybe not.  \n \n ", "start_char_idx": 775, "end_char_idx": 1271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71c950e8-6cff-445b-89dc-a309b7a69cbd": {"__data__": {"id_": "71c950e8-6cff-445b-89dc-a309b7a69cbd", "embedding": null, "metadata": {"window": "Hey, guys.  Just wanted to ask actually still a \nlittle bit more on Medical but - we really want to focus on the at -Home business and, you know, \nobviously this is a business you guys got into several years ago and at times you've sp oken about it \nclearly with COVID - I would imagine that the home business has really accelerated, you kind of hear \nthat in the home health sector as well.  \n \n  Can you give us a sense more of, you know, what the make -up of this business is, you know, \nany kind  of metrics around the size of this business now within medical, sort of the growth rates \nrelative to the overall business and some of the dynamics that are impacting this that might be more \npositive or, you know, or more of a headwind because of the pande mic relative to the rest of the \nbusiness - I'd imagine that maybe this has PPE requirements that are hindering you or maybe not.  \n \n  Just wanted to get more sense on this segment is like - it could be a bigger contributor going \nforward, thanks.  \n \n Mike Kaufman n:  Yes, thanks for the question.  \n ", "original_text": "Just wanted to get more sense on this segment is like - it could be a bigger contributor going \nforward, thanks.  \n \n", "page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1203bfd5-ad97-415c-8620-a142c7e42944", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c55b8d20862f53a38766e258737ea7fc3c0a4f56e9bd7c9c3fbb7de9c7441bc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e106f78-491c-4f18-8e0a-b143d6d2ca5c", "node_type": "1", "metadata": {"window": "Thanks  for taking the question.  Hey, guys.  Just wanted to ask actually still a \nlittle bit more on Medical but - we really want to focus on the at -Home business and, you know, \nobviously this is a business you guys got into several years ago and at times you've sp oken about it \nclearly with COVID - I would imagine that the home business has really accelerated, you kind of hear \nthat in the home health sector as well.  \n \n  Can you give us a sense more of, you know, what the make -up of this business is, you know, \nany kind  of metrics around the size of this business now within medical, sort of the growth rates \nrelative to the overall business and some of the dynamics that are impacting this that might be more \npositive or, you know, or more of a headwind because of the pande mic relative to the rest of the \nbusiness - I'd imagine that maybe this has PPE requirements that are hindering you or maybe not.  \n \n  Just wanted to get more sense on this segment is like - it could be a bigger contributor going \nforward, thanks.  \n \n Mike Kaufman n:  Yes, thanks for the question.  \n ", "original_text": "Can you give us a sense more of, you know, what the make -up of this business is, you know, \nany kind  of metrics around the size of this business now within medical, sort of the growth rates \nrelative to the overall business and some of the dynamics that are impacting this that might be more \npositive or, you know, or more of a headwind because of the pande mic relative to the rest of the \nbusiness - I'd imagine that maybe this has PPE requirements that are hindering you or maybe not.  \n \n ", "page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe013ac671ecf85c74227412bc771049d93df9f24301dece19465998a5f0c547", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb194900-2bc0-48b0-b875-640ffaab0ee5", "node_type": "1", "metadata": {"window": "Just wanted to ask actually still a \nlittle bit more on Medical but - we really want to focus on the at -Home business and, you know, \nobviously this is a business you guys got into several years ago and at times you've sp oken about it \nclearly with COVID - I would imagine that the home business has really accelerated, you kind of hear \nthat in the home health sector as well.  \n \n  Can you give us a sense more of, you know, what the make -up of this business is, you know, \nany kind  of metrics around the size of this business now within medical, sort of the growth rates \nrelative to the overall business and some of the dynamics that are impacting this that might be more \npositive or, you know, or more of a headwind because of the pande mic relative to the rest of the \nbusiness - I'd imagine that maybe this has PPE requirements that are hindering you or maybe not.  \n \n  Just wanted to get more sense on this segment is like - it could be a bigger contributor going \nforward, thanks.  \n \n Mike Kaufman n:  Yes, thanks for the question.  \n ", "original_text": "Mike Kaufman n:  Yes, thanks for the question.  \n "}, "hash": "43b8951c25e90a4c65a599208a309f9739f30a67b5dcba9125e022285d842bf7", "class_name": "RelatedNodeInfo"}}, "text": "Just wanted to get more sense on this segment is like - it could be a bigger contributor going \nforward, thanks.  \n \n", "start_char_idx": 1271, "end_char_idx": 1388, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb194900-2bc0-48b0-b875-640ffaab0ee5": {"__data__": {"id_": "eb194900-2bc0-48b0-b875-640ffaab0ee5", "embedding": null, "metadata": {"window": "Just wanted to ask actually still a \nlittle bit more on Medical but - we really want to focus on the at -Home business and, you know, \nobviously this is a business you guys got into several years ago and at times you've sp oken about it \nclearly with COVID - I would imagine that the home business has really accelerated, you kind of hear \nthat in the home health sector as well.  \n \n  Can you give us a sense more of, you know, what the make -up of this business is, you know, \nany kind  of metrics around the size of this business now within medical, sort of the growth rates \nrelative to the overall business and some of the dynamics that are impacting this that might be more \npositive or, you know, or more of a headwind because of the pande mic relative to the rest of the \nbusiness - I'd imagine that maybe this has PPE requirements that are hindering you or maybe not.  \n \n  Just wanted to get more sense on this segment is like - it could be a bigger contributor going \nforward, thanks.  \n \n Mike Kaufman n:  Yes, thanks for the question.  \n ", "original_text": "Mike Kaufman n:  Yes, thanks for the question.  \n ", "page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1203bfd5-ad97-415c-8620-a142c7e42944", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c55b8d20862f53a38766e258737ea7fc3c0a4f56e9bd7c9c3fbb7de9c7441bc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71c950e8-6cff-445b-89dc-a309b7a69cbd", "node_type": "1", "metadata": {"window": "Hey, guys.  Just wanted to ask actually still a \nlittle bit more on Medical but - we really want to focus on the at -Home business and, you know, \nobviously this is a business you guys got into several years ago and at times you've sp oken about it \nclearly with COVID - I would imagine that the home business has really accelerated, you kind of hear \nthat in the home health sector as well.  \n \n  Can you give us a sense more of, you know, what the make -up of this business is, you know, \nany kind  of metrics around the size of this business now within medical, sort of the growth rates \nrelative to the overall business and some of the dynamics that are impacting this that might be more \npositive or, you know, or more of a headwind because of the pande mic relative to the rest of the \nbusiness - I'd imagine that maybe this has PPE requirements that are hindering you or maybe not.  \n \n  Just wanted to get more sense on this segment is like - it could be a bigger contributor going \nforward, thanks.  \n \n Mike Kaufman n:  Yes, thanks for the question.  \n ", "original_text": "Just wanted to get more sense on this segment is like - it could be a bigger contributor going \nforward, thanks.  \n \n", "page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce010191bfca03523fd01fa2ffdf502a71f32ca0b71933b8dbe1cba641af04b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2bb43c3-06c3-44e7-b105-b1035c9c15f4", "node_type": "1", "metadata": {"window": " \nPage 18 of 31 \n \n You know, it's interesting.  We did take a look at that business.  We really haven't seen much \nimpact on that business from the pandemic.  Because if you think about it it's people that are at home.  \n \n ", "original_text": " \nPage 18 of 31 \n \n You know, it's interesting. "}, "hash": "1c124f7c4465fb84de883eb915bbb36b6079639ad517339f3cbf2dd27bc5b951", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufman n:  Yes, thanks for the question.  \n ", "start_char_idx": 1388, "end_char_idx": 1438, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2bb43c3-06c3-44e7-b105-b1035c9c15f4": {"__data__": {"id_": "c2bb43c3-06c3-44e7-b105-b1035c9c15f4", "embedding": null, "metadata": {"window": " \nPage 18 of 31 \n \n You know, it's interesting.  We did take a look at that business.  We really haven't seen much \nimpact on that business from the pandemic.  Because if you think about it it's people that are at home.  \n \n ", "original_text": " \nPage 18 of 31 \n \n You know, it's interesting. ", "page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c854892-2d3f-4fb8-9537-8c1dc858f5cf", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ba75892df5d6edff1336401fda825bb021f4cc3ef8ecf596d0dd9d1cc292c0b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb194900-2bc0-48b0-b875-640ffaab0ee5", "node_type": "1", "metadata": {"window": "Just wanted to ask actually still a \nlittle bit more on Medical but - we really want to focus on the at -Home business and, you know, \nobviously this is a business you guys got into several years ago and at times you've sp oken about it \nclearly with COVID - I would imagine that the home business has really accelerated, you kind of hear \nthat in the home health sector as well.  \n \n  Can you give us a sense more of, you know, what the make -up of this business is, you know, \nany kind  of metrics around the size of this business now within medical, sort of the growth rates \nrelative to the overall business and some of the dynamics that are impacting this that might be more \npositive or, you know, or more of a headwind because of the pande mic relative to the rest of the \nbusiness - I'd imagine that maybe this has PPE requirements that are hindering you or maybe not.  \n \n  Just wanted to get more sense on this segment is like - it could be a bigger contributor going \nforward, thanks.  \n \n Mike Kaufman n:  Yes, thanks for the question.  \n ", "original_text": "Mike Kaufman n:  Yes, thanks for the question.  \n ", "page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a2857064f8439e128cf5d9e221092a46cadf58062178e70eb2ba6df3c64b18d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbcb9245-c4a4-4d2c-852f-89e6d9903875", "node_type": "1", "metadata": {"window": " \nPage 18 of 31 \n \n You know, it's interesting.  We did take a look at that business.  We really haven't seen much \nimpact on that business from the pandemic.  Because if you think about it it's people that are at home.  \n \n  And so they don't real ly have a need for PPE there because they're essentially treating \nthemselves. ", "original_text": "We did take a look at that business. "}, "hash": "6844e576a8da9a6b4f002cefd050143a8cd29f531f9c466a460b53a81070f9fe", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 18 of 31 \n \n You know, it's interesting. ", "start_char_idx": 0, "end_char_idx": 48, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbcb9245-c4a4-4d2c-852f-89e6d9903875": {"__data__": {"id_": "dbcb9245-c4a4-4d2c-852f-89e6d9903875", "embedding": null, "metadata": {"window": " \nPage 18 of 31 \n \n You know, it's interesting.  We did take a look at that business.  We really haven't seen much \nimpact on that business from the pandemic.  Because if you think about it it's people that are at home.  \n \n  And so they don't real ly have a need for PPE there because they're essentially treating \nthemselves. ", "original_text": "We did take a look at that business. ", "page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c854892-2d3f-4fb8-9537-8c1dc858f5cf", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ba75892df5d6edff1336401fda825bb021f4cc3ef8ecf596d0dd9d1cc292c0b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2bb43c3-06c3-44e7-b105-b1035c9c15f4", "node_type": "1", "metadata": {"window": " \nPage 18 of 31 \n \n You know, it's interesting.  We did take a look at that business.  We really haven't seen much \nimpact on that business from the pandemic.  Because if you think about it it's people that are at home.  \n \n ", "original_text": " \nPage 18 of 31 \n \n You know, it's interesting. ", "page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc9f18ef0617d9d28fc84d66a6fcd96170b666d36a994ae15df7714b39b8c4ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a58f672b-65de-4694-8619-18fbfda68c0c", "node_type": "1", "metadata": {"window": " \nPage 18 of 31 \n \n You know, it's interesting.  We did take a look at that business.  We really haven't seen much \nimpact on that business from the pandemic.  Because if you think about it it's people that are at home.  \n \n  And so they don't real ly have a need for PPE there because they're essentially treating \nthemselves.  And so we continue to just deliver products to the home.  \n \n ", "original_text": "We really haven't seen much \nimpact on that business from the pandemic. "}, "hash": "0db20528fc291508c7b441c3ce3f04b4fc49e762f254512cc01047f5d8c4d04f", "class_name": "RelatedNodeInfo"}}, "text": "We did take a look at that business. ", "start_char_idx": 48, "end_char_idx": 85, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a58f672b-65de-4694-8619-18fbfda68c0c": {"__data__": {"id_": "a58f672b-65de-4694-8619-18fbfda68c0c", "embedding": null, "metadata": {"window": " \nPage 18 of 31 \n \n You know, it's interesting.  We did take a look at that business.  We really haven't seen much \nimpact on that business from the pandemic.  Because if you think about it it's people that are at home.  \n \n  And so they don't real ly have a need for PPE there because they're essentially treating \nthemselves.  And so we continue to just deliver products to the home.  \n \n ", "original_text": "We really haven't seen much \nimpact on that business from the pandemic. ", "page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c854892-2d3f-4fb8-9537-8c1dc858f5cf", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ba75892df5d6edff1336401fda825bb021f4cc3ef8ecf596d0dd9d1cc292c0b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbcb9245-c4a4-4d2c-852f-89e6d9903875", "node_type": "1", "metadata": {"window": " \nPage 18 of 31 \n \n You know, it's interesting.  We did take a look at that business.  We really haven't seen much \nimpact on that business from the pandemic.  Because if you think about it it's people that are at home.  \n \n  And so they don't real ly have a need for PPE there because they're essentially treating \nthemselves. ", "original_text": "We did take a look at that business. ", "page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9fa2a5f813ba35007b0a7c1e576cb95884ac2dfd9ba97549e0131339d7913deb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73a15440-c6b6-4d63-a9c7-ab6a08483d7c", "node_type": "1", "metadata": {"window": " \nPage 18 of 31 \n \n You know, it's interesting.  We did take a look at that business.  We really haven't seen much \nimpact on that business from the pandemic.  Because if you think about it it's people that are at home.  \n \n  And so they don't real ly have a need for PPE there because they're essentially treating \nthemselves.  And so we continue to just deliver products to the home.  \n \n  So that's a business that continues to grow well for us. ", "original_text": "Because if you think about it it's people that are at home.  \n \n "}, "hash": "6fb938fc4c4fc3db53cdc63b3f8ab2b478dec6a2bb01b930de3b528f5b94619c", "class_name": "RelatedNodeInfo"}}, "text": "We really haven't seen much \nimpact on that business from the pandemic. ", "start_char_idx": 85, "end_char_idx": 157, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73a15440-c6b6-4d63-a9c7-ab6a08483d7c": {"__data__": {"id_": "73a15440-c6b6-4d63-a9c7-ab6a08483d7c", "embedding": null, "metadata": {"window": " \nPage 18 of 31 \n \n You know, it's interesting.  We did take a look at that business.  We really haven't seen much \nimpact on that business from the pandemic.  Because if you think about it it's people that are at home.  \n \n  And so they don't real ly have a need for PPE there because they're essentially treating \nthemselves.  And so we continue to just deliver products to the home.  \n \n  So that's a business that continues to grow well for us. ", "original_text": "Because if you think about it it's people that are at home.  \n \n ", "page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c854892-2d3f-4fb8-9537-8c1dc858f5cf", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ba75892df5d6edff1336401fda825bb021f4cc3ef8ecf596d0dd9d1cc292c0b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a58f672b-65de-4694-8619-18fbfda68c0c", "node_type": "1", "metadata": {"window": " \nPage 18 of 31 \n \n You know, it's interesting.  We did take a look at that business.  We really haven't seen much \nimpact on that business from the pandemic.  Because if you think about it it's people that are at home.  \n \n  And so they don't real ly have a need for PPE there because they're essentially treating \nthemselves.  And so we continue to just deliver products to the home.  \n \n ", "original_text": "We really haven't seen much \nimpact on that business from the pandemic. ", "page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "663e44031c8420e42d509b217746c50b824888f59144e7950ddeb3eab6c84f67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80af2dc2-32d1-44e8-8f77-d2474808c035", "node_type": "1", "metadata": {"window": "We did take a look at that business.  We really haven't seen much \nimpact on that business from the pandemic.  Because if you think about it it's people that are at home.  \n \n  And so they don't real ly have a need for PPE there because they're essentially treating \nthemselves.  And so we continue to just deliver products to the home.  \n \n  So that's a business that continues to grow well for us.  We see it as one of our strategic growth \nareas. ", "original_text": "And so they don't real ly have a need for PPE there because they're essentially treating \nthemselves. "}, "hash": "48584664b25d4e5c98f38bf5c964c7269a9f32e17a3d8c71343c338a22252c3e", "class_name": "RelatedNodeInfo"}}, "text": "Because if you think about it it's people that are at home.  \n \n ", "start_char_idx": 157, "end_char_idx": 222, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80af2dc2-32d1-44e8-8f77-d2474808c035": {"__data__": {"id_": "80af2dc2-32d1-44e8-8f77-d2474808c035", "embedding": null, "metadata": {"window": "We did take a look at that business.  We really haven't seen much \nimpact on that business from the pandemic.  Because if you think about it it's people that are at home.  \n \n  And so they don't real ly have a need for PPE there because they're essentially treating \nthemselves.  And so we continue to just deliver products to the home.  \n \n  So that's a business that continues to grow well for us.  We see it as one of our strategic growth \nareas. ", "original_text": "And so they don't real ly have a need for PPE there because they're essentially treating \nthemselves. ", "page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c854892-2d3f-4fb8-9537-8c1dc858f5cf", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ba75892df5d6edff1336401fda825bb021f4cc3ef8ecf596d0dd9d1cc292c0b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73a15440-c6b6-4d63-a9c7-ab6a08483d7c", "node_type": "1", "metadata": {"window": " \nPage 18 of 31 \n \n You know, it's interesting.  We did take a look at that business.  We really haven't seen much \nimpact on that business from the pandemic.  Because if you think about it it's people that are at home.  \n \n  And so they don't real ly have a need for PPE there because they're essentially treating \nthemselves.  And so we continue to just deliver products to the home.  \n \n  So that's a business that continues to grow well for us. ", "original_text": "Because if you think about it it's people that are at home.  \n \n ", "page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5616782cef8a9747fd64d0d213d488b41e3bff1ed748992d08b943a66be2513c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e7f6b3b-015d-4e7e-b0a5-8d076e2b55ee", "node_type": "1", "metadata": {"window": "We really haven't seen much \nimpact on that business from the pandemic.  Because if you think about it it's people that are at home.  \n \n  And so they don't real ly have a need for PPE there because they're essentially treating \nthemselves.  And so we continue to just deliver products to the home.  \n \n  So that's a business that continues to grow well for us.  We see it as one of our strategic growth \nareas.  We're absolute ly going to continue to invest in it and we do see care moving more and more to \nthe home.  \n \n ", "original_text": "And so we continue to just deliver products to the home.  \n \n "}, "hash": "fd50c16790a7f0daed03d7feca9c877212e10c55d0cbfd2884461fc29744ed5a", "class_name": "RelatedNodeInfo"}}, "text": "And so they don't real ly have a need for PPE there because they're essentially treating \nthemselves. ", "start_char_idx": 222, "end_char_idx": 324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e7f6b3b-015d-4e7e-b0a5-8d076e2b55ee": {"__data__": {"id_": "4e7f6b3b-015d-4e7e-b0a5-8d076e2b55ee", "embedding": null, "metadata": {"window": "We really haven't seen much \nimpact on that business from the pandemic.  Because if you think about it it's people that are at home.  \n \n  And so they don't real ly have a need for PPE there because they're essentially treating \nthemselves.  And so we continue to just deliver products to the home.  \n \n  So that's a business that continues to grow well for us.  We see it as one of our strategic growth \nareas.  We're absolute ly going to continue to invest in it and we do see care moving more and more to \nthe home.  \n \n ", "original_text": "And so we continue to just deliver products to the home.  \n \n ", "page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c854892-2d3f-4fb8-9537-8c1dc858f5cf", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ba75892df5d6edff1336401fda825bb021f4cc3ef8ecf596d0dd9d1cc292c0b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80af2dc2-32d1-44e8-8f77-d2474808c035", "node_type": "1", "metadata": {"window": "We did take a look at that business.  We really haven't seen much \nimpact on that business from the pandemic.  Because if you think about it it's people that are at home.  \n \n  And so they don't real ly have a need for PPE there because they're essentially treating \nthemselves.  And so we continue to just deliver products to the home.  \n \n  So that's a business that continues to grow well for us.  We see it as one of our strategic growth \nareas. ", "original_text": "And so they don't real ly have a need for PPE there because they're essentially treating \nthemselves. ", "page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98e736bdf6b96ed0ce64897cb7b13ece298061a598d79328cfb53094b97a03a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "853c1a37-60a4-497e-95af-069473f24ec3", "node_type": "1", "metadata": {"window": "Because if you think about it it's people that are at home.  \n \n  And so they don't real ly have a need for PPE there because they're essentially treating \nthemselves.  And so we continue to just deliver products to the home.  \n \n  So that's a business that continues to grow well for us.  We see it as one of our strategic growth \nareas.  We're absolute ly going to continue to invest in it and we do see care moving more and more to \nthe home.  \n \n  But we really didn't see much from the pandemic affected either negatively or positively and to \nalso be helpful - it's about a $2 billion top -line business that, ag ain, we feel great about.  \n \n", "original_text": "So that's a business that continues to grow well for us. "}, "hash": "b56e6c8c622eff4da92c5085c4d2c8472c3e2b34bd6ce015b70f168e53f22758", "class_name": "RelatedNodeInfo"}}, "text": "And so we continue to just deliver products to the home.  \n \n ", "start_char_idx": 324, "end_char_idx": 386, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "853c1a37-60a4-497e-95af-069473f24ec3": {"__data__": {"id_": "853c1a37-60a4-497e-95af-069473f24ec3", "embedding": null, "metadata": {"window": "Because if you think about it it's people that are at home.  \n \n  And so they don't real ly have a need for PPE there because they're essentially treating \nthemselves.  And so we continue to just deliver products to the home.  \n \n  So that's a business that continues to grow well for us.  We see it as one of our strategic growth \nareas.  We're absolute ly going to continue to invest in it and we do see care moving more and more to \nthe home.  \n \n  But we really didn't see much from the pandemic affected either negatively or positively and to \nalso be helpful - it's about a $2 billion top -line business that, ag ain, we feel great about.  \n \n", "original_text": "So that's a business that continues to grow well for us. ", "page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c854892-2d3f-4fb8-9537-8c1dc858f5cf", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ba75892df5d6edff1336401fda825bb021f4cc3ef8ecf596d0dd9d1cc292c0b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e7f6b3b-015d-4e7e-b0a5-8d076e2b55ee", "node_type": "1", "metadata": {"window": "We really haven't seen much \nimpact on that business from the pandemic.  Because if you think about it it's people that are at home.  \n \n  And so they don't real ly have a need for PPE there because they're essentially treating \nthemselves.  And so we continue to just deliver products to the home.  \n \n  So that's a business that continues to grow well for us.  We see it as one of our strategic growth \nareas.  We're absolute ly going to continue to invest in it and we do see care moving more and more to \nthe home.  \n \n ", "original_text": "And so we continue to just deliver products to the home.  \n \n ", "page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aeee3aeef1d6e96e4c07fdb4d22488d666abb90c416fc421a095a646fe48d5ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b52ca8b-f39a-464a-a428-ae8e1ddcb941", "node_type": "1", "metadata": {"window": "And so they don't real ly have a need for PPE there because they're essentially treating \nthemselves.  And so we continue to just deliver products to the home.  \n \n  So that's a business that continues to grow well for us.  We see it as one of our strategic growth \nareas.  We're absolute ly going to continue to invest in it and we do see care moving more and more to \nthe home.  \n \n  But we really didn't see much from the pandemic affected either negatively or positively and to \nalso be helpful - it's about a $2 billion top -line business that, ag ain, we feel great about.  \n \n Charles R hyee:  Any kind of growth rate kind of estimates you can provide us relative to the total \nbusiness?  \n \n", "original_text": "We see it as one of our strategic growth \nareas. "}, "hash": "625e4a8074afb458e4b9d85b658b670bbfcef1ed72998f8c8a4766813cb89137", "class_name": "RelatedNodeInfo"}}, "text": "So that's a business that continues to grow well for us. ", "start_char_idx": 386, "end_char_idx": 443, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b52ca8b-f39a-464a-a428-ae8e1ddcb941": {"__data__": {"id_": "8b52ca8b-f39a-464a-a428-ae8e1ddcb941", "embedding": null, "metadata": {"window": "And so they don't real ly have a need for PPE there because they're essentially treating \nthemselves.  And so we continue to just deliver products to the home.  \n \n  So that's a business that continues to grow well for us.  We see it as one of our strategic growth \nareas.  We're absolute ly going to continue to invest in it and we do see care moving more and more to \nthe home.  \n \n  But we really didn't see much from the pandemic affected either negatively or positively and to \nalso be helpful - it's about a $2 billion top -line business that, ag ain, we feel great about.  \n \n Charles R hyee:  Any kind of growth rate kind of estimates you can provide us relative to the total \nbusiness?  \n \n", "original_text": "We see it as one of our strategic growth \nareas. ", "page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c854892-2d3f-4fb8-9537-8c1dc858f5cf", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ba75892df5d6edff1336401fda825bb021f4cc3ef8ecf596d0dd9d1cc292c0b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "853c1a37-60a4-497e-95af-069473f24ec3", "node_type": "1", "metadata": {"window": "Because if you think about it it's people that are at home.  \n \n  And so they don't real ly have a need for PPE there because they're essentially treating \nthemselves.  And so we continue to just deliver products to the home.  \n \n  So that's a business that continues to grow well for us.  We see it as one of our strategic growth \nareas.  We're absolute ly going to continue to invest in it and we do see care moving more and more to \nthe home.  \n \n  But we really didn't see much from the pandemic affected either negatively or positively and to \nalso be helpful - it's about a $2 billion top -line business that, ag ain, we feel great about.  \n \n", "original_text": "So that's a business that continues to grow well for us. ", "page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5093478241ad658366bd89b9f8036eb37f32f6df49191c4eab8ab2ec495a1ce9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fbf4d4c0-cf07-4d21-8cbe-4694658971ea", "node_type": "1", "metadata": {"window": "And so we continue to just deliver products to the home.  \n \n  So that's a business that continues to grow well for us.  We see it as one of our strategic growth \nareas.  We're absolute ly going to continue to invest in it and we do see care moving more and more to \nthe home.  \n \n  But we really didn't see much from the pandemic affected either negatively or positively and to \nalso be helpful - it's about a $2 billion top -line business that, ag ain, we feel great about.  \n \n Charles R hyee:  Any kind of growth rate kind of estimates you can provide us relative to the total \nbusiness?  \n \n Mike Kaufma nn:  You know, that's a business that over the last several years that's been growing \nsomewhere in the high single to low double digits depending on the year and some of the various \nintroductions of products and we would expect that to be able to continue to grow like that going \nforward.  \n \n", "original_text": "We're absolute ly going to continue to invest in it and we do see care moving more and more to \nthe home.  \n \n "}, "hash": "f2cd49900e983c7e2a8d0437cc4acef3affe33fa6b9ca480d32807c905efdd87", "class_name": "RelatedNodeInfo"}}, "text": "We see it as one of our strategic growth \nareas. ", "start_char_idx": 443, "end_char_idx": 492, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbf4d4c0-cf07-4d21-8cbe-4694658971ea": {"__data__": {"id_": "fbf4d4c0-cf07-4d21-8cbe-4694658971ea", "embedding": null, "metadata": {"window": "And so we continue to just deliver products to the home.  \n \n  So that's a business that continues to grow well for us.  We see it as one of our strategic growth \nareas.  We're absolute ly going to continue to invest in it and we do see care moving more and more to \nthe home.  \n \n  But we really didn't see much from the pandemic affected either negatively or positively and to \nalso be helpful - it's about a $2 billion top -line business that, ag ain, we feel great about.  \n \n Charles R hyee:  Any kind of growth rate kind of estimates you can provide us relative to the total \nbusiness?  \n \n Mike Kaufma nn:  You know, that's a business that over the last several years that's been growing \nsomewhere in the high single to low double digits depending on the year and some of the various \nintroductions of products and we would expect that to be able to continue to grow like that going \nforward.  \n \n", "original_text": "We're absolute ly going to continue to invest in it and we do see care moving more and more to \nthe home.  \n \n ", "page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c854892-2d3f-4fb8-9537-8c1dc858f5cf", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ba75892df5d6edff1336401fda825bb021f4cc3ef8ecf596d0dd9d1cc292c0b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b52ca8b-f39a-464a-a428-ae8e1ddcb941", "node_type": "1", "metadata": {"window": "And so they don't real ly have a need for PPE there because they're essentially treating \nthemselves.  And so we continue to just deliver products to the home.  \n \n  So that's a business that continues to grow well for us.  We see it as one of our strategic growth \nareas.  We're absolute ly going to continue to invest in it and we do see care moving more and more to \nthe home.  \n \n  But we really didn't see much from the pandemic affected either negatively or positively and to \nalso be helpful - it's about a $2 billion top -line business that, ag ain, we feel great about.  \n \n Charles R hyee:  Any kind of growth rate kind of estimates you can provide us relative to the total \nbusiness?  \n \n", "original_text": "We see it as one of our strategic growth \nareas. ", "page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8902706c10e25047d16101c0aeeefeb63dd17f0c23a4eaeeeadefd6b238b2333", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6d90fc0-ba96-4822-b279-0eddc51e45a2", "node_type": "1", "metadata": {"window": "So that's a business that continues to grow well for us.  We see it as one of our strategic growth \nareas.  We're absolute ly going to continue to invest in it and we do see care moving more and more to \nthe home.  \n \n  But we really didn't see much from the pandemic affected either negatively or positively and to \nalso be helpful - it's about a $2 billion top -line business that, ag ain, we feel great about.  \n \n Charles R hyee:  Any kind of growth rate kind of estimates you can provide us relative to the total \nbusiness?  \n \n Mike Kaufma nn:  You know, that's a business that over the last several years that's been growing \nsomewhere in the high single to low double digits depending on the year and some of the various \nintroductions of products and we would expect that to be able to continue to grow like that going \nforward.  \n \n Charles R hyee:  Great. ", "original_text": "But we really didn't see much from the pandemic affected either negatively or positively and to \nalso be helpful - it's about a $2 billion top -line business that, ag ain, we feel great about.  \n \n"}, "hash": "7c0cdc07204e80a79ba8578653d26b6a0af1c827dbc81c03a3e4529904bb2b48", "class_name": "RelatedNodeInfo"}}, "text": "We're absolute ly going to continue to invest in it and we do see care moving more and more to \nthe home.  \n \n ", "start_char_idx": 492, "end_char_idx": 603, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6d90fc0-ba96-4822-b279-0eddc51e45a2": {"__data__": {"id_": "d6d90fc0-ba96-4822-b279-0eddc51e45a2", "embedding": null, "metadata": {"window": "So that's a business that continues to grow well for us.  We see it as one of our strategic growth \nareas.  We're absolute ly going to continue to invest in it and we do see care moving more and more to \nthe home.  \n \n  But we really didn't see much from the pandemic affected either negatively or positively and to \nalso be helpful - it's about a $2 billion top -line business that, ag ain, we feel great about.  \n \n Charles R hyee:  Any kind of growth rate kind of estimates you can provide us relative to the total \nbusiness?  \n \n Mike Kaufma nn:  You know, that's a business that over the last several years that's been growing \nsomewhere in the high single to low double digits depending on the year and some of the various \nintroductions of products and we would expect that to be able to continue to grow like that going \nforward.  \n \n Charles R hyee:  Great. ", "original_text": "But we really didn't see much from the pandemic affected either negatively or positively and to \nalso be helpful - it's about a $2 billion top -line business that, ag ain, we feel great about.  \n \n", "page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c854892-2d3f-4fb8-9537-8c1dc858f5cf", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ba75892df5d6edff1336401fda825bb021f4cc3ef8ecf596d0dd9d1cc292c0b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fbf4d4c0-cf07-4d21-8cbe-4694658971ea", "node_type": "1", "metadata": {"window": "And so we continue to just deliver products to the home.  \n \n  So that's a business that continues to grow well for us.  We see it as one of our strategic growth \nareas.  We're absolute ly going to continue to invest in it and we do see care moving more and more to \nthe home.  \n \n  But we really didn't see much from the pandemic affected either negatively or positively and to \nalso be helpful - it's about a $2 billion top -line business that, ag ain, we feel great about.  \n \n Charles R hyee:  Any kind of growth rate kind of estimates you can provide us relative to the total \nbusiness?  \n \n Mike Kaufma nn:  You know, that's a business that over the last several years that's been growing \nsomewhere in the high single to low double digits depending on the year and some of the various \nintroductions of products and we would expect that to be able to continue to grow like that going \nforward.  \n \n", "original_text": "We're absolute ly going to continue to invest in it and we do see care moving more and more to \nthe home.  \n \n ", "page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "df5f9b3c6622246901691a2c6b07ad1e3b1419f25a10c6000155ef4ff62f1226", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "687fc24a-7e68-46a4-8213-ff41a9684267", "node_type": "1", "metadata": {"window": "We see it as one of our strategic growth \nareas.  We're absolute ly going to continue to invest in it and we do see care moving more and more to \nthe home.  \n \n  But we really didn't see much from the pandemic affected either negatively or positively and to \nalso be helpful - it's about a $2 billion top -line business that, ag ain, we feel great about.  \n \n Charles R hyee:  Any kind of growth rate kind of estimates you can provide us relative to the total \nbusiness?  \n \n Mike Kaufma nn:  You know, that's a business that over the last several years that's been growing \nsomewhere in the high single to low double digits depending on the year and some of the various \nintroductions of products and we would expect that to be able to continue to grow like that going \nforward.  \n \n Charles R hyee:  Great.  Thanks a lot.  \n \n", "original_text": "Charles R hyee:  Any kind of growth rate kind of estimates you can provide us relative to the total \nbusiness?  \n \n"}, "hash": "ca6956fa555620fb437220ab49349354d2d86c407fc8d7f61bc6407eab456dcd", "class_name": "RelatedNodeInfo"}}, "text": "But we really didn't see much from the pandemic affected either negatively or positively and to \nalso be helpful - it's about a $2 billion top -line business that, ag ain, we feel great about.  \n \n", "start_char_idx": 603, "end_char_idx": 800, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "687fc24a-7e68-46a4-8213-ff41a9684267": {"__data__": {"id_": "687fc24a-7e68-46a4-8213-ff41a9684267", "embedding": null, "metadata": {"window": "We see it as one of our strategic growth \nareas.  We're absolute ly going to continue to invest in it and we do see care moving more and more to \nthe home.  \n \n  But we really didn't see much from the pandemic affected either negatively or positively and to \nalso be helpful - it's about a $2 billion top -line business that, ag ain, we feel great about.  \n \n Charles R hyee:  Any kind of growth rate kind of estimates you can provide us relative to the total \nbusiness?  \n \n Mike Kaufma nn:  You know, that's a business that over the last several years that's been growing \nsomewhere in the high single to low double digits depending on the year and some of the various \nintroductions of products and we would expect that to be able to continue to grow like that going \nforward.  \n \n Charles R hyee:  Great.  Thanks a lot.  \n \n", "original_text": "Charles R hyee:  Any kind of growth rate kind of estimates you can provide us relative to the total \nbusiness?  \n \n", "page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c854892-2d3f-4fb8-9537-8c1dc858f5cf", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ba75892df5d6edff1336401fda825bb021f4cc3ef8ecf596d0dd9d1cc292c0b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6d90fc0-ba96-4822-b279-0eddc51e45a2", "node_type": "1", "metadata": {"window": "So that's a business that continues to grow well for us.  We see it as one of our strategic growth \nareas.  We're absolute ly going to continue to invest in it and we do see care moving more and more to \nthe home.  \n \n  But we really didn't see much from the pandemic affected either negatively or positively and to \nalso be helpful - it's about a $2 billion top -line business that, ag ain, we feel great about.  \n \n Charles R hyee:  Any kind of growth rate kind of estimates you can provide us relative to the total \nbusiness?  \n \n Mike Kaufma nn:  You know, that's a business that over the last several years that's been growing \nsomewhere in the high single to low double digits depending on the year and some of the various \nintroductions of products and we would expect that to be able to continue to grow like that going \nforward.  \n \n Charles R hyee:  Great. ", "original_text": "But we really didn't see much from the pandemic affected either negatively or positively and to \nalso be helpful - it's about a $2 billion top -line business that, ag ain, we feel great about.  \n \n", "page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e014e2153b09c7de904d66e4f59387b359132bd9ac70b4e8aef0e96c52eb74e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10e586bd-10c2-4b5e-b7f8-abc07dbba3dd", "node_type": "1", "metadata": {"window": "We're absolute ly going to continue to invest in it and we do see care moving more and more to \nthe home.  \n \n  But we really didn't see much from the pandemic affected either negatively or positively and to \nalso be helpful - it's about a $2 billion top -line business that, ag ain, we feel great about.  \n \n Charles R hyee:  Any kind of growth rate kind of estimates you can provide us relative to the total \nbusiness?  \n \n Mike Kaufma nn:  You know, that's a business that over the last several years that's been growing \nsomewhere in the high single to low double digits depending on the year and some of the various \nintroductions of products and we would expect that to be able to continue to grow like that going \nforward.  \n \n Charles R hyee:  Great.  Thanks a lot.  \n \n Mike Kaufmann:  Yes, thanks Charles.  ", "original_text": "Mike Kaufma nn:  You know, that's a business that over the last several years that's been growing \nsomewhere in the high single to low double digits depending on the year and some of the various \nintroductions of products and we would expect that to be able to continue to grow like that going \nforward.  \n \n"}, "hash": "1ebf1bb1b2493eabef74865902dde9c8630e868a297af62e84989a8a94c586c4", "class_name": "RelatedNodeInfo"}}, "text": "Charles R hyee:  Any kind of growth rate kind of estimates you can provide us relative to the total \nbusiness?  \n \n", "start_char_idx": 800, "end_char_idx": 915, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10e586bd-10c2-4b5e-b7f8-abc07dbba3dd": {"__data__": {"id_": "10e586bd-10c2-4b5e-b7f8-abc07dbba3dd", "embedding": null, "metadata": {"window": "We're absolute ly going to continue to invest in it and we do see care moving more and more to \nthe home.  \n \n  But we really didn't see much from the pandemic affected either negatively or positively and to \nalso be helpful - it's about a $2 billion top -line business that, ag ain, we feel great about.  \n \n Charles R hyee:  Any kind of growth rate kind of estimates you can provide us relative to the total \nbusiness?  \n \n Mike Kaufma nn:  You know, that's a business that over the last several years that's been growing \nsomewhere in the high single to low double digits depending on the year and some of the various \nintroductions of products and we would expect that to be able to continue to grow like that going \nforward.  \n \n Charles R hyee:  Great.  Thanks a lot.  \n \n Mike Kaufmann:  Yes, thanks Charles.  ", "original_text": "Mike Kaufma nn:  You know, that's a business that over the last several years that's been growing \nsomewhere in the high single to low double digits depending on the year and some of the various \nintroductions of products and we would expect that to be able to continue to grow like that going \nforward.  \n \n", "page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c854892-2d3f-4fb8-9537-8c1dc858f5cf", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ba75892df5d6edff1336401fda825bb021f4cc3ef8ecf596d0dd9d1cc292c0b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "687fc24a-7e68-46a4-8213-ff41a9684267", "node_type": "1", "metadata": {"window": "We see it as one of our strategic growth \nareas.  We're absolute ly going to continue to invest in it and we do see care moving more and more to \nthe home.  \n \n  But we really didn't see much from the pandemic affected either negatively or positively and to \nalso be helpful - it's about a $2 billion top -line business that, ag ain, we feel great about.  \n \n Charles R hyee:  Any kind of growth rate kind of estimates you can provide us relative to the total \nbusiness?  \n \n Mike Kaufma nn:  You know, that's a business that over the last several years that's been growing \nsomewhere in the high single to low double digits depending on the year and some of the various \nintroductions of products and we would expect that to be able to continue to grow like that going \nforward.  \n \n Charles R hyee:  Great.  Thanks a lot.  \n \n", "original_text": "Charles R hyee:  Any kind of growth rate kind of estimates you can provide us relative to the total \nbusiness?  \n \n", "page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0db72e2079211d04ac1ba3da6a42c8a5940dcad4fffec71ef0966702d99c66e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff3a7f64-af73-4b34-86e4-a356dab49917", "node_type": "1", "metadata": {"window": "But we really didn't see much from the pandemic affected either negatively or positively and to \nalso be helpful - it's about a $2 billion top -line business that, ag ain, we feel great about.  \n \n Charles R hyee:  Any kind of growth rate kind of estimates you can provide us relative to the total \nbusiness?  \n \n Mike Kaufma nn:  You know, that's a business that over the last several years that's been growing \nsomewhere in the high single to low double digits depending on the year and some of the various \nintroductions of products and we would expect that to be able to continue to grow like that going \nforward.  \n \n Charles R hyee:  Great.  Thanks a lot.  \n \n Mike Kaufmann:  Yes, thanks Charles.  ", "original_text": "Charles R hyee:  Great. "}, "hash": "72a2b31d5fd6f963285ced3985104732a1e303f68453fcfbcc2e32740f843abe", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufma nn:  You know, that's a business that over the last several years that's been growing \nsomewhere in the high single to low double digits depending on the year and some of the various \nintroductions of products and we would expect that to be able to continue to grow like that going \nforward.  \n \n", "start_char_idx": 915, "end_char_idx": 1223, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff3a7f64-af73-4b34-86e4-a356dab49917": {"__data__": {"id_": "ff3a7f64-af73-4b34-86e4-a356dab49917", "embedding": null, "metadata": {"window": "But we really didn't see much from the pandemic affected either negatively or positively and to \nalso be helpful - it's about a $2 billion top -line business that, ag ain, we feel great about.  \n \n Charles R hyee:  Any kind of growth rate kind of estimates you can provide us relative to the total \nbusiness?  \n \n Mike Kaufma nn:  You know, that's a business that over the last several years that's been growing \nsomewhere in the high single to low double digits depending on the year and some of the various \nintroductions of products and we would expect that to be able to continue to grow like that going \nforward.  \n \n Charles R hyee:  Great.  Thanks a lot.  \n \n Mike Kaufmann:  Yes, thanks Charles.  ", "original_text": "Charles R hyee:  Great. ", "page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c854892-2d3f-4fb8-9537-8c1dc858f5cf", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ba75892df5d6edff1336401fda825bb021f4cc3ef8ecf596d0dd9d1cc292c0b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10e586bd-10c2-4b5e-b7f8-abc07dbba3dd", "node_type": "1", "metadata": {"window": "We're absolute ly going to continue to invest in it and we do see care moving more and more to \nthe home.  \n \n  But we really didn't see much from the pandemic affected either negatively or positively and to \nalso be helpful - it's about a $2 billion top -line business that, ag ain, we feel great about.  \n \n Charles R hyee:  Any kind of growth rate kind of estimates you can provide us relative to the total \nbusiness?  \n \n Mike Kaufma nn:  You know, that's a business that over the last several years that's been growing \nsomewhere in the high single to low double digits depending on the year and some of the various \nintroductions of products and we would expect that to be able to continue to grow like that going \nforward.  \n \n Charles R hyee:  Great.  Thanks a lot.  \n \n Mike Kaufmann:  Yes, thanks Charles.  ", "original_text": "Mike Kaufma nn:  You know, that's a business that over the last several years that's been growing \nsomewhere in the high single to low double digits depending on the year and some of the various \nintroductions of products and we would expect that to be able to continue to grow like that going \nforward.  \n \n", "page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ffa8a64e2f84e4e1b1b05c09ba1e0becb6334fbf4ec6871415e30624bb827ad4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9649b482-475b-42d8-886f-7d85e663108e", "node_type": "1", "metadata": {"window": "Charles R hyee:  Any kind of growth rate kind of estimates you can provide us relative to the total \nbusiness?  \n \n Mike Kaufma nn:  You know, that's a business that over the last several years that's been growing \nsomewhere in the high single to low double digits depending on the year and some of the various \nintroductions of products and we would expect that to be able to continue to grow like that going \nforward.  \n \n Charles R hyee:  Great.  Thanks a lot.  \n \n Mike Kaufmann:  Yes, thanks Charles.  ", "original_text": "Thanks a lot.  \n \n"}, "hash": "6319a406c478a1bb21aae4a482fc398c25a820ae1e6633b8c15b11afa291fee8", "class_name": "RelatedNodeInfo"}}, "text": "Charles R hyee:  Great. ", "start_char_idx": 1223, "end_char_idx": 1247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9649b482-475b-42d8-886f-7d85e663108e": {"__data__": {"id_": "9649b482-475b-42d8-886f-7d85e663108e", "embedding": null, "metadata": {"window": "Charles R hyee:  Any kind of growth rate kind of estimates you can provide us relative to the total \nbusiness?  \n \n Mike Kaufma nn:  You know, that's a business that over the last several years that's been growing \nsomewhere in the high single to low double digits depending on the year and some of the various \nintroductions of products and we would expect that to be able to continue to grow like that going \nforward.  \n \n Charles R hyee:  Great.  Thanks a lot.  \n \n Mike Kaufmann:  Yes, thanks Charles.  ", "original_text": "Thanks a lot.  \n \n", "page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c854892-2d3f-4fb8-9537-8c1dc858f5cf", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ba75892df5d6edff1336401fda825bb021f4cc3ef8ecf596d0dd9d1cc292c0b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff3a7f64-af73-4b34-86e4-a356dab49917", "node_type": "1", "metadata": {"window": "But we really didn't see much from the pandemic affected either negatively or positively and to \nalso be helpful - it's about a $2 billion top -line business that, ag ain, we feel great about.  \n \n Charles R hyee:  Any kind of growth rate kind of estimates you can provide us relative to the total \nbusiness?  \n \n Mike Kaufma nn:  You know, that's a business that over the last several years that's been growing \nsomewhere in the high single to low double digits depending on the year and some of the various \nintroductions of products and we would expect that to be able to continue to grow like that going \nforward.  \n \n Charles R hyee:  Great.  Thanks a lot.  \n \n Mike Kaufmann:  Yes, thanks Charles.  ", "original_text": "Charles R hyee:  Great. ", "page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49a2e7495cd97c67dabaf45b3ee716231d1516505b5328e9c1043ce7380d5f68", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ac25cc4-5f11-4965-aa21-8e0d8bd0051c", "node_type": "1", "metadata": {"window": "Mike Kaufma nn:  You know, that's a business that over the last several years that's been growing \nsomewhere in the high single to low double digits depending on the year and some of the various \nintroductions of products and we would expect that to be able to continue to grow like that going \nforward.  \n \n Charles R hyee:  Great.  Thanks a lot.  \n \n Mike Kaufmann:  Yes, thanks Charles.  ", "original_text": "Mike Kaufmann:  Yes, thanks Charles.  "}, "hash": "93dd525f23bed572790bae2936d5cad2505d92d1b66b80455ab35ca55049714f", "class_name": "RelatedNodeInfo"}}, "text": "Thanks a lot.  \n \n", "start_char_idx": 1247, "end_char_idx": 1265, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ac25cc4-5f11-4965-aa21-8e0d8bd0051c": {"__data__": {"id_": "8ac25cc4-5f11-4965-aa21-8e0d8bd0051c", "embedding": null, "metadata": {"window": "Mike Kaufma nn:  You know, that's a business that over the last several years that's been growing \nsomewhere in the high single to low double digits depending on the year and some of the various \nintroductions of products and we would expect that to be able to continue to grow like that going \nforward.  \n \n Charles R hyee:  Great.  Thanks a lot.  \n \n Mike Kaufmann:  Yes, thanks Charles.  ", "original_text": "Mike Kaufmann:  Yes, thanks Charles.  ", "page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c854892-2d3f-4fb8-9537-8c1dc858f5cf", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ba75892df5d6edff1336401fda825bb021f4cc3ef8ecf596d0dd9d1cc292c0b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9649b482-475b-42d8-886f-7d85e663108e", "node_type": "1", "metadata": {"window": "Charles R hyee:  Any kind of growth rate kind of estimates you can provide us relative to the total \nbusiness?  \n \n Mike Kaufma nn:  You know, that's a business that over the last several years that's been growing \nsomewhere in the high single to low double digits depending on the year and some of the various \nintroductions of products and we would expect that to be able to continue to grow like that going \nforward.  \n \n Charles R hyee:  Great.  Thanks a lot.  \n \n Mike Kaufmann:  Yes, thanks Charles.  ", "original_text": "Thanks a lot.  \n \n", "page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13d8eccb605f9a575f57ac97d2b81143754c1bcfa6fc5042942f8e26d05f3114", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd922fc6-f078-414a-a3cf-4600ae9d3a03", "node_type": "1", "metadata": {"window": " \nPage 19 of 31 \n \n \nOperator:  Thank you, and we'll next go to Lisa Gill with JP Morgan.  Please go ahead.  \n \n Lisa Gill:  Thanks very much.  Good morning.  \n \n ", "original_text": " \nPage 19 of 31 \n \n \nOperator:  Thank you, and we'll next go to Lisa Gill with JP Morgan. "}, "hash": "ff13ff3869887c90080d21d71a69e51cbae537ab1b2ac1062a972cf5ee5d94da", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes, thanks Charles.  ", "start_char_idx": 1265, "end_char_idx": 1303, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd922fc6-f078-414a-a3cf-4600ae9d3a03": {"__data__": {"id_": "dd922fc6-f078-414a-a3cf-4600ae9d3a03", "embedding": null, "metadata": {"window": " \nPage 19 of 31 \n \n \nOperator:  Thank you, and we'll next go to Lisa Gill with JP Morgan.  Please go ahead.  \n \n Lisa Gill:  Thanks very much.  Good morning.  \n \n ", "original_text": " \nPage 19 of 31 \n \n \nOperator:  Thank you, and we'll next go to Lisa Gill with JP Morgan. ", "page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "338c4ec9-a1cf-40ca-a930-96ab8b67eb44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b639d4859168a3409a50c4e5d5054fa5aef6e5db54b09143ebb9c2ee5014f931", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ac25cc4-5f11-4965-aa21-8e0d8bd0051c", "node_type": "1", "metadata": {"window": "Mike Kaufma nn:  You know, that's a business that over the last several years that's been growing \nsomewhere in the high single to low double digits depending on the year and some of the various \nintroductions of products and we would expect that to be able to continue to grow like that going \nforward.  \n \n Charles R hyee:  Great.  Thanks a lot.  \n \n Mike Kaufmann:  Yes, thanks Charles.  ", "original_text": "Mike Kaufmann:  Yes, thanks Charles.  ", "page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "091a6b581335ecdb26bd491932a9ec0b69d77fbec70554fa3ea549e5fb36c329", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aee34d0e-165e-4947-8be1-1ac884430560", "node_type": "1", "metadata": {"window": " \nPage 19 of 31 \n \n \nOperator:  Thank you, and we'll next go to Lisa Gill with JP Morgan.  Please go ahead.  \n \n Lisa Gill:  Thanks very much.  Good morning.  \n \n  Mike, just curious if you have any update on the opioids side. ", "original_text": "Please go ahead.  \n \n"}, "hash": "b735e7cc3b0ea02e72ab13ddaf0f798ed8e2126c4a18117e05c0ba3bfae6bfb9", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 19 of 31 \n \n \nOperator:  Thank you, and we'll next go to Lisa Gill with JP Morgan. ", "start_char_idx": 0, "end_char_idx": 90, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aee34d0e-165e-4947-8be1-1ac884430560": {"__data__": {"id_": "aee34d0e-165e-4947-8be1-1ac884430560", "embedding": null, "metadata": {"window": " \nPage 19 of 31 \n \n \nOperator:  Thank you, and we'll next go to Lisa Gill with JP Morgan.  Please go ahead.  \n \n Lisa Gill:  Thanks very much.  Good morning.  \n \n  Mike, just curious if you have any update on the opioids side. ", "original_text": "Please go ahead.  \n \n", "page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "338c4ec9-a1cf-40ca-a930-96ab8b67eb44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b639d4859168a3409a50c4e5d5054fa5aef6e5db54b09143ebb9c2ee5014f931", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd922fc6-f078-414a-a3cf-4600ae9d3a03", "node_type": "1", "metadata": {"window": " \nPage 19 of 31 \n \n \nOperator:  Thank you, and we'll next go to Lisa Gill with JP Morgan.  Please go ahead.  \n \n Lisa Gill:  Thanks very much.  Good morning.  \n \n ", "original_text": " \nPage 19 of 31 \n \n \nOperator:  Thank you, and we'll next go to Lisa Gill with JP Morgan. ", "page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4b3c70da160b81ac481b51430ecf6258f258fd8a573d64738d60b15db4046ed1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f700e947-0fb3-46be-92df-ed7b9bae9666", "node_type": "1", "metadata": {"window": " \nPage 19 of 31 \n \n \nOperator:  Thank you, and we'll next go to Lisa Gill with JP Morgan.  Please go ahead.  \n \n Lisa Gill:  Thanks very much.  Good morning.  \n \n  Mike, just curious if you have any update on the opioids side.  You know, I know the next court \ncases are s upposed to come in October but - and any update there? ", "original_text": "Lisa Gill:  Thanks very much. "}, "hash": "40965e9d66c166efec7aafffb8e9996a87933137e87dc116e1b73c368f76f140", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 90, "end_char_idx": 111, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f700e947-0fb3-46be-92df-ed7b9bae9666": {"__data__": {"id_": "f700e947-0fb3-46be-92df-ed7b9bae9666", "embedding": null, "metadata": {"window": " \nPage 19 of 31 \n \n \nOperator:  Thank you, and we'll next go to Lisa Gill with JP Morgan.  Please go ahead.  \n \n Lisa Gill:  Thanks very much.  Good morning.  \n \n  Mike, just curious if you have any update on the opioids side.  You know, I know the next court \ncases are s upposed to come in October but - and any update there? ", "original_text": "Lisa Gill:  Thanks very much. ", "page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "338c4ec9-a1cf-40ca-a930-96ab8b67eb44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b639d4859168a3409a50c4e5d5054fa5aef6e5db54b09143ebb9c2ee5014f931", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aee34d0e-165e-4947-8be1-1ac884430560", "node_type": "1", "metadata": {"window": " \nPage 19 of 31 \n \n \nOperator:  Thank you, and we'll next go to Lisa Gill with JP Morgan.  Please go ahead.  \n \n Lisa Gill:  Thanks very much.  Good morning.  \n \n  Mike, just curious if you have any update on the opioids side. ", "original_text": "Please go ahead.  \n \n", "page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9aa7ee71fa06aa83969e7dacbe231360f566ebd91295ef5dbd9c6b848d66c5bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4add8834-82a8-4a4a-8128-ab29dff7c8a6", "node_type": "1", "metadata": {"window": " \nPage 19 of 31 \n \n \nOperator:  Thank you, and we'll next go to Lisa Gill with JP Morgan.  Please go ahead.  \n \n Lisa Gill:  Thanks very much.  Good morning.  \n \n  Mike, just curious if you have any update on the opioids side.  You know, I know the next court \ncases are s upposed to come in October but - and any update there?  I know you increased the \nexpen ses to $100 million so I'm just curious if you were getting any closer?  \n \n", "original_text": "Good morning.  \n \n "}, "hash": "fcf84886176927a4bb3414ec02a94decc3761e5e4ff90c6334174d95cacf3668", "class_name": "RelatedNodeInfo"}}, "text": "Lisa Gill:  Thanks very much. ", "start_char_idx": 111, "end_char_idx": 141, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4add8834-82a8-4a4a-8128-ab29dff7c8a6": {"__data__": {"id_": "4add8834-82a8-4a4a-8128-ab29dff7c8a6", "embedding": null, "metadata": {"window": " \nPage 19 of 31 \n \n \nOperator:  Thank you, and we'll next go to Lisa Gill with JP Morgan.  Please go ahead.  \n \n Lisa Gill:  Thanks very much.  Good morning.  \n \n  Mike, just curious if you have any update on the opioids side.  You know, I know the next court \ncases are s upposed to come in October but - and any update there?  I know you increased the \nexpen ses to $100 million so I'm just curious if you were getting any closer?  \n \n", "original_text": "Good morning.  \n \n ", "page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "338c4ec9-a1cf-40ca-a930-96ab8b67eb44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b639d4859168a3409a50c4e5d5054fa5aef6e5db54b09143ebb9c2ee5014f931", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f700e947-0fb3-46be-92df-ed7b9bae9666", "node_type": "1", "metadata": {"window": " \nPage 19 of 31 \n \n \nOperator:  Thank you, and we'll next go to Lisa Gill with JP Morgan.  Please go ahead.  \n \n Lisa Gill:  Thanks very much.  Good morning.  \n \n  Mike, just curious if you have any update on the opioids side.  You know, I know the next court \ncases are s upposed to come in October but - and any update there? ", "original_text": "Lisa Gill:  Thanks very much. ", "page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e2ab4df58beaf8db26baae755d7ecaff8e2e72ed8459c68f08c9b5d0cd6993c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8890c6d2-58f0-4016-bac9-d7baf0148963", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Lisa Gill:  Thanks very much.  Good morning.  \n \n  Mike, just curious if you have any update on the opioids side.  You know, I know the next court \ncases are s upposed to come in October but - and any update there?  I know you increased the \nexpen ses to $100 million so I'm just curious if you were getting any closer?  \n \n Mike Kaufmann:  You know it's always a great question. ", "original_text": "Mike, just curious if you have any update on the opioids side. "}, "hash": "d332b9b5f027184d17590725c715a1bfd4186708574c5b98948b2010fe5d92a2", "class_name": "RelatedNodeInfo"}}, "text": "Good morning.  \n \n ", "start_char_idx": 141, "end_char_idx": 160, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8890c6d2-58f0-4016-bac9-d7baf0148963": {"__data__": {"id_": "8890c6d2-58f0-4016-bac9-d7baf0148963", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Lisa Gill:  Thanks very much.  Good morning.  \n \n  Mike, just curious if you have any update on the opioids side.  You know, I know the next court \ncases are s upposed to come in October but - and any update there?  I know you increased the \nexpen ses to $100 million so I'm just curious if you were getting any closer?  \n \n Mike Kaufmann:  You know it's always a great question. ", "original_text": "Mike, just curious if you have any update on the opioids side. ", "page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "338c4ec9-a1cf-40ca-a930-96ab8b67eb44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b639d4859168a3409a50c4e5d5054fa5aef6e5db54b09143ebb9c2ee5014f931", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4add8834-82a8-4a4a-8128-ab29dff7c8a6", "node_type": "1", "metadata": {"window": " \nPage 19 of 31 \n \n \nOperator:  Thank you, and we'll next go to Lisa Gill with JP Morgan.  Please go ahead.  \n \n Lisa Gill:  Thanks very much.  Good morning.  \n \n  Mike, just curious if you have any update on the opioids side.  You know, I know the next court \ncases are s upposed to come in October but - and any update there?  I know you increased the \nexpen ses to $100 million so I'm just curious if you were getting any closer?  \n \n", "original_text": "Good morning.  \n \n ", "page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc3f558bc9633d88196c1523d73e59f744a45118862fc91585ff6d4cddd18422", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c716b3c-8b13-4905-825c-e1d0b817c7e2", "node_type": "1", "metadata": {"window": "Lisa Gill:  Thanks very much.  Good morning.  \n \n  Mike, just curious if you have any update on the opioids side.  You know, I know the next court \ncases are s upposed to come in October but - and any update there?  I know you increased the \nexpen ses to $100 million so I'm just curious if you were getting any closer?  \n \n Mike Kaufmann:  You know it's always a great question.  I would tell you that we continue to make \nprogress on it while the COVID was happening so conversations continued to happen between us \nand the various attorney generals in the states but as far as anything that I can give you I wouldn't \nsay any major updates other than that we continue to make prog ress and have productive \nconversations.  \n \n ", "original_text": "You know, I know the next court \ncases are s upposed to come in October but - and any update there? "}, "hash": "3b852be77ad3446647be5e3e1d7c5f24b5c8f3c11f1ca30d212cbac7c18d5214", "class_name": "RelatedNodeInfo"}}, "text": "Mike, just curious if you have any update on the opioids side. ", "start_char_idx": 160, "end_char_idx": 223, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c716b3c-8b13-4905-825c-e1d0b817c7e2": {"__data__": {"id_": "8c716b3c-8b13-4905-825c-e1d0b817c7e2", "embedding": null, "metadata": {"window": "Lisa Gill:  Thanks very much.  Good morning.  \n \n  Mike, just curious if you have any update on the opioids side.  You know, I know the next court \ncases are s upposed to come in October but - and any update there?  I know you increased the \nexpen ses to $100 million so I'm just curious if you were getting any closer?  \n \n Mike Kaufmann:  You know it's always a great question.  I would tell you that we continue to make \nprogress on it while the COVID was happening so conversations continued to happen between us \nand the various attorney generals in the states but as far as anything that I can give you I wouldn't \nsay any major updates other than that we continue to make prog ress and have productive \nconversations.  \n \n ", "original_text": "You know, I know the next court \ncases are s upposed to come in October but - and any update there? ", "page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "338c4ec9-a1cf-40ca-a930-96ab8b67eb44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b639d4859168a3409a50c4e5d5054fa5aef6e5db54b09143ebb9c2ee5014f931", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8890c6d2-58f0-4016-bac9-d7baf0148963", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Lisa Gill:  Thanks very much.  Good morning.  \n \n  Mike, just curious if you have any update on the opioids side.  You know, I know the next court \ncases are s upposed to come in October but - and any update there?  I know you increased the \nexpen ses to $100 million so I'm just curious if you were getting any closer?  \n \n Mike Kaufmann:  You know it's always a great question. ", "original_text": "Mike, just curious if you have any update on the opioids side. ", "page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0eea704e2cdb6679021794ceb26ea78ce2a6f2f400474a1c2917cd76ff93455c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4fc98ee4-baf9-4208-9de8-7011f2c8e375", "node_type": "1", "metadata": {"window": "Good morning.  \n \n  Mike, just curious if you have any update on the opioids side.  You know, I know the next court \ncases are s upposed to come in October but - and any update there?  I know you increased the \nexpen ses to $100 million so I'm just curious if you were getting any closer?  \n \n Mike Kaufmann:  You know it's always a great question.  I would tell you that we continue to make \nprogress on it while the COVID was happening so conversations continued to happen between us \nand the various attorney generals in the states but as far as anything that I can give you I wouldn't \nsay any major updates other than that we continue to make prog ress and have productive \nconversations.  \n \n  The spend of 100 million in FY 21 is essentially what we spent in FY 20 so we're not expecting \nany incremental additional spend in those fees.  \n \n ", "original_text": "I know you increased the \nexpen ses to $100 million so I'm just curious if you were getting any closer?  \n \n"}, "hash": "1392965057ba1bc0bd8010595d6ca00e82e24e8e4c1edb285f8d936c93322737", "class_name": "RelatedNodeInfo"}}, "text": "You know, I know the next court \ncases are s upposed to come in October but - and any update there? ", "start_char_idx": 223, "end_char_idx": 323, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4fc98ee4-baf9-4208-9de8-7011f2c8e375": {"__data__": {"id_": "4fc98ee4-baf9-4208-9de8-7011f2c8e375", "embedding": null, "metadata": {"window": "Good morning.  \n \n  Mike, just curious if you have any update on the opioids side.  You know, I know the next court \ncases are s upposed to come in October but - and any update there?  I know you increased the \nexpen ses to $100 million so I'm just curious if you were getting any closer?  \n \n Mike Kaufmann:  You know it's always a great question.  I would tell you that we continue to make \nprogress on it while the COVID was happening so conversations continued to happen between us \nand the various attorney generals in the states but as far as anything that I can give you I wouldn't \nsay any major updates other than that we continue to make prog ress and have productive \nconversations.  \n \n  The spend of 100 million in FY 21 is essentially what we spent in FY 20 so we're not expecting \nany incremental additional spend in those fees.  \n \n ", "original_text": "I know you increased the \nexpen ses to $100 million so I'm just curious if you were getting any closer?  \n \n", "page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "338c4ec9-a1cf-40ca-a930-96ab8b67eb44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b639d4859168a3409a50c4e5d5054fa5aef6e5db54b09143ebb9c2ee5014f931", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c716b3c-8b13-4905-825c-e1d0b817c7e2", "node_type": "1", "metadata": {"window": "Lisa Gill:  Thanks very much.  Good morning.  \n \n  Mike, just curious if you have any update on the opioids side.  You know, I know the next court \ncases are s upposed to come in October but - and any update there?  I know you increased the \nexpen ses to $100 million so I'm just curious if you were getting any closer?  \n \n Mike Kaufmann:  You know it's always a great question.  I would tell you that we continue to make \nprogress on it while the COVID was happening so conversations continued to happen between us \nand the various attorney generals in the states but as far as anything that I can give you I wouldn't \nsay any major updates other than that we continue to make prog ress and have productive \nconversations.  \n \n ", "original_text": "You know, I know the next court \ncases are s upposed to come in October but - and any update there? ", "page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "69d69e40eda5725f0a124f85326197e85b38ae66febf30d4bf5b0da91f4dcde5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6a9e078-48d4-47a8-8d36-499224853e17", "node_type": "1", "metadata": {"window": "Mike, just curious if you have any update on the opioids side.  You know, I know the next court \ncases are s upposed to come in October but - and any update there?  I know you increased the \nexpen ses to $100 million so I'm just curious if you were getting any closer?  \n \n Mike Kaufmann:  You know it's always a great question.  I would tell you that we continue to make \nprogress on it while the COVID was happening so conversations continued to happen between us \nand the various attorney generals in the states but as far as anything that I can give you I wouldn't \nsay any major updates other than that we continue to make prog ress and have productive \nconversations.  \n \n  The spend of 100 million in FY 21 is essentially what we spent in FY 20 so we're not expecting \nany incremental additional spend in those fees.  \n \n  Thanks for the question.  \n \n", "original_text": "Mike Kaufmann:  You know it's always a great question. "}, "hash": "2fcf86f169bf285cdf25cadecb9a4c5238cd484cddde1c8e30478e9966e88c4a", "class_name": "RelatedNodeInfo"}}, "text": "I know you increased the \nexpen ses to $100 million so I'm just curious if you were getting any closer?  \n \n", "start_char_idx": 323, "end_char_idx": 431, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6a9e078-48d4-47a8-8d36-499224853e17": {"__data__": {"id_": "d6a9e078-48d4-47a8-8d36-499224853e17", "embedding": null, "metadata": {"window": "Mike, just curious if you have any update on the opioids side.  You know, I know the next court \ncases are s upposed to come in October but - and any update there?  I know you increased the \nexpen ses to $100 million so I'm just curious if you were getting any closer?  \n \n Mike Kaufmann:  You know it's always a great question.  I would tell you that we continue to make \nprogress on it while the COVID was happening so conversations continued to happen between us \nand the various attorney generals in the states but as far as anything that I can give you I wouldn't \nsay any major updates other than that we continue to make prog ress and have productive \nconversations.  \n \n  The spend of 100 million in FY 21 is essentially what we spent in FY 20 so we're not expecting \nany incremental additional spend in those fees.  \n \n  Thanks for the question.  \n \n", "original_text": "Mike Kaufmann:  You know it's always a great question. ", "page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "338c4ec9-a1cf-40ca-a930-96ab8b67eb44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b639d4859168a3409a50c4e5d5054fa5aef6e5db54b09143ebb9c2ee5014f931", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4fc98ee4-baf9-4208-9de8-7011f2c8e375", "node_type": "1", "metadata": {"window": "Good morning.  \n \n  Mike, just curious if you have any update on the opioids side.  You know, I know the next court \ncases are s upposed to come in October but - and any update there?  I know you increased the \nexpen ses to $100 million so I'm just curious if you were getting any closer?  \n \n Mike Kaufmann:  You know it's always a great question.  I would tell you that we continue to make \nprogress on it while the COVID was happening so conversations continued to happen between us \nand the various attorney generals in the states but as far as anything that I can give you I wouldn't \nsay any major updates other than that we continue to make prog ress and have productive \nconversations.  \n \n  The spend of 100 million in FY 21 is essentially what we spent in FY 20 so we're not expecting \nany incremental additional spend in those fees.  \n \n ", "original_text": "I know you increased the \nexpen ses to $100 million so I'm just curious if you were getting any closer?  \n \n", "page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e6067a685679eb98cd0e1681c1302830c6a53db6303f5d443e88916a657e5d20", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b4f728d-0881-4d9d-9028-bafa921ba161", "node_type": "1", "metadata": {"window": "You know, I know the next court \ncases are s upposed to come in October but - and any update there?  I know you increased the \nexpen ses to $100 million so I'm just curious if you were getting any closer?  \n \n Mike Kaufmann:  You know it's always a great question.  I would tell you that we continue to make \nprogress on it while the COVID was happening so conversations continued to happen between us \nand the various attorney generals in the states but as far as anything that I can give you I wouldn't \nsay any major updates other than that we continue to make prog ress and have productive \nconversations.  \n \n  The spend of 100 million in FY 21 is essentially what we spent in FY 20 so we're not expecting \nany incremental additional spend in those fees.  \n \n  Thanks for the question.  \n \n Operator:  Thank you. ", "original_text": "I would tell you that we continue to make \nprogress on it while the COVID was happening so conversations continued to happen between us \nand the various attorney generals in the states but as far as anything that I can give you I wouldn't \nsay any major updates other than that we continue to make prog ress and have productive \nconversations.  \n \n "}, "hash": "75806715dbb3a6f8bd135681ec903bac6b15621cf28d317ddcccae580a8e53e2", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  You know it's always a great question. ", "start_char_idx": 431, "end_char_idx": 486, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b4f728d-0881-4d9d-9028-bafa921ba161": {"__data__": {"id_": "9b4f728d-0881-4d9d-9028-bafa921ba161", "embedding": null, "metadata": {"window": "You know, I know the next court \ncases are s upposed to come in October but - and any update there?  I know you increased the \nexpen ses to $100 million so I'm just curious if you were getting any closer?  \n \n Mike Kaufmann:  You know it's always a great question.  I would tell you that we continue to make \nprogress on it while the COVID was happening so conversations continued to happen between us \nand the various attorney generals in the states but as far as anything that I can give you I wouldn't \nsay any major updates other than that we continue to make prog ress and have productive \nconversations.  \n \n  The spend of 100 million in FY 21 is essentially what we spent in FY 20 so we're not expecting \nany incremental additional spend in those fees.  \n \n  Thanks for the question.  \n \n Operator:  Thank you. ", "original_text": "I would tell you that we continue to make \nprogress on it while the COVID was happening so conversations continued to happen between us \nand the various attorney generals in the states but as far as anything that I can give you I wouldn't \nsay any major updates other than that we continue to make prog ress and have productive \nconversations.  \n \n ", "page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "338c4ec9-a1cf-40ca-a930-96ab8b67eb44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b639d4859168a3409a50c4e5d5054fa5aef6e5db54b09143ebb9c2ee5014f931", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6a9e078-48d4-47a8-8d36-499224853e17", "node_type": "1", "metadata": {"window": "Mike, just curious if you have any update on the opioids side.  You know, I know the next court \ncases are s upposed to come in October but - and any update there?  I know you increased the \nexpen ses to $100 million so I'm just curious if you were getting any closer?  \n \n Mike Kaufmann:  You know it's always a great question.  I would tell you that we continue to make \nprogress on it while the COVID was happening so conversations continued to happen between us \nand the various attorney generals in the states but as far as anything that I can give you I wouldn't \nsay any major updates other than that we continue to make prog ress and have productive \nconversations.  \n \n  The spend of 100 million in FY 21 is essentially what we spent in FY 20 so we're not expecting \nany incremental additional spend in those fees.  \n \n  Thanks for the question.  \n \n", "original_text": "Mike Kaufmann:  You know it's always a great question. ", "page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "48d79854c28a88a10c8ecc69fecf8ec64e53ed5c34d3ed11db14c88e1e1e1636", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8712c1b9-6317-497b-8cd9-6772a29c3c02", "node_type": "1", "metadata": {"window": "I know you increased the \nexpen ses to $100 million so I'm just curious if you were getting any closer?  \n \n Mike Kaufmann:  You know it's always a great question.  I would tell you that we continue to make \nprogress on it while the COVID was happening so conversations continued to happen between us \nand the various attorney generals in the states but as far as anything that I can give you I wouldn't \nsay any major updates other than that we continue to make prog ress and have productive \nconversations.  \n \n  The spend of 100 million in FY 21 is essentially what we spent in FY 20 so we're not expecting \nany incremental additional spend in those fees.  \n \n  Thanks for the question.  \n \n Operator:  Thank you.  We'll next go to Rick y Goldwasser, with Morgan Stanley. ", "original_text": "The spend of 100 million in FY 21 is essentially what we spent in FY 20 so we're not expecting \nany incremental additional spend in those fees.  \n \n "}, "hash": "74630a6b0bcd24b6d01e772b5adaf1c3addd507b861ef151f499f15e77fb192a", "class_name": "RelatedNodeInfo"}}, "text": "I would tell you that we continue to make \nprogress on it while the COVID was happening so conversations continued to happen between us \nand the various attorney generals in the states but as far as anything that I can give you I wouldn't \nsay any major updates other than that we continue to make prog ress and have productive \nconversations.  \n \n ", "start_char_idx": 486, "end_char_idx": 835, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8712c1b9-6317-497b-8cd9-6772a29c3c02": {"__data__": {"id_": "8712c1b9-6317-497b-8cd9-6772a29c3c02", "embedding": null, "metadata": {"window": "I know you increased the \nexpen ses to $100 million so I'm just curious if you were getting any closer?  \n \n Mike Kaufmann:  You know it's always a great question.  I would tell you that we continue to make \nprogress on it while the COVID was happening so conversations continued to happen between us \nand the various attorney generals in the states but as far as anything that I can give you I wouldn't \nsay any major updates other than that we continue to make prog ress and have productive \nconversations.  \n \n  The spend of 100 million in FY 21 is essentially what we spent in FY 20 so we're not expecting \nany incremental additional spend in those fees.  \n \n  Thanks for the question.  \n \n Operator:  Thank you.  We'll next go to Rick y Goldwasser, with Morgan Stanley. ", "original_text": "The spend of 100 million in FY 21 is essentially what we spent in FY 20 so we're not expecting \nany incremental additional spend in those fees.  \n \n ", "page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "338c4ec9-a1cf-40ca-a930-96ab8b67eb44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b639d4859168a3409a50c4e5d5054fa5aef6e5db54b09143ebb9c2ee5014f931", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b4f728d-0881-4d9d-9028-bafa921ba161", "node_type": "1", "metadata": {"window": "You know, I know the next court \ncases are s upposed to come in October but - and any update there?  I know you increased the \nexpen ses to $100 million so I'm just curious if you were getting any closer?  \n \n Mike Kaufmann:  You know it's always a great question.  I would tell you that we continue to make \nprogress on it while the COVID was happening so conversations continued to happen between us \nand the various attorney generals in the states but as far as anything that I can give you I wouldn't \nsay any major updates other than that we continue to make prog ress and have productive \nconversations.  \n \n  The spend of 100 million in FY 21 is essentially what we spent in FY 20 so we're not expecting \nany incremental additional spend in those fees.  \n \n  Thanks for the question.  \n \n Operator:  Thank you. ", "original_text": "I would tell you that we continue to make \nprogress on it while the COVID was happening so conversations continued to happen between us \nand the various attorney generals in the states but as far as anything that I can give you I wouldn't \nsay any major updates other than that we continue to make prog ress and have productive \nconversations.  \n \n ", "page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5cfb876aad67dbd15ef54d738ebdc8f06943648ed84415e22ed1667667c9871d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e06c071b-aa27-4cf8-89d2-a9636a170145", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  You know it's always a great question.  I would tell you that we continue to make \nprogress on it while the COVID was happening so conversations continued to happen between us \nand the various attorney generals in the states but as far as anything that I can give you I wouldn't \nsay any major updates other than that we continue to make prog ress and have productive \nconversations.  \n \n  The spend of 100 million in FY 21 is essentially what we spent in FY 20 so we're not expecting \nany incremental additional spend in those fees.  \n \n  Thanks for the question.  \n \n Operator:  Thank you.  We'll next go to Rick y Goldwasser, with Morgan Stanley.  Please go ahead.  \n ", "original_text": "Thanks for the question.  \n \n"}, "hash": "95a0c6fd52516a4d7d81cc8dae55529a372a9f9d3cdac90e299e1a20e0a39825", "class_name": "RelatedNodeInfo"}}, "text": "The spend of 100 million in FY 21 is essentially what we spent in FY 20 so we're not expecting \nany incremental additional spend in those fees.  \n \n ", "start_char_idx": 835, "end_char_idx": 984, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e06c071b-aa27-4cf8-89d2-a9636a170145": {"__data__": {"id_": "e06c071b-aa27-4cf8-89d2-a9636a170145", "embedding": null, "metadata": {"window": "Mike Kaufmann:  You know it's always a great question.  I would tell you that we continue to make \nprogress on it while the COVID was happening so conversations continued to happen between us \nand the various attorney generals in the states but as far as anything that I can give you I wouldn't \nsay any major updates other than that we continue to make prog ress and have productive \nconversations.  \n \n  The spend of 100 million in FY 21 is essentially what we spent in FY 20 so we're not expecting \nany incremental additional spend in those fees.  \n \n  Thanks for the question.  \n \n Operator:  Thank you.  We'll next go to Rick y Goldwasser, with Morgan Stanley.  Please go ahead.  \n ", "original_text": "Thanks for the question.  \n \n", "page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "338c4ec9-a1cf-40ca-a930-96ab8b67eb44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b639d4859168a3409a50c4e5d5054fa5aef6e5db54b09143ebb9c2ee5014f931", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8712c1b9-6317-497b-8cd9-6772a29c3c02", "node_type": "1", "metadata": {"window": "I know you increased the \nexpen ses to $100 million so I'm just curious if you were getting any closer?  \n \n Mike Kaufmann:  You know it's always a great question.  I would tell you that we continue to make \nprogress on it while the COVID was happening so conversations continued to happen between us \nand the various attorney generals in the states but as far as anything that I can give you I wouldn't \nsay any major updates other than that we continue to make prog ress and have productive \nconversations.  \n \n  The spend of 100 million in FY 21 is essentially what we spent in FY 20 so we're not expecting \nany incremental additional spend in those fees.  \n \n  Thanks for the question.  \n \n Operator:  Thank you.  We'll next go to Rick y Goldwasser, with Morgan Stanley. ", "original_text": "The spend of 100 million in FY 21 is essentially what we spent in FY 20 so we're not expecting \nany incremental additional spend in those fees.  \n \n ", "page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4cebc6fdbf4cb6648ea73418d5ba7e969459207b9096e40314f2f55c3860cb25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d4fe1df-5e59-4310-9fa7-add3ca1bf32e", "node_type": "1", "metadata": {"window": "I would tell you that we continue to make \nprogress on it while the COVID was happening so conversations continued to happen between us \nand the various attorney generals in the states but as far as anything that I can give you I wouldn't \nsay any major updates other than that we continue to make prog ress and have productive \nconversations.  \n \n  The spend of 100 million in FY 21 is essentially what we spent in FY 20 so we're not expecting \nany incremental additional spend in those fees.  \n \n  Thanks for the question.  \n \n Operator:  Thank you.  We'll next go to Rick y Goldwasser, with Morgan Stanley.  Please go ahead.  \n ", "original_text": "Operator:  Thank you. "}, "hash": "0c9d24c36287c8e339f0d67c04a599a766e951c822498d722f4cd4eb8312a668", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question.  \n \n", "start_char_idx": 984, "end_char_idx": 1013, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d4fe1df-5e59-4310-9fa7-add3ca1bf32e": {"__data__": {"id_": "0d4fe1df-5e59-4310-9fa7-add3ca1bf32e", "embedding": null, "metadata": {"window": "I would tell you that we continue to make \nprogress on it while the COVID was happening so conversations continued to happen between us \nand the various attorney generals in the states but as far as anything that I can give you I wouldn't \nsay any major updates other than that we continue to make prog ress and have productive \nconversations.  \n \n  The spend of 100 million in FY 21 is essentially what we spent in FY 20 so we're not expecting \nany incremental additional spend in those fees.  \n \n  Thanks for the question.  \n \n Operator:  Thank you.  We'll next go to Rick y Goldwasser, with Morgan Stanley.  Please go ahead.  \n ", "original_text": "Operator:  Thank you. ", "page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "338c4ec9-a1cf-40ca-a930-96ab8b67eb44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b639d4859168a3409a50c4e5d5054fa5aef6e5db54b09143ebb9c2ee5014f931", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e06c071b-aa27-4cf8-89d2-a9636a170145", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  You know it's always a great question.  I would tell you that we continue to make \nprogress on it while the COVID was happening so conversations continued to happen between us \nand the various attorney generals in the states but as far as anything that I can give you I wouldn't \nsay any major updates other than that we continue to make prog ress and have productive \nconversations.  \n \n  The spend of 100 million in FY 21 is essentially what we spent in FY 20 so we're not expecting \nany incremental additional spend in those fees.  \n \n  Thanks for the question.  \n \n Operator:  Thank you.  We'll next go to Rick y Goldwasser, with Morgan Stanley.  Please go ahead.  \n ", "original_text": "Thanks for the question.  \n \n", "page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40c64f340bb9423529e626746f8e3a009aa985d3f55da9123b3c10f732944c76", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13b7bdaa-6e08-4b14-b3ad-391dd3948f8d", "node_type": "1", "metadata": {"window": "The spend of 100 million in FY 21 is essentially what we spent in FY 20 so we're not expecting \nany incremental additional spend in those fees.  \n \n  Thanks for the question.  \n \n Operator:  Thank you.  We'll next go to Rick y Goldwasser, with Morgan Stanley.  Please go ahead.  \n ", "original_text": "We'll next go to Rick y Goldwasser, with Morgan Stanley. "}, "hash": "d1a1f1c14491b884cc41616911564a2aa25a4e52bed8a444be8d493b36734a01", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you. ", "start_char_idx": 1013, "end_char_idx": 1035, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13b7bdaa-6e08-4b14-b3ad-391dd3948f8d": {"__data__": {"id_": "13b7bdaa-6e08-4b14-b3ad-391dd3948f8d", "embedding": null, "metadata": {"window": "The spend of 100 million in FY 21 is essentially what we spent in FY 20 so we're not expecting \nany incremental additional spend in those fees.  \n \n  Thanks for the question.  \n \n Operator:  Thank you.  We'll next go to Rick y Goldwasser, with Morgan Stanley.  Please go ahead.  \n ", "original_text": "We'll next go to Rick y Goldwasser, with Morgan Stanley. ", "page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "338c4ec9-a1cf-40ca-a930-96ab8b67eb44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b639d4859168a3409a50c4e5d5054fa5aef6e5db54b09143ebb9c2ee5014f931", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d4fe1df-5e59-4310-9fa7-add3ca1bf32e", "node_type": "1", "metadata": {"window": "I would tell you that we continue to make \nprogress on it while the COVID was happening so conversations continued to happen between us \nand the various attorney generals in the states but as far as anything that I can give you I wouldn't \nsay any major updates other than that we continue to make prog ress and have productive \nconversations.  \n \n  The spend of 100 million in FY 21 is essentially what we spent in FY 20 so we're not expecting \nany incremental additional spend in those fees.  \n \n  Thanks for the question.  \n \n Operator:  Thank you.  We'll next go to Rick y Goldwasser, with Morgan Stanley.  Please go ahead.  \n ", "original_text": "Operator:  Thank you. ", "page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c61d894d6b8d8940245a9da9a700666b4686cca5e50d917478eb50489f2d7e56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77c6135b-2441-4074-b94d-2ce4561fa250", "node_type": "1", "metadata": {"window": "Thanks for the question.  \n \n Operator:  Thank you.  We'll next go to Rick y Goldwasser, with Morgan Stanley.  Please go ahead.  \n ", "original_text": "Please go ahead.  \n "}, "hash": "1af4098d329f3099f91c37175cbab35a81caa0a790e7da76da163966b21e39af", "class_name": "RelatedNodeInfo"}}, "text": "We'll next go to Rick y Goldwasser, with Morgan Stanley. ", "start_char_idx": 1035, "end_char_idx": 1092, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77c6135b-2441-4074-b94d-2ce4561fa250": {"__data__": {"id_": "77c6135b-2441-4074-b94d-2ce4561fa250", "embedding": null, "metadata": {"window": "Thanks for the question.  \n \n Operator:  Thank you.  We'll next go to Rick y Goldwasser, with Morgan Stanley.  Please go ahead.  \n ", "original_text": "Please go ahead.  \n ", "page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "338c4ec9-a1cf-40ca-a930-96ab8b67eb44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b639d4859168a3409a50c4e5d5054fa5aef6e5db54b09143ebb9c2ee5014f931", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13b7bdaa-6e08-4b14-b3ad-391dd3948f8d", "node_type": "1", "metadata": {"window": "The spend of 100 million in FY 21 is essentially what we spent in FY 20 so we're not expecting \nany incremental additional spend in those fees.  \n \n  Thanks for the question.  \n \n Operator:  Thank you.  We'll next go to Rick y Goldwasser, with Morgan Stanley.  Please go ahead.  \n ", "original_text": "We'll next go to Rick y Goldwasser, with Morgan Stanley. ", "page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "48bc0ea8cce79c395bcd57bc975c0b3d046ba3869d1ffaba08e5e078fbcdb581", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "edc49521-ab8a-483a-b8eb-bab245be0f72", "node_type": "1", "metadata": {"window": " \nPage 20 of 31 \n \nRicky Goldwasser:  Ah, yes.  Hi, good morning.  A couple of questions here on the Pharma segment \noutlook.  \n \n  So when you think about the variables of the impact coming in - last quarter you talked a lot \nabout nuclear - how is nuclear progressed in the quarter and importantly how do you think about the \nprogression in the - bits and better than your guidance? ", "original_text": " \nPage 20 of 31 \n \nRicky Goldwasser:  Ah, yes. "}, "hash": "b6dd82fdc3dd76ff4cad39ec52756ef16b200cbe22692f1a31b97524883bf0d9", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 90, "end_char_idx": 110, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "edc49521-ab8a-483a-b8eb-bab245be0f72": {"__data__": {"id_": "edc49521-ab8a-483a-b8eb-bab245be0f72", "embedding": null, "metadata": {"window": " \nPage 20 of 31 \n \nRicky Goldwasser:  Ah, yes.  Hi, good morning.  A couple of questions here on the Pharma segment \noutlook.  \n \n  So when you think about the variables of the impact coming in - last quarter you talked a lot \nabout nuclear - how is nuclear progressed in the quarter and importantly how do you think about the \nprogression in the - bits and better than your guidance? ", "original_text": " \nPage 20 of 31 \n \nRicky Goldwasser:  Ah, yes. ", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5cf9837e75aa495766e68d3dabbc1b86412e7dfca9d0b701b1580be6f41eaf48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77c6135b-2441-4074-b94d-2ce4561fa250", "node_type": "1", "metadata": {"window": "Thanks for the question.  \n \n Operator:  Thank you.  We'll next go to Rick y Goldwasser, with Morgan Stanley.  Please go ahead.  \n ", "original_text": "Please go ahead.  \n ", "page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6a76b68f672aa4baa611ca9bcb41764273c4bb45cb81d8f7b79a5a1e99e972a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39e265d6-6aee-4142-b7a4-653fe8b30b2e", "node_type": "1", "metadata": {"window": " \nPage 20 of 31 \n \nRicky Goldwasser:  Ah, yes.  Hi, good morning.  A couple of questions here on the Pharma segment \noutlook.  \n \n  So when you think about the variables of the impact coming in - last quarter you talked a lot \nabout nuclear - how is nuclear progressed in the quarter and importantly how do you think about the \nprogression in the - bits and better than your guidance?  And then when on your slide when you talk \nabout brand inflation, you talk about continued less dollar contribution each year. ", "original_text": "Hi, good morning. "}, "hash": "a51221dbed832eefd1956a07447d4daeb3ce69f0f2b54afd5b272dc1ab2de6bc", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 20 of 31 \n \nRicky Goldwasser:  Ah, yes. ", "start_char_idx": 0, "end_char_idx": 47, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39e265d6-6aee-4142-b7a4-653fe8b30b2e": {"__data__": {"id_": "39e265d6-6aee-4142-b7a4-653fe8b30b2e", "embedding": null, "metadata": {"window": " \nPage 20 of 31 \n \nRicky Goldwasser:  Ah, yes.  Hi, good morning.  A couple of questions here on the Pharma segment \noutlook.  \n \n  So when you think about the variables of the impact coming in - last quarter you talked a lot \nabout nuclear - how is nuclear progressed in the quarter and importantly how do you think about the \nprogression in the - bits and better than your guidance?  And then when on your slide when you talk \nabout brand inflation, you talk about continued less dollar contribution each year. ", "original_text": "Hi, good morning. ", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5cf9837e75aa495766e68d3dabbc1b86412e7dfca9d0b701b1580be6f41eaf48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "edc49521-ab8a-483a-b8eb-bab245be0f72", "node_type": "1", "metadata": {"window": " \nPage 20 of 31 \n \nRicky Goldwasser:  Ah, yes.  Hi, good morning.  A couple of questions here on the Pharma segment \noutlook.  \n \n  So when you think about the variables of the impact coming in - last quarter you talked a lot \nabout nuclear - how is nuclear progressed in the quarter and importantly how do you think about the \nprogression in the - bits and better than your guidance? ", "original_text": " \nPage 20 of 31 \n \nRicky Goldwasser:  Ah, yes. ", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "154b5ae8d829c6a6120ac3abebffeb84c5b8d0720fbdc09918d813385cdd4cc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe2563c3-67e0-4e9d-aa14-210e68a5f958", "node_type": "1", "metadata": {"window": " \nPage 20 of 31 \n \nRicky Goldwasser:  Ah, yes.  Hi, good morning.  A couple of questions here on the Pharma segment \noutlook.  \n \n  So when you think about the variables of the impact coming in - last quarter you talked a lot \nabout nuclear - how is nuclear progressed in the quarter and importantly how do you think about the \nprogression in the - bits and better than your guidance?  And then when on your slide when you talk \nabout brand inflation, you talk about continued less dollar contribution each year.  So can you maybe \ngive a little bit more color on that?  \n \n", "original_text": "A couple of questions here on the Pharma segment \noutlook.  \n \n "}, "hash": "d3fad434c1855639e682445d14509f3569a372abed91caf7386db14af0df1002", "class_name": "RelatedNodeInfo"}}, "text": "Hi, good morning. ", "start_char_idx": 47, "end_char_idx": 65, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe2563c3-67e0-4e9d-aa14-210e68a5f958": {"__data__": {"id_": "fe2563c3-67e0-4e9d-aa14-210e68a5f958", "embedding": null, "metadata": {"window": " \nPage 20 of 31 \n \nRicky Goldwasser:  Ah, yes.  Hi, good morning.  A couple of questions here on the Pharma segment \noutlook.  \n \n  So when you think about the variables of the impact coming in - last quarter you talked a lot \nabout nuclear - how is nuclear progressed in the quarter and importantly how do you think about the \nprogression in the - bits and better than your guidance?  And then when on your slide when you talk \nabout brand inflation, you talk about continued less dollar contribution each year.  So can you maybe \ngive a little bit more color on that?  \n \n", "original_text": "A couple of questions here on the Pharma segment \noutlook.  \n \n ", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5cf9837e75aa495766e68d3dabbc1b86412e7dfca9d0b701b1580be6f41eaf48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39e265d6-6aee-4142-b7a4-653fe8b30b2e", "node_type": "1", "metadata": {"window": " \nPage 20 of 31 \n \nRicky Goldwasser:  Ah, yes.  Hi, good morning.  A couple of questions here on the Pharma segment \noutlook.  \n \n  So when you think about the variables of the impact coming in - last quarter you talked a lot \nabout nuclear - how is nuclear progressed in the quarter and importantly how do you think about the \nprogression in the - bits and better than your guidance?  And then when on your slide when you talk \nabout brand inflation, you talk about continued less dollar contribution each year. ", "original_text": "Hi, good morning. ", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5653a5960c05cfa6fccc5e0efd8f10e674604fb35ed52ce36aac8b070158d42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8fada0e-6df6-4489-a744-f02769fe79ef", "node_type": "1", "metadata": {"window": " \nPage 20 of 31 \n \nRicky Goldwasser:  Ah, yes.  Hi, good morning.  A couple of questions here on the Pharma segment \noutlook.  \n \n  So when you think about the variables of the impact coming in - last quarter you talked a lot \nabout nuclear - how is nuclear progressed in the quarter and importantly how do you think about the \nprogression in the - bits and better than your guidance?  And then when on your slide when you talk \nabout brand inflation, you talk about continued less dollar contribution each year.  So can you maybe \ngive a little bit more color on that?  \n \n Mike Kaufmann:  Sure. ", "original_text": "So when you think about the variables of the impact coming in - last quarter you talked a lot \nabout nuclear - how is nuclear progressed in the quarter and importantly how do you think about the \nprogression in the - bits and better than your guidance? "}, "hash": "653fe3152cc4bb199f25e906d79d4f7fb502444716f64b9bc1ba2c14e9a52f55", "class_name": "RelatedNodeInfo"}}, "text": "A couple of questions here on the Pharma segment \noutlook.  \n \n ", "start_char_idx": 65, "end_char_idx": 129, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8fada0e-6df6-4489-a744-f02769fe79ef": {"__data__": {"id_": "d8fada0e-6df6-4489-a744-f02769fe79ef", "embedding": null, "metadata": {"window": " \nPage 20 of 31 \n \nRicky Goldwasser:  Ah, yes.  Hi, good morning.  A couple of questions here on the Pharma segment \noutlook.  \n \n  So when you think about the variables of the impact coming in - last quarter you talked a lot \nabout nuclear - how is nuclear progressed in the quarter and importantly how do you think about the \nprogression in the - bits and better than your guidance?  And then when on your slide when you talk \nabout brand inflation, you talk about continued less dollar contribution each year.  So can you maybe \ngive a little bit more color on that?  \n \n Mike Kaufmann:  Sure. ", "original_text": "So when you think about the variables of the impact coming in - last quarter you talked a lot \nabout nuclear - how is nuclear progressed in the quarter and importantly how do you think about the \nprogression in the - bits and better than your guidance? ", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5cf9837e75aa495766e68d3dabbc1b86412e7dfca9d0b701b1580be6f41eaf48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe2563c3-67e0-4e9d-aa14-210e68a5f958", "node_type": "1", "metadata": {"window": " \nPage 20 of 31 \n \nRicky Goldwasser:  Ah, yes.  Hi, good morning.  A couple of questions here on the Pharma segment \noutlook.  \n \n  So when you think about the variables of the impact coming in - last quarter you talked a lot \nabout nuclear - how is nuclear progressed in the quarter and importantly how do you think about the \nprogression in the - bits and better than your guidance?  And then when on your slide when you talk \nabout brand inflation, you talk about continued less dollar contribution each year.  So can you maybe \ngive a little bit more color on that?  \n \n", "original_text": "A couple of questions here on the Pharma segment \noutlook.  \n \n ", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9f6d6617bd76fa4ebdf8708bb79c03fdd1e62a2dd94da8278b0a54267773019e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61d80c5f-5f1e-4389-961e-fe53d22f98a7", "node_type": "1", "metadata": {"window": "Hi, good morning.  A couple of questions here on the Pharma segment \noutlook.  \n \n  So when you think about the variables of the impact coming in - last quarter you talked a lot \nabout nuclear - how is nuclear progressed in the quarter and importantly how do you think about the \nprogression in the - bits and better than your guidance?  And then when on your slide when you talk \nabout brand inflation, you talk about continued less dollar contribution each year.  So can you maybe \ngive a little bit more color on that?  \n \n Mike Kaufmann:  Sure.  Let me start with nuclear. ", "original_text": "And then when on your slide when you talk \nabout brand inflation, you talk about continued less dollar contribution each year. "}, "hash": "8276c604a9ef598ca7aad6a79ece73cce83c7540b24a98691343f2613497d68b", "class_name": "RelatedNodeInfo"}}, "text": "So when you think about the variables of the impact coming in - last quarter you talked a lot \nabout nuclear - how is nuclear progressed in the quarter and importantly how do you think about the \nprogression in the - bits and better than your guidance? ", "start_char_idx": 129, "end_char_idx": 382, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61d80c5f-5f1e-4389-961e-fe53d22f98a7": {"__data__": {"id_": "61d80c5f-5f1e-4389-961e-fe53d22f98a7", "embedding": null, "metadata": {"window": "Hi, good morning.  A couple of questions here on the Pharma segment \noutlook.  \n \n  So when you think about the variables of the impact coming in - last quarter you talked a lot \nabout nuclear - how is nuclear progressed in the quarter and importantly how do you think about the \nprogression in the - bits and better than your guidance?  And then when on your slide when you talk \nabout brand inflation, you talk about continued less dollar contribution each year.  So can you maybe \ngive a little bit more color on that?  \n \n Mike Kaufmann:  Sure.  Let me start with nuclear. ", "original_text": "And then when on your slide when you talk \nabout brand inflation, you talk about continued less dollar contribution each year. ", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5cf9837e75aa495766e68d3dabbc1b86412e7dfca9d0b701b1580be6f41eaf48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8fada0e-6df6-4489-a744-f02769fe79ef", "node_type": "1", "metadata": {"window": " \nPage 20 of 31 \n \nRicky Goldwasser:  Ah, yes.  Hi, good morning.  A couple of questions here on the Pharma segment \noutlook.  \n \n  So when you think about the variables of the impact coming in - last quarter you talked a lot \nabout nuclear - how is nuclear progressed in the quarter and importantly how do you think about the \nprogression in the - bits and better than your guidance?  And then when on your slide when you talk \nabout brand inflation, you talk about continued less dollar contribution each year.  So can you maybe \ngive a little bit more color on that?  \n \n Mike Kaufmann:  Sure. ", "original_text": "So when you think about the variables of the impact coming in - last quarter you talked a lot \nabout nuclear - how is nuclear progressed in the quarter and importantly how do you think about the \nprogression in the - bits and better than your guidance? ", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "543c6d02f0923b0d42e9c016172218c181731da80bcf65da2be4b6ee5013ccae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d457991-93e9-458c-840f-d343381cf1e0", "node_type": "1", "metadata": {"window": "A couple of questions here on the Pharma segment \noutlook.  \n \n  So when you think about the variables of the impact coming in - last quarter you talked a lot \nabout nuclear - how is nuclear progressed in the quarter and importantly how do you think about the \nprogression in the - bits and better than your guidance?  And then when on your slide when you talk \nabout brand inflation, you talk about continued less dollar contribution each year.  So can you maybe \ngive a little bit more color on that?  \n \n Mike Kaufmann:  Sure.  Let me start with nuclear.  Nuclear was the business in our P segment that \nwas by far the most significantly impacted. ", "original_text": "So can you maybe \ngive a little bit more color on that?  \n \n"}, "hash": "9ebf2b343b915f162d20fcd6891e32dad7de79a6646a937302be0bc88abccd21", "class_name": "RelatedNodeInfo"}}, "text": "And then when on your slide when you talk \nabout brand inflation, you talk about continued less dollar contribution each year. ", "start_char_idx": 382, "end_char_idx": 509, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d457991-93e9-458c-840f-d343381cf1e0": {"__data__": {"id_": "2d457991-93e9-458c-840f-d343381cf1e0", "embedding": null, "metadata": {"window": "A couple of questions here on the Pharma segment \noutlook.  \n \n  So when you think about the variables of the impact coming in - last quarter you talked a lot \nabout nuclear - how is nuclear progressed in the quarter and importantly how do you think about the \nprogression in the - bits and better than your guidance?  And then when on your slide when you talk \nabout brand inflation, you talk about continued less dollar contribution each year.  So can you maybe \ngive a little bit more color on that?  \n \n Mike Kaufmann:  Sure.  Let me start with nuclear.  Nuclear was the business in our P segment that \nwas by far the most significantly impacted. ", "original_text": "So can you maybe \ngive a little bit more color on that?  \n \n", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5cf9837e75aa495766e68d3dabbc1b86412e7dfca9d0b701b1580be6f41eaf48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61d80c5f-5f1e-4389-961e-fe53d22f98a7", "node_type": "1", "metadata": {"window": "Hi, good morning.  A couple of questions here on the Pharma segment \noutlook.  \n \n  So when you think about the variables of the impact coming in - last quarter you talked a lot \nabout nuclear - how is nuclear progressed in the quarter and importantly how do you think about the \nprogression in the - bits and better than your guidance?  And then when on your slide when you talk \nabout brand inflation, you talk about continued less dollar contribution each year.  So can you maybe \ngive a little bit more color on that?  \n \n Mike Kaufmann:  Sure.  Let me start with nuclear. ", "original_text": "And then when on your slide when you talk \nabout brand inflation, you talk about continued less dollar contribution each year. ", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "591ab4a8b41eaecee2ac07934eb8fdaebd0ff1564ef4d26e7cb9d38c3656637b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "384ac847-5d4b-42c9-be89-6085ce5271fd", "node_type": "1", "metadata": {"window": "So when you think about the variables of the impact coming in - last quarter you talked a lot \nabout nuclear - how is nuclear progressed in the quarter and importantly how do you think about the \nprogression in the - bits and better than your guidance?  And then when on your slide when you talk \nabout brand inflation, you talk about continued less dollar contribution each year.  So can you maybe \ngive a little bit more color on that?  \n \n Mike Kaufmann:  Sure.  Let me start with nuclear.  Nuclear was the business in our P segment that \nwas by far the most significantly impacted.  It\u2019s a very high fixed cost business . ", "original_text": "Mike Kaufmann:  Sure. "}, "hash": "37a2a811a5621669ec373d05f1d636c5a42a58863817bae025f85495cd285241", "class_name": "RelatedNodeInfo"}}, "text": "So can you maybe \ngive a little bit more color on that?  \n \n", "start_char_idx": 509, "end_char_idx": 569, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "384ac847-5d4b-42c9-be89-6085ce5271fd": {"__data__": {"id_": "384ac847-5d4b-42c9-be89-6085ce5271fd", "embedding": null, "metadata": {"window": "So when you think about the variables of the impact coming in - last quarter you talked a lot \nabout nuclear - how is nuclear progressed in the quarter and importantly how do you think about the \nprogression in the - bits and better than your guidance?  And then when on your slide when you talk \nabout brand inflation, you talk about continued less dollar contribution each year.  So can you maybe \ngive a little bit more color on that?  \n \n Mike Kaufmann:  Sure.  Let me start with nuclear.  Nuclear was the business in our P segment that \nwas by far the most significantly impacted.  It\u2019s a very high fixed cost business . ", "original_text": "Mike Kaufmann:  Sure. ", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5cf9837e75aa495766e68d3dabbc1b86412e7dfca9d0b701b1580be6f41eaf48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d457991-93e9-458c-840f-d343381cf1e0", "node_type": "1", "metadata": {"window": "A couple of questions here on the Pharma segment \noutlook.  \n \n  So when you think about the variables of the impact coming in - last quarter you talked a lot \nabout nuclear - how is nuclear progressed in the quarter and importantly how do you think about the \nprogression in the - bits and better than your guidance?  And then when on your slide when you talk \nabout brand inflation, you talk about continued less dollar contribution each year.  So can you maybe \ngive a little bit more color on that?  \n \n Mike Kaufmann:  Sure.  Let me start with nuclear.  Nuclear was the business in our P segment that \nwas by far the most significantly impacted. ", "original_text": "So can you maybe \ngive a little bit more color on that?  \n \n", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8c6889a990437e80d25f1b87883e43f7e86c770b1cdc7d136d1fdd4fe2240c92", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a15c7f31-adf2-4197-b949-02f48c6e5b93", "node_type": "1", "metadata": {"window": "And then when on your slide when you talk \nabout brand inflation, you talk about continued less dollar contribution each year.  So can you maybe \ngive a little bit more color on that?  \n \n Mike Kaufmann:  Sure.  Let me start with nuclear.  Nuclear was the business in our P segment that \nwas by far the most significantly impacted.  It\u2019s a very high fixed cost business .  And so as you can \nimagine when your procedures go down you still need drivers, you still need pharmacists, you still - \nand you have a raw material that you\u2019re getting less products off of because it is radioactive and so \nit\u2019s deteriorating. ", "original_text": "Let me start with nuclear. "}, "hash": "1b17b3dfad044f1db794570ba24cfea52e713aad708d783dafc967c18035d26c", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Sure. ", "start_char_idx": 569, "end_char_idx": 591, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a15c7f31-adf2-4197-b949-02f48c6e5b93": {"__data__": {"id_": "a15c7f31-adf2-4197-b949-02f48c6e5b93", "embedding": null, "metadata": {"window": "And then when on your slide when you talk \nabout brand inflation, you talk about continued less dollar contribution each year.  So can you maybe \ngive a little bit more color on that?  \n \n Mike Kaufmann:  Sure.  Let me start with nuclear.  Nuclear was the business in our P segment that \nwas by far the most significantly impacted.  It\u2019s a very high fixed cost business .  And so as you can \nimagine when your procedures go down you still need drivers, you still need pharmacists, you still - \nand you have a raw material that you\u2019re getting less products off of because it is radioactive and so \nit\u2019s deteriorating. ", "original_text": "Let me start with nuclear. ", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5cf9837e75aa495766e68d3dabbc1b86412e7dfca9d0b701b1580be6f41eaf48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "384ac847-5d4b-42c9-be89-6085ce5271fd", "node_type": "1", "metadata": {"window": "So when you think about the variables of the impact coming in - last quarter you talked a lot \nabout nuclear - how is nuclear progressed in the quarter and importantly how do you think about the \nprogression in the - bits and better than your guidance?  And then when on your slide when you talk \nabout brand inflation, you talk about continued less dollar contribution each year.  So can you maybe \ngive a little bit more color on that?  \n \n Mike Kaufmann:  Sure.  Let me start with nuclear.  Nuclear was the business in our P segment that \nwas by far the most significantly impacted.  It\u2019s a very high fixed cost business . ", "original_text": "Mike Kaufmann:  Sure. ", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3258a5ad4555cadc4377b88ff629d5dfde96ce9507504747dfd1ef8232aaf4d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "823b3a00-03fd-4312-b648-dc99143ef1fe", "node_type": "1", "metadata": {"window": "So can you maybe \ngive a little bit more color on that?  \n \n Mike Kaufmann:  Sure.  Let me start with nuclear.  Nuclear was the business in our P segment that \nwas by far the most significantly impacted.  It\u2019s a very high fixed cost business .  And so as you can \nimagine when your procedures go down you still need drivers, you still need pharmacists, you still - \nand you have a raw material that you\u2019re getting less products off of because it is radioactive and so \nit\u2019s deteriorating.  So that busin ess was down significantly as we expected but it did rebound a little bit \nbetter, just a little bit better than we expected as elective procedures started to come back a little \nfaster. ", "original_text": "Nuclear was the business in our P segment that \nwas by far the most significantly impacted. "}, "hash": "e792d649e6a065e01cb154160b95525eadadadb2ba1521cc1ddc515e090ea3cf", "class_name": "RelatedNodeInfo"}}, "text": "Let me start with nuclear. ", "start_char_idx": 591, "end_char_idx": 618, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "823b3a00-03fd-4312-b648-dc99143ef1fe": {"__data__": {"id_": "823b3a00-03fd-4312-b648-dc99143ef1fe", "embedding": null, "metadata": {"window": "So can you maybe \ngive a little bit more color on that?  \n \n Mike Kaufmann:  Sure.  Let me start with nuclear.  Nuclear was the business in our P segment that \nwas by far the most significantly impacted.  It\u2019s a very high fixed cost business .  And so as you can \nimagine when your procedures go down you still need drivers, you still need pharmacists, you still - \nand you have a raw material that you\u2019re getting less products off of because it is radioactive and so \nit\u2019s deteriorating.  So that busin ess was down significantly as we expected but it did rebound a little bit \nbetter, just a little bit better than we expected as elective procedures started to come back a little \nfaster. ", "original_text": "Nuclear was the business in our P segment that \nwas by far the most significantly impacted. ", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5cf9837e75aa495766e68d3dabbc1b86412e7dfca9d0b701b1580be6f41eaf48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a15c7f31-adf2-4197-b949-02f48c6e5b93", "node_type": "1", "metadata": {"window": "And then when on your slide when you talk \nabout brand inflation, you talk about continued less dollar contribution each year.  So can you maybe \ngive a little bit more color on that?  \n \n Mike Kaufmann:  Sure.  Let me start with nuclear.  Nuclear was the business in our P segment that \nwas by far the most significantly impacted.  It\u2019s a very high fixed cost business .  And so as you can \nimagine when your procedures go down you still need drivers, you still need pharmacists, you still - \nand you have a raw material that you\u2019re getting less products off of because it is radioactive and so \nit\u2019s deteriorating. ", "original_text": "Let me start with nuclear. ", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "425dedf4a6b20ab756fda08d793f32bed29ea91717dbd2e69729796796c130f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ba21d56-67b8-48a9-93be-4cabc945c660", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Sure.  Let me start with nuclear.  Nuclear was the business in our P segment that \nwas by far the most significantly impacted.  It\u2019s a very high fixed cost business .  And so as you can \nimagine when your procedures go down you still need drivers, you still need pharmacists, you still - \nand you have a raw material that you\u2019re getting less products off of because it is radioactive and so \nit\u2019s deteriorating.  So that busin ess was down significantly as we expected but it did rebound a little bit \nbetter, just a little bit better than we expected as elective procedures started to come back a little \nfaster.  They probably track closest to elective procedures on the P side is the  nuclear business.  \n \n ", "original_text": "It\u2019s a very high fixed cost business . "}, "hash": "56ee458f40fe6d16c26ace85850475d5b7f4a0751c649d67f53ed442e6fb1c4c", "class_name": "RelatedNodeInfo"}}, "text": "Nuclear was the business in our P segment that \nwas by far the most significantly impacted. ", "start_char_idx": 618, "end_char_idx": 710, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ba21d56-67b8-48a9-93be-4cabc945c660": {"__data__": {"id_": "5ba21d56-67b8-48a9-93be-4cabc945c660", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Sure.  Let me start with nuclear.  Nuclear was the business in our P segment that \nwas by far the most significantly impacted.  It\u2019s a very high fixed cost business .  And so as you can \nimagine when your procedures go down you still need drivers, you still need pharmacists, you still - \nand you have a raw material that you\u2019re getting less products off of because it is radioactive and so \nit\u2019s deteriorating.  So that busin ess was down significantly as we expected but it did rebound a little bit \nbetter, just a little bit better than we expected as elective procedures started to come back a little \nfaster.  They probably track closest to elective procedures on the P side is the  nuclear business.  \n \n ", "original_text": "It\u2019s a very high fixed cost business . ", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5cf9837e75aa495766e68d3dabbc1b86412e7dfca9d0b701b1580be6f41eaf48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "823b3a00-03fd-4312-b648-dc99143ef1fe", "node_type": "1", "metadata": {"window": "So can you maybe \ngive a little bit more color on that?  \n \n Mike Kaufmann:  Sure.  Let me start with nuclear.  Nuclear was the business in our P segment that \nwas by far the most significantly impacted.  It\u2019s a very high fixed cost business .  And so as you can \nimagine when your procedures go down you still need drivers, you still need pharmacists, you still - \nand you have a raw material that you\u2019re getting less products off of because it is radioactive and so \nit\u2019s deteriorating.  So that busin ess was down significantly as we expected but it did rebound a little bit \nbetter, just a little bit better than we expected as elective procedures started to come back a little \nfaster. ", "original_text": "Nuclear was the business in our P segment that \nwas by far the most significantly impacted. ", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "064de4323bafb053d91678051b6dc893faa9013b16255c5a1cd5c4f8bdbb1cd4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e8d98a7-c730-4fe1-9c70-0706267eacb7", "node_type": "1", "metadata": {"window": "Let me start with nuclear.  Nuclear was the business in our P segment that \nwas by far the most significantly impacted.  It\u2019s a very high fixed cost business .  And so as you can \nimagine when your procedures go down you still need drivers, you still need pharmacists, you still - \nand you have a raw material that you\u2019re getting less products off of because it is radioactive and so \nit\u2019s deteriorating.  So that busin ess was down significantly as we expected but it did rebound a little bit \nbetter, just a little bit better than we expected as elective procedures started to come back a little \nfaster.  They probably track closest to elective procedures on the P side is the  nuclear business.  \n \n  So we continue to believe in the long term for that business. ", "original_text": "And so as you can \nimagine when your procedures go down you still need drivers, you still need pharmacists, you still - \nand you have a raw material that you\u2019re getting less products off of because it is radioactive and so \nit\u2019s deteriorating. "}, "hash": "f75908fd6328928d1f80e9f6f683be2644cd11c1dd8e1b3ebaf018e38c7b2b70", "class_name": "RelatedNodeInfo"}}, "text": "It\u2019s a very high fixed cost business . ", "start_char_idx": 710, "end_char_idx": 749, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e8d98a7-c730-4fe1-9c70-0706267eacb7": {"__data__": {"id_": "6e8d98a7-c730-4fe1-9c70-0706267eacb7", "embedding": null, "metadata": {"window": "Let me start with nuclear.  Nuclear was the business in our P segment that \nwas by far the most significantly impacted.  It\u2019s a very high fixed cost business .  And so as you can \nimagine when your procedures go down you still need drivers, you still need pharmacists, you still - \nand you have a raw material that you\u2019re getting less products off of because it is radioactive and so \nit\u2019s deteriorating.  So that busin ess was down significantly as we expected but it did rebound a little bit \nbetter, just a little bit better than we expected as elective procedures started to come back a little \nfaster.  They probably track closest to elective procedures on the P side is the  nuclear business.  \n \n  So we continue to believe in the long term for that business. ", "original_text": "And so as you can \nimagine when your procedures go down you still need drivers, you still need pharmacists, you still - \nand you have a raw material that you\u2019re getting less products off of because it is radioactive and so \nit\u2019s deteriorating. ", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5cf9837e75aa495766e68d3dabbc1b86412e7dfca9d0b701b1580be6f41eaf48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ba21d56-67b8-48a9-93be-4cabc945c660", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Sure.  Let me start with nuclear.  Nuclear was the business in our P segment that \nwas by far the most significantly impacted.  It\u2019s a very high fixed cost business .  And so as you can \nimagine when your procedures go down you still need drivers, you still need pharmacists, you still - \nand you have a raw material that you\u2019re getting less products off of because it is radioactive and so \nit\u2019s deteriorating.  So that busin ess was down significantly as we expected but it did rebound a little bit \nbetter, just a little bit better than we expected as elective procedures started to come back a little \nfaster.  They probably track closest to elective procedures on the P side is the  nuclear business.  \n \n ", "original_text": "It\u2019s a very high fixed cost business . ", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9262cfe544f3b18c75719a3460647b9d2ca90a3d2fa26eb5af5f8b6bba0b43eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c524bc8f-c6ab-46e8-bd70-78647ab39e13", "node_type": "1", "metadata": {"window": "Nuclear was the business in our P segment that \nwas by far the most significantly impacted.  It\u2019s a very high fixed cost business .  And so as you can \nimagine when your procedures go down you still need drivers, you still need pharmacists, you still - \nand you have a raw material that you\u2019re getting less products off of because it is radioactive and so \nit\u2019s deteriorating.  So that busin ess was down significantly as we expected but it did rebound a little bit \nbetter, just a little bit better than we expected as elective procedures started to come back a little \nfaster.  They probably track closest to elective procedures on the P side is the  nuclear business.  \n \n  So we continue to believe in the long term for that business.  We continue to make investments \nin theranostics opportunities with manufacturers. ", "original_text": "So that busin ess was down significantly as we expected but it did rebound a little bit \nbetter, just a little bit better than we expected as elective procedures started to come back a little \nfaster. "}, "hash": "924e6b3955813a71ee386fcafff7224ed4e286b879ec3939d170aea92181d930", "class_name": "RelatedNodeInfo"}}, "text": "And so as you can \nimagine when your procedures go down you still need drivers, you still need pharmacists, you still - \nand you have a raw material that you\u2019re getting less products off of because it is radioactive and so \nit\u2019s deteriorating. ", "start_char_idx": 749, "end_char_idx": 993, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c524bc8f-c6ab-46e8-bd70-78647ab39e13": {"__data__": {"id_": "c524bc8f-c6ab-46e8-bd70-78647ab39e13", "embedding": null, "metadata": {"window": "Nuclear was the business in our P segment that \nwas by far the most significantly impacted.  It\u2019s a very high fixed cost business .  And so as you can \nimagine when your procedures go down you still need drivers, you still need pharmacists, you still - \nand you have a raw material that you\u2019re getting less products off of because it is radioactive and so \nit\u2019s deteriorating.  So that busin ess was down significantly as we expected but it did rebound a little bit \nbetter, just a little bit better than we expected as elective procedures started to come back a little \nfaster.  They probably track closest to elective procedures on the P side is the  nuclear business.  \n \n  So we continue to believe in the long term for that business.  We continue to make investments \nin theranostics opportunities with manufacturers. ", "original_text": "So that busin ess was down significantly as we expected but it did rebound a little bit \nbetter, just a little bit better than we expected as elective procedures started to come back a little \nfaster. ", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5cf9837e75aa495766e68d3dabbc1b86412e7dfca9d0b701b1580be6f41eaf48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e8d98a7-c730-4fe1-9c70-0706267eacb7", "node_type": "1", "metadata": {"window": "Let me start with nuclear.  Nuclear was the business in our P segment that \nwas by far the most significantly impacted.  It\u2019s a very high fixed cost business .  And so as you can \nimagine when your procedures go down you still need drivers, you still need pharmacists, you still - \nand you have a raw material that you\u2019re getting less products off of because it is radioactive and so \nit\u2019s deteriorating.  So that busin ess was down significantly as we expected but it did rebound a little bit \nbetter, just a little bit better than we expected as elective procedures started to come back a little \nfaster.  They probably track closest to elective procedures on the P side is the  nuclear business.  \n \n  So we continue to believe in the long term for that business. ", "original_text": "And so as you can \nimagine when your procedures go down you still need drivers, you still need pharmacists, you still - \nand you have a raw material that you\u2019re getting less products off of because it is radioactive and so \nit\u2019s deteriorating. ", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "145cf9ab726af6ad06aed6e15307b49c8c4b0b5e6933228babad3555dc95c7f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23d26b13-ace6-46cd-a74c-54a129bbc687", "node_type": "1", "metadata": {"window": "It\u2019s a very high fixed cost business .  And so as you can \nimagine when your procedures go down you still need drivers, you still need pharmacists, you still - \nand you have a raw material that you\u2019re getting less products off of because it is radioactive and so \nit\u2019s deteriorating.  So that busin ess was down significantly as we expected but it did rebound a little bit \nbetter, just a little bit better than we expected as elective procedures started to come back a little \nfaster.  They probably track closest to elective procedures on the P side is the  nuclear business.  \n \n  So we continue to believe in the long term for that business.  We continue to make investments \nin theranostics opportunities with manufacturers.  And we still really like that business but it was one of \nthe biggest tailwinds1 in our phar maceutical segment.  \n \n  \n \n", "original_text": "They probably track closest to elective procedures on the P side is the  nuclear business.  \n \n "}, "hash": "5d503c9f0ebde4d8e2ba870bf0a4df01ab2cd58db21937b09af249c98f43e180", "class_name": "RelatedNodeInfo"}}, "text": "So that busin ess was down significantly as we expected but it did rebound a little bit \nbetter, just a little bit better than we expected as elective procedures started to come back a little \nfaster. ", "start_char_idx": 993, "end_char_idx": 1194, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23d26b13-ace6-46cd-a74c-54a129bbc687": {"__data__": {"id_": "23d26b13-ace6-46cd-a74c-54a129bbc687", "embedding": null, "metadata": {"window": "It\u2019s a very high fixed cost business .  And so as you can \nimagine when your procedures go down you still need drivers, you still need pharmacists, you still - \nand you have a raw material that you\u2019re getting less products off of because it is radioactive and so \nit\u2019s deteriorating.  So that busin ess was down significantly as we expected but it did rebound a little bit \nbetter, just a little bit better than we expected as elective procedures started to come back a little \nfaster.  They probably track closest to elective procedures on the P side is the  nuclear business.  \n \n  So we continue to believe in the long term for that business.  We continue to make investments \nin theranostics opportunities with manufacturers.  And we still really like that business but it was one of \nthe biggest tailwinds1 in our phar maceutical segment.  \n \n  \n \n", "original_text": "They probably track closest to elective procedures on the P side is the  nuclear business.  \n \n ", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5cf9837e75aa495766e68d3dabbc1b86412e7dfca9d0b701b1580be6f41eaf48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c524bc8f-c6ab-46e8-bd70-78647ab39e13", "node_type": "1", "metadata": {"window": "Nuclear was the business in our P segment that \nwas by far the most significantly impacted.  It\u2019s a very high fixed cost business .  And so as you can \nimagine when your procedures go down you still need drivers, you still need pharmacists, you still - \nand you have a raw material that you\u2019re getting less products off of because it is radioactive and so \nit\u2019s deteriorating.  So that busin ess was down significantly as we expected but it did rebound a little bit \nbetter, just a little bit better than we expected as elective procedures started to come back a little \nfaster.  They probably track closest to elective procedures on the P side is the  nuclear business.  \n \n  So we continue to believe in the long term for that business.  We continue to make investments \nin theranostics opportunities with manufacturers. ", "original_text": "So that busin ess was down significantly as we expected but it did rebound a little bit \nbetter, just a little bit better than we expected as elective procedures started to come back a little \nfaster. ", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5903385520ad6a868afed14b9e1b5923787fd8be3030a4eb4014458c0a2f5eab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58608f97-6a32-4d68-8af9-dd4b2469066b", "node_type": "1", "metadata": {"window": "And so as you can \nimagine when your procedures go down you still need drivers, you still need pharmacists, you still - \nand you have a raw material that you\u2019re getting less products off of because it is radioactive and so \nit\u2019s deteriorating.  So that busin ess was down significantly as we expected but it did rebound a little bit \nbetter, just a little bit better than we expected as elective procedures started to come back a little \nfaster.  They probably track closest to elective procedures on the P side is the  nuclear business.  \n \n  So we continue to believe in the long term for that business.  We continue to make investments \nin theranostics opportunities with manufacturers.  And we still really like that business but it was one of \nthe biggest tailwinds1 in our phar maceutical segment.  \n \n  \n \n 1Was subsequently clarified later in the call and updated to \u201cheadwind\u201d  \n ", "original_text": "So we continue to believe in the long term for that business. "}, "hash": "3c0cb7be239e327d57ee2b63f9e88c65c816efec89a8299f85b19c73298f52df", "class_name": "RelatedNodeInfo"}}, "text": "They probably track closest to elective procedures on the P side is the  nuclear business.  \n \n ", "start_char_idx": 1194, "end_char_idx": 1290, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58608f97-6a32-4d68-8af9-dd4b2469066b": {"__data__": {"id_": "58608f97-6a32-4d68-8af9-dd4b2469066b", "embedding": null, "metadata": {"window": "And so as you can \nimagine when your procedures go down you still need drivers, you still need pharmacists, you still - \nand you have a raw material that you\u2019re getting less products off of because it is radioactive and so \nit\u2019s deteriorating.  So that busin ess was down significantly as we expected but it did rebound a little bit \nbetter, just a little bit better than we expected as elective procedures started to come back a little \nfaster.  They probably track closest to elective procedures on the P side is the  nuclear business.  \n \n  So we continue to believe in the long term for that business.  We continue to make investments \nin theranostics opportunities with manufacturers.  And we still really like that business but it was one of \nthe biggest tailwinds1 in our phar maceutical segment.  \n \n  \n \n 1Was subsequently clarified later in the call and updated to \u201cheadwind\u201d  \n ", "original_text": "So we continue to believe in the long term for that business. ", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5cf9837e75aa495766e68d3dabbc1b86412e7dfca9d0b701b1580be6f41eaf48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23d26b13-ace6-46cd-a74c-54a129bbc687", "node_type": "1", "metadata": {"window": "It\u2019s a very high fixed cost business .  And so as you can \nimagine when your procedures go down you still need drivers, you still need pharmacists, you still - \nand you have a raw material that you\u2019re getting less products off of because it is radioactive and so \nit\u2019s deteriorating.  So that busin ess was down significantly as we expected but it did rebound a little bit \nbetter, just a little bit better than we expected as elective procedures started to come back a little \nfaster.  They probably track closest to elective procedures on the P side is the  nuclear business.  \n \n  So we continue to believe in the long term for that business.  We continue to make investments \nin theranostics opportunities with manufacturers.  And we still really like that business but it was one of \nthe biggest tailwinds1 in our phar maceutical segment.  \n \n  \n \n", "original_text": "They probably track closest to elective procedures on the P side is the  nuclear business.  \n \n ", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b9157f2183bcb7e13e2902fe825f002a029f8e1c9d0a359d65e7f780c92164d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a2c6d55-36cd-4fed-8efa-752a01a607c7", "node_type": "1", "metadata": {"window": "So that busin ess was down significantly as we expected but it did rebound a little bit \nbetter, just a little bit better than we expected as elective procedures started to come back a little \nfaster.  They probably track closest to elective procedures on the P side is the  nuclear business.  \n \n  So we continue to believe in the long term for that business.  We continue to make investments \nin theranostics opportunities with manufacturers.  And we still really like that business but it was one of \nthe biggest tailwinds1 in our phar maceutical segment.  \n \n  \n \n 1Was subsequently clarified later in the call and updated to \u201cheadwind\u201d  \n ", "original_text": "We continue to make investments \nin theranostics opportunities with manufacturers. "}, "hash": "ce335b2a71b271f8437f33c0085b36474d846730a8e308661683e24324049da0", "class_name": "RelatedNodeInfo"}}, "text": "So we continue to believe in the long term for that business. ", "start_char_idx": 1290, "end_char_idx": 1352, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a2c6d55-36cd-4fed-8efa-752a01a607c7": {"__data__": {"id_": "8a2c6d55-36cd-4fed-8efa-752a01a607c7", "embedding": null, "metadata": {"window": "So that busin ess was down significantly as we expected but it did rebound a little bit \nbetter, just a little bit better than we expected as elective procedures started to come back a little \nfaster.  They probably track closest to elective procedures on the P side is the  nuclear business.  \n \n  So we continue to believe in the long term for that business.  We continue to make investments \nin theranostics opportunities with manufacturers.  And we still really like that business but it was one of \nthe biggest tailwinds1 in our phar maceutical segment.  \n \n  \n \n 1Was subsequently clarified later in the call and updated to \u201cheadwind\u201d  \n ", "original_text": "We continue to make investments \nin theranostics opportunities with manufacturers. ", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5cf9837e75aa495766e68d3dabbc1b86412e7dfca9d0b701b1580be6f41eaf48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58608f97-6a32-4d68-8af9-dd4b2469066b", "node_type": "1", "metadata": {"window": "And so as you can \nimagine when your procedures go down you still need drivers, you still need pharmacists, you still - \nand you have a raw material that you\u2019re getting less products off of because it is radioactive and so \nit\u2019s deteriorating.  So that busin ess was down significantly as we expected but it did rebound a little bit \nbetter, just a little bit better than we expected as elective procedures started to come back a little \nfaster.  They probably track closest to elective procedures on the P side is the  nuclear business.  \n \n  So we continue to believe in the long term for that business.  We continue to make investments \nin theranostics opportunities with manufacturers.  And we still really like that business but it was one of \nthe biggest tailwinds1 in our phar maceutical segment.  \n \n  \n \n 1Was subsequently clarified later in the call and updated to \u201cheadwind\u201d  \n ", "original_text": "So we continue to believe in the long term for that business. ", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4eddebc3aa7807cc5f475ba8a0906c04900f3eeee3081c2e0c4a57135165dc4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a925d074-75f5-4e2a-b172-b3adb2dbcaec", "node_type": "1", "metadata": {"window": "They probably track closest to elective procedures on the P side is the  nuclear business.  \n \n  So we continue to believe in the long term for that business.  We continue to make investments \nin theranostics opportunities with manufacturers.  And we still really like that business but it was one of \nthe biggest tailwinds1 in our phar maceutical segment.  \n \n  \n \n 1Was subsequently clarified later in the call and updated to \u201cheadwind\u201d  \n ", "original_text": "And we still really like that business but it was one of \nthe biggest tailwinds1 in our phar maceutical segment.  \n \n  \n \n"}, "hash": "4aa7899aa7ad45387f3d004a1a3a8a6b64d372575ad453c18f9a46ee4fa19966", "class_name": "RelatedNodeInfo"}}, "text": "We continue to make investments \nin theranostics opportunities with manufacturers. ", "start_char_idx": 1352, "end_char_idx": 1435, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a925d074-75f5-4e2a-b172-b3adb2dbcaec": {"__data__": {"id_": "a925d074-75f5-4e2a-b172-b3adb2dbcaec", "embedding": null, "metadata": {"window": "They probably track closest to elective procedures on the P side is the  nuclear business.  \n \n  So we continue to believe in the long term for that business.  We continue to make investments \nin theranostics opportunities with manufacturers.  And we still really like that business but it was one of \nthe biggest tailwinds1 in our phar maceutical segment.  \n \n  \n \n 1Was subsequently clarified later in the call and updated to \u201cheadwind\u201d  \n ", "original_text": "And we still really like that business but it was one of \nthe biggest tailwinds1 in our phar maceutical segment.  \n \n  \n \n", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5cf9837e75aa495766e68d3dabbc1b86412e7dfca9d0b701b1580be6f41eaf48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a2c6d55-36cd-4fed-8efa-752a01a607c7", "node_type": "1", "metadata": {"window": "So that busin ess was down significantly as we expected but it did rebound a little bit \nbetter, just a little bit better than we expected as elective procedures started to come back a little \nfaster.  They probably track closest to elective procedures on the P side is the  nuclear business.  \n \n  So we continue to believe in the long term for that business.  We continue to make investments \nin theranostics opportunities with manufacturers.  And we still really like that business but it was one of \nthe biggest tailwinds1 in our phar maceutical segment.  \n \n  \n \n 1Was subsequently clarified later in the call and updated to \u201cheadwind\u201d  \n ", "original_text": "We continue to make investments \nin theranostics opportunities with manufacturers. ", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c8e058fea06130bfb1680b79458903ef474a3fc01695905798da541bceb0850", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9575c02-153b-45b4-9737-bc7b72370f36", "node_type": "1", "metadata": {"window": "So we continue to believe in the long term for that business.  We continue to make investments \nin theranostics opportunities with manufacturers.  And we still really like that business but it was one of \nthe biggest tailwinds1 in our phar maceutical segment.  \n \n  \n \n 1Was subsequently clarified later in the call and updated to \u201cheadwind\u201d  \n ", "original_text": "1Was subsequently clarified later in the call and updated to \u201cheadwind\u201d  \n "}, "hash": "bcc7b97fb024384e3532f46191682518f4031bb8fa923fd7b1c40fa0e0308128", "class_name": "RelatedNodeInfo"}}, "text": "And we still really like that business but it was one of \nthe biggest tailwinds1 in our phar maceutical segment.  \n \n  \n \n", "start_char_idx": 1435, "end_char_idx": 1557, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9575c02-153b-45b4-9737-bc7b72370f36": {"__data__": {"id_": "e9575c02-153b-45b4-9737-bc7b72370f36", "embedding": null, "metadata": {"window": "So we continue to believe in the long term for that business.  We continue to make investments \nin theranostics opportunities with manufacturers.  And we still really like that business but it was one of \nthe biggest tailwinds1 in our phar maceutical segment.  \n \n  \n \n 1Was subsequently clarified later in the call and updated to \u201cheadwind\u201d  \n ", "original_text": "1Was subsequently clarified later in the call and updated to \u201cheadwind\u201d  \n ", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5cf9837e75aa495766e68d3dabbc1b86412e7dfca9d0b701b1580be6f41eaf48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a925d074-75f5-4e2a-b172-b3adb2dbcaec", "node_type": "1", "metadata": {"window": "They probably track closest to elective procedures on the P side is the  nuclear business.  \n \n  So we continue to believe in the long term for that business.  We continue to make investments \nin theranostics opportunities with manufacturers.  And we still really like that business but it was one of \nthe biggest tailwinds1 in our phar maceutical segment.  \n \n  \n \n 1Was subsequently clarified later in the call and updated to \u201cheadwind\u201d  \n ", "original_text": "And we still really like that business but it was one of \nthe biggest tailwinds1 in our phar maceutical segment.  \n \n  \n \n", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "521b488a6e99f34046514acaf5c8fa01c6f3ba810c7ec2ca1bb80ea8aeb22e67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e71652ab-6337-416c-b9c9-64235b85c145", "node_type": "1", "metadata": {"window": " \nPage 21 of 31 \n \nAs far as the brand component goes really what we\u2019re saying there is we expect inflation to be \nthe same as it was this year roughly.  But because some of the fee for service arrangements and mix \nhas changed a little bit there'll be less of the brand margin that is contingent to inflation this year than \nwe\u2019ve - in FY21 than in FY20 which it\u2019s already at 95% or so is at already non -contingent.  So we see \nthat gett ing even a little bit higher in next year.  The \u2013 so I\u2019ll end it there.  \n \n", "original_text": " \nPage 21 of 31 \n \nAs far as the brand component goes really what we\u2019re saying there is we expect inflation to be \nthe same as it was this year roughly. "}, "hash": "3303158d2bf686dc1197ec77d78d9eadba8dbc2c0fc73c1565e24be4683b6246", "class_name": "RelatedNodeInfo"}}, "text": "1Was subsequently clarified later in the call and updated to \u201cheadwind\u201d  \n ", "start_char_idx": 1557, "end_char_idx": 1632, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e71652ab-6337-416c-b9c9-64235b85c145": {"__data__": {"id_": "e71652ab-6337-416c-b9c9-64235b85c145", "embedding": null, "metadata": {"window": " \nPage 21 of 31 \n \nAs far as the brand component goes really what we\u2019re saying there is we expect inflation to be \nthe same as it was this year roughly.  But because some of the fee for service arrangements and mix \nhas changed a little bit there'll be less of the brand margin that is contingent to inflation this year than \nwe\u2019ve - in FY21 than in FY20 which it\u2019s already at 95% or so is at already non -contingent.  So we see \nthat gett ing even a little bit higher in next year.  The \u2013 so I\u2019ll end it there.  \n \n", "original_text": " \nPage 21 of 31 \n \nAs far as the brand component goes really what we\u2019re saying there is we expect inflation to be \nthe same as it was this year roughly. ", "page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44979e2c-e074-4f22-a939-50ea3bd188dd", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c7bfdafcc2ddd0548f805f4cd6ea0198bfcb8d01c0b41ca0e6d3099eaaf29aad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9575c02-153b-45b4-9737-bc7b72370f36", "node_type": "1", "metadata": {"window": "So we continue to believe in the long term for that business.  We continue to make investments \nin theranostics opportunities with manufacturers.  And we still really like that business but it was one of \nthe biggest tailwinds1 in our phar maceutical segment.  \n \n  \n \n 1Was subsequently clarified later in the call and updated to \u201cheadwind\u201d  \n ", "original_text": "1Was subsequently clarified later in the call and updated to \u201cheadwind\u201d  \n ", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "180f69215c39aeb412f15a24ede5a6b205f1a01de7a6b5ba3e01b3634281c588", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60160942-3fb9-4ca5-9630-5ecb80bf59fb", "node_type": "1", "metadata": {"window": " \nPage 21 of 31 \n \nAs far as the brand component goes really what we\u2019re saying there is we expect inflation to be \nthe same as it was this year roughly.  But because some of the fee for service arrangements and mix \nhas changed a little bit there'll be less of the brand margin that is contingent to inflation this year than \nwe\u2019ve - in FY21 than in FY20 which it\u2019s already at 95% or so is at already non -contingent.  So we see \nthat gett ing even a little bit higher in next year.  The \u2013 so I\u2019ll end it there.  \n \n Ricky Goldwasser:  Just can I do a quick follow -up on the nuclear?  \n \n", "original_text": "But because some of the fee for service arrangements and mix \nhas changed a little bit there'll be less of the brand margin that is contingent to inflation this year than \nwe\u2019ve - in FY21 than in FY20 which it\u2019s already at 95% or so is at already non -contingent. "}, "hash": "5a02a9a40ca8853a2af4cb918c6142958816bed34fb7a52bf29d3deb8da4e156", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 21 of 31 \n \nAs far as the brand component goes really what we\u2019re saying there is we expect inflation to be \nthe same as it was this year roughly. ", "start_char_idx": 0, "end_char_idx": 153, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60160942-3fb9-4ca5-9630-5ecb80bf59fb": {"__data__": {"id_": "60160942-3fb9-4ca5-9630-5ecb80bf59fb", "embedding": null, "metadata": {"window": " \nPage 21 of 31 \n \nAs far as the brand component goes really what we\u2019re saying there is we expect inflation to be \nthe same as it was this year roughly.  But because some of the fee for service arrangements and mix \nhas changed a little bit there'll be less of the brand margin that is contingent to inflation this year than \nwe\u2019ve - in FY21 than in FY20 which it\u2019s already at 95% or so is at already non -contingent.  So we see \nthat gett ing even a little bit higher in next year.  The \u2013 so I\u2019ll end it there.  \n \n Ricky Goldwasser:  Just can I do a quick follow -up on the nuclear?  \n \n", "original_text": "But because some of the fee for service arrangements and mix \nhas changed a little bit there'll be less of the brand margin that is contingent to inflation this year than \nwe\u2019ve - in FY21 than in FY20 which it\u2019s already at 95% or so is at already non -contingent. ", "page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44979e2c-e074-4f22-a939-50ea3bd188dd", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c7bfdafcc2ddd0548f805f4cd6ea0198bfcb8d01c0b41ca0e6d3099eaaf29aad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e71652ab-6337-416c-b9c9-64235b85c145", "node_type": "1", "metadata": {"window": " \nPage 21 of 31 \n \nAs far as the brand component goes really what we\u2019re saying there is we expect inflation to be \nthe same as it was this year roughly.  But because some of the fee for service arrangements and mix \nhas changed a little bit there'll be less of the brand margin that is contingent to inflation this year than \nwe\u2019ve - in FY21 than in FY20 which it\u2019s already at 95% or so is at already non -contingent.  So we see \nthat gett ing even a little bit higher in next year.  The \u2013 so I\u2019ll end it there.  \n \n", "original_text": " \nPage 21 of 31 \n \nAs far as the brand component goes really what we\u2019re saying there is we expect inflation to be \nthe same as it was this year roughly. ", "page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f777988b885278ee84def3fb487a05995f8d18eee7ca7e1abce236d7a01e1871", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f1a4a76-f275-470e-be10-9dadb5608bc0", "node_type": "1", "metadata": {"window": " \nPage 21 of 31 \n \nAs far as the brand component goes really what we\u2019re saying there is we expect inflation to be \nthe same as it was this year roughly.  But because some of the fee for service arrangements and mix \nhas changed a little bit there'll be less of the brand margin that is contingent to inflation this year than \nwe\u2019ve - in FY21 than in FY20 which it\u2019s already at 95% or so is at already non -contingent.  So we see \nthat gett ing even a little bit higher in next year.  The \u2013 so I\u2019ll end it there.  \n \n Ricky Goldwasser:  Just can I do a quick follow -up on the nuclear?  \n \n Mike Kaufmann:  Sure.  \n \n", "original_text": "So we see \nthat gett ing even a little bit higher in next year. "}, "hash": "f6d46959b1fb11e40c368826219793e90a48ebd417f6a715fe7b4aaab1ff45a8", "class_name": "RelatedNodeInfo"}}, "text": "But because some of the fee for service arrangements and mix \nhas changed a little bit there'll be less of the brand margin that is contingent to inflation this year than \nwe\u2019ve - in FY21 than in FY20 which it\u2019s already at 95% or so is at already non -contingent. ", "start_char_idx": 153, "end_char_idx": 417, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f1a4a76-f275-470e-be10-9dadb5608bc0": {"__data__": {"id_": "2f1a4a76-f275-470e-be10-9dadb5608bc0", "embedding": null, "metadata": {"window": " \nPage 21 of 31 \n \nAs far as the brand component goes really what we\u2019re saying there is we expect inflation to be \nthe same as it was this year roughly.  But because some of the fee for service arrangements and mix \nhas changed a little bit there'll be less of the brand margin that is contingent to inflation this year than \nwe\u2019ve - in FY21 than in FY20 which it\u2019s already at 95% or so is at already non -contingent.  So we see \nthat gett ing even a little bit higher in next year.  The \u2013 so I\u2019ll end it there.  \n \n Ricky Goldwasser:  Just can I do a quick follow -up on the nuclear?  \n \n Mike Kaufmann:  Sure.  \n \n", "original_text": "So we see \nthat gett ing even a little bit higher in next year. ", "page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44979e2c-e074-4f22-a939-50ea3bd188dd", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c7bfdafcc2ddd0548f805f4cd6ea0198bfcb8d01c0b41ca0e6d3099eaaf29aad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60160942-3fb9-4ca5-9630-5ecb80bf59fb", "node_type": "1", "metadata": {"window": " \nPage 21 of 31 \n \nAs far as the brand component goes really what we\u2019re saying there is we expect inflation to be \nthe same as it was this year roughly.  But because some of the fee for service arrangements and mix \nhas changed a little bit there'll be less of the brand margin that is contingent to inflation this year than \nwe\u2019ve - in FY21 than in FY20 which it\u2019s already at 95% or so is at already non -contingent.  So we see \nthat gett ing even a little bit higher in next year.  The \u2013 so I\u2019ll end it there.  \n \n Ricky Goldwasser:  Just can I do a quick follow -up on the nuclear?  \n \n", "original_text": "But because some of the fee for service arrangements and mix \nhas changed a little bit there'll be less of the brand margin that is contingent to inflation this year than \nwe\u2019ve - in FY21 than in FY20 which it\u2019s already at 95% or so is at already non -contingent. ", "page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab2a31999aaacd1dba1138070d32ab2a75f651fc664bf7f4760c82429cb2bf33", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29b018f3-7f81-4b84-994a-e9e557158649", "node_type": "1", "metadata": {"window": " \nPage 21 of 31 \n \nAs far as the brand component goes really what we\u2019re saying there is we expect inflation to be \nthe same as it was this year roughly.  But because some of the fee for service arrangements and mix \nhas changed a little bit there'll be less of the brand margin that is contingent to inflation this year than \nwe\u2019ve - in FY21 than in FY20 which it\u2019s already at 95% or so is at already non -contingent.  So we see \nthat gett ing even a little bit higher in next year.  The \u2013 so I\u2019ll end it there.  \n \n Ricky Goldwasser:  Just can I do a quick follow -up on the nuclear?  \n \n Mike Kaufmann:  Sure.  \n \n Ricky Goldwasser:  So if you exclude then the nuclear because to your point is the most significant \nimpact, can you maybe talk a little bit about what type of growth you\u2019d expect for the rest of the \nbusiness in fiscal year '21?  \n \n", "original_text": "The \u2013 so I\u2019ll end it there.  \n \n"}, "hash": "e5868551a70924b7dad947f7a399870b3a45256766bf06c8b7fa1ce59f74f51d", "class_name": "RelatedNodeInfo"}}, "text": "So we see \nthat gett ing even a little bit higher in next year. ", "start_char_idx": 417, "end_char_idx": 481, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29b018f3-7f81-4b84-994a-e9e557158649": {"__data__": {"id_": "29b018f3-7f81-4b84-994a-e9e557158649", "embedding": null, "metadata": {"window": " \nPage 21 of 31 \n \nAs far as the brand component goes really what we\u2019re saying there is we expect inflation to be \nthe same as it was this year roughly.  But because some of the fee for service arrangements and mix \nhas changed a little bit there'll be less of the brand margin that is contingent to inflation this year than \nwe\u2019ve - in FY21 than in FY20 which it\u2019s already at 95% or so is at already non -contingent.  So we see \nthat gett ing even a little bit higher in next year.  The \u2013 so I\u2019ll end it there.  \n \n Ricky Goldwasser:  Just can I do a quick follow -up on the nuclear?  \n \n Mike Kaufmann:  Sure.  \n \n Ricky Goldwasser:  So if you exclude then the nuclear because to your point is the most significant \nimpact, can you maybe talk a little bit about what type of growth you\u2019d expect for the rest of the \nbusiness in fiscal year '21?  \n \n", "original_text": "The \u2013 so I\u2019ll end it there.  \n \n", "page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44979e2c-e074-4f22-a939-50ea3bd188dd", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c7bfdafcc2ddd0548f805f4cd6ea0198bfcb8d01c0b41ca0e6d3099eaaf29aad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f1a4a76-f275-470e-be10-9dadb5608bc0", "node_type": "1", "metadata": {"window": " \nPage 21 of 31 \n \nAs far as the brand component goes really what we\u2019re saying there is we expect inflation to be \nthe same as it was this year roughly.  But because some of the fee for service arrangements and mix \nhas changed a little bit there'll be less of the brand margin that is contingent to inflation this year than \nwe\u2019ve - in FY21 than in FY20 which it\u2019s already at 95% or so is at already non -contingent.  So we see \nthat gett ing even a little bit higher in next year.  The \u2013 so I\u2019ll end it there.  \n \n Ricky Goldwasser:  Just can I do a quick follow -up on the nuclear?  \n \n Mike Kaufmann:  Sure.  \n \n", "original_text": "So we see \nthat gett ing even a little bit higher in next year. ", "page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55ac8d89f3ba804d5f7018b0abd3cd46a58da93cbca24eb3cc4c9ab024d682a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c24a432e-33fb-44ef-88ba-0d4653268fd5", "node_type": "1", "metadata": {"window": "But because some of the fee for service arrangements and mix \nhas changed a little bit there'll be less of the brand margin that is contingent to inflation this year than \nwe\u2019ve - in FY21 than in FY20 which it\u2019s already at 95% or so is at already non -contingent.  So we see \nthat gett ing even a little bit higher in next year.  The \u2013 so I\u2019ll end it there.  \n \n Ricky Goldwasser:  Just can I do a quick follow -up on the nuclear?  \n \n Mike Kaufmann:  Sure.  \n \n Ricky Goldwasser:  So if you exclude then the nuclear because to your point is the most significant \nimpact, can you maybe talk a little bit about what type of growth you\u2019d expect for the rest of the \nbusiness in fiscal year '21?  \n \n Mike Kaufmann:  So just to be clear, I think I might of said the word tailwind on nuclear and I meant \nheadwind for Q4. \n \n", "original_text": "Ricky Goldwasser:  Just can I do a quick follow -up on the nuclear?  \n \n"}, "hash": "57a44bcad102daa1ca7d5b488fd2063d064c1cd2b72a860d8bfca180de6c4981", "class_name": "RelatedNodeInfo"}}, "text": "The \u2013 so I\u2019ll end it there.  \n \n", "start_char_idx": 481, "end_char_idx": 513, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c24a432e-33fb-44ef-88ba-0d4653268fd5": {"__data__": {"id_": "c24a432e-33fb-44ef-88ba-0d4653268fd5", "embedding": null, "metadata": {"window": "But because some of the fee for service arrangements and mix \nhas changed a little bit there'll be less of the brand margin that is contingent to inflation this year than \nwe\u2019ve - in FY21 than in FY20 which it\u2019s already at 95% or so is at already non -contingent.  So we see \nthat gett ing even a little bit higher in next year.  The \u2013 so I\u2019ll end it there.  \n \n Ricky Goldwasser:  Just can I do a quick follow -up on the nuclear?  \n \n Mike Kaufmann:  Sure.  \n \n Ricky Goldwasser:  So if you exclude then the nuclear because to your point is the most significant \nimpact, can you maybe talk a little bit about what type of growth you\u2019d expect for the rest of the \nbusiness in fiscal year '21?  \n \n Mike Kaufmann:  So just to be clear, I think I might of said the word tailwind on nuclear and I meant \nheadwind for Q4. \n \n", "original_text": "Ricky Goldwasser:  Just can I do a quick follow -up on the nuclear?  \n \n", "page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44979e2c-e074-4f22-a939-50ea3bd188dd", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c7bfdafcc2ddd0548f805f4cd6ea0198bfcb8d01c0b41ca0e6d3099eaaf29aad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29b018f3-7f81-4b84-994a-e9e557158649", "node_type": "1", "metadata": {"window": " \nPage 21 of 31 \n \nAs far as the brand component goes really what we\u2019re saying there is we expect inflation to be \nthe same as it was this year roughly.  But because some of the fee for service arrangements and mix \nhas changed a little bit there'll be less of the brand margin that is contingent to inflation this year than \nwe\u2019ve - in FY21 than in FY20 which it\u2019s already at 95% or so is at already non -contingent.  So we see \nthat gett ing even a little bit higher in next year.  The \u2013 so I\u2019ll end it there.  \n \n Ricky Goldwasser:  Just can I do a quick follow -up on the nuclear?  \n \n Mike Kaufmann:  Sure.  \n \n Ricky Goldwasser:  So if you exclude then the nuclear because to your point is the most significant \nimpact, can you maybe talk a little bit about what type of growth you\u2019d expect for the rest of the \nbusiness in fiscal year '21?  \n \n", "original_text": "The \u2013 so I\u2019ll end it there.  \n \n", "page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "53f345192c888ac453d6dbc15117c013ace67a86ce5f070ac5906178ca314b0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4cf2eff0-468f-4ed1-aca6-155c844c4241", "node_type": "1", "metadata": {"window": "So we see \nthat gett ing even a little bit higher in next year.  The \u2013 so I\u2019ll end it there.  \n \n Ricky Goldwasser:  Just can I do a quick follow -up on the nuclear?  \n \n Mike Kaufmann:  Sure.  \n \n Ricky Goldwasser:  So if you exclude then the nuclear because to your point is the most significant \nimpact, can you maybe talk a little bit about what type of growth you\u2019d expect for the rest of the \nbusiness in fiscal year '21?  \n \n Mike Kaufmann:  So just to be clear, I think I might of said the word tailwind on nuclear and I meant \nheadwind for Q4. \n \n Ricky Goldwasser:  Yes.  \n \n", "original_text": "Mike Kaufmann:  Sure.  \n \n"}, "hash": "a93f12bb05c217b22fdfdda9758f080b98645d641c7b99b69b2a5e172cc7b11b", "class_name": "RelatedNodeInfo"}}, "text": "Ricky Goldwasser:  Just can I do a quick follow -up on the nuclear?  \n \n", "start_char_idx": 513, "end_char_idx": 585, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4cf2eff0-468f-4ed1-aca6-155c844c4241": {"__data__": {"id_": "4cf2eff0-468f-4ed1-aca6-155c844c4241", "embedding": null, "metadata": {"window": "So we see \nthat gett ing even a little bit higher in next year.  The \u2013 so I\u2019ll end it there.  \n \n Ricky Goldwasser:  Just can I do a quick follow -up on the nuclear?  \n \n Mike Kaufmann:  Sure.  \n \n Ricky Goldwasser:  So if you exclude then the nuclear because to your point is the most significant \nimpact, can you maybe talk a little bit about what type of growth you\u2019d expect for the rest of the \nbusiness in fiscal year '21?  \n \n Mike Kaufmann:  So just to be clear, I think I might of said the word tailwind on nuclear and I meant \nheadwind for Q4. \n \n Ricky Goldwasser:  Yes.  \n \n", "original_text": "Mike Kaufmann:  Sure.  \n \n", "page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44979e2c-e074-4f22-a939-50ea3bd188dd", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c7bfdafcc2ddd0548f805f4cd6ea0198bfcb8d01c0b41ca0e6d3099eaaf29aad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c24a432e-33fb-44ef-88ba-0d4653268fd5", "node_type": "1", "metadata": {"window": "But because some of the fee for service arrangements and mix \nhas changed a little bit there'll be less of the brand margin that is contingent to inflation this year than \nwe\u2019ve - in FY21 than in FY20 which it\u2019s already at 95% or so is at already non -contingent.  So we see \nthat gett ing even a little bit higher in next year.  The \u2013 so I\u2019ll end it there.  \n \n Ricky Goldwasser:  Just can I do a quick follow -up on the nuclear?  \n \n Mike Kaufmann:  Sure.  \n \n Ricky Goldwasser:  So if you exclude then the nuclear because to your point is the most significant \nimpact, can you maybe talk a little bit about what type of growth you\u2019d expect for the rest of the \nbusiness in fiscal year '21?  \n \n Mike Kaufmann:  So just to be clear, I think I might of said the word tailwind on nuclear and I meant \nheadwind for Q4. \n \n", "original_text": "Ricky Goldwasser:  Just can I do a quick follow -up on the nuclear?  \n \n", "page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ffbd1020371bdb172ed9dcb8ccf49c46099aecd5c60a1f8807a7a01a54416434", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70516d1f-0fa6-4d3f-8090-2dcaed2c8378", "node_type": "1", "metadata": {"window": "The \u2013 so I\u2019ll end it there.  \n \n Ricky Goldwasser:  Just can I do a quick follow -up on the nuclear?  \n \n Mike Kaufmann:  Sure.  \n \n Ricky Goldwasser:  So if you exclude then the nuclear because to your point is the most significant \nimpact, can you maybe talk a little bit about what type of growth you\u2019d expect for the rest of the \nbusiness in fiscal year '21?  \n \n Mike Kaufmann:  So just to be clear, I think I might of said the word tailwind on nuclear and I meant \nheadwind for Q4. \n \n Ricky Goldwasser:  Yes.  \n \n Mike Kaufmann:  So I apologize for that. ", "original_text": "Ricky Goldwasser:  So if you exclude then the nuclear because to your point is the most significant \nimpact, can you maybe talk a little bit about what type of growth you\u2019d expect for the rest of the \nbusiness in fiscal year '21?  \n \n"}, "hash": "91ccc3156e1b579eb618ca1399b198d90d3352d4c36d0aa45bc794877e7d5a28", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Sure.  \n \n", "start_char_idx": 585, "end_char_idx": 611, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70516d1f-0fa6-4d3f-8090-2dcaed2c8378": {"__data__": {"id_": "70516d1f-0fa6-4d3f-8090-2dcaed2c8378", "embedding": null, "metadata": {"window": "The \u2013 so I\u2019ll end it there.  \n \n Ricky Goldwasser:  Just can I do a quick follow -up on the nuclear?  \n \n Mike Kaufmann:  Sure.  \n \n Ricky Goldwasser:  So if you exclude then the nuclear because to your point is the most significant \nimpact, can you maybe talk a little bit about what type of growth you\u2019d expect for the rest of the \nbusiness in fiscal year '21?  \n \n Mike Kaufmann:  So just to be clear, I think I might of said the word tailwind on nuclear and I meant \nheadwind for Q4. \n \n Ricky Goldwasser:  Yes.  \n \n Mike Kaufmann:  So I apologize for that. ", "original_text": "Ricky Goldwasser:  So if you exclude then the nuclear because to your point is the most significant \nimpact, can you maybe talk a little bit about what type of growth you\u2019d expect for the rest of the \nbusiness in fiscal year '21?  \n \n", "page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44979e2c-e074-4f22-a939-50ea3bd188dd", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c7bfdafcc2ddd0548f805f4cd6ea0198bfcb8d01c0b41ca0e6d3099eaaf29aad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4cf2eff0-468f-4ed1-aca6-155c844c4241", "node_type": "1", "metadata": {"window": "So we see \nthat gett ing even a little bit higher in next year.  The \u2013 so I\u2019ll end it there.  \n \n Ricky Goldwasser:  Just can I do a quick follow -up on the nuclear?  \n \n Mike Kaufmann:  Sure.  \n \n Ricky Goldwasser:  So if you exclude then the nuclear because to your point is the most significant \nimpact, can you maybe talk a little bit about what type of growth you\u2019d expect for the rest of the \nbusiness in fiscal year '21?  \n \n Mike Kaufmann:  So just to be clear, I think I might of said the word tailwind on nuclear and I meant \nheadwind for Q4. \n \n Ricky Goldwasser:  Yes.  \n \n", "original_text": "Mike Kaufmann:  Sure.  \n \n", "page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5fe8d1fdd31535400f00240e5895a0456be77de6eb775dd63a328d7de665c380", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "103fac21-6791-424c-b681-fa7717557bec", "node_type": "1", "metadata": {"window": "Ricky Goldwasser:  Just can I do a quick follow -up on the nuclear?  \n \n Mike Kaufmann:  Sure.  \n \n Ricky Goldwasser:  So if you exclude then the nuclear because to your point is the most significant \nimpact, can you maybe talk a little bit about what type of growth you\u2019d expect for the rest of the \nbusiness in fiscal year '21?  \n \n Mike Kaufmann:  So just to be clear, I think I might of said the word tailwind on nuclear and I meant \nheadwind for Q4. \n \n Ricky Goldwasser:  Yes.  \n \n Mike Kaufmann:  So I apologize for that.  I think everybody probably knew that. ", "original_text": "Mike Kaufmann:  So just to be clear, I think I might of said the word tailwind on nuclear and I meant \nheadwind for Q4. \n \n"}, "hash": "ee0175b365461a0457ac0576f306d9ea040953404ceeb7bd602d3dd9fe0e12dd", "class_name": "RelatedNodeInfo"}}, "text": "Ricky Goldwasser:  So if you exclude then the nuclear because to your point is the most significant \nimpact, can you maybe talk a little bit about what type of growth you\u2019d expect for the rest of the \nbusiness in fiscal year '21?  \n \n", "start_char_idx": 611, "end_char_idx": 845, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "103fac21-6791-424c-b681-fa7717557bec": {"__data__": {"id_": "103fac21-6791-424c-b681-fa7717557bec", "embedding": null, "metadata": {"window": "Ricky Goldwasser:  Just can I do a quick follow -up on the nuclear?  \n \n Mike Kaufmann:  Sure.  \n \n Ricky Goldwasser:  So if you exclude then the nuclear because to your point is the most significant \nimpact, can you maybe talk a little bit about what type of growth you\u2019d expect for the rest of the \nbusiness in fiscal year '21?  \n \n Mike Kaufmann:  So just to be clear, I think I might of said the word tailwind on nuclear and I meant \nheadwind for Q4. \n \n Ricky Goldwasser:  Yes.  \n \n Mike Kaufmann:  So I apologize for that.  I think everybody probably knew that. ", "original_text": "Mike Kaufmann:  So just to be clear, I think I might of said the word tailwind on nuclear and I meant \nheadwind for Q4. \n \n", "page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44979e2c-e074-4f22-a939-50ea3bd188dd", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c7bfdafcc2ddd0548f805f4cd6ea0198bfcb8d01c0b41ca0e6d3099eaaf29aad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70516d1f-0fa6-4d3f-8090-2dcaed2c8378", "node_type": "1", "metadata": {"window": "The \u2013 so I\u2019ll end it there.  \n \n Ricky Goldwasser:  Just can I do a quick follow -up on the nuclear?  \n \n Mike Kaufmann:  Sure.  \n \n Ricky Goldwasser:  So if you exclude then the nuclear because to your point is the most significant \nimpact, can you maybe talk a little bit about what type of growth you\u2019d expect for the rest of the \nbusiness in fiscal year '21?  \n \n Mike Kaufmann:  So just to be clear, I think I might of said the word tailwind on nuclear and I meant \nheadwind for Q4. \n \n Ricky Goldwasser:  Yes.  \n \n Mike Kaufmann:  So I apologize for that. ", "original_text": "Ricky Goldwasser:  So if you exclude then the nuclear because to your point is the most significant \nimpact, can you maybe talk a little bit about what type of growth you\u2019d expect for the rest of the \nbusiness in fiscal year '21?  \n \n", "page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "578c13ba830cb41b4f5957a3f947d68183af4cfeaa88f114521ee37005f04287", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71700b78-f7c9-41ab-a3d5-1f08c96b64d5", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Sure.  \n \n Ricky Goldwasser:  So if you exclude then the nuclear because to your point is the most significant \nimpact, can you maybe talk a little bit about what type of growth you\u2019d expect for the rest of the \nbusiness in fiscal year '21?  \n \n Mike Kaufmann:  So just to be clear, I think I might of said the word tailwind on nuclear and I meant \nheadwind for Q4. \n \n Ricky Goldwasser:  Yes.  \n \n Mike Kaufmann:  So I apologize for that.  I think everybody probably knew that.  But as far as growth \nare you talking about specifically the nuclear or overall for the Pharma segment?  \n \n", "original_text": "Ricky Goldwasser:  Yes.  \n \n"}, "hash": "24ccc8518262030ebef18f8e2a75e374acfa75de8096e2806be3c74bd4c79e6a", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  So just to be clear, I think I might of said the word tailwind on nuclear and I meant \nheadwind for Q4. \n \n", "start_char_idx": 845, "end_char_idx": 968, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71700b78-f7c9-41ab-a3d5-1f08c96b64d5": {"__data__": {"id_": "71700b78-f7c9-41ab-a3d5-1f08c96b64d5", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Sure.  \n \n Ricky Goldwasser:  So if you exclude then the nuclear because to your point is the most significant \nimpact, can you maybe talk a little bit about what type of growth you\u2019d expect for the rest of the \nbusiness in fiscal year '21?  \n \n Mike Kaufmann:  So just to be clear, I think I might of said the word tailwind on nuclear and I meant \nheadwind for Q4. \n \n Ricky Goldwasser:  Yes.  \n \n Mike Kaufmann:  So I apologize for that.  I think everybody probably knew that.  But as far as growth \nare you talking about specifically the nuclear or overall for the Pharma segment?  \n \n", "original_text": "Ricky Goldwasser:  Yes.  \n \n", "page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44979e2c-e074-4f22-a939-50ea3bd188dd", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c7bfdafcc2ddd0548f805f4cd6ea0198bfcb8d01c0b41ca0e6d3099eaaf29aad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "103fac21-6791-424c-b681-fa7717557bec", "node_type": "1", "metadata": {"window": "Ricky Goldwasser:  Just can I do a quick follow -up on the nuclear?  \n \n Mike Kaufmann:  Sure.  \n \n Ricky Goldwasser:  So if you exclude then the nuclear because to your point is the most significant \nimpact, can you maybe talk a little bit about what type of growth you\u2019d expect for the rest of the \nbusiness in fiscal year '21?  \n \n Mike Kaufmann:  So just to be clear, I think I might of said the word tailwind on nuclear and I meant \nheadwind for Q4. \n \n Ricky Goldwasser:  Yes.  \n \n Mike Kaufmann:  So I apologize for that.  I think everybody probably knew that. ", "original_text": "Mike Kaufmann:  So just to be clear, I think I might of said the word tailwind on nuclear and I meant \nheadwind for Q4. \n \n", "page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdf580f6c3909d57e174830a6059a0ee95eceb1094afe78076a01d6846185989", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb1bc6fb-2b94-4e4f-9707-86adcb8c3b6a", "node_type": "1", "metadata": {"window": "Ricky Goldwasser:  So if you exclude then the nuclear because to your point is the most significant \nimpact, can you maybe talk a little bit about what type of growth you\u2019d expect for the rest of the \nbusiness in fiscal year '21?  \n \n Mike Kaufmann:  So just to be clear, I think I might of said the word tailwind on nuclear and I meant \nheadwind for Q4. \n \n Ricky Goldwasser:  Yes.  \n \n Mike Kaufmann:  So I apologize for that.  I think everybody probably knew that.  But as far as growth \nare you talking about specifically the nuclear or overall for the Pharma segment?  \n \n Ricky Goldwasser:  Overall for the Pharma s egment, so once you exclude that nuclear that has the \nmost negative impact...  ", "original_text": "Mike Kaufmann:  So I apologize for that. "}, "hash": "14b4e51a6ebe646f007dc8512eb0adca301f66067dcbfe6054f5f8442c23b60c", "class_name": "RelatedNodeInfo"}}, "text": "Ricky Goldwasser:  Yes.  \n \n", "start_char_idx": 968, "end_char_idx": 996, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb1bc6fb-2b94-4e4f-9707-86adcb8c3b6a": {"__data__": {"id_": "bb1bc6fb-2b94-4e4f-9707-86adcb8c3b6a", "embedding": null, "metadata": {"window": "Ricky Goldwasser:  So if you exclude then the nuclear because to your point is the most significant \nimpact, can you maybe talk a little bit about what type of growth you\u2019d expect for the rest of the \nbusiness in fiscal year '21?  \n \n Mike Kaufmann:  So just to be clear, I think I might of said the word tailwind on nuclear and I meant \nheadwind for Q4. \n \n Ricky Goldwasser:  Yes.  \n \n Mike Kaufmann:  So I apologize for that.  I think everybody probably knew that.  But as far as growth \nare you talking about specifically the nuclear or overall for the Pharma segment?  \n \n Ricky Goldwasser:  Overall for the Pharma s egment, so once you exclude that nuclear that has the \nmost negative impact...  ", "original_text": "Mike Kaufmann:  So I apologize for that. ", "page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44979e2c-e074-4f22-a939-50ea3bd188dd", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c7bfdafcc2ddd0548f805f4cd6ea0198bfcb8d01c0b41ca0e6d3099eaaf29aad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71700b78-f7c9-41ab-a3d5-1f08c96b64d5", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Sure.  \n \n Ricky Goldwasser:  So if you exclude then the nuclear because to your point is the most significant \nimpact, can you maybe talk a little bit about what type of growth you\u2019d expect for the rest of the \nbusiness in fiscal year '21?  \n \n Mike Kaufmann:  So just to be clear, I think I might of said the word tailwind on nuclear and I meant \nheadwind for Q4. \n \n Ricky Goldwasser:  Yes.  \n \n Mike Kaufmann:  So I apologize for that.  I think everybody probably knew that.  But as far as growth \nare you talking about specifically the nuclear or overall for the Pharma segment?  \n \n", "original_text": "Ricky Goldwasser:  Yes.  \n \n", "page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eb681626581434374cc00b819e82ea7cb6a42295d910fb28d4e98a5d7c44b8eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a40a6b08-e640-4683-9649-2e60308a6a2d", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  So just to be clear, I think I might of said the word tailwind on nuclear and I meant \nheadwind for Q4. \n \n Ricky Goldwasser:  Yes.  \n \n Mike Kaufmann:  So I apologize for that.  I think everybody probably knew that.  But as far as growth \nare you talking about specifically the nuclear or overall for the Pharma segment?  \n \n Ricky Goldwasser:  Overall for the Pharma s egment, so once you exclude that nuclear that has the \nmost negative impact...  ", "original_text": "I think everybody probably knew that. "}, "hash": "fd511d1da37548d8d7b21ee5499851c0c9df1398d10e092f6d51ebe6c7dc2794", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  So I apologize for that. ", "start_char_idx": 996, "end_char_idx": 1037, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a40a6b08-e640-4683-9649-2e60308a6a2d": {"__data__": {"id_": "a40a6b08-e640-4683-9649-2e60308a6a2d", "embedding": null, "metadata": {"window": "Mike Kaufmann:  So just to be clear, I think I might of said the word tailwind on nuclear and I meant \nheadwind for Q4. \n \n Ricky Goldwasser:  Yes.  \n \n Mike Kaufmann:  So I apologize for that.  I think everybody probably knew that.  But as far as growth \nare you talking about specifically the nuclear or overall for the Pharma segment?  \n \n Ricky Goldwasser:  Overall for the Pharma s egment, so once you exclude that nuclear that has the \nmost negative impact...  ", "original_text": "I think everybody probably knew that. ", "page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44979e2c-e074-4f22-a939-50ea3bd188dd", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c7bfdafcc2ddd0548f805f4cd6ea0198bfcb8d01c0b41ca0e6d3099eaaf29aad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb1bc6fb-2b94-4e4f-9707-86adcb8c3b6a", "node_type": "1", "metadata": {"window": "Ricky Goldwasser:  So if you exclude then the nuclear because to your point is the most significant \nimpact, can you maybe talk a little bit about what type of growth you\u2019d expect for the rest of the \nbusiness in fiscal year '21?  \n \n Mike Kaufmann:  So just to be clear, I think I might of said the word tailwind on nuclear and I meant \nheadwind for Q4. \n \n Ricky Goldwasser:  Yes.  \n \n Mike Kaufmann:  So I apologize for that.  I think everybody probably knew that.  But as far as growth \nare you talking about specifically the nuclear or overall for the Pharma segment?  \n \n Ricky Goldwasser:  Overall for the Pharma s egment, so once you exclude that nuclear that has the \nmost negative impact...  ", "original_text": "Mike Kaufmann:  So I apologize for that. ", "page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def259b44c5567acda7fa28464c51d3a8f50bc252dffe25b682e3eade4a162b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "823b47cb-c3a1-4fe6-8fcc-a98c53e5652f", "node_type": "1", "metadata": {"window": "Ricky Goldwasser:  Yes.  \n \n Mike Kaufmann:  So I apologize for that.  I think everybody probably knew that.  But as far as growth \nare you talking about specifically the nuclear or overall for the Pharma segment?  \n \n Ricky Goldwasser:  Overall for the Pharma s egment, so once you exclude that nuclear that has the \nmost negative impact...  ", "original_text": "But as far as growth \nare you talking about specifically the nuclear or overall for the Pharma segment?  \n \n"}, "hash": "deaab6e9e5c848b1c2b4e3dd7b6db5f75ed873290163ecce1a5b558e19a4e18b", "class_name": "RelatedNodeInfo"}}, "text": "I think everybody probably knew that. ", "start_char_idx": 1037, "end_char_idx": 1075, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "823b47cb-c3a1-4fe6-8fcc-a98c53e5652f": {"__data__": {"id_": "823b47cb-c3a1-4fe6-8fcc-a98c53e5652f", "embedding": null, "metadata": {"window": "Ricky Goldwasser:  Yes.  \n \n Mike Kaufmann:  So I apologize for that.  I think everybody probably knew that.  But as far as growth \nare you talking about specifically the nuclear or overall for the Pharma segment?  \n \n Ricky Goldwasser:  Overall for the Pharma s egment, so once you exclude that nuclear that has the \nmost negative impact...  ", "original_text": "But as far as growth \nare you talking about specifically the nuclear or overall for the Pharma segment?  \n \n", "page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44979e2c-e074-4f22-a939-50ea3bd188dd", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c7bfdafcc2ddd0548f805f4cd6ea0198bfcb8d01c0b41ca0e6d3099eaaf29aad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a40a6b08-e640-4683-9649-2e60308a6a2d", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  So just to be clear, I think I might of said the word tailwind on nuclear and I meant \nheadwind for Q4. \n \n Ricky Goldwasser:  Yes.  \n \n Mike Kaufmann:  So I apologize for that.  I think everybody probably knew that.  But as far as growth \nare you talking about specifically the nuclear or overall for the Pharma segment?  \n \n Ricky Goldwasser:  Overall for the Pharma s egment, so once you exclude that nuclear that has the \nmost negative impact...  ", "original_text": "I think everybody probably knew that. ", "page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe2bc3c29846d8d08ac2b9e287873eeefb59d2ca9324fd51281740276bb2fa85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d31d1af-9119-4c1d-ab65-b8f76a30c7c8", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  So I apologize for that.  I think everybody probably knew that.  But as far as growth \nare you talking about specifically the nuclear or overall for the Pharma segment?  \n \n Ricky Goldwasser:  Overall for the Pharma s egment, so once you exclude that nuclear that has the \nmost negative impact...  ", "original_text": "Ricky Goldwasser:  Overall for the Pharma s egment, so once you exclude that nuclear that has the \nmost negative impact...  "}, "hash": "5dc1f6096f5405c0e7c1f47912084ecdd5f7afbd288f2919157ce0a0d87cef82", "class_name": "RelatedNodeInfo"}}, "text": "But as far as growth \nare you talking about specifically the nuclear or overall for the Pharma segment?  \n \n", "start_char_idx": 1075, "end_char_idx": 1183, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d31d1af-9119-4c1d-ab65-b8f76a30c7c8": {"__data__": {"id_": "8d31d1af-9119-4c1d-ab65-b8f76a30c7c8", "embedding": null, "metadata": {"window": "Mike Kaufmann:  So I apologize for that.  I think everybody probably knew that.  But as far as growth \nare you talking about specifically the nuclear or overall for the Pharma segment?  \n \n Ricky Goldwasser:  Overall for the Pharma s egment, so once you exclude that nuclear that has the \nmost negative impact...  ", "original_text": "Ricky Goldwasser:  Overall for the Pharma s egment, so once you exclude that nuclear that has the \nmost negative impact...  ", "page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44979e2c-e074-4f22-a939-50ea3bd188dd", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c7bfdafcc2ddd0548f805f4cd6ea0198bfcb8d01c0b41ca0e6d3099eaaf29aad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "823b47cb-c3a1-4fe6-8fcc-a98c53e5652f", "node_type": "1", "metadata": {"window": "Ricky Goldwasser:  Yes.  \n \n Mike Kaufmann:  So I apologize for that.  I think everybody probably knew that.  But as far as growth \nare you talking about specifically the nuclear or overall for the Pharma segment?  \n \n Ricky Goldwasser:  Overall for the Pharma s egment, so once you exclude that nuclear that has the \nmost negative impact...  ", "original_text": "But as far as growth \nare you talking about specifically the nuclear or overall for the Pharma segment?  \n \n", "page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b4f5d7d82d7483f7eb7ba9ea81a38e7e58b6548039032cd81da6012981fffa6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d9431f7-6601-4bdd-9073-4a1c48f864b2", "node_type": "1", "metadata": {"window": " \nPage 22 of 31 \n \n \nMike Kaufmann:  Yes.  \n \n Ricky Goldwasser:  ...what type of - of course just because I'm trying to quantify it and adjust for it?  \n \n Mike Kaufmann:  Yes the - we would see the Pharma  segment more tightly aligned to physician office \nvisits are probably going to be the biggest driver.  I would say that what we\u2019ve been seeing in some of \nthe IQVIA data and various sources like that we feel like that that\u2019s a business that we expect to be \naveraging down in the mid -single digits for the year. ", "original_text": " \nPage 22 of 31 \n \n \nMike Kaufmann:  Yes.  \n \n"}, "hash": "9ecb6caf488dec4d3c0df17887b7a85b0524c9ee6f79eb6dd776a048a881975e", "class_name": "RelatedNodeInfo"}}, "text": "Ricky Goldwasser:  Overall for the Pharma s egment, so once you exclude that nuclear that has the \nmost negative impact...  ", "start_char_idx": 1183, "end_char_idx": 1307, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d9431f7-6601-4bdd-9073-4a1c48f864b2": {"__data__": {"id_": "4d9431f7-6601-4bdd-9073-4a1c48f864b2", "embedding": null, "metadata": {"window": " \nPage 22 of 31 \n \n \nMike Kaufmann:  Yes.  \n \n Ricky Goldwasser:  ...what type of - of course just because I'm trying to quantify it and adjust for it?  \n \n Mike Kaufmann:  Yes the - we would see the Pharma  segment more tightly aligned to physician office \nvisits are probably going to be the biggest driver.  I would say that what we\u2019ve been seeing in some of \nthe IQVIA data and various sources like that we feel like that that\u2019s a business that we expect to be \naveraging down in the mid -single digits for the year. ", "original_text": " \nPage 22 of 31 \n \n \nMike Kaufmann:  Yes.  \n \n", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8291a5de-e14a-4b76-a285-09a126f85d3f", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a730697e2a2f7b137e9284fb429d2cea65946e3eedd1d048b66afc6f0efcbde7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d31d1af-9119-4c1d-ab65-b8f76a30c7c8", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  So I apologize for that.  I think everybody probably knew that.  But as far as growth \nare you talking about specifically the nuclear or overall for the Pharma segment?  \n \n Ricky Goldwasser:  Overall for the Pharma s egment, so once you exclude that nuclear that has the \nmost negative impact...  ", "original_text": "Ricky Goldwasser:  Overall for the Pharma s egment, so once you exclude that nuclear that has the \nmost negative impact...  ", "page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d632db484fc83ff2de2f1bc2e607f419de79e9521146877cb7ab4bbf540b6cb4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3bff864b-8300-41f4-a756-b38a88bb3c8d", "node_type": "1", "metadata": {"window": " \nPage 22 of 31 \n \n \nMike Kaufmann:  Yes.  \n \n Ricky Goldwasser:  ...what type of - of course just because I'm trying to quantify it and adjust for it?  \n \n Mike Kaufmann:  Yes the - we would see the Pharma  segment more tightly aligned to physician office \nvisits are probably going to be the biggest driver.  I would say that what we\u2019ve been seeing in some of \nthe IQVIA data and various sources like that we feel like that that\u2019s a business that we expect to be \naveraging down in the mid -single digits for the year.  And similar to the way I described it we think it \nwill be down mid -single digits compared to pre -COVID early in the year with it also exiting at pre -\nCOVID levels at the end of our fiscal year with kind o f a steady improvement over the year. ", "original_text": "Ricky Goldwasser:  ...what type of - of course just because I'm trying to quantify it and adjust for it?  \n \n"}, "hash": "8096fcac2b996b3484fa29eece65c86e68cf7eff216d207fc454623c5d909256", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 22 of 31 \n \n \nMike Kaufmann:  Yes.  \n \n", "start_char_idx": 0, "end_char_idx": 46, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3bff864b-8300-41f4-a756-b38a88bb3c8d": {"__data__": {"id_": "3bff864b-8300-41f4-a756-b38a88bb3c8d", "embedding": null, "metadata": {"window": " \nPage 22 of 31 \n \n \nMike Kaufmann:  Yes.  \n \n Ricky Goldwasser:  ...what type of - of course just because I'm trying to quantify it and adjust for it?  \n \n Mike Kaufmann:  Yes the - we would see the Pharma  segment more tightly aligned to physician office \nvisits are probably going to be the biggest driver.  I would say that what we\u2019ve been seeing in some of \nthe IQVIA data and various sources like that we feel like that that\u2019s a business that we expect to be \naveraging down in the mid -single digits for the year.  And similar to the way I described it we think it \nwill be down mid -single digits compared to pre -COVID early in the year with it also exiting at pre -\nCOVID levels at the end of our fiscal year with kind o f a steady improvement over the year. ", "original_text": "Ricky Goldwasser:  ...what type of - of course just because I'm trying to quantify it and adjust for it?  \n \n", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8291a5de-e14a-4b76-a285-09a126f85d3f", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a730697e2a2f7b137e9284fb429d2cea65946e3eedd1d048b66afc6f0efcbde7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d9431f7-6601-4bdd-9073-4a1c48f864b2", "node_type": "1", "metadata": {"window": " \nPage 22 of 31 \n \n \nMike Kaufmann:  Yes.  \n \n Ricky Goldwasser:  ...what type of - of course just because I'm trying to quantify it and adjust for it?  \n \n Mike Kaufmann:  Yes the - we would see the Pharma  segment more tightly aligned to physician office \nvisits are probably going to be the biggest driver.  I would say that what we\u2019ve been seeing in some of \nthe IQVIA data and various sources like that we feel like that that\u2019s a business that we expect to be \naveraging down in the mid -single digits for the year. ", "original_text": " \nPage 22 of 31 \n \n \nMike Kaufmann:  Yes.  \n \n", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "641f0d872dd954dd628d4085d27752e4f126a93e0e45873b8a5715e7a0de87c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e085180-a8f1-4823-aa6f-f9f468ba48e9", "node_type": "1", "metadata": {"window": " \nPage 22 of 31 \n \n \nMike Kaufmann:  Yes.  \n \n Ricky Goldwasser:  ...what type of - of course just because I'm trying to quantify it and adjust for it?  \n \n Mike Kaufmann:  Yes the - we would see the Pharma  segment more tightly aligned to physician office \nvisits are probably going to be the biggest driver.  I would say that what we\u2019ve been seeing in some of \nthe IQVIA data and various sources like that we feel like that that\u2019s a business that we expect to be \naveraging down in the mid -single digits for the year.  And similar to the way I described it we think it \nwill be down mid -single digits compared to pre -COVID early in the year with it also exiting at pre -\nCOVID levels at the end of our fiscal year with kind o f a steady improvement over the year.  Thanks \nfor the questions. ", "original_text": "Mike Kaufmann:  Yes the - we would see the Pharma  segment more tightly aligned to physician office \nvisits are probably going to be the biggest driver. "}, "hash": "c984e955c7be2f8ebfc93e5ad19fe8d6f115930023879539b25afa59bd253f34", "class_name": "RelatedNodeInfo"}}, "text": "Ricky Goldwasser:  ...what type of - of course just because I'm trying to quantify it and adjust for it?  \n \n", "start_char_idx": 46, "end_char_idx": 155, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e085180-a8f1-4823-aa6f-f9f468ba48e9": {"__data__": {"id_": "0e085180-a8f1-4823-aa6f-f9f468ba48e9", "embedding": null, "metadata": {"window": " \nPage 22 of 31 \n \n \nMike Kaufmann:  Yes.  \n \n Ricky Goldwasser:  ...what type of - of course just because I'm trying to quantify it and adjust for it?  \n \n Mike Kaufmann:  Yes the - we would see the Pharma  segment more tightly aligned to physician office \nvisits are probably going to be the biggest driver.  I would say that what we\u2019ve been seeing in some of \nthe IQVIA data and various sources like that we feel like that that\u2019s a business that we expect to be \naveraging down in the mid -single digits for the year.  And similar to the way I described it we think it \nwill be down mid -single digits compared to pre -COVID early in the year with it also exiting at pre -\nCOVID levels at the end of our fiscal year with kind o f a steady improvement over the year.  Thanks \nfor the questions. ", "original_text": "Mike Kaufmann:  Yes the - we would see the Pharma  segment more tightly aligned to physician office \nvisits are probably going to be the biggest driver. ", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8291a5de-e14a-4b76-a285-09a126f85d3f", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a730697e2a2f7b137e9284fb429d2cea65946e3eedd1d048b66afc6f0efcbde7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3bff864b-8300-41f4-a756-b38a88bb3c8d", "node_type": "1", "metadata": {"window": " \nPage 22 of 31 \n \n \nMike Kaufmann:  Yes.  \n \n Ricky Goldwasser:  ...what type of - of course just because I'm trying to quantify it and adjust for it?  \n \n Mike Kaufmann:  Yes the - we would see the Pharma  segment more tightly aligned to physician office \nvisits are probably going to be the biggest driver.  I would say that what we\u2019ve been seeing in some of \nthe IQVIA data and various sources like that we feel like that that\u2019s a business that we expect to be \naveraging down in the mid -single digits for the year.  And similar to the way I described it we think it \nwill be down mid -single digits compared to pre -COVID early in the year with it also exiting at pre -\nCOVID levels at the end of our fiscal year with kind o f a steady improvement over the year. ", "original_text": "Ricky Goldwasser:  ...what type of - of course just because I'm trying to quantify it and adjust for it?  \n \n", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84fc208d44af06d948ec9e2a41978dfc4b51c796e9ca8baab7b7c2c29a2ebf13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32dea304-bf5d-47ea-ba70-82a2d04d53a2", "node_type": "1", "metadata": {"window": " \nPage 22 of 31 \n \n \nMike Kaufmann:  Yes.  \n \n Ricky Goldwasser:  ...what type of - of course just because I'm trying to quantify it and adjust for it?  \n \n Mike Kaufmann:  Yes the - we would see the Pharma  segment more tightly aligned to physician office \nvisits are probably going to be the biggest driver.  I would say that what we\u2019ve been seeing in some of \nthe IQVIA data and various sources like that we feel like that that\u2019s a business that we expect to be \naveraging down in the mid -single digits for the year.  And similar to the way I described it we think it \nwill be down mid -single digits compared to pre -COVID early in the year with it also exiting at pre -\nCOVID levels at the end of our fiscal year with kind o f a steady improvement over the year.  Thanks \nfor the questions.  Next question?  \n \n", "original_text": "I would say that what we\u2019ve been seeing in some of \nthe IQVIA data and various sources like that we feel like that that\u2019s a business that we expect to be \naveraging down in the mid -single digits for the year. "}, "hash": "5b5f3bbcbd56e52aec01a42a13629c7aef435f8ccf5dfc1f0101ef234cb721df", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes the - we would see the Pharma  segment more tightly aligned to physician office \nvisits are probably going to be the biggest driver. ", "start_char_idx": 155, "end_char_idx": 308, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32dea304-bf5d-47ea-ba70-82a2d04d53a2": {"__data__": {"id_": "32dea304-bf5d-47ea-ba70-82a2d04d53a2", "embedding": null, "metadata": {"window": " \nPage 22 of 31 \n \n \nMike Kaufmann:  Yes.  \n \n Ricky Goldwasser:  ...what type of - of course just because I'm trying to quantify it and adjust for it?  \n \n Mike Kaufmann:  Yes the - we would see the Pharma  segment more tightly aligned to physician office \nvisits are probably going to be the biggest driver.  I would say that what we\u2019ve been seeing in some of \nthe IQVIA data and various sources like that we feel like that that\u2019s a business that we expect to be \naveraging down in the mid -single digits for the year.  And similar to the way I described it we think it \nwill be down mid -single digits compared to pre -COVID early in the year with it also exiting at pre -\nCOVID levels at the end of our fiscal year with kind o f a steady improvement over the year.  Thanks \nfor the questions.  Next question?  \n \n", "original_text": "I would say that what we\u2019ve been seeing in some of \nthe IQVIA data and various sources like that we feel like that that\u2019s a business that we expect to be \naveraging down in the mid -single digits for the year. ", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8291a5de-e14a-4b76-a285-09a126f85d3f", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a730697e2a2f7b137e9284fb429d2cea65946e3eedd1d048b66afc6f0efcbde7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e085180-a8f1-4823-aa6f-f9f468ba48e9", "node_type": "1", "metadata": {"window": " \nPage 22 of 31 \n \n \nMike Kaufmann:  Yes.  \n \n Ricky Goldwasser:  ...what type of - of course just because I'm trying to quantify it and adjust for it?  \n \n Mike Kaufmann:  Yes the - we would see the Pharma  segment more tightly aligned to physician office \nvisits are probably going to be the biggest driver.  I would say that what we\u2019ve been seeing in some of \nthe IQVIA data and various sources like that we feel like that that\u2019s a business that we expect to be \naveraging down in the mid -single digits for the year.  And similar to the way I described it we think it \nwill be down mid -single digits compared to pre -COVID early in the year with it also exiting at pre -\nCOVID levels at the end of our fiscal year with kind o f a steady improvement over the year.  Thanks \nfor the questions. ", "original_text": "Mike Kaufmann:  Yes the - we would see the Pharma  segment more tightly aligned to physician office \nvisits are probably going to be the biggest driver. ", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a08ccb43770bfd30132cc09918e50f8d41730d32abbc180d3a2b38d3ba014145", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bcaa7e55-c7b7-4481-907d-dd7f77f70ef7", "node_type": "1", "metadata": {"window": "Ricky Goldwasser:  ...what type of - of course just because I'm trying to quantify it and adjust for it?  \n \n Mike Kaufmann:  Yes the - we would see the Pharma  segment more tightly aligned to physician office \nvisits are probably going to be the biggest driver.  I would say that what we\u2019ve been seeing in some of \nthe IQVIA data and various sources like that we feel like that that\u2019s a business that we expect to be \naveraging down in the mid -single digits for the year.  And similar to the way I described it we think it \nwill be down mid -single digits compared to pre -COVID early in the year with it also exiting at pre -\nCOVID levels at the end of our fiscal year with kind o f a steady improvement over the year.  Thanks \nfor the questions.  Next question?  \n \n Operator:  Thank you. ", "original_text": "And similar to the way I described it we think it \nwill be down mid -single digits compared to pre -COVID early in the year with it also exiting at pre -\nCOVID levels at the end of our fiscal year with kind o f a steady improvement over the year. "}, "hash": "145ebcf94d57655f552094be9d285d65559c4f175f7fa52c520c9f8844c45feb", "class_name": "RelatedNodeInfo"}}, "text": "I would say that what we\u2019ve been seeing in some of \nthe IQVIA data and various sources like that we feel like that that\u2019s a business that we expect to be \naveraging down in the mid -single digits for the year. ", "start_char_idx": 308, "end_char_idx": 518, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bcaa7e55-c7b7-4481-907d-dd7f77f70ef7": {"__data__": {"id_": "bcaa7e55-c7b7-4481-907d-dd7f77f70ef7", "embedding": null, "metadata": {"window": "Ricky Goldwasser:  ...what type of - of course just because I'm trying to quantify it and adjust for it?  \n \n Mike Kaufmann:  Yes the - we would see the Pharma  segment more tightly aligned to physician office \nvisits are probably going to be the biggest driver.  I would say that what we\u2019ve been seeing in some of \nthe IQVIA data and various sources like that we feel like that that\u2019s a business that we expect to be \naveraging down in the mid -single digits for the year.  And similar to the way I described it we think it \nwill be down mid -single digits compared to pre -COVID early in the year with it also exiting at pre -\nCOVID levels at the end of our fiscal year with kind o f a steady improvement over the year.  Thanks \nfor the questions.  Next question?  \n \n Operator:  Thank you. ", "original_text": "And similar to the way I described it we think it \nwill be down mid -single digits compared to pre -COVID early in the year with it also exiting at pre -\nCOVID levels at the end of our fiscal year with kind o f a steady improvement over the year. ", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8291a5de-e14a-4b76-a285-09a126f85d3f", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a730697e2a2f7b137e9284fb429d2cea65946e3eedd1d048b66afc6f0efcbde7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32dea304-bf5d-47ea-ba70-82a2d04d53a2", "node_type": "1", "metadata": {"window": " \nPage 22 of 31 \n \n \nMike Kaufmann:  Yes.  \n \n Ricky Goldwasser:  ...what type of - of course just because I'm trying to quantify it and adjust for it?  \n \n Mike Kaufmann:  Yes the - we would see the Pharma  segment more tightly aligned to physician office \nvisits are probably going to be the biggest driver.  I would say that what we\u2019ve been seeing in some of \nthe IQVIA data and various sources like that we feel like that that\u2019s a business that we expect to be \naveraging down in the mid -single digits for the year.  And similar to the way I described it we think it \nwill be down mid -single digits compared to pre -COVID early in the year with it also exiting at pre -\nCOVID levels at the end of our fiscal year with kind o f a steady improvement over the year.  Thanks \nfor the questions.  Next question?  \n \n", "original_text": "I would say that what we\u2019ve been seeing in some of \nthe IQVIA data and various sources like that we feel like that that\u2019s a business that we expect to be \naveraging down in the mid -single digits for the year. ", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84eb24151d6e2c942f1450e550f423d508cf1304283f310fbc71d9658a4a4be0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3cd633bc-cf92-4f6b-bd82-294e04921c05", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes the - we would see the Pharma  segment more tightly aligned to physician office \nvisits are probably going to be the biggest driver.  I would say that what we\u2019ve been seeing in some of \nthe IQVIA data and various sources like that we feel like that that\u2019s a business that we expect to be \naveraging down in the mid -single digits for the year.  And similar to the way I described it we think it \nwill be down mid -single digits compared to pre -COVID early in the year with it also exiting at pre -\nCOVID levels at the end of our fiscal year with kind o f a steady improvement over the year.  Thanks \nfor the questions.  Next question?  \n \n Operator:  Thank you.  We'll next go to Eric Coldwell with Baird. ", "original_text": "Thanks \nfor the questions. "}, "hash": "76e8851df36bac030189061d6f455ec3d7d15f65dacf38e986bd88144bbab9f0", "class_name": "RelatedNodeInfo"}}, "text": "And similar to the way I described it we think it \nwill be down mid -single digits compared to pre -COVID early in the year with it also exiting at pre -\nCOVID levels at the end of our fiscal year with kind o f a steady improvement over the year. ", "start_char_idx": 518, "end_char_idx": 765, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3cd633bc-cf92-4f6b-bd82-294e04921c05": {"__data__": {"id_": "3cd633bc-cf92-4f6b-bd82-294e04921c05", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes the - we would see the Pharma  segment more tightly aligned to physician office \nvisits are probably going to be the biggest driver.  I would say that what we\u2019ve been seeing in some of \nthe IQVIA data and various sources like that we feel like that that\u2019s a business that we expect to be \naveraging down in the mid -single digits for the year.  And similar to the way I described it we think it \nwill be down mid -single digits compared to pre -COVID early in the year with it also exiting at pre -\nCOVID levels at the end of our fiscal year with kind o f a steady improvement over the year.  Thanks \nfor the questions.  Next question?  \n \n Operator:  Thank you.  We'll next go to Eric Coldwell with Baird. ", "original_text": "Thanks \nfor the questions. ", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8291a5de-e14a-4b76-a285-09a126f85d3f", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a730697e2a2f7b137e9284fb429d2cea65946e3eedd1d048b66afc6f0efcbde7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bcaa7e55-c7b7-4481-907d-dd7f77f70ef7", "node_type": "1", "metadata": {"window": "Ricky Goldwasser:  ...what type of - of course just because I'm trying to quantify it and adjust for it?  \n \n Mike Kaufmann:  Yes the - we would see the Pharma  segment more tightly aligned to physician office \nvisits are probably going to be the biggest driver.  I would say that what we\u2019ve been seeing in some of \nthe IQVIA data and various sources like that we feel like that that\u2019s a business that we expect to be \naveraging down in the mid -single digits for the year.  And similar to the way I described it we think it \nwill be down mid -single digits compared to pre -COVID early in the year with it also exiting at pre -\nCOVID levels at the end of our fiscal year with kind o f a steady improvement over the year.  Thanks \nfor the questions.  Next question?  \n \n Operator:  Thank you. ", "original_text": "And similar to the way I described it we think it \nwill be down mid -single digits compared to pre -COVID early in the year with it also exiting at pre -\nCOVID levels at the end of our fiscal year with kind o f a steady improvement over the year. ", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2312b9c5a2340ac426a85abab749fc7724872a2f5a3166f1ec12b1b790044a31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68510a7b-9816-451e-bfb2-b10bc6b22dc5", "node_type": "1", "metadata": {"window": "I would say that what we\u2019ve been seeing in some of \nthe IQVIA data and various sources like that we feel like that that\u2019s a business that we expect to be \naveraging down in the mid -single digits for the year.  And similar to the way I described it we think it \nwill be down mid -single digits compared to pre -COVID early in the year with it also exiting at pre -\nCOVID levels at the end of our fiscal year with kind o f a steady improvement over the year.  Thanks \nfor the questions.  Next question?  \n \n Operator:  Thank you.  We'll next go to Eric Coldwell with Baird.  Please go ahead.  \n \n", "original_text": "Next question?  \n \n"}, "hash": "ef850ed79dec3c341a818d763d8c9b8a7f480fbb3217ae7b75af56686d3aa022", "class_name": "RelatedNodeInfo"}}, "text": "Thanks \nfor the questions. ", "start_char_idx": 765, "end_char_idx": 792, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68510a7b-9816-451e-bfb2-b10bc6b22dc5": {"__data__": {"id_": "68510a7b-9816-451e-bfb2-b10bc6b22dc5", "embedding": null, "metadata": {"window": "I would say that what we\u2019ve been seeing in some of \nthe IQVIA data and various sources like that we feel like that that\u2019s a business that we expect to be \naveraging down in the mid -single digits for the year.  And similar to the way I described it we think it \nwill be down mid -single digits compared to pre -COVID early in the year with it also exiting at pre -\nCOVID levels at the end of our fiscal year with kind o f a steady improvement over the year.  Thanks \nfor the questions.  Next question?  \n \n Operator:  Thank you.  We'll next go to Eric Coldwell with Baird.  Please go ahead.  \n \n", "original_text": "Next question?  \n \n", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8291a5de-e14a-4b76-a285-09a126f85d3f", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a730697e2a2f7b137e9284fb429d2cea65946e3eedd1d048b66afc6f0efcbde7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3cd633bc-cf92-4f6b-bd82-294e04921c05", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes the - we would see the Pharma  segment more tightly aligned to physician office \nvisits are probably going to be the biggest driver.  I would say that what we\u2019ve been seeing in some of \nthe IQVIA data and various sources like that we feel like that that\u2019s a business that we expect to be \naveraging down in the mid -single digits for the year.  And similar to the way I described it we think it \nwill be down mid -single digits compared to pre -COVID early in the year with it also exiting at pre -\nCOVID levels at the end of our fiscal year with kind o f a steady improvement over the year.  Thanks \nfor the questions.  Next question?  \n \n Operator:  Thank you.  We'll next go to Eric Coldwell with Baird. ", "original_text": "Thanks \nfor the questions. ", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "454d5ce4ecd055e8151b5a8fd2d1790f89887019d344e1d88d4cd1592f3d757c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "455244ab-548b-4ddd-ae87-103bd4b7de2d", "node_type": "1", "metadata": {"window": "And similar to the way I described it we think it \nwill be down mid -single digits compared to pre -COVID early in the year with it also exiting at pre -\nCOVID levels at the end of our fiscal year with kind o f a steady improvement over the year.  Thanks \nfor the questions.  Next question?  \n \n Operator:  Thank you.  We'll next go to Eric Coldwell with Baird.  Please go ahead.  \n \n Eric Coldwell:  Thanks very much. ", "original_text": "Operator:  Thank you. "}, "hash": "8d68d70352312132270e995900dbf5902c15384db97c85cf3dd973c7f12735ea", "class_name": "RelatedNodeInfo"}}, "text": "Next question?  \n \n", "start_char_idx": 792, "end_char_idx": 811, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "455244ab-548b-4ddd-ae87-103bd4b7de2d": {"__data__": {"id_": "455244ab-548b-4ddd-ae87-103bd4b7de2d", "embedding": null, "metadata": {"window": "And similar to the way I described it we think it \nwill be down mid -single digits compared to pre -COVID early in the year with it also exiting at pre -\nCOVID levels at the end of our fiscal year with kind o f a steady improvement over the year.  Thanks \nfor the questions.  Next question?  \n \n Operator:  Thank you.  We'll next go to Eric Coldwell with Baird.  Please go ahead.  \n \n Eric Coldwell:  Thanks very much. ", "original_text": "Operator:  Thank you. ", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8291a5de-e14a-4b76-a285-09a126f85d3f", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a730697e2a2f7b137e9284fb429d2cea65946e3eedd1d048b66afc6f0efcbde7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68510a7b-9816-451e-bfb2-b10bc6b22dc5", "node_type": "1", "metadata": {"window": "I would say that what we\u2019ve been seeing in some of \nthe IQVIA data and various sources like that we feel like that that\u2019s a business that we expect to be \naveraging down in the mid -single digits for the year.  And similar to the way I described it we think it \nwill be down mid -single digits compared to pre -COVID early in the year with it also exiting at pre -\nCOVID levels at the end of our fiscal year with kind o f a steady improvement over the year.  Thanks \nfor the questions.  Next question?  \n \n Operator:  Thank you.  We'll next go to Eric Coldwell with Baird.  Please go ahead.  \n \n", "original_text": "Next question?  \n \n", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "58a7ef4d0ad5de4ee09327ef9a891a9e8733d34017014f76534079ad8b6afea1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "841dc174-3876-465c-9c5f-dc17ca7ad0a0", "node_type": "1", "metadata": {"window": "Thanks \nfor the questions.  Next question?  \n \n Operator:  Thank you.  We'll next go to Eric Coldwell with Baird.  Please go ahead.  \n \n Eric Coldwell:  Thanks very much.  I was hoping you could dissect some of the comments on the \ngenerics program challenges cited or headwinds cited in 4Q, trying to get a sense of what the total \ndynamics were there. ", "original_text": "We'll next go to Eric Coldwell with Baird. "}, "hash": "2729f670b4630002bc3e13a610e7d0dae99484a52e3c531d475ead7f021cab7f", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you. ", "start_char_idx": 811, "end_char_idx": 833, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "841dc174-3876-465c-9c5f-dc17ca7ad0a0": {"__data__": {"id_": "841dc174-3876-465c-9c5f-dc17ca7ad0a0", "embedding": null, "metadata": {"window": "Thanks \nfor the questions.  Next question?  \n \n Operator:  Thank you.  We'll next go to Eric Coldwell with Baird.  Please go ahead.  \n \n Eric Coldwell:  Thanks very much.  I was hoping you could dissect some of the comments on the \ngenerics program challenges cited or headwinds cited in 4Q, trying to get a sense of what the total \ndynamics were there. ", "original_text": "We'll next go to Eric Coldwell with Baird. ", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8291a5de-e14a-4b76-a285-09a126f85d3f", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a730697e2a2f7b137e9284fb429d2cea65946e3eedd1d048b66afc6f0efcbde7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "455244ab-548b-4ddd-ae87-103bd4b7de2d", "node_type": "1", "metadata": {"window": "And similar to the way I described it we think it \nwill be down mid -single digits compared to pre -COVID early in the year with it also exiting at pre -\nCOVID levels at the end of our fiscal year with kind o f a steady improvement over the year.  Thanks \nfor the questions.  Next question?  \n \n Operator:  Thank you.  We'll next go to Eric Coldwell with Baird.  Please go ahead.  \n \n Eric Coldwell:  Thanks very much. ", "original_text": "Operator:  Thank you. ", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d3c28047029c776c6a23ebbc5d13c7e5d393ee96d5a99b01b1a6e617c64af9fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "601ffe31-18de-42f2-b0d9-cc1bda8128f5", "node_type": "1", "metadata": {"window": "Next question?  \n \n Operator:  Thank you.  We'll next go to Eric Coldwell with Baird.  Please go ahead.  \n \n Eric Coldwell:  Thanks very much.  I was hoping you could dissect some of the comments on the \ngenerics program challenges cited or headwinds cited in 4Q, trying to get a sense of what the total \ndynamics were there.  Was it more about volumes due to mix impacts and healthcare access during \nthe last quarter or was it more about something specific to C ardinal, your procurement or your \nchannel successes? ", "original_text": "Please go ahead.  \n \n"}, "hash": "aba7e7c5cf58bf59de82df2fd560dfb3a0035f43694c5229bb69fb6f5479da86", "class_name": "RelatedNodeInfo"}}, "text": "We'll next go to Eric Coldwell with Baird. ", "start_char_idx": 833, "end_char_idx": 876, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "601ffe31-18de-42f2-b0d9-cc1bda8128f5": {"__data__": {"id_": "601ffe31-18de-42f2-b0d9-cc1bda8128f5", "embedding": null, "metadata": {"window": "Next question?  \n \n Operator:  Thank you.  We'll next go to Eric Coldwell with Baird.  Please go ahead.  \n \n Eric Coldwell:  Thanks very much.  I was hoping you could dissect some of the comments on the \ngenerics program challenges cited or headwinds cited in 4Q, trying to get a sense of what the total \ndynamics were there.  Was it more about volumes due to mix impacts and healthcare access during \nthe last quarter or was it more about something specific to C ardinal, your procurement or your \nchannel successes? ", "original_text": "Please go ahead.  \n \n", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8291a5de-e14a-4b76-a285-09a126f85d3f", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a730697e2a2f7b137e9284fb429d2cea65946e3eedd1d048b66afc6f0efcbde7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "841dc174-3876-465c-9c5f-dc17ca7ad0a0", "node_type": "1", "metadata": {"window": "Thanks \nfor the questions.  Next question?  \n \n Operator:  Thank you.  We'll next go to Eric Coldwell with Baird.  Please go ahead.  \n \n Eric Coldwell:  Thanks very much.  I was hoping you could dissect some of the comments on the \ngenerics program challenges cited or headwinds cited in 4Q, trying to get a sense of what the total \ndynamics were there. ", "original_text": "We'll next go to Eric Coldwell with Baird. ", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "217a78f414973ba77c45b3364928364ec85a30b5ddab1901dc0847d385f1c1fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04d34d83-93e5-4fec-a6b5-57fe504821f6", "node_type": "1", "metadata": {"window": "Operator:  Thank you.  We'll next go to Eric Coldwell with Baird.  Please go ahead.  \n \n Eric Coldwell:  Thanks very much.  I was hoping you could dissect some of the comments on the \ngenerics program challenges cited or headwinds cited in 4Q, trying to get a sense of what the total \ndynamics were there.  Was it more about volumes due to mix impacts and healthcare access during \nthe last quarter or was it more about something specific to C ardinal, your procurement or your \nchannel successes?  Thanks very much.  \n \n", "original_text": "Eric Coldwell:  Thanks very much. "}, "hash": "65c87991756ab0631791f522f1e73eaf46470c0527e99379f1c7e0f43996f9c3", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 876, "end_char_idx": 897, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04d34d83-93e5-4fec-a6b5-57fe504821f6": {"__data__": {"id_": "04d34d83-93e5-4fec-a6b5-57fe504821f6", "embedding": null, "metadata": {"window": "Operator:  Thank you.  We'll next go to Eric Coldwell with Baird.  Please go ahead.  \n \n Eric Coldwell:  Thanks very much.  I was hoping you could dissect some of the comments on the \ngenerics program challenges cited or headwinds cited in 4Q, trying to get a sense of what the total \ndynamics were there.  Was it more about volumes due to mix impacts and healthcare access during \nthe last quarter or was it more about something specific to C ardinal, your procurement or your \nchannel successes?  Thanks very much.  \n \n", "original_text": "Eric Coldwell:  Thanks very much. ", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8291a5de-e14a-4b76-a285-09a126f85d3f", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a730697e2a2f7b137e9284fb429d2cea65946e3eedd1d048b66afc6f0efcbde7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "601ffe31-18de-42f2-b0d9-cc1bda8128f5", "node_type": "1", "metadata": {"window": "Next question?  \n \n Operator:  Thank you.  We'll next go to Eric Coldwell with Baird.  Please go ahead.  \n \n Eric Coldwell:  Thanks very much.  I was hoping you could dissect some of the comments on the \ngenerics program challenges cited or headwinds cited in 4Q, trying to get a sense of what the total \ndynamics were there.  Was it more about volumes due to mix impacts and healthcare access during \nthe last quarter or was it more about something specific to C ardinal, your procurement or your \nchannel successes? ", "original_text": "Please go ahead.  \n \n", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1c01eed9a85f0107cc8d7a6266a090f8beff90888e9a675439ee54b91eb4311", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0ae42bd-612d-475a-8847-8c4b24e1666e", "node_type": "1", "metadata": {"window": "We'll next go to Eric Coldwell with Baird.  Please go ahead.  \n \n Eric Coldwell:  Thanks very much.  I was hoping you could dissect some of the comments on the \ngenerics program challenges cited or headwinds cited in 4Q, trying to get a sense of what the total \ndynamics were there.  Was it more about volumes due to mix impacts and healthcare access during \nthe last quarter or was it more about something specific to C ardinal, your procurement or your \nchannel successes?  Thanks very much.  \n \n Mike Kaufmann:  Yes, thank you. ", "original_text": "I was hoping you could dissect some of the comments on the \ngenerics program challenges cited or headwinds cited in 4Q, trying to get a sense of what the total \ndynamics were there. "}, "hash": "1409eaf0ac52912e6b1b77f47422f60b14be67ea2874df3f528d525209205c88", "class_name": "RelatedNodeInfo"}}, "text": "Eric Coldwell:  Thanks very much. ", "start_char_idx": 897, "end_char_idx": 931, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0ae42bd-612d-475a-8847-8c4b24e1666e": {"__data__": {"id_": "c0ae42bd-612d-475a-8847-8c4b24e1666e", "embedding": null, "metadata": {"window": "We'll next go to Eric Coldwell with Baird.  Please go ahead.  \n \n Eric Coldwell:  Thanks very much.  I was hoping you could dissect some of the comments on the \ngenerics program challenges cited or headwinds cited in 4Q, trying to get a sense of what the total \ndynamics were there.  Was it more about volumes due to mix impacts and healthcare access during \nthe last quarter or was it more about something specific to C ardinal, your procurement or your \nchannel successes?  Thanks very much.  \n \n Mike Kaufmann:  Yes, thank you. ", "original_text": "I was hoping you could dissect some of the comments on the \ngenerics program challenges cited or headwinds cited in 4Q, trying to get a sense of what the total \ndynamics were there. ", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8291a5de-e14a-4b76-a285-09a126f85d3f", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a730697e2a2f7b137e9284fb429d2cea65946e3eedd1d048b66afc6f0efcbde7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04d34d83-93e5-4fec-a6b5-57fe504821f6", "node_type": "1", "metadata": {"window": "Operator:  Thank you.  We'll next go to Eric Coldwell with Baird.  Please go ahead.  \n \n Eric Coldwell:  Thanks very much.  I was hoping you could dissect some of the comments on the \ngenerics program challenges cited or headwinds cited in 4Q, trying to get a sense of what the total \ndynamics were there.  Was it more about volumes due to mix impacts and healthcare access during \nthe last quarter or was it more about something specific to C ardinal, your procurement or your \nchannel successes?  Thanks very much.  \n \n", "original_text": "Eric Coldwell:  Thanks very much. ", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f803965c5f06521f171aa078c151c03104db6f9e7e14e730b703923d5c3dcfb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95b698c0-f15e-4226-a1c8-b3ca805f41d9", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Eric Coldwell:  Thanks very much.  I was hoping you could dissect some of the comments on the \ngenerics program challenges cited or headwinds cited in 4Q, trying to get a sense of what the total \ndynamics were there.  Was it more about volumes due to mix impacts and healthcare access during \nthe last quarter or was it more about something specific to C ardinal, your procurement or your \nchannel successes?  Thanks very much.  \n \n Mike Kaufmann:  Yes, thank you.  No I wouldn\u2019t say there was anything unusual in there, nothing I \nwould call out other than the COVID impact related to just the volumes. ", "original_text": "Was it more about volumes due to mix impacts and healthcare access during \nthe last quarter or was it more about something specific to C ardinal, your procurement or your \nchannel successes? "}, "hash": "7287704531932d85ae281b6ca27216674802c4441483d077e34a78f84e8224ef", "class_name": "RelatedNodeInfo"}}, "text": "I was hoping you could dissect some of the comments on the \ngenerics program challenges cited or headwinds cited in 4Q, trying to get a sense of what the total \ndynamics were there. ", "start_char_idx": 931, "end_char_idx": 1113, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95b698c0-f15e-4226-a1c8-b3ca805f41d9": {"__data__": {"id_": "95b698c0-f15e-4226-a1c8-b3ca805f41d9", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Eric Coldwell:  Thanks very much.  I was hoping you could dissect some of the comments on the \ngenerics program challenges cited or headwinds cited in 4Q, trying to get a sense of what the total \ndynamics were there.  Was it more about volumes due to mix impacts and healthcare access during \nthe last quarter or was it more about something specific to C ardinal, your procurement or your \nchannel successes?  Thanks very much.  \n \n Mike Kaufmann:  Yes, thank you.  No I wouldn\u2019t say there was anything unusual in there, nothing I \nwould call out other than the COVID impact related to just the volumes. ", "original_text": "Was it more about volumes due to mix impacts and healthcare access during \nthe last quarter or was it more about something specific to C ardinal, your procurement or your \nchannel successes? ", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8291a5de-e14a-4b76-a285-09a126f85d3f", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a730697e2a2f7b137e9284fb429d2cea65946e3eedd1d048b66afc6f0efcbde7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0ae42bd-612d-475a-8847-8c4b24e1666e", "node_type": "1", "metadata": {"window": "We'll next go to Eric Coldwell with Baird.  Please go ahead.  \n \n Eric Coldwell:  Thanks very much.  I was hoping you could dissect some of the comments on the \ngenerics program challenges cited or headwinds cited in 4Q, trying to get a sense of what the total \ndynamics were there.  Was it more about volumes due to mix impacts and healthcare access during \nthe last quarter or was it more about something specific to C ardinal, your procurement or your \nchannel successes?  Thanks very much.  \n \n Mike Kaufmann:  Yes, thank you. ", "original_text": "I was hoping you could dissect some of the comments on the \ngenerics program challenges cited or headwinds cited in 4Q, trying to get a sense of what the total \ndynamics were there. ", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "620f7a728df3ae3259839249e7805d10f1359f80e02809c5aed5754537937381", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b61404a-bbcb-40c3-a5a8-5483fcdac7f9", "node_type": "1", "metadata": {"window": "Eric Coldwell:  Thanks very much.  I was hoping you could dissect some of the comments on the \ngenerics program challenges cited or headwinds cited in 4Q, trying to get a sense of what the total \ndynamics were there.  Was it more about volumes due to mix impacts and healthcare access during \nthe last quarter or was it more about something specific to C ardinal, your procurement or your \nchannel successes?  Thanks very much.  \n \n Mike Kaufmann:  Yes, thank you.  No I wouldn\u2019t say there was anything unusual in there, nothing I \nwould call out other than the COVID impact related to just the volumes.  So it\u2019s hard to know to your \ncomment around whether it\u2019s driven by insurance coverage o r those types of things. ", "original_text": "Thanks very much.  \n \n"}, "hash": "04703db7dc8ff23cda44f9fbce4003d58e8f718b5e7db75deb0cfe7bcf626afd", "class_name": "RelatedNodeInfo"}}, "text": "Was it more about volumes due to mix impacts and healthcare access during \nthe last quarter or was it more about something specific to C ardinal, your procurement or your \nchannel successes? ", "start_char_idx": 1113, "end_char_idx": 1304, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b61404a-bbcb-40c3-a5a8-5483fcdac7f9": {"__data__": {"id_": "4b61404a-bbcb-40c3-a5a8-5483fcdac7f9", "embedding": null, "metadata": {"window": "Eric Coldwell:  Thanks very much.  I was hoping you could dissect some of the comments on the \ngenerics program challenges cited or headwinds cited in 4Q, trying to get a sense of what the total \ndynamics were there.  Was it more about volumes due to mix impacts and healthcare access during \nthe last quarter or was it more about something specific to C ardinal, your procurement or your \nchannel successes?  Thanks very much.  \n \n Mike Kaufmann:  Yes, thank you.  No I wouldn\u2019t say there was anything unusual in there, nothing I \nwould call out other than the COVID impact related to just the volumes.  So it\u2019s hard to know to your \ncomment around whether it\u2019s driven by insurance coverage o r those types of things. ", "original_text": "Thanks very much.  \n \n", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8291a5de-e14a-4b76-a285-09a126f85d3f", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a730697e2a2f7b137e9284fb429d2cea65946e3eedd1d048b66afc6f0efcbde7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95b698c0-f15e-4226-a1c8-b3ca805f41d9", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Eric Coldwell:  Thanks very much.  I was hoping you could dissect some of the comments on the \ngenerics program challenges cited or headwinds cited in 4Q, trying to get a sense of what the total \ndynamics were there.  Was it more about volumes due to mix impacts and healthcare access during \nthe last quarter or was it more about something specific to C ardinal, your procurement or your \nchannel successes?  Thanks very much.  \n \n Mike Kaufmann:  Yes, thank you.  No I wouldn\u2019t say there was anything unusual in there, nothing I \nwould call out other than the COVID impact related to just the volumes. ", "original_text": "Was it more about volumes due to mix impacts and healthcare access during \nthe last quarter or was it more about something specific to C ardinal, your procurement or your \nchannel successes? ", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b94b7d45e53f1eaee10715d1530dc4fa58b7f2183d826c5b6ae670cda5d41980", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f47e7b3-6f25-40dc-8e34-534e632586f7", "node_type": "1", "metadata": {"window": "I was hoping you could dissect some of the comments on the \ngenerics program challenges cited or headwinds cited in 4Q, trying to get a sense of what the total \ndynamics were there.  Was it more about volumes due to mix impacts and healthcare access during \nthe last quarter or was it more about something specific to C ardinal, your procurement or your \nchannel successes?  Thanks very much.  \n \n Mike Kaufmann:  Yes, thank you.  No I wouldn\u2019t say there was anything unusual in there, nothing I \nwould call out other than the COVID impact related to just the volumes.  So it\u2019s hard to know to your \ncomment around whether it\u2019s driven by insurance coverage o r those types of things.  That piece has ", "original_text": "Mike Kaufmann:  Yes, thank you. "}, "hash": "5026dd7f2673a1300cf0b8ea4e16a0a3c94b88baed0dd9fc0850ff5c57d58485", "class_name": "RelatedNodeInfo"}}, "text": "Thanks very much.  \n \n", "start_char_idx": 1304, "end_char_idx": 1326, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f47e7b3-6f25-40dc-8e34-534e632586f7": {"__data__": {"id_": "0f47e7b3-6f25-40dc-8e34-534e632586f7", "embedding": null, "metadata": {"window": "I was hoping you could dissect some of the comments on the \ngenerics program challenges cited or headwinds cited in 4Q, trying to get a sense of what the total \ndynamics were there.  Was it more about volumes due to mix impacts and healthcare access during \nthe last quarter or was it more about something specific to C ardinal, your procurement or your \nchannel successes?  Thanks very much.  \n \n Mike Kaufmann:  Yes, thank you.  No I wouldn\u2019t say there was anything unusual in there, nothing I \nwould call out other than the COVID impact related to just the volumes.  So it\u2019s hard to know to your \ncomment around whether it\u2019s driven by insurance coverage o r those types of things.  That piece has ", "original_text": "Mike Kaufmann:  Yes, thank you. ", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8291a5de-e14a-4b76-a285-09a126f85d3f", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a730697e2a2f7b137e9284fb429d2cea65946e3eedd1d048b66afc6f0efcbde7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b61404a-bbcb-40c3-a5a8-5483fcdac7f9", "node_type": "1", "metadata": {"window": "Eric Coldwell:  Thanks very much.  I was hoping you could dissect some of the comments on the \ngenerics program challenges cited or headwinds cited in 4Q, trying to get a sense of what the total \ndynamics were there.  Was it more about volumes due to mix impacts and healthcare access during \nthe last quarter or was it more about something specific to C ardinal, your procurement or your \nchannel successes?  Thanks very much.  \n \n Mike Kaufmann:  Yes, thank you.  No I wouldn\u2019t say there was anything unusual in there, nothing I \nwould call out other than the COVID impact related to just the volumes.  So it\u2019s hard to know to your \ncomment around whether it\u2019s driven by insurance coverage o r those types of things. ", "original_text": "Thanks very much.  \n \n", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "de1adc1e091fa9e4fea21eb956b18c04b4e9a23712170ca944f06f2118887c80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "341707fb-0c18-4a2a-9026-9777d22f5dcd", "node_type": "1", "metadata": {"window": "Was it more about volumes due to mix impacts and healthcare access during \nthe last quarter or was it more about something specific to C ardinal, your procurement or your \nchannel successes?  Thanks very much.  \n \n Mike Kaufmann:  Yes, thank you.  No I wouldn\u2019t say there was anything unusual in there, nothing I \nwould call out other than the COVID impact related to just the volumes.  So it\u2019s hard to know to your \ncomment around whether it\u2019s driven by insurance coverage o r those types of things.  That piece has ", "original_text": "No I wouldn\u2019t say there was anything unusual in there, nothing I \nwould call out other than the COVID impact related to just the volumes. "}, "hash": "3c35ec0954c9a878b3af8006e1e25d50c388fa8ca5a71afb3640ce7aec207a97", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes, thank you. ", "start_char_idx": 1326, "end_char_idx": 1358, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "341707fb-0c18-4a2a-9026-9777d22f5dcd": {"__data__": {"id_": "341707fb-0c18-4a2a-9026-9777d22f5dcd", "embedding": null, "metadata": {"window": "Was it more about volumes due to mix impacts and healthcare access during \nthe last quarter or was it more about something specific to C ardinal, your procurement or your \nchannel successes?  Thanks very much.  \n \n Mike Kaufmann:  Yes, thank you.  No I wouldn\u2019t say there was anything unusual in there, nothing I \nwould call out other than the COVID impact related to just the volumes.  So it\u2019s hard to know to your \ncomment around whether it\u2019s driven by insurance coverage o r those types of things.  That piece has ", "original_text": "No I wouldn\u2019t say there was anything unusual in there, nothing I \nwould call out other than the COVID impact related to just the volumes. ", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8291a5de-e14a-4b76-a285-09a126f85d3f", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a730697e2a2f7b137e9284fb429d2cea65946e3eedd1d048b66afc6f0efcbde7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f47e7b3-6f25-40dc-8e34-534e632586f7", "node_type": "1", "metadata": {"window": "I was hoping you could dissect some of the comments on the \ngenerics program challenges cited or headwinds cited in 4Q, trying to get a sense of what the total \ndynamics were there.  Was it more about volumes due to mix impacts and healthcare access during \nthe last quarter or was it more about something specific to C ardinal, your procurement or your \nchannel successes?  Thanks very much.  \n \n Mike Kaufmann:  Yes, thank you.  No I wouldn\u2019t say there was anything unusual in there, nothing I \nwould call out other than the COVID impact related to just the volumes.  So it\u2019s hard to know to your \ncomment around whether it\u2019s driven by insurance coverage o r those types of things.  That piece has ", "original_text": "Mike Kaufmann:  Yes, thank you. ", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "181a96a1206ea29f44e2ecaf4dd3a24a3c5d9f3b773b150ce32a58da81f06d22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c142b3e8-cffa-445d-ad34-eee6ae233e8f", "node_type": "1", "metadata": {"window": "Thanks very much.  \n \n Mike Kaufmann:  Yes, thank you.  No I wouldn\u2019t say there was anything unusual in there, nothing I \nwould call out other than the COVID impact related to just the volumes.  So it\u2019s hard to know to your \ncomment around whether it\u2019s driven by insurance coverage o r those types of things.  That piece has ", "original_text": "So it\u2019s hard to know to your \ncomment around whether it\u2019s driven by insurance coverage o r those types of things. "}, "hash": "eddb8161f2436b73d2165b79135ce78538f7d0b0781ada5400f65dde35b7ff4c", "class_name": "RelatedNodeInfo"}}, "text": "No I wouldn\u2019t say there was anything unusual in there, nothing I \nwould call out other than the COVID impact related to just the volumes. ", "start_char_idx": 1358, "end_char_idx": 1496, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c142b3e8-cffa-445d-ad34-eee6ae233e8f": {"__data__": {"id_": "c142b3e8-cffa-445d-ad34-eee6ae233e8f", "embedding": null, "metadata": {"window": "Thanks very much.  \n \n Mike Kaufmann:  Yes, thank you.  No I wouldn\u2019t say there was anything unusual in there, nothing I \nwould call out other than the COVID impact related to just the volumes.  So it\u2019s hard to know to your \ncomment around whether it\u2019s driven by insurance coverage o r those types of things.  That piece has ", "original_text": "So it\u2019s hard to know to your \ncomment around whether it\u2019s driven by insurance coverage o r those types of things. ", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8291a5de-e14a-4b76-a285-09a126f85d3f", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a730697e2a2f7b137e9284fb429d2cea65946e3eedd1d048b66afc6f0efcbde7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "341707fb-0c18-4a2a-9026-9777d22f5dcd", "node_type": "1", "metadata": {"window": "Was it more about volumes due to mix impacts and healthcare access during \nthe last quarter or was it more about something specific to C ardinal, your procurement or your \nchannel successes?  Thanks very much.  \n \n Mike Kaufmann:  Yes, thank you.  No I wouldn\u2019t say there was anything unusual in there, nothing I \nwould call out other than the COVID impact related to just the volumes.  So it\u2019s hard to know to your \ncomment around whether it\u2019s driven by insurance coverage o r those types of things.  That piece has ", "original_text": "No I wouldn\u2019t say there was anything unusual in there, nothing I \nwould call out other than the COVID impact related to just the volumes. ", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa39a203b4ed88b3d2a24d07a855a0af7fc7f85e61b29082d1df46ed36af2d9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0280c184-bc0c-4fbb-a4d3-20dea8e44be5", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes, thank you.  No I wouldn\u2019t say there was anything unusual in there, nothing I \nwould call out other than the COVID impact related to just the volumes.  So it\u2019s hard to know to your \ncomment around whether it\u2019s driven by insurance coverage o r those types of things.  That piece has ", "original_text": "That piece has "}, "hash": "be69a538116887f52d06da3cfa5c277286a510edae9c221bdbe7a084abb579e0", "class_name": "RelatedNodeInfo"}}, "text": "So it\u2019s hard to know to your \ncomment around whether it\u2019s driven by insurance coverage o r those types of things. ", "start_char_idx": 1496, "end_char_idx": 1610, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0280c184-bc0c-4fbb-a4d3-20dea8e44be5": {"__data__": {"id_": "0280c184-bc0c-4fbb-a4d3-20dea8e44be5", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes, thank you.  No I wouldn\u2019t say there was anything unusual in there, nothing I \nwould call out other than the COVID impact related to just the volumes.  So it\u2019s hard to know to your \ncomment around whether it\u2019s driven by insurance coverage o r those types of things.  That piece has ", "original_text": "That piece has ", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8291a5de-e14a-4b76-a285-09a126f85d3f", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a730697e2a2f7b137e9284fb429d2cea65946e3eedd1d048b66afc6f0efcbde7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c142b3e8-cffa-445d-ad34-eee6ae233e8f", "node_type": "1", "metadata": {"window": "Thanks very much.  \n \n Mike Kaufmann:  Yes, thank you.  No I wouldn\u2019t say there was anything unusual in there, nothing I \nwould call out other than the COVID impact related to just the volumes.  So it\u2019s hard to know to your \ncomment around whether it\u2019s driven by insurance coverage o r those types of things.  That piece has ", "original_text": "So it\u2019s hard to know to your \ncomment around whether it\u2019s driven by insurance coverage o r those types of things. ", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b31f759ebe42b4f4dc567835396c4c42781b0c2b7f3036f4b343772a7321568", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb3e29e3-0fdb-49fb-9fbe-e4aaad1ce60a", "node_type": "1", "metadata": {"window": " \nPage 23 of 31 \n \nbeen kind of hard to figure out.  But overall our - the generics piece being down a little bit more in Q4 \nis really just related to COVID volumes.  \n \n Eric Coldwell:  And Mike can you give us a sense about what you\u2019re se eing about deflation dynamics \nin that market buy side, sell side pricing, et cetera?  \n \n Mike Kaufmann:  Yes, what we saw, you know, was really pretty consistent dynamics throughout the \nwhole year. ", "original_text": " \nPage 23 of 31 \n \nbeen kind of hard to figure out. "}, "hash": "e2dda8d5993a08ecfec1cff56638ac1aa849d46dda3b9b674ea76cb7755fc139", "class_name": "RelatedNodeInfo"}}, "text": "That piece has ", "start_char_idx": 1610, "end_char_idx": 1625, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb3e29e3-0fdb-49fb-9fbe-e4aaad1ce60a": {"__data__": {"id_": "cb3e29e3-0fdb-49fb-9fbe-e4aaad1ce60a", "embedding": null, "metadata": {"window": " \nPage 23 of 31 \n \nbeen kind of hard to figure out.  But overall our - the generics piece being down a little bit more in Q4 \nis really just related to COVID volumes.  \n \n Eric Coldwell:  And Mike can you give us a sense about what you\u2019re se eing about deflation dynamics \nin that market buy side, sell side pricing, et cetera?  \n \n Mike Kaufmann:  Yes, what we saw, you know, was really pretty consistent dynamics throughout the \nwhole year. ", "original_text": " \nPage 23 of 31 \n \nbeen kind of hard to figure out. ", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c280f916c5b9e1818637175b2052bb8848ff35d69ba2b26aed8034cdfa560659", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0280c184-bc0c-4fbb-a4d3-20dea8e44be5", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes, thank you.  No I wouldn\u2019t say there was anything unusual in there, nothing I \nwould call out other than the COVID impact related to just the volumes.  So it\u2019s hard to know to your \ncomment around whether it\u2019s driven by insurance coverage o r those types of things.  That piece has ", "original_text": "That piece has ", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebd515a9f98fe7c292a2c9065c16f10ef1296e611c410df4b5d34109398eb019", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6da41465-5555-4295-9f1d-4fdeb06c66f5", "node_type": "1", "metadata": {"window": " \nPage 23 of 31 \n \nbeen kind of hard to figure out.  But overall our - the generics piece being down a little bit more in Q4 \nis really just related to COVID volumes.  \n \n Eric Coldwell:  And Mike can you give us a sense about what you\u2019re se eing about deflation dynamics \nin that market buy side, sell side pricing, et cetera?  \n \n Mike Kaufmann:  Yes, what we saw, you know, was really pretty consistent dynamics throughout the \nwhole year.  As we had mentioned a while back we started to see some impro vement of our Q4 of \nFY19. ", "original_text": "But overall our - the generics piece being down a little bit more in Q4 \nis really just related to COVID volumes.  \n \n"}, "hash": "a18d1fea68e81175421ce55f40d06b0fe769612854ebe8fd2950f1598f46aa41", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 23 of 31 \n \nbeen kind of hard to figure out. ", "start_char_idx": 0, "end_char_idx": 52, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6da41465-5555-4295-9f1d-4fdeb06c66f5": {"__data__": {"id_": "6da41465-5555-4295-9f1d-4fdeb06c66f5", "embedding": null, "metadata": {"window": " \nPage 23 of 31 \n \nbeen kind of hard to figure out.  But overall our - the generics piece being down a little bit more in Q4 \nis really just related to COVID volumes.  \n \n Eric Coldwell:  And Mike can you give us a sense about what you\u2019re se eing about deflation dynamics \nin that market buy side, sell side pricing, et cetera?  \n \n Mike Kaufmann:  Yes, what we saw, you know, was really pretty consistent dynamics throughout the \nwhole year.  As we had mentioned a while back we started to see some impro vement of our Q4 of \nFY19. ", "original_text": "But overall our - the generics piece being down a little bit more in Q4 \nis really just related to COVID volumes.  \n \n", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c280f916c5b9e1818637175b2052bb8848ff35d69ba2b26aed8034cdfa560659", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb3e29e3-0fdb-49fb-9fbe-e4aaad1ce60a", "node_type": "1", "metadata": {"window": " \nPage 23 of 31 \n \nbeen kind of hard to figure out.  But overall our - the generics piece being down a little bit more in Q4 \nis really just related to COVID volumes.  \n \n Eric Coldwell:  And Mike can you give us a sense about what you\u2019re se eing about deflation dynamics \nin that market buy side, sell side pricing, et cetera?  \n \n Mike Kaufmann:  Yes, what we saw, you know, was really pretty consistent dynamics throughout the \nwhole year. ", "original_text": " \nPage 23 of 31 \n \nbeen kind of hard to figure out. ", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5771a91781afc896749abb4408f081dfa5cd122b47b361e8a1da04fa3a4f5567", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a98888b8-d7aa-4ecb-967e-a6c3c5de7bf9", "node_type": "1", "metadata": {"window": " \nPage 23 of 31 \n \nbeen kind of hard to figure out.  But overall our - the generics piece being down a little bit more in Q4 \nis really just related to COVID volumes.  \n \n Eric Coldwell:  And Mike can you give us a sense about what you\u2019re se eing about deflation dynamics \nin that market buy side, sell side pricing, et cetera?  \n \n Mike Kaufmann:  Yes, what we saw, you know, was really pretty consistent dynamics throughout the \nwhole year.  As we had mentioned a while back we started to see some impro vement of our Q4 of \nFY19.  And that just continued during the whole year. ", "original_text": "Eric Coldwell:  And Mike can you give us a sense about what you\u2019re se eing about deflation dynamics \nin that market buy side, sell side pricing, et cetera?  \n \n"}, "hash": "7cc80a07b35bf7612ea0a523a22215f55050522a9d0ec0678b6afd0750fe04a8", "class_name": "RelatedNodeInfo"}}, "text": "But overall our - the generics piece being down a little bit more in Q4 \nis really just related to COVID volumes.  \n \n", "start_char_idx": 52, "end_char_idx": 170, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a98888b8-d7aa-4ecb-967e-a6c3c5de7bf9": {"__data__": {"id_": "a98888b8-d7aa-4ecb-967e-a6c3c5de7bf9", "embedding": null, "metadata": {"window": " \nPage 23 of 31 \n \nbeen kind of hard to figure out.  But overall our - the generics piece being down a little bit more in Q4 \nis really just related to COVID volumes.  \n \n Eric Coldwell:  And Mike can you give us a sense about what you\u2019re se eing about deflation dynamics \nin that market buy side, sell side pricing, et cetera?  \n \n Mike Kaufmann:  Yes, what we saw, you know, was really pretty consistent dynamics throughout the \nwhole year.  As we had mentioned a while back we started to see some impro vement of our Q4 of \nFY19.  And that just continued during the whole year. ", "original_text": "Eric Coldwell:  And Mike can you give us a sense about what you\u2019re se eing about deflation dynamics \nin that market buy side, sell side pricing, et cetera?  \n \n", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c280f916c5b9e1818637175b2052bb8848ff35d69ba2b26aed8034cdfa560659", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6da41465-5555-4295-9f1d-4fdeb06c66f5", "node_type": "1", "metadata": {"window": " \nPage 23 of 31 \n \nbeen kind of hard to figure out.  But overall our - the generics piece being down a little bit more in Q4 \nis really just related to COVID volumes.  \n \n Eric Coldwell:  And Mike can you give us a sense about what you\u2019re se eing about deflation dynamics \nin that market buy side, sell side pricing, et cetera?  \n \n Mike Kaufmann:  Yes, what we saw, you know, was really pretty consistent dynamics throughout the \nwhole year.  As we had mentioned a while back we started to see some impro vement of our Q4 of \nFY19. ", "original_text": "But overall our - the generics piece being down a little bit more in Q4 \nis really just related to COVID volumes.  \n \n", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "339d2c388e33a1eae320c0cbd1373a6eec49f0daa7279ad36e6a7c3fbfeac287", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e90515a0-b9ea-4271-8a86-73a85e0559d5", "node_type": "1", "metadata": {"window": " \nPage 23 of 31 \n \nbeen kind of hard to figure out.  But overall our - the generics piece being down a little bit more in Q4 \nis really just related to COVID volumes.  \n \n Eric Coldwell:  And Mike can you give us a sense about what you\u2019re se eing about deflation dynamics \nin that market buy side, sell side pricing, et cetera?  \n \n Mike Kaufmann:  Yes, what we saw, you know, was really pretty consistent dynamics throughout the \nwhole year.  As we had mentioned a while back we started to see some impro vement of our Q4 of \nFY19.  And that just continued during the whole year.  So it stayed improved. ", "original_text": "Mike Kaufmann:  Yes, what we saw, you know, was really pretty consistent dynamics throughout the \nwhole year. "}, "hash": "cc1ca9c411595040710d7354cc43d9f998acbc1b4819d52930012ad0ee20695a", "class_name": "RelatedNodeInfo"}}, "text": "Eric Coldwell:  And Mike can you give us a sense about what you\u2019re se eing about deflation dynamics \nin that market buy side, sell side pricing, et cetera?  \n \n", "start_char_idx": 170, "end_char_idx": 330, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e90515a0-b9ea-4271-8a86-73a85e0559d5": {"__data__": {"id_": "e90515a0-b9ea-4271-8a86-73a85e0559d5", "embedding": null, "metadata": {"window": " \nPage 23 of 31 \n \nbeen kind of hard to figure out.  But overall our - the generics piece being down a little bit more in Q4 \nis really just related to COVID volumes.  \n \n Eric Coldwell:  And Mike can you give us a sense about what you\u2019re se eing about deflation dynamics \nin that market buy side, sell side pricing, et cetera?  \n \n Mike Kaufmann:  Yes, what we saw, you know, was really pretty consistent dynamics throughout the \nwhole year.  As we had mentioned a while back we started to see some impro vement of our Q4 of \nFY19.  And that just continued during the whole year.  So it stayed improved. ", "original_text": "Mike Kaufmann:  Yes, what we saw, you know, was really pretty consistent dynamics throughout the \nwhole year. ", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c280f916c5b9e1818637175b2052bb8848ff35d69ba2b26aed8034cdfa560659", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a98888b8-d7aa-4ecb-967e-a6c3c5de7bf9", "node_type": "1", "metadata": {"window": " \nPage 23 of 31 \n \nbeen kind of hard to figure out.  But overall our - the generics piece being down a little bit more in Q4 \nis really just related to COVID volumes.  \n \n Eric Coldwell:  And Mike can you give us a sense about what you\u2019re se eing about deflation dynamics \nin that market buy side, sell side pricing, et cetera?  \n \n Mike Kaufmann:  Yes, what we saw, you know, was really pretty consistent dynamics throughout the \nwhole year.  As we had mentioned a while back we started to see some impro vement of our Q4 of \nFY19.  And that just continued during the whole year. ", "original_text": "Eric Coldwell:  And Mike can you give us a sense about what you\u2019re se eing about deflation dynamics \nin that market buy side, sell side pricing, et cetera?  \n \n", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ee1f62c15d835ab0474822802e087982b338705861138c5d88f56d2e1962030c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18b74887-07dd-4af0-9a46-2b5a7aab2d05", "node_type": "1", "metadata": {"window": "But overall our - the generics piece being down a little bit more in Q4 \nis really just related to COVID volumes.  \n \n Eric Coldwell:  And Mike can you give us a sense about what you\u2019re se eing about deflation dynamics \nin that market buy side, sell side pricing, et cetera?  \n \n Mike Kaufmann:  Yes, what we saw, you know, was really pretty consistent dynamics throughout the \nwhole year.  As we had mentioned a while back we started to see some impro vement of our Q4 of \nFY19.  And that just continued during the whole year.  So it stayed improved.  It bounced around up \nand down a little bit quarter to quarter, but generally it stayed pretty consistent during the whole year.  \n \n ", "original_text": "As we had mentioned a while back we started to see some impro vement of our Q4 of \nFY19. "}, "hash": "a56d7c85c6860d86160c8c51187ca5c6f8b682c08518525b9bcb5ac908637d0b", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes, what we saw, you know, was really pretty consistent dynamics throughout the \nwhole year. ", "start_char_idx": 330, "end_char_idx": 440, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18b74887-07dd-4af0-9a46-2b5a7aab2d05": {"__data__": {"id_": "18b74887-07dd-4af0-9a46-2b5a7aab2d05", "embedding": null, "metadata": {"window": "But overall our - the generics piece being down a little bit more in Q4 \nis really just related to COVID volumes.  \n \n Eric Coldwell:  And Mike can you give us a sense about what you\u2019re se eing about deflation dynamics \nin that market buy side, sell side pricing, et cetera?  \n \n Mike Kaufmann:  Yes, what we saw, you know, was really pretty consistent dynamics throughout the \nwhole year.  As we had mentioned a while back we started to see some impro vement of our Q4 of \nFY19.  And that just continued during the whole year.  So it stayed improved.  It bounced around up \nand down a little bit quarter to quarter, but generally it stayed pretty consistent during the whole year.  \n \n ", "original_text": "As we had mentioned a while back we started to see some impro vement of our Q4 of \nFY19. ", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c280f916c5b9e1818637175b2052bb8848ff35d69ba2b26aed8034cdfa560659", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e90515a0-b9ea-4271-8a86-73a85e0559d5", "node_type": "1", "metadata": {"window": " \nPage 23 of 31 \n \nbeen kind of hard to figure out.  But overall our - the generics piece being down a little bit more in Q4 \nis really just related to COVID volumes.  \n \n Eric Coldwell:  And Mike can you give us a sense about what you\u2019re se eing about deflation dynamics \nin that market buy side, sell side pricing, et cetera?  \n \n Mike Kaufmann:  Yes, what we saw, you know, was really pretty consistent dynamics throughout the \nwhole year.  As we had mentioned a while back we started to see some impro vement of our Q4 of \nFY19.  And that just continued during the whole year.  So it stayed improved. ", "original_text": "Mike Kaufmann:  Yes, what we saw, you know, was really pretty consistent dynamics throughout the \nwhole year. ", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01f6e8139a69b71bbb9c6fa94ae6a1773ac12a4c36a0b62012a55e3cb2dc5d45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06d11cd1-da0d-46f7-a2b0-ecd9829d5e37", "node_type": "1", "metadata": {"window": "Eric Coldwell:  And Mike can you give us a sense about what you\u2019re se eing about deflation dynamics \nin that market buy side, sell side pricing, et cetera?  \n \n Mike Kaufmann:  Yes, what we saw, you know, was really pretty consistent dynamics throughout the \nwhole year.  As we had mentioned a while back we started to see some impro vement of our Q4 of \nFY19.  And that just continued during the whole year.  So it stayed improved.  It bounced around up \nand down a little bit quarter to quarter, but generally it stayed pretty consistent during the whole year.  \n \n  And we're just projecting that  to be just a little bit better next year than this year but relatively \npretty consistent. ", "original_text": "And that just continued during the whole year. "}, "hash": "079b3fa73e199cae442bb1b385dba937ea20160f7b7b87f2b20c2768df7a65eb", "class_name": "RelatedNodeInfo"}}, "text": "As we had mentioned a while back we started to see some impro vement of our Q4 of \nFY19. ", "start_char_idx": 440, "end_char_idx": 529, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06d11cd1-da0d-46f7-a2b0-ecd9829d5e37": {"__data__": {"id_": "06d11cd1-da0d-46f7-a2b0-ecd9829d5e37", "embedding": null, "metadata": {"window": "Eric Coldwell:  And Mike can you give us a sense about what you\u2019re se eing about deflation dynamics \nin that market buy side, sell side pricing, et cetera?  \n \n Mike Kaufmann:  Yes, what we saw, you know, was really pretty consistent dynamics throughout the \nwhole year.  As we had mentioned a while back we started to see some impro vement of our Q4 of \nFY19.  And that just continued during the whole year.  So it stayed improved.  It bounced around up \nand down a little bit quarter to quarter, but generally it stayed pretty consistent during the whole year.  \n \n  And we're just projecting that  to be just a little bit better next year than this year but relatively \npretty consistent. ", "original_text": "And that just continued during the whole year. ", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c280f916c5b9e1818637175b2052bb8848ff35d69ba2b26aed8034cdfa560659", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18b74887-07dd-4af0-9a46-2b5a7aab2d05", "node_type": "1", "metadata": {"window": "But overall our - the generics piece being down a little bit more in Q4 \nis really just related to COVID volumes.  \n \n Eric Coldwell:  And Mike can you give us a sense about what you\u2019re se eing about deflation dynamics \nin that market buy side, sell side pricing, et cetera?  \n \n Mike Kaufmann:  Yes, what we saw, you know, was really pretty consistent dynamics throughout the \nwhole year.  As we had mentioned a while back we started to see some impro vement of our Q4 of \nFY19.  And that just continued during the whole year.  So it stayed improved.  It bounced around up \nand down a little bit quarter to quarter, but generally it stayed pretty consistent during the whole year.  \n \n ", "original_text": "As we had mentioned a while back we started to see some impro vement of our Q4 of \nFY19. ", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "312b144b816b2bda62eb2eefdfdbfd8de54c8e39d70d0f6b70b86f8098fee25b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67977b1d-b92b-4600-9a8d-c44e71b600fe", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes, what we saw, you know, was really pretty consistent dynamics throughout the \nwhole year.  As we had mentioned a while back we started to see some impro vement of our Q4 of \nFY19.  And that just continued during the whole year.  So it stayed improved.  It bounced around up \nand down a little bit quarter to quarter, but generally it stayed pretty consistent during the whole year.  \n \n  And we're just projecting that  to be just a little bit better next year than this year but relatively \npretty consistent.  And next year we expect our overall generic program to be a net tailwind which it \nwas this year, but remember at the beginning of the year we thought it would be a n et headwind. ", "original_text": "So it stayed improved. "}, "hash": "466fcabc8e6fbfd017460ce0c1c17916630218ad2ef276b73c591ce1603f8038", "class_name": "RelatedNodeInfo"}}, "text": "And that just continued during the whole year. ", "start_char_idx": 529, "end_char_idx": 576, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67977b1d-b92b-4600-9a8d-c44e71b600fe": {"__data__": {"id_": "67977b1d-b92b-4600-9a8d-c44e71b600fe", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes, what we saw, you know, was really pretty consistent dynamics throughout the \nwhole year.  As we had mentioned a while back we started to see some impro vement of our Q4 of \nFY19.  And that just continued during the whole year.  So it stayed improved.  It bounced around up \nand down a little bit quarter to quarter, but generally it stayed pretty consistent during the whole year.  \n \n  And we're just projecting that  to be just a little bit better next year than this year but relatively \npretty consistent.  And next year we expect our overall generic program to be a net tailwind which it \nwas this year, but remember at the beginning of the year we thought it would be a n et headwind. ", "original_text": "So it stayed improved. ", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c280f916c5b9e1818637175b2052bb8848ff35d69ba2b26aed8034cdfa560659", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06d11cd1-da0d-46f7-a2b0-ecd9829d5e37", "node_type": "1", "metadata": {"window": "Eric Coldwell:  And Mike can you give us a sense about what you\u2019re se eing about deflation dynamics \nin that market buy side, sell side pricing, et cetera?  \n \n Mike Kaufmann:  Yes, what we saw, you know, was really pretty consistent dynamics throughout the \nwhole year.  As we had mentioned a while back we started to see some impro vement of our Q4 of \nFY19.  And that just continued during the whole year.  So it stayed improved.  It bounced around up \nand down a little bit quarter to quarter, but generally it stayed pretty consistent during the whole year.  \n \n  And we're just projecting that  to be just a little bit better next year than this year but relatively \npretty consistent. ", "original_text": "And that just continued during the whole year. ", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ab94bed788892f724b7c72bbfedacb711a291ec2a151c8b6a875d1e55711246", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95edb33f-85c7-4d2b-8a65-165163080947", "node_type": "1", "metadata": {"window": "As we had mentioned a while back we started to see some impro vement of our Q4 of \nFY19.  And that just continued during the whole year.  So it stayed improved.  It bounced around up \nand down a little bit quarter to quarter, but generally it stayed pretty consistent during the whole year.  \n \n  And we're just projecting that  to be just a little bit better next year than this year but relatively \npretty consistent.  And next year we expect our overall generic program to be a net tailwind which it \nwas this year, but remember at the beginning of the year we thought it would be a n et headwind.  So \nwe were able to flip it around this year and we expect it now to be a net tailwind for us in FY21.  \n \n", "original_text": "It bounced around up \nand down a little bit quarter to quarter, but generally it stayed pretty consistent during the whole year.  \n \n "}, "hash": "54ce261db1e7e4868672d47b94dacbcb13289de4171cdeb52e676e77a5b43477", "class_name": "RelatedNodeInfo"}}, "text": "So it stayed improved. ", "start_char_idx": 576, "end_char_idx": 599, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95edb33f-85c7-4d2b-8a65-165163080947": {"__data__": {"id_": "95edb33f-85c7-4d2b-8a65-165163080947", "embedding": null, "metadata": {"window": "As we had mentioned a while back we started to see some impro vement of our Q4 of \nFY19.  And that just continued during the whole year.  So it stayed improved.  It bounced around up \nand down a little bit quarter to quarter, but generally it stayed pretty consistent during the whole year.  \n \n  And we're just projecting that  to be just a little bit better next year than this year but relatively \npretty consistent.  And next year we expect our overall generic program to be a net tailwind which it \nwas this year, but remember at the beginning of the year we thought it would be a n et headwind.  So \nwe were able to flip it around this year and we expect it now to be a net tailwind for us in FY21.  \n \n", "original_text": "It bounced around up \nand down a little bit quarter to quarter, but generally it stayed pretty consistent during the whole year.  \n \n ", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c280f916c5b9e1818637175b2052bb8848ff35d69ba2b26aed8034cdfa560659", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67977b1d-b92b-4600-9a8d-c44e71b600fe", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes, what we saw, you know, was really pretty consistent dynamics throughout the \nwhole year.  As we had mentioned a while back we started to see some impro vement of our Q4 of \nFY19.  And that just continued during the whole year.  So it stayed improved.  It bounced around up \nand down a little bit quarter to quarter, but generally it stayed pretty consistent during the whole year.  \n \n  And we're just projecting that  to be just a little bit better next year than this year but relatively \npretty consistent.  And next year we expect our overall generic program to be a net tailwind which it \nwas this year, but remember at the beginning of the year we thought it would be a n et headwind. ", "original_text": "So it stayed improved. ", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "25a8d0303908cf95e81b49523b5e3c7532fa05f7c37554544f24481bdb5f38e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1abb3c0-9980-4451-a15d-dd9f997f5843", "node_type": "1", "metadata": {"window": "And that just continued during the whole year.  So it stayed improved.  It bounced around up \nand down a little bit quarter to quarter, but generally it stayed pretty consistent during the whole year.  \n \n  And we're just projecting that  to be just a little bit better next year than this year but relatively \npretty consistent.  And next year we expect our overall generic program to be a net tailwind which it \nwas this year, but remember at the beginning of the year we thought it would be a n et headwind.  So \nwe were able to flip it around this year and we expect it now to be a net tailwind for us in FY21.  \n \n Eric Coldwell:  That\u2019s helpful. ", "original_text": "And we're just projecting that  to be just a little bit better next year than this year but relatively \npretty consistent. "}, "hash": "54c56110af46e65b58102ece755ade2e1d4ec4bac28ecd3b8a7da76fe1a92814", "class_name": "RelatedNodeInfo"}}, "text": "It bounced around up \nand down a little bit quarter to quarter, but generally it stayed pretty consistent during the whole year.  \n \n ", "start_char_idx": 599, "end_char_idx": 733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1abb3c0-9980-4451-a15d-dd9f997f5843": {"__data__": {"id_": "d1abb3c0-9980-4451-a15d-dd9f997f5843", "embedding": null, "metadata": {"window": "And that just continued during the whole year.  So it stayed improved.  It bounced around up \nand down a little bit quarter to quarter, but generally it stayed pretty consistent during the whole year.  \n \n  And we're just projecting that  to be just a little bit better next year than this year but relatively \npretty consistent.  And next year we expect our overall generic program to be a net tailwind which it \nwas this year, but remember at the beginning of the year we thought it would be a n et headwind.  So \nwe were able to flip it around this year and we expect it now to be a net tailwind for us in FY21.  \n \n Eric Coldwell:  That\u2019s helpful. ", "original_text": "And we're just projecting that  to be just a little bit better next year than this year but relatively \npretty consistent. ", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c280f916c5b9e1818637175b2052bb8848ff35d69ba2b26aed8034cdfa560659", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95edb33f-85c7-4d2b-8a65-165163080947", "node_type": "1", "metadata": {"window": "As we had mentioned a while back we started to see some impro vement of our Q4 of \nFY19.  And that just continued during the whole year.  So it stayed improved.  It bounced around up \nand down a little bit quarter to quarter, but generally it stayed pretty consistent during the whole year.  \n \n  And we're just projecting that  to be just a little bit better next year than this year but relatively \npretty consistent.  And next year we expect our overall generic program to be a net tailwind which it \nwas this year, but remember at the beginning of the year we thought it would be a n et headwind.  So \nwe were able to flip it around this year and we expect it now to be a net tailwind for us in FY21.  \n \n", "original_text": "It bounced around up \nand down a little bit quarter to quarter, but generally it stayed pretty consistent during the whole year.  \n \n ", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f073e802f0a814085868e9efa461586443a627b4a5d4e0d003ba205233d8b6f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbb9c025-1bf6-4323-aade-905b2533c43e", "node_type": "1", "metadata": {"window": "So it stayed improved.  It bounced around up \nand down a little bit quarter to quarter, but generally it stayed pretty consistent during the whole year.  \n \n  And we're just projecting that  to be just a little bit better next year than this year but relatively \npretty consistent.  And next year we expect our overall generic program to be a net tailwind which it \nwas this year, but remember at the beginning of the year we thought it would be a n et headwind.  So \nwe were able to flip it around this year and we expect it now to be a net tailwind for us in FY21.  \n \n Eric Coldwell:  That\u2019s helpful.  Thanks very much.  \n \n", "original_text": "And next year we expect our overall generic program to be a net tailwind which it \nwas this year, but remember at the beginning of the year we thought it would be a n et headwind. "}, "hash": "355e80a12813e1e521db6a325767cba41e2d8d37264fcf38789eaaa53c075219", "class_name": "RelatedNodeInfo"}}, "text": "And we're just projecting that  to be just a little bit better next year than this year but relatively \npretty consistent. ", "start_char_idx": 733, "end_char_idx": 856, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbb9c025-1bf6-4323-aade-905b2533c43e": {"__data__": {"id_": "dbb9c025-1bf6-4323-aade-905b2533c43e", "embedding": null, "metadata": {"window": "So it stayed improved.  It bounced around up \nand down a little bit quarter to quarter, but generally it stayed pretty consistent during the whole year.  \n \n  And we're just projecting that  to be just a little bit better next year than this year but relatively \npretty consistent.  And next year we expect our overall generic program to be a net tailwind which it \nwas this year, but remember at the beginning of the year we thought it would be a n et headwind.  So \nwe were able to flip it around this year and we expect it now to be a net tailwind for us in FY21.  \n \n Eric Coldwell:  That\u2019s helpful.  Thanks very much.  \n \n", "original_text": "And next year we expect our overall generic program to be a net tailwind which it \nwas this year, but remember at the beginning of the year we thought it would be a n et headwind. ", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c280f916c5b9e1818637175b2052bb8848ff35d69ba2b26aed8034cdfa560659", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1abb3c0-9980-4451-a15d-dd9f997f5843", "node_type": "1", "metadata": {"window": "And that just continued during the whole year.  So it stayed improved.  It bounced around up \nand down a little bit quarter to quarter, but generally it stayed pretty consistent during the whole year.  \n \n  And we're just projecting that  to be just a little bit better next year than this year but relatively \npretty consistent.  And next year we expect our overall generic program to be a net tailwind which it \nwas this year, but remember at the beginning of the year we thought it would be a n et headwind.  So \nwe were able to flip it around this year and we expect it now to be a net tailwind for us in FY21.  \n \n Eric Coldwell:  That\u2019s helpful. ", "original_text": "And we're just projecting that  to be just a little bit better next year than this year but relatively \npretty consistent. ", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc5a444e720a0490edab0cbc987f2d2cf689e843d87470a3a60c2cd9e7f42b09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc8478fd-705f-4e7b-855e-62d2fd7d8de3", "node_type": "1", "metadata": {"window": "It bounced around up \nand down a little bit quarter to quarter, but generally it stayed pretty consistent during the whole year.  \n \n  And we're just projecting that  to be just a little bit better next year than this year but relatively \npretty consistent.  And next year we expect our overall generic program to be a net tailwind which it \nwas this year, but remember at the beginning of the year we thought it would be a n et headwind.  So \nwe were able to flip it around this year and we expect it now to be a net tailwind for us in FY21.  \n \n Eric Coldwell:  That\u2019s helpful.  Thanks very much.  \n \n Operator:  Thank you. ", "original_text": "So \nwe were able to flip it around this year and we expect it now to be a net tailwind for us in FY21.  \n \n"}, "hash": "30875c5eb98edd6765c4ba279a98f48dc1b68251c62b5aaed3020483069c8679", "class_name": "RelatedNodeInfo"}}, "text": "And next year we expect our overall generic program to be a net tailwind which it \nwas this year, but remember at the beginning of the year we thought it would be a n et headwind. ", "start_char_idx": 856, "end_char_idx": 1036, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc8478fd-705f-4e7b-855e-62d2fd7d8de3": {"__data__": {"id_": "cc8478fd-705f-4e7b-855e-62d2fd7d8de3", "embedding": null, "metadata": {"window": "It bounced around up \nand down a little bit quarter to quarter, but generally it stayed pretty consistent during the whole year.  \n \n  And we're just projecting that  to be just a little bit better next year than this year but relatively \npretty consistent.  And next year we expect our overall generic program to be a net tailwind which it \nwas this year, but remember at the beginning of the year we thought it would be a n et headwind.  So \nwe were able to flip it around this year and we expect it now to be a net tailwind for us in FY21.  \n \n Eric Coldwell:  That\u2019s helpful.  Thanks very much.  \n \n Operator:  Thank you. ", "original_text": "So \nwe were able to flip it around this year and we expect it now to be a net tailwind for us in FY21.  \n \n", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c280f916c5b9e1818637175b2052bb8848ff35d69ba2b26aed8034cdfa560659", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbb9c025-1bf6-4323-aade-905b2533c43e", "node_type": "1", "metadata": {"window": "So it stayed improved.  It bounced around up \nand down a little bit quarter to quarter, but generally it stayed pretty consistent during the whole year.  \n \n  And we're just projecting that  to be just a little bit better next year than this year but relatively \npretty consistent.  And next year we expect our overall generic program to be a net tailwind which it \nwas this year, but remember at the beginning of the year we thought it would be a n et headwind.  So \nwe were able to flip it around this year and we expect it now to be a net tailwind for us in FY21.  \n \n Eric Coldwell:  That\u2019s helpful.  Thanks very much.  \n \n", "original_text": "And next year we expect our overall generic program to be a net tailwind which it \nwas this year, but remember at the beginning of the year we thought it would be a n et headwind. ", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "df9a829fdc392d711a27a3d5dbb2abe023a5a40fba07f51efb14b1a41442fca2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14e3f531-5ac1-4619-b67e-fdb531dc9b35", "node_type": "1", "metadata": {"window": "And we're just projecting that  to be just a little bit better next year than this year but relatively \npretty consistent.  And next year we expect our overall generic program to be a net tailwind which it \nwas this year, but remember at the beginning of the year we thought it would be a n et headwind.  So \nwe were able to flip it around this year and we expect it now to be a net tailwind for us in FY21.  \n \n Eric Coldwell:  That\u2019s helpful.  Thanks very much.  \n \n Operator:  Thank you.  And we'll next go to Robert Jones with Goldman Sachs. ", "original_text": "Eric Coldwell:  That\u2019s helpful. "}, "hash": "d6dffb0a296be4ea775cab727b787b36598f8fb731a55d1e9e1c6cbabe5ae83d", "class_name": "RelatedNodeInfo"}}, "text": "So \nwe were able to flip it around this year and we expect it now to be a net tailwind for us in FY21.  \n \n", "start_char_idx": 1036, "end_char_idx": 1143, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14e3f531-5ac1-4619-b67e-fdb531dc9b35": {"__data__": {"id_": "14e3f531-5ac1-4619-b67e-fdb531dc9b35", "embedding": null, "metadata": {"window": "And we're just projecting that  to be just a little bit better next year than this year but relatively \npretty consistent.  And next year we expect our overall generic program to be a net tailwind which it \nwas this year, but remember at the beginning of the year we thought it would be a n et headwind.  So \nwe were able to flip it around this year and we expect it now to be a net tailwind for us in FY21.  \n \n Eric Coldwell:  That\u2019s helpful.  Thanks very much.  \n \n Operator:  Thank you.  And we'll next go to Robert Jones with Goldman Sachs. ", "original_text": "Eric Coldwell:  That\u2019s helpful. ", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c280f916c5b9e1818637175b2052bb8848ff35d69ba2b26aed8034cdfa560659", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc8478fd-705f-4e7b-855e-62d2fd7d8de3", "node_type": "1", "metadata": {"window": "It bounced around up \nand down a little bit quarter to quarter, but generally it stayed pretty consistent during the whole year.  \n \n  And we're just projecting that  to be just a little bit better next year than this year but relatively \npretty consistent.  And next year we expect our overall generic program to be a net tailwind which it \nwas this year, but remember at the beginning of the year we thought it would be a n et headwind.  So \nwe were able to flip it around this year and we expect it now to be a net tailwind for us in FY21.  \n \n Eric Coldwell:  That\u2019s helpful.  Thanks very much.  \n \n Operator:  Thank you. ", "original_text": "So \nwe were able to flip it around this year and we expect it now to be a net tailwind for us in FY21.  \n \n", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88e9522786d6d83b3e858cacf7b923249416b2dbdd57687c05a3b0f4bb8133c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25d3c256-7f64-4c6b-b506-6431c459c111", "node_type": "1", "metadata": {"window": "And next year we expect our overall generic program to be a net tailwind which it \nwas this year, but remember at the beginning of the year we thought it would be a n et headwind.  So \nwe were able to flip it around this year and we expect it now to be a net tailwind for us in FY21.  \n \n Eric Coldwell:  That\u2019s helpful.  Thanks very much.  \n \n Operator:  Thank you.  And we'll next go to Robert Jones with Goldman Sachs.  Please go ahe ad. \n \n", "original_text": "Thanks very much.  \n \n"}, "hash": "9ed7bc3abdad26da71ae61a6e3fb78fedb721a254eccc25ff91be3d442e4acd9", "class_name": "RelatedNodeInfo"}}, "text": "Eric Coldwell:  That\u2019s helpful. ", "start_char_idx": 1143, "end_char_idx": 1175, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25d3c256-7f64-4c6b-b506-6431c459c111": {"__data__": {"id_": "25d3c256-7f64-4c6b-b506-6431c459c111", "embedding": null, "metadata": {"window": "And next year we expect our overall generic program to be a net tailwind which it \nwas this year, but remember at the beginning of the year we thought it would be a n et headwind.  So \nwe were able to flip it around this year and we expect it now to be a net tailwind for us in FY21.  \n \n Eric Coldwell:  That\u2019s helpful.  Thanks very much.  \n \n Operator:  Thank you.  And we'll next go to Robert Jones with Goldman Sachs.  Please go ahe ad. \n \n", "original_text": "Thanks very much.  \n \n", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c280f916c5b9e1818637175b2052bb8848ff35d69ba2b26aed8034cdfa560659", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14e3f531-5ac1-4619-b67e-fdb531dc9b35", "node_type": "1", "metadata": {"window": "And we're just projecting that  to be just a little bit better next year than this year but relatively \npretty consistent.  And next year we expect our overall generic program to be a net tailwind which it \nwas this year, but remember at the beginning of the year we thought it would be a n et headwind.  So \nwe were able to flip it around this year and we expect it now to be a net tailwind for us in FY21.  \n \n Eric Coldwell:  That\u2019s helpful.  Thanks very much.  \n \n Operator:  Thank you.  And we'll next go to Robert Jones with Goldman Sachs. ", "original_text": "Eric Coldwell:  That\u2019s helpful. ", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81dd54fbc25969c09b115cf80d50b15cec582f112012e5c94b76a7747b6631eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36aeb147-8704-4f75-96e7-c1a0d00020cd", "node_type": "1", "metadata": {"window": "So \nwe were able to flip it around this year and we expect it now to be a net tailwind for us in FY21.  \n \n Eric Coldwell:  That\u2019s helpful.  Thanks very much.  \n \n Operator:  Thank you.  And we'll next go to Robert Jones with Goldman Sachs.  Please go ahe ad. \n \n Robert Jones:  Great, thanks for the questions. ", "original_text": "Operator:  Thank you. "}, "hash": "a5271697d76716e1fc679e0707c26861a81db652c305c173d1d8724d6fcc2850", "class_name": "RelatedNodeInfo"}}, "text": "Thanks very much.  \n \n", "start_char_idx": 1175, "end_char_idx": 1197, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36aeb147-8704-4f75-96e7-c1a0d00020cd": {"__data__": {"id_": "36aeb147-8704-4f75-96e7-c1a0d00020cd", "embedding": null, "metadata": {"window": "So \nwe were able to flip it around this year and we expect it now to be a net tailwind for us in FY21.  \n \n Eric Coldwell:  That\u2019s helpful.  Thanks very much.  \n \n Operator:  Thank you.  And we'll next go to Robert Jones with Goldman Sachs.  Please go ahe ad. \n \n Robert Jones:  Great, thanks for the questions. ", "original_text": "Operator:  Thank you. ", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c280f916c5b9e1818637175b2052bb8848ff35d69ba2b26aed8034cdfa560659", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25d3c256-7f64-4c6b-b506-6431c459c111", "node_type": "1", "metadata": {"window": "And next year we expect our overall generic program to be a net tailwind which it \nwas this year, but remember at the beginning of the year we thought it would be a n et headwind.  So \nwe were able to flip it around this year and we expect it now to be a net tailwind for us in FY21.  \n \n Eric Coldwell:  That\u2019s helpful.  Thanks very much.  \n \n Operator:  Thank you.  And we'll next go to Robert Jones with Goldman Sachs.  Please go ahe ad. \n \n", "original_text": "Thanks very much.  \n \n", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "903dfea4a12554a26146969c3321f55eb8551a746e1f2e5c0fd999e4b1b4984d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2c9724a-78ef-4c6b-9f01-8ac4f64e481d", "node_type": "1", "metadata": {"window": "Eric Coldwell:  That\u2019s helpful.  Thanks very much.  \n \n Operator:  Thank you.  And we'll next go to Robert Jones with Goldman Sachs.  Please go ahe ad. \n \n Robert Jones:  Great, thanks for the questions.  Mike I know you clarified that the 100 million is \nincremental for next year but I was hoping maybe you could talk a little bit about the cadence, how we \nshould think about layering that into the numbers as we think about the progression from quarter to \nquarter. ", "original_text": "And we'll next go to Robert Jones with Goldman Sachs. "}, "hash": "ab381dee1d6cd1bed242b048eacb6c71b7d839326bfeee33146a22a5707ff948", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you. ", "start_char_idx": 1197, "end_char_idx": 1219, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2c9724a-78ef-4c6b-9f01-8ac4f64e481d": {"__data__": {"id_": "d2c9724a-78ef-4c6b-9f01-8ac4f64e481d", "embedding": null, "metadata": {"window": "Eric Coldwell:  That\u2019s helpful.  Thanks very much.  \n \n Operator:  Thank you.  And we'll next go to Robert Jones with Goldman Sachs.  Please go ahe ad. \n \n Robert Jones:  Great, thanks for the questions.  Mike I know you clarified that the 100 million is \nincremental for next year but I was hoping maybe you could talk a little bit about the cadence, how we \nshould think about layering that into the numbers as we think about the progression from quarter to \nquarter. ", "original_text": "And we'll next go to Robert Jones with Goldman Sachs. ", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c280f916c5b9e1818637175b2052bb8848ff35d69ba2b26aed8034cdfa560659", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36aeb147-8704-4f75-96e7-c1a0d00020cd", "node_type": "1", "metadata": {"window": "So \nwe were able to flip it around this year and we expect it now to be a net tailwind for us in FY21.  \n \n Eric Coldwell:  That\u2019s helpful.  Thanks very much.  \n \n Operator:  Thank you.  And we'll next go to Robert Jones with Goldman Sachs.  Please go ahe ad. \n \n Robert Jones:  Great, thanks for the questions. ", "original_text": "Operator:  Thank you. ", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8bba90f9edfea7566ba93c751ea031d687909a498dd54391138dbfb3fc20dd45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f728fa75-c160-46c2-a84b-98f0ee696546", "node_type": "1", "metadata": {"window": "Thanks very much.  \n \n Operator:  Thank you.  And we'll next go to Robert Jones with Goldman Sachs.  Please go ahe ad. \n \n Robert Jones:  Great, thanks for the questions.  Mike I know you clarified that the 100 million is \nincremental for next year but I was hoping maybe you could talk a little bit about the cadence, how we \nshould think about layering that into the numbers as we think about the progression from quarter to \nquarter.  And then anymore comments just around where that, you know, headwind might lie in next ", "original_text": "Please go ahe ad. \n \n"}, "hash": "484ddfd12be638aa49954023ad537c7425685b36b30c2144c834b35978521305", "class_name": "RelatedNodeInfo"}}, "text": "And we'll next go to Robert Jones with Goldman Sachs. ", "start_char_idx": 1219, "end_char_idx": 1273, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f728fa75-c160-46c2-a84b-98f0ee696546": {"__data__": {"id_": "f728fa75-c160-46c2-a84b-98f0ee696546", "embedding": null, "metadata": {"window": "Thanks very much.  \n \n Operator:  Thank you.  And we'll next go to Robert Jones with Goldman Sachs.  Please go ahe ad. \n \n Robert Jones:  Great, thanks for the questions.  Mike I know you clarified that the 100 million is \nincremental for next year but I was hoping maybe you could talk a little bit about the cadence, how we \nshould think about layering that into the numbers as we think about the progression from quarter to \nquarter.  And then anymore comments just around where that, you know, headwind might lie in next ", "original_text": "Please go ahe ad. \n \n", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c280f916c5b9e1818637175b2052bb8848ff35d69ba2b26aed8034cdfa560659", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2c9724a-78ef-4c6b-9f01-8ac4f64e481d", "node_type": "1", "metadata": {"window": "Eric Coldwell:  That\u2019s helpful.  Thanks very much.  \n \n Operator:  Thank you.  And we'll next go to Robert Jones with Goldman Sachs.  Please go ahe ad. \n \n Robert Jones:  Great, thanks for the questions.  Mike I know you clarified that the 100 million is \nincremental for next year but I was hoping maybe you could talk a little bit about the cadence, how we \nshould think about layering that into the numbers as we think about the progression from quarter to \nquarter. ", "original_text": "And we'll next go to Robert Jones with Goldman Sachs. ", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b72f13125bbe5ac8a54ba8e41e71e377e4fe6a5f3a8da60fbe8a527591c42a4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf24ed21-9a1b-4095-b8e6-3cfb494f6863", "node_type": "1", "metadata": {"window": "Operator:  Thank you.  And we'll next go to Robert Jones with Goldman Sachs.  Please go ahe ad. \n \n Robert Jones:  Great, thanks for the questions.  Mike I know you clarified that the 100 million is \nincremental for next year but I was hoping maybe you could talk a little bit about the cadence, how we \nshould think about layering that into the numbers as we think about the progression from quarter to \nquarter.  And then anymore comments just around where that, you know, headwind might lie in next ", "original_text": "Robert Jones:  Great, thanks for the questions. "}, "hash": "fdf277fb779085c58ea7c1fde684cde650414a874ccc7e29d49d2190efcd8dda", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahe ad. \n \n", "start_char_idx": 1273, "end_char_idx": 1294, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf24ed21-9a1b-4095-b8e6-3cfb494f6863": {"__data__": {"id_": "bf24ed21-9a1b-4095-b8e6-3cfb494f6863", "embedding": null, "metadata": {"window": "Operator:  Thank you.  And we'll next go to Robert Jones with Goldman Sachs.  Please go ahe ad. \n \n Robert Jones:  Great, thanks for the questions.  Mike I know you clarified that the 100 million is \nincremental for next year but I was hoping maybe you could talk a little bit about the cadence, how we \nshould think about layering that into the numbers as we think about the progression from quarter to \nquarter.  And then anymore comments just around where that, you know, headwind might lie in next ", "original_text": "Robert Jones:  Great, thanks for the questions. ", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c280f916c5b9e1818637175b2052bb8848ff35d69ba2b26aed8034cdfa560659", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f728fa75-c160-46c2-a84b-98f0ee696546", "node_type": "1", "metadata": {"window": "Thanks very much.  \n \n Operator:  Thank you.  And we'll next go to Robert Jones with Goldman Sachs.  Please go ahe ad. \n \n Robert Jones:  Great, thanks for the questions.  Mike I know you clarified that the 100 million is \nincremental for next year but I was hoping maybe you could talk a little bit about the cadence, how we \nshould think about layering that into the numbers as we think about the progression from quarter to \nquarter.  And then anymore comments just around where that, you know, headwind might lie in next ", "original_text": "Please go ahe ad. \n \n", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bac6940f225e1dca0edaadb6e734d97ef9a9a752523de04bd99a86bb1f7d1ee1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28b68abc-0012-48ca-a567-13c38848ac1c", "node_type": "1", "metadata": {"window": "And we'll next go to Robert Jones with Goldman Sachs.  Please go ahe ad. \n \n Robert Jones:  Great, thanks for the questions.  Mike I know you clarified that the 100 million is \nincremental for next year but I was hoping maybe you could talk a little bit about the cadence, how we \nshould think about layering that into the numbers as we think about the progression from quarter to \nquarter.  And then anymore comments just around where that, you know, headwind might lie in next ", "original_text": "Mike I know you clarified that the 100 million is \nincremental for next year but I was hoping maybe you could talk a little bit about the cadence, how we \nshould think about layering that into the numbers as we think about the progression from quarter to \nquarter. "}, "hash": "0e3b683d349de150511be92f94202c28fde2c142625cecef467afe1be4162d1e", "class_name": "RelatedNodeInfo"}}, "text": "Robert Jones:  Great, thanks for the questions. ", "start_char_idx": 1294, "end_char_idx": 1342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28b68abc-0012-48ca-a567-13c38848ac1c": {"__data__": {"id_": "28b68abc-0012-48ca-a567-13c38848ac1c", "embedding": null, "metadata": {"window": "And we'll next go to Robert Jones with Goldman Sachs.  Please go ahe ad. \n \n Robert Jones:  Great, thanks for the questions.  Mike I know you clarified that the 100 million is \nincremental for next year but I was hoping maybe you could talk a little bit about the cadence, how we \nshould think about layering that into the numbers as we think about the progression from quarter to \nquarter.  And then anymore comments just around where that, you know, headwind might lie in next ", "original_text": "Mike I know you clarified that the 100 million is \nincremental for next year but I was hoping maybe you could talk a little bit about the cadence, how we \nshould think about layering that into the numbers as we think about the progression from quarter to \nquarter. ", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c280f916c5b9e1818637175b2052bb8848ff35d69ba2b26aed8034cdfa560659", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf24ed21-9a1b-4095-b8e6-3cfb494f6863", "node_type": "1", "metadata": {"window": "Operator:  Thank you.  And we'll next go to Robert Jones with Goldman Sachs.  Please go ahe ad. \n \n Robert Jones:  Great, thanks for the questions.  Mike I know you clarified that the 100 million is \nincremental for next year but I was hoping maybe you could talk a little bit about the cadence, how we \nshould think about layering that into the numbers as we think about the progression from quarter to \nquarter.  And then anymore comments just around where that, you know, headwind might lie in next ", "original_text": "Robert Jones:  Great, thanks for the questions. ", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b1d4274b9f8ea490c3277a61dcac47b5288e8afb52a8b58a3150c9ede0f0965", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d24d938-caaf-4b22-a40f-2608b5e4be55", "node_type": "1", "metadata": {"window": "Please go ahe ad. \n \n Robert Jones:  Great, thanks for the questions.  Mike I know you clarified that the 100 million is \nincremental for next year but I was hoping maybe you could talk a little bit about the cadence, how we \nshould think about layering that into the numbers as we think about the progression from quarter to \nquarter.  And then anymore comments just around where that, you know, headwind might lie in next ", "original_text": "And then anymore comments just around where that, you know, headwind might lie in next "}, "hash": "b550515b38d3d52442bc44338a540be9ca840e4802de6492e08b466c7f0427a1", "class_name": "RelatedNodeInfo"}}, "text": "Mike I know you clarified that the 100 million is \nincremental for next year but I was hoping maybe you could talk a little bit about the cadence, how we \nshould think about layering that into the numbers as we think about the progression from quarter to \nquarter. ", "start_char_idx": 1342, "end_char_idx": 1607, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d24d938-caaf-4b22-a40f-2608b5e4be55": {"__data__": {"id_": "5d24d938-caaf-4b22-a40f-2608b5e4be55", "embedding": null, "metadata": {"window": "Please go ahe ad. \n \n Robert Jones:  Great, thanks for the questions.  Mike I know you clarified that the 100 million is \nincremental for next year but I was hoping maybe you could talk a little bit about the cadence, how we \nshould think about layering that into the numbers as we think about the progression from quarter to \nquarter.  And then anymore comments just around where that, you know, headwind might lie in next ", "original_text": "And then anymore comments just around where that, you know, headwind might lie in next ", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c280f916c5b9e1818637175b2052bb8848ff35d69ba2b26aed8034cdfa560659", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28b68abc-0012-48ca-a567-13c38848ac1c", "node_type": "1", "metadata": {"window": "And we'll next go to Robert Jones with Goldman Sachs.  Please go ahe ad. \n \n Robert Jones:  Great, thanks for the questions.  Mike I know you clarified that the 100 million is \nincremental for next year but I was hoping maybe you could talk a little bit about the cadence, how we \nshould think about layering that into the numbers as we think about the progression from quarter to \nquarter.  And then anymore comments just around where that, you know, headwind might lie in next ", "original_text": "Mike I know you clarified that the 100 million is \nincremental for next year but I was hoping maybe you could talk a little bit about the cadence, how we \nshould think about layering that into the numbers as we think about the progression from quarter to \nquarter. ", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86c689cc4c068461c91f3e57b3b759d5cec3d31c27e33c0c83247c648aae6a9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b517694-3be0-4813-afdb-be2a48120ccf", "node_type": "1", "metadata": {"window": " \nPage 24 of 31 \n \nyear\u2019s numbers versus this year\u2019s as we think about nuclear, you know, lower utilization, the PPE \nprocurement.   Just anything around the buckets would be helpful.  \n \n Jason Hollar:  Yes this is Jason.  Let me start here. ", "original_text": " \nPage 24 of 31 \n \nyear\u2019s numbers versus this year\u2019s as we think about nuclear, you know, lower utilization, the PPE \nprocurement.  "}, "hash": "37ae63efd6c9de37e0377cb555060a137e0d195751a6ae6d629747f439e44ebd", "class_name": "RelatedNodeInfo"}}, "text": "And then anymore comments just around where that, you know, headwind might lie in next ", "start_char_idx": 1607, "end_char_idx": 1694, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b517694-3be0-4813-afdb-be2a48120ccf": {"__data__": {"id_": "4b517694-3be0-4813-afdb-be2a48120ccf", "embedding": null, "metadata": {"window": " \nPage 24 of 31 \n \nyear\u2019s numbers versus this year\u2019s as we think about nuclear, you know, lower utilization, the PPE \nprocurement.   Just anything around the buckets would be helpful.  \n \n Jason Hollar:  Yes this is Jason.  Let me start here. ", "original_text": " \nPage 24 of 31 \n \nyear\u2019s numbers versus this year\u2019s as we think about nuclear, you know, lower utilization, the PPE \nprocurement.  ", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf26c2cb-b152-4f3c-a15e-c9296bf73bad", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65b7b304b76a27616e3a9ef00d523078afd4c0bcefec6ea14f7445ad786b9d6d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d24d938-caaf-4b22-a40f-2608b5e4be55", "node_type": "1", "metadata": {"window": "Please go ahe ad. \n \n Robert Jones:  Great, thanks for the questions.  Mike I know you clarified that the 100 million is \nincremental for next year but I was hoping maybe you could talk a little bit about the cadence, how we \nshould think about layering that into the numbers as we think about the progression from quarter to \nquarter.  And then anymore comments just around where that, you know, headwind might lie in next ", "original_text": "And then anymore comments just around where that, you know, headwind might lie in next ", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86e56d874a513defad67d5bc0055f6c6df6920d5162b6ae3a9f75a71271051d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6be5b1fa-d6b8-43c3-a30e-6c4a5da1107c", "node_type": "1", "metadata": {"window": " \nPage 24 of 31 \n \nyear\u2019s numbers versus this year\u2019s as we think about nuclear, you know, lower utilization, the PPE \nprocurement.   Just anything around the buckets would be helpful.  \n \n Jason Hollar:  Yes this is Jason.  Let me start here.  As it relates to the cadence as Mike indicated we \nsee in the fourth quarter of '20 that we were exiting the mid to high teens for elective procedures \nbeing down. ", "original_text": "Just anything around the buckets would be helpful.  \n \n"}, "hash": "9a908f029d3b88112e60b3424488f02f540edb20c8be0c508b36488d382491ef", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 24 of 31 \n \nyear\u2019s numbers versus this year\u2019s as we think about nuclear, you know, lower utilization, the PPE \nprocurement.  ", "start_char_idx": 0, "end_char_idx": 132, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6be5b1fa-d6b8-43c3-a30e-6c4a5da1107c": {"__data__": {"id_": "6be5b1fa-d6b8-43c3-a30e-6c4a5da1107c", "embedding": null, "metadata": {"window": " \nPage 24 of 31 \n \nyear\u2019s numbers versus this year\u2019s as we think about nuclear, you know, lower utilization, the PPE \nprocurement.   Just anything around the buckets would be helpful.  \n \n Jason Hollar:  Yes this is Jason.  Let me start here.  As it relates to the cadence as Mike indicated we \nsee in the fourth quarter of '20 that we were exiting the mid to high teens for elective procedures \nbeing down. ", "original_text": "Just anything around the buckets would be helpful.  \n \n", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf26c2cb-b152-4f3c-a15e-c9296bf73bad", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65b7b304b76a27616e3a9ef00d523078afd4c0bcefec6ea14f7445ad786b9d6d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b517694-3be0-4813-afdb-be2a48120ccf", "node_type": "1", "metadata": {"window": " \nPage 24 of 31 \n \nyear\u2019s numbers versus this year\u2019s as we think about nuclear, you know, lower utilization, the PPE \nprocurement.   Just anything around the buckets would be helpful.  \n \n Jason Hollar:  Yes this is Jason.  Let me start here. ", "original_text": " \nPage 24 of 31 \n \nyear\u2019s numbers versus this year\u2019s as we think about nuclear, you know, lower utilization, the PPE \nprocurement.  ", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7444a1d2cfe748f7653b74a28af4aec6940f39b5b014d4cec921595fd8086ff0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97bb9dd3-8eef-4427-827e-9578716c71d7", "node_type": "1", "metadata": {"window": " \nPage 24 of 31 \n \nyear\u2019s numbers versus this year\u2019s as we think about nuclear, you know, lower utilization, the PPE \nprocurement.   Just anything around the buckets would be helpful.  \n \n Jason Hollar:  Yes this is Jason.  Let me start here.  As it relates to the cadence as Mike indicated we \nsee in the fourth quarter of '20 that we were exiting the mid to high teens for elective procedures \nbeing down.  And of course in our guidance we have high single digits down. ", "original_text": "Jason Hollar:  Yes this is Jason. "}, "hash": "7fee6f94033a788bdbfdb11b9f369351422cb85b68fecdc0bb7fad0a3ddf7f5a", "class_name": "RelatedNodeInfo"}}, "text": "Just anything around the buckets would be helpful.  \n \n", "start_char_idx": 132, "end_char_idx": 187, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97bb9dd3-8eef-4427-827e-9578716c71d7": {"__data__": {"id_": "97bb9dd3-8eef-4427-827e-9578716c71d7", "embedding": null, "metadata": {"window": " \nPage 24 of 31 \n \nyear\u2019s numbers versus this year\u2019s as we think about nuclear, you know, lower utilization, the PPE \nprocurement.   Just anything around the buckets would be helpful.  \n \n Jason Hollar:  Yes this is Jason.  Let me start here.  As it relates to the cadence as Mike indicated we \nsee in the fourth quarter of '20 that we were exiting the mid to high teens for elective procedures \nbeing down.  And of course in our guidance we have high single digits down. ", "original_text": "Jason Hollar:  Yes this is Jason. ", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf26c2cb-b152-4f3c-a15e-c9296bf73bad", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65b7b304b76a27616e3a9ef00d523078afd4c0bcefec6ea14f7445ad786b9d6d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6be5b1fa-d6b8-43c3-a30e-6c4a5da1107c", "node_type": "1", "metadata": {"window": " \nPage 24 of 31 \n \nyear\u2019s numbers versus this year\u2019s as we think about nuclear, you know, lower utilization, the PPE \nprocurement.   Just anything around the buckets would be helpful.  \n \n Jason Hollar:  Yes this is Jason.  Let me start here.  As it relates to the cadence as Mike indicated we \nsee in the fourth quarter of '20 that we were exiting the mid to high teens for elective procedures \nbeing down. ", "original_text": "Just anything around the buckets would be helpful.  \n \n", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23609c65ed4dfbbbd333f20cad774264603511b624d3454f4aaa9f341d7013e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "296597f7-3cfd-4117-b603-d01e9a923cf2", "node_type": "1", "metadata": {"window": " \nPage 24 of 31 \n \nyear\u2019s numbers versus this year\u2019s as we think about nuclear, you know, lower utilization, the PPE \nprocurement.   Just anything around the buckets would be helpful.  \n \n Jason Hollar:  Yes this is Jason.  Let me start here.  As it relates to the cadence as Mike indicated we \nsee in the fourth quarter of '20 that we were exiting the mid to high teens for elective procedures \nbeing down.  And of course in our guidance we have high single digits down.  So you would as an \naverage for the year. ", "original_text": "Let me start here. "}, "hash": "32b8c79647bffab985ccb1f6c5b194a9ce35d9d2285882717a3979ffb287cea2", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yes this is Jason. ", "start_char_idx": 187, "end_char_idx": 221, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "296597f7-3cfd-4117-b603-d01e9a923cf2": {"__data__": {"id_": "296597f7-3cfd-4117-b603-d01e9a923cf2", "embedding": null, "metadata": {"window": " \nPage 24 of 31 \n \nyear\u2019s numbers versus this year\u2019s as we think about nuclear, you know, lower utilization, the PPE \nprocurement.   Just anything around the buckets would be helpful.  \n \n Jason Hollar:  Yes this is Jason.  Let me start here.  As it relates to the cadence as Mike indicated we \nsee in the fourth quarter of '20 that we were exiting the mid to high teens for elective procedures \nbeing down.  And of course in our guidance we have high single digits down.  So you would as an \naverage for the year. ", "original_text": "Let me start here. ", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf26c2cb-b152-4f3c-a15e-c9296bf73bad", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65b7b304b76a27616e3a9ef00d523078afd4c0bcefec6ea14f7445ad786b9d6d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97bb9dd3-8eef-4427-827e-9578716c71d7", "node_type": "1", "metadata": {"window": " \nPage 24 of 31 \n \nyear\u2019s numbers versus this year\u2019s as we think about nuclear, you know, lower utilization, the PPE \nprocurement.   Just anything around the buckets would be helpful.  \n \n Jason Hollar:  Yes this is Jason.  Let me start here.  As it relates to the cadence as Mike indicated we \nsee in the fourth quarter of '20 that we were exiting the mid to high teens for elective procedures \nbeing down.  And of course in our guidance we have high single digits down. ", "original_text": "Jason Hollar:  Yes this is Jason. ", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0955e5724fb3b4b2d2109f42fbc924561dcce13a66b63d997717b568ee71c4e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "004c201d-dc1d-4d40-864a-aaccf997730d", "node_type": "1", "metadata": {"window": "Just anything around the buckets would be helpful.  \n \n Jason Hollar:  Yes this is Jason.  Let me start here.  As it relates to the cadence as Mike indicated we \nsee in the fourth quarter of '20 that we were exiting the mid to high teens for elective procedures \nbeing down.  And of course in our guidance we have high single digits down.  So you would as an \naverage for the year.  And so you can see that that will try then from that high, mid to high single digits \nto essentially at pre -COVID levels by the end of the ye ar giving you that average at the high single \ndigits.  \n \n ", "original_text": "As it relates to the cadence as Mike indicated we \nsee in the fourth quarter of '20 that we were exiting the mid to high teens for elective procedures \nbeing down. "}, "hash": "6aede22b78a151f887a7e202f3f2609fc80f08b63447dabd352153debe64c80a", "class_name": "RelatedNodeInfo"}}, "text": "Let me start here. ", "start_char_idx": 221, "end_char_idx": 240, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "004c201d-dc1d-4d40-864a-aaccf997730d": {"__data__": {"id_": "004c201d-dc1d-4d40-864a-aaccf997730d", "embedding": null, "metadata": {"window": "Just anything around the buckets would be helpful.  \n \n Jason Hollar:  Yes this is Jason.  Let me start here.  As it relates to the cadence as Mike indicated we \nsee in the fourth quarter of '20 that we were exiting the mid to high teens for elective procedures \nbeing down.  And of course in our guidance we have high single digits down.  So you would as an \naverage for the year.  And so you can see that that will try then from that high, mid to high single digits \nto essentially at pre -COVID levels by the end of the ye ar giving you that average at the high single \ndigits.  \n \n ", "original_text": "As it relates to the cadence as Mike indicated we \nsee in the fourth quarter of '20 that we were exiting the mid to high teens for elective procedures \nbeing down. ", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf26c2cb-b152-4f3c-a15e-c9296bf73bad", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65b7b304b76a27616e3a9ef00d523078afd4c0bcefec6ea14f7445ad786b9d6d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "296597f7-3cfd-4117-b603-d01e9a923cf2", "node_type": "1", "metadata": {"window": " \nPage 24 of 31 \n \nyear\u2019s numbers versus this year\u2019s as we think about nuclear, you know, lower utilization, the PPE \nprocurement.   Just anything around the buckets would be helpful.  \n \n Jason Hollar:  Yes this is Jason.  Let me start here.  As it relates to the cadence as Mike indicated we \nsee in the fourth quarter of '20 that we were exiting the mid to high teens for elective procedures \nbeing down.  And of course in our guidance we have high single digits down.  So you would as an \naverage for the year. ", "original_text": "Let me start here. ", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4882805e9927020c5ccd6744da52896ef6be6363e1a4fd91c0d3f7a454b6dbf7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "113cae38-ff65-4ae9-8ba8-d9e77ca6d479", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes this is Jason.  Let me start here.  As it relates to the cadence as Mike indicated we \nsee in the fourth quarter of '20 that we were exiting the mid to high teens for elective procedures \nbeing down.  And of course in our guidance we have high single digits down.  So you would as an \naverage for the year.  And so you can see that that will try then from that high, mid to high single digits \nto essentially at pre -COVID levels by the end of the ye ar giving you that average at the high single \ndigits.  \n \n  So yes, so there\u2019s going to be some choppiness along the way but we do anticipate that it\u2019s a \nrelatively steady march back towards pre -COVID levels by year end. ", "original_text": "And of course in our guidance we have high single digits down. "}, "hash": "0bb91d40bbcb5b3fcc5de20e8373d2141f64bca6b5b277af3155b7b089bbe7aa", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to the cadence as Mike indicated we \nsee in the fourth quarter of '20 that we were exiting the mid to high teens for elective procedures \nbeing down. ", "start_char_idx": 240, "end_char_idx": 404, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "113cae38-ff65-4ae9-8ba8-d9e77ca6d479": {"__data__": {"id_": "113cae38-ff65-4ae9-8ba8-d9e77ca6d479", "embedding": null, "metadata": {"window": "Jason Hollar:  Yes this is Jason.  Let me start here.  As it relates to the cadence as Mike indicated we \nsee in the fourth quarter of '20 that we were exiting the mid to high teens for elective procedures \nbeing down.  And of course in our guidance we have high single digits down.  So you would as an \naverage for the year.  And so you can see that that will try then from that high, mid to high single digits \nto essentially at pre -COVID levels by the end of the ye ar giving you that average at the high single \ndigits.  \n \n  So yes, so there\u2019s going to be some choppiness along the way but we do anticipate that it\u2019s a \nrelatively steady march back towards pre -COVID levels by year end. ", "original_text": "And of course in our guidance we have high single digits down. ", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf26c2cb-b152-4f3c-a15e-c9296bf73bad", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65b7b304b76a27616e3a9ef00d523078afd4c0bcefec6ea14f7445ad786b9d6d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "004c201d-dc1d-4d40-864a-aaccf997730d", "node_type": "1", "metadata": {"window": "Just anything around the buckets would be helpful.  \n \n Jason Hollar:  Yes this is Jason.  Let me start here.  As it relates to the cadence as Mike indicated we \nsee in the fourth quarter of '20 that we were exiting the mid to high teens for elective procedures \nbeing down.  And of course in our guidance we have high single digits down.  So you would as an \naverage for the year.  And so you can see that that will try then from that high, mid to high single digits \nto essentially at pre -COVID levels by the end of the ye ar giving you that average at the high single \ndigits.  \n \n ", "original_text": "As it relates to the cadence as Mike indicated we \nsee in the fourth quarter of '20 that we were exiting the mid to high teens for elective procedures \nbeing down. ", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7011405b9f6384854c4dbcc4fe028f7061487227d94ec476f084bad25794633b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a13e7c19-e489-4271-9094-d81add8e4530", "node_type": "1", "metadata": {"window": "Let me start here.  As it relates to the cadence as Mike indicated we \nsee in the fourth quarter of '20 that we were exiting the mid to high teens for elective procedures \nbeing down.  And of course in our guidance we have high single digits down.  So you would as an \naverage for the year.  And so you can see that that will try then from that high, mid to high single digits \nto essentially at pre -COVID levels by the end of the ye ar giving you that average at the high single \ndigits.  \n \n  So yes, so there\u2019s going to be some choppiness along the way but we do anticipate that it\u2019s a \nrelatively steady march back towards pre -COVID levels by year end.  So that certainly means from a \nmath per spective that we would anticipate it being front end loaded more of an impact in the front \nhalf. ", "original_text": "So you would as an \naverage for the year. "}, "hash": "15378b9981fa842e066b0ea0c2216852e2cda562c684d95991dbff3d2cf26266", "class_name": "RelatedNodeInfo"}}, "text": "And of course in our guidance we have high single digits down. ", "start_char_idx": 404, "end_char_idx": 467, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a13e7c19-e489-4271-9094-d81add8e4530": {"__data__": {"id_": "a13e7c19-e489-4271-9094-d81add8e4530", "embedding": null, "metadata": {"window": "Let me start here.  As it relates to the cadence as Mike indicated we \nsee in the fourth quarter of '20 that we were exiting the mid to high teens for elective procedures \nbeing down.  And of course in our guidance we have high single digits down.  So you would as an \naverage for the year.  And so you can see that that will try then from that high, mid to high single digits \nto essentially at pre -COVID levels by the end of the ye ar giving you that average at the high single \ndigits.  \n \n  So yes, so there\u2019s going to be some choppiness along the way but we do anticipate that it\u2019s a \nrelatively steady march back towards pre -COVID levels by year end.  So that certainly means from a \nmath per spective that we would anticipate it being front end loaded more of an impact in the front \nhalf. ", "original_text": "So you would as an \naverage for the year. ", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf26c2cb-b152-4f3c-a15e-c9296bf73bad", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65b7b304b76a27616e3a9ef00d523078afd4c0bcefec6ea14f7445ad786b9d6d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "113cae38-ff65-4ae9-8ba8-d9e77ca6d479", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes this is Jason.  Let me start here.  As it relates to the cadence as Mike indicated we \nsee in the fourth quarter of '20 that we were exiting the mid to high teens for elective procedures \nbeing down.  And of course in our guidance we have high single digits down.  So you would as an \naverage for the year.  And so you can see that that will try then from that high, mid to high single digits \nto essentially at pre -COVID levels by the end of the ye ar giving you that average at the high single \ndigits.  \n \n  So yes, so there\u2019s going to be some choppiness along the way but we do anticipate that it\u2019s a \nrelatively steady march back towards pre -COVID levels by year end. ", "original_text": "And of course in our guidance we have high single digits down. ", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3993b212cf5ef50def17bb06e15302e8be8f0464722bf5d97ddf4c2d1a43f8fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f92a8c2-2c8c-4e8c-af98-217a224e5539", "node_type": "1", "metadata": {"window": "As it relates to the cadence as Mike indicated we \nsee in the fourth quarter of '20 that we were exiting the mid to high teens for elective procedures \nbeing down.  And of course in our guidance we have high single digits down.  So you would as an \naverage for the year.  And so you can see that that will try then from that high, mid to high single digits \nto essentially at pre -COVID levels by the end of the ye ar giving you that average at the high single \ndigits.  \n \n  So yes, so there\u2019s going to be some choppiness along the way but we do anticipate that it\u2019s a \nrelatively steady march back towards pre -COVID levels by year end.  So that certainly means from a \nmath per spective that we would anticipate it being front end loaded more of an impact in the front \nhalf.  I also made a comment to my remarks about the cost side related to PPE being also more \nanticipated for the first half of the year. ", "original_text": "And so you can see that that will try then from that high, mid to high single digits \nto essentially at pre -COVID levels by the end of the ye ar giving you that average at the high single \ndigits.  \n \n "}, "hash": "c26c8e7173c078f9c0727cdf6bcffe3115b5463f694fc564251ec4380ea3eacc", "class_name": "RelatedNodeInfo"}}, "text": "So you would as an \naverage for the year. ", "start_char_idx": 467, "end_char_idx": 509, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f92a8c2-2c8c-4e8c-af98-217a224e5539": {"__data__": {"id_": "3f92a8c2-2c8c-4e8c-af98-217a224e5539", "embedding": null, "metadata": {"window": "As it relates to the cadence as Mike indicated we \nsee in the fourth quarter of '20 that we were exiting the mid to high teens for elective procedures \nbeing down.  And of course in our guidance we have high single digits down.  So you would as an \naverage for the year.  And so you can see that that will try then from that high, mid to high single digits \nto essentially at pre -COVID levels by the end of the ye ar giving you that average at the high single \ndigits.  \n \n  So yes, so there\u2019s going to be some choppiness along the way but we do anticipate that it\u2019s a \nrelatively steady march back towards pre -COVID levels by year end.  So that certainly means from a \nmath per spective that we would anticipate it being front end loaded more of an impact in the front \nhalf.  I also made a comment to my remarks about the cost side related to PPE being also more \nanticipated for the first half of the year. ", "original_text": "And so you can see that that will try then from that high, mid to high single digits \nto essentially at pre -COVID levels by the end of the ye ar giving you that average at the high single \ndigits.  \n \n ", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf26c2cb-b152-4f3c-a15e-c9296bf73bad", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65b7b304b76a27616e3a9ef00d523078afd4c0bcefec6ea14f7445ad786b9d6d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a13e7c19-e489-4271-9094-d81add8e4530", "node_type": "1", "metadata": {"window": "Let me start here.  As it relates to the cadence as Mike indicated we \nsee in the fourth quarter of '20 that we were exiting the mid to high teens for elective procedures \nbeing down.  And of course in our guidance we have high single digits down.  So you would as an \naverage for the year.  And so you can see that that will try then from that high, mid to high single digits \nto essentially at pre -COVID levels by the end of the ye ar giving you that average at the high single \ndigits.  \n \n  So yes, so there\u2019s going to be some choppiness along the way but we do anticipate that it\u2019s a \nrelatively steady march back towards pre -COVID levels by year end.  So that certainly means from a \nmath per spective that we would anticipate it being front end loaded more of an impact in the front \nhalf. ", "original_text": "So you would as an \naverage for the year. ", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f06fba10d1758aecf1515630e0e50d4d1a859c6c5ca408f55a12d2ccc8958af7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6bd4861e-04aa-45f6-8eb1-dbc8edb4b3a2", "node_type": "1", "metadata": {"window": "And of course in our guidance we have high single digits down.  So you would as an \naverage for the year.  And so you can see that that will try then from that high, mid to high single digits \nto essentially at pre -COVID levels by the end of the ye ar giving you that average at the high single \ndigits.  \n \n  So yes, so there\u2019s going to be some choppiness along the way but we do anticipate that it\u2019s a \nrelatively steady march back towards pre -COVID levels by year end.  So that certainly means from a \nmath per spective that we would anticipate it being front end loaded more of an impact in the front \nhalf.  I also made a comment to my remarks about the cost side related to PPE being also more \nanticipated for the first half of the year.  So for those reasons we woul d expect to there be an \noverweighting in the first half versus second half.  \n \n ", "original_text": "So yes, so there\u2019s going to be some choppiness along the way but we do anticipate that it\u2019s a \nrelatively steady march back towards pre -COVID levels by year end. "}, "hash": "22f7d82817396b7afab9b3aa5394a35d0fbece5769a6ad354e6e236e1283397f", "class_name": "RelatedNodeInfo"}}, "text": "And so you can see that that will try then from that high, mid to high single digits \nto essentially at pre -COVID levels by the end of the ye ar giving you that average at the high single \ndigits.  \n \n ", "start_char_idx": 509, "end_char_idx": 712, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6bd4861e-04aa-45f6-8eb1-dbc8edb4b3a2": {"__data__": {"id_": "6bd4861e-04aa-45f6-8eb1-dbc8edb4b3a2", "embedding": null, "metadata": {"window": "And of course in our guidance we have high single digits down.  So you would as an \naverage for the year.  And so you can see that that will try then from that high, mid to high single digits \nto essentially at pre -COVID levels by the end of the ye ar giving you that average at the high single \ndigits.  \n \n  So yes, so there\u2019s going to be some choppiness along the way but we do anticipate that it\u2019s a \nrelatively steady march back towards pre -COVID levels by year end.  So that certainly means from a \nmath per spective that we would anticipate it being front end loaded more of an impact in the front \nhalf.  I also made a comment to my remarks about the cost side related to PPE being also more \nanticipated for the first half of the year.  So for those reasons we woul d expect to there be an \noverweighting in the first half versus second half.  \n \n ", "original_text": "So yes, so there\u2019s going to be some choppiness along the way but we do anticipate that it\u2019s a \nrelatively steady march back towards pre -COVID levels by year end. ", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf26c2cb-b152-4f3c-a15e-c9296bf73bad", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65b7b304b76a27616e3a9ef00d523078afd4c0bcefec6ea14f7445ad786b9d6d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f92a8c2-2c8c-4e8c-af98-217a224e5539", "node_type": "1", "metadata": {"window": "As it relates to the cadence as Mike indicated we \nsee in the fourth quarter of '20 that we were exiting the mid to high teens for elective procedures \nbeing down.  And of course in our guidance we have high single digits down.  So you would as an \naverage for the year.  And so you can see that that will try then from that high, mid to high single digits \nto essentially at pre -COVID levels by the end of the ye ar giving you that average at the high single \ndigits.  \n \n  So yes, so there\u2019s going to be some choppiness along the way but we do anticipate that it\u2019s a \nrelatively steady march back towards pre -COVID levels by year end.  So that certainly means from a \nmath per spective that we would anticipate it being front end loaded more of an impact in the front \nhalf.  I also made a comment to my remarks about the cost side related to PPE being also more \nanticipated for the first half of the year. ", "original_text": "And so you can see that that will try then from that high, mid to high single digits \nto essentially at pre -COVID levels by the end of the ye ar giving you that average at the high single \ndigits.  \n \n ", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "804443e9fcf62e85571c80f4eda151e1765a305f0ee6fa80e393ef8e61530e53", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5ece1f9-f967-480a-83a5-fdfc29e204f0", "node_type": "1", "metadata": {"window": "So you would as an \naverage for the year.  And so you can see that that will try then from that high, mid to high single digits \nto essentially at pre -COVID levels by the end of the ye ar giving you that average at the high single \ndigits.  \n \n  So yes, so there\u2019s going to be some choppiness along the way but we do anticipate that it\u2019s a \nrelatively steady march back towards pre -COVID levels by year end.  So that certainly means from a \nmath per spective that we would anticipate it being front end loaded more of an impact in the front \nhalf.  I also made a comment to my remarks about the cost side related to PPE being also more \nanticipated for the first half of the year.  So for those reasons we woul d expect to there be an \noverweighting in the first half versus second half.  \n \n  And as it relates to where we foresee those impacts, again most of the '21 impact relative to \n'20 is going to be in more medical. ", "original_text": "So that certainly means from a \nmath per spective that we would anticipate it being front end loaded more of an impact in the front \nhalf. "}, "hash": "9f5906deeb32afc8bf4fea5ca3e2a7fd13df94ad3905eec5604131eb697c55f2", "class_name": "RelatedNodeInfo"}}, "text": "So yes, so there\u2019s going to be some choppiness along the way but we do anticipate that it\u2019s a \nrelatively steady march back towards pre -COVID levels by year end. ", "start_char_idx": 712, "end_char_idx": 875, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5ece1f9-f967-480a-83a5-fdfc29e204f0": {"__data__": {"id_": "a5ece1f9-f967-480a-83a5-fdfc29e204f0", "embedding": null, "metadata": {"window": "So you would as an \naverage for the year.  And so you can see that that will try then from that high, mid to high single digits \nto essentially at pre -COVID levels by the end of the ye ar giving you that average at the high single \ndigits.  \n \n  So yes, so there\u2019s going to be some choppiness along the way but we do anticipate that it\u2019s a \nrelatively steady march back towards pre -COVID levels by year end.  So that certainly means from a \nmath per spective that we would anticipate it being front end loaded more of an impact in the front \nhalf.  I also made a comment to my remarks about the cost side related to PPE being also more \nanticipated for the first half of the year.  So for those reasons we woul d expect to there be an \noverweighting in the first half versus second half.  \n \n  And as it relates to where we foresee those impacts, again most of the '21 impact relative to \n'20 is going to be in more medical. ", "original_text": "So that certainly means from a \nmath per spective that we would anticipate it being front end loaded more of an impact in the front \nhalf. ", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf26c2cb-b152-4f3c-a15e-c9296bf73bad", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65b7b304b76a27616e3a9ef00d523078afd4c0bcefec6ea14f7445ad786b9d6d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6bd4861e-04aa-45f6-8eb1-dbc8edb4b3a2", "node_type": "1", "metadata": {"window": "And of course in our guidance we have high single digits down.  So you would as an \naverage for the year.  And so you can see that that will try then from that high, mid to high single digits \nto essentially at pre -COVID levels by the end of the ye ar giving you that average at the high single \ndigits.  \n \n  So yes, so there\u2019s going to be some choppiness along the way but we do anticipate that it\u2019s a \nrelatively steady march back towards pre -COVID levels by year end.  So that certainly means from a \nmath per spective that we would anticipate it being front end loaded more of an impact in the front \nhalf.  I also made a comment to my remarks about the cost side related to PPE being also more \nanticipated for the first half of the year.  So for those reasons we woul d expect to there be an \noverweighting in the first half versus second half.  \n \n ", "original_text": "So yes, so there\u2019s going to be some choppiness along the way but we do anticipate that it\u2019s a \nrelatively steady march back towards pre -COVID levels by year end. ", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87b009fdf4dd39e0d7b899f791bfc20da09cf67fb0c4529819a71393729c0a95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0579de0b-9138-49e3-ac58-3c28ae3625d5", "node_type": "1", "metadata": {"window": "And so you can see that that will try then from that high, mid to high single digits \nto essentially at pre -COVID levels by the end of the ye ar giving you that average at the high single \ndigits.  \n \n  So yes, so there\u2019s going to be some choppiness along the way but we do anticipate that it\u2019s a \nrelatively steady march back towards pre -COVID levels by year end.  So that certainly means from a \nmath per spective that we would anticipate it being front end loaded more of an impact in the front \nhalf.  I also made a comment to my remarks about the cost side related to PPE being also more \nanticipated for the first half of the year.  So for those reasons we woul d expect to there be an \noverweighting in the first half versus second half.  \n \n  And as it relates to where we foresee those impacts, again most of the '21 impact relative to \n'20 is going to be in more medical.  And so as you highlight areas like nuclear, that \u2019s going to be, you \nknow, again a steady improvement. ", "original_text": "I also made a comment to my remarks about the cost side related to PPE being also more \nanticipated for the first half of the year. "}, "hash": "a29041106d937f5daf20bc1563eae26c7a4411d569ff1b8bc29218252cbed3dd", "class_name": "RelatedNodeInfo"}}, "text": "So that certainly means from a \nmath per spective that we would anticipate it being front end loaded more of an impact in the front \nhalf. ", "start_char_idx": 875, "end_char_idx": 1014, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0579de0b-9138-49e3-ac58-3c28ae3625d5": {"__data__": {"id_": "0579de0b-9138-49e3-ac58-3c28ae3625d5", "embedding": null, "metadata": {"window": "And so you can see that that will try then from that high, mid to high single digits \nto essentially at pre -COVID levels by the end of the ye ar giving you that average at the high single \ndigits.  \n \n  So yes, so there\u2019s going to be some choppiness along the way but we do anticipate that it\u2019s a \nrelatively steady march back towards pre -COVID levels by year end.  So that certainly means from a \nmath per spective that we would anticipate it being front end loaded more of an impact in the front \nhalf.  I also made a comment to my remarks about the cost side related to PPE being also more \nanticipated for the first half of the year.  So for those reasons we woul d expect to there be an \noverweighting in the first half versus second half.  \n \n  And as it relates to where we foresee those impacts, again most of the '21 impact relative to \n'20 is going to be in more medical.  And so as you highlight areas like nuclear, that \u2019s going to be, you \nknow, again a steady improvement. ", "original_text": "I also made a comment to my remarks about the cost side related to PPE being also more \nanticipated for the first half of the year. ", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf26c2cb-b152-4f3c-a15e-c9296bf73bad", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65b7b304b76a27616e3a9ef00d523078afd4c0bcefec6ea14f7445ad786b9d6d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5ece1f9-f967-480a-83a5-fdfc29e204f0", "node_type": "1", "metadata": {"window": "So you would as an \naverage for the year.  And so you can see that that will try then from that high, mid to high single digits \nto essentially at pre -COVID levels by the end of the ye ar giving you that average at the high single \ndigits.  \n \n  So yes, so there\u2019s going to be some choppiness along the way but we do anticipate that it\u2019s a \nrelatively steady march back towards pre -COVID levels by year end.  So that certainly means from a \nmath per spective that we would anticipate it being front end loaded more of an impact in the front \nhalf.  I also made a comment to my remarks about the cost side related to PPE being also more \nanticipated for the first half of the year.  So for those reasons we woul d expect to there be an \noverweighting in the first half versus second half.  \n \n  And as it relates to where we foresee those impacts, again most of the '21 impact relative to \n'20 is going to be in more medical. ", "original_text": "So that certainly means from a \nmath per spective that we would anticipate it being front end loaded more of an impact in the front \nhalf. ", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be17861a74f38ccaa43f395f21cf441b4b3f8a68be5e9020071d67a9e7472e66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "181662ac-a270-4592-96d0-848d3bd32013", "node_type": "1", "metadata": {"window": "So yes, so there\u2019s going to be some choppiness along the way but we do anticipate that it\u2019s a \nrelatively steady march back towards pre -COVID levels by year end.  So that certainly means from a \nmath per spective that we would anticipate it being front end loaded more of an impact in the front \nhalf.  I also made a comment to my remarks about the cost side related to PPE being also more \nanticipated for the first half of the year.  So for those reasons we woul d expect to there be an \noverweighting in the first half versus second half.  \n \n  And as it relates to where we foresee those impacts, again most of the '21 impact relative to \n'20 is going to be in more medical.  And so as you highlight areas like nuclear, that \u2019s going to be, you \nknow, again a steady improvement.  We would anticipate over the course of the year that\u2019s tied to \nphysician office visits but more of that impact of '20 we'll see in medical and specifically in the \nproducts and distribution of that busin ess and related to both the costs as well as the underlying \nvolume related to both the physician office visits and the elective procedures.  \n \n", "original_text": "So for those reasons we woul d expect to there be an \noverweighting in the first half versus second half.  \n \n "}, "hash": "7893d1db29d362ff15f1714e06e777cb8afd5432469da58f4d1f5a9354d3ef1f", "class_name": "RelatedNodeInfo"}}, "text": "I also made a comment to my remarks about the cost side related to PPE being also more \nanticipated for the first half of the year. ", "start_char_idx": 1014, "end_char_idx": 1146, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "181662ac-a270-4592-96d0-848d3bd32013": {"__data__": {"id_": "181662ac-a270-4592-96d0-848d3bd32013", "embedding": null, "metadata": {"window": "So yes, so there\u2019s going to be some choppiness along the way but we do anticipate that it\u2019s a \nrelatively steady march back towards pre -COVID levels by year end.  So that certainly means from a \nmath per spective that we would anticipate it being front end loaded more of an impact in the front \nhalf.  I also made a comment to my remarks about the cost side related to PPE being also more \nanticipated for the first half of the year.  So for those reasons we woul d expect to there be an \noverweighting in the first half versus second half.  \n \n  And as it relates to where we foresee those impacts, again most of the '21 impact relative to \n'20 is going to be in more medical.  And so as you highlight areas like nuclear, that \u2019s going to be, you \nknow, again a steady improvement.  We would anticipate over the course of the year that\u2019s tied to \nphysician office visits but more of that impact of '20 we'll see in medical and specifically in the \nproducts and distribution of that busin ess and related to both the costs as well as the underlying \nvolume related to both the physician office visits and the elective procedures.  \n \n", "original_text": "So for those reasons we woul d expect to there be an \noverweighting in the first half versus second half.  \n \n ", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf26c2cb-b152-4f3c-a15e-c9296bf73bad", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65b7b304b76a27616e3a9ef00d523078afd4c0bcefec6ea14f7445ad786b9d6d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0579de0b-9138-49e3-ac58-3c28ae3625d5", "node_type": "1", "metadata": {"window": "And so you can see that that will try then from that high, mid to high single digits \nto essentially at pre -COVID levels by the end of the ye ar giving you that average at the high single \ndigits.  \n \n  So yes, so there\u2019s going to be some choppiness along the way but we do anticipate that it\u2019s a \nrelatively steady march back towards pre -COVID levels by year end.  So that certainly means from a \nmath per spective that we would anticipate it being front end loaded more of an impact in the front \nhalf.  I also made a comment to my remarks about the cost side related to PPE being also more \nanticipated for the first half of the year.  So for those reasons we woul d expect to there be an \noverweighting in the first half versus second half.  \n \n  And as it relates to where we foresee those impacts, again most of the '21 impact relative to \n'20 is going to be in more medical.  And so as you highlight areas like nuclear, that \u2019s going to be, you \nknow, again a steady improvement. ", "original_text": "I also made a comment to my remarks about the cost side related to PPE being also more \nanticipated for the first half of the year. ", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5294afd1c1a9e4744dbe3ae4a8ba4ee04b22c2422f56e2685ff31642a1da1a4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "677a0ba6-420e-4573-b34b-7ee01081aae0", "node_type": "1", "metadata": {"window": "So that certainly means from a \nmath per spective that we would anticipate it being front end loaded more of an impact in the front \nhalf.  I also made a comment to my remarks about the cost side related to PPE being also more \nanticipated for the first half of the year.  So for those reasons we woul d expect to there be an \noverweighting in the first half versus second half.  \n \n  And as it relates to where we foresee those impacts, again most of the '21 impact relative to \n'20 is going to be in more medical.  And so as you highlight areas like nuclear, that \u2019s going to be, you \nknow, again a steady improvement.  We would anticipate over the course of the year that\u2019s tied to \nphysician office visits but more of that impact of '20 we'll see in medical and specifically in the \nproducts and distribution of that busin ess and related to both the costs as well as the underlying \nvolume related to both the physician office visits and the elective procedures.  \n \n Robert Jones:  Okay thank you.  \n ", "original_text": "And as it relates to where we foresee those impacts, again most of the '21 impact relative to \n'20 is going to be in more medical. "}, "hash": "371aaddace83e965e668bf983ecf67bb6eca5ed1539acd69ff7ad2e5b34bd9df", "class_name": "RelatedNodeInfo"}}, "text": "So for those reasons we woul d expect to there be an \noverweighting in the first half versus second half.  \n \n ", "start_char_idx": 1146, "end_char_idx": 1257, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "677a0ba6-420e-4573-b34b-7ee01081aae0": {"__data__": {"id_": "677a0ba6-420e-4573-b34b-7ee01081aae0", "embedding": null, "metadata": {"window": "So that certainly means from a \nmath per spective that we would anticipate it being front end loaded more of an impact in the front \nhalf.  I also made a comment to my remarks about the cost side related to PPE being also more \nanticipated for the first half of the year.  So for those reasons we woul d expect to there be an \noverweighting in the first half versus second half.  \n \n  And as it relates to where we foresee those impacts, again most of the '21 impact relative to \n'20 is going to be in more medical.  And so as you highlight areas like nuclear, that \u2019s going to be, you \nknow, again a steady improvement.  We would anticipate over the course of the year that\u2019s tied to \nphysician office visits but more of that impact of '20 we'll see in medical and specifically in the \nproducts and distribution of that busin ess and related to both the costs as well as the underlying \nvolume related to both the physician office visits and the elective procedures.  \n \n Robert Jones:  Okay thank you.  \n ", "original_text": "And as it relates to where we foresee those impacts, again most of the '21 impact relative to \n'20 is going to be in more medical. ", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf26c2cb-b152-4f3c-a15e-c9296bf73bad", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65b7b304b76a27616e3a9ef00d523078afd4c0bcefec6ea14f7445ad786b9d6d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "181662ac-a270-4592-96d0-848d3bd32013", "node_type": "1", "metadata": {"window": "So yes, so there\u2019s going to be some choppiness along the way but we do anticipate that it\u2019s a \nrelatively steady march back towards pre -COVID levels by year end.  So that certainly means from a \nmath per spective that we would anticipate it being front end loaded more of an impact in the front \nhalf.  I also made a comment to my remarks about the cost side related to PPE being also more \nanticipated for the first half of the year.  So for those reasons we woul d expect to there be an \noverweighting in the first half versus second half.  \n \n  And as it relates to where we foresee those impacts, again most of the '21 impact relative to \n'20 is going to be in more medical.  And so as you highlight areas like nuclear, that \u2019s going to be, you \nknow, again a steady improvement.  We would anticipate over the course of the year that\u2019s tied to \nphysician office visits but more of that impact of '20 we'll see in medical and specifically in the \nproducts and distribution of that busin ess and related to both the costs as well as the underlying \nvolume related to both the physician office visits and the elective procedures.  \n \n", "original_text": "So for those reasons we woul d expect to there be an \noverweighting in the first half versus second half.  \n \n ", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ea5c9ae0cee5066d53fea58cca6a0dc60ca97c8476709370a9fa8b0aac928d6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16f03256-9f99-4d19-acce-6ecb6ad6298c", "node_type": "1", "metadata": {"window": "I also made a comment to my remarks about the cost side related to PPE being also more \nanticipated for the first half of the year.  So for those reasons we woul d expect to there be an \noverweighting in the first half versus second half.  \n \n  And as it relates to where we foresee those impacts, again most of the '21 impact relative to \n'20 is going to be in more medical.  And so as you highlight areas like nuclear, that \u2019s going to be, you \nknow, again a steady improvement.  We would anticipate over the course of the year that\u2019s tied to \nphysician office visits but more of that impact of '20 we'll see in medical and specifically in the \nproducts and distribution of that busin ess and related to both the costs as well as the underlying \nvolume related to both the physician office visits and the elective procedures.  \n \n Robert Jones:  Okay thank you.  \n ", "original_text": "And so as you highlight areas like nuclear, that \u2019s going to be, you \nknow, again a steady improvement. "}, "hash": "2051f090d64b0f64cf9fd6eb24601b58c5bbe14409857e95b5241537e088b411", "class_name": "RelatedNodeInfo"}}, "text": "And as it relates to where we foresee those impacts, again most of the '21 impact relative to \n'20 is going to be in more medical. ", "start_char_idx": 1257, "end_char_idx": 1388, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16f03256-9f99-4d19-acce-6ecb6ad6298c": {"__data__": {"id_": "16f03256-9f99-4d19-acce-6ecb6ad6298c", "embedding": null, "metadata": {"window": "I also made a comment to my remarks about the cost side related to PPE being also more \nanticipated for the first half of the year.  So for those reasons we woul d expect to there be an \noverweighting in the first half versus second half.  \n \n  And as it relates to where we foresee those impacts, again most of the '21 impact relative to \n'20 is going to be in more medical.  And so as you highlight areas like nuclear, that \u2019s going to be, you \nknow, again a steady improvement.  We would anticipate over the course of the year that\u2019s tied to \nphysician office visits but more of that impact of '20 we'll see in medical and specifically in the \nproducts and distribution of that busin ess and related to both the costs as well as the underlying \nvolume related to both the physician office visits and the elective procedures.  \n \n Robert Jones:  Okay thank you.  \n ", "original_text": "And so as you highlight areas like nuclear, that \u2019s going to be, you \nknow, again a steady improvement. ", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf26c2cb-b152-4f3c-a15e-c9296bf73bad", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65b7b304b76a27616e3a9ef00d523078afd4c0bcefec6ea14f7445ad786b9d6d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "677a0ba6-420e-4573-b34b-7ee01081aae0", "node_type": "1", "metadata": {"window": "So that certainly means from a \nmath per spective that we would anticipate it being front end loaded more of an impact in the front \nhalf.  I also made a comment to my remarks about the cost side related to PPE being also more \nanticipated for the first half of the year.  So for those reasons we woul d expect to there be an \noverweighting in the first half versus second half.  \n \n  And as it relates to where we foresee those impacts, again most of the '21 impact relative to \n'20 is going to be in more medical.  And so as you highlight areas like nuclear, that \u2019s going to be, you \nknow, again a steady improvement.  We would anticipate over the course of the year that\u2019s tied to \nphysician office visits but more of that impact of '20 we'll see in medical and specifically in the \nproducts and distribution of that busin ess and related to both the costs as well as the underlying \nvolume related to both the physician office visits and the elective procedures.  \n \n Robert Jones:  Okay thank you.  \n ", "original_text": "And as it relates to where we foresee those impacts, again most of the '21 impact relative to \n'20 is going to be in more medical. ", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc4355430a415a84aeb552461b88a2619429e974cc010d2f8fb00e7da7d4adc9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fddc61da-f54a-4317-ab00-bba6c9d5c796", "node_type": "1", "metadata": {"window": "So for those reasons we woul d expect to there be an \noverweighting in the first half versus second half.  \n \n  And as it relates to where we foresee those impacts, again most of the '21 impact relative to \n'20 is going to be in more medical.  And so as you highlight areas like nuclear, that \u2019s going to be, you \nknow, again a steady improvement.  We would anticipate over the course of the year that\u2019s tied to \nphysician office visits but more of that impact of '20 we'll see in medical and specifically in the \nproducts and distribution of that busin ess and related to both the costs as well as the underlying \nvolume related to both the physician office visits and the elective procedures.  \n \n Robert Jones:  Okay thank you.  \n ", "original_text": "We would anticipate over the course of the year that\u2019s tied to \nphysician office visits but more of that impact of '20 we'll see in medical and specifically in the \nproducts and distribution of that busin ess and related to both the costs as well as the underlying \nvolume related to both the physician office visits and the elective procedures.  \n \n"}, "hash": "a53faddcca180f7348f598cd888717a649f59fa20ff1861d931358f9a41e5ad1", "class_name": "RelatedNodeInfo"}}, "text": "And so as you highlight areas like nuclear, that \u2019s going to be, you \nknow, again a steady improvement. ", "start_char_idx": 1388, "end_char_idx": 1492, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fddc61da-f54a-4317-ab00-bba6c9d5c796": {"__data__": {"id_": "fddc61da-f54a-4317-ab00-bba6c9d5c796", "embedding": null, "metadata": {"window": "So for those reasons we woul d expect to there be an \noverweighting in the first half versus second half.  \n \n  And as it relates to where we foresee those impacts, again most of the '21 impact relative to \n'20 is going to be in more medical.  And so as you highlight areas like nuclear, that \u2019s going to be, you \nknow, again a steady improvement.  We would anticipate over the course of the year that\u2019s tied to \nphysician office visits but more of that impact of '20 we'll see in medical and specifically in the \nproducts and distribution of that busin ess and related to both the costs as well as the underlying \nvolume related to both the physician office visits and the elective procedures.  \n \n Robert Jones:  Okay thank you.  \n ", "original_text": "We would anticipate over the course of the year that\u2019s tied to \nphysician office visits but more of that impact of '20 we'll see in medical and specifically in the \nproducts and distribution of that busin ess and related to both the costs as well as the underlying \nvolume related to both the physician office visits and the elective procedures.  \n \n", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf26c2cb-b152-4f3c-a15e-c9296bf73bad", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65b7b304b76a27616e3a9ef00d523078afd4c0bcefec6ea14f7445ad786b9d6d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16f03256-9f99-4d19-acce-6ecb6ad6298c", "node_type": "1", "metadata": {"window": "I also made a comment to my remarks about the cost side related to PPE being also more \nanticipated for the first half of the year.  So for those reasons we woul d expect to there be an \noverweighting in the first half versus second half.  \n \n  And as it relates to where we foresee those impacts, again most of the '21 impact relative to \n'20 is going to be in more medical.  And so as you highlight areas like nuclear, that \u2019s going to be, you \nknow, again a steady improvement.  We would anticipate over the course of the year that\u2019s tied to \nphysician office visits but more of that impact of '20 we'll see in medical and specifically in the \nproducts and distribution of that busin ess and related to both the costs as well as the underlying \nvolume related to both the physician office visits and the elective procedures.  \n \n Robert Jones:  Okay thank you.  \n ", "original_text": "And so as you highlight areas like nuclear, that \u2019s going to be, you \nknow, again a steady improvement. ", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91cac2bb79b9ad185a1e0f6731d455040f2b5c005cd7b9c2fd7be64a818184c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87adc9b4-47f6-4962-929f-16a24d882479", "node_type": "1", "metadata": {"window": "And as it relates to where we foresee those impacts, again most of the '21 impact relative to \n'20 is going to be in more medical.  And so as you highlight areas like nuclear, that \u2019s going to be, you \nknow, again a steady improvement.  We would anticipate over the course of the year that\u2019s tied to \nphysician office visits but more of that impact of '20 we'll see in medical and specifically in the \nproducts and distribution of that busin ess and related to both the costs as well as the underlying \nvolume related to both the physician office visits and the elective procedures.  \n \n Robert Jones:  Okay thank you.  \n ", "original_text": "Robert Jones:  Okay thank you.  \n "}, "hash": "ff43a03906e191a731dfe7b793a87fe27c6b47b449ada2bbe1fdaf5b1e94b987", "class_name": "RelatedNodeInfo"}}, "text": "We would anticipate over the course of the year that\u2019s tied to \nphysician office visits but more of that impact of '20 we'll see in medical and specifically in the \nproducts and distribution of that busin ess and related to both the costs as well as the underlying \nvolume related to both the physician office visits and the elective procedures.  \n \n", "start_char_idx": 1492, "end_char_idx": 1842, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87adc9b4-47f6-4962-929f-16a24d882479": {"__data__": {"id_": "87adc9b4-47f6-4962-929f-16a24d882479", "embedding": null, "metadata": {"window": "And as it relates to where we foresee those impacts, again most of the '21 impact relative to \n'20 is going to be in more medical.  And so as you highlight areas like nuclear, that \u2019s going to be, you \nknow, again a steady improvement.  We would anticipate over the course of the year that\u2019s tied to \nphysician office visits but more of that impact of '20 we'll see in medical and specifically in the \nproducts and distribution of that busin ess and related to both the costs as well as the underlying \nvolume related to both the physician office visits and the elective procedures.  \n \n Robert Jones:  Okay thank you.  \n ", "original_text": "Robert Jones:  Okay thank you.  \n ", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf26c2cb-b152-4f3c-a15e-c9296bf73bad", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65b7b304b76a27616e3a9ef00d523078afd4c0bcefec6ea14f7445ad786b9d6d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fddc61da-f54a-4317-ab00-bba6c9d5c796", "node_type": "1", "metadata": {"window": "So for those reasons we woul d expect to there be an \noverweighting in the first half versus second half.  \n \n  And as it relates to where we foresee those impacts, again most of the '21 impact relative to \n'20 is going to be in more medical.  And so as you highlight areas like nuclear, that \u2019s going to be, you \nknow, again a steady improvement.  We would anticipate over the course of the year that\u2019s tied to \nphysician office visits but more of that impact of '20 we'll see in medical and specifically in the \nproducts and distribution of that busin ess and related to both the costs as well as the underlying \nvolume related to both the physician office visits and the elective procedures.  \n \n Robert Jones:  Okay thank you.  \n ", "original_text": "We would anticipate over the course of the year that\u2019s tied to \nphysician office visits but more of that impact of '20 we'll see in medical and specifically in the \nproducts and distribution of that busin ess and related to both the costs as well as the underlying \nvolume related to both the physician office visits and the elective procedures.  \n \n", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1f077cfc1354ae56a923f0acb0339941f80612614ecef915675f7ed4fcc7738", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "259777eb-a771-4cf7-ab66-2593b6b42af2", "node_type": "1", "metadata": {"window": " \nPage 25 of 31 \n \nOperator:  Thank you.  And we'll next go to George Hill with Deutsche Bank.  Please g o ahead.  \n \n George Hill:  Hey good morning guys and thanks for taking the question. ", "original_text": " \nPage 25 of 31 \n \nOperator:  Thank you. "}, "hash": "27fdc9c2328fe8f3fbbaf05e3c2df05e5775f345756aef45422e66a5e3cc137f", "class_name": "RelatedNodeInfo"}}, "text": "Robert Jones:  Okay thank you.  \n ", "start_char_idx": 1842, "end_char_idx": 1876, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "259777eb-a771-4cf7-ab66-2593b6b42af2": {"__data__": {"id_": "259777eb-a771-4cf7-ab66-2593b6b42af2", "embedding": null, "metadata": {"window": " \nPage 25 of 31 \n \nOperator:  Thank you.  And we'll next go to George Hill with Deutsche Bank.  Please g o ahead.  \n \n George Hill:  Hey good morning guys and thanks for taking the question. ", "original_text": " \nPage 25 of 31 \n \nOperator:  Thank you. ", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d575b634c571396f1b55ba24ef79053dd3baee6bda6ca4e03ee2c4fea5d8dbc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87adc9b4-47f6-4962-929f-16a24d882479", "node_type": "1", "metadata": {"window": "And as it relates to where we foresee those impacts, again most of the '21 impact relative to \n'20 is going to be in more medical.  And so as you highlight areas like nuclear, that \u2019s going to be, you \nknow, again a steady improvement.  We would anticipate over the course of the year that\u2019s tied to \nphysician office visits but more of that impact of '20 we'll see in medical and specifically in the \nproducts and distribution of that busin ess and related to both the costs as well as the underlying \nvolume related to both the physician office visits and the elective procedures.  \n \n Robert Jones:  Okay thank you.  \n ", "original_text": "Robert Jones:  Okay thank you.  \n ", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8509e51f16b4246c714cd31f35eece6fb64468aaf456d3000a9f20c3f0e05be5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22d75d1a-4af8-4afc-be3a-72dc20cf8abc", "node_type": "1", "metadata": {"window": " \nPage 25 of 31 \n \nOperator:  Thank you.  And we'll next go to George Hill with Deutsche Bank.  Please g o ahead.  \n \n George Hill:  Hey good morning guys and thanks for taking the question.  Mike I was wondering if \nyou\u2019d provide a little color on your conversations with your upstream and downstream partners \naround utilization just because if you listen to some of  the talks from the MCOs they're generally \nexpecting utilization to increase in the back half of this calendar year where it sounds like you\u2019re still \ncalling for a significant decrease. ", "original_text": "And we'll next go to George Hill with Deutsche Bank. "}, "hash": "fc5a770e135fb2078480d96c6b9103f1c67cd360fca9398e7d1f8b83048d83fe", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 25 of 31 \n \nOperator:  Thank you. ", "start_char_idx": 0, "end_char_idx": 41, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22d75d1a-4af8-4afc-be3a-72dc20cf8abc": {"__data__": {"id_": "22d75d1a-4af8-4afc-be3a-72dc20cf8abc", "embedding": null, "metadata": {"window": " \nPage 25 of 31 \n \nOperator:  Thank you.  And we'll next go to George Hill with Deutsche Bank.  Please g o ahead.  \n \n George Hill:  Hey good morning guys and thanks for taking the question.  Mike I was wondering if \nyou\u2019d provide a little color on your conversations with your upstream and downstream partners \naround utilization just because if you listen to some of  the talks from the MCOs they're generally \nexpecting utilization to increase in the back half of this calendar year where it sounds like you\u2019re still \ncalling for a significant decrease. ", "original_text": "And we'll next go to George Hill with Deutsche Bank. ", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d575b634c571396f1b55ba24ef79053dd3baee6bda6ca4e03ee2c4fea5d8dbc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "259777eb-a771-4cf7-ab66-2593b6b42af2", "node_type": "1", "metadata": {"window": " \nPage 25 of 31 \n \nOperator:  Thank you.  And we'll next go to George Hill with Deutsche Bank.  Please g o ahead.  \n \n George Hill:  Hey good morning guys and thanks for taking the question. ", "original_text": " \nPage 25 of 31 \n \nOperator:  Thank you. ", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "37853e5dc438aa97eb2e433a04f58b3d65ac87d70803bca3dc807f22b1cc6e46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76b4577a-f25d-4f82-a832-2e0e010f8ec6", "node_type": "1", "metadata": {"window": " \nPage 25 of 31 \n \nOperator:  Thank you.  And we'll next go to George Hill with Deutsche Bank.  Please g o ahead.  \n \n George Hill:  Hey good morning guys and thanks for taking the question.  Mike I was wondering if \nyou\u2019d provide a little color on your conversations with your upstream and downstream partners \naround utilization just because if you listen to some of  the talks from the MCOs they're generally \nexpecting utilization to increase in the back half of this calendar year where it sounds like you\u2019re still \ncalling for a significant decrease.  We'd just love any extra color on the conversations you\u2019ve had to \nhelp us bridge the gap. ", "original_text": "Please g o ahead.  \n \n"}, "hash": "17efa5b5569c2b81251fb2e45c3a3008104a217746fae6ebfc2235cf2bec1eef", "class_name": "RelatedNodeInfo"}}, "text": "And we'll next go to George Hill with Deutsche Bank. ", "start_char_idx": 41, "end_char_idx": 94, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76b4577a-f25d-4f82-a832-2e0e010f8ec6": {"__data__": {"id_": "76b4577a-f25d-4f82-a832-2e0e010f8ec6", "embedding": null, "metadata": {"window": " \nPage 25 of 31 \n \nOperator:  Thank you.  And we'll next go to George Hill with Deutsche Bank.  Please g o ahead.  \n \n George Hill:  Hey good morning guys and thanks for taking the question.  Mike I was wondering if \nyou\u2019d provide a little color on your conversations with your upstream and downstream partners \naround utilization just because if you listen to some of  the talks from the MCOs they're generally \nexpecting utilization to increase in the back half of this calendar year where it sounds like you\u2019re still \ncalling for a significant decrease.  We'd just love any extra color on the conversations you\u2019ve had to \nhelp us bridge the gap. ", "original_text": "Please g o ahead.  \n \n", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d575b634c571396f1b55ba24ef79053dd3baee6bda6ca4e03ee2c4fea5d8dbc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22d75d1a-4af8-4afc-be3a-72dc20cf8abc", "node_type": "1", "metadata": {"window": " \nPage 25 of 31 \n \nOperator:  Thank you.  And we'll next go to George Hill with Deutsche Bank.  Please g o ahead.  \n \n George Hill:  Hey good morning guys and thanks for taking the question.  Mike I was wondering if \nyou\u2019d provide a little color on your conversations with your upstream and downstream partners \naround utilization just because if you listen to some of  the talks from the MCOs they're generally \nexpecting utilization to increase in the back half of this calendar year where it sounds like you\u2019re still \ncalling for a significant decrease. ", "original_text": "And we'll next go to George Hill with Deutsche Bank. ", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2461c1411aebf34c6d4cfec726fbad7c55d705fa1aea71a1a2ce7b0f70b5c8e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2e580bf-a1b5-4f44-ac0d-a70ea4782367", "node_type": "1", "metadata": {"window": " \nPage 25 of 31 \n \nOperator:  Thank you.  And we'll next go to George Hill with Deutsche Bank.  Please g o ahead.  \n \n George Hill:  Hey good morning guys and thanks for taking the question.  Mike I was wondering if \nyou\u2019d provide a little color on your conversations with your upstream and downstream partners \naround utilization just because if you listen to some of  the talks from the MCOs they're generally \nexpecting utilization to increase in the back half of this calendar year where it sounds like you\u2019re still \ncalling for a significant decrease.  We'd just love any extra color on the conversations you\u2019ve had to \nhelp us bridge the gap.  Thank you.  \n \n", "original_text": "George Hill:  Hey good morning guys and thanks for taking the question. "}, "hash": "e8577f199c5f83ca71fea3c5cf67b208a107cd02c17376219f610236f1798dda", "class_name": "RelatedNodeInfo"}}, "text": "Please g o ahead.  \n \n", "start_char_idx": 94, "end_char_idx": 116, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2e580bf-a1b5-4f44-ac0d-a70ea4782367": {"__data__": {"id_": "d2e580bf-a1b5-4f44-ac0d-a70ea4782367", "embedding": null, "metadata": {"window": " \nPage 25 of 31 \n \nOperator:  Thank you.  And we'll next go to George Hill with Deutsche Bank.  Please g o ahead.  \n \n George Hill:  Hey good morning guys and thanks for taking the question.  Mike I was wondering if \nyou\u2019d provide a little color on your conversations with your upstream and downstream partners \naround utilization just because if you listen to some of  the talks from the MCOs they're generally \nexpecting utilization to increase in the back half of this calendar year where it sounds like you\u2019re still \ncalling for a significant decrease.  We'd just love any extra color on the conversations you\u2019ve had to \nhelp us bridge the gap.  Thank you.  \n \n", "original_text": "George Hill:  Hey good morning guys and thanks for taking the question. ", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d575b634c571396f1b55ba24ef79053dd3baee6bda6ca4e03ee2c4fea5d8dbc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76b4577a-f25d-4f82-a832-2e0e010f8ec6", "node_type": "1", "metadata": {"window": " \nPage 25 of 31 \n \nOperator:  Thank you.  And we'll next go to George Hill with Deutsche Bank.  Please g o ahead.  \n \n George Hill:  Hey good morning guys and thanks for taking the question.  Mike I was wondering if \nyou\u2019d provide a little color on your conversations with your upstream and downstream partners \naround utilization just because if you listen to some of  the talks from the MCOs they're generally \nexpecting utilization to increase in the back half of this calendar year where it sounds like you\u2019re still \ncalling for a significant decrease.  We'd just love any extra color on the conversations you\u2019ve had to \nhelp us bridge the gap. ", "original_text": "Please g o ahead.  \n \n", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb605b4038081bf9a4cc16ea81d89367ff5b02865257c05962ffdde36d312ad2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30bdea05-494b-475d-adee-1eacfeeb8065", "node_type": "1", "metadata": {"window": "And we'll next go to George Hill with Deutsche Bank.  Please g o ahead.  \n \n George Hill:  Hey good morning guys and thanks for taking the question.  Mike I was wondering if \nyou\u2019d provide a little color on your conversations with your upstream and downstream partners \naround utilization just because if you listen to some of  the talks from the MCOs they're generally \nexpecting utilization to increase in the back half of this calendar year where it sounds like you\u2019re still \ncalling for a significant decrease.  We'd just love any extra color on the conversations you\u2019ve had to \nhelp us bridge the gap.  Thank you.  \n \n Mike Kaufmann:  Yes, you know, we\u2019ve been talking to outside consultants, been talking to our \ncustomers, you know, senior execs there as you can imagine to a lot of folks to try to put together our \nthought process. ", "original_text": "Mike I was wondering if \nyou\u2019d provide a little color on your conversations with your upstream and downstream partners \naround utilization just because if you listen to some of  the talks from the MCOs they're generally \nexpecting utilization to increase in the back half of this calendar year where it sounds like you\u2019re still \ncalling for a significant decrease. "}, "hash": "c279c8ca80beadb8edf7a7e3872ce1a071d7a15c2c3ee3a1ab3dbce88b2518c9", "class_name": "RelatedNodeInfo"}}, "text": "George Hill:  Hey good morning guys and thanks for taking the question. ", "start_char_idx": 116, "end_char_idx": 188, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30bdea05-494b-475d-adee-1eacfeeb8065": {"__data__": {"id_": "30bdea05-494b-475d-adee-1eacfeeb8065", "embedding": null, "metadata": {"window": "And we'll next go to George Hill with Deutsche Bank.  Please g o ahead.  \n \n George Hill:  Hey good morning guys and thanks for taking the question.  Mike I was wondering if \nyou\u2019d provide a little color on your conversations with your upstream and downstream partners \naround utilization just because if you listen to some of  the talks from the MCOs they're generally \nexpecting utilization to increase in the back half of this calendar year where it sounds like you\u2019re still \ncalling for a significant decrease.  We'd just love any extra color on the conversations you\u2019ve had to \nhelp us bridge the gap.  Thank you.  \n \n Mike Kaufmann:  Yes, you know, we\u2019ve been talking to outside consultants, been talking to our \ncustomers, you know, senior execs there as you can imagine to a lot of folks to try to put together our \nthought process. ", "original_text": "Mike I was wondering if \nyou\u2019d provide a little color on your conversations with your upstream and downstream partners \naround utilization just because if you listen to some of  the talks from the MCOs they're generally \nexpecting utilization to increase in the back half of this calendar year where it sounds like you\u2019re still \ncalling for a significant decrease. ", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d575b634c571396f1b55ba24ef79053dd3baee6bda6ca4e03ee2c4fea5d8dbc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2e580bf-a1b5-4f44-ac0d-a70ea4782367", "node_type": "1", "metadata": {"window": " \nPage 25 of 31 \n \nOperator:  Thank you.  And we'll next go to George Hill with Deutsche Bank.  Please g o ahead.  \n \n George Hill:  Hey good morning guys and thanks for taking the question.  Mike I was wondering if \nyou\u2019d provide a little color on your conversations with your upstream and downstream partners \naround utilization just because if you listen to some of  the talks from the MCOs they're generally \nexpecting utilization to increase in the back half of this calendar year where it sounds like you\u2019re still \ncalling for a significant decrease.  We'd just love any extra color on the conversations you\u2019ve had to \nhelp us bridge the gap.  Thank you.  \n \n", "original_text": "George Hill:  Hey good morning guys and thanks for taking the question. ", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d29cbcc29e6cc22459e539383a7a2e067937b12912c24718ffc2372b338a7c27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0722405a-aa5e-4bab-bc08-5867bed364de", "node_type": "1", "metadata": {"window": "Please g o ahead.  \n \n George Hill:  Hey good morning guys and thanks for taking the question.  Mike I was wondering if \nyou\u2019d provide a little color on your conversations with your upstream and downstream partners \naround utilization just because if you listen to some of  the talks from the MCOs they're generally \nexpecting utilization to increase in the back half of this calendar year where it sounds like you\u2019re still \ncalling for a significant decrease.  We'd just love any extra color on the conversations you\u2019ve had to \nhelp us bridge the gap.  Thank you.  \n \n Mike Kaufmann:  Yes, you know, we\u2019ve been talking to outside consultants, been talking to our \ncustomers, you know, senior execs there as you can imagine to a lot of folks to try to put together our \nthought process.  So I beli eve it\u2019s well really well -informed but, you know, it\u2019s hard for anyone to know \nfor sure. ", "original_text": "We'd just love any extra color on the conversations you\u2019ve had to \nhelp us bridge the gap. "}, "hash": "63dcfb673526b7007c5989a6dcb80b97dfdc996d2c58ae63273d9e608796e190", "class_name": "RelatedNodeInfo"}}, "text": "Mike I was wondering if \nyou\u2019d provide a little color on your conversations with your upstream and downstream partners \naround utilization just because if you listen to some of  the talks from the MCOs they're generally \nexpecting utilization to increase in the back half of this calendar year where it sounds like you\u2019re still \ncalling for a significant decrease. ", "start_char_idx": 188, "end_char_idx": 553, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0722405a-aa5e-4bab-bc08-5867bed364de": {"__data__": {"id_": "0722405a-aa5e-4bab-bc08-5867bed364de", "embedding": null, "metadata": {"window": "Please g o ahead.  \n \n George Hill:  Hey good morning guys and thanks for taking the question.  Mike I was wondering if \nyou\u2019d provide a little color on your conversations with your upstream and downstream partners \naround utilization just because if you listen to some of  the talks from the MCOs they're generally \nexpecting utilization to increase in the back half of this calendar year where it sounds like you\u2019re still \ncalling for a significant decrease.  We'd just love any extra color on the conversations you\u2019ve had to \nhelp us bridge the gap.  Thank you.  \n \n Mike Kaufmann:  Yes, you know, we\u2019ve been talking to outside consultants, been talking to our \ncustomers, you know, senior execs there as you can imagine to a lot of folks to try to put together our \nthought process.  So I beli eve it\u2019s well really well -informed but, you know, it\u2019s hard for anyone to know \nfor sure. ", "original_text": "We'd just love any extra color on the conversations you\u2019ve had to \nhelp us bridge the gap. ", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d575b634c571396f1b55ba24ef79053dd3baee6bda6ca4e03ee2c4fea5d8dbc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30bdea05-494b-475d-adee-1eacfeeb8065", "node_type": "1", "metadata": {"window": "And we'll next go to George Hill with Deutsche Bank.  Please g o ahead.  \n \n George Hill:  Hey good morning guys and thanks for taking the question.  Mike I was wondering if \nyou\u2019d provide a little color on your conversations with your upstream and downstream partners \naround utilization just because if you listen to some of  the talks from the MCOs they're generally \nexpecting utilization to increase in the back half of this calendar year where it sounds like you\u2019re still \ncalling for a significant decrease.  We'd just love any extra color on the conversations you\u2019ve had to \nhelp us bridge the gap.  Thank you.  \n \n Mike Kaufmann:  Yes, you know, we\u2019ve been talking to outside consultants, been talking to our \ncustomers, you know, senior execs there as you can imagine to a lot of folks to try to put together our \nthought process. ", "original_text": "Mike I was wondering if \nyou\u2019d provide a little color on your conversations with your upstream and downstream partners \naround utilization just because if you listen to some of  the talks from the MCOs they're generally \nexpecting utilization to increase in the back half of this calendar year where it sounds like you\u2019re still \ncalling for a significant decrease. ", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "20efa70a9c89daf8273782daad799e0f2f4d3feff25148bf7a7c462cef458a25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04e4b335-ecc3-4441-99ba-47b8d8d44ce5", "node_type": "1", "metadata": {"window": "George Hill:  Hey good morning guys and thanks for taking the question.  Mike I was wondering if \nyou\u2019d provide a little color on your conversations with your upstream and downstream partners \naround utilization just because if you listen to some of  the talks from the MCOs they're generally \nexpecting utilization to increase in the back half of this calendar year where it sounds like you\u2019re still \ncalling for a significant decrease.  We'd just love any extra color on the conversations you\u2019ve had to \nhelp us bridge the gap.  Thank you.  \n \n Mike Kaufmann:  Yes, you know, we\u2019ve been talking to outside consultants, been talking to our \ncustomers, you know, senior execs there as you can imagine to a lot of folks to try to put together our \nthought process.  So I beli eve it\u2019s well really well -informed but, you know, it\u2019s hard for anyone to know \nfor sure.  But our take is that we won\u2019t see any of our businesses med or pharma back to pre -COVID \nlevels until we're exiting our fiscal '21 so, you know, in that, May, June time  frame of next year. ", "original_text": "Thank you.  \n \n"}, "hash": "78d08a0905f3415515a5ab429466eb0104c4671fdc9f65d188cac194102a6f47", "class_name": "RelatedNodeInfo"}}, "text": "We'd just love any extra color on the conversations you\u2019ve had to \nhelp us bridge the gap. ", "start_char_idx": 553, "end_char_idx": 644, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04e4b335-ecc3-4441-99ba-47b8d8d44ce5": {"__data__": {"id_": "04e4b335-ecc3-4441-99ba-47b8d8d44ce5", "embedding": null, "metadata": {"window": "George Hill:  Hey good morning guys and thanks for taking the question.  Mike I was wondering if \nyou\u2019d provide a little color on your conversations with your upstream and downstream partners \naround utilization just because if you listen to some of  the talks from the MCOs they're generally \nexpecting utilization to increase in the back half of this calendar year where it sounds like you\u2019re still \ncalling for a significant decrease.  We'd just love any extra color on the conversations you\u2019ve had to \nhelp us bridge the gap.  Thank you.  \n \n Mike Kaufmann:  Yes, you know, we\u2019ve been talking to outside consultants, been talking to our \ncustomers, you know, senior execs there as you can imagine to a lot of folks to try to put together our \nthought process.  So I beli eve it\u2019s well really well -informed but, you know, it\u2019s hard for anyone to know \nfor sure.  But our take is that we won\u2019t see any of our businesses med or pharma back to pre -COVID \nlevels until we're exiting our fiscal '21 so, you know, in that, May, June time  frame of next year. ", "original_text": "Thank you.  \n \n", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d575b634c571396f1b55ba24ef79053dd3baee6bda6ca4e03ee2c4fea5d8dbc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0722405a-aa5e-4bab-bc08-5867bed364de", "node_type": "1", "metadata": {"window": "Please g o ahead.  \n \n George Hill:  Hey good morning guys and thanks for taking the question.  Mike I was wondering if \nyou\u2019d provide a little color on your conversations with your upstream and downstream partners \naround utilization just because if you listen to some of  the talks from the MCOs they're generally \nexpecting utilization to increase in the back half of this calendar year where it sounds like you\u2019re still \ncalling for a significant decrease.  We'd just love any extra color on the conversations you\u2019ve had to \nhelp us bridge the gap.  Thank you.  \n \n Mike Kaufmann:  Yes, you know, we\u2019ve been talking to outside consultants, been talking to our \ncustomers, you know, senior execs there as you can imagine to a lot of folks to try to put together our \nthought process.  So I beli eve it\u2019s well really well -informed but, you know, it\u2019s hard for anyone to know \nfor sure. ", "original_text": "We'd just love any extra color on the conversations you\u2019ve had to \nhelp us bridge the gap. ", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd8ae5130a6e99c54cc63f4d567001ade31b72c7df4a68c14b9394c92c6db94f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2fe3836-f5f6-4eff-9320-accf7c5a5efb", "node_type": "1", "metadata": {"window": "Mike I was wondering if \nyou\u2019d provide a little color on your conversations with your upstream and downstream partners \naround utilization just because if you listen to some of  the talks from the MCOs they're generally \nexpecting utilization to increase in the back half of this calendar year where it sounds like you\u2019re still \ncalling for a significant decrease.  We'd just love any extra color on the conversations you\u2019ve had to \nhelp us bridge the gap.  Thank you.  \n \n Mike Kaufmann:  Yes, you know, we\u2019ve been talking to outside consultants, been talking to our \ncustomers, you know, senior execs there as you can imagine to a lot of folks to try to put together our \nthought process.  So I beli eve it\u2019s well really well -informed but, you know, it\u2019s hard for anyone to know \nfor sure.  But our take is that we won\u2019t see any of our businesses med or pharma back to pre -COVID \nlevels until we're exiting our fiscal '21 so, you know, in that, May, June time  frame of next year.  And \nagain as we said start out on electives in mid to high teens working its way up. ", "original_text": "Mike Kaufmann:  Yes, you know, we\u2019ve been talking to outside consultants, been talking to our \ncustomers, you know, senior execs there as you can imagine to a lot of folks to try to put together our \nthought process. "}, "hash": "b3cc2d3aab2406cdf6c488586e1022b07bd959d8e8e4941521fb884d2e4e36f2", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n \n", "start_char_idx": 644, "end_char_idx": 659, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2fe3836-f5f6-4eff-9320-accf7c5a5efb": {"__data__": {"id_": "a2fe3836-f5f6-4eff-9320-accf7c5a5efb", "embedding": null, "metadata": {"window": "Mike I was wondering if \nyou\u2019d provide a little color on your conversations with your upstream and downstream partners \naround utilization just because if you listen to some of  the talks from the MCOs they're generally \nexpecting utilization to increase in the back half of this calendar year where it sounds like you\u2019re still \ncalling for a significant decrease.  We'd just love any extra color on the conversations you\u2019ve had to \nhelp us bridge the gap.  Thank you.  \n \n Mike Kaufmann:  Yes, you know, we\u2019ve been talking to outside consultants, been talking to our \ncustomers, you know, senior execs there as you can imagine to a lot of folks to try to put together our \nthought process.  So I beli eve it\u2019s well really well -informed but, you know, it\u2019s hard for anyone to know \nfor sure.  But our take is that we won\u2019t see any of our businesses med or pharma back to pre -COVID \nlevels until we're exiting our fiscal '21 so, you know, in that, May, June time  frame of next year.  And \nagain as we said start out on electives in mid to high teens working its way up. ", "original_text": "Mike Kaufmann:  Yes, you know, we\u2019ve been talking to outside consultants, been talking to our \ncustomers, you know, senior execs there as you can imagine to a lot of folks to try to put together our \nthought process. ", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d575b634c571396f1b55ba24ef79053dd3baee6bda6ca4e03ee2c4fea5d8dbc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04e4b335-ecc3-4441-99ba-47b8d8d44ce5", "node_type": "1", "metadata": {"window": "George Hill:  Hey good morning guys and thanks for taking the question.  Mike I was wondering if \nyou\u2019d provide a little color on your conversations with your upstream and downstream partners \naround utilization just because if you listen to some of  the talks from the MCOs they're generally \nexpecting utilization to increase in the back half of this calendar year where it sounds like you\u2019re still \ncalling for a significant decrease.  We'd just love any extra color on the conversations you\u2019ve had to \nhelp us bridge the gap.  Thank you.  \n \n Mike Kaufmann:  Yes, you know, we\u2019ve been talking to outside consultants, been talking to our \ncustomers, you know, senior execs there as you can imagine to a lot of folks to try to put together our \nthought process.  So I beli eve it\u2019s well really well -informed but, you know, it\u2019s hard for anyone to know \nfor sure.  But our take is that we won\u2019t see any of our businesses med or pharma back to pre -COVID \nlevels until we're exiting our fiscal '21 so, you know, in that, May, June time  frame of next year. ", "original_text": "Thank you.  \n \n", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f878d84d35c4b7d00aa30fb8e8bb125c4590b3fa66e8c0f592cad0a831860f52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40aa2f2a-0191-443f-ad4b-270b723f70bc", "node_type": "1", "metadata": {"window": "We'd just love any extra color on the conversations you\u2019ve had to \nhelp us bridge the gap.  Thank you.  \n \n Mike Kaufmann:  Yes, you know, we\u2019ve been talking to outside consultants, been talking to our \ncustomers, you know, senior execs there as you can imagine to a lot of folks to try to put together our \nthought process.  So I beli eve it\u2019s well really well -informed but, you know, it\u2019s hard for anyone to know \nfor sure.  But our take is that we won\u2019t see any of our businesses med or pharma back to pre -COVID \nlevels until we're exiting our fiscal '21 so, you know, in that, May, June time  frame of next year.  And \nagain as we said start out on electives in mid to high teens working its way up.  And then on physician \noffice visits in more the mid -single digits down and working its way up.  \n \n ", "original_text": "So I beli eve it\u2019s well really well -informed but, you know, it\u2019s hard for anyone to know \nfor sure. "}, "hash": "7e8dea853691e42d08750e7ec30530e6decbc03b909e4cd42ce700e22fc68d5c", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes, you know, we\u2019ve been talking to outside consultants, been talking to our \ncustomers, you know, senior execs there as you can imagine to a lot of folks to try to put together our \nthought process. ", "start_char_idx": 659, "end_char_idx": 876, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40aa2f2a-0191-443f-ad4b-270b723f70bc": {"__data__": {"id_": "40aa2f2a-0191-443f-ad4b-270b723f70bc", "embedding": null, "metadata": {"window": "We'd just love any extra color on the conversations you\u2019ve had to \nhelp us bridge the gap.  Thank you.  \n \n Mike Kaufmann:  Yes, you know, we\u2019ve been talking to outside consultants, been talking to our \ncustomers, you know, senior execs there as you can imagine to a lot of folks to try to put together our \nthought process.  So I beli eve it\u2019s well really well -informed but, you know, it\u2019s hard for anyone to know \nfor sure.  But our take is that we won\u2019t see any of our businesses med or pharma back to pre -COVID \nlevels until we're exiting our fiscal '21 so, you know, in that, May, June time  frame of next year.  And \nagain as we said start out on electives in mid to high teens working its way up.  And then on physician \noffice visits in more the mid -single digits down and working its way up.  \n \n ", "original_text": "So I beli eve it\u2019s well really well -informed but, you know, it\u2019s hard for anyone to know \nfor sure. ", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d575b634c571396f1b55ba24ef79053dd3baee6bda6ca4e03ee2c4fea5d8dbc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2fe3836-f5f6-4eff-9320-accf7c5a5efb", "node_type": "1", "metadata": {"window": "Mike I was wondering if \nyou\u2019d provide a little color on your conversations with your upstream and downstream partners \naround utilization just because if you listen to some of  the talks from the MCOs they're generally \nexpecting utilization to increase in the back half of this calendar year where it sounds like you\u2019re still \ncalling for a significant decrease.  We'd just love any extra color on the conversations you\u2019ve had to \nhelp us bridge the gap.  Thank you.  \n \n Mike Kaufmann:  Yes, you know, we\u2019ve been talking to outside consultants, been talking to our \ncustomers, you know, senior execs there as you can imagine to a lot of folks to try to put together our \nthought process.  So I beli eve it\u2019s well really well -informed but, you know, it\u2019s hard for anyone to know \nfor sure.  But our take is that we won\u2019t see any of our businesses med or pharma back to pre -COVID \nlevels until we're exiting our fiscal '21 so, you know, in that, May, June time  frame of next year.  And \nagain as we said start out on electives in mid to high teens working its way up. ", "original_text": "Mike Kaufmann:  Yes, you know, we\u2019ve been talking to outside consultants, been talking to our \ncustomers, you know, senior execs there as you can imagine to a lot of folks to try to put together our \nthought process. ", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8cca7d86f285669672ebd3686eda99d8ea23d428eb431ad1635d114670420085", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34a4504d-7b73-42b1-bfb6-7dd6df339ca0", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Mike Kaufmann:  Yes, you know, we\u2019ve been talking to outside consultants, been talking to our \ncustomers, you know, senior execs there as you can imagine to a lot of folks to try to put together our \nthought process.  So I beli eve it\u2019s well really well -informed but, you know, it\u2019s hard for anyone to know \nfor sure.  But our take is that we won\u2019t see any of our businesses med or pharma back to pre -COVID \nlevels until we're exiting our fiscal '21 so, you know, in that, May, June time  frame of next year.  And \nagain as we said start out on electives in mid to high teens working its way up.  And then on physician \noffice visits in more the mid -single digits down and working its way up.  \n \n  So that is based on a lot of discussions with folks. ", "original_text": "But our take is that we won\u2019t see any of our businesses med or pharma back to pre -COVID \nlevels until we're exiting our fiscal '21 so, you know, in that, May, June time  frame of next year. "}, "hash": "bd52c161ddbcf8c8434f9fe91d55362cb735c8beadb885eb973c4ac493add651", "class_name": "RelatedNodeInfo"}}, "text": "So I beli eve it\u2019s well really well -informed but, you know, it\u2019s hard for anyone to know \nfor sure. ", "start_char_idx": 876, "end_char_idx": 977, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34a4504d-7b73-42b1-bfb6-7dd6df339ca0": {"__data__": {"id_": "34a4504d-7b73-42b1-bfb6-7dd6df339ca0", "embedding": null, "metadata": {"window": "Thank you.  \n \n Mike Kaufmann:  Yes, you know, we\u2019ve been talking to outside consultants, been talking to our \ncustomers, you know, senior execs there as you can imagine to a lot of folks to try to put together our \nthought process.  So I beli eve it\u2019s well really well -informed but, you know, it\u2019s hard for anyone to know \nfor sure.  But our take is that we won\u2019t see any of our businesses med or pharma back to pre -COVID \nlevels until we're exiting our fiscal '21 so, you know, in that, May, June time  frame of next year.  And \nagain as we said start out on electives in mid to high teens working its way up.  And then on physician \noffice visits in more the mid -single digits down and working its way up.  \n \n  So that is based on a lot of discussions with folks. ", "original_text": "But our take is that we won\u2019t see any of our businesses med or pharma back to pre -COVID \nlevels until we're exiting our fiscal '21 so, you know, in that, May, June time  frame of next year. ", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d575b634c571396f1b55ba24ef79053dd3baee6bda6ca4e03ee2c4fea5d8dbc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40aa2f2a-0191-443f-ad4b-270b723f70bc", "node_type": "1", "metadata": {"window": "We'd just love any extra color on the conversations you\u2019ve had to \nhelp us bridge the gap.  Thank you.  \n \n Mike Kaufmann:  Yes, you know, we\u2019ve been talking to outside consultants, been talking to our \ncustomers, you know, senior execs there as you can imagine to a lot of folks to try to put together our \nthought process.  So I beli eve it\u2019s well really well -informed but, you know, it\u2019s hard for anyone to know \nfor sure.  But our take is that we won\u2019t see any of our businesses med or pharma back to pre -COVID \nlevels until we're exiting our fiscal '21 so, you know, in that, May, June time  frame of next year.  And \nagain as we said start out on electives in mid to high teens working its way up.  And then on physician \noffice visits in more the mid -single digits down and working its way up.  \n \n ", "original_text": "So I beli eve it\u2019s well really well -informed but, you know, it\u2019s hard for anyone to know \nfor sure. ", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0305c78a5ce4c51e8e42d67764bb94d85222a810e748a4c589f4b6d301f4c352", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "926158d7-923c-48d6-88be-bb64a0395b83", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes, you know, we\u2019ve been talking to outside consultants, been talking to our \ncustomers, you know, senior execs there as you can imagine to a lot of folks to try to put together our \nthought process.  So I beli eve it\u2019s well really well -informed but, you know, it\u2019s hard for anyone to know \nfor sure.  But our take is that we won\u2019t see any of our businesses med or pharma back to pre -COVID \nlevels until we're exiting our fiscal '21 so, you know, in that, May, June time  frame of next year.  And \nagain as we said start out on electives in mid to high teens working its way up.  And then on physician \noffice visits in more the mid -single digits down and working its way up.  \n \n  So that is based on a lot of discussions with folks.  And I don\u2019t think we're hearing - there was a \nlot of early comments around pent -up demand and potentially going above 100%. ", "original_text": "And \nagain as we said start out on electives in mid to high teens working its way up. "}, "hash": "06c762428ef6f16253611c3703c7035142b5a284efbb401d2b2e652dad4a2366", "class_name": "RelatedNodeInfo"}}, "text": "But our take is that we won\u2019t see any of our businesses med or pharma back to pre -COVID \nlevels until we're exiting our fiscal '21 so, you know, in that, May, June time  frame of next year. ", "start_char_idx": 977, "end_char_idx": 1168, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "926158d7-923c-48d6-88be-bb64a0395b83": {"__data__": {"id_": "926158d7-923c-48d6-88be-bb64a0395b83", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes, you know, we\u2019ve been talking to outside consultants, been talking to our \ncustomers, you know, senior execs there as you can imagine to a lot of folks to try to put together our \nthought process.  So I beli eve it\u2019s well really well -informed but, you know, it\u2019s hard for anyone to know \nfor sure.  But our take is that we won\u2019t see any of our businesses med or pharma back to pre -COVID \nlevels until we're exiting our fiscal '21 so, you know, in that, May, June time  frame of next year.  And \nagain as we said start out on electives in mid to high teens working its way up.  And then on physician \noffice visits in more the mid -single digits down and working its way up.  \n \n  So that is based on a lot of discussions with folks.  And I don\u2019t think we're hearing - there was a \nlot of early comments around pent -up demand and potentially going above 100%. ", "original_text": "And \nagain as we said start out on electives in mid to high teens working its way up. ", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d575b634c571396f1b55ba24ef79053dd3baee6bda6ca4e03ee2c4fea5d8dbc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34a4504d-7b73-42b1-bfb6-7dd6df339ca0", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Mike Kaufmann:  Yes, you know, we\u2019ve been talking to outside consultants, been talking to our \ncustomers, you know, senior execs there as you can imagine to a lot of folks to try to put together our \nthought process.  So I beli eve it\u2019s well really well -informed but, you know, it\u2019s hard for anyone to know \nfor sure.  But our take is that we won\u2019t see any of our businesses med or pharma back to pre -COVID \nlevels until we're exiting our fiscal '21 so, you know, in that, May, June time  frame of next year.  And \nagain as we said start out on electives in mid to high teens working its way up.  And then on physician \noffice visits in more the mid -single digits down and working its way up.  \n \n  So that is based on a lot of discussions with folks. ", "original_text": "But our take is that we won\u2019t see any of our businesses med or pharma back to pre -COVID \nlevels until we're exiting our fiscal '21 so, you know, in that, May, June time  frame of next year. ", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8237d5f254d53e5d273093b030f864e9e2514a67582344c33d96f73e8c2d6326", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25b050b0-1fad-417c-8809-21d8a4b9f002", "node_type": "1", "metadata": {"window": "So I beli eve it\u2019s well really well -informed but, you know, it\u2019s hard for anyone to know \nfor sure.  But our take is that we won\u2019t see any of our businesses med or pharma back to pre -COVID \nlevels until we're exiting our fiscal '21 so, you know, in that, May, June time  frame of next year.  And \nagain as we said start out on electives in mid to high teens working its way up.  And then on physician \noffice visits in more the mid -single digits down and working its way up.  \n \n  So that is based on a lot of discussions with folks.  And I don\u2019t think we're hearing - there was a \nlot of early comments around pent -up demand and potentially going above 100%.  But as we talk to \npeople when they think about the ability to drive throughput the, still the psyche of folks willing to go \nback to the hospitals, et cetera, we're not really hearing people talking about that pent -up demand \nkind of coming through like we did before. ", "original_text": "And then on physician \noffice visits in more the mid -single digits down and working its way up.  \n \n "}, "hash": "01a2e4c5424348162317d01b364fa953bed84283e59ccd73345b6c9251d7456c", "class_name": "RelatedNodeInfo"}}, "text": "And \nagain as we said start out on electives in mid to high teens working its way up. ", "start_char_idx": 1168, "end_char_idx": 1254, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25b050b0-1fad-417c-8809-21d8a4b9f002": {"__data__": {"id_": "25b050b0-1fad-417c-8809-21d8a4b9f002", "embedding": null, "metadata": {"window": "So I beli eve it\u2019s well really well -informed but, you know, it\u2019s hard for anyone to know \nfor sure.  But our take is that we won\u2019t see any of our businesses med or pharma back to pre -COVID \nlevels until we're exiting our fiscal '21 so, you know, in that, May, June time  frame of next year.  And \nagain as we said start out on electives in mid to high teens working its way up.  And then on physician \noffice visits in more the mid -single digits down and working its way up.  \n \n  So that is based on a lot of discussions with folks.  And I don\u2019t think we're hearing - there was a \nlot of early comments around pent -up demand and potentially going above 100%.  But as we talk to \npeople when they think about the ability to drive throughput the, still the psyche of folks willing to go \nback to the hospitals, et cetera, we're not really hearing people talking about that pent -up demand \nkind of coming through like we did before. ", "original_text": "And then on physician \noffice visits in more the mid -single digits down and working its way up.  \n \n ", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d575b634c571396f1b55ba24ef79053dd3baee6bda6ca4e03ee2c4fea5d8dbc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "926158d7-923c-48d6-88be-bb64a0395b83", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes, you know, we\u2019ve been talking to outside consultants, been talking to our \ncustomers, you know, senior execs there as you can imagine to a lot of folks to try to put together our \nthought process.  So I beli eve it\u2019s well really well -informed but, you know, it\u2019s hard for anyone to know \nfor sure.  But our take is that we won\u2019t see any of our businesses med or pharma back to pre -COVID \nlevels until we're exiting our fiscal '21 so, you know, in that, May, June time  frame of next year.  And \nagain as we said start out on electives in mid to high teens working its way up.  And then on physician \noffice visits in more the mid -single digits down and working its way up.  \n \n  So that is based on a lot of discussions with folks.  And I don\u2019t think we're hearing - there was a \nlot of early comments around pent -up demand and potentially going above 100%. ", "original_text": "And \nagain as we said start out on electives in mid to high teens working its way up. ", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f90c545e307a26e1b920548f38a1d2956882470df82792005eaa7434c698188", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7903286-aa50-466d-95a7-0422353bb9d3", "node_type": "1", "metadata": {"window": "But our take is that we won\u2019t see any of our businesses med or pharma back to pre -COVID \nlevels until we're exiting our fiscal '21 so, you know, in that, May, June time  frame of next year.  And \nagain as we said start out on electives in mid to high teens working its way up.  And then on physician \noffice visits in more the mid -single digits down and working its way up.  \n \n  So that is based on a lot of discussions with folks.  And I don\u2019t think we're hearing - there was a \nlot of early comments around pent -up demand and potentially going above 100%.  But as we talk to \npeople when they think about the ability to drive throughput the, still the psyche of folks willing to go \nback to the hospitals, et cetera, we're not really hearing people talking about that pent -up demand \nkind of coming through like we did before.  So that\u2019s why we think we're just getting back to kind of \npre-COVID levels.  \n \n", "original_text": "So that is based on a lot of discussions with folks. "}, "hash": "b6f93b49591f3b097bb0b661017ea598384c9fca4ed54b6740e218e4e2c875aa", "class_name": "RelatedNodeInfo"}}, "text": "And then on physician \noffice visits in more the mid -single digits down and working its way up.  \n \n ", "start_char_idx": 1254, "end_char_idx": 1356, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7903286-aa50-466d-95a7-0422353bb9d3": {"__data__": {"id_": "c7903286-aa50-466d-95a7-0422353bb9d3", "embedding": null, "metadata": {"window": "But our take is that we won\u2019t see any of our businesses med or pharma back to pre -COVID \nlevels until we're exiting our fiscal '21 so, you know, in that, May, June time  frame of next year.  And \nagain as we said start out on electives in mid to high teens working its way up.  And then on physician \noffice visits in more the mid -single digits down and working its way up.  \n \n  So that is based on a lot of discussions with folks.  And I don\u2019t think we're hearing - there was a \nlot of early comments around pent -up demand and potentially going above 100%.  But as we talk to \npeople when they think about the ability to drive throughput the, still the psyche of folks willing to go \nback to the hospitals, et cetera, we're not really hearing people talking about that pent -up demand \nkind of coming through like we did before.  So that\u2019s why we think we're just getting back to kind of \npre-COVID levels.  \n \n", "original_text": "So that is based on a lot of discussions with folks. ", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d575b634c571396f1b55ba24ef79053dd3baee6bda6ca4e03ee2c4fea5d8dbc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25b050b0-1fad-417c-8809-21d8a4b9f002", "node_type": "1", "metadata": {"window": "So I beli eve it\u2019s well really well -informed but, you know, it\u2019s hard for anyone to know \nfor sure.  But our take is that we won\u2019t see any of our businesses med or pharma back to pre -COVID \nlevels until we're exiting our fiscal '21 so, you know, in that, May, June time  frame of next year.  And \nagain as we said start out on electives in mid to high teens working its way up.  And then on physician \noffice visits in more the mid -single digits down and working its way up.  \n \n  So that is based on a lot of discussions with folks.  And I don\u2019t think we're hearing - there was a \nlot of early comments around pent -up demand and potentially going above 100%.  But as we talk to \npeople when they think about the ability to drive throughput the, still the psyche of folks willing to go \nback to the hospitals, et cetera, we're not really hearing people talking about that pent -up demand \nkind of coming through like we did before. ", "original_text": "And then on physician \noffice visits in more the mid -single digits down and working its way up.  \n \n ", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3437c7454b9cf56814780f2f0c1b23e2196539289ecc9088eb29961fae224fa7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93b31103-4785-43a8-9e58-7e4f408c77ea", "node_type": "1", "metadata": {"window": "And \nagain as we said start out on electives in mid to high teens working its way up.  And then on physician \noffice visits in more the mid -single digits down and working its way up.  \n \n  So that is based on a lot of discussions with folks.  And I don\u2019t think we're hearing - there was a \nlot of early comments around pent -up demand and potentially going above 100%.  But as we talk to \npeople when they think about the ability to drive throughput the, still the psyche of folks willing to go \nback to the hospitals, et cetera, we're not really hearing people talking about that pent -up demand \nkind of coming through like we did before.  So that\u2019s why we think we're just getting back to kind of \npre-COVID levels.  \n \n George Hill:  Thank you.  \n ", "original_text": "And I don\u2019t think we're hearing - there was a \nlot of early comments around pent -up demand and potentially going above 100%. "}, "hash": "5baf55434170e384f20a8bb34afdcdea99ff921d0986fbf0e30bb6aa8fc5363a", "class_name": "RelatedNodeInfo"}}, "text": "So that is based on a lot of discussions with folks. ", "start_char_idx": 1356, "end_char_idx": 1409, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93b31103-4785-43a8-9e58-7e4f408c77ea": {"__data__": {"id_": "93b31103-4785-43a8-9e58-7e4f408c77ea", "embedding": null, "metadata": {"window": "And \nagain as we said start out on electives in mid to high teens working its way up.  And then on physician \noffice visits in more the mid -single digits down and working its way up.  \n \n  So that is based on a lot of discussions with folks.  And I don\u2019t think we're hearing - there was a \nlot of early comments around pent -up demand and potentially going above 100%.  But as we talk to \npeople when they think about the ability to drive throughput the, still the psyche of folks willing to go \nback to the hospitals, et cetera, we're not really hearing people talking about that pent -up demand \nkind of coming through like we did before.  So that\u2019s why we think we're just getting back to kind of \npre-COVID levels.  \n \n George Hill:  Thank you.  \n ", "original_text": "And I don\u2019t think we're hearing - there was a \nlot of early comments around pent -up demand and potentially going above 100%. ", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d575b634c571396f1b55ba24ef79053dd3baee6bda6ca4e03ee2c4fea5d8dbc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7903286-aa50-466d-95a7-0422353bb9d3", "node_type": "1", "metadata": {"window": "But our take is that we won\u2019t see any of our businesses med or pharma back to pre -COVID \nlevels until we're exiting our fiscal '21 so, you know, in that, May, June time  frame of next year.  And \nagain as we said start out on electives in mid to high teens working its way up.  And then on physician \noffice visits in more the mid -single digits down and working its way up.  \n \n  So that is based on a lot of discussions with folks.  And I don\u2019t think we're hearing - there was a \nlot of early comments around pent -up demand and potentially going above 100%.  But as we talk to \npeople when they think about the ability to drive throughput the, still the psyche of folks willing to go \nback to the hospitals, et cetera, we're not really hearing people talking about that pent -up demand \nkind of coming through like we did before.  So that\u2019s why we think we're just getting back to kind of \npre-COVID levels.  \n \n", "original_text": "So that is based on a lot of discussions with folks. ", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87e52b8e4387361d40443690b69678cfea0f4bf6a7f3ab34461f3ba24b9a9af6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc66c50e-b9f6-43ae-91c1-29fc15343783", "node_type": "1", "metadata": {"window": "And then on physician \noffice visits in more the mid -single digits down and working its way up.  \n \n  So that is based on a lot of discussions with folks.  And I don\u2019t think we're hearing - there was a \nlot of early comments around pent -up demand and potentially going above 100%.  But as we talk to \npeople when they think about the ability to drive throughput the, still the psyche of folks willing to go \nback to the hospitals, et cetera, we're not really hearing people talking about that pent -up demand \nkind of coming through like we did before.  So that\u2019s why we think we're just getting back to kind of \npre-COVID levels.  \n \n George Hill:  Thank you.  \n ", "original_text": "But as we talk to \npeople when they think about the ability to drive throughput the, still the psyche of folks willing to go \nback to the hospitals, et cetera, we're not really hearing people talking about that pent -up demand \nkind of coming through like we did before. "}, "hash": "bda24752bdb93e11c5ee30db8e796a83af3b1d90dccb9f0cb238710ca3bc18c8", "class_name": "RelatedNodeInfo"}}, "text": "And I don\u2019t think we're hearing - there was a \nlot of early comments around pent -up demand and potentially going above 100%. ", "start_char_idx": 1409, "end_char_idx": 1535, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc66c50e-b9f6-43ae-91c1-29fc15343783": {"__data__": {"id_": "bc66c50e-b9f6-43ae-91c1-29fc15343783", "embedding": null, "metadata": {"window": "And then on physician \noffice visits in more the mid -single digits down and working its way up.  \n \n  So that is based on a lot of discussions with folks.  And I don\u2019t think we're hearing - there was a \nlot of early comments around pent -up demand and potentially going above 100%.  But as we talk to \npeople when they think about the ability to drive throughput the, still the psyche of folks willing to go \nback to the hospitals, et cetera, we're not really hearing people talking about that pent -up demand \nkind of coming through like we did before.  So that\u2019s why we think we're just getting back to kind of \npre-COVID levels.  \n \n George Hill:  Thank you.  \n ", "original_text": "But as we talk to \npeople when they think about the ability to drive throughput the, still the psyche of folks willing to go \nback to the hospitals, et cetera, we're not really hearing people talking about that pent -up demand \nkind of coming through like we did before. ", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d575b634c571396f1b55ba24ef79053dd3baee6bda6ca4e03ee2c4fea5d8dbc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93b31103-4785-43a8-9e58-7e4f408c77ea", "node_type": "1", "metadata": {"window": "And \nagain as we said start out on electives in mid to high teens working its way up.  And then on physician \noffice visits in more the mid -single digits down and working its way up.  \n \n  So that is based on a lot of discussions with folks.  And I don\u2019t think we're hearing - there was a \nlot of early comments around pent -up demand and potentially going above 100%.  But as we talk to \npeople when they think about the ability to drive throughput the, still the psyche of folks willing to go \nback to the hospitals, et cetera, we're not really hearing people talking about that pent -up demand \nkind of coming through like we did before.  So that\u2019s why we think we're just getting back to kind of \npre-COVID levels.  \n \n George Hill:  Thank you.  \n ", "original_text": "And I don\u2019t think we're hearing - there was a \nlot of early comments around pent -up demand and potentially going above 100%. ", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f91f1f8f53f736439291b423c578972e640effc1f1b50fc0f46f94022aa24dec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93fca1f5-3039-4a9e-bad6-5c2441c1e9f1", "node_type": "1", "metadata": {"window": "So that is based on a lot of discussions with folks.  And I don\u2019t think we're hearing - there was a \nlot of early comments around pent -up demand and potentially going above 100%.  But as we talk to \npeople when they think about the ability to drive throughput the, still the psyche of folks willing to go \nback to the hospitals, et cetera, we're not really hearing people talking about that pent -up demand \nkind of coming through like we did before.  So that\u2019s why we think we're just getting back to kind of \npre-COVID levels.  \n \n George Hill:  Thank you.  \n ", "original_text": "So that\u2019s why we think we're just getting back to kind of \npre-COVID levels.  \n \n"}, "hash": "68a0b5be4f596754329399c4b830c61a92b3adf8e7675f6e19bcd04e9ebc7fd3", "class_name": "RelatedNodeInfo"}}, "text": "But as we talk to \npeople when they think about the ability to drive throughput the, still the psyche of folks willing to go \nback to the hospitals, et cetera, we're not really hearing people talking about that pent -up demand \nkind of coming through like we did before. ", "start_char_idx": 1535, "end_char_idx": 1806, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93fca1f5-3039-4a9e-bad6-5c2441c1e9f1": {"__data__": {"id_": "93fca1f5-3039-4a9e-bad6-5c2441c1e9f1", "embedding": null, "metadata": {"window": "So that is based on a lot of discussions with folks.  And I don\u2019t think we're hearing - there was a \nlot of early comments around pent -up demand and potentially going above 100%.  But as we talk to \npeople when they think about the ability to drive throughput the, still the psyche of folks willing to go \nback to the hospitals, et cetera, we're not really hearing people talking about that pent -up demand \nkind of coming through like we did before.  So that\u2019s why we think we're just getting back to kind of \npre-COVID levels.  \n \n George Hill:  Thank you.  \n ", "original_text": "So that\u2019s why we think we're just getting back to kind of \npre-COVID levels.  \n \n", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d575b634c571396f1b55ba24ef79053dd3baee6bda6ca4e03ee2c4fea5d8dbc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc66c50e-b9f6-43ae-91c1-29fc15343783", "node_type": "1", "metadata": {"window": "And then on physician \noffice visits in more the mid -single digits down and working its way up.  \n \n  So that is based on a lot of discussions with folks.  And I don\u2019t think we're hearing - there was a \nlot of early comments around pent -up demand and potentially going above 100%.  But as we talk to \npeople when they think about the ability to drive throughput the, still the psyche of folks willing to go \nback to the hospitals, et cetera, we're not really hearing people talking about that pent -up demand \nkind of coming through like we did before.  So that\u2019s why we think we're just getting back to kind of \npre-COVID levels.  \n \n George Hill:  Thank you.  \n ", "original_text": "But as we talk to \npeople when they think about the ability to drive throughput the, still the psyche of folks willing to go \nback to the hospitals, et cetera, we're not really hearing people talking about that pent -up demand \nkind of coming through like we did before. ", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d5f910dd1b1e34de21668c2a0d12676a22312cbe9fe2442992bcf07043e34bf4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb8c1be0-3c54-4171-97de-1a0345ad0335", "node_type": "1", "metadata": {"window": "And I don\u2019t think we're hearing - there was a \nlot of early comments around pent -up demand and potentially going above 100%.  But as we talk to \npeople when they think about the ability to drive throughput the, still the psyche of folks willing to go \nback to the hospitals, et cetera, we're not really hearing people talking about that pent -up demand \nkind of coming through like we did before.  So that\u2019s why we think we're just getting back to kind of \npre-COVID levels.  \n \n George Hill:  Thank you.  \n ", "original_text": "George Hill:  Thank you.  \n "}, "hash": "f1567f463356959a154fb3b5d4af94c73e690018cfdeff92e2476938e845a662", "class_name": "RelatedNodeInfo"}}, "text": "So that\u2019s why we think we're just getting back to kind of \npre-COVID levels.  \n \n", "start_char_idx": 1806, "end_char_idx": 1887, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb8c1be0-3c54-4171-97de-1a0345ad0335": {"__data__": {"id_": "bb8c1be0-3c54-4171-97de-1a0345ad0335", "embedding": null, "metadata": {"window": "And I don\u2019t think we're hearing - there was a \nlot of early comments around pent -up demand and potentially going above 100%.  But as we talk to \npeople when they think about the ability to drive throughput the, still the psyche of folks willing to go \nback to the hospitals, et cetera, we're not really hearing people talking about that pent -up demand \nkind of coming through like we did before.  So that\u2019s why we think we're just getting back to kind of \npre-COVID levels.  \n \n George Hill:  Thank you.  \n ", "original_text": "George Hill:  Thank you.  \n ", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d575b634c571396f1b55ba24ef79053dd3baee6bda6ca4e03ee2c4fea5d8dbc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93fca1f5-3039-4a9e-bad6-5c2441c1e9f1", "node_type": "1", "metadata": {"window": "So that is based on a lot of discussions with folks.  And I don\u2019t think we're hearing - there was a \nlot of early comments around pent -up demand and potentially going above 100%.  But as we talk to \npeople when they think about the ability to drive throughput the, still the psyche of folks willing to go \nback to the hospitals, et cetera, we're not really hearing people talking about that pent -up demand \nkind of coming through like we did before.  So that\u2019s why we think we're just getting back to kind of \npre-COVID levels.  \n \n George Hill:  Thank you.  \n ", "original_text": "So that\u2019s why we think we're just getting back to kind of \npre-COVID levels.  \n \n", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d7fc88672dcfada8ff172f63df516cd84dc6a320f34628126299ffa2afc78436", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "510241fd-2d89-4fa3-999e-23248c5cb265", "node_type": "1", "metadata": {"window": " \nPage 26 of 31 \n \nOperator:  Thank you.  We'll next go to Eric Percher with Nephron Research.  Please go ahead.  \n \n Eric Percher:  Thank you. ", "original_text": " \nPage 26 of 31 \n \nOperator:  Thank you. "}, "hash": "44084a6ecced1b3c70566035c4da64682c17fc6b8bb479b55e2ffa121c360c09", "class_name": "RelatedNodeInfo"}}, "text": "George Hill:  Thank you.  \n ", "start_char_idx": 1887, "end_char_idx": 1915, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "510241fd-2d89-4fa3-999e-23248c5cb265": {"__data__": {"id_": "510241fd-2d89-4fa3-999e-23248c5cb265", "embedding": null, "metadata": {"window": " \nPage 26 of 31 \n \nOperator:  Thank you.  We'll next go to Eric Percher with Nephron Research.  Please go ahead.  \n \n Eric Percher:  Thank you. ", "original_text": " \nPage 26 of 31 \n \nOperator:  Thank you. ", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8350e855-9008-407e-8b5d-0c99fd0658e2", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb47ec5189858a26f3fb34e25d9a8535d64deaf9ffcea5fa5268f410a7ea09f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb8c1be0-3c54-4171-97de-1a0345ad0335", "node_type": "1", "metadata": {"window": "And I don\u2019t think we're hearing - there was a \nlot of early comments around pent -up demand and potentially going above 100%.  But as we talk to \npeople when they think about the ability to drive throughput the, still the psyche of folks willing to go \nback to the hospitals, et cetera, we're not really hearing people talking about that pent -up demand \nkind of coming through like we did before.  So that\u2019s why we think we're just getting back to kind of \npre-COVID levels.  \n \n George Hill:  Thank you.  \n ", "original_text": "George Hill:  Thank you.  \n ", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a97a15199ba876ed2a956d5235e70a091f1c5a576bff2c1156ede093db266df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ed6a480-b637-4fcd-85ac-a1cf1d46100b", "node_type": "1", "metadata": {"window": " \nPage 26 of 31 \n \nOperator:  Thank you.  We'll next go to Eric Percher with Nephron Research.  Please go ahead.  \n \n Eric Percher:  Thank you.  Mike can you help us understand the dynamics of PPE and maybe on the \ncontracting side sounds like you\u2019re definitely taking on more expense be it bou ght or manufactured \nyourself. ", "original_text": "We'll next go to Eric Percher with Nephron Research. "}, "hash": "2983a961980347d544f441334d552019edbf82cc9640e6b4833f35831b5e2a14", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 26 of 31 \n \nOperator:  Thank you. ", "start_char_idx": 0, "end_char_idx": 41, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ed6a480-b637-4fcd-85ac-a1cf1d46100b": {"__data__": {"id_": "3ed6a480-b637-4fcd-85ac-a1cf1d46100b", "embedding": null, "metadata": {"window": " \nPage 26 of 31 \n \nOperator:  Thank you.  We'll next go to Eric Percher with Nephron Research.  Please go ahead.  \n \n Eric Percher:  Thank you.  Mike can you help us understand the dynamics of PPE and maybe on the \ncontracting side sounds like you\u2019re definitely taking on more expense be it bou ght or manufactured \nyourself. ", "original_text": "We'll next go to Eric Percher with Nephron Research. ", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8350e855-9008-407e-8b5d-0c99fd0658e2", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb47ec5189858a26f3fb34e25d9a8535d64deaf9ffcea5fa5268f410a7ea09f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "510241fd-2d89-4fa3-999e-23248c5cb265", "node_type": "1", "metadata": {"window": " \nPage 26 of 31 \n \nOperator:  Thank you.  We'll next go to Eric Percher with Nephron Research.  Please go ahead.  \n \n Eric Percher:  Thank you. ", "original_text": " \nPage 26 of 31 \n \nOperator:  Thank you. ", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f2342f517e3bb0efe518b365a77146db7d7583d0c34c16aa63d020b56bfa16d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4dbd95dd-2d29-4e15-a7aa-3d449d631da4", "node_type": "1", "metadata": {"window": " \nPage 26 of 31 \n \nOperator:  Thank you.  We'll next go to Eric Percher with Nephron Research.  Please go ahead.  \n \n Eric Percher:  Thank you.  Mike can you help us understand the dynamics of PPE and maybe on the \ncontracting side sounds like you\u2019re definitely taking on more expense be it bou ght or manufactured \nyourself.  Is there an agreement amongst the market that pricing is not going up or are we seeing \nincreases in pricing that overtime will be passed on to the marketplace?  \n \n", "original_text": "Please go ahead.  \n \n"}, "hash": "d4ea6b7d3f5d1b75976af08c8cd2cf4d960fb390fcf87cb294d0647d635ed490", "class_name": "RelatedNodeInfo"}}, "text": "We'll next go to Eric Percher with Nephron Research. ", "start_char_idx": 41, "end_char_idx": 94, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4dbd95dd-2d29-4e15-a7aa-3d449d631da4": {"__data__": {"id_": "4dbd95dd-2d29-4e15-a7aa-3d449d631da4", "embedding": null, "metadata": {"window": " \nPage 26 of 31 \n \nOperator:  Thank you.  We'll next go to Eric Percher with Nephron Research.  Please go ahead.  \n \n Eric Percher:  Thank you.  Mike can you help us understand the dynamics of PPE and maybe on the \ncontracting side sounds like you\u2019re definitely taking on more expense be it bou ght or manufactured \nyourself.  Is there an agreement amongst the market that pricing is not going up or are we seeing \nincreases in pricing that overtime will be passed on to the marketplace?  \n \n", "original_text": "Please go ahead.  \n \n", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8350e855-9008-407e-8b5d-0c99fd0658e2", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb47ec5189858a26f3fb34e25d9a8535d64deaf9ffcea5fa5268f410a7ea09f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ed6a480-b637-4fcd-85ac-a1cf1d46100b", "node_type": "1", "metadata": {"window": " \nPage 26 of 31 \n \nOperator:  Thank you.  We'll next go to Eric Percher with Nephron Research.  Please go ahead.  \n \n Eric Percher:  Thank you.  Mike can you help us understand the dynamics of PPE and maybe on the \ncontracting side sounds like you\u2019re definitely taking on more expense be it bou ght or manufactured \nyourself. ", "original_text": "We'll next go to Eric Percher with Nephron Research. ", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78241e9b5eb021b9750e7db78528706c3c6dcf9c08d06e5a062e9922731a29ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11d433d0-f003-4d4d-80db-1350fbcac224", "node_type": "1", "metadata": {"window": " \nPage 26 of 31 \n \nOperator:  Thank you.  We'll next go to Eric Percher with Nephron Research.  Please go ahead.  \n \n Eric Percher:  Thank you.  Mike can you help us understand the dynamics of PPE and maybe on the \ncontracting side sounds like you\u2019re definitely taking on more expense be it bou ght or manufactured \nyourself.  Is there an agreement amongst the market that pricing is not going up or are we seeing \nincreases in pricing that overtime will be passed on to the marketplace?  \n \n Mike Kaufmann:  That\u2019s a great question. ", "original_text": "Eric Percher:  Thank you. "}, "hash": "8f4cc64047fa49539cbc4ef7c98ca619017858b509eebfa33623ab9a4d02dd8c", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 94, "end_char_idx": 115, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11d433d0-f003-4d4d-80db-1350fbcac224": {"__data__": {"id_": "11d433d0-f003-4d4d-80db-1350fbcac224", "embedding": null, "metadata": {"window": " \nPage 26 of 31 \n \nOperator:  Thank you.  We'll next go to Eric Percher with Nephron Research.  Please go ahead.  \n \n Eric Percher:  Thank you.  Mike can you help us understand the dynamics of PPE and maybe on the \ncontracting side sounds like you\u2019re definitely taking on more expense be it bou ght or manufactured \nyourself.  Is there an agreement amongst the market that pricing is not going up or are we seeing \nincreases in pricing that overtime will be passed on to the marketplace?  \n \n Mike Kaufmann:  That\u2019s a great question. ", "original_text": "Eric Percher:  Thank you. ", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8350e855-9008-407e-8b5d-0c99fd0658e2", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb47ec5189858a26f3fb34e25d9a8535d64deaf9ffcea5fa5268f410a7ea09f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4dbd95dd-2d29-4e15-a7aa-3d449d631da4", "node_type": "1", "metadata": {"window": " \nPage 26 of 31 \n \nOperator:  Thank you.  We'll next go to Eric Percher with Nephron Research.  Please go ahead.  \n \n Eric Percher:  Thank you.  Mike can you help us understand the dynamics of PPE and maybe on the \ncontracting side sounds like you\u2019re definitely taking on more expense be it bou ght or manufactured \nyourself.  Is there an agreement amongst the market that pricing is not going up or are we seeing \nincreases in pricing that overtime will be passed on to the marketplace?  \n \n", "original_text": "Please go ahead.  \n \n", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02c54430d430639ffc563c0868567ae67397e5207c6f5bc231cb3132c9a4106c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31943cf9-752d-4977-ab92-d761302a38d8", "node_type": "1", "metadata": {"window": "We'll next go to Eric Percher with Nephron Research.  Please go ahead.  \n \n Eric Percher:  Thank you.  Mike can you help us understand the dynamics of PPE and maybe on the \ncontracting side sounds like you\u2019re definitely taking on more expense be it bou ght or manufactured \nyourself.  Is there an agreement amongst the market that pricing is not going up or are we seeing \nincreases in pricing that overtime will be passed on to the marketplace?  \n \n Mike Kaufmann:  That\u2019s a great question.  As Jason mentioned in hi s script when we think about the \nheadwind in medical around COVID, part of it is related to actual volumes, elective procedures and \npart of it is related to cost increases on certain categories of PPE. ", "original_text": "Mike can you help us understand the dynamics of PPE and maybe on the \ncontracting side sounds like you\u2019re definitely taking on more expense be it bou ght or manufactured \nyourself. "}, "hash": "9dcf60ebe863d354a1c80248fa8afcc52679f5b33020d768c5034f7b6ebd5688", "class_name": "RelatedNodeInfo"}}, "text": "Eric Percher:  Thank you. ", "start_char_idx": 115, "end_char_idx": 141, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31943cf9-752d-4977-ab92-d761302a38d8": {"__data__": {"id_": "31943cf9-752d-4977-ab92-d761302a38d8", "embedding": null, "metadata": {"window": "We'll next go to Eric Percher with Nephron Research.  Please go ahead.  \n \n Eric Percher:  Thank you.  Mike can you help us understand the dynamics of PPE and maybe on the \ncontracting side sounds like you\u2019re definitely taking on more expense be it bou ght or manufactured \nyourself.  Is there an agreement amongst the market that pricing is not going up or are we seeing \nincreases in pricing that overtime will be passed on to the marketplace?  \n \n Mike Kaufmann:  That\u2019s a great question.  As Jason mentioned in hi s script when we think about the \nheadwind in medical around COVID, part of it is related to actual volumes, elective procedures and \npart of it is related to cost increases on certain categories of PPE. ", "original_text": "Mike can you help us understand the dynamics of PPE and maybe on the \ncontracting side sounds like you\u2019re definitely taking on more expense be it bou ght or manufactured \nyourself. ", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8350e855-9008-407e-8b5d-0c99fd0658e2", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb47ec5189858a26f3fb34e25d9a8535d64deaf9ffcea5fa5268f410a7ea09f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11d433d0-f003-4d4d-80db-1350fbcac224", "node_type": "1", "metadata": {"window": " \nPage 26 of 31 \n \nOperator:  Thank you.  We'll next go to Eric Percher with Nephron Research.  Please go ahead.  \n \n Eric Percher:  Thank you.  Mike can you help us understand the dynamics of PPE and maybe on the \ncontracting side sounds like you\u2019re definitely taking on more expense be it bou ght or manufactured \nyourself.  Is there an agreement amongst the market that pricing is not going up or are we seeing \nincreases in pricing that overtime will be passed on to the marketplace?  \n \n Mike Kaufmann:  That\u2019s a great question. ", "original_text": "Eric Percher:  Thank you. ", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "25550f7a5fb39870b79a5dd54cf76e5917e3eba3edbaa72af9d9948e4d85649a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff1d27c4-e505-42e0-83d7-99c439bc1777", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Eric Percher:  Thank you.  Mike can you help us understand the dynamics of PPE and maybe on the \ncontracting side sounds like you\u2019re definitely taking on more expense be it bou ght or manufactured \nyourself.  Is there an agreement amongst the market that pricing is not going up or are we seeing \nincreases in pricing that overtime will be passed on to the marketplace?  \n \n Mike Kaufmann:  That\u2019s a great question.  As Jason mentioned in hi s script when we think about the \nheadwind in medical around COVID, part of it is related to actual volumes, elective procedures and \npart of it is related to cost increases on certain categories of PPE.  So to your point, we are seeing \nprice increases on PPE , some of them incredibly significant on key categories and so we've seen \nthose now for a couple months.  \n \n ", "original_text": "Is there an agreement amongst the market that pricing is not going up or are we seeing \nincreases in pricing that overtime will be passed on to the marketplace?  \n \n"}, "hash": "c977bd9c78c510cbff9c21720c8fa28a819f67d03d623e12d915f5293fc24579", "class_name": "RelatedNodeInfo"}}, "text": "Mike can you help us understand the dynamics of PPE and maybe on the \ncontracting side sounds like you\u2019re definitely taking on more expense be it bou ght or manufactured \nyourself. ", "start_char_idx": 141, "end_char_idx": 322, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff1d27c4-e505-42e0-83d7-99c439bc1777": {"__data__": {"id_": "ff1d27c4-e505-42e0-83d7-99c439bc1777", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Eric Percher:  Thank you.  Mike can you help us understand the dynamics of PPE and maybe on the \ncontracting side sounds like you\u2019re definitely taking on more expense be it bou ght or manufactured \nyourself.  Is there an agreement amongst the market that pricing is not going up or are we seeing \nincreases in pricing that overtime will be passed on to the marketplace?  \n \n Mike Kaufmann:  That\u2019s a great question.  As Jason mentioned in hi s script when we think about the \nheadwind in medical around COVID, part of it is related to actual volumes, elective procedures and \npart of it is related to cost increases on certain categories of PPE.  So to your point, we are seeing \nprice increases on PPE , some of them incredibly significant on key categories and so we've seen \nthose now for a couple months.  \n \n ", "original_text": "Is there an agreement amongst the market that pricing is not going up or are we seeing \nincreases in pricing that overtime will be passed on to the marketplace?  \n \n", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8350e855-9008-407e-8b5d-0c99fd0658e2", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb47ec5189858a26f3fb34e25d9a8535d64deaf9ffcea5fa5268f410a7ea09f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31943cf9-752d-4977-ab92-d761302a38d8", "node_type": "1", "metadata": {"window": "We'll next go to Eric Percher with Nephron Research.  Please go ahead.  \n \n Eric Percher:  Thank you.  Mike can you help us understand the dynamics of PPE and maybe on the \ncontracting side sounds like you\u2019re definitely taking on more expense be it bou ght or manufactured \nyourself.  Is there an agreement amongst the market that pricing is not going up or are we seeing \nincreases in pricing that overtime will be passed on to the marketplace?  \n \n Mike Kaufmann:  That\u2019s a great question.  As Jason mentioned in hi s script when we think about the \nheadwind in medical around COVID, part of it is related to actual volumes, elective procedures and \npart of it is related to cost increases on certain categories of PPE. ", "original_text": "Mike can you help us understand the dynamics of PPE and maybe on the \ncontracting side sounds like you\u2019re definitely taking on more expense be it bou ght or manufactured \nyourself. ", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52cdd4c0dd000384bc831a17388e63f77b824f11478cc57c31c9b73ba040653c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d1c772e-c9b2-4ede-ade2-c6757e890006", "node_type": "1", "metadata": {"window": "Eric Percher:  Thank you.  Mike can you help us understand the dynamics of PPE and maybe on the \ncontracting side sounds like you\u2019re definitely taking on more expense be it bou ght or manufactured \nyourself.  Is there an agreement amongst the market that pricing is not going up or are we seeing \nincreases in pricing that overtime will be passed on to the marketplace?  \n \n Mike Kaufmann:  That\u2019s a great question.  As Jason mentioned in hi s script when we think about the \nheadwind in medical around COVID, part of it is related to actual volumes, elective procedures and \npart of it is related to cost increases on certain categories of PPE.  So to your point, we are seeing \nprice increases on PPE , some of them incredibly significant on key categories and so we've seen \nthose now for a couple months.  \n \n  So as you can imagine we\u2019ve been having to procure some inventory at higher costs. ", "original_text": "Mike Kaufmann:  That\u2019s a great question. "}, "hash": "1a67da8a15b6588a10ae218dd4acb46f66f266c473c8f62529b661a702c78e2e", "class_name": "RelatedNodeInfo"}}, "text": "Is there an agreement amongst the market that pricing is not going up or are we seeing \nincreases in pricing that overtime will be passed on to the marketplace?  \n \n", "start_char_idx": 322, "end_char_idx": 487, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d1c772e-c9b2-4ede-ade2-c6757e890006": {"__data__": {"id_": "5d1c772e-c9b2-4ede-ade2-c6757e890006", "embedding": null, "metadata": {"window": "Eric Percher:  Thank you.  Mike can you help us understand the dynamics of PPE and maybe on the \ncontracting side sounds like you\u2019re definitely taking on more expense be it bou ght or manufactured \nyourself.  Is there an agreement amongst the market that pricing is not going up or are we seeing \nincreases in pricing that overtime will be passed on to the marketplace?  \n \n Mike Kaufmann:  That\u2019s a great question.  As Jason mentioned in hi s script when we think about the \nheadwind in medical around COVID, part of it is related to actual volumes, elective procedures and \npart of it is related to cost increases on certain categories of PPE.  So to your point, we are seeing \nprice increases on PPE , some of them incredibly significant on key categories and so we've seen \nthose now for a couple months.  \n \n  So as you can imagine we\u2019ve been having to procure some inventory at higher costs. ", "original_text": "Mike Kaufmann:  That\u2019s a great question. ", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8350e855-9008-407e-8b5d-0c99fd0658e2", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb47ec5189858a26f3fb34e25d9a8535d64deaf9ffcea5fa5268f410a7ea09f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff1d27c4-e505-42e0-83d7-99c439bc1777", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Eric Percher:  Thank you.  Mike can you help us understand the dynamics of PPE and maybe on the \ncontracting side sounds like you\u2019re definitely taking on more expense be it bou ght or manufactured \nyourself.  Is there an agreement amongst the market that pricing is not going up or are we seeing \nincreases in pricing that overtime will be passed on to the marketplace?  \n \n Mike Kaufmann:  That\u2019s a great question.  As Jason mentioned in hi s script when we think about the \nheadwind in medical around COVID, part of it is related to actual volumes, elective procedures and \npart of it is related to cost increases on certain categories of PPE.  So to your point, we are seeing \nprice increases on PPE , some of them incredibly significant on key categories and so we've seen \nthose now for a couple months.  \n \n ", "original_text": "Is there an agreement amongst the market that pricing is not going up or are we seeing \nincreases in pricing that overtime will be passed on to the marketplace?  \n \n", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "94feb03c45e1deea4dfd7a07c39cc43bbe740ff9dfc9af5dc155bc780189c5d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "daae7d2d-f18d-430f-9f71-6ec0e4cfc582", "node_type": "1", "metadata": {"window": "Mike can you help us understand the dynamics of PPE and maybe on the \ncontracting side sounds like you\u2019re definitely taking on more expense be it bou ght or manufactured \nyourself.  Is there an agreement amongst the market that pricing is not going up or are we seeing \nincreases in pricing that overtime will be passed on to the marketplace?  \n \n Mike Kaufmann:  That\u2019s a great question.  As Jason mentioned in hi s script when we think about the \nheadwind in medical around COVID, part of it is related to actual volumes, elective procedures and \npart of it is related to cost increases on certain categories of PPE.  So to your point, we are seeing \nprice increases on PPE , some of them incredibly significant on key categories and so we've seen \nthose now for a couple months.  \n \n  So as you can imagine we\u2019ve been having to procure some inventory at higher costs.  And, you \nknow, one of the things that we never want to do if we ca n help it is to pass on price increases to our \ncustomers. ", "original_text": "As Jason mentioned in hi s script when we think about the \nheadwind in medical around COVID, part of it is related to actual volumes, elective procedures and \npart of it is related to cost increases on certain categories of PPE. "}, "hash": "c117569eafe6942a486105e425cdb13653318b4e40e166318d55abdbab397796", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  That\u2019s a great question. ", "start_char_idx": 487, "end_char_idx": 528, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "daae7d2d-f18d-430f-9f71-6ec0e4cfc582": {"__data__": {"id_": "daae7d2d-f18d-430f-9f71-6ec0e4cfc582", "embedding": null, "metadata": {"window": "Mike can you help us understand the dynamics of PPE and maybe on the \ncontracting side sounds like you\u2019re definitely taking on more expense be it bou ght or manufactured \nyourself.  Is there an agreement amongst the market that pricing is not going up or are we seeing \nincreases in pricing that overtime will be passed on to the marketplace?  \n \n Mike Kaufmann:  That\u2019s a great question.  As Jason mentioned in hi s script when we think about the \nheadwind in medical around COVID, part of it is related to actual volumes, elective procedures and \npart of it is related to cost increases on certain categories of PPE.  So to your point, we are seeing \nprice increases on PPE , some of them incredibly significant on key categories and so we've seen \nthose now for a couple months.  \n \n  So as you can imagine we\u2019ve been having to procure some inventory at higher costs.  And, you \nknow, one of the things that we never want to do if we ca n help it is to pass on price increases to our \ncustomers. ", "original_text": "As Jason mentioned in hi s script when we think about the \nheadwind in medical around COVID, part of it is related to actual volumes, elective procedures and \npart of it is related to cost increases on certain categories of PPE. ", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8350e855-9008-407e-8b5d-0c99fd0658e2", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb47ec5189858a26f3fb34e25d9a8535d64deaf9ffcea5fa5268f410a7ea09f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d1c772e-c9b2-4ede-ade2-c6757e890006", "node_type": "1", "metadata": {"window": "Eric Percher:  Thank you.  Mike can you help us understand the dynamics of PPE and maybe on the \ncontracting side sounds like you\u2019re definitely taking on more expense be it bou ght or manufactured \nyourself.  Is there an agreement amongst the market that pricing is not going up or are we seeing \nincreases in pricing that overtime will be passed on to the marketplace?  \n \n Mike Kaufmann:  That\u2019s a great question.  As Jason mentioned in hi s script when we think about the \nheadwind in medical around COVID, part of it is related to actual volumes, elective procedures and \npart of it is related to cost increases on certain categories of PPE.  So to your point, we are seeing \nprice increases on PPE , some of them incredibly significant on key categories and so we've seen \nthose now for a couple months.  \n \n  So as you can imagine we\u2019ve been having to procure some inventory at higher costs. ", "original_text": "Mike Kaufmann:  That\u2019s a great question. ", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40e827036c59b3539be46c559e5fbf08d72ffd6557e8e8c6b00b397a1373e39e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e4c3603-e33c-4034-a9fb-3f7f0213e2a1", "node_type": "1", "metadata": {"window": "Is there an agreement amongst the market that pricing is not going up or are we seeing \nincreases in pricing that overtime will be passed on to the marketplace?  \n \n Mike Kaufmann:  That\u2019s a great question.  As Jason mentioned in hi s script when we think about the \nheadwind in medical around COVID, part of it is related to actual volumes, elective procedures and \npart of it is related to cost increases on certain categories of PPE.  So to your point, we are seeing \nprice increases on PPE , some of them incredibly significant on key categories and so we've seen \nthose now for a couple months.  \n \n  So as you can imagine we\u2019ve been having to procure some inventory at higher costs.  And, you \nknow, one of the things that we never want to do if we ca n help it is to pass on price increases to our \ncustomers.  We really view our job as being able to drive down costs for them and help them do that. \n", "original_text": "So to your point, we are seeing \nprice increases on PPE , some of them incredibly significant on key categories and so we've seen \nthose now for a couple months.  \n \n "}, "hash": "2119c2a10f3a72051897b75f0f7828232949a0f05cca42bada280821fa56c094", "class_name": "RelatedNodeInfo"}}, "text": "As Jason mentioned in hi s script when we think about the \nheadwind in medical around COVID, part of it is related to actual volumes, elective procedures and \npart of it is related to cost increases on certain categories of PPE. ", "start_char_idx": 528, "end_char_idx": 757, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e4c3603-e33c-4034-a9fb-3f7f0213e2a1": {"__data__": {"id_": "0e4c3603-e33c-4034-a9fb-3f7f0213e2a1", "embedding": null, "metadata": {"window": "Is there an agreement amongst the market that pricing is not going up or are we seeing \nincreases in pricing that overtime will be passed on to the marketplace?  \n \n Mike Kaufmann:  That\u2019s a great question.  As Jason mentioned in hi s script when we think about the \nheadwind in medical around COVID, part of it is related to actual volumes, elective procedures and \npart of it is related to cost increases on certain categories of PPE.  So to your point, we are seeing \nprice increases on PPE , some of them incredibly significant on key categories and so we've seen \nthose now for a couple months.  \n \n  So as you can imagine we\u2019ve been having to procure some inventory at higher costs.  And, you \nknow, one of the things that we never want to do if we ca n help it is to pass on price increases to our \ncustomers.  We really view our job as being able to drive down costs for them and help them do that. \n", "original_text": "So to your point, we are seeing \nprice increases on PPE , some of them incredibly significant on key categories and so we've seen \nthose now for a couple months.  \n \n ", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8350e855-9008-407e-8b5d-0c99fd0658e2", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb47ec5189858a26f3fb34e25d9a8535d64deaf9ffcea5fa5268f410a7ea09f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "daae7d2d-f18d-430f-9f71-6ec0e4cfc582", "node_type": "1", "metadata": {"window": "Mike can you help us understand the dynamics of PPE and maybe on the \ncontracting side sounds like you\u2019re definitely taking on more expense be it bou ght or manufactured \nyourself.  Is there an agreement amongst the market that pricing is not going up or are we seeing \nincreases in pricing that overtime will be passed on to the marketplace?  \n \n Mike Kaufmann:  That\u2019s a great question.  As Jason mentioned in hi s script when we think about the \nheadwind in medical around COVID, part of it is related to actual volumes, elective procedures and \npart of it is related to cost increases on certain categories of PPE.  So to your point, we are seeing \nprice increases on PPE , some of them incredibly significant on key categories and so we've seen \nthose now for a couple months.  \n \n  So as you can imagine we\u2019ve been having to procure some inventory at higher costs.  And, you \nknow, one of the things that we never want to do if we ca n help it is to pass on price increases to our \ncustomers. ", "original_text": "As Jason mentioned in hi s script when we think about the \nheadwind in medical around COVID, part of it is related to actual volumes, elective procedures and \npart of it is related to cost increases on certain categories of PPE. ", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2db00c8891e852a5861f00011303b88cff509aa249687fdd5facad5ff9c75dba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c472a46-62d9-409f-88d9-43f0124843c6", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  That\u2019s a great question.  As Jason mentioned in hi s script when we think about the \nheadwind in medical around COVID, part of it is related to actual volumes, elective procedures and \npart of it is related to cost increases on certain categories of PPE.  So to your point, we are seeing \nprice increases on PPE , some of them incredibly significant on key categories and so we've seen \nthose now for a couple months.  \n \n  So as you can imagine we\u2019ve been having to procure some inventory at higher costs.  And, you \nknow, one of the things that we never want to do if we ca n help it is to pass on price increases to our \ncustomers.  We really view our job as being able to drive down costs for them and help them do that. \n But in order to balance the ability for them to be able to actually have products to protect their workers \nand for us to be able to procure them, we have had to acquire some product at higher prices and we \nare working with our customers to adjust our pricing to them appropriately.  \n \n ", "original_text": "So as you can imagine we\u2019ve been having to procure some inventory at higher costs. "}, "hash": "48af95f991d53c4c39b8a093c96a9742170bc0d21b3d0657e29ab6331bb99234", "class_name": "RelatedNodeInfo"}}, "text": "So to your point, we are seeing \nprice increases on PPE , some of them incredibly significant on key categories and so we've seen \nthose now for a couple months.  \n \n ", "start_char_idx": 757, "end_char_idx": 924, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c472a46-62d9-409f-88d9-43f0124843c6": {"__data__": {"id_": "9c472a46-62d9-409f-88d9-43f0124843c6", "embedding": null, "metadata": {"window": "Mike Kaufmann:  That\u2019s a great question.  As Jason mentioned in hi s script when we think about the \nheadwind in medical around COVID, part of it is related to actual volumes, elective procedures and \npart of it is related to cost increases on certain categories of PPE.  So to your point, we are seeing \nprice increases on PPE , some of them incredibly significant on key categories and so we've seen \nthose now for a couple months.  \n \n  So as you can imagine we\u2019ve been having to procure some inventory at higher costs.  And, you \nknow, one of the things that we never want to do if we ca n help it is to pass on price increases to our \ncustomers.  We really view our job as being able to drive down costs for them and help them do that. \n But in order to balance the ability for them to be able to actually have products to protect their workers \nand for us to be able to procure them, we have had to acquire some product at higher prices and we \nare working with our customers to adjust our pricing to them appropriately.  \n \n ", "original_text": "So as you can imagine we\u2019ve been having to procure some inventory at higher costs. ", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8350e855-9008-407e-8b5d-0c99fd0658e2", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb47ec5189858a26f3fb34e25d9a8535d64deaf9ffcea5fa5268f410a7ea09f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e4c3603-e33c-4034-a9fb-3f7f0213e2a1", "node_type": "1", "metadata": {"window": "Is there an agreement amongst the market that pricing is not going up or are we seeing \nincreases in pricing that overtime will be passed on to the marketplace?  \n \n Mike Kaufmann:  That\u2019s a great question.  As Jason mentioned in hi s script when we think about the \nheadwind in medical around COVID, part of it is related to actual volumes, elective procedures and \npart of it is related to cost increases on certain categories of PPE.  So to your point, we are seeing \nprice increases on PPE , some of them incredibly significant on key categories and so we've seen \nthose now for a couple months.  \n \n  So as you can imagine we\u2019ve been having to procure some inventory at higher costs.  And, you \nknow, one of the things that we never want to do if we ca n help it is to pass on price increases to our \ncustomers.  We really view our job as being able to drive down costs for them and help them do that. \n", "original_text": "So to your point, we are seeing \nprice increases on PPE , some of them incredibly significant on key categories and so we've seen \nthose now for a couple months.  \n \n ", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5e43037b4ad92f74e787f11664888d8b27e75e91cd4a4449d6f3d138f891f7ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e670dec1-7c6b-4f5c-94d9-1bb85a8765c6", "node_type": "1", "metadata": {"window": "As Jason mentioned in hi s script when we think about the \nheadwind in medical around COVID, part of it is related to actual volumes, elective procedures and \npart of it is related to cost increases on certain categories of PPE.  So to your point, we are seeing \nprice increases on PPE , some of them incredibly significant on key categories and so we've seen \nthose now for a couple months.  \n \n  So as you can imagine we\u2019ve been having to procure some inventory at higher costs.  And, you \nknow, one of the things that we never want to do if we ca n help it is to pass on price increases to our \ncustomers.  We really view our job as being able to drive down costs for them and help them do that. \n But in order to balance the ability for them to be able to actually have products to protect their workers \nand for us to be able to procure them, we have had to acquire some product at higher prices and we \nare working with our customers to adjust our pricing to them appropriately.  \n \n  This is not an area where we look to profit from this. ", "original_text": "And, you \nknow, one of the things that we never want to do if we ca n help it is to pass on price increases to our \ncustomers. "}, "hash": "0aee7579a86e5786e25165ee15d1fce13ad15e05ff7f3721b723a9f5c6c786ec", "class_name": "RelatedNodeInfo"}}, "text": "So as you can imagine we\u2019ve been having to procure some inventory at higher costs. ", "start_char_idx": 924, "end_char_idx": 1007, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e670dec1-7c6b-4f5c-94d9-1bb85a8765c6": {"__data__": {"id_": "e670dec1-7c6b-4f5c-94d9-1bb85a8765c6", "embedding": null, "metadata": {"window": "As Jason mentioned in hi s script when we think about the \nheadwind in medical around COVID, part of it is related to actual volumes, elective procedures and \npart of it is related to cost increases on certain categories of PPE.  So to your point, we are seeing \nprice increases on PPE , some of them incredibly significant on key categories and so we've seen \nthose now for a couple months.  \n \n  So as you can imagine we\u2019ve been having to procure some inventory at higher costs.  And, you \nknow, one of the things that we never want to do if we ca n help it is to pass on price increases to our \ncustomers.  We really view our job as being able to drive down costs for them and help them do that. \n But in order to balance the ability for them to be able to actually have products to protect their workers \nand for us to be able to procure them, we have had to acquire some product at higher prices and we \nare working with our customers to adjust our pricing to them appropriately.  \n \n  This is not an area where we look to profit from this. ", "original_text": "And, you \nknow, one of the things that we never want to do if we ca n help it is to pass on price increases to our \ncustomers. ", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8350e855-9008-407e-8b5d-0c99fd0658e2", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb47ec5189858a26f3fb34e25d9a8535d64deaf9ffcea5fa5268f410a7ea09f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c472a46-62d9-409f-88d9-43f0124843c6", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  That\u2019s a great question.  As Jason mentioned in hi s script when we think about the \nheadwind in medical around COVID, part of it is related to actual volumes, elective procedures and \npart of it is related to cost increases on certain categories of PPE.  So to your point, we are seeing \nprice increases on PPE , some of them incredibly significant on key categories and so we've seen \nthose now for a couple months.  \n \n  So as you can imagine we\u2019ve been having to procure some inventory at higher costs.  And, you \nknow, one of the things that we never want to do if we ca n help it is to pass on price increases to our \ncustomers.  We really view our job as being able to drive down costs for them and help them do that. \n But in order to balance the ability for them to be able to actually have products to protect their workers \nand for us to be able to procure them, we have had to acquire some product at higher prices and we \nare working with our customers to adjust our pricing to them appropriately.  \n \n ", "original_text": "So as you can imagine we\u2019ve been having to procure some inventory at higher costs. ", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e5f62a4936fd09ed16bd7225cfcb28c645b573c5ae51c1f63dcb6e6c6719ae3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a299591a-97f5-42b0-b46d-1cae35cdd22a", "node_type": "1", "metadata": {"window": "So to your point, we are seeing \nprice increases on PPE , some of them incredibly significant on key categories and so we've seen \nthose now for a couple months.  \n \n  So as you can imagine we\u2019ve been having to procure some inventory at higher costs.  And, you \nknow, one of the things that we never want to do if we ca n help it is to pass on price increases to our \ncustomers.  We really view our job as being able to drive down costs for them and help them do that. \n But in order to balance the ability for them to be able to actually have products to protect their workers \nand for us to be able to procure them, we have had to acquire some product at higher prices and we \nare working with our customers to adjust our pricing to them appropriately.  \n \n  This is not an area where we look to profit from this.  This is something where we  would look to \ntry to just maintain our margin dollars in the area. ", "original_text": "We really view our job as being able to drive down costs for them and help them do that. \n"}, "hash": "02c989f1462c3fa01e10262029da8e3faa96ec9b3cf9c4f9d1baef4583660fd5", "class_name": "RelatedNodeInfo"}}, "text": "And, you \nknow, one of the things that we never want to do if we ca n help it is to pass on price increases to our \ncustomers. ", "start_char_idx": 1007, "end_char_idx": 1134, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a299591a-97f5-42b0-b46d-1cae35cdd22a": {"__data__": {"id_": "a299591a-97f5-42b0-b46d-1cae35cdd22a", "embedding": null, "metadata": {"window": "So to your point, we are seeing \nprice increases on PPE , some of them incredibly significant on key categories and so we've seen \nthose now for a couple months.  \n \n  So as you can imagine we\u2019ve been having to procure some inventory at higher costs.  And, you \nknow, one of the things that we never want to do if we ca n help it is to pass on price increases to our \ncustomers.  We really view our job as being able to drive down costs for them and help them do that. \n But in order to balance the ability for them to be able to actually have products to protect their workers \nand for us to be able to procure them, we have had to acquire some product at higher prices and we \nare working with our customers to adjust our pricing to them appropriately.  \n \n  This is not an area where we look to profit from this.  This is something where we  would look to \ntry to just maintain our margin dollars in the area. ", "original_text": "We really view our job as being able to drive down costs for them and help them do that. \n", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8350e855-9008-407e-8b5d-0c99fd0658e2", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb47ec5189858a26f3fb34e25d9a8535d64deaf9ffcea5fa5268f410a7ea09f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e670dec1-7c6b-4f5c-94d9-1bb85a8765c6", "node_type": "1", "metadata": {"window": "As Jason mentioned in hi s script when we think about the \nheadwind in medical around COVID, part of it is related to actual volumes, elective procedures and \npart of it is related to cost increases on certain categories of PPE.  So to your point, we are seeing \nprice increases on PPE , some of them incredibly significant on key categories and so we've seen \nthose now for a couple months.  \n \n  So as you can imagine we\u2019ve been having to procure some inventory at higher costs.  And, you \nknow, one of the things that we never want to do if we ca n help it is to pass on price increases to our \ncustomers.  We really view our job as being able to drive down costs for them and help them do that. \n But in order to balance the ability for them to be able to actually have products to protect their workers \nand for us to be able to procure them, we have had to acquire some product at higher prices and we \nare working with our customers to adjust our pricing to them appropriately.  \n \n  This is not an area where we look to profit from this. ", "original_text": "And, you \nknow, one of the things that we never want to do if we ca n help it is to pass on price increases to our \ncustomers. ", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f641d4426397c53d8f84a3aaaef9e57b7e10f6767ebddb4ff6055d84c16fdd83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88bd6670-7499-4a3c-9fa0-04b9b0ead76e", "node_type": "1", "metadata": {"window": "So as you can imagine we\u2019ve been having to procure some inventory at higher costs.  And, you \nknow, one of the things that we never want to do if we ca n help it is to pass on price increases to our \ncustomers.  We really view our job as being able to drive down costs for them and help them do that. \n But in order to balance the ability for them to be able to actually have products to protect their workers \nand for us to be able to procure them, we have had to acquire some product at higher prices and we \nare working with our customers to adjust our pricing to them appropriately.  \n \n  This is not an area where we look to profit from this.  This is something where we  would look to \ntry to just maintain our margin dollars in the area.  And so we want to work very collaboratively with \nour customers. ", "original_text": "But in order to balance the ability for them to be able to actually have products to protect their workers \nand for us to be able to procure them, we have had to acquire some product at higher prices and we \nare working with our customers to adjust our pricing to them appropriately.  \n \n "}, "hash": "2da1e4aabb40a006c9a1faee6bd77604b8e1a91b109d177c5038dc54cdd9b92f", "class_name": "RelatedNodeInfo"}}, "text": "We really view our job as being able to drive down costs for them and help them do that. \n", "start_char_idx": 1134, "end_char_idx": 1224, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88bd6670-7499-4a3c-9fa0-04b9b0ead76e": {"__data__": {"id_": "88bd6670-7499-4a3c-9fa0-04b9b0ead76e", "embedding": null, "metadata": {"window": "So as you can imagine we\u2019ve been having to procure some inventory at higher costs.  And, you \nknow, one of the things that we never want to do if we ca n help it is to pass on price increases to our \ncustomers.  We really view our job as being able to drive down costs for them and help them do that. \n But in order to balance the ability for them to be able to actually have products to protect their workers \nand for us to be able to procure them, we have had to acquire some product at higher prices and we \nare working with our customers to adjust our pricing to them appropriately.  \n \n  This is not an area where we look to profit from this.  This is something where we  would look to \ntry to just maintain our margin dollars in the area.  And so we want to work very collaboratively with \nour customers. ", "original_text": "But in order to balance the ability for them to be able to actually have products to protect their workers \nand for us to be able to procure them, we have had to acquire some product at higher prices and we \nare working with our customers to adjust our pricing to them appropriately.  \n \n ", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8350e855-9008-407e-8b5d-0c99fd0658e2", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb47ec5189858a26f3fb34e25d9a8535d64deaf9ffcea5fa5268f410a7ea09f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a299591a-97f5-42b0-b46d-1cae35cdd22a", "node_type": "1", "metadata": {"window": "So to your point, we are seeing \nprice increases on PPE , some of them incredibly significant on key categories and so we've seen \nthose now for a couple months.  \n \n  So as you can imagine we\u2019ve been having to procure some inventory at higher costs.  And, you \nknow, one of the things that we never want to do if we ca n help it is to pass on price increases to our \ncustomers.  We really view our job as being able to drive down costs for them and help them do that. \n But in order to balance the ability for them to be able to actually have products to protect their workers \nand for us to be able to procure them, we have had to acquire some product at higher prices and we \nare working with our customers to adjust our pricing to them appropriately.  \n \n  This is not an area where we look to profit from this.  This is something where we  would look to \ntry to just maintain our margin dollars in the area. ", "original_text": "We really view our job as being able to drive down costs for them and help them do that. \n", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18336b89ce41c6d4ef418a99f3652dc52a989c350b9bca6b452d05e4d714e08b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb96adff-f751-4aa5-9618-74badfc0e6ad", "node_type": "1", "metadata": {"window": "And, you \nknow, one of the things that we never want to do if we ca n help it is to pass on price increases to our \ncustomers.  We really view our job as being able to drive down costs for them and help them do that. \n But in order to balance the ability for them to be able to actually have products to protect their workers \nand for us to be able to procure them, we have had to acquire some product at higher prices and we \nare working with our customers to adjust our pricing to them appropriately.  \n \n  This is not an area where we look to profit from this.  This is something where we  would look to \ntry to just maintain our margin dollars in the area.  And so we want to work very collaboratively with \nour customers.  But there has been and will be a need for at least a period of time for us to work with \nthem to adjust some pricing in certa in areas of PPE.  \n \n", "original_text": "This is not an area where we look to profit from this. "}, "hash": "7573fce9655c0fbac8554f39e7703c48b5252cb75fcdaf529dd9e747d96e737e", "class_name": "RelatedNodeInfo"}}, "text": "But in order to balance the ability for them to be able to actually have products to protect their workers \nand for us to be able to procure them, we have had to acquire some product at higher prices and we \nare working with our customers to adjust our pricing to them appropriately.  \n \n ", "start_char_idx": 1224, "end_char_idx": 1513, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb96adff-f751-4aa5-9618-74badfc0e6ad": {"__data__": {"id_": "fb96adff-f751-4aa5-9618-74badfc0e6ad", "embedding": null, "metadata": {"window": "And, you \nknow, one of the things that we never want to do if we ca n help it is to pass on price increases to our \ncustomers.  We really view our job as being able to drive down costs for them and help them do that. \n But in order to balance the ability for them to be able to actually have products to protect their workers \nand for us to be able to procure them, we have had to acquire some product at higher prices and we \nare working with our customers to adjust our pricing to them appropriately.  \n \n  This is not an area where we look to profit from this.  This is something where we  would look to \ntry to just maintain our margin dollars in the area.  And so we want to work very collaboratively with \nour customers.  But there has been and will be a need for at least a period of time for us to work with \nthem to adjust some pricing in certa in areas of PPE.  \n \n", "original_text": "This is not an area where we look to profit from this. ", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8350e855-9008-407e-8b5d-0c99fd0658e2", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb47ec5189858a26f3fb34e25d9a8535d64deaf9ffcea5fa5268f410a7ea09f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88bd6670-7499-4a3c-9fa0-04b9b0ead76e", "node_type": "1", "metadata": {"window": "So as you can imagine we\u2019ve been having to procure some inventory at higher costs.  And, you \nknow, one of the things that we never want to do if we ca n help it is to pass on price increases to our \ncustomers.  We really view our job as being able to drive down costs for them and help them do that. \n But in order to balance the ability for them to be able to actually have products to protect their workers \nand for us to be able to procure them, we have had to acquire some product at higher prices and we \nare working with our customers to adjust our pricing to them appropriately.  \n \n  This is not an area where we look to profit from this.  This is something where we  would look to \ntry to just maintain our margin dollars in the area.  And so we want to work very collaboratively with \nour customers. ", "original_text": "But in order to balance the ability for them to be able to actually have products to protect their workers \nand for us to be able to procure them, we have had to acquire some product at higher prices and we \nare working with our customers to adjust our pricing to them appropriately.  \n \n ", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "14209929bb4f8380e05cb40bd2d32040a3bb75732bd71d50c7fb504cc70a98a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2092668c-882f-4476-a84d-d6fd9f1c4243", "node_type": "1", "metadata": {"window": "We really view our job as being able to drive down costs for them and help them do that. \n But in order to balance the ability for them to be able to actually have products to protect their workers \nand for us to be able to procure them, we have had to acquire some product at higher prices and we \nare working with our customers to adjust our pricing to them appropriately.  \n \n  This is not an area where we look to profit from this.  This is something where we  would look to \ntry to just maintain our margin dollars in the area.  And so we want to work very collaboratively with \nour customers.  But there has been and will be a need for at least a period of time for us to work with \nthem to adjust some pricing in certa in areas of PPE.  \n \n Eric Percher:  Thank you.  ", "original_text": "This is something where we  would look to \ntry to just maintain our margin dollars in the area. "}, "hash": "76848e6977bc336c4494bf02ff3ba8f6a0ad27d368e43b5cf018814687f2e35f", "class_name": "RelatedNodeInfo"}}, "text": "This is not an area where we look to profit from this. ", "start_char_idx": 1513, "end_char_idx": 1568, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2092668c-882f-4476-a84d-d6fd9f1c4243": {"__data__": {"id_": "2092668c-882f-4476-a84d-d6fd9f1c4243", "embedding": null, "metadata": {"window": "We really view our job as being able to drive down costs for them and help them do that. \n But in order to balance the ability for them to be able to actually have products to protect their workers \nand for us to be able to procure them, we have had to acquire some product at higher prices and we \nare working with our customers to adjust our pricing to them appropriately.  \n \n  This is not an area where we look to profit from this.  This is something where we  would look to \ntry to just maintain our margin dollars in the area.  And so we want to work very collaboratively with \nour customers.  But there has been and will be a need for at least a period of time for us to work with \nthem to adjust some pricing in certa in areas of PPE.  \n \n Eric Percher:  Thank you.  ", "original_text": "This is something where we  would look to \ntry to just maintain our margin dollars in the area. ", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8350e855-9008-407e-8b5d-0c99fd0658e2", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb47ec5189858a26f3fb34e25d9a8535d64deaf9ffcea5fa5268f410a7ea09f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb96adff-f751-4aa5-9618-74badfc0e6ad", "node_type": "1", "metadata": {"window": "And, you \nknow, one of the things that we never want to do if we ca n help it is to pass on price increases to our \ncustomers.  We really view our job as being able to drive down costs for them and help them do that. \n But in order to balance the ability for them to be able to actually have products to protect their workers \nand for us to be able to procure them, we have had to acquire some product at higher prices and we \nare working with our customers to adjust our pricing to them appropriately.  \n \n  This is not an area where we look to profit from this.  This is something where we  would look to \ntry to just maintain our margin dollars in the area.  And so we want to work very collaboratively with \nour customers.  But there has been and will be a need for at least a period of time for us to work with \nthem to adjust some pricing in certa in areas of PPE.  \n \n", "original_text": "This is not an area where we look to profit from this. ", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a35428a1a275487c561af747d3efb7be2874d7acce9f06091b904edc3625a8a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c70c576b-1fb6-401d-83a7-411d8e10f7aa", "node_type": "1", "metadata": {"window": "But in order to balance the ability for them to be able to actually have products to protect their workers \nand for us to be able to procure them, we have had to acquire some product at higher prices and we \nare working with our customers to adjust our pricing to them appropriately.  \n \n  This is not an area where we look to profit from this.  This is something where we  would look to \ntry to just maintain our margin dollars in the area.  And so we want to work very collaboratively with \nour customers.  But there has been and will be a need for at least a period of time for us to work with \nthem to adjust some pricing in certa in areas of PPE.  \n \n Eric Percher:  Thank you.  ", "original_text": "And so we want to work very collaboratively with \nour customers. "}, "hash": "6dc1dfaf5b732ad0e72ff3bea8d20cf99d7d51e018175ce03f3bec1ec8016079", "class_name": "RelatedNodeInfo"}}, "text": "This is something where we  would look to \ntry to just maintain our margin dollars in the area. ", "start_char_idx": 1568, "end_char_idx": 1664, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c70c576b-1fb6-401d-83a7-411d8e10f7aa": {"__data__": {"id_": "c70c576b-1fb6-401d-83a7-411d8e10f7aa", "embedding": null, "metadata": {"window": "But in order to balance the ability for them to be able to actually have products to protect their workers \nand for us to be able to procure them, we have had to acquire some product at higher prices and we \nare working with our customers to adjust our pricing to them appropriately.  \n \n  This is not an area where we look to profit from this.  This is something where we  would look to \ntry to just maintain our margin dollars in the area.  And so we want to work very collaboratively with \nour customers.  But there has been and will be a need for at least a period of time for us to work with \nthem to adjust some pricing in certa in areas of PPE.  \n \n Eric Percher:  Thank you.  ", "original_text": "And so we want to work very collaboratively with \nour customers. ", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8350e855-9008-407e-8b5d-0c99fd0658e2", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb47ec5189858a26f3fb34e25d9a8535d64deaf9ffcea5fa5268f410a7ea09f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2092668c-882f-4476-a84d-d6fd9f1c4243", "node_type": "1", "metadata": {"window": "We really view our job as being able to drive down costs for them and help them do that. \n But in order to balance the ability for them to be able to actually have products to protect their workers \nand for us to be able to procure them, we have had to acquire some product at higher prices and we \nare working with our customers to adjust our pricing to them appropriately.  \n \n  This is not an area where we look to profit from this.  This is something where we  would look to \ntry to just maintain our margin dollars in the area.  And so we want to work very collaboratively with \nour customers.  But there has been and will be a need for at least a period of time for us to work with \nthem to adjust some pricing in certa in areas of PPE.  \n \n Eric Percher:  Thank you.  ", "original_text": "This is something where we  would look to \ntry to just maintain our margin dollars in the area. ", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4786f015e8d306106ddb27fe9fca1de7326eb8036a37aae9e9d3f24de8e7fd2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "127918cc-009f-4ebe-bd57-f685ed4a6380", "node_type": "1", "metadata": {"window": "This is not an area where we look to profit from this.  This is something where we  would look to \ntry to just maintain our margin dollars in the area.  And so we want to work very collaboratively with \nour customers.  But there has been and will be a need for at least a period of time for us to work with \nthem to adjust some pricing in certa in areas of PPE.  \n \n Eric Percher:  Thank you.  ", "original_text": "But there has been and will be a need for at least a period of time for us to work with \nthem to adjust some pricing in certa in areas of PPE.  \n \n"}, "hash": "3c34b80fc9ec6e47fc2e1402b603e736b0d7ebb707acb8d48123a627532f7683", "class_name": "RelatedNodeInfo"}}, "text": "And so we want to work very collaboratively with \nour customers. ", "start_char_idx": 1664, "end_char_idx": 1729, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "127918cc-009f-4ebe-bd57-f685ed4a6380": {"__data__": {"id_": "127918cc-009f-4ebe-bd57-f685ed4a6380", "embedding": null, "metadata": {"window": "This is not an area where we look to profit from this.  This is something where we  would look to \ntry to just maintain our margin dollars in the area.  And so we want to work very collaboratively with \nour customers.  But there has been and will be a need for at least a period of time for us to work with \nthem to adjust some pricing in certa in areas of PPE.  \n \n Eric Percher:  Thank you.  ", "original_text": "But there has been and will be a need for at least a period of time for us to work with \nthem to adjust some pricing in certa in areas of PPE.  \n \n", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8350e855-9008-407e-8b5d-0c99fd0658e2", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb47ec5189858a26f3fb34e25d9a8535d64deaf9ffcea5fa5268f410a7ea09f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c70c576b-1fb6-401d-83a7-411d8e10f7aa", "node_type": "1", "metadata": {"window": "But in order to balance the ability for them to be able to actually have products to protect their workers \nand for us to be able to procure them, we have had to acquire some product at higher prices and we \nare working with our customers to adjust our pricing to them appropriately.  \n \n  This is not an area where we look to profit from this.  This is something where we  would look to \ntry to just maintain our margin dollars in the area.  And so we want to work very collaboratively with \nour customers.  But there has been and will be a need for at least a period of time for us to work with \nthem to adjust some pricing in certa in areas of PPE.  \n \n Eric Percher:  Thank you.  ", "original_text": "And so we want to work very collaboratively with \nour customers. ", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "93d52017800d9021aa63619f73cd9833ce1aa8daac70b1dd2fc4fd1714f9b385", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2908dbc6-d79f-4cb0-8b30-82d8edce6893", "node_type": "1", "metadata": {"window": "This is something where we  would look to \ntry to just maintain our margin dollars in the area.  And so we want to work very collaboratively with \nour customers.  But there has been and will be a need for at least a period of time for us to work with \nthem to adjust some pricing in certa in areas of PPE.  \n \n Eric Percher:  Thank you.  ", "original_text": "Eric Percher:  Thank you.  "}, "hash": "6374787ae633784550b88deb8325ea7caa42fd35c65208f8ccd5b20864bdbd65", "class_name": "RelatedNodeInfo"}}, "text": "But there has been and will be a need for at least a period of time for us to work with \nthem to adjust some pricing in certa in areas of PPE.  \n \n", "start_char_idx": 1729, "end_char_idx": 1876, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2908dbc6-d79f-4cb0-8b30-82d8edce6893": {"__data__": {"id_": "2908dbc6-d79f-4cb0-8b30-82d8edce6893", "embedding": null, "metadata": {"window": "This is something where we  would look to \ntry to just maintain our margin dollars in the area.  And so we want to work very collaboratively with \nour customers.  But there has been and will be a need for at least a period of time for us to work with \nthem to adjust some pricing in certa in areas of PPE.  \n \n Eric Percher:  Thank you.  ", "original_text": "Eric Percher:  Thank you.  ", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8350e855-9008-407e-8b5d-0c99fd0658e2", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb47ec5189858a26f3fb34e25d9a8535d64deaf9ffcea5fa5268f410a7ea09f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "127918cc-009f-4ebe-bd57-f685ed4a6380", "node_type": "1", "metadata": {"window": "This is not an area where we look to profit from this.  This is something where we  would look to \ntry to just maintain our margin dollars in the area.  And so we want to work very collaboratively with \nour customers.  But there has been and will be a need for at least a period of time for us to work with \nthem to adjust some pricing in certa in areas of PPE.  \n \n Eric Percher:  Thank you.  ", "original_text": "But there has been and will be a need for at least a period of time for us to work with \nthem to adjust some pricing in certa in areas of PPE.  \n \n", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c28cb2433ec35b69f2097079e9855ea3e1c7fe024615bfb7a6a0a20deac9dab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4aaa0b4-c079-4977-9d27-5cd7d6a76a1e", "node_type": "1", "metadata": {"window": " \nPage 27 of 31 \n \n \nOperator:  Thank you.  We'll next go to Stephen Baxter with Wolfe Research.  Please go ahead.  \n \n Stephen Baxter:  Hey thanks for the question. ", "original_text": " \nPage 27 of 31 \n \n \nOperator:  Thank you. "}, "hash": "de4c968acd957f1d2a41ef52d95bcf7711cac28ed732f60b3832b613ce03d686", "class_name": "RelatedNodeInfo"}}, "text": "Eric Percher:  Thank you.  ", "start_char_idx": 1876, "end_char_idx": 1903, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4aaa0b4-c079-4977-9d27-5cd7d6a76a1e": {"__data__": {"id_": "a4aaa0b4-c079-4977-9d27-5cd7d6a76a1e", "embedding": null, "metadata": {"window": " \nPage 27 of 31 \n \n \nOperator:  Thank you.  We'll next go to Stephen Baxter with Wolfe Research.  Please go ahead.  \n \n Stephen Baxter:  Hey thanks for the question. ", "original_text": " \nPage 27 of 31 \n \n \nOperator:  Thank you. ", "page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1d5ca99a-62c2-481c-bc71-e592b11cf6c6", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ffcbb486dba2a9527f66edd6ca79bb37d5848e67108ba2664fc2f4335513c7d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2908dbc6-d79f-4cb0-8b30-82d8edce6893", "node_type": "1", "metadata": {"window": "This is something where we  would look to \ntry to just maintain our margin dollars in the area.  And so we want to work very collaboratively with \nour customers.  But there has been and will be a need for at least a period of time for us to work with \nthem to adjust some pricing in certa in areas of PPE.  \n \n Eric Percher:  Thank you.  ", "original_text": "Eric Percher:  Thank you.  ", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "635b9484e7b6b42a0b37791535825300e054ad1840ca474fc81244b8e2cbe969", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea92ec35-be24-4d74-ba05-b68598d718e5", "node_type": "1", "metadata": {"window": " \nPage 27 of 31 \n \n \nOperator:  Thank you.  We'll next go to Stephen Baxter with Wolfe Research.  Please go ahead.  \n \n Stephen Baxter:  Hey thanks for the question.  I wanted to ask about cash flow. ", "original_text": "We'll next go to Stephen Baxter with Wolfe Research. "}, "hash": "fa4eecd6321f6fa2606081080a914db1c592be0bb92d1d360481b41a417cc90c", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 27 of 31 \n \n \nOperator:  Thank you. ", "start_char_idx": 0, "end_char_idx": 43, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea92ec35-be24-4d74-ba05-b68598d718e5": {"__data__": {"id_": "ea92ec35-be24-4d74-ba05-b68598d718e5", "embedding": null, "metadata": {"window": " \nPage 27 of 31 \n \n \nOperator:  Thank you.  We'll next go to Stephen Baxter with Wolfe Research.  Please go ahead.  \n \n Stephen Baxter:  Hey thanks for the question.  I wanted to ask about cash flow. ", "original_text": "We'll next go to Stephen Baxter with Wolfe Research. ", "page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1d5ca99a-62c2-481c-bc71-e592b11cf6c6", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ffcbb486dba2a9527f66edd6ca79bb37d5848e67108ba2664fc2f4335513c7d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4aaa0b4-c079-4977-9d27-5cd7d6a76a1e", "node_type": "1", "metadata": {"window": " \nPage 27 of 31 \n \n \nOperator:  Thank you.  We'll next go to Stephen Baxter with Wolfe Research.  Please go ahead.  \n \n Stephen Baxter:  Hey thanks for the question. ", "original_text": " \nPage 27 of 31 \n \n \nOperator:  Thank you. ", "page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "becc05662ff4c8eedcd7249b333327201c52da01c98bb7fd63459cb89c9a7188", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bcf0b12c-e095-445c-8316-cff7f1be32c3", "node_type": "1", "metadata": {"window": " \nPage 27 of 31 \n \n \nOperator:  Thank you.  We'll next go to Stephen Baxter with Wolfe Research.  Please go ahead.  \n \n Stephen Baxter:  Hey thanks for the question.  I wanted to ask about cash flow.  It\u2019s been a pretty \nvolatile line item f or you as working capital swung, was hoping you could talk a little bit about whether \n2020 was maybe more of an appropriate or normalized level for your cash flow and also anything you \ncan share about your expectations for fiscal 2021 and whether we should  be thinking about, you \nknow, directionally with ETS or with the there\u2019s other backers we should keep in mind? ", "original_text": "Please go ahead.  \n \n"}, "hash": "459fe00ccf98ffa2e23cea492888a91f596fb6f3180d7090d9764234ab425b68", "class_name": "RelatedNodeInfo"}}, "text": "We'll next go to Stephen Baxter with Wolfe Research. ", "start_char_idx": 43, "end_char_idx": 96, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bcf0b12c-e095-445c-8316-cff7f1be32c3": {"__data__": {"id_": "bcf0b12c-e095-445c-8316-cff7f1be32c3", "embedding": null, "metadata": {"window": " \nPage 27 of 31 \n \n \nOperator:  Thank you.  We'll next go to Stephen Baxter with Wolfe Research.  Please go ahead.  \n \n Stephen Baxter:  Hey thanks for the question.  I wanted to ask about cash flow.  It\u2019s been a pretty \nvolatile line item f or you as working capital swung, was hoping you could talk a little bit about whether \n2020 was maybe more of an appropriate or normalized level for your cash flow and also anything you \ncan share about your expectations for fiscal 2021 and whether we should  be thinking about, you \nknow, directionally with ETS or with the there\u2019s other backers we should keep in mind? ", "original_text": "Please go ahead.  \n \n", "page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1d5ca99a-62c2-481c-bc71-e592b11cf6c6", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ffcbb486dba2a9527f66edd6ca79bb37d5848e67108ba2664fc2f4335513c7d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea92ec35-be24-4d74-ba05-b68598d718e5", "node_type": "1", "metadata": {"window": " \nPage 27 of 31 \n \n \nOperator:  Thank you.  We'll next go to Stephen Baxter with Wolfe Research.  Please go ahead.  \n \n Stephen Baxter:  Hey thanks for the question.  I wanted to ask about cash flow. ", "original_text": "We'll next go to Stephen Baxter with Wolfe Research. ", "page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "256f5466fd88cbb850b5b6d718e9a4e751e43f5270cdcdedbad97a5336888ea6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e37e9811-3e7e-4e1d-abd6-3e947a429e0a", "node_type": "1", "metadata": {"window": " \nPage 27 of 31 \n \n \nOperator:  Thank you.  We'll next go to Stephen Baxter with Wolfe Research.  Please go ahead.  \n \n Stephen Baxter:  Hey thanks for the question.  I wanted to ask about cash flow.  It\u2019s been a pretty \nvolatile line item f or you as working capital swung, was hoping you could talk a little bit about whether \n2020 was maybe more of an appropriate or normalized level for your cash flow and also anything you \ncan share about your expectations for fiscal 2021 and whether we should  be thinking about, you \nknow, directionally with ETS or with the there\u2019s other backers we should keep in mind?  Thanks.  \n \n", "original_text": "Stephen Baxter:  Hey thanks for the question. "}, "hash": "e72cd4b58a130046f9494ec30c52c0892cfc2ec9b8f44c945ae96a493e7534ec", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 96, "end_char_idx": 117, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e37e9811-3e7e-4e1d-abd6-3e947a429e0a": {"__data__": {"id_": "e37e9811-3e7e-4e1d-abd6-3e947a429e0a", "embedding": null, "metadata": {"window": " \nPage 27 of 31 \n \n \nOperator:  Thank you.  We'll next go to Stephen Baxter with Wolfe Research.  Please go ahead.  \n \n Stephen Baxter:  Hey thanks for the question.  I wanted to ask about cash flow.  It\u2019s been a pretty \nvolatile line item f or you as working capital swung, was hoping you could talk a little bit about whether \n2020 was maybe more of an appropriate or normalized level for your cash flow and also anything you \ncan share about your expectations for fiscal 2021 and whether we should  be thinking about, you \nknow, directionally with ETS or with the there\u2019s other backers we should keep in mind?  Thanks.  \n \n", "original_text": "Stephen Baxter:  Hey thanks for the question. ", "page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1d5ca99a-62c2-481c-bc71-e592b11cf6c6", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ffcbb486dba2a9527f66edd6ca79bb37d5848e67108ba2664fc2f4335513c7d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bcf0b12c-e095-445c-8316-cff7f1be32c3", "node_type": "1", "metadata": {"window": " \nPage 27 of 31 \n \n \nOperator:  Thank you.  We'll next go to Stephen Baxter with Wolfe Research.  Please go ahead.  \n \n Stephen Baxter:  Hey thanks for the question.  I wanted to ask about cash flow.  It\u2019s been a pretty \nvolatile line item f or you as working capital swung, was hoping you could talk a little bit about whether \n2020 was maybe more of an appropriate or normalized level for your cash flow and also anything you \ncan share about your expectations for fiscal 2021 and whether we should  be thinking about, you \nknow, directionally with ETS or with the there\u2019s other backers we should keep in mind? ", "original_text": "Please go ahead.  \n \n", "page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "847ce47b3913271430f523634f3e8da8be65ccc0955601fb22e49a901fd0461d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df3d167a-ae8c-4048-bd41-1e2dcebc16e6", "node_type": "1", "metadata": {"window": "We'll next go to Stephen Baxter with Wolfe Research.  Please go ahead.  \n \n Stephen Baxter:  Hey thanks for the question.  I wanted to ask about cash flow.  It\u2019s been a pretty \nvolatile line item f or you as working capital swung, was hoping you could talk a little bit about whether \n2020 was maybe more of an appropriate or normalized level for your cash flow and also anything you \ncan share about your expectations for fiscal 2021 and whether we should  be thinking about, you \nknow, directionally with ETS or with the there\u2019s other backers we should keep in mind?  Thanks.  \n \n Jason Hollar:  Yes, sure, thanks for the question and you appropriately highlight that there was some \nvolatility within the fiscal year '20 as well as we saw in Q3 very strong cash flow as a lot of that \nvolume surge benefited us and we sold out of inventory and a little bit of the carryover effect than for \nQ4. \n \n ", "original_text": "I wanted to ask about cash flow. "}, "hash": "08f76d3921dd6cbfef32ec092353adc05c1d5274927af52d938fb6578fc797ee", "class_name": "RelatedNodeInfo"}}, "text": "Stephen Baxter:  Hey thanks for the question. ", "start_char_idx": 117, "end_char_idx": 163, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df3d167a-ae8c-4048-bd41-1e2dcebc16e6": {"__data__": {"id_": "df3d167a-ae8c-4048-bd41-1e2dcebc16e6", "embedding": null, "metadata": {"window": "We'll next go to Stephen Baxter with Wolfe Research.  Please go ahead.  \n \n Stephen Baxter:  Hey thanks for the question.  I wanted to ask about cash flow.  It\u2019s been a pretty \nvolatile line item f or you as working capital swung, was hoping you could talk a little bit about whether \n2020 was maybe more of an appropriate or normalized level for your cash flow and also anything you \ncan share about your expectations for fiscal 2021 and whether we should  be thinking about, you \nknow, directionally with ETS or with the there\u2019s other backers we should keep in mind?  Thanks.  \n \n Jason Hollar:  Yes, sure, thanks for the question and you appropriately highlight that there was some \nvolatility within the fiscal year '20 as well as we saw in Q3 very strong cash flow as a lot of that \nvolume surge benefited us and we sold out of inventory and a little bit of the carryover effect than for \nQ4. \n \n ", "original_text": "I wanted to ask about cash flow. ", "page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1d5ca99a-62c2-481c-bc71-e592b11cf6c6", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ffcbb486dba2a9527f66edd6ca79bb37d5848e67108ba2664fc2f4335513c7d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e37e9811-3e7e-4e1d-abd6-3e947a429e0a", "node_type": "1", "metadata": {"window": " \nPage 27 of 31 \n \n \nOperator:  Thank you.  We'll next go to Stephen Baxter with Wolfe Research.  Please go ahead.  \n \n Stephen Baxter:  Hey thanks for the question.  I wanted to ask about cash flow.  It\u2019s been a pretty \nvolatile line item f or you as working capital swung, was hoping you could talk a little bit about whether \n2020 was maybe more of an appropriate or normalized level for your cash flow and also anything you \ncan share about your expectations for fiscal 2021 and whether we should  be thinking about, you \nknow, directionally with ETS or with the there\u2019s other backers we should keep in mind?  Thanks.  \n \n", "original_text": "Stephen Baxter:  Hey thanks for the question. ", "page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74711ca769b909009597207ab6508967a88011aa2f6cd642377e8c48758bf3d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "891d70ff-e497-4562-9f56-cc85cfa81270", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Stephen Baxter:  Hey thanks for the question.  I wanted to ask about cash flow.  It\u2019s been a pretty \nvolatile line item f or you as working capital swung, was hoping you could talk a little bit about whether \n2020 was maybe more of an appropriate or normalized level for your cash flow and also anything you \ncan share about your expectations for fiscal 2021 and whether we should  be thinking about, you \nknow, directionally with ETS or with the there\u2019s other backers we should keep in mind?  Thanks.  \n \n Jason Hollar:  Yes, sure, thanks for the question and you appropriately highlight that there was some \nvolatility within the fiscal year '20 as well as we saw in Q3 very strong cash flow as a lot of that \nvolume surge benefited us and we sold out of inventory and a little bit of the carryover effect than for \nQ4. \n \n  So when you look at the two quarters together I think they\u2019re relatively indic ative of what you \nshould expect. ", "original_text": "It\u2019s been a pretty \nvolatile line item f or you as working capital swung, was hoping you could talk a little bit about whether \n2020 was maybe more of an appropriate or normalized level for your cash flow and also anything you \ncan share about your expectations for fiscal 2021 and whether we should  be thinking about, you \nknow, directionally with ETS or with the there\u2019s other backers we should keep in mind? "}, "hash": "bf5454c55527e5fe6a0850a10eedb922c1b26fd6ab934a40cd00856827223187", "class_name": "RelatedNodeInfo"}}, "text": "I wanted to ask about cash flow. ", "start_char_idx": 163, "end_char_idx": 196, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "891d70ff-e497-4562-9f56-cc85cfa81270": {"__data__": {"id_": "891d70ff-e497-4562-9f56-cc85cfa81270", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Stephen Baxter:  Hey thanks for the question.  I wanted to ask about cash flow.  It\u2019s been a pretty \nvolatile line item f or you as working capital swung, was hoping you could talk a little bit about whether \n2020 was maybe more of an appropriate or normalized level for your cash flow and also anything you \ncan share about your expectations for fiscal 2021 and whether we should  be thinking about, you \nknow, directionally with ETS or with the there\u2019s other backers we should keep in mind?  Thanks.  \n \n Jason Hollar:  Yes, sure, thanks for the question and you appropriately highlight that there was some \nvolatility within the fiscal year '20 as well as we saw in Q3 very strong cash flow as a lot of that \nvolume surge benefited us and we sold out of inventory and a little bit of the carryover effect than for \nQ4. \n \n  So when you look at the two quarters together I think they\u2019re relatively indic ative of what you \nshould expect. ", "original_text": "It\u2019s been a pretty \nvolatile line item f or you as working capital swung, was hoping you could talk a little bit about whether \n2020 was maybe more of an appropriate or normalized level for your cash flow and also anything you \ncan share about your expectations for fiscal 2021 and whether we should  be thinking about, you \nknow, directionally with ETS or with the there\u2019s other backers we should keep in mind? ", "page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1d5ca99a-62c2-481c-bc71-e592b11cf6c6", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ffcbb486dba2a9527f66edd6ca79bb37d5848e67108ba2664fc2f4335513c7d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df3d167a-ae8c-4048-bd41-1e2dcebc16e6", "node_type": "1", "metadata": {"window": "We'll next go to Stephen Baxter with Wolfe Research.  Please go ahead.  \n \n Stephen Baxter:  Hey thanks for the question.  I wanted to ask about cash flow.  It\u2019s been a pretty \nvolatile line item f or you as working capital swung, was hoping you could talk a little bit about whether \n2020 was maybe more of an appropriate or normalized level for your cash flow and also anything you \ncan share about your expectations for fiscal 2021 and whether we should  be thinking about, you \nknow, directionally with ETS or with the there\u2019s other backers we should keep in mind?  Thanks.  \n \n Jason Hollar:  Yes, sure, thanks for the question and you appropriately highlight that there was some \nvolatility within the fiscal year '20 as well as we saw in Q3 very strong cash flow as a lot of that \nvolume surge benefited us and we sold out of inventory and a little bit of the carryover effect than for \nQ4. \n \n ", "original_text": "I wanted to ask about cash flow. ", "page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64be2d9b7f23947c72981027fb929fea86f3495135a09bda8de829cc708d3a40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e8a1de4-0a2b-4ef2-b80d-e1c2e07f504d", "node_type": "1", "metadata": {"window": "Stephen Baxter:  Hey thanks for the question.  I wanted to ask about cash flow.  It\u2019s been a pretty \nvolatile line item f or you as working capital swung, was hoping you could talk a little bit about whether \n2020 was maybe more of an appropriate or normalized level for your cash flow and also anything you \ncan share about your expectations for fiscal 2021 and whether we should  be thinking about, you \nknow, directionally with ETS or with the there\u2019s other backers we should keep in mind?  Thanks.  \n \n Jason Hollar:  Yes, sure, thanks for the question and you appropriately highlight that there was some \nvolatility within the fiscal year '20 as well as we saw in Q3 very strong cash flow as a lot of that \nvolume surge benefited us and we sold out of inventory and a little bit of the carryover effect than for \nQ4. \n \n  So when you look at the two quarters together I think they\u2019re relatively indic ative of what you \nshould expect.  I think the one thing to keep in mind I think we\u2019ve been very consistent about the day \nof the week in which the quarter and the year ends is very important to us. ", "original_text": "Thanks.  \n \n"}, "hash": "45dcb72711dd5d373e9463555bcabf3f3352821d8bfeed717129f80696b81a3d", "class_name": "RelatedNodeInfo"}}, "text": "It\u2019s been a pretty \nvolatile line item f or you as working capital swung, was hoping you could talk a little bit about whether \n2020 was maybe more of an appropriate or normalized level for your cash flow and also anything you \ncan share about your expectations for fiscal 2021 and whether we should  be thinking about, you \nknow, directionally with ETS or with the there\u2019s other backers we should keep in mind? ", "start_char_idx": 196, "end_char_idx": 608, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e8a1de4-0a2b-4ef2-b80d-e1c2e07f504d": {"__data__": {"id_": "9e8a1de4-0a2b-4ef2-b80d-e1c2e07f504d", "embedding": null, "metadata": {"window": "Stephen Baxter:  Hey thanks for the question.  I wanted to ask about cash flow.  It\u2019s been a pretty \nvolatile line item f or you as working capital swung, was hoping you could talk a little bit about whether \n2020 was maybe more of an appropriate or normalized level for your cash flow and also anything you \ncan share about your expectations for fiscal 2021 and whether we should  be thinking about, you \nknow, directionally with ETS or with the there\u2019s other backers we should keep in mind?  Thanks.  \n \n Jason Hollar:  Yes, sure, thanks for the question and you appropriately highlight that there was some \nvolatility within the fiscal year '20 as well as we saw in Q3 very strong cash flow as a lot of that \nvolume surge benefited us and we sold out of inventory and a little bit of the carryover effect than for \nQ4. \n \n  So when you look at the two quarters together I think they\u2019re relatively indic ative of what you \nshould expect.  I think the one thing to keep in mind I think we\u2019ve been very consistent about the day \nof the week in which the quarter and the year ends is very important to us. ", "original_text": "Thanks.  \n \n", "page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1d5ca99a-62c2-481c-bc71-e592b11cf6c6", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ffcbb486dba2a9527f66edd6ca79bb37d5848e67108ba2664fc2f4335513c7d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "891d70ff-e497-4562-9f56-cc85cfa81270", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Stephen Baxter:  Hey thanks for the question.  I wanted to ask about cash flow.  It\u2019s been a pretty \nvolatile line item f or you as working capital swung, was hoping you could talk a little bit about whether \n2020 was maybe more of an appropriate or normalized level for your cash flow and also anything you \ncan share about your expectations for fiscal 2021 and whether we should  be thinking about, you \nknow, directionally with ETS or with the there\u2019s other backers we should keep in mind?  Thanks.  \n \n Jason Hollar:  Yes, sure, thanks for the question and you appropriately highlight that there was some \nvolatility within the fiscal year '20 as well as we saw in Q3 very strong cash flow as a lot of that \nvolume surge benefited us and we sold out of inventory and a little bit of the carryover effect than for \nQ4. \n \n  So when you look at the two quarters together I think they\u2019re relatively indic ative of what you \nshould expect. ", "original_text": "It\u2019s been a pretty \nvolatile line item f or you as working capital swung, was hoping you could talk a little bit about whether \n2020 was maybe more of an appropriate or normalized level for your cash flow and also anything you \ncan share about your expectations for fiscal 2021 and whether we should  be thinking about, you \nknow, directionally with ETS or with the there\u2019s other backers we should keep in mind? ", "page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6993c19774be87377411a7f37a35d91d38c24eabf078df721bf4365a501d47ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18638624-ec2b-4b2c-b012-72ec8bcb097c", "node_type": "1", "metadata": {"window": "I wanted to ask about cash flow.  It\u2019s been a pretty \nvolatile line item f or you as working capital swung, was hoping you could talk a little bit about whether \n2020 was maybe more of an appropriate or normalized level for your cash flow and also anything you \ncan share about your expectations for fiscal 2021 and whether we should  be thinking about, you \nknow, directionally with ETS or with the there\u2019s other backers we should keep in mind?  Thanks.  \n \n Jason Hollar:  Yes, sure, thanks for the question and you appropriately highlight that there was some \nvolatility within the fiscal year '20 as well as we saw in Q3 very strong cash flow as a lot of that \nvolume surge benefited us and we sold out of inventory and a little bit of the carryover effect than for \nQ4. \n \n  So when you look at the two quarters together I think they\u2019re relatively indic ative of what you \nshould expect.  I think the one thing to keep in mind I think we\u2019ve been very consistent about the day \nof the week in which the quarter and the year ends is very important to us.  And for fiscal year '20 it \nwas more adverse compared to many  other years in just in terms of how the calendar fell. ", "original_text": "Jason Hollar:  Yes, sure, thanks for the question and you appropriately highlight that there was some \nvolatility within the fiscal year '20 as well as we saw in Q3 very strong cash flow as a lot of that \nvolume surge benefited us and we sold out of inventory and a little bit of the carryover effect than for \nQ4. \n \n "}, "hash": "e3636952ac40561f84805bf6feda353745ed9156afb7ad2480e048c75c3596b8", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 608, "end_char_idx": 620, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18638624-ec2b-4b2c-b012-72ec8bcb097c": {"__data__": {"id_": "18638624-ec2b-4b2c-b012-72ec8bcb097c", "embedding": null, "metadata": {"window": "I wanted to ask about cash flow.  It\u2019s been a pretty \nvolatile line item f or you as working capital swung, was hoping you could talk a little bit about whether \n2020 was maybe more of an appropriate or normalized level for your cash flow and also anything you \ncan share about your expectations for fiscal 2021 and whether we should  be thinking about, you \nknow, directionally with ETS or with the there\u2019s other backers we should keep in mind?  Thanks.  \n \n Jason Hollar:  Yes, sure, thanks for the question and you appropriately highlight that there was some \nvolatility within the fiscal year '20 as well as we saw in Q3 very strong cash flow as a lot of that \nvolume surge benefited us and we sold out of inventory and a little bit of the carryover effect than for \nQ4. \n \n  So when you look at the two quarters together I think they\u2019re relatively indic ative of what you \nshould expect.  I think the one thing to keep in mind I think we\u2019ve been very consistent about the day \nof the week in which the quarter and the year ends is very important to us.  And for fiscal year '20 it \nwas more adverse compared to many  other years in just in terms of how the calendar fell. ", "original_text": "Jason Hollar:  Yes, sure, thanks for the question and you appropriately highlight that there was some \nvolatility within the fiscal year '20 as well as we saw in Q3 very strong cash flow as a lot of that \nvolume surge benefited us and we sold out of inventory and a little bit of the carryover effect than for \nQ4. \n \n ", "page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1d5ca99a-62c2-481c-bc71-e592b11cf6c6", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ffcbb486dba2a9527f66edd6ca79bb37d5848e67108ba2664fc2f4335513c7d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e8a1de4-0a2b-4ef2-b80d-e1c2e07f504d", "node_type": "1", "metadata": {"window": "Stephen Baxter:  Hey thanks for the question.  I wanted to ask about cash flow.  It\u2019s been a pretty \nvolatile line item f or you as working capital swung, was hoping you could talk a little bit about whether \n2020 was maybe more of an appropriate or normalized level for your cash flow and also anything you \ncan share about your expectations for fiscal 2021 and whether we should  be thinking about, you \nknow, directionally with ETS or with the there\u2019s other backers we should keep in mind?  Thanks.  \n \n Jason Hollar:  Yes, sure, thanks for the question and you appropriately highlight that there was some \nvolatility within the fiscal year '20 as well as we saw in Q3 very strong cash flow as a lot of that \nvolume surge benefited us and we sold out of inventory and a little bit of the carryover effect than for \nQ4. \n \n  So when you look at the two quarters together I think they\u2019re relatively indic ative of what you \nshould expect.  I think the one thing to keep in mind I think we\u2019ve been very consistent about the day \nof the week in which the quarter and the year ends is very important to us. ", "original_text": "Thanks.  \n \n", "page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "14d84d6f2c0c2e2a54b59a8eb3a77e92545cf2600abd92d70a2ae790b500112b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19293be8-a574-47ba-b277-16ca4eaedbf4", "node_type": "1", "metadata": {"window": "It\u2019s been a pretty \nvolatile line item f or you as working capital swung, was hoping you could talk a little bit about whether \n2020 was maybe more of an appropriate or normalized level for your cash flow and also anything you \ncan share about your expectations for fiscal 2021 and whether we should  be thinking about, you \nknow, directionally with ETS or with the there\u2019s other backers we should keep in mind?  Thanks.  \n \n Jason Hollar:  Yes, sure, thanks for the question and you appropriately highlight that there was some \nvolatility within the fiscal year '20 as well as we saw in Q3 very strong cash flow as a lot of that \nvolume surge benefited us and we sold out of inventory and a little bit of the carryover effect than for \nQ4. \n \n  So when you look at the two quarters together I think they\u2019re relatively indic ative of what you \nshould expect.  I think the one thing to keep in mind I think we\u2019ve been very consistent about the day \nof the week in which the quarter and the year ends is very important to us.  And for fiscal year '20 it \nwas more adverse compared to many  other years in just in terms of how the calendar fell.  So at this \n$2 billion level I think it\u2019s a little bit low from a calendarization perspective. ", "original_text": "So when you look at the two quarters together I think they\u2019re relatively indic ative of what you \nshould expect. "}, "hash": "a77e4d531d45c03df2bfa78071b95031a00e3f5f88370fa1dd4eaf0f50e63713", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yes, sure, thanks for the question and you appropriately highlight that there was some \nvolatility within the fiscal year '20 as well as we saw in Q3 very strong cash flow as a lot of that \nvolume surge benefited us and we sold out of inventory and a little bit of the carryover effect than for \nQ4. \n \n ", "start_char_idx": 620, "end_char_idx": 939, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19293be8-a574-47ba-b277-16ca4eaedbf4": {"__data__": {"id_": "19293be8-a574-47ba-b277-16ca4eaedbf4", "embedding": null, "metadata": {"window": "It\u2019s been a pretty \nvolatile line item f or you as working capital swung, was hoping you could talk a little bit about whether \n2020 was maybe more of an appropriate or normalized level for your cash flow and also anything you \ncan share about your expectations for fiscal 2021 and whether we should  be thinking about, you \nknow, directionally with ETS or with the there\u2019s other backers we should keep in mind?  Thanks.  \n \n Jason Hollar:  Yes, sure, thanks for the question and you appropriately highlight that there was some \nvolatility within the fiscal year '20 as well as we saw in Q3 very strong cash flow as a lot of that \nvolume surge benefited us and we sold out of inventory and a little bit of the carryover effect than for \nQ4. \n \n  So when you look at the two quarters together I think they\u2019re relatively indic ative of what you \nshould expect.  I think the one thing to keep in mind I think we\u2019ve been very consistent about the day \nof the week in which the quarter and the year ends is very important to us.  And for fiscal year '20 it \nwas more adverse compared to many  other years in just in terms of how the calendar fell.  So at this \n$2 billion level I think it\u2019s a little bit low from a calendarization perspective. ", "original_text": "So when you look at the two quarters together I think they\u2019re relatively indic ative of what you \nshould expect. ", "page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1d5ca99a-62c2-481c-bc71-e592b11cf6c6", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ffcbb486dba2a9527f66edd6ca79bb37d5848e67108ba2664fc2f4335513c7d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18638624-ec2b-4b2c-b012-72ec8bcb097c", "node_type": "1", "metadata": {"window": "I wanted to ask about cash flow.  It\u2019s been a pretty \nvolatile line item f or you as working capital swung, was hoping you could talk a little bit about whether \n2020 was maybe more of an appropriate or normalized level for your cash flow and also anything you \ncan share about your expectations for fiscal 2021 and whether we should  be thinking about, you \nknow, directionally with ETS or with the there\u2019s other backers we should keep in mind?  Thanks.  \n \n Jason Hollar:  Yes, sure, thanks for the question and you appropriately highlight that there was some \nvolatility within the fiscal year '20 as well as we saw in Q3 very strong cash flow as a lot of that \nvolume surge benefited us and we sold out of inventory and a little bit of the carryover effect than for \nQ4. \n \n  So when you look at the two quarters together I think they\u2019re relatively indic ative of what you \nshould expect.  I think the one thing to keep in mind I think we\u2019ve been very consistent about the day \nof the week in which the quarter and the year ends is very important to us.  And for fiscal year '20 it \nwas more adverse compared to many  other years in just in terms of how the calendar fell. ", "original_text": "Jason Hollar:  Yes, sure, thanks for the question and you appropriately highlight that there was some \nvolatility within the fiscal year '20 as well as we saw in Q3 very strong cash flow as a lot of that \nvolume surge benefited us and we sold out of inventory and a little bit of the carryover effect than for \nQ4. \n \n ", "page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca6eaa315d0c29b2708e662cc17b179baf6842f985db7d92bd89d11f9f5d865b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9cb2bc8-8132-4c8b-9b7c-8f4d114d2f00", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Jason Hollar:  Yes, sure, thanks for the question and you appropriately highlight that there was some \nvolatility within the fiscal year '20 as well as we saw in Q3 very strong cash flow as a lot of that \nvolume surge benefited us and we sold out of inventory and a little bit of the carryover effect than for \nQ4. \n \n  So when you look at the two quarters together I think they\u2019re relatively indic ative of what you \nshould expect.  I think the one thing to keep in mind I think we\u2019ve been very consistent about the day \nof the week in which the quarter and the year ends is very important to us.  And for fiscal year '20 it \nwas more adverse compared to many  other years in just in terms of how the calendar fell.  So at this \n$2 billion level I think it\u2019s a little bit low from a calendarization perspective.  And I think next year in \nfiscal year '21 it will be a little bit more normal in that regard. ", "original_text": "I think the one thing to keep in mind I think we\u2019ve been very consistent about the day \nof the week in which the quarter and the year ends is very important to us. "}, "hash": "6d368d2971b7ef7bd59c1e6543f570c271e1a4a830d895ae93c59b0d15e320a0", "class_name": "RelatedNodeInfo"}}, "text": "So when you look at the two quarters together I think they\u2019re relatively indic ative of what you \nshould expect. ", "start_char_idx": 939, "end_char_idx": 1052, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9cb2bc8-8132-4c8b-9b7c-8f4d114d2f00": {"__data__": {"id_": "d9cb2bc8-8132-4c8b-9b7c-8f4d114d2f00", "embedding": null, "metadata": {"window": "Thanks.  \n \n Jason Hollar:  Yes, sure, thanks for the question and you appropriately highlight that there was some \nvolatility within the fiscal year '20 as well as we saw in Q3 very strong cash flow as a lot of that \nvolume surge benefited us and we sold out of inventory and a little bit of the carryover effect than for \nQ4. \n \n  So when you look at the two quarters together I think they\u2019re relatively indic ative of what you \nshould expect.  I think the one thing to keep in mind I think we\u2019ve been very consistent about the day \nof the week in which the quarter and the year ends is very important to us.  And for fiscal year '20 it \nwas more adverse compared to many  other years in just in terms of how the calendar fell.  So at this \n$2 billion level I think it\u2019s a little bit low from a calendarization perspective.  And I think next year in \nfiscal year '21 it will be a little bit more normal in that regard. ", "original_text": "I think the one thing to keep in mind I think we\u2019ve been very consistent about the day \nof the week in which the quarter and the year ends is very important to us. ", "page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1d5ca99a-62c2-481c-bc71-e592b11cf6c6", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ffcbb486dba2a9527f66edd6ca79bb37d5848e67108ba2664fc2f4335513c7d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19293be8-a574-47ba-b277-16ca4eaedbf4", "node_type": "1", "metadata": {"window": "It\u2019s been a pretty \nvolatile line item f or you as working capital swung, was hoping you could talk a little bit about whether \n2020 was maybe more of an appropriate or normalized level for your cash flow and also anything you \ncan share about your expectations for fiscal 2021 and whether we should  be thinking about, you \nknow, directionally with ETS or with the there\u2019s other backers we should keep in mind?  Thanks.  \n \n Jason Hollar:  Yes, sure, thanks for the question and you appropriately highlight that there was some \nvolatility within the fiscal year '20 as well as we saw in Q3 very strong cash flow as a lot of that \nvolume surge benefited us and we sold out of inventory and a little bit of the carryover effect than for \nQ4. \n \n  So when you look at the two quarters together I think they\u2019re relatively indic ative of what you \nshould expect.  I think the one thing to keep in mind I think we\u2019ve been very consistent about the day \nof the week in which the quarter and the year ends is very important to us.  And for fiscal year '20 it \nwas more adverse compared to many  other years in just in terms of how the calendar fell.  So at this \n$2 billion level I think it\u2019s a little bit low from a calendarization perspective. ", "original_text": "So when you look at the two quarters together I think they\u2019re relatively indic ative of what you \nshould expect. ", "page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "802e38bcd52cb86989718c893ca1fd0fdcf2314bd9f3cff48e12ccbef4e3af05", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90a09c99-07a2-4301-a464-453cdeefedbd", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes, sure, thanks for the question and you appropriately highlight that there was some \nvolatility within the fiscal year '20 as well as we saw in Q3 very strong cash flow as a lot of that \nvolume surge benefited us and we sold out of inventory and a little bit of the carryover effect than for \nQ4. \n \n  So when you look at the two quarters together I think they\u2019re relatively indic ative of what you \nshould expect.  I think the one thing to keep in mind I think we\u2019ve been very consistent about the day \nof the week in which the quarter and the year ends is very important to us.  And for fiscal year '20 it \nwas more adverse compared to many  other years in just in terms of how the calendar fell.  So at this \n$2 billion level I think it\u2019s a little bit low from a calendarization perspective.  And I think next year in \nfiscal year '21 it will be a little bit more normal in that regard.  And all other  things being equal I\u2019d \nexpect it to be a little bit better but then of course it all comes down to other factors that may impact \nthe underlying cash flow.  \n \n", "original_text": "And for fiscal year '20 it \nwas more adverse compared to many  other years in just in terms of how the calendar fell. "}, "hash": "c586e0f3884c077c26200dcca13cb3d79d4207c8757d7684261719f44a3ced8a", "class_name": "RelatedNodeInfo"}}, "text": "I think the one thing to keep in mind I think we\u2019ve been very consistent about the day \nof the week in which the quarter and the year ends is very important to us. ", "start_char_idx": 1052, "end_char_idx": 1216, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90a09c99-07a2-4301-a464-453cdeefedbd": {"__data__": {"id_": "90a09c99-07a2-4301-a464-453cdeefedbd", "embedding": null, "metadata": {"window": "Jason Hollar:  Yes, sure, thanks for the question and you appropriately highlight that there was some \nvolatility within the fiscal year '20 as well as we saw in Q3 very strong cash flow as a lot of that \nvolume surge benefited us and we sold out of inventory and a little bit of the carryover effect than for \nQ4. \n \n  So when you look at the two quarters together I think they\u2019re relatively indic ative of what you \nshould expect.  I think the one thing to keep in mind I think we\u2019ve been very consistent about the day \nof the week in which the quarter and the year ends is very important to us.  And for fiscal year '20 it \nwas more adverse compared to many  other years in just in terms of how the calendar fell.  So at this \n$2 billion level I think it\u2019s a little bit low from a calendarization perspective.  And I think next year in \nfiscal year '21 it will be a little bit more normal in that regard.  And all other  things being equal I\u2019d \nexpect it to be a little bit better but then of course it all comes down to other factors that may impact \nthe underlying cash flow.  \n \n", "original_text": "And for fiscal year '20 it \nwas more adverse compared to many  other years in just in terms of how the calendar fell. ", "page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1d5ca99a-62c2-481c-bc71-e592b11cf6c6", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ffcbb486dba2a9527f66edd6ca79bb37d5848e67108ba2664fc2f4335513c7d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9cb2bc8-8132-4c8b-9b7c-8f4d114d2f00", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Jason Hollar:  Yes, sure, thanks for the question and you appropriately highlight that there was some \nvolatility within the fiscal year '20 as well as we saw in Q3 very strong cash flow as a lot of that \nvolume surge benefited us and we sold out of inventory and a little bit of the carryover effect than for \nQ4. \n \n  So when you look at the two quarters together I think they\u2019re relatively indic ative of what you \nshould expect.  I think the one thing to keep in mind I think we\u2019ve been very consistent about the day \nof the week in which the quarter and the year ends is very important to us.  And for fiscal year '20 it \nwas more adverse compared to many  other years in just in terms of how the calendar fell.  So at this \n$2 billion level I think it\u2019s a little bit low from a calendarization perspective.  And I think next year in \nfiscal year '21 it will be a little bit more normal in that regard. ", "original_text": "I think the one thing to keep in mind I think we\u2019ve been very consistent about the day \nof the week in which the quarter and the year ends is very important to us. ", "page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74fd18558af631d777b3a094ebbaf7f102c0bf97e52fff256e12f10eff94512c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5950fa1f-feba-4980-98fa-d0a4caac1c03", "node_type": "1", "metadata": {"window": "So when you look at the two quarters together I think they\u2019re relatively indic ative of what you \nshould expect.  I think the one thing to keep in mind I think we\u2019ve been very consistent about the day \nof the week in which the quarter and the year ends is very important to us.  And for fiscal year '20 it \nwas more adverse compared to many  other years in just in terms of how the calendar fell.  So at this \n$2 billion level I think it\u2019s a little bit low from a calendarization perspective.  And I think next year in \nfiscal year '21 it will be a little bit more normal in that regard.  And all other  things being equal I\u2019d \nexpect it to be a little bit better but then of course it all comes down to other factors that may impact \nthe underlying cash flow.  \n \n Stephen Baxter:  Thank you.  \n ", "original_text": "So at this \n$2 billion level I think it\u2019s a little bit low from a calendarization perspective. "}, "hash": "6b52fc5e098afeb79ed70323d2d7185f9ae34a43a230249960b329b5deec9413", "class_name": "RelatedNodeInfo"}}, "text": "And for fiscal year '20 it \nwas more adverse compared to many  other years in just in terms of how the calendar fell. ", "start_char_idx": 1216, "end_char_idx": 1334, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5950fa1f-feba-4980-98fa-d0a4caac1c03": {"__data__": {"id_": "5950fa1f-feba-4980-98fa-d0a4caac1c03", "embedding": null, "metadata": {"window": "So when you look at the two quarters together I think they\u2019re relatively indic ative of what you \nshould expect.  I think the one thing to keep in mind I think we\u2019ve been very consistent about the day \nof the week in which the quarter and the year ends is very important to us.  And for fiscal year '20 it \nwas more adverse compared to many  other years in just in terms of how the calendar fell.  So at this \n$2 billion level I think it\u2019s a little bit low from a calendarization perspective.  And I think next year in \nfiscal year '21 it will be a little bit more normal in that regard.  And all other  things being equal I\u2019d \nexpect it to be a little bit better but then of course it all comes down to other factors that may impact \nthe underlying cash flow.  \n \n Stephen Baxter:  Thank you.  \n ", "original_text": "So at this \n$2 billion level I think it\u2019s a little bit low from a calendarization perspective. ", "page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1d5ca99a-62c2-481c-bc71-e592b11cf6c6", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ffcbb486dba2a9527f66edd6ca79bb37d5848e67108ba2664fc2f4335513c7d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90a09c99-07a2-4301-a464-453cdeefedbd", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes, sure, thanks for the question and you appropriately highlight that there was some \nvolatility within the fiscal year '20 as well as we saw in Q3 very strong cash flow as a lot of that \nvolume surge benefited us and we sold out of inventory and a little bit of the carryover effect than for \nQ4. \n \n  So when you look at the two quarters together I think they\u2019re relatively indic ative of what you \nshould expect.  I think the one thing to keep in mind I think we\u2019ve been very consistent about the day \nof the week in which the quarter and the year ends is very important to us.  And for fiscal year '20 it \nwas more adverse compared to many  other years in just in terms of how the calendar fell.  So at this \n$2 billion level I think it\u2019s a little bit low from a calendarization perspective.  And I think next year in \nfiscal year '21 it will be a little bit more normal in that regard.  And all other  things being equal I\u2019d \nexpect it to be a little bit better but then of course it all comes down to other factors that may impact \nthe underlying cash flow.  \n \n", "original_text": "And for fiscal year '20 it \nwas more adverse compared to many  other years in just in terms of how the calendar fell. ", "page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef311214cc743822721b85fc6b8fe86f9e3d3c34dcdf291ed4e0f187b6ccbc61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09372fc5-0656-4432-8eb2-30b4a24b2f49", "node_type": "1", "metadata": {"window": "I think the one thing to keep in mind I think we\u2019ve been very consistent about the day \nof the week in which the quarter and the year ends is very important to us.  And for fiscal year '20 it \nwas more adverse compared to many  other years in just in terms of how the calendar fell.  So at this \n$2 billion level I think it\u2019s a little bit low from a calendarization perspective.  And I think next year in \nfiscal year '21 it will be a little bit more normal in that regard.  And all other  things being equal I\u2019d \nexpect it to be a little bit better but then of course it all comes down to other factors that may impact \nthe underlying cash flow.  \n \n Stephen Baxter:  Thank you.  \n ", "original_text": "And I think next year in \nfiscal year '21 it will be a little bit more normal in that regard. "}, "hash": "e2f50ff6caf4dedf22db3769da57968c5f430d845b21089d960de4cfc7eb62d4", "class_name": "RelatedNodeInfo"}}, "text": "So at this \n$2 billion level I think it\u2019s a little bit low from a calendarization perspective. ", "start_char_idx": 1334, "end_char_idx": 1429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09372fc5-0656-4432-8eb2-30b4a24b2f49": {"__data__": {"id_": "09372fc5-0656-4432-8eb2-30b4a24b2f49", "embedding": null, "metadata": {"window": "I think the one thing to keep in mind I think we\u2019ve been very consistent about the day \nof the week in which the quarter and the year ends is very important to us.  And for fiscal year '20 it \nwas more adverse compared to many  other years in just in terms of how the calendar fell.  So at this \n$2 billion level I think it\u2019s a little bit low from a calendarization perspective.  And I think next year in \nfiscal year '21 it will be a little bit more normal in that regard.  And all other  things being equal I\u2019d \nexpect it to be a little bit better but then of course it all comes down to other factors that may impact \nthe underlying cash flow.  \n \n Stephen Baxter:  Thank you.  \n ", "original_text": "And I think next year in \nfiscal year '21 it will be a little bit more normal in that regard. ", "page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1d5ca99a-62c2-481c-bc71-e592b11cf6c6", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ffcbb486dba2a9527f66edd6ca79bb37d5848e67108ba2664fc2f4335513c7d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5950fa1f-feba-4980-98fa-d0a4caac1c03", "node_type": "1", "metadata": {"window": "So when you look at the two quarters together I think they\u2019re relatively indic ative of what you \nshould expect.  I think the one thing to keep in mind I think we\u2019ve been very consistent about the day \nof the week in which the quarter and the year ends is very important to us.  And for fiscal year '20 it \nwas more adverse compared to many  other years in just in terms of how the calendar fell.  So at this \n$2 billion level I think it\u2019s a little bit low from a calendarization perspective.  And I think next year in \nfiscal year '21 it will be a little bit more normal in that regard.  And all other  things being equal I\u2019d \nexpect it to be a little bit better but then of course it all comes down to other factors that may impact \nthe underlying cash flow.  \n \n Stephen Baxter:  Thank you.  \n ", "original_text": "So at this \n$2 billion level I think it\u2019s a little bit low from a calendarization perspective. ", "page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5050bf300cf021cd1a056d29e3dc09b022e8593c99c63919b376795880d5da66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4e3a009-f1c2-4b88-b940-a379006cf300", "node_type": "1", "metadata": {"window": "And for fiscal year '20 it \nwas more adverse compared to many  other years in just in terms of how the calendar fell.  So at this \n$2 billion level I think it\u2019s a little bit low from a calendarization perspective.  And I think next year in \nfiscal year '21 it will be a little bit more normal in that regard.  And all other  things being equal I\u2019d \nexpect it to be a little bit better but then of course it all comes down to other factors that may impact \nthe underlying cash flow.  \n \n Stephen Baxter:  Thank you.  \n ", "original_text": "And all other  things being equal I\u2019d \nexpect it to be a little bit better but then of course it all comes down to other factors that may impact \nthe underlying cash flow.  \n \n"}, "hash": "1fe294551365f781d26e3ec5d32ff04ccef08fa0af6c7fb302290cbf26aa026a", "class_name": "RelatedNodeInfo"}}, "text": "And I think next year in \nfiscal year '21 it will be a little bit more normal in that regard. ", "start_char_idx": 1429, "end_char_idx": 1523, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4e3a009-f1c2-4b88-b940-a379006cf300": {"__data__": {"id_": "c4e3a009-f1c2-4b88-b940-a379006cf300", "embedding": null, "metadata": {"window": "And for fiscal year '20 it \nwas more adverse compared to many  other years in just in terms of how the calendar fell.  So at this \n$2 billion level I think it\u2019s a little bit low from a calendarization perspective.  And I think next year in \nfiscal year '21 it will be a little bit more normal in that regard.  And all other  things being equal I\u2019d \nexpect it to be a little bit better but then of course it all comes down to other factors that may impact \nthe underlying cash flow.  \n \n Stephen Baxter:  Thank you.  \n ", "original_text": "And all other  things being equal I\u2019d \nexpect it to be a little bit better but then of course it all comes down to other factors that may impact \nthe underlying cash flow.  \n \n", "page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1d5ca99a-62c2-481c-bc71-e592b11cf6c6", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ffcbb486dba2a9527f66edd6ca79bb37d5848e67108ba2664fc2f4335513c7d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09372fc5-0656-4432-8eb2-30b4a24b2f49", "node_type": "1", "metadata": {"window": "I think the one thing to keep in mind I think we\u2019ve been very consistent about the day \nof the week in which the quarter and the year ends is very important to us.  And for fiscal year '20 it \nwas more adverse compared to many  other years in just in terms of how the calendar fell.  So at this \n$2 billion level I think it\u2019s a little bit low from a calendarization perspective.  And I think next year in \nfiscal year '21 it will be a little bit more normal in that regard.  And all other  things being equal I\u2019d \nexpect it to be a little bit better but then of course it all comes down to other factors that may impact \nthe underlying cash flow.  \n \n Stephen Baxter:  Thank you.  \n ", "original_text": "And I think next year in \nfiscal year '21 it will be a little bit more normal in that regard. ", "page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ee7c9a07c0e1aa5903ac7d0b3d73c445a26442bbbd7a7a86d03e08b6b5e7e5aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8a66a33-be7b-4846-b8f5-68e52505864f", "node_type": "1", "metadata": {"window": "So at this \n$2 billion level I think it\u2019s a little bit low from a calendarization perspective.  And I think next year in \nfiscal year '21 it will be a little bit more normal in that regard.  And all other  things being equal I\u2019d \nexpect it to be a little bit better but then of course it all comes down to other factors that may impact \nthe underlying cash flow.  \n \n Stephen Baxter:  Thank you.  \n ", "original_text": "Stephen Baxter:  Thank you.  \n "}, "hash": "19ff253a8927717fbc8d0cff10022acb007d536293e1d541aa2fd10e50b3190e", "class_name": "RelatedNodeInfo"}}, "text": "And all other  things being equal I\u2019d \nexpect it to be a little bit better but then of course it all comes down to other factors that may impact \nthe underlying cash flow.  \n \n", "start_char_idx": 1523, "end_char_idx": 1699, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8a66a33-be7b-4846-b8f5-68e52505864f": {"__data__": {"id_": "e8a66a33-be7b-4846-b8f5-68e52505864f", "embedding": null, "metadata": {"window": "So at this \n$2 billion level I think it\u2019s a little bit low from a calendarization perspective.  And I think next year in \nfiscal year '21 it will be a little bit more normal in that regard.  And all other  things being equal I\u2019d \nexpect it to be a little bit better but then of course it all comes down to other factors that may impact \nthe underlying cash flow.  \n \n Stephen Baxter:  Thank you.  \n ", "original_text": "Stephen Baxter:  Thank you.  \n ", "page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1d5ca99a-62c2-481c-bc71-e592b11cf6c6", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ffcbb486dba2a9527f66edd6ca79bb37d5848e67108ba2664fc2f4335513c7d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4e3a009-f1c2-4b88-b940-a379006cf300", "node_type": "1", "metadata": {"window": "And for fiscal year '20 it \nwas more adverse compared to many  other years in just in terms of how the calendar fell.  So at this \n$2 billion level I think it\u2019s a little bit low from a calendarization perspective.  And I think next year in \nfiscal year '21 it will be a little bit more normal in that regard.  And all other  things being equal I\u2019d \nexpect it to be a little bit better but then of course it all comes down to other factors that may impact \nthe underlying cash flow.  \n \n Stephen Baxter:  Thank you.  \n ", "original_text": "And all other  things being equal I\u2019d \nexpect it to be a little bit better but then of course it all comes down to other factors that may impact \nthe underlying cash flow.  \n \n", "page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1682402a25f8ca7248683f715e8b9407dad7c4cec38e5f5acf469a0e21c380c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3bc5bd06-0eb7-476b-9a85-c97049671882", "node_type": "1", "metadata": {"window": " \nPage 28 of 31 \n \nKevin Moran:  Next question please.  \n \n Operator:  Thank you.  We'll next go to Steve Valliquette with Barclays.  Please go ahead.  \n \n", "original_text": " \nPage 28 of 31 \n \nKevin Moran:  Next question please.  \n \n"}, "hash": "1826934750483cd5a72c4e04a3db21c4f1f5d26e5d567bb26507737031dd2106", "class_name": "RelatedNodeInfo"}}, "text": "Stephen Baxter:  Thank you.  \n ", "start_char_idx": 1699, "end_char_idx": 1730, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3bc5bd06-0eb7-476b-9a85-c97049671882": {"__data__": {"id_": "3bc5bd06-0eb7-476b-9a85-c97049671882", "embedding": null, "metadata": {"window": " \nPage 28 of 31 \n \nKevin Moran:  Next question please.  \n \n Operator:  Thank you.  We'll next go to Steve Valliquette with Barclays.  Please go ahead.  \n \n", "original_text": " \nPage 28 of 31 \n \nKevin Moran:  Next question please.  \n \n", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ad72de4aefbd50a4bb9b94ed9c93e7d2871818afe8d3f81f17a3cfd57c744b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8a66a33-be7b-4846-b8f5-68e52505864f", "node_type": "1", "metadata": {"window": "So at this \n$2 billion level I think it\u2019s a little bit low from a calendarization perspective.  And I think next year in \nfiscal year '21 it will be a little bit more normal in that regard.  And all other  things being equal I\u2019d \nexpect it to be a little bit better but then of course it all comes down to other factors that may impact \nthe underlying cash flow.  \n \n Stephen Baxter:  Thank you.  \n ", "original_text": "Stephen Baxter:  Thank you.  \n ", "page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8d8c0f26f9c9b8cf313d5ba107010965ce73e7e82c6c56ebfec5420371ef355", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a99c3054-fd26-4a00-bde6-dff7d72b8340", "node_type": "1", "metadata": {"window": " \nPage 28 of 31 \n \nKevin Moran:  Next question please.  \n \n Operator:  Thank you.  We'll next go to Steve Valliquette with Barclays.  Please go ahead.  \n \n Jonathan Young:  Hi. ", "original_text": "Operator:  Thank you. "}, "hash": "5594b80313e670e908100c84fc081b20c09b96b1121b952bc5a1fc260fa0eb59", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 28 of 31 \n \nKevin Moran:  Next question please.  \n \n", "start_char_idx": 0, "end_char_idx": 59, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a99c3054-fd26-4a00-bde6-dff7d72b8340": {"__data__": {"id_": "a99c3054-fd26-4a00-bde6-dff7d72b8340", "embedding": null, "metadata": {"window": " \nPage 28 of 31 \n \nKevin Moran:  Next question please.  \n \n Operator:  Thank you.  We'll next go to Steve Valliquette with Barclays.  Please go ahead.  \n \n Jonathan Young:  Hi. ", "original_text": "Operator:  Thank you. ", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ad72de4aefbd50a4bb9b94ed9c93e7d2871818afe8d3f81f17a3cfd57c744b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3bc5bd06-0eb7-476b-9a85-c97049671882", "node_type": "1", "metadata": {"window": " \nPage 28 of 31 \n \nKevin Moran:  Next question please.  \n \n Operator:  Thank you.  We'll next go to Steve Valliquette with Barclays.  Please go ahead.  \n \n", "original_text": " \nPage 28 of 31 \n \nKevin Moran:  Next question please.  \n \n", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e9bf8b5a1baa97bdfc42a0e548c139a4f872f05b400d1aa222b31a1164e5e91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c175e8b0-4170-4672-b564-a037f131f198", "node_type": "1", "metadata": {"window": " \nPage 28 of 31 \n \nKevin Moran:  Next question please.  \n \n Operator:  Thank you.  We'll next go to Steve Valliquette with Barclays.  Please go ahead.  \n \n Jonathan Young:  Hi.  This is Jonathan Young on for Steve. ", "original_text": "We'll next go to Steve Valliquette with Barclays. "}, "hash": "78a55b8ed4e99f6b55c9cbea7ff1ec4c74999a1400c98b94a9f06454953790b3", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you. ", "start_char_idx": 59, "end_char_idx": 81, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c175e8b0-4170-4672-b564-a037f131f198": {"__data__": {"id_": "c175e8b0-4170-4672-b564-a037f131f198", "embedding": null, "metadata": {"window": " \nPage 28 of 31 \n \nKevin Moran:  Next question please.  \n \n Operator:  Thank you.  We'll next go to Steve Valliquette with Barclays.  Please go ahead.  \n \n Jonathan Young:  Hi.  This is Jonathan Young on for Steve. ", "original_text": "We'll next go to Steve Valliquette with Barclays. ", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ad72de4aefbd50a4bb9b94ed9c93e7d2871818afe8d3f81f17a3cfd57c744b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a99c3054-fd26-4a00-bde6-dff7d72b8340", "node_type": "1", "metadata": {"window": " \nPage 28 of 31 \n \nKevin Moran:  Next question please.  \n \n Operator:  Thank you.  We'll next go to Steve Valliquette with Barclays.  Please go ahead.  \n \n Jonathan Young:  Hi. ", "original_text": "Operator:  Thank you. ", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ae02f1ddad00ad23bb35f7e1ef177a83b814d3059945657e05d230395690d27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee0d6bf3-5a41-45b9-b9ed-d6c9e5f39c6e", "node_type": "1", "metadata": {"window": " \nPage 28 of 31 \n \nKevin Moran:  Next question please.  \n \n Operator:  Thank you.  We'll next go to Steve Valliquette with Barclays.  Please go ahead.  \n \n Jonathan Young:  Hi.  This is Jonathan Young on for Steve.  I guess just in relation to the mid -teens \ndown volumes that you\u2019re seeing on the medical side is that what is currently being experienced kind \nof what you saw in July? ", "original_text": "Please go ahead.  \n \n"}, "hash": "270db455997a00bceb414ee8910f58ebe30f05b1694b42c46a99d6785614eeac", "class_name": "RelatedNodeInfo"}}, "text": "We'll next go to Steve Valliquette with Barclays. ", "start_char_idx": 81, "end_char_idx": 131, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee0d6bf3-5a41-45b9-b9ed-d6c9e5f39c6e": {"__data__": {"id_": "ee0d6bf3-5a41-45b9-b9ed-d6c9e5f39c6e", "embedding": null, "metadata": {"window": " \nPage 28 of 31 \n \nKevin Moran:  Next question please.  \n \n Operator:  Thank you.  We'll next go to Steve Valliquette with Barclays.  Please go ahead.  \n \n Jonathan Young:  Hi.  This is Jonathan Young on for Steve.  I guess just in relation to the mid -teens \ndown volumes that you\u2019re seeing on the medical side is that what is currently being experienced kind \nof what you saw in July? ", "original_text": "Please go ahead.  \n \n", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ad72de4aefbd50a4bb9b94ed9c93e7d2871818afe8d3f81f17a3cfd57c744b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c175e8b0-4170-4672-b564-a037f131f198", "node_type": "1", "metadata": {"window": " \nPage 28 of 31 \n \nKevin Moran:  Next question please.  \n \n Operator:  Thank you.  We'll next go to Steve Valliquette with Barclays.  Please go ahead.  \n \n Jonathan Young:  Hi.  This is Jonathan Young on for Steve. ", "original_text": "We'll next go to Steve Valliquette with Barclays. ", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd2b3098e9eb41470750992aed8eb66b7340e16a5850af0618b1655c410b02b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50048eff-c9d9-4a3e-85b0-07e4f9073315", "node_type": "1", "metadata": {"window": "Operator:  Thank you.  We'll next go to Steve Valliquette with Barclays.  Please go ahead.  \n \n Jonathan Young:  Hi.  This is Jonathan Young on for Steve.  I guess just in relation to the mid -teens \ndown volumes that you\u2019re seeing on the medical side is that what is currently being experienced kind \nof what you saw in July?  And I guess is there any benefit that you're building in related to an elevated \nflu season or the, you know, theoretical potential of any COVID vaccine? ", "original_text": "Jonathan Young:  Hi. "}, "hash": "ec44bf6ed24153b2e6ca731bc677fdbe6fc303aa270fa372a1e5582922f76c65", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 131, "end_char_idx": 152, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50048eff-c9d9-4a3e-85b0-07e4f9073315": {"__data__": {"id_": "50048eff-c9d9-4a3e-85b0-07e4f9073315", "embedding": null, "metadata": {"window": "Operator:  Thank you.  We'll next go to Steve Valliquette with Barclays.  Please go ahead.  \n \n Jonathan Young:  Hi.  This is Jonathan Young on for Steve.  I guess just in relation to the mid -teens \ndown volumes that you\u2019re seeing on the medical side is that what is currently being experienced kind \nof what you saw in July?  And I guess is there any benefit that you're building in related to an elevated \nflu season or the, you know, theoretical potential of any COVID vaccine? ", "original_text": "Jonathan Young:  Hi. ", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ad72de4aefbd50a4bb9b94ed9c93e7d2871818afe8d3f81f17a3cfd57c744b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee0d6bf3-5a41-45b9-b9ed-d6c9e5f39c6e", "node_type": "1", "metadata": {"window": " \nPage 28 of 31 \n \nKevin Moran:  Next question please.  \n \n Operator:  Thank you.  We'll next go to Steve Valliquette with Barclays.  Please go ahead.  \n \n Jonathan Young:  Hi.  This is Jonathan Young on for Steve.  I guess just in relation to the mid -teens \ndown volumes that you\u2019re seeing on the medical side is that what is currently being experienced kind \nof what you saw in July? ", "original_text": "Please go ahead.  \n \n", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "594e6c2c546c02682d722fba5f7602afe2e46ba1f86d76893db5c1c4deab0c81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b96c112f-5b4a-42e4-aacb-23279e00cdc1", "node_type": "1", "metadata": {"window": "We'll next go to Steve Valliquette with Barclays.  Please go ahead.  \n \n Jonathan Young:  Hi.  This is Jonathan Young on for Steve.  I guess just in relation to the mid -teens \ndown volumes that you\u2019re seeing on the medical side is that what is currently being experienced kind \nof what you saw in July?  And I guess is there any benefit that you're building in related to an elevated \nflu season or the, you know, theoretical potential of any COVID vaccine?  Thanks.  \n \n", "original_text": "This is Jonathan Young on for Steve. "}, "hash": "4a14f17bb9c0c1166e1290867abe8e8e8c877761325b11a62a6e7986d533c8e4", "class_name": "RelatedNodeInfo"}}, "text": "Jonathan Young:  Hi. ", "start_char_idx": 152, "end_char_idx": 173, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b96c112f-5b4a-42e4-aacb-23279e00cdc1": {"__data__": {"id_": "b96c112f-5b4a-42e4-aacb-23279e00cdc1", "embedding": null, "metadata": {"window": "We'll next go to Steve Valliquette with Barclays.  Please go ahead.  \n \n Jonathan Young:  Hi.  This is Jonathan Young on for Steve.  I guess just in relation to the mid -teens \ndown volumes that you\u2019re seeing on the medical side is that what is currently being experienced kind \nof what you saw in July?  And I guess is there any benefit that you're building in related to an elevated \nflu season or the, you know, theoretical potential of any COVID vaccine?  Thanks.  \n \n", "original_text": "This is Jonathan Young on for Steve. ", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ad72de4aefbd50a4bb9b94ed9c93e7d2871818afe8d3f81f17a3cfd57c744b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50048eff-c9d9-4a3e-85b0-07e4f9073315", "node_type": "1", "metadata": {"window": "Operator:  Thank you.  We'll next go to Steve Valliquette with Barclays.  Please go ahead.  \n \n Jonathan Young:  Hi.  This is Jonathan Young on for Steve.  I guess just in relation to the mid -teens \ndown volumes that you\u2019re seeing on the medical side is that what is currently being experienced kind \nof what you saw in July?  And I guess is there any benefit that you're building in related to an elevated \nflu season or the, you know, theoretical potential of any COVID vaccine? ", "original_text": "Jonathan Young:  Hi. ", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a26396015240da5dae4580289cc9c3dbba63d5573857bf5c2d8535306cbef44", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ae2d983-1e6a-448a-b7ec-530088519d8f", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Jonathan Young:  Hi.  This is Jonathan Young on for Steve.  I guess just in relation to the mid -teens \ndown volumes that you\u2019re seeing on the medical side is that what is currently being experienced kind \nof what you saw in July?  And I guess is there any benefit that you're building in related to an elevated \nflu season or the, you know, theoretical potential of any COVID vaccine?  Thanks.  \n \n Mike Kaufmann:  Yes, right now from a flu season and  standpoint we're just in expecting a normal flu \nseason. ", "original_text": "I guess just in relation to the mid -teens \ndown volumes that you\u2019re seeing on the medical side is that what is currently being experienced kind \nof what you saw in July? "}, "hash": "3bea698930642670d66e757a588e8055f6746927c7bcf76a76c51b97d0c6d7e0", "class_name": "RelatedNodeInfo"}}, "text": "This is Jonathan Young on for Steve. ", "start_char_idx": 173, "end_char_idx": 210, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ae2d983-1e6a-448a-b7ec-530088519d8f": {"__data__": {"id_": "9ae2d983-1e6a-448a-b7ec-530088519d8f", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Jonathan Young:  Hi.  This is Jonathan Young on for Steve.  I guess just in relation to the mid -teens \ndown volumes that you\u2019re seeing on the medical side is that what is currently being experienced kind \nof what you saw in July?  And I guess is there any benefit that you're building in related to an elevated \nflu season or the, you know, theoretical potential of any COVID vaccine?  Thanks.  \n \n Mike Kaufmann:  Yes, right now from a flu season and  standpoint we're just in expecting a normal flu \nseason. ", "original_text": "I guess just in relation to the mid -teens \ndown volumes that you\u2019re seeing on the medical side is that what is currently being experienced kind \nof what you saw in July? ", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ad72de4aefbd50a4bb9b94ed9c93e7d2871818afe8d3f81f17a3cfd57c744b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b96c112f-5b4a-42e4-aacb-23279e00cdc1", "node_type": "1", "metadata": {"window": "We'll next go to Steve Valliquette with Barclays.  Please go ahead.  \n \n Jonathan Young:  Hi.  This is Jonathan Young on for Steve.  I guess just in relation to the mid -teens \ndown volumes that you\u2019re seeing on the medical side is that what is currently being experienced kind \nof what you saw in July?  And I guess is there any benefit that you're building in related to an elevated \nflu season or the, you know, theoretical potential of any COVID vaccine?  Thanks.  \n \n", "original_text": "This is Jonathan Young on for Steve. ", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb4761c32ad66f7d698b57311362dd919e8e5807c3b7d84fa86679c1884a606d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ec2a23c-6e82-49c5-b246-e982b8b9643e", "node_type": "1", "metadata": {"window": "Jonathan Young:  Hi.  This is Jonathan Young on for Steve.  I guess just in relation to the mid -teens \ndown volumes that you\u2019re seeing on the medical side is that what is currently being experienced kind \nof what you saw in July?  And I guess is there any benefit that you're building in related to an elevated \nflu season or the, you know, theoretical potential of any COVID vaccine?  Thanks.  \n \n Mike Kaufmann:  Yes, right now from a flu season and  standpoint we're just in expecting a normal flu \nseason.  We\u2019ve not built in anything different from that. ", "original_text": "And I guess is there any benefit that you're building in related to an elevated \nflu season or the, you know, theoretical potential of any COVID vaccine? "}, "hash": "42c98c80159305b3fb06852f7e77920e37b378aee51ce9054c0352c3d1b180b1", "class_name": "RelatedNodeInfo"}}, "text": "I guess just in relation to the mid -teens \ndown volumes that you\u2019re seeing on the medical side is that what is currently being experienced kind \nof what you saw in July? ", "start_char_idx": 210, "end_char_idx": 381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ec2a23c-6e82-49c5-b246-e982b8b9643e": {"__data__": {"id_": "2ec2a23c-6e82-49c5-b246-e982b8b9643e", "embedding": null, "metadata": {"window": "Jonathan Young:  Hi.  This is Jonathan Young on for Steve.  I guess just in relation to the mid -teens \ndown volumes that you\u2019re seeing on the medical side is that what is currently being experienced kind \nof what you saw in July?  And I guess is there any benefit that you're building in related to an elevated \nflu season or the, you know, theoretical potential of any COVID vaccine?  Thanks.  \n \n Mike Kaufmann:  Yes, right now from a flu season and  standpoint we're just in expecting a normal flu \nseason.  We\u2019ve not built in anything different from that. ", "original_text": "And I guess is there any benefit that you're building in related to an elevated \nflu season or the, you know, theoretical potential of any COVID vaccine? ", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ad72de4aefbd50a4bb9b94ed9c93e7d2871818afe8d3f81f17a3cfd57c744b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ae2d983-1e6a-448a-b7ec-530088519d8f", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Jonathan Young:  Hi.  This is Jonathan Young on for Steve.  I guess just in relation to the mid -teens \ndown volumes that you\u2019re seeing on the medical side is that what is currently being experienced kind \nof what you saw in July?  And I guess is there any benefit that you're building in related to an elevated \nflu season or the, you know, theoretical potential of any COVID vaccine?  Thanks.  \n \n Mike Kaufmann:  Yes, right now from a flu season and  standpoint we're just in expecting a normal flu \nseason. ", "original_text": "I guess just in relation to the mid -teens \ndown volumes that you\u2019re seeing on the medical side is that what is currently being experienced kind \nof what you saw in July? ", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2bd6f9b315acf56946ae74d14f274278b1f193acb9b15a72c4f1d6ad957ea3f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23f5bddd-7269-4180-bea3-1832b38ea3af", "node_type": "1", "metadata": {"window": "This is Jonathan Young on for Steve.  I guess just in relation to the mid -teens \ndown volumes that you\u2019re seeing on the medical side is that what is currently being experienced kind \nof what you saw in July?  And I guess is there any benefit that you're building in related to an elevated \nflu season or the, you know, theoretical potential of any COVID vaccine?  Thanks.  \n \n Mike Kaufmann:  Yes, right now from a flu season and  standpoint we're just in expecting a normal flu \nseason.  We\u2019ve not built in anything different from that.  As far as vaccines go, you know, we are - \nwe're obviously like everyone very hopeful that a vaccine will become available. ", "original_text": "Thanks.  \n \n"}, "hash": "59999280674021eeced21bd75a8afac668731f321fab6e388653dea0493d2982", "class_name": "RelatedNodeInfo"}}, "text": "And I guess is there any benefit that you're building in related to an elevated \nflu season or the, you know, theoretical potential of any COVID vaccine? ", "start_char_idx": 381, "end_char_idx": 535, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23f5bddd-7269-4180-bea3-1832b38ea3af": {"__data__": {"id_": "23f5bddd-7269-4180-bea3-1832b38ea3af", "embedding": null, "metadata": {"window": "This is Jonathan Young on for Steve.  I guess just in relation to the mid -teens \ndown volumes that you\u2019re seeing on the medical side is that what is currently being experienced kind \nof what you saw in July?  And I guess is there any benefit that you're building in related to an elevated \nflu season or the, you know, theoretical potential of any COVID vaccine?  Thanks.  \n \n Mike Kaufmann:  Yes, right now from a flu season and  standpoint we're just in expecting a normal flu \nseason.  We\u2019ve not built in anything different from that.  As far as vaccines go, you know, we are - \nwe're obviously like everyone very hopeful that a vaccine will become available. ", "original_text": "Thanks.  \n \n", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ad72de4aefbd50a4bb9b94ed9c93e7d2871818afe8d3f81f17a3cfd57c744b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ec2a23c-6e82-49c5-b246-e982b8b9643e", "node_type": "1", "metadata": {"window": "Jonathan Young:  Hi.  This is Jonathan Young on for Steve.  I guess just in relation to the mid -teens \ndown volumes that you\u2019re seeing on the medical side is that what is currently being experienced kind \nof what you saw in July?  And I guess is there any benefit that you're building in related to an elevated \nflu season or the, you know, theoretical potential of any COVID vaccine?  Thanks.  \n \n Mike Kaufmann:  Yes, right now from a flu season and  standpoint we're just in expecting a normal flu \nseason.  We\u2019ve not built in anything different from that. ", "original_text": "And I guess is there any benefit that you're building in related to an elevated \nflu season or the, you know, theoretical potential of any COVID vaccine? ", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29ba67e2efd1c3713a980bebf69d763cb8d86a08f482e12f59a6f67411ae948d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "afe537ad-3d14-43d1-9336-792023d809b4", "node_type": "1", "metadata": {"window": "I guess just in relation to the mid -teens \ndown volumes that you\u2019re seeing on the medical side is that what is currently being experienced kind \nof what you saw in July?  And I guess is there any benefit that you're building in related to an elevated \nflu season or the, you know, theoretical potential of any COVID vaccine?  Thanks.  \n \n Mike Kaufmann:  Yes, right now from a flu season and  standpoint we're just in expecting a normal flu \nseason.  We\u2019ve not built in anything different from that.  As far as vaccines go, you know, we are - \nwe're obviously like everyone very hopeful that a vaccine will become available.  We're very, you \nknow, excit ed that that could happen.  \n \n ", "original_text": "Mike Kaufmann:  Yes, right now from a flu season and  standpoint we're just in expecting a normal flu \nseason. "}, "hash": "2bafda3888aa2f902f58acc67e5451e0f54f4e00c262af77a91b00e0744fcfaa", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 535, "end_char_idx": 547, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "afe537ad-3d14-43d1-9336-792023d809b4": {"__data__": {"id_": "afe537ad-3d14-43d1-9336-792023d809b4", "embedding": null, "metadata": {"window": "I guess just in relation to the mid -teens \ndown volumes that you\u2019re seeing on the medical side is that what is currently being experienced kind \nof what you saw in July?  And I guess is there any benefit that you're building in related to an elevated \nflu season or the, you know, theoretical potential of any COVID vaccine?  Thanks.  \n \n Mike Kaufmann:  Yes, right now from a flu season and  standpoint we're just in expecting a normal flu \nseason.  We\u2019ve not built in anything different from that.  As far as vaccines go, you know, we are - \nwe're obviously like everyone very hopeful that a vaccine will become available.  We're very, you \nknow, excit ed that that could happen.  \n \n ", "original_text": "Mike Kaufmann:  Yes, right now from a flu season and  standpoint we're just in expecting a normal flu \nseason. ", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ad72de4aefbd50a4bb9b94ed9c93e7d2871818afe8d3f81f17a3cfd57c744b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23f5bddd-7269-4180-bea3-1832b38ea3af", "node_type": "1", "metadata": {"window": "This is Jonathan Young on for Steve.  I guess just in relation to the mid -teens \ndown volumes that you\u2019re seeing on the medical side is that what is currently being experienced kind \nof what you saw in July?  And I guess is there any benefit that you're building in related to an elevated \nflu season or the, you know, theoretical potential of any COVID vaccine?  Thanks.  \n \n Mike Kaufmann:  Yes, right now from a flu season and  standpoint we're just in expecting a normal flu \nseason.  We\u2019ve not built in anything different from that.  As far as vaccines go, you know, we are - \nwe're obviously like everyone very hopeful that a vaccine will become available. ", "original_text": "Thanks.  \n \n", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2570019637cd7d297c0f1e8e39a3adb4c84481fb09541bea2fcd7b865cf201a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87a0dc2f-4b14-40c2-8606-afe2bde6d6e4", "node_type": "1", "metadata": {"window": "And I guess is there any benefit that you're building in related to an elevated \nflu season or the, you know, theoretical potential of any COVID vaccine?  Thanks.  \n \n Mike Kaufmann:  Yes, right now from a flu season and  standpoint we're just in expecting a normal flu \nseason.  We\u2019ve not built in anything different from that.  As far as vaccines go, you know, we are - \nwe're obviously like everyone very hopeful that a vaccine will become available.  We're very, you \nknow, excit ed that that could happen.  \n \n  We know that we have the absolute capabilities to be part of the solution of getting vaccines to \nfolks and would expect and hope that we would be part of that. ", "original_text": "We\u2019ve not built in anything different from that. "}, "hash": "9dd26f8327e90a46e62c4413bb7248c477ad4cdbf7f4424f7f94a09fa1d8549b", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes, right now from a flu season and  standpoint we're just in expecting a normal flu \nseason. ", "start_char_idx": 547, "end_char_idx": 658, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87a0dc2f-4b14-40c2-8606-afe2bde6d6e4": {"__data__": {"id_": "87a0dc2f-4b14-40c2-8606-afe2bde6d6e4", "embedding": null, "metadata": {"window": "And I guess is there any benefit that you're building in related to an elevated \nflu season or the, you know, theoretical potential of any COVID vaccine?  Thanks.  \n \n Mike Kaufmann:  Yes, right now from a flu season and  standpoint we're just in expecting a normal flu \nseason.  We\u2019ve not built in anything different from that.  As far as vaccines go, you know, we are - \nwe're obviously like everyone very hopeful that a vaccine will become available.  We're very, you \nknow, excit ed that that could happen.  \n \n  We know that we have the absolute capabilities to be part of the solution of getting vaccines to \nfolks and would expect and hope that we would be part of that. ", "original_text": "We\u2019ve not built in anything different from that. ", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ad72de4aefbd50a4bb9b94ed9c93e7d2871818afe8d3f81f17a3cfd57c744b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "afe537ad-3d14-43d1-9336-792023d809b4", "node_type": "1", "metadata": {"window": "I guess just in relation to the mid -teens \ndown volumes that you\u2019re seeing on the medical side is that what is currently being experienced kind \nof what you saw in July?  And I guess is there any benefit that you're building in related to an elevated \nflu season or the, you know, theoretical potential of any COVID vaccine?  Thanks.  \n \n Mike Kaufmann:  Yes, right now from a flu season and  standpoint we're just in expecting a normal flu \nseason.  We\u2019ve not built in anything different from that.  As far as vaccines go, you know, we are - \nwe're obviously like everyone very hopeful that a vaccine will become available.  We're very, you \nknow, excit ed that that could happen.  \n \n ", "original_text": "Mike Kaufmann:  Yes, right now from a flu season and  standpoint we're just in expecting a normal flu \nseason. ", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0e2d7b006c1fe9fcaae2f280f5b58b859c275141844a5577a64dd2958b82dd3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3cfdd5f5-516b-474c-90ac-97cf3c392ce1", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Mike Kaufmann:  Yes, right now from a flu season and  standpoint we're just in expecting a normal flu \nseason.  We\u2019ve not built in anything different from that.  As far as vaccines go, you know, we are - \nwe're obviously like everyone very hopeful that a vaccine will become available.  We're very, you \nknow, excit ed that that could happen.  \n \n  We know that we have the absolute capabilities to be part of the solution of getting vaccines to \nfolks and would expect and hope that we would be part of that.  But even if we were we don\u2019t see that \nas a big upside in terms of e arnings if there was a vaccine to distribute. ", "original_text": "As far as vaccines go, you know, we are - \nwe're obviously like everyone very hopeful that a vaccine will become available. "}, "hash": "75b2b6917d96ae2484caa2db441a3f30d1cdd630835584ef34da2ff9ea05d757", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019ve not built in anything different from that. ", "start_char_idx": 658, "end_char_idx": 707, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3cfdd5f5-516b-474c-90ac-97cf3c392ce1": {"__data__": {"id_": "3cfdd5f5-516b-474c-90ac-97cf3c392ce1", "embedding": null, "metadata": {"window": "Thanks.  \n \n Mike Kaufmann:  Yes, right now from a flu season and  standpoint we're just in expecting a normal flu \nseason.  We\u2019ve not built in anything different from that.  As far as vaccines go, you know, we are - \nwe're obviously like everyone very hopeful that a vaccine will become available.  We're very, you \nknow, excit ed that that could happen.  \n \n  We know that we have the absolute capabilities to be part of the solution of getting vaccines to \nfolks and would expect and hope that we would be part of that.  But even if we were we don\u2019t see that \nas a big upside in terms of e arnings if there was a vaccine to distribute. ", "original_text": "As far as vaccines go, you know, we are - \nwe're obviously like everyone very hopeful that a vaccine will become available. ", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ad72de4aefbd50a4bb9b94ed9c93e7d2871818afe8d3f81f17a3cfd57c744b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87a0dc2f-4b14-40c2-8606-afe2bde6d6e4", "node_type": "1", "metadata": {"window": "And I guess is there any benefit that you're building in related to an elevated \nflu season or the, you know, theoretical potential of any COVID vaccine?  Thanks.  \n \n Mike Kaufmann:  Yes, right now from a flu season and  standpoint we're just in expecting a normal flu \nseason.  We\u2019ve not built in anything different from that.  As far as vaccines go, you know, we are - \nwe're obviously like everyone very hopeful that a vaccine will become available.  We're very, you \nknow, excit ed that that could happen.  \n \n  We know that we have the absolute capabilities to be part of the solution of getting vaccines to \nfolks and would expect and hope that we would be part of that. ", "original_text": "We\u2019ve not built in anything different from that. ", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2da908e30c73a47f4daf821e235f2358de4c1d1721529e2b68ed93870158dcac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "405d8c48-9242-481b-a352-69f635b0177d", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes, right now from a flu season and  standpoint we're just in expecting a normal flu \nseason.  We\u2019ve not built in anything different from that.  As far as vaccines go, you know, we are - \nwe're obviously like everyone very hopeful that a vaccine will become available.  We're very, you \nknow, excit ed that that could happen.  \n \n  We know that we have the absolute capabilities to be part of the solution of getting vaccines to \nfolks and would expect and hope that we would be part of that.  But even if we were we don\u2019t see that \nas a big upside in terms of e arnings if there was a vaccine to distribute.  So I think from those two \nstandpoints that\u2019s how I would see those two.  \n \n ", "original_text": "We're very, you \nknow, excit ed that that could happen.  \n \n "}, "hash": "c95c3603198cb34512758765abda0884a8adec924724dc6868374cbe89dcdeba", "class_name": "RelatedNodeInfo"}}, "text": "As far as vaccines go, you know, we are - \nwe're obviously like everyone very hopeful that a vaccine will become available. ", "start_char_idx": 707, "end_char_idx": 831, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "405d8c48-9242-481b-a352-69f635b0177d": {"__data__": {"id_": "405d8c48-9242-481b-a352-69f635b0177d", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes, right now from a flu season and  standpoint we're just in expecting a normal flu \nseason.  We\u2019ve not built in anything different from that.  As far as vaccines go, you know, we are - \nwe're obviously like everyone very hopeful that a vaccine will become available.  We're very, you \nknow, excit ed that that could happen.  \n \n  We know that we have the absolute capabilities to be part of the solution of getting vaccines to \nfolks and would expect and hope that we would be part of that.  But even if we were we don\u2019t see that \nas a big upside in terms of e arnings if there was a vaccine to distribute.  So I think from those two \nstandpoints that\u2019s how I would see those two.  \n \n ", "original_text": "We're very, you \nknow, excit ed that that could happen.  \n \n ", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ad72de4aefbd50a4bb9b94ed9c93e7d2871818afe8d3f81f17a3cfd57c744b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3cfdd5f5-516b-474c-90ac-97cf3c392ce1", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Mike Kaufmann:  Yes, right now from a flu season and  standpoint we're just in expecting a normal flu \nseason.  We\u2019ve not built in anything different from that.  As far as vaccines go, you know, we are - \nwe're obviously like everyone very hopeful that a vaccine will become available.  We're very, you \nknow, excit ed that that could happen.  \n \n  We know that we have the absolute capabilities to be part of the solution of getting vaccines to \nfolks and would expect and hope that we would be part of that.  But even if we were we don\u2019t see that \nas a big upside in terms of e arnings if there was a vaccine to distribute. ", "original_text": "As far as vaccines go, you know, we are - \nwe're obviously like everyone very hopeful that a vaccine will become available. ", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bdf0501ef3a33238c5ff4ad9e00272f661db9f19aa8441da6eb6abe89a5b2a33", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe31cd10-ed02-497a-b25d-e8c17ab05a6f", "node_type": "1", "metadata": {"window": "We\u2019ve not built in anything different from that.  As far as vaccines go, you know, we are - \nwe're obviously like everyone very hopeful that a vaccine will become available.  We're very, you \nknow, excit ed that that could happen.  \n \n  We know that we have the absolute capabilities to be part of the solution of getting vaccines to \nfolks and would expect and hope that we would be part of that.  But even if we were we don\u2019t see that \nas a big upside in terms of e arnings if there was a vaccine to distribute.  So I think from those two \nstandpoints that\u2019s how I would see those two.  \n \n  Oh, and July, you mentioned July. ", "original_text": "We know that we have the absolute capabilities to be part of the solution of getting vaccines to \nfolks and would expect and hope that we would be part of that. "}, "hash": "52b9806c044984b2e121bf449729bcddf5e86176caac69299b45d8bda57b34c4", "class_name": "RelatedNodeInfo"}}, "text": "We're very, you \nknow, excit ed that that could happen.  \n \n ", "start_char_idx": 831, "end_char_idx": 892, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe31cd10-ed02-497a-b25d-e8c17ab05a6f": {"__data__": {"id_": "fe31cd10-ed02-497a-b25d-e8c17ab05a6f", "embedding": null, "metadata": {"window": "We\u2019ve not built in anything different from that.  As far as vaccines go, you know, we are - \nwe're obviously like everyone very hopeful that a vaccine will become available.  We're very, you \nknow, excit ed that that could happen.  \n \n  We know that we have the absolute capabilities to be part of the solution of getting vaccines to \nfolks and would expect and hope that we would be part of that.  But even if we were we don\u2019t see that \nas a big upside in terms of e arnings if there was a vaccine to distribute.  So I think from those two \nstandpoints that\u2019s how I would see those two.  \n \n  Oh, and July, you mentioned July. ", "original_text": "We know that we have the absolute capabilities to be part of the solution of getting vaccines to \nfolks and would expect and hope that we would be part of that. ", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ad72de4aefbd50a4bb9b94ed9c93e7d2871818afe8d3f81f17a3cfd57c744b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "405d8c48-9242-481b-a352-69f635b0177d", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes, right now from a flu season and  standpoint we're just in expecting a normal flu \nseason.  We\u2019ve not built in anything different from that.  As far as vaccines go, you know, we are - \nwe're obviously like everyone very hopeful that a vaccine will become available.  We're very, you \nknow, excit ed that that could happen.  \n \n  We know that we have the absolute capabilities to be part of the solution of getting vaccines to \nfolks and would expect and hope that we would be part of that.  But even if we were we don\u2019t see that \nas a big upside in terms of e arnings if there was a vaccine to distribute.  So I think from those two \nstandpoints that\u2019s how I would see those two.  \n \n ", "original_text": "We're very, you \nknow, excit ed that that could happen.  \n \n ", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6ba55f2236f8c5e306bd6bea55e5de9d61f35c34f5f515ffc689e54e8cd61846", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ce2b79a-6584-4960-b0a1-82eb9d8d67e7", "node_type": "1", "metadata": {"window": "As far as vaccines go, you know, we are - \nwe're obviously like everyone very hopeful that a vaccine will become available.  We're very, you \nknow, excit ed that that could happen.  \n \n  We know that we have the absolute capabilities to be part of the solution of getting vaccines to \nfolks and would expect and hope that we would be part of that.  But even if we were we don\u2019t see that \nas a big upside in terms of e arnings if there was a vaccine to distribute.  So I think from those two \nstandpoints that\u2019s how I would see those two.  \n \n  Oh, and July, you mentioned July.  What we're seeing in July really is just basically on track to \nwhat we said with our expectations that  we would enter the year like we said on electives in that mid -\nteens to high teens and then grow. ", "original_text": "But even if we were we don\u2019t see that \nas a big upside in terms of e arnings if there was a vaccine to distribute. "}, "hash": "c3cc3a1911467175da173eaa13ff0e8dd161f7c4ec691763dc11c39b9fdd7a71", "class_name": "RelatedNodeInfo"}}, "text": "We know that we have the absolute capabilities to be part of the solution of getting vaccines to \nfolks and would expect and hope that we would be part of that. ", "start_char_idx": 892, "end_char_idx": 1053, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ce2b79a-6584-4960-b0a1-82eb9d8d67e7": {"__data__": {"id_": "0ce2b79a-6584-4960-b0a1-82eb9d8d67e7", "embedding": null, "metadata": {"window": "As far as vaccines go, you know, we are - \nwe're obviously like everyone very hopeful that a vaccine will become available.  We're very, you \nknow, excit ed that that could happen.  \n \n  We know that we have the absolute capabilities to be part of the solution of getting vaccines to \nfolks and would expect and hope that we would be part of that.  But even if we were we don\u2019t see that \nas a big upside in terms of e arnings if there was a vaccine to distribute.  So I think from those two \nstandpoints that\u2019s how I would see those two.  \n \n  Oh, and July, you mentioned July.  What we're seeing in July really is just basically on track to \nwhat we said with our expectations that  we would enter the year like we said on electives in that mid -\nteens to high teens and then grow. ", "original_text": "But even if we were we don\u2019t see that \nas a big upside in terms of e arnings if there was a vaccine to distribute. ", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ad72de4aefbd50a4bb9b94ed9c93e7d2871818afe8d3f81f17a3cfd57c744b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe31cd10-ed02-497a-b25d-e8c17ab05a6f", "node_type": "1", "metadata": {"window": "We\u2019ve not built in anything different from that.  As far as vaccines go, you know, we are - \nwe're obviously like everyone very hopeful that a vaccine will become available.  We're very, you \nknow, excit ed that that could happen.  \n \n  We know that we have the absolute capabilities to be part of the solution of getting vaccines to \nfolks and would expect and hope that we would be part of that.  But even if we were we don\u2019t see that \nas a big upside in terms of e arnings if there was a vaccine to distribute.  So I think from those two \nstandpoints that\u2019s how I would see those two.  \n \n  Oh, and July, you mentioned July. ", "original_text": "We know that we have the absolute capabilities to be part of the solution of getting vaccines to \nfolks and would expect and hope that we would be part of that. ", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "702de5731a509d1b8eb74a4d46027b9f701ffdacc3a0ef7c7fa222845aa73e66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8fa59a78-ee3b-47d0-8ac0-5123b34a4798", "node_type": "1", "metadata": {"window": "We're very, you \nknow, excit ed that that could happen.  \n \n  We know that we have the absolute capabilities to be part of the solution of getting vaccines to \nfolks and would expect and hope that we would be part of that.  But even if we were we don\u2019t see that \nas a big upside in terms of e arnings if there was a vaccine to distribute.  So I think from those two \nstandpoints that\u2019s how I would see those two.  \n \n  Oh, and July, you mentioned July.  What we're seeing in July really is just basically on track to \nwhat we said with our expectations that  we would enter the year like we said on electives in that mid -\nteens to high teens and then grow.  And there\u2019s nothing in July that would indicate that the current \nassumptions that we have built into our plan aren\u2019t playing out.  \n \n", "original_text": "So I think from those two \nstandpoints that\u2019s how I would see those two.  \n \n "}, "hash": "fc4038249a74a1a98608caae4d1dd723293ce931131d4594b9813e065a5c45b6", "class_name": "RelatedNodeInfo"}}, "text": "But even if we were we don\u2019t see that \nas a big upside in terms of e arnings if there was a vaccine to distribute. ", "start_char_idx": 1053, "end_char_idx": 1168, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8fa59a78-ee3b-47d0-8ac0-5123b34a4798": {"__data__": {"id_": "8fa59a78-ee3b-47d0-8ac0-5123b34a4798", "embedding": null, "metadata": {"window": "We're very, you \nknow, excit ed that that could happen.  \n \n  We know that we have the absolute capabilities to be part of the solution of getting vaccines to \nfolks and would expect and hope that we would be part of that.  But even if we were we don\u2019t see that \nas a big upside in terms of e arnings if there was a vaccine to distribute.  So I think from those two \nstandpoints that\u2019s how I would see those two.  \n \n  Oh, and July, you mentioned July.  What we're seeing in July really is just basically on track to \nwhat we said with our expectations that  we would enter the year like we said on electives in that mid -\nteens to high teens and then grow.  And there\u2019s nothing in July that would indicate that the current \nassumptions that we have built into our plan aren\u2019t playing out.  \n \n", "original_text": "So I think from those two \nstandpoints that\u2019s how I would see those two.  \n \n ", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ad72de4aefbd50a4bb9b94ed9c93e7d2871818afe8d3f81f17a3cfd57c744b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ce2b79a-6584-4960-b0a1-82eb9d8d67e7", "node_type": "1", "metadata": {"window": "As far as vaccines go, you know, we are - \nwe're obviously like everyone very hopeful that a vaccine will become available.  We're very, you \nknow, excit ed that that could happen.  \n \n  We know that we have the absolute capabilities to be part of the solution of getting vaccines to \nfolks and would expect and hope that we would be part of that.  But even if we were we don\u2019t see that \nas a big upside in terms of e arnings if there was a vaccine to distribute.  So I think from those two \nstandpoints that\u2019s how I would see those two.  \n \n  Oh, and July, you mentioned July.  What we're seeing in July really is just basically on track to \nwhat we said with our expectations that  we would enter the year like we said on electives in that mid -\nteens to high teens and then grow. ", "original_text": "But even if we were we don\u2019t see that \nas a big upside in terms of e arnings if there was a vaccine to distribute. ", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79e5b45d7bfc0da96cc56a80d413462534f85d63b0bb4f169668e2507b3c59b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d288e05b-31df-414c-9464-938eaca7096f", "node_type": "1", "metadata": {"window": "We know that we have the absolute capabilities to be part of the solution of getting vaccines to \nfolks and would expect and hope that we would be part of that.  But even if we were we don\u2019t see that \nas a big upside in terms of e arnings if there was a vaccine to distribute.  So I think from those two \nstandpoints that\u2019s how I would see those two.  \n \n  Oh, and July, you mentioned July.  What we're seeing in July really is just basically on track to \nwhat we said with our expectations that  we would enter the year like we said on electives in that mid -\nteens to high teens and then grow.  And there\u2019s nothing in July that would indicate that the current \nassumptions that we have built into our plan aren\u2019t playing out.  \n \n Jonathan Young:  Thanks.  ", "original_text": "Oh, and July, you mentioned July. "}, "hash": "c48d5de3e87020172cca0abaeb9f50fa53017055e8b113114e9fbf61892162f3", "class_name": "RelatedNodeInfo"}}, "text": "So I think from those two \nstandpoints that\u2019s how I would see those two.  \n \n ", "start_char_idx": 1168, "end_char_idx": 1246, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d288e05b-31df-414c-9464-938eaca7096f": {"__data__": {"id_": "d288e05b-31df-414c-9464-938eaca7096f", "embedding": null, "metadata": {"window": "We know that we have the absolute capabilities to be part of the solution of getting vaccines to \nfolks and would expect and hope that we would be part of that.  But even if we were we don\u2019t see that \nas a big upside in terms of e arnings if there was a vaccine to distribute.  So I think from those two \nstandpoints that\u2019s how I would see those two.  \n \n  Oh, and July, you mentioned July.  What we're seeing in July really is just basically on track to \nwhat we said with our expectations that  we would enter the year like we said on electives in that mid -\nteens to high teens and then grow.  And there\u2019s nothing in July that would indicate that the current \nassumptions that we have built into our plan aren\u2019t playing out.  \n \n Jonathan Young:  Thanks.  ", "original_text": "Oh, and July, you mentioned July. ", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ad72de4aefbd50a4bb9b94ed9c93e7d2871818afe8d3f81f17a3cfd57c744b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8fa59a78-ee3b-47d0-8ac0-5123b34a4798", "node_type": "1", "metadata": {"window": "We're very, you \nknow, excit ed that that could happen.  \n \n  We know that we have the absolute capabilities to be part of the solution of getting vaccines to \nfolks and would expect and hope that we would be part of that.  But even if we were we don\u2019t see that \nas a big upside in terms of e arnings if there was a vaccine to distribute.  So I think from those two \nstandpoints that\u2019s how I would see those two.  \n \n  Oh, and July, you mentioned July.  What we're seeing in July really is just basically on track to \nwhat we said with our expectations that  we would enter the year like we said on electives in that mid -\nteens to high teens and then grow.  And there\u2019s nothing in July that would indicate that the current \nassumptions that we have built into our plan aren\u2019t playing out.  \n \n", "original_text": "So I think from those two \nstandpoints that\u2019s how I would see those two.  \n \n ", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38a776f98997367859788a3d8b8f003db96875c74fc20922f2b8c7ace2103152", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96bcc8d1-f48a-4fdb-9d5c-3043b694d671", "node_type": "1", "metadata": {"window": "But even if we were we don\u2019t see that \nas a big upside in terms of e arnings if there was a vaccine to distribute.  So I think from those two \nstandpoints that\u2019s how I would see those two.  \n \n  Oh, and July, you mentioned July.  What we're seeing in July really is just basically on track to \nwhat we said with our expectations that  we would enter the year like we said on electives in that mid -\nteens to high teens and then grow.  And there\u2019s nothing in July that would indicate that the current \nassumptions that we have built into our plan aren\u2019t playing out.  \n \n Jonathan Young:  Thanks.  ", "original_text": "What we're seeing in July really is just basically on track to \nwhat we said with our expectations that  we would enter the year like we said on electives in that mid -\nteens to high teens and then grow. "}, "hash": "7d3bb867f67d7342323bcb6da251dbfdcf2bfa700947482fd68159ae0a2ebaac", "class_name": "RelatedNodeInfo"}}, "text": "Oh, and July, you mentioned July. ", "start_char_idx": 1246, "end_char_idx": 1280, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96bcc8d1-f48a-4fdb-9d5c-3043b694d671": {"__data__": {"id_": "96bcc8d1-f48a-4fdb-9d5c-3043b694d671", "embedding": null, "metadata": {"window": "But even if we were we don\u2019t see that \nas a big upside in terms of e arnings if there was a vaccine to distribute.  So I think from those two \nstandpoints that\u2019s how I would see those two.  \n \n  Oh, and July, you mentioned July.  What we're seeing in July really is just basically on track to \nwhat we said with our expectations that  we would enter the year like we said on electives in that mid -\nteens to high teens and then grow.  And there\u2019s nothing in July that would indicate that the current \nassumptions that we have built into our plan aren\u2019t playing out.  \n \n Jonathan Young:  Thanks.  ", "original_text": "What we're seeing in July really is just basically on track to \nwhat we said with our expectations that  we would enter the year like we said on electives in that mid -\nteens to high teens and then grow. ", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ad72de4aefbd50a4bb9b94ed9c93e7d2871818afe8d3f81f17a3cfd57c744b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d288e05b-31df-414c-9464-938eaca7096f", "node_type": "1", "metadata": {"window": "We know that we have the absolute capabilities to be part of the solution of getting vaccines to \nfolks and would expect and hope that we would be part of that.  But even if we were we don\u2019t see that \nas a big upside in terms of e arnings if there was a vaccine to distribute.  So I think from those two \nstandpoints that\u2019s how I would see those two.  \n \n  Oh, and July, you mentioned July.  What we're seeing in July really is just basically on track to \nwhat we said with our expectations that  we would enter the year like we said on electives in that mid -\nteens to high teens and then grow.  And there\u2019s nothing in July that would indicate that the current \nassumptions that we have built into our plan aren\u2019t playing out.  \n \n Jonathan Young:  Thanks.  ", "original_text": "Oh, and July, you mentioned July. ", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d3ac42950a25d90a14ef9ebc330f89c178defe7da98bbd72049758e2cbc620e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8605552-cf4d-4038-bd62-dedb13114691", "node_type": "1", "metadata": {"window": "So I think from those two \nstandpoints that\u2019s how I would see those two.  \n \n  Oh, and July, you mentioned July.  What we're seeing in July really is just basically on track to \nwhat we said with our expectations that  we would enter the year like we said on electives in that mid -\nteens to high teens and then grow.  And there\u2019s nothing in July that would indicate that the current \nassumptions that we have built into our plan aren\u2019t playing out.  \n \n Jonathan Young:  Thanks.  ", "original_text": "And there\u2019s nothing in July that would indicate that the current \nassumptions that we have built into our plan aren\u2019t playing out.  \n \n"}, "hash": "34bfeac2461dff98032aeae2f488596fef35841cebee45012611c573743c4287", "class_name": "RelatedNodeInfo"}}, "text": "What we're seeing in July really is just basically on track to \nwhat we said with our expectations that  we would enter the year like we said on electives in that mid -\nteens to high teens and then grow. ", "start_char_idx": 1280, "end_char_idx": 1484, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8605552-cf4d-4038-bd62-dedb13114691": {"__data__": {"id_": "b8605552-cf4d-4038-bd62-dedb13114691", "embedding": null, "metadata": {"window": "So I think from those two \nstandpoints that\u2019s how I would see those two.  \n \n  Oh, and July, you mentioned July.  What we're seeing in July really is just basically on track to \nwhat we said with our expectations that  we would enter the year like we said on electives in that mid -\nteens to high teens and then grow.  And there\u2019s nothing in July that would indicate that the current \nassumptions that we have built into our plan aren\u2019t playing out.  \n \n Jonathan Young:  Thanks.  ", "original_text": "And there\u2019s nothing in July that would indicate that the current \nassumptions that we have built into our plan aren\u2019t playing out.  \n \n", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ad72de4aefbd50a4bb9b94ed9c93e7d2871818afe8d3f81f17a3cfd57c744b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96bcc8d1-f48a-4fdb-9d5c-3043b694d671", "node_type": "1", "metadata": {"window": "But even if we were we don\u2019t see that \nas a big upside in terms of e arnings if there was a vaccine to distribute.  So I think from those two \nstandpoints that\u2019s how I would see those two.  \n \n  Oh, and July, you mentioned July.  What we're seeing in July really is just basically on track to \nwhat we said with our expectations that  we would enter the year like we said on electives in that mid -\nteens to high teens and then grow.  And there\u2019s nothing in July that would indicate that the current \nassumptions that we have built into our plan aren\u2019t playing out.  \n \n Jonathan Young:  Thanks.  ", "original_text": "What we're seeing in July really is just basically on track to \nwhat we said with our expectations that  we would enter the year like we said on electives in that mid -\nteens to high teens and then grow. ", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "17ee85da2dbbb9e623b9946d32497c6443934a81fec7c00bd5b19e8bd70cd936", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a88fccaa-697c-45ff-beeb-2b408068b3fb", "node_type": "1", "metadata": {"window": "Oh, and July, you mentioned July.  What we're seeing in July really is just basically on track to \nwhat we said with our expectations that  we would enter the year like we said on electives in that mid -\nteens to high teens and then grow.  And there\u2019s nothing in July that would indicate that the current \nassumptions that we have built into our plan aren\u2019t playing out.  \n \n Jonathan Young:  Thanks.  ", "original_text": "Jonathan Young:  Thanks.  "}, "hash": "a31fdca8180b31d038633314dcedbe286bc7f4880ce490fbfe677ce4a595ba68", "class_name": "RelatedNodeInfo"}}, "text": "And there\u2019s nothing in July that would indicate that the current \nassumptions that we have built into our plan aren\u2019t playing out.  \n \n", "start_char_idx": 1484, "end_char_idx": 1619, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a88fccaa-697c-45ff-beeb-2b408068b3fb": {"__data__": {"id_": "a88fccaa-697c-45ff-beeb-2b408068b3fb", "embedding": null, "metadata": {"window": "Oh, and July, you mentioned July.  What we're seeing in July really is just basically on track to \nwhat we said with our expectations that  we would enter the year like we said on electives in that mid -\nteens to high teens and then grow.  And there\u2019s nothing in July that would indicate that the current \nassumptions that we have built into our plan aren\u2019t playing out.  \n \n Jonathan Young:  Thanks.  ", "original_text": "Jonathan Young:  Thanks.  ", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ad72de4aefbd50a4bb9b94ed9c93e7d2871818afe8d3f81f17a3cfd57c744b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8605552-cf4d-4038-bd62-dedb13114691", "node_type": "1", "metadata": {"window": "So I think from those two \nstandpoints that\u2019s how I would see those two.  \n \n  Oh, and July, you mentioned July.  What we're seeing in July really is just basically on track to \nwhat we said with our expectations that  we would enter the year like we said on electives in that mid -\nteens to high teens and then grow.  And there\u2019s nothing in July that would indicate that the current \nassumptions that we have built into our plan aren\u2019t playing out.  \n \n Jonathan Young:  Thanks.  ", "original_text": "And there\u2019s nothing in July that would indicate that the current \nassumptions that we have built into our plan aren\u2019t playing out.  \n \n", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b5d77b3e1542576a4d28bd0899799986440f25644da21d0cd462c68f875292b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a894a97b-1c05-4e6d-af5f-4c3f6964bf78", "node_type": "1", "metadata": {"window": " \nPage 29 of 31 \n \n \nOperator:  Thank you.  We'll next go to Kevin Caliendo with UBS.  \n \n Kevin Caliendo:  Hi.  Thanks for taking my call. ", "original_text": " \nPage 29 of 31 \n \n \nOperator:  Thank you. "}, "hash": "a254a7ca057734aabb5ee84478b188ddfc7e75aaa5218a8ee79a297146ef2314", "class_name": "RelatedNodeInfo"}}, "text": "Jonathan Young:  Thanks.  ", "start_char_idx": 1619, "end_char_idx": 1645, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a894a97b-1c05-4e6d-af5f-4c3f6964bf78": {"__data__": {"id_": "a894a97b-1c05-4e6d-af5f-4c3f6964bf78", "embedding": null, "metadata": {"window": " \nPage 29 of 31 \n \n \nOperator:  Thank you.  We'll next go to Kevin Caliendo with UBS.  \n \n Kevin Caliendo:  Hi.  Thanks for taking my call. ", "original_text": " \nPage 29 of 31 \n \n \nOperator:  Thank you. ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8902963b-6af6-4797-9436-bd1772a8635d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d606c3ef91f0086c8b1b86a9a91426b2bd9a1f022be5ab05df6342f6be9bb30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a88fccaa-697c-45ff-beeb-2b408068b3fb", "node_type": "1", "metadata": {"window": "Oh, and July, you mentioned July.  What we're seeing in July really is just basically on track to \nwhat we said with our expectations that  we would enter the year like we said on electives in that mid -\nteens to high teens and then grow.  And there\u2019s nothing in July that would indicate that the current \nassumptions that we have built into our plan aren\u2019t playing out.  \n \n Jonathan Young:  Thanks.  ", "original_text": "Jonathan Young:  Thanks.  ", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03a8f8faeffaafbd1e521735f12556b6c592a657e67f7ad41affe89b3d64ed74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e0b8ffd-6d0d-497e-9991-e3bda1742094", "node_type": "1", "metadata": {"window": " \nPage 29 of 31 \n \n \nOperator:  Thank you.  We'll next go to Kevin Caliendo with UBS.  \n \n Kevin Caliendo:  Hi.  Thanks for taking my call.  Just thinking a little bit around the cash flow question \nand if we subtract out the dividends in your capex expenditures you don\u2019t have a lot bu ilt-in for share \nbuyback. ", "original_text": "We'll next go to Kevin Caliendo with UBS.  \n \n"}, "hash": "a4646a32d19d33b5b6400c87b3de5f62b68d039b763042914dfb410ed708b90f", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 29 of 31 \n \n \nOperator:  Thank you. ", "start_char_idx": 0, "end_char_idx": 43, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e0b8ffd-6d0d-497e-9991-e3bda1742094": {"__data__": {"id_": "5e0b8ffd-6d0d-497e-9991-e3bda1742094", "embedding": null, "metadata": {"window": " \nPage 29 of 31 \n \n \nOperator:  Thank you.  We'll next go to Kevin Caliendo with UBS.  \n \n Kevin Caliendo:  Hi.  Thanks for taking my call.  Just thinking a little bit around the cash flow question \nand if we subtract out the dividends in your capex expenditures you don\u2019t have a lot bu ilt-in for share \nbuyback. ", "original_text": "We'll next go to Kevin Caliendo with UBS.  \n \n", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8902963b-6af6-4797-9436-bd1772a8635d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d606c3ef91f0086c8b1b86a9a91426b2bd9a1f022be5ab05df6342f6be9bb30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a894a97b-1c05-4e6d-af5f-4c3f6964bf78", "node_type": "1", "metadata": {"window": " \nPage 29 of 31 \n \n \nOperator:  Thank you.  We'll next go to Kevin Caliendo with UBS.  \n \n Kevin Caliendo:  Hi.  Thanks for taking my call. ", "original_text": " \nPage 29 of 31 \n \n \nOperator:  Thank you. ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ea6b3f6e3e553345ea9f468a0cefcad12a5984d606467c47281cb5b792aab4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "371fc9e2-b852-4118-916d-ae2183b77f61", "node_type": "1", "metadata": {"window": " \nPage 29 of 31 \n \n \nOperator:  Thank you.  We'll next go to Kevin Caliendo with UBS.  \n \n Kevin Caliendo:  Hi.  Thanks for taking my call.  Just thinking a little bit around the cash flow question \nand if we subtract out the dividends in your capex expenditures you don\u2019t have a lot bu ilt-in for share \nbuyback.  You have $500 million of debt being repaid. ", "original_text": "Kevin Caliendo:  Hi. "}, "hash": "fc9746ee960710a1dd7134060d5772574ffd5d2b1749dac7c92be333ef24c57f", "class_name": "RelatedNodeInfo"}}, "text": "We'll next go to Kevin Caliendo with UBS.  \n \n", "start_char_idx": 43, "end_char_idx": 89, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "371fc9e2-b852-4118-916d-ae2183b77f61": {"__data__": {"id_": "371fc9e2-b852-4118-916d-ae2183b77f61", "embedding": null, "metadata": {"window": " \nPage 29 of 31 \n \n \nOperator:  Thank you.  We'll next go to Kevin Caliendo with UBS.  \n \n Kevin Caliendo:  Hi.  Thanks for taking my call.  Just thinking a little bit around the cash flow question \nand if we subtract out the dividends in your capex expenditures you don\u2019t have a lot bu ilt-in for share \nbuyback.  You have $500 million of debt being repaid. ", "original_text": "Kevin Caliendo:  Hi. ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8902963b-6af6-4797-9436-bd1772a8635d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d606c3ef91f0086c8b1b86a9a91426b2bd9a1f022be5ab05df6342f6be9bb30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e0b8ffd-6d0d-497e-9991-e3bda1742094", "node_type": "1", "metadata": {"window": " \nPage 29 of 31 \n \n \nOperator:  Thank you.  We'll next go to Kevin Caliendo with UBS.  \n \n Kevin Caliendo:  Hi.  Thanks for taking my call.  Just thinking a little bit around the cash flow question \nand if we subtract out the dividends in your capex expenditures you don\u2019t have a lot bu ilt-in for share \nbuyback. ", "original_text": "We'll next go to Kevin Caliendo with UBS.  \n \n", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bfa44579b3c07d2b4fceddf0a937f81c28bfcf7710d5146ef391ab844c5a4008", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4251048-745d-48fb-9cdc-5d0ee7c18edf", "node_type": "1", "metadata": {"window": " \nPage 29 of 31 \n \n \nOperator:  Thank you.  We'll next go to Kevin Caliendo with UBS.  \n \n Kevin Caliendo:  Hi.  Thanks for taking my call.  Just thinking a little bit around the cash flow question \nand if we subtract out the dividends in your capex expenditures you don\u2019t have a lot bu ilt-in for share \nbuyback.  You have $500 million of debt being repaid.  And the math there would suggest there's still in \nexcess of you know, $400 million, $500 million, may be more to play with.  \n \n ", "original_text": "Thanks for taking my call. "}, "hash": "297da0e9f9cc82e3648203611a63eed7cff33efa922c6698cd39d74ab910d0ec", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Caliendo:  Hi. ", "start_char_idx": 89, "end_char_idx": 110, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4251048-745d-48fb-9cdc-5d0ee7c18edf": {"__data__": {"id_": "b4251048-745d-48fb-9cdc-5d0ee7c18edf", "embedding": null, "metadata": {"window": " \nPage 29 of 31 \n \n \nOperator:  Thank you.  We'll next go to Kevin Caliendo with UBS.  \n \n Kevin Caliendo:  Hi.  Thanks for taking my call.  Just thinking a little bit around the cash flow question \nand if we subtract out the dividends in your capex expenditures you don\u2019t have a lot bu ilt-in for share \nbuyback.  You have $500 million of debt being repaid.  And the math there would suggest there's still in \nexcess of you know, $400 million, $500 million, may be more to play with.  \n \n ", "original_text": "Thanks for taking my call. ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8902963b-6af6-4797-9436-bd1772a8635d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d606c3ef91f0086c8b1b86a9a91426b2bd9a1f022be5ab05df6342f6be9bb30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "371fc9e2-b852-4118-916d-ae2183b77f61", "node_type": "1", "metadata": {"window": " \nPage 29 of 31 \n \n \nOperator:  Thank you.  We'll next go to Kevin Caliendo with UBS.  \n \n Kevin Caliendo:  Hi.  Thanks for taking my call.  Just thinking a little bit around the cash flow question \nand if we subtract out the dividends in your capex expenditures you don\u2019t have a lot bu ilt-in for share \nbuyback.  You have $500 million of debt being repaid. ", "original_text": "Kevin Caliendo:  Hi. ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e91fc6a9beec81b0bb16f82e5512261a99b974a95c671a76caa5f52747ed367a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d159b10-dfd0-4263-9eaf-a9d388c48d73", "node_type": "1", "metadata": {"window": "We'll next go to Kevin Caliendo with UBS.  \n \n Kevin Caliendo:  Hi.  Thanks for taking my call.  Just thinking a little bit around the cash flow question \nand if we subtract out the dividends in your capex expenditures you don\u2019t have a lot bu ilt-in for share \nbuyback.  You have $500 million of debt being repaid.  And the math there would suggest there's still in \nexcess of you know, $400 million, $500 million, may be more to play with.  \n \n  If we think about sort of where the company is at this point  but the cash on hand and the \nbalance sheet being in better shape than it was a year ago what would be the optimal use of that? ", "original_text": "Just thinking a little bit around the cash flow question \nand if we subtract out the dividends in your capex expenditures you don\u2019t have a lot bu ilt-in for share \nbuyback. "}, "hash": "f53abf1c2221413696b0bf642a80fb88b672ac220ca8b8f9f0c4d081ef020ae0", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking my call. ", "start_char_idx": 110, "end_char_idx": 137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d159b10-dfd0-4263-9eaf-a9d388c48d73": {"__data__": {"id_": "0d159b10-dfd0-4263-9eaf-a9d388c48d73", "embedding": null, "metadata": {"window": "We'll next go to Kevin Caliendo with UBS.  \n \n Kevin Caliendo:  Hi.  Thanks for taking my call.  Just thinking a little bit around the cash flow question \nand if we subtract out the dividends in your capex expenditures you don\u2019t have a lot bu ilt-in for share \nbuyback.  You have $500 million of debt being repaid.  And the math there would suggest there's still in \nexcess of you know, $400 million, $500 million, may be more to play with.  \n \n  If we think about sort of where the company is at this point  but the cash on hand and the \nbalance sheet being in better shape than it was a year ago what would be the optimal use of that? ", "original_text": "Just thinking a little bit around the cash flow question \nand if we subtract out the dividends in your capex expenditures you don\u2019t have a lot bu ilt-in for share \nbuyback. ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8902963b-6af6-4797-9436-bd1772a8635d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d606c3ef91f0086c8b1b86a9a91426b2bd9a1f022be5ab05df6342f6be9bb30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4251048-745d-48fb-9cdc-5d0ee7c18edf", "node_type": "1", "metadata": {"window": " \nPage 29 of 31 \n \n \nOperator:  Thank you.  We'll next go to Kevin Caliendo with UBS.  \n \n Kevin Caliendo:  Hi.  Thanks for taking my call.  Just thinking a little bit around the cash flow question \nand if we subtract out the dividends in your capex expenditures you don\u2019t have a lot bu ilt-in for share \nbuyback.  You have $500 million of debt being repaid.  And the math there would suggest there's still in \nexcess of you know, $400 million, $500 million, may be more to play with.  \n \n ", "original_text": "Thanks for taking my call. ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ddb32adc4fab874fedaaf0091748769e1c5ae0550f32a5359126ef17517af2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "504671ac-4822-4cd1-a074-e97084c039b1", "node_type": "1", "metadata": {"window": "Kevin Caliendo:  Hi.  Thanks for taking my call.  Just thinking a little bit around the cash flow question \nand if we subtract out the dividends in your capex expenditures you don\u2019t have a lot bu ilt-in for share \nbuyback.  You have $500 million of debt being repaid.  And the math there would suggest there's still in \nexcess of you know, $400 million, $500 million, may be more to play with.  \n \n  If we think about sort of where the company is at this point  but the cash on hand and the \nbalance sheet being in better shape than it was a year ago what would be the optimal use of that?  Is \nthere M&A opportunities? ", "original_text": "You have $500 million of debt being repaid. "}, "hash": "1b09ae36442e63b08d2951583d042d85767624421be5e1a98e1c12483c5c94cb", "class_name": "RelatedNodeInfo"}}, "text": "Just thinking a little bit around the cash flow question \nand if we subtract out the dividends in your capex expenditures you don\u2019t have a lot bu ilt-in for share \nbuyback. ", "start_char_idx": 137, "end_char_idx": 310, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "504671ac-4822-4cd1-a074-e97084c039b1": {"__data__": {"id_": "504671ac-4822-4cd1-a074-e97084c039b1", "embedding": null, "metadata": {"window": "Kevin Caliendo:  Hi.  Thanks for taking my call.  Just thinking a little bit around the cash flow question \nand if we subtract out the dividends in your capex expenditures you don\u2019t have a lot bu ilt-in for share \nbuyback.  You have $500 million of debt being repaid.  And the math there would suggest there's still in \nexcess of you know, $400 million, $500 million, may be more to play with.  \n \n  If we think about sort of where the company is at this point  but the cash on hand and the \nbalance sheet being in better shape than it was a year ago what would be the optimal use of that?  Is \nthere M&A opportunities? ", "original_text": "You have $500 million of debt being repaid. ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8902963b-6af6-4797-9436-bd1772a8635d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d606c3ef91f0086c8b1b86a9a91426b2bd9a1f022be5ab05df6342f6be9bb30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d159b10-dfd0-4263-9eaf-a9d388c48d73", "node_type": "1", "metadata": {"window": "We'll next go to Kevin Caliendo with UBS.  \n \n Kevin Caliendo:  Hi.  Thanks for taking my call.  Just thinking a little bit around the cash flow question \nand if we subtract out the dividends in your capex expenditures you don\u2019t have a lot bu ilt-in for share \nbuyback.  You have $500 million of debt being repaid.  And the math there would suggest there's still in \nexcess of you know, $400 million, $500 million, may be more to play with.  \n \n  If we think about sort of where the company is at this point  but the cash on hand and the \nbalance sheet being in better shape than it was a year ago what would be the optimal use of that? ", "original_text": "Just thinking a little bit around the cash flow question \nand if we subtract out the dividends in your capex expenditures you don\u2019t have a lot bu ilt-in for share \nbuyback. ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d98a01aa7b9b97eecc025911f4cee7b4f3197653460cc32b16319ab872278d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d15db728-d44b-4eb2-8ec1-1dfc30ab24ac", "node_type": "1", "metadata": {"window": "Thanks for taking my call.  Just thinking a little bit around the cash flow question \nand if we subtract out the dividends in your capex expenditures you don\u2019t have a lot bu ilt-in for share \nbuyback.  You have $500 million of debt being repaid.  And the math there would suggest there's still in \nexcess of you know, $400 million, $500 million, may be more to play with.  \n \n  If we think about sort of where the company is at this point  but the cash on hand and the \nbalance sheet being in better shape than it was a year ago what would be the optimal use of that?  Is \nthere M&A opportunities?  Is there potential that you would start to buy back stock? ", "original_text": "And the math there would suggest there's still in \nexcess of you know, $400 million, $500 million, may be more to play with.  \n \n "}, "hash": "0ac3d38e65bc60e7e8cd3d7120a9e92370ecb4c815345852873fbf401bbf9f3c", "class_name": "RelatedNodeInfo"}}, "text": "You have $500 million of debt being repaid. ", "start_char_idx": 310, "end_char_idx": 354, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d15db728-d44b-4eb2-8ec1-1dfc30ab24ac": {"__data__": {"id_": "d15db728-d44b-4eb2-8ec1-1dfc30ab24ac", "embedding": null, "metadata": {"window": "Thanks for taking my call.  Just thinking a little bit around the cash flow question \nand if we subtract out the dividends in your capex expenditures you don\u2019t have a lot bu ilt-in for share \nbuyback.  You have $500 million of debt being repaid.  And the math there would suggest there's still in \nexcess of you know, $400 million, $500 million, may be more to play with.  \n \n  If we think about sort of where the company is at this point  but the cash on hand and the \nbalance sheet being in better shape than it was a year ago what would be the optimal use of that?  Is \nthere M&A opportunities?  Is there potential that you would start to buy back stock? ", "original_text": "And the math there would suggest there's still in \nexcess of you know, $400 million, $500 million, may be more to play with.  \n \n ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8902963b-6af6-4797-9436-bd1772a8635d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d606c3ef91f0086c8b1b86a9a91426b2bd9a1f022be5ab05df6342f6be9bb30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "504671ac-4822-4cd1-a074-e97084c039b1", "node_type": "1", "metadata": {"window": "Kevin Caliendo:  Hi.  Thanks for taking my call.  Just thinking a little bit around the cash flow question \nand if we subtract out the dividends in your capex expenditures you don\u2019t have a lot bu ilt-in for share \nbuyback.  You have $500 million of debt being repaid.  And the math there would suggest there's still in \nexcess of you know, $400 million, $500 million, may be more to play with.  \n \n  If we think about sort of where the company is at this point  but the cash on hand and the \nbalance sheet being in better shape than it was a year ago what would be the optimal use of that?  Is \nthere M&A opportunities? ", "original_text": "You have $500 million of debt being repaid. ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7fba935dfdd785b0feeab9e55c61d8267e8416a843df7b773ebe2f43936dcfd2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44b10553-b90a-4519-885e-ebb443337528", "node_type": "1", "metadata": {"window": "Just thinking a little bit around the cash flow question \nand if we subtract out the dividends in your capex expenditures you don\u2019t have a lot bu ilt-in for share \nbuyback.  You have $500 million of debt being repaid.  And the math there would suggest there's still in \nexcess of you know, $400 million, $500 million, may be more to play with.  \n \n  If we think about sort of where the company is at this point  but the cash on hand and the \nbalance sheet being in better shape than it was a year ago what would be the optimal use of that?  Is \nthere M&A opportunities?  Is there potential that you would start to buy back stock?  Can you just talk a \nlittle bit about what  you might do with that any excess cash?  \n \n", "original_text": "If we think about sort of where the company is at this point  but the cash on hand and the \nbalance sheet being in better shape than it was a year ago what would be the optimal use of that? "}, "hash": "04dabb8c2909247347a2fdf01f777579fa9527ab4e7b59739a2ff5b95bf87449", "class_name": "RelatedNodeInfo"}}, "text": "And the math there would suggest there's still in \nexcess of you know, $400 million, $500 million, may be more to play with.  \n \n ", "start_char_idx": 354, "end_char_idx": 484, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44b10553-b90a-4519-885e-ebb443337528": {"__data__": {"id_": "44b10553-b90a-4519-885e-ebb443337528", "embedding": null, "metadata": {"window": "Just thinking a little bit around the cash flow question \nand if we subtract out the dividends in your capex expenditures you don\u2019t have a lot bu ilt-in for share \nbuyback.  You have $500 million of debt being repaid.  And the math there would suggest there's still in \nexcess of you know, $400 million, $500 million, may be more to play with.  \n \n  If we think about sort of where the company is at this point  but the cash on hand and the \nbalance sheet being in better shape than it was a year ago what would be the optimal use of that?  Is \nthere M&A opportunities?  Is there potential that you would start to buy back stock?  Can you just talk a \nlittle bit about what  you might do with that any excess cash?  \n \n", "original_text": "If we think about sort of where the company is at this point  but the cash on hand and the \nbalance sheet being in better shape than it was a year ago what would be the optimal use of that? ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8902963b-6af6-4797-9436-bd1772a8635d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d606c3ef91f0086c8b1b86a9a91426b2bd9a1f022be5ab05df6342f6be9bb30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d15db728-d44b-4eb2-8ec1-1dfc30ab24ac", "node_type": "1", "metadata": {"window": "Thanks for taking my call.  Just thinking a little bit around the cash flow question \nand if we subtract out the dividends in your capex expenditures you don\u2019t have a lot bu ilt-in for share \nbuyback.  You have $500 million of debt being repaid.  And the math there would suggest there's still in \nexcess of you know, $400 million, $500 million, may be more to play with.  \n \n  If we think about sort of where the company is at this point  but the cash on hand and the \nbalance sheet being in better shape than it was a year ago what would be the optimal use of that?  Is \nthere M&A opportunities?  Is there potential that you would start to buy back stock? ", "original_text": "And the math there would suggest there's still in \nexcess of you know, $400 million, $500 million, may be more to play with.  \n \n ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79a58e0cb7f1b89ea5d30db7d1b0d6701dda96e15764e7bc446316382681ca25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17cfba9d-a0fc-4bbe-ac9d-5de48173ab5a", "node_type": "1", "metadata": {"window": "You have $500 million of debt being repaid.  And the math there would suggest there's still in \nexcess of you know, $400 million, $500 million, may be more to play with.  \n \n  If we think about sort of where the company is at this point  but the cash on hand and the \nbalance sheet being in better shape than it was a year ago what would be the optimal use of that?  Is \nthere M&A opportunities?  Is there potential that you would start to buy back stock?  Can you just talk a \nlittle bit about what  you might do with that any excess cash?  \n \n Jason Hollar:  Sure yes, this is Jason. ", "original_text": "Is \nthere M&A opportunities? "}, "hash": "0917add6aef34f071e72869d48352d81ca60d746039c900cec6e712715ffc5c7", "class_name": "RelatedNodeInfo"}}, "text": "If we think about sort of where the company is at this point  but the cash on hand and the \nbalance sheet being in better shape than it was a year ago what would be the optimal use of that? ", "start_char_idx": 484, "end_char_idx": 674, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17cfba9d-a0fc-4bbe-ac9d-5de48173ab5a": {"__data__": {"id_": "17cfba9d-a0fc-4bbe-ac9d-5de48173ab5a", "embedding": null, "metadata": {"window": "You have $500 million of debt being repaid.  And the math there would suggest there's still in \nexcess of you know, $400 million, $500 million, may be more to play with.  \n \n  If we think about sort of where the company is at this point  but the cash on hand and the \nbalance sheet being in better shape than it was a year ago what would be the optimal use of that?  Is \nthere M&A opportunities?  Is there potential that you would start to buy back stock?  Can you just talk a \nlittle bit about what  you might do with that any excess cash?  \n \n Jason Hollar:  Sure yes, this is Jason. ", "original_text": "Is \nthere M&A opportunities? ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8902963b-6af6-4797-9436-bd1772a8635d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d606c3ef91f0086c8b1b86a9a91426b2bd9a1f022be5ab05df6342f6be9bb30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44b10553-b90a-4519-885e-ebb443337528", "node_type": "1", "metadata": {"window": "Just thinking a little bit around the cash flow question \nand if we subtract out the dividends in your capex expenditures you don\u2019t have a lot bu ilt-in for share \nbuyback.  You have $500 million of debt being repaid.  And the math there would suggest there's still in \nexcess of you know, $400 million, $500 million, may be more to play with.  \n \n  If we think about sort of where the company is at this point  but the cash on hand and the \nbalance sheet being in better shape than it was a year ago what would be the optimal use of that?  Is \nthere M&A opportunities?  Is there potential that you would start to buy back stock?  Can you just talk a \nlittle bit about what  you might do with that any excess cash?  \n \n", "original_text": "If we think about sort of where the company is at this point  but the cash on hand and the \nbalance sheet being in better shape than it was a year ago what would be the optimal use of that? ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6390363addc4619a1bd499ad7d9d84deb6f4647b51cd9b1a8dbfcca08f3be011", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e34e4692-5d33-4577-9392-e80cc2e71c70", "node_type": "1", "metadata": {"window": "And the math there would suggest there's still in \nexcess of you know, $400 million, $500 million, may be more to play with.  \n \n  If we think about sort of where the company is at this point  but the cash on hand and the \nbalance sheet being in better shape than it was a year ago what would be the optimal use of that?  Is \nthere M&A opportunities?  Is there potential that you would start to buy back stock?  Can you just talk a \nlittle bit about what  you might do with that any excess cash?  \n \n Jason Hollar:  Sure yes, this is Jason.  Let me start with that. ", "original_text": "Is there potential that you would start to buy back stock? "}, "hash": "1f4a0b3d2fc8a12ca61e5aa20a6fadc0292588f608e5d49750b6fed415719d0c", "class_name": "RelatedNodeInfo"}}, "text": "Is \nthere M&A opportunities? ", "start_char_idx": 674, "end_char_idx": 703, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e34e4692-5d33-4577-9392-e80cc2e71c70": {"__data__": {"id_": "e34e4692-5d33-4577-9392-e80cc2e71c70", "embedding": null, "metadata": {"window": "And the math there would suggest there's still in \nexcess of you know, $400 million, $500 million, may be more to play with.  \n \n  If we think about sort of where the company is at this point  but the cash on hand and the \nbalance sheet being in better shape than it was a year ago what would be the optimal use of that?  Is \nthere M&A opportunities?  Is there potential that you would start to buy back stock?  Can you just talk a \nlittle bit about what  you might do with that any excess cash?  \n \n Jason Hollar:  Sure yes, this is Jason.  Let me start with that. ", "original_text": "Is there potential that you would start to buy back stock? ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8902963b-6af6-4797-9436-bd1772a8635d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d606c3ef91f0086c8b1b86a9a91426b2bd9a1f022be5ab05df6342f6be9bb30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17cfba9d-a0fc-4bbe-ac9d-5de48173ab5a", "node_type": "1", "metadata": {"window": "You have $500 million of debt being repaid.  And the math there would suggest there's still in \nexcess of you know, $400 million, $500 million, may be more to play with.  \n \n  If we think about sort of where the company is at this point  but the cash on hand and the \nbalance sheet being in better shape than it was a year ago what would be the optimal use of that?  Is \nthere M&A opportunities?  Is there potential that you would start to buy back stock?  Can you just talk a \nlittle bit about what  you might do with that any excess cash?  \n \n Jason Hollar:  Sure yes, this is Jason. ", "original_text": "Is \nthere M&A opportunities? ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9ab6bfe9611fd1ffef931f8a10c22a94d5aea7311c9d27d8bd43d899d5ec318", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c5f00a4-521b-48cd-b828-38e81f5ef2cc", "node_type": "1", "metadata": {"window": "If we think about sort of where the company is at this point  but the cash on hand and the \nbalance sheet being in better shape than it was a year ago what would be the optimal use of that?  Is \nthere M&A opportunities?  Is there potential that you would start to buy back stock?  Can you just talk a \nlittle bit about what  you might do with that any excess cash?  \n \n Jason Hollar:  Sure yes, this is Jason.  Let me start with that.  And I think your math is fairly accurate \nthere. ", "original_text": "Can you just talk a \nlittle bit about what  you might do with that any excess cash?  \n \n"}, "hash": "c8c577f98cf5007ec6015b2d8ed9125d23f229f69db471a224b9377c98030609", "class_name": "RelatedNodeInfo"}}, "text": "Is there potential that you would start to buy back stock? ", "start_char_idx": 703, "end_char_idx": 762, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c5f00a4-521b-48cd-b828-38e81f5ef2cc": {"__data__": {"id_": "3c5f00a4-521b-48cd-b828-38e81f5ef2cc", "embedding": null, "metadata": {"window": "If we think about sort of where the company is at this point  but the cash on hand and the \nbalance sheet being in better shape than it was a year ago what would be the optimal use of that?  Is \nthere M&A opportunities?  Is there potential that you would start to buy back stock?  Can you just talk a \nlittle bit about what  you might do with that any excess cash?  \n \n Jason Hollar:  Sure yes, this is Jason.  Let me start with that.  And I think your math is fairly accurate \nthere. ", "original_text": "Can you just talk a \nlittle bit about what  you might do with that any excess cash?  \n \n", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8902963b-6af6-4797-9436-bd1772a8635d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d606c3ef91f0086c8b1b86a9a91426b2bd9a1f022be5ab05df6342f6be9bb30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e34e4692-5d33-4577-9392-e80cc2e71c70", "node_type": "1", "metadata": {"window": "And the math there would suggest there's still in \nexcess of you know, $400 million, $500 million, may be more to play with.  \n \n  If we think about sort of where the company is at this point  but the cash on hand and the \nbalance sheet being in better shape than it was a year ago what would be the optimal use of that?  Is \nthere M&A opportunities?  Is there potential that you would start to buy back stock?  Can you just talk a \nlittle bit about what  you might do with that any excess cash?  \n \n Jason Hollar:  Sure yes, this is Jason.  Let me start with that. ", "original_text": "Is there potential that you would start to buy back stock? ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eddc9904cfee40ad9f04ca86f6ff298ce13b8ac4d3a5542298c8fbf037d0af8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b91842ca-f695-45f1-81b8-bc145814af2c", "node_type": "1", "metadata": {"window": "Is \nthere M&A opportunities?  Is there potential that you would start to buy back stock?  Can you just talk a \nlittle bit about what  you might do with that any excess cash?  \n \n Jason Hollar:  Sure yes, this is Jason.  Let me start with that.  And I think your math is fairly accurate \nthere.  This does give us some flexibility and I think that\u2019s where I would start is just recognizing that \nwe are in a little bit more uncertain of an environment as is typical. ", "original_text": "Jason Hollar:  Sure yes, this is Jason. "}, "hash": "5626bf4880f37d6cfd82464a28e9a00d4ce4b1e2477a07d4df9b1f9dce5a44b1", "class_name": "RelatedNodeInfo"}}, "text": "Can you just talk a \nlittle bit about what  you might do with that any excess cash?  \n \n", "start_char_idx": 762, "end_char_idx": 850, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b91842ca-f695-45f1-81b8-bc145814af2c": {"__data__": {"id_": "b91842ca-f695-45f1-81b8-bc145814af2c", "embedding": null, "metadata": {"window": "Is \nthere M&A opportunities?  Is there potential that you would start to buy back stock?  Can you just talk a \nlittle bit about what  you might do with that any excess cash?  \n \n Jason Hollar:  Sure yes, this is Jason.  Let me start with that.  And I think your math is fairly accurate \nthere.  This does give us some flexibility and I think that\u2019s where I would start is just recognizing that \nwe are in a little bit more uncertain of an environment as is typical. ", "original_text": "Jason Hollar:  Sure yes, this is Jason. ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8902963b-6af6-4797-9436-bd1772a8635d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d606c3ef91f0086c8b1b86a9a91426b2bd9a1f022be5ab05df6342f6be9bb30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c5f00a4-521b-48cd-b828-38e81f5ef2cc", "node_type": "1", "metadata": {"window": "If we think about sort of where the company is at this point  but the cash on hand and the \nbalance sheet being in better shape than it was a year ago what would be the optimal use of that?  Is \nthere M&A opportunities?  Is there potential that you would start to buy back stock?  Can you just talk a \nlittle bit about what  you might do with that any excess cash?  \n \n Jason Hollar:  Sure yes, this is Jason.  Let me start with that.  And I think your math is fairly accurate \nthere. ", "original_text": "Can you just talk a \nlittle bit about what  you might do with that any excess cash?  \n \n", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b3edc8ba8cf2474e76909dc1d8d5a644397359d16e0b02cb8dd366ea81b23972", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ae30aaf-3fba-4426-aac9-795b900643cb", "node_type": "1", "metadata": {"window": "Is there potential that you would start to buy back stock?  Can you just talk a \nlittle bit about what  you might do with that any excess cash?  \n \n Jason Hollar:  Sure yes, this is Jason.  Let me start with that.  And I think your math is fairly accurate \nthere.  This does give us some flexibility and I think that\u2019s where I would start is just recognizing that \nwe are in a little bit more uncertain of an environment as is typical.  And so this guidance does give us \na little bit more flexibility to be able to react to any type of situation that may occur.  \n \n ", "original_text": "Let me start with that. "}, "hash": "3af33c0dc14b61a2aeeb4a73a8d7e8274f84585b89375d1d1d2f0a34b60c2f8d", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Sure yes, this is Jason. ", "start_char_idx": 850, "end_char_idx": 890, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ae30aaf-3fba-4426-aac9-795b900643cb": {"__data__": {"id_": "7ae30aaf-3fba-4426-aac9-795b900643cb", "embedding": null, "metadata": {"window": "Is there potential that you would start to buy back stock?  Can you just talk a \nlittle bit about what  you might do with that any excess cash?  \n \n Jason Hollar:  Sure yes, this is Jason.  Let me start with that.  And I think your math is fairly accurate \nthere.  This does give us some flexibility and I think that\u2019s where I would start is just recognizing that \nwe are in a little bit more uncertain of an environment as is typical.  And so this guidance does give us \na little bit more flexibility to be able to react to any type of situation that may occur.  \n \n ", "original_text": "Let me start with that. ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8902963b-6af6-4797-9436-bd1772a8635d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d606c3ef91f0086c8b1b86a9a91426b2bd9a1f022be5ab05df6342f6be9bb30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b91842ca-f695-45f1-81b8-bc145814af2c", "node_type": "1", "metadata": {"window": "Is \nthere M&A opportunities?  Is there potential that you would start to buy back stock?  Can you just talk a \nlittle bit about what  you might do with that any excess cash?  \n \n Jason Hollar:  Sure yes, this is Jason.  Let me start with that.  And I think your math is fairly accurate \nthere.  This does give us some flexibility and I think that\u2019s where I would start is just recognizing that \nwe are in a little bit more uncertain of an environment as is typical. ", "original_text": "Jason Hollar:  Sure yes, this is Jason. ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b96cd150ca17f7c1f2f3ff4b9d40d32aac974e01abe3a000c3c8142b3c49238e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c476f603-0426-4280-86c1-2085ce8f8d76", "node_type": "1", "metadata": {"window": "Can you just talk a \nlittle bit about what  you might do with that any excess cash?  \n \n Jason Hollar:  Sure yes, this is Jason.  Let me start with that.  And I think your math is fairly accurate \nthere.  This does give us some flexibility and I think that\u2019s where I would start is just recognizing that \nwe are in a little bit more uncertain of an environment as is typical.  And so this guidance does give us \na little bit more flexibility to be able to react to any type of situation that may occur.  \n \n  One thing you mentioned is the debt pay down of $500 million.  ", "original_text": "And I think your math is fairly accurate \nthere. "}, "hash": "9c65b7703d5220fb1c3743c546db74bd207330f2ed8c91306cc3f7fdfbc10609", "class_name": "RelatedNodeInfo"}}, "text": "Let me start with that. ", "start_char_idx": 890, "end_char_idx": 914, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c476f603-0426-4280-86c1-2085ce8f8d76": {"__data__": {"id_": "c476f603-0426-4280-86c1-2085ce8f8d76", "embedding": null, "metadata": {"window": "Can you just talk a \nlittle bit about what  you might do with that any excess cash?  \n \n Jason Hollar:  Sure yes, this is Jason.  Let me start with that.  And I think your math is fairly accurate \nthere.  This does give us some flexibility and I think that\u2019s where I would start is just recognizing that \nwe are in a little bit more uncertain of an environment as is typical.  And so this guidance does give us \na little bit more flexibility to be able to react to any type of situation that may occur.  \n \n  One thing you mentioned is the debt pay down of $500 million.  ", "original_text": "And I think your math is fairly accurate \nthere. ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8902963b-6af6-4797-9436-bd1772a8635d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d606c3ef91f0086c8b1b86a9a91426b2bd9a1f022be5ab05df6342f6be9bb30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ae30aaf-3fba-4426-aac9-795b900643cb", "node_type": "1", "metadata": {"window": "Is there potential that you would start to buy back stock?  Can you just talk a \nlittle bit about what  you might do with that any excess cash?  \n \n Jason Hollar:  Sure yes, this is Jason.  Let me start with that.  And I think your math is fairly accurate \nthere.  This does give us some flexibility and I think that\u2019s where I would start is just recognizing that \nwe are in a little bit more uncertain of an environment as is typical.  And so this guidance does give us \na little bit more flexibility to be able to react to any type of situation that may occur.  \n \n ", "original_text": "Let me start with that. ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e86595921cc313dd30fdc1cc0492e41f9b2c907085003b6e5d1600dc90a93b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0be8ef39-4145-43c3-a490-6fc14f0bb1c4", "node_type": "1", "metadata": {"window": "Jason Hollar:  Sure yes, this is Jason.  Let me start with that.  And I think your math is fairly accurate \nthere.  This does give us some flexibility and I think that\u2019s where I would start is just recognizing that \nwe are in a little bit more uncertain of an environment as is typical.  And so this guidance does give us \na little bit more flexibility to be able to react to any type of situation that may occur.  \n \n  One thing you mentioned is the debt pay down of $500 million.   I did highlight at least $500 \nmillion in my script. ", "original_text": "This does give us some flexibility and I think that\u2019s where I would start is just recognizing that \nwe are in a little bit more uncertain of an environment as is typical. "}, "hash": "59a55014d41d11205cdb3ebaea247aeb51e98ce7c2edbff004c02483a7172823", "class_name": "RelatedNodeInfo"}}, "text": "And I think your math is fairly accurate \nthere. ", "start_char_idx": 914, "end_char_idx": 963, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0be8ef39-4145-43c3-a490-6fc14f0bb1c4": {"__data__": {"id_": "0be8ef39-4145-43c3-a490-6fc14f0bb1c4", "embedding": null, "metadata": {"window": "Jason Hollar:  Sure yes, this is Jason.  Let me start with that.  And I think your math is fairly accurate \nthere.  This does give us some flexibility and I think that\u2019s where I would start is just recognizing that \nwe are in a little bit more uncertain of an environment as is typical.  And so this guidance does give us \na little bit more flexibility to be able to react to any type of situation that may occur.  \n \n  One thing you mentioned is the debt pay down of $500 million.   I did highlight at least $500 \nmillion in my script. ", "original_text": "This does give us some flexibility and I think that\u2019s where I would start is just recognizing that \nwe are in a little bit more uncertain of an environment as is typical. ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8902963b-6af6-4797-9436-bd1772a8635d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d606c3ef91f0086c8b1b86a9a91426b2bd9a1f022be5ab05df6342f6be9bb30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c476f603-0426-4280-86c1-2085ce8f8d76", "node_type": "1", "metadata": {"window": "Can you just talk a \nlittle bit about what  you might do with that any excess cash?  \n \n Jason Hollar:  Sure yes, this is Jason.  Let me start with that.  And I think your math is fairly accurate \nthere.  This does give us some flexibility and I think that\u2019s where I would start is just recognizing that \nwe are in a little bit more uncertain of an environment as is typical.  And so this guidance does give us \na little bit more flexibility to be able to react to any type of situation that may occur.  \n \n  One thing you mentioned is the debt pay down of $500 million.  ", "original_text": "And I think your math is fairly accurate \nthere. ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00899ba3f1423bdc32de58fec2f501e70ae32b21a5c1c391fecdbd4d4d453b49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4afddbb-67ce-434c-a7a2-a5722be5a457", "node_type": "1", "metadata": {"window": "Let me start with that.  And I think your math is fairly accurate \nthere.  This does give us some flexibility and I think that\u2019s where I would start is just recognizing that \nwe are in a little bit more uncertain of an environment as is typical.  And so this guidance does give us \na little bit more flexibility to be able to react to any type of situation that may occur.  \n \n  One thing you mentioned is the debt pay down of $500 million.   I did highlight at least $500 \nmillion in my script.  So that\u2019s an example of, you know, we\u2019ll see how comfortable we are with that \ntype of capacity and then, you know, determined where to go from there.  \n \n ", "original_text": "And so this guidance does give us \na little bit more flexibility to be able to react to any type of situation that may occur.  \n \n "}, "hash": "da10c63a249803a98ab16abd730392bafa53a71a8ec9bb4552fbb2207bc89a45", "class_name": "RelatedNodeInfo"}}, "text": "This does give us some flexibility and I think that\u2019s where I would start is just recognizing that \nwe are in a little bit more uncertain of an environment as is typical. ", "start_char_idx": 963, "end_char_idx": 1134, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4afddbb-67ce-434c-a7a2-a5722be5a457": {"__data__": {"id_": "a4afddbb-67ce-434c-a7a2-a5722be5a457", "embedding": null, "metadata": {"window": "Let me start with that.  And I think your math is fairly accurate \nthere.  This does give us some flexibility and I think that\u2019s where I would start is just recognizing that \nwe are in a little bit more uncertain of an environment as is typical.  And so this guidance does give us \na little bit more flexibility to be able to react to any type of situation that may occur.  \n \n  One thing you mentioned is the debt pay down of $500 million.   I did highlight at least $500 \nmillion in my script.  So that\u2019s an example of, you know, we\u2019ll see how comfortable we are with that \ntype of capacity and then, you know, determined where to go from there.  \n \n ", "original_text": "And so this guidance does give us \na little bit more flexibility to be able to react to any type of situation that may occur.  \n \n ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8902963b-6af6-4797-9436-bd1772a8635d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d606c3ef91f0086c8b1b86a9a91426b2bd9a1f022be5ab05df6342f6be9bb30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0be8ef39-4145-43c3-a490-6fc14f0bb1c4", "node_type": "1", "metadata": {"window": "Jason Hollar:  Sure yes, this is Jason.  Let me start with that.  And I think your math is fairly accurate \nthere.  This does give us some flexibility and I think that\u2019s where I would start is just recognizing that \nwe are in a little bit more uncertain of an environment as is typical.  And so this guidance does give us \na little bit more flexibility to be able to react to any type of situation that may occur.  \n \n  One thing you mentioned is the debt pay down of $500 million.   I did highlight at least $500 \nmillion in my script. ", "original_text": "This does give us some flexibility and I think that\u2019s where I would start is just recognizing that \nwe are in a little bit more uncertain of an environment as is typical. ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54beb2ca827fe1f1657e3ccf16f9391f3ca5c1d42f0bdf8da26e059bcc90464d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4524ee8a-2f40-4996-8692-8453e7a2c0bb", "node_type": "1", "metadata": {"window": "And I think your math is fairly accurate \nthere.  This does give us some flexibility and I think that\u2019s where I would start is just recognizing that \nwe are in a little bit more uncertain of an environment as is typical.  And so this guidance does give us \na little bit more flexibility to be able to react to any type of situation that may occur.  \n \n  One thing you mentioned is the debt pay down of $500 million.   I did highlight at least $500 \nmillion in my script.  So that\u2019s an example of, you know, we\u2019ll see how comfortable we are with that \ntype of capacity and then, you know, determined where to go from there.  \n \n  We have about a $1.4B coming due in 2022 in terms o f the next tower of debt. ", "original_text": "One thing you mentioned is the debt pay down of $500 million.  "}, "hash": "39006921d4c87502acef7e6cebaea1d254dfddc70a04937555579a9e4d6283b4", "class_name": "RelatedNodeInfo"}}, "text": "And so this guidance does give us \na little bit more flexibility to be able to react to any type of situation that may occur.  \n \n ", "start_char_idx": 1134, "end_char_idx": 1265, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4524ee8a-2f40-4996-8692-8453e7a2c0bb": {"__data__": {"id_": "4524ee8a-2f40-4996-8692-8453e7a2c0bb", "embedding": null, "metadata": {"window": "And I think your math is fairly accurate \nthere.  This does give us some flexibility and I think that\u2019s where I would start is just recognizing that \nwe are in a little bit more uncertain of an environment as is typical.  And so this guidance does give us \na little bit more flexibility to be able to react to any type of situation that may occur.  \n \n  One thing you mentioned is the debt pay down of $500 million.   I did highlight at least $500 \nmillion in my script.  So that\u2019s an example of, you know, we\u2019ll see how comfortable we are with that \ntype of capacity and then, you know, determined where to go from there.  \n \n  We have about a $1.4B coming due in 2022 in terms o f the next tower of debt. ", "original_text": "One thing you mentioned is the debt pay down of $500 million.  ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8902963b-6af6-4797-9436-bd1772a8635d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d606c3ef91f0086c8b1b86a9a91426b2bd9a1f022be5ab05df6342f6be9bb30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4afddbb-67ce-434c-a7a2-a5722be5a457", "node_type": "1", "metadata": {"window": "Let me start with that.  And I think your math is fairly accurate \nthere.  This does give us some flexibility and I think that\u2019s where I would start is just recognizing that \nwe are in a little bit more uncertain of an environment as is typical.  And so this guidance does give us \na little bit more flexibility to be able to react to any type of situation that may occur.  \n \n  One thing you mentioned is the debt pay down of $500 million.   I did highlight at least $500 \nmillion in my script.  So that\u2019s an example of, you know, we\u2019ll see how comfortable we are with that \ntype of capacity and then, you know, determined where to go from there.  \n \n ", "original_text": "And so this guidance does give us \na little bit more flexibility to be able to react to any type of situation that may occur.  \n \n ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8903aaf0bf53012cd9c86f595baf902d97bde15ecea8c3492552990dc6e55151", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5141a33b-12b5-4388-8df6-288c1d4f62be", "node_type": "1", "metadata": {"window": "This does give us some flexibility and I think that\u2019s where I would start is just recognizing that \nwe are in a little bit more uncertain of an environment as is typical.  And so this guidance does give us \na little bit more flexibility to be able to react to any type of situation that may occur.  \n \n  One thing you mentioned is the debt pay down of $500 million.   I did highlight at least $500 \nmillion in my script.  So that\u2019s an example of, you know, we\u2019ll see how comfortable we are with that \ntype of capacity and then, you know, determined where to go from there.  \n \n  We have about a $1.4B coming due in 2022 in terms o f the next tower of debt.  And so that\u2019s \njust something we have in our sites and want to think about. ", "original_text": "I did highlight at least $500 \nmillion in my script. "}, "hash": "ece5906fc3ac54a85831c4859e49cd72a8734dca3f2d5a7229dfa37d51a28b0d", "class_name": "RelatedNodeInfo"}}, "text": "One thing you mentioned is the debt pay down of $500 million.  ", "start_char_idx": 1265, "end_char_idx": 1328, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5141a33b-12b5-4388-8df6-288c1d4f62be": {"__data__": {"id_": "5141a33b-12b5-4388-8df6-288c1d4f62be", "embedding": null, "metadata": {"window": "This does give us some flexibility and I think that\u2019s where I would start is just recognizing that \nwe are in a little bit more uncertain of an environment as is typical.  And so this guidance does give us \na little bit more flexibility to be able to react to any type of situation that may occur.  \n \n  One thing you mentioned is the debt pay down of $500 million.   I did highlight at least $500 \nmillion in my script.  So that\u2019s an example of, you know, we\u2019ll see how comfortable we are with that \ntype of capacity and then, you know, determined where to go from there.  \n \n  We have about a $1.4B coming due in 2022 in terms o f the next tower of debt.  And so that\u2019s \njust something we have in our sites and want to think about. ", "original_text": "I did highlight at least $500 \nmillion in my script. ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8902963b-6af6-4797-9436-bd1772a8635d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d606c3ef91f0086c8b1b86a9a91426b2bd9a1f022be5ab05df6342f6be9bb30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4524ee8a-2f40-4996-8692-8453e7a2c0bb", "node_type": "1", "metadata": {"window": "And I think your math is fairly accurate \nthere.  This does give us some flexibility and I think that\u2019s where I would start is just recognizing that \nwe are in a little bit more uncertain of an environment as is typical.  And so this guidance does give us \na little bit more flexibility to be able to react to any type of situation that may occur.  \n \n  One thing you mentioned is the debt pay down of $500 million.   I did highlight at least $500 \nmillion in my script.  So that\u2019s an example of, you know, we\u2019ll see how comfortable we are with that \ntype of capacity and then, you know, determined where to go from there.  \n \n  We have about a $1.4B coming due in 2022 in terms o f the next tower of debt. ", "original_text": "One thing you mentioned is the debt pay down of $500 million.  ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "735678a0a8df2abb3c9ea6e647fbaf04b9a82dc7ef1257ebc3ff023b3f52eb89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8caf2268-5302-41ee-9838-9081c77a168b", "node_type": "1", "metadata": {"window": "And so this guidance does give us \na little bit more flexibility to be able to react to any type of situation that may occur.  \n \n  One thing you mentioned is the debt pay down of $500 million.   I did highlight at least $500 \nmillion in my script.  So that\u2019s an example of, you know, we\u2019ll see how comfortable we are with that \ntype of capacity and then, you know, determined where to go from there.  \n \n  We have about a $1.4B coming due in 2022 in terms o f the next tower of debt.  And so that\u2019s \njust something we have in our sites and want to think about.  And then we have a little bit of repo built ", "original_text": "So that\u2019s an example of, you know, we\u2019ll see how comfortable we are with that \ntype of capacity and then, you know, determined where to go from there.  \n \n "}, "hash": "4833a0a95df4690e9038b01a95670d9a098dc3ae3721455a558ce870550f9708", "class_name": "RelatedNodeInfo"}}, "text": "I did highlight at least $500 \nmillion in my script. ", "start_char_idx": 1328, "end_char_idx": 1381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8caf2268-5302-41ee-9838-9081c77a168b": {"__data__": {"id_": "8caf2268-5302-41ee-9838-9081c77a168b", "embedding": null, "metadata": {"window": "And so this guidance does give us \na little bit more flexibility to be able to react to any type of situation that may occur.  \n \n  One thing you mentioned is the debt pay down of $500 million.   I did highlight at least $500 \nmillion in my script.  So that\u2019s an example of, you know, we\u2019ll see how comfortable we are with that \ntype of capacity and then, you know, determined where to go from there.  \n \n  We have about a $1.4B coming due in 2022 in terms o f the next tower of debt.  And so that\u2019s \njust something we have in our sites and want to think about.  And then we have a little bit of repo built ", "original_text": "So that\u2019s an example of, you know, we\u2019ll see how comfortable we are with that \ntype of capacity and then, you know, determined where to go from there.  \n \n ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8902963b-6af6-4797-9436-bd1772a8635d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d606c3ef91f0086c8b1b86a9a91426b2bd9a1f022be5ab05df6342f6be9bb30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5141a33b-12b5-4388-8df6-288c1d4f62be", "node_type": "1", "metadata": {"window": "This does give us some flexibility and I think that\u2019s where I would start is just recognizing that \nwe are in a little bit more uncertain of an environment as is typical.  And so this guidance does give us \na little bit more flexibility to be able to react to any type of situation that may occur.  \n \n  One thing you mentioned is the debt pay down of $500 million.   I did highlight at least $500 \nmillion in my script.  So that\u2019s an example of, you know, we\u2019ll see how comfortable we are with that \ntype of capacity and then, you know, determined where to go from there.  \n \n  We have about a $1.4B coming due in 2022 in terms o f the next tower of debt.  And so that\u2019s \njust something we have in our sites and want to think about. ", "original_text": "I did highlight at least $500 \nmillion in my script. ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "047949b2b2089ee9b1ae5ba6e84592579437cb2e1c89c152fecb747a823e5141", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e300c023-f6cf-4f4e-8158-47ec8033e82a", "node_type": "1", "metadata": {"window": "One thing you mentioned is the debt pay down of $500 million.   I did highlight at least $500 \nmillion in my script.  So that\u2019s an example of, you know, we\u2019ll see how comfortable we are with that \ntype of capacity and then, you know, determined where to go from there.  \n \n  We have about a $1.4B coming due in 2022 in terms o f the next tower of debt.  And so that\u2019s \njust something we have in our sites and want to think about.  And then we have a little bit of repo built ", "original_text": "We have about a $1.4B coming due in 2022 in terms o f the next tower of debt. "}, "hash": "a1f6e03ea9a2d18b356a3fc04b4601d80190ff5606094c866cb807d7357ef17c", "class_name": "RelatedNodeInfo"}}, "text": "So that\u2019s an example of, you know, we\u2019ll see how comfortable we are with that \ntype of capacity and then, you know, determined where to go from there.  \n \n ", "start_char_idx": 1381, "end_char_idx": 1537, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e300c023-f6cf-4f4e-8158-47ec8033e82a": {"__data__": {"id_": "e300c023-f6cf-4f4e-8158-47ec8033e82a", "embedding": null, "metadata": {"window": "One thing you mentioned is the debt pay down of $500 million.   I did highlight at least $500 \nmillion in my script.  So that\u2019s an example of, you know, we\u2019ll see how comfortable we are with that \ntype of capacity and then, you know, determined where to go from there.  \n \n  We have about a $1.4B coming due in 2022 in terms o f the next tower of debt.  And so that\u2019s \njust something we have in our sites and want to think about.  And then we have a little bit of repo built ", "original_text": "We have about a $1.4B coming due in 2022 in terms o f the next tower of debt. ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8902963b-6af6-4797-9436-bd1772a8635d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d606c3ef91f0086c8b1b86a9a91426b2bd9a1f022be5ab05df6342f6be9bb30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8caf2268-5302-41ee-9838-9081c77a168b", "node_type": "1", "metadata": {"window": "And so this guidance does give us \na little bit more flexibility to be able to react to any type of situation that may occur.  \n \n  One thing you mentioned is the debt pay down of $500 million.   I did highlight at least $500 \nmillion in my script.  So that\u2019s an example of, you know, we\u2019ll see how comfortable we are with that \ntype of capacity and then, you know, determined where to go from there.  \n \n  We have about a $1.4B coming due in 2022 in terms o f the next tower of debt.  And so that\u2019s \njust something we have in our sites and want to think about.  And then we have a little bit of repo built ", "original_text": "So that\u2019s an example of, you know, we\u2019ll see how comfortable we are with that \ntype of capacity and then, you know, determined where to go from there.  \n \n ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28392575b744f99e0928be730e5bd12676976d2d96ea5765d99f2baed5dcd1af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d492b02-bafb-4e69-8f64-6c1bcb2a2ffa", "node_type": "1", "metadata": {"window": "I did highlight at least $500 \nmillion in my script.  So that\u2019s an example of, you know, we\u2019ll see how comfortable we are with that \ntype of capacity and then, you know, determined where to go from there.  \n \n  We have about a $1.4B coming due in 2022 in terms o f the next tower of debt.  And so that\u2019s \njust something we have in our sites and want to think about.  And then we have a little bit of repo built ", "original_text": "And so that\u2019s \njust something we have in our sites and want to think about. "}, "hash": "b7512ffc03f8aa6c54a3a7c8339b162c4ca7367370a6c9e9b5b9c4b2bacf8993", "class_name": "RelatedNodeInfo"}}, "text": "We have about a $1.4B coming due in 2022 in terms o f the next tower of debt. ", "start_char_idx": 1537, "end_char_idx": 1615, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d492b02-bafb-4e69-8f64-6c1bcb2a2ffa": {"__data__": {"id_": "9d492b02-bafb-4e69-8f64-6c1bcb2a2ffa", "embedding": null, "metadata": {"window": "I did highlight at least $500 \nmillion in my script.  So that\u2019s an example of, you know, we\u2019ll see how comfortable we are with that \ntype of capacity and then, you know, determined where to go from there.  \n \n  We have about a $1.4B coming due in 2022 in terms o f the next tower of debt.  And so that\u2019s \njust something we have in our sites and want to think about.  And then we have a little bit of repo built ", "original_text": "And so that\u2019s \njust something we have in our sites and want to think about. ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8902963b-6af6-4797-9436-bd1772a8635d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d606c3ef91f0086c8b1b86a9a91426b2bd9a1f022be5ab05df6342f6be9bb30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e300c023-f6cf-4f4e-8158-47ec8033e82a", "node_type": "1", "metadata": {"window": "One thing you mentioned is the debt pay down of $500 million.   I did highlight at least $500 \nmillion in my script.  So that\u2019s an example of, you know, we\u2019ll see how comfortable we are with that \ntype of capacity and then, you know, determined where to go from there.  \n \n  We have about a $1.4B coming due in 2022 in terms o f the next tower of debt.  And so that\u2019s \njust something we have in our sites and want to think about.  And then we have a little bit of repo built ", "original_text": "We have about a $1.4B coming due in 2022 in terms o f the next tower of debt. ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c516ebfbeb20e774bd3ad903536721d4c7c946a0fc616af0ddb7d12a3640b8ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f91eab8-21bc-4738-a648-ae357804a8be", "node_type": "1", "metadata": {"window": "So that\u2019s an example of, you know, we\u2019ll see how comfortable we are with that \ntype of capacity and then, you know, determined where to go from there.  \n \n  We have about a $1.4B coming due in 2022 in terms o f the next tower of debt.  And so that\u2019s \njust something we have in our sites and want to think about.  And then we have a little bit of repo built ", "original_text": "And then we have a little bit of repo built "}, "hash": "38dd51bda117ca8f3726b9c0a9fa85b34cf9a5ac5205210fed3ededec0d8d2fc", "class_name": "RelatedNodeInfo"}}, "text": "And so that\u2019s \njust something we have in our sites and want to think about. ", "start_char_idx": 1615, "end_char_idx": 1691, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f91eab8-21bc-4738-a648-ae357804a8be": {"__data__": {"id_": "6f91eab8-21bc-4738-a648-ae357804a8be", "embedding": null, "metadata": {"window": "So that\u2019s an example of, you know, we\u2019ll see how comfortable we are with that \ntype of capacity and then, you know, determined where to go from there.  \n \n  We have about a $1.4B coming due in 2022 in terms o f the next tower of debt.  And so that\u2019s \njust something we have in our sites and want to think about.  And then we have a little bit of repo built ", "original_text": "And then we have a little bit of repo built ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8902963b-6af6-4797-9436-bd1772a8635d", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d606c3ef91f0086c8b1b86a9a91426b2bd9a1f022be5ab05df6342f6be9bb30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d492b02-bafb-4e69-8f64-6c1bcb2a2ffa", "node_type": "1", "metadata": {"window": "I did highlight at least $500 \nmillion in my script.  So that\u2019s an example of, you know, we\u2019ll see how comfortable we are with that \ntype of capacity and then, you know, determined where to go from there.  \n \n  We have about a $1.4B coming due in 2022 in terms o f the next tower of debt.  And so that\u2019s \njust something we have in our sites and want to think about.  And then we have a little bit of repo built ", "original_text": "And so that\u2019s \njust something we have in our sites and want to think about. ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0cbe2138cf046f86d46baddcb474db945c5f533bb5a073fea66adf1bafe7c880", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9230ce05-6d99-402b-b9b0-d77413b575b3", "node_type": "1", "metadata": {"window": " \nPage 30 of 31 \n \ninto our share guidance.  And the exact timing and amount of that is something that we will continue to \nevaluate  based upon all the other factors.  So and yes so next question?  \n \n Operator:  Thank you. ", "original_text": " \nPage 30 of 31 \n \ninto our share guidance. "}, "hash": "52da7b3718b8e0e2f497df3412169218c45fde3f541b12b0609a8155500f8224", "class_name": "RelatedNodeInfo"}}, "text": "And then we have a little bit of repo built ", "start_char_idx": 1691, "end_char_idx": 1735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9230ce05-6d99-402b-b9b0-d77413b575b3": {"__data__": {"id_": "9230ce05-6d99-402b-b9b0-d77413b575b3", "embedding": null, "metadata": {"window": " \nPage 30 of 31 \n \ninto our share guidance.  And the exact timing and amount of that is something that we will continue to \nevaluate  based upon all the other factors.  So and yes so next question?  \n \n Operator:  Thank you. ", "original_text": " \nPage 30 of 31 \n \ninto our share guidance. ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8402db9403696f1e9678026f6e69655c1c920e312c73df8b6b0efd53ec34fa62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f91eab8-21bc-4738-a648-ae357804a8be", "node_type": "1", "metadata": {"window": "So that\u2019s an example of, you know, we\u2019ll see how comfortable we are with that \ntype of capacity and then, you know, determined where to go from there.  \n \n  We have about a $1.4B coming due in 2022 in terms o f the next tower of debt.  And so that\u2019s \njust something we have in our sites and want to think about.  And then we have a little bit of repo built ", "original_text": "And then we have a little bit of repo built ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7fee30ed2aba351f6dd8eb2a7388e3ede422ffac21ed8c0bf27b5acf1face73a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2318968a-340a-4646-8a4a-7667dc30f096", "node_type": "1", "metadata": {"window": " \nPage 30 of 31 \n \ninto our share guidance.  And the exact timing and amount of that is something that we will continue to \nevaluate  based upon all the other factors.  So and yes so next question?  \n \n Operator:  Thank you.  And our last question will come from Jailendra Singh with Credit Suisse. \n", "original_text": "And the exact timing and amount of that is something that we will continue to \nevaluate  based upon all the other factors. "}, "hash": "809b5cdca7e573bb75720c73415f923db3577645a3be6c8f0bde23a5eca7e3c3", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 30 of 31 \n \ninto our share guidance. ", "start_char_idx": 0, "end_char_idx": 44, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2318968a-340a-4646-8a4a-7667dc30f096": {"__data__": {"id_": "2318968a-340a-4646-8a4a-7667dc30f096", "embedding": null, "metadata": {"window": " \nPage 30 of 31 \n \ninto our share guidance.  And the exact timing and amount of that is something that we will continue to \nevaluate  based upon all the other factors.  So and yes so next question?  \n \n Operator:  Thank you.  And our last question will come from Jailendra Singh with Credit Suisse. \n", "original_text": "And the exact timing and amount of that is something that we will continue to \nevaluate  based upon all the other factors. ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8402db9403696f1e9678026f6e69655c1c920e312c73df8b6b0efd53ec34fa62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9230ce05-6d99-402b-b9b0-d77413b575b3", "node_type": "1", "metadata": {"window": " \nPage 30 of 31 \n \ninto our share guidance.  And the exact timing and amount of that is something that we will continue to \nevaluate  based upon all the other factors.  So and yes so next question?  \n \n Operator:  Thank you. ", "original_text": " \nPage 30 of 31 \n \ninto our share guidance. ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5c32b21f33d830607350df79c93f33414371172aa0ea3ca3d6f8c3808a354626", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be652523-47ff-4eaa-978b-bcc6ced42850", "node_type": "1", "metadata": {"window": " \nPage 30 of 31 \n \ninto our share guidance.  And the exact timing and amount of that is something that we will continue to \nevaluate  based upon all the other factors.  So and yes so next question?  \n \n Operator:  Thank you.  And our last question will come from Jailendra Singh with Credit Suisse. \n Please go ahead.  \n \n", "original_text": "So and yes so next question?  \n \n"}, "hash": "05ccac3711a7ce059a5f0c6bafb3eb9fab77b18c49c3e25583bedd8e7c512277", "class_name": "RelatedNodeInfo"}}, "text": "And the exact timing and amount of that is something that we will continue to \nevaluate  based upon all the other factors. ", "start_char_idx": 44, "end_char_idx": 167, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be652523-47ff-4eaa-978b-bcc6ced42850": {"__data__": {"id_": "be652523-47ff-4eaa-978b-bcc6ced42850", "embedding": null, "metadata": {"window": " \nPage 30 of 31 \n \ninto our share guidance.  And the exact timing and amount of that is something that we will continue to \nevaluate  based upon all the other factors.  So and yes so next question?  \n \n Operator:  Thank you.  And our last question will come from Jailendra Singh with Credit Suisse. \n Please go ahead.  \n \n", "original_text": "So and yes so next question?  \n \n", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8402db9403696f1e9678026f6e69655c1c920e312c73df8b6b0efd53ec34fa62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2318968a-340a-4646-8a4a-7667dc30f096", "node_type": "1", "metadata": {"window": " \nPage 30 of 31 \n \ninto our share guidance.  And the exact timing and amount of that is something that we will continue to \nevaluate  based upon all the other factors.  So and yes so next question?  \n \n Operator:  Thank you.  And our last question will come from Jailendra Singh with Credit Suisse. \n", "original_text": "And the exact timing and amount of that is something that we will continue to \nevaluate  based upon all the other factors. ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f999a46f37a6e5c4cc391012e617ca5cc65f245d08d6e0df29400612e3c5266f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac8d3b08-a322-489c-82fe-5ca58e4fb7f1", "node_type": "1", "metadata": {"window": " \nPage 30 of 31 \n \ninto our share guidance.  And the exact timing and amount of that is something that we will continue to \nevaluate  based upon all the other factors.  So and yes so next question?  \n \n Operator:  Thank you.  And our last question will come from Jailendra Singh with Credit Suisse. \n Please go ahead.  \n \n Jailendra Singh:  Thanks for squeezing me in there. ", "original_text": "Operator:  Thank you. "}, "hash": "b43db3f214cba33600579fe015fbc3b8afbdca1b63988582c2aa5c2af618ebff", "class_name": "RelatedNodeInfo"}}, "text": "So and yes so next question?  \n \n", "start_char_idx": 167, "end_char_idx": 200, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac8d3b08-a322-489c-82fe-5ca58e4fb7f1": {"__data__": {"id_": "ac8d3b08-a322-489c-82fe-5ca58e4fb7f1", "embedding": null, "metadata": {"window": " \nPage 30 of 31 \n \ninto our share guidance.  And the exact timing and amount of that is something that we will continue to \nevaluate  based upon all the other factors.  So and yes so next question?  \n \n Operator:  Thank you.  And our last question will come from Jailendra Singh with Credit Suisse. \n Please go ahead.  \n \n Jailendra Singh:  Thanks for squeezing me in there. ", "original_text": "Operator:  Thank you. ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8402db9403696f1e9678026f6e69655c1c920e312c73df8b6b0efd53ec34fa62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be652523-47ff-4eaa-978b-bcc6ced42850", "node_type": "1", "metadata": {"window": " \nPage 30 of 31 \n \ninto our share guidance.  And the exact timing and amount of that is something that we will continue to \nevaluate  based upon all the other factors.  So and yes so next question?  \n \n Operator:  Thank you.  And our last question will come from Jailendra Singh with Credit Suisse. \n Please go ahead.  \n \n", "original_text": "So and yes so next question?  \n \n", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb5e89a1e4c74c9caaf2a9e66325f9956f226065b616768a439b86dbdd4b9a4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d72dd814-c3a8-4d29-9998-b2d8836f10d2", "node_type": "1", "metadata": {"window": "And the exact timing and amount of that is something that we will continue to \nevaluate  based upon all the other factors.  So and yes so next question?  \n \n Operator:  Thank you.  And our last question will come from Jailendra Singh with Credit Suisse. \n Please go ahead.  \n \n Jailendra Singh:  Thanks for squeezing me in there.  So I\u2019m thinking about PPE.  ", "original_text": "And our last question will come from Jailendra Singh with Credit Suisse. \n"}, "hash": "9be57ce682f7f2e1953144067114c2f7ba56c1261d8938344bd9cff3da95e952", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you. ", "start_char_idx": 200, "end_char_idx": 222, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d72dd814-c3a8-4d29-9998-b2d8836f10d2": {"__data__": {"id_": "d72dd814-c3a8-4d29-9998-b2d8836f10d2", "embedding": null, "metadata": {"window": "And the exact timing and amount of that is something that we will continue to \nevaluate  based upon all the other factors.  So and yes so next question?  \n \n Operator:  Thank you.  And our last question will come from Jailendra Singh with Credit Suisse. \n Please go ahead.  \n \n Jailendra Singh:  Thanks for squeezing me in there.  So I\u2019m thinking about PPE.  ", "original_text": "And our last question will come from Jailendra Singh with Credit Suisse. \n", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8402db9403696f1e9678026f6e69655c1c920e312c73df8b6b0efd53ec34fa62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac8d3b08-a322-489c-82fe-5ca58e4fb7f1", "node_type": "1", "metadata": {"window": " \nPage 30 of 31 \n \ninto our share guidance.  And the exact timing and amount of that is something that we will continue to \nevaluate  based upon all the other factors.  So and yes so next question?  \n \n Operator:  Thank you.  And our last question will come from Jailendra Singh with Credit Suisse. \n Please go ahead.  \n \n Jailendra Singh:  Thanks for squeezing me in there. ", "original_text": "Operator:  Thank you. ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f01676299f5a9b7313e3e499d888e04acdf267b7baf371bc182df16512138d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "182344c3-c7c3-4265-907f-b27bcbe65c19", "node_type": "1", "metadata": {"window": "So and yes so next question?  \n \n Operator:  Thank you.  And our last question will come from Jailendra Singh with Credit Suisse. \n Please go ahead.  \n \n Jailendra Singh:  Thanks for squeezing me in there.  So I\u2019m thinking about PPE.   I know you talked \nbefore about rationalizing your manufacturing footprint. ", "original_text": "Please go ahead.  \n \n"}, "hash": "421df1addfd76abc1426769476ed27414083953a5fc15a321091c0c1cc305ce4", "class_name": "RelatedNodeInfo"}}, "text": "And our last question will come from Jailendra Singh with Credit Suisse. \n", "start_char_idx": 222, "end_char_idx": 296, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "182344c3-c7c3-4265-907f-b27bcbe65c19": {"__data__": {"id_": "182344c3-c7c3-4265-907f-b27bcbe65c19", "embedding": null, "metadata": {"window": "So and yes so next question?  \n \n Operator:  Thank you.  And our last question will come from Jailendra Singh with Credit Suisse. \n Please go ahead.  \n \n Jailendra Singh:  Thanks for squeezing me in there.  So I\u2019m thinking about PPE.   I know you talked \nbefore about rationalizing your manufacturing footprint. ", "original_text": "Please go ahead.  \n \n", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8402db9403696f1e9678026f6e69655c1c920e312c73df8b6b0efd53ec34fa62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d72dd814-c3a8-4d29-9998-b2d8836f10d2", "node_type": "1", "metadata": {"window": "And the exact timing and amount of that is something that we will continue to \nevaluate  based upon all the other factors.  So and yes so next question?  \n \n Operator:  Thank you.  And our last question will come from Jailendra Singh with Credit Suisse. \n Please go ahead.  \n \n Jailendra Singh:  Thanks for squeezing me in there.  So I\u2019m thinking about PPE.  ", "original_text": "And our last question will come from Jailendra Singh with Credit Suisse. \n", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf7f6ffb56cbea0b3fc195984943d75d86c23cb98da1a048d678a9f77272f623", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a7cb92d-0884-4881-8518-e7ae8c9e02cb", "node_type": "1", "metadata": {"window": "Operator:  Thank you.  And our last question will come from Jailendra Singh with Credit Suisse. \n Please go ahead.  \n \n Jailendra Singh:  Thanks for squeezing me in there.  So I\u2019m thinking about PPE.   I know you talked \nbefore about rationalizing your manufacturing footprint.  Can you talk about how the increased costs in \nthat business area and how COVID maybe impacting your thought process with respect to your \noverall global footprint?  \n \n", "original_text": "Jailendra Singh:  Thanks for squeezing me in there. "}, "hash": "2428f393870a8082875e4e40aebb8cdeae3453acf8e0339dfa569b43556a3724", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 296, "end_char_idx": 317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a7cb92d-0884-4881-8518-e7ae8c9e02cb": {"__data__": {"id_": "2a7cb92d-0884-4881-8518-e7ae8c9e02cb", "embedding": null, "metadata": {"window": "Operator:  Thank you.  And our last question will come from Jailendra Singh with Credit Suisse. \n Please go ahead.  \n \n Jailendra Singh:  Thanks for squeezing me in there.  So I\u2019m thinking about PPE.   I know you talked \nbefore about rationalizing your manufacturing footprint.  Can you talk about how the increased costs in \nthat business area and how COVID maybe impacting your thought process with respect to your \noverall global footprint?  \n \n", "original_text": "Jailendra Singh:  Thanks for squeezing me in there. ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8402db9403696f1e9678026f6e69655c1c920e312c73df8b6b0efd53ec34fa62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "182344c3-c7c3-4265-907f-b27bcbe65c19", "node_type": "1", "metadata": {"window": "So and yes so next question?  \n \n Operator:  Thank you.  And our last question will come from Jailendra Singh with Credit Suisse. \n Please go ahead.  \n \n Jailendra Singh:  Thanks for squeezing me in there.  So I\u2019m thinking about PPE.   I know you talked \nbefore about rationalizing your manufacturing footprint. ", "original_text": "Please go ahead.  \n \n", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d4c6799374c3befad5b501871b2b762cac54f756104db9ccc28b2370c7f7df7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3bedbe59-fe79-4bab-9162-b0a539bc95a4", "node_type": "1", "metadata": {"window": "And our last question will come from Jailendra Singh with Credit Suisse. \n Please go ahead.  \n \n Jailendra Singh:  Thanks for squeezing me in there.  So I\u2019m thinking about PPE.   I know you talked \nbefore about rationalizing your manufacturing footprint.  Can you talk about how the increased costs in \nthat business area and how COVID maybe impacting your thought process with respect to your \noverall global footprint?  \n \n Mike Kaufmann:  Yes it\u2019s a great question. ", "original_text": "So I\u2019m thinking about PPE.  "}, "hash": "6a9791e2d09aea8e052893cf5710c96fae2a7fe7559a34d7a6fbe4d0a58e4237", "class_name": "RelatedNodeInfo"}}, "text": "Jailendra Singh:  Thanks for squeezing me in there. ", "start_char_idx": 317, "end_char_idx": 369, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3bedbe59-fe79-4bab-9162-b0a539bc95a4": {"__data__": {"id_": "3bedbe59-fe79-4bab-9162-b0a539bc95a4", "embedding": null, "metadata": {"window": "And our last question will come from Jailendra Singh with Credit Suisse. \n Please go ahead.  \n \n Jailendra Singh:  Thanks for squeezing me in there.  So I\u2019m thinking about PPE.   I know you talked \nbefore about rationalizing your manufacturing footprint.  Can you talk about how the increased costs in \nthat business area and how COVID maybe impacting your thought process with respect to your \noverall global footprint?  \n \n Mike Kaufmann:  Yes it\u2019s a great question. ", "original_text": "So I\u2019m thinking about PPE.  ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8402db9403696f1e9678026f6e69655c1c920e312c73df8b6b0efd53ec34fa62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a7cb92d-0884-4881-8518-e7ae8c9e02cb", "node_type": "1", "metadata": {"window": "Operator:  Thank you.  And our last question will come from Jailendra Singh with Credit Suisse. \n Please go ahead.  \n \n Jailendra Singh:  Thanks for squeezing me in there.  So I\u2019m thinking about PPE.   I know you talked \nbefore about rationalizing your manufacturing footprint.  Can you talk about how the increased costs in \nthat business area and how COVID maybe impacting your thought process with respect to your \noverall global footprint?  \n \n", "original_text": "Jailendra Singh:  Thanks for squeezing me in there. ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1fcea3b37bd7a5f7ab7b96e8418940958a08d54ed7b7530aa490bbd632a8c83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a791aea3-448f-48aa-8b47-e27d69e463f8", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Jailendra Singh:  Thanks for squeezing me in there.  So I\u2019m thinking about PPE.   I know you talked \nbefore about rationalizing your manufacturing footprint.  Can you talk about how the increased costs in \nthat business area and how COVID maybe impacting your thought process with respect to your \noverall global footprint?  \n \n Mike Kaufmann:  Yes it\u2019s a great question.  It clearly has changed our thinking a little bit our global \nfootprint. ", "original_text": "I know you talked \nbefore about rationalizing your manufacturing footprint. "}, "hash": "f55e054a2e2ba0efbfeaf138f376514f948522b6c083da8e932451438698a8b6", "class_name": "RelatedNodeInfo"}}, "text": "So I\u2019m thinking about PPE.  ", "start_char_idx": 369, "end_char_idx": 397, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a791aea3-448f-48aa-8b47-e27d69e463f8": {"__data__": {"id_": "a791aea3-448f-48aa-8b47-e27d69e463f8", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Jailendra Singh:  Thanks for squeezing me in there.  So I\u2019m thinking about PPE.   I know you talked \nbefore about rationalizing your manufacturing footprint.  Can you talk about how the increased costs in \nthat business area and how COVID maybe impacting your thought process with respect to your \noverall global footprint?  \n \n Mike Kaufmann:  Yes it\u2019s a great question.  It clearly has changed our thinking a little bit our global \nfootprint. ", "original_text": "I know you talked \nbefore about rationalizing your manufacturing footprint. ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8402db9403696f1e9678026f6e69655c1c920e312c73df8b6b0efd53ec34fa62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3bedbe59-fe79-4bab-9162-b0a539bc95a4", "node_type": "1", "metadata": {"window": "And our last question will come from Jailendra Singh with Credit Suisse. \n Please go ahead.  \n \n Jailendra Singh:  Thanks for squeezing me in there.  So I\u2019m thinking about PPE.   I know you talked \nbefore about rationalizing your manufacturing footprint.  Can you talk about how the increased costs in \nthat business area and how COVID maybe impacting your thought process with respect to your \noverall global footprint?  \n \n Mike Kaufmann:  Yes it\u2019s a great question. ", "original_text": "So I\u2019m thinking about PPE.  ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd7497a893b6c8cef83c2ee49fcac2e10a1bda032f81d470171bd3f32d00a037", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7323e892-f853-41db-afec-692ccdd6198c", "node_type": "1", "metadata": {"window": "Jailendra Singh:  Thanks for squeezing me in there.  So I\u2019m thinking about PPE.   I know you talked \nbefore about rationalizing your manufacturing footprint.  Can you talk about how the increased costs in \nthat business area and how COVID maybe impacting your thought process with respect to your \noverall global footprint?  \n \n Mike Kaufmann:  Yes it\u2019s a great question.  It clearly has changed our thinking a little bit our global \nfootprint.  Many of the plans that we had planned are still moving forward because a lot of our \nproducts that we actually manufacture ourselves are higher end OR type of, you know, surgical types \nof products and so we're continuing down that line.  \n \n ", "original_text": "Can you talk about how the increased costs in \nthat business area and how COVID maybe impacting your thought process with respect to your \noverall global footprint?  \n \n"}, "hash": "79b5de7ebc852cc90e72444a34624ab184774d9da19b6009bcdf10b5670449ed", "class_name": "RelatedNodeInfo"}}, "text": "I know you talked \nbefore about rationalizing your manufacturing footprint. ", "start_char_idx": 397, "end_char_idx": 473, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7323e892-f853-41db-afec-692ccdd6198c": {"__data__": {"id_": "7323e892-f853-41db-afec-692ccdd6198c", "embedding": null, "metadata": {"window": "Jailendra Singh:  Thanks for squeezing me in there.  So I\u2019m thinking about PPE.   I know you talked \nbefore about rationalizing your manufacturing footprint.  Can you talk about how the increased costs in \nthat business area and how COVID maybe impacting your thought process with respect to your \noverall global footprint?  \n \n Mike Kaufmann:  Yes it\u2019s a great question.  It clearly has changed our thinking a little bit our global \nfootprint.  Many of the plans that we had planned are still moving forward because a lot of our \nproducts that we actually manufacture ourselves are higher end OR type of, you know, surgical types \nof products and so we're continuing down that line.  \n \n ", "original_text": "Can you talk about how the increased costs in \nthat business area and how COVID maybe impacting your thought process with respect to your \noverall global footprint?  \n \n", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8402db9403696f1e9678026f6e69655c1c920e312c73df8b6b0efd53ec34fa62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a791aea3-448f-48aa-8b47-e27d69e463f8", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Jailendra Singh:  Thanks for squeezing me in there.  So I\u2019m thinking about PPE.   I know you talked \nbefore about rationalizing your manufacturing footprint.  Can you talk about how the increased costs in \nthat business area and how COVID maybe impacting your thought process with respect to your \noverall global footprint?  \n \n Mike Kaufmann:  Yes it\u2019s a great question.  It clearly has changed our thinking a little bit our global \nfootprint. ", "original_text": "I know you talked \nbefore about rationalizing your manufacturing footprint. ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "14a6ac7f5f811523bd2867424a99a9e75c2bb00c6d70a47acb75d456173eed98", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b50d2550-a23c-4e3b-8dfd-51ae42dcaeb5", "node_type": "1", "metadata": {"window": "So I\u2019m thinking about PPE.   I know you talked \nbefore about rationalizing your manufacturing footprint.  Can you talk about how the increased costs in \nthat business area and how COVID maybe impacting your thought process with respect to your \noverall global footprint?  \n \n Mike Kaufmann:  Yes it\u2019s a great question.  It clearly has changed our thinking a little bit our global \nfootprint.  Many of the plans that we had planned are still moving forward because a lot of our \nproducts that we actually manufacture ourselves are higher end OR type of, you know, surgical types \nof products and so we're continuing down that line.  \n \n  But as far as our PPE production I would say we're looking at a couple different things. ", "original_text": "Mike Kaufmann:  Yes it\u2019s a great question. "}, "hash": "2f4bf60418262670cedb9af15b1aefa3c1c13f5e67097bbf31ce696fa6adc316", "class_name": "RelatedNodeInfo"}}, "text": "Can you talk about how the increased costs in \nthat business area and how COVID maybe impacting your thought process with respect to your \noverall global footprint?  \n \n", "start_char_idx": 473, "end_char_idx": 642, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b50d2550-a23c-4e3b-8dfd-51ae42dcaeb5": {"__data__": {"id_": "b50d2550-a23c-4e3b-8dfd-51ae42dcaeb5", "embedding": null, "metadata": {"window": "So I\u2019m thinking about PPE.   I know you talked \nbefore about rationalizing your manufacturing footprint.  Can you talk about how the increased costs in \nthat business area and how COVID maybe impacting your thought process with respect to your \noverall global footprint?  \n \n Mike Kaufmann:  Yes it\u2019s a great question.  It clearly has changed our thinking a little bit our global \nfootprint.  Many of the plans that we had planned are still moving forward because a lot of our \nproducts that we actually manufacture ourselves are higher end OR type of, you know, surgical types \nof products and so we're continuing down that line.  \n \n  But as far as our PPE production I would say we're looking at a couple different things. ", "original_text": "Mike Kaufmann:  Yes it\u2019s a great question. ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8402db9403696f1e9678026f6e69655c1c920e312c73df8b6b0efd53ec34fa62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7323e892-f853-41db-afec-692ccdd6198c", "node_type": "1", "metadata": {"window": "Jailendra Singh:  Thanks for squeezing me in there.  So I\u2019m thinking about PPE.   I know you talked \nbefore about rationalizing your manufacturing footprint.  Can you talk about how the increased costs in \nthat business area and how COVID maybe impacting your thought process with respect to your \noverall global footprint?  \n \n Mike Kaufmann:  Yes it\u2019s a great question.  It clearly has changed our thinking a little bit our global \nfootprint.  Many of the plans that we had planned are still moving forward because a lot of our \nproducts that we actually manufacture ourselves are higher end OR type of, you know, surgical types \nof products and so we're continuing down that line.  \n \n ", "original_text": "Can you talk about how the increased costs in \nthat business area and how COVID maybe impacting your thought process with respect to your \noverall global footprint?  \n \n", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c0ccc9fa734e32b13d95e6dfb441f8079adb03d54554e92bff7010ab7dec9ada", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8cc57c54-fc60-4ce6-8094-b2dc01ca9ab9", "node_type": "1", "metadata": {"window": "I know you talked \nbefore about rationalizing your manufacturing footprint.  Can you talk about how the increased costs in \nthat business area and how COVID maybe impacting your thought process with respect to your \noverall global footprint?  \n \n Mike Kaufmann:  Yes it\u2019s a great question.  It clearly has changed our thinking a little bit our global \nfootprint.  Many of the plans that we had planned are still moving forward because a lot of our \nproducts that we actually manufacture ourselves are higher end OR type of, you know, surgical types \nof products and so we're continuing down that line.  \n \n  But as far as our PPE production I would say we're looking at a couple different things.  One is \nwe're evaluating the countries from which we're sourcing to make sure  that we're not overly \ndependent on any single company or product type. ", "original_text": "It clearly has changed our thinking a little bit our global \nfootprint. "}, "hash": "2ca4115492b5fb2cf93a5fcb83fbb8750cd0b9d9d6c60f5160cadb9cb3c32de1", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes it\u2019s a great question. ", "start_char_idx": 642, "end_char_idx": 685, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8cc57c54-fc60-4ce6-8094-b2dc01ca9ab9": {"__data__": {"id_": "8cc57c54-fc60-4ce6-8094-b2dc01ca9ab9", "embedding": null, "metadata": {"window": "I know you talked \nbefore about rationalizing your manufacturing footprint.  Can you talk about how the increased costs in \nthat business area and how COVID maybe impacting your thought process with respect to your \noverall global footprint?  \n \n Mike Kaufmann:  Yes it\u2019s a great question.  It clearly has changed our thinking a little bit our global \nfootprint.  Many of the plans that we had planned are still moving forward because a lot of our \nproducts that we actually manufacture ourselves are higher end OR type of, you know, surgical types \nof products and so we're continuing down that line.  \n \n  But as far as our PPE production I would say we're looking at a couple different things.  One is \nwe're evaluating the countries from which we're sourcing to make sure  that we're not overly \ndependent on any single company or product type. ", "original_text": "It clearly has changed our thinking a little bit our global \nfootprint. ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8402db9403696f1e9678026f6e69655c1c920e312c73df8b6b0efd53ec34fa62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b50d2550-a23c-4e3b-8dfd-51ae42dcaeb5", "node_type": "1", "metadata": {"window": "So I\u2019m thinking about PPE.   I know you talked \nbefore about rationalizing your manufacturing footprint.  Can you talk about how the increased costs in \nthat business area and how COVID maybe impacting your thought process with respect to your \noverall global footprint?  \n \n Mike Kaufmann:  Yes it\u2019s a great question.  It clearly has changed our thinking a little bit our global \nfootprint.  Many of the plans that we had planned are still moving forward because a lot of our \nproducts that we actually manufacture ourselves are higher end OR type of, you know, surgical types \nof products and so we're continuing down that line.  \n \n  But as far as our PPE production I would say we're looking at a couple different things. ", "original_text": "Mike Kaufmann:  Yes it\u2019s a great question. ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f7be061ffc956c83a38ea57348de1f2cfccf43ad4ae22b3e69837aad9d8d37a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c80e944-94b4-468c-a14e-285c823c5fb5", "node_type": "1", "metadata": {"window": "Can you talk about how the increased costs in \nthat business area and how COVID maybe impacting your thought process with respect to your \noverall global footprint?  \n \n Mike Kaufmann:  Yes it\u2019s a great question.  It clearly has changed our thinking a little bit our global \nfootprint.  Many of the plans that we had planned are still moving forward because a lot of our \nproducts that we actually manufacture ourselves are higher end OR type of, you know, surgical types \nof products and so we're continuing down that line.  \n \n  But as far as our PPE production I would say we're looking at a couple different things.  One is \nwe're evaluating the countries from which we're sourcing to make sure  that we're not overly \ndependent on any single company or product type.  And so that we will look at that because for \nexample a lot of gowns were produced in China. ", "original_text": "Many of the plans that we had planned are still moving forward because a lot of our \nproducts that we actually manufacture ourselves are higher end OR type of, you know, surgical types \nof products and so we're continuing down that line.  \n \n "}, "hash": "62eb2722abc12cbe62523ccced3808f4ea1dfe0a758a56feb7dae241c31c1359", "class_name": "RelatedNodeInfo"}}, "text": "It clearly has changed our thinking a little bit our global \nfootprint. ", "start_char_idx": 685, "end_char_idx": 757, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c80e944-94b4-468c-a14e-285c823c5fb5": {"__data__": {"id_": "1c80e944-94b4-468c-a14e-285c823c5fb5", "embedding": null, "metadata": {"window": "Can you talk about how the increased costs in \nthat business area and how COVID maybe impacting your thought process with respect to your \noverall global footprint?  \n \n Mike Kaufmann:  Yes it\u2019s a great question.  It clearly has changed our thinking a little bit our global \nfootprint.  Many of the plans that we had planned are still moving forward because a lot of our \nproducts that we actually manufacture ourselves are higher end OR type of, you know, surgical types \nof products and so we're continuing down that line.  \n \n  But as far as our PPE production I would say we're looking at a couple different things.  One is \nwe're evaluating the countries from which we're sourcing to make sure  that we're not overly \ndependent on any single company or product type.  And so that we will look at that because for \nexample a lot of gowns were produced in China. ", "original_text": "Many of the plans that we had planned are still moving forward because a lot of our \nproducts that we actually manufacture ourselves are higher end OR type of, you know, surgical types \nof products and so we're continuing down that line.  \n \n ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8402db9403696f1e9678026f6e69655c1c920e312c73df8b6b0efd53ec34fa62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8cc57c54-fc60-4ce6-8094-b2dc01ca9ab9", "node_type": "1", "metadata": {"window": "I know you talked \nbefore about rationalizing your manufacturing footprint.  Can you talk about how the increased costs in \nthat business area and how COVID maybe impacting your thought process with respect to your \noverall global footprint?  \n \n Mike Kaufmann:  Yes it\u2019s a great question.  It clearly has changed our thinking a little bit our global \nfootprint.  Many of the plans that we had planned are still moving forward because a lot of our \nproducts that we actually manufacture ourselves are higher end OR type of, you know, surgical types \nof products and so we're continuing down that line.  \n \n  But as far as our PPE production I would say we're looking at a couple different things.  One is \nwe're evaluating the countries from which we're sourcing to make sure  that we're not overly \ndependent on any single company or product type. ", "original_text": "It clearly has changed our thinking a little bit our global \nfootprint. ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa53e52431650d8ba3307dd66a1be88a70462dd874d1ff1c61493959993cfaf6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aca17415-74c0-4e3a-bed8-567c3263bfed", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes it\u2019s a great question.  It clearly has changed our thinking a little bit our global \nfootprint.  Many of the plans that we had planned are still moving forward because a lot of our \nproducts that we actually manufacture ourselves are higher end OR type of, you know, surgical types \nof products and so we're continuing down that line.  \n \n  But as far as our PPE production I would say we're looking at a couple different things.  One is \nwe're evaluating the countries from which we're sourcing to make sure  that we're not overly \ndependent on any single company or product type.  And so that we will look at that because for \nexample a lot of gowns were produced in China.  And going forward we want to make sure that we \nhave a more diverse supply chain not only ove rall, but for individual items. ", "original_text": "But as far as our PPE production I would say we're looking at a couple different things. "}, "hash": "68bd8036cf78a416d59011f0abca7f805f8ce4cc3b7b13bff8734b20a12ff091", "class_name": "RelatedNodeInfo"}}, "text": "Many of the plans that we had planned are still moving forward because a lot of our \nproducts that we actually manufacture ourselves are higher end OR type of, you know, surgical types \nof products and so we're continuing down that line.  \n \n ", "start_char_idx": 757, "end_char_idx": 1000, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aca17415-74c0-4e3a-bed8-567c3263bfed": {"__data__": {"id_": "aca17415-74c0-4e3a-bed8-567c3263bfed", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes it\u2019s a great question.  It clearly has changed our thinking a little bit our global \nfootprint.  Many of the plans that we had planned are still moving forward because a lot of our \nproducts that we actually manufacture ourselves are higher end OR type of, you know, surgical types \nof products and so we're continuing down that line.  \n \n  But as far as our PPE production I would say we're looking at a couple different things.  One is \nwe're evaluating the countries from which we're sourcing to make sure  that we're not overly \ndependent on any single company or product type.  And so that we will look at that because for \nexample a lot of gowns were produced in China.  And going forward we want to make sure that we \nhave a more diverse supply chain not only ove rall, but for individual items. ", "original_text": "But as far as our PPE production I would say we're looking at a couple different things. ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8402db9403696f1e9678026f6e69655c1c920e312c73df8b6b0efd53ec34fa62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c80e944-94b4-468c-a14e-285c823c5fb5", "node_type": "1", "metadata": {"window": "Can you talk about how the increased costs in \nthat business area and how COVID maybe impacting your thought process with respect to your \noverall global footprint?  \n \n Mike Kaufmann:  Yes it\u2019s a great question.  It clearly has changed our thinking a little bit our global \nfootprint.  Many of the plans that we had planned are still moving forward because a lot of our \nproducts that we actually manufacture ourselves are higher end OR type of, you know, surgical types \nof products and so we're continuing down that line.  \n \n  But as far as our PPE production I would say we're looking at a couple different things.  One is \nwe're evaluating the countries from which we're sourcing to make sure  that we're not overly \ndependent on any single company or product type.  And so that we will look at that because for \nexample a lot of gowns were produced in China. ", "original_text": "Many of the plans that we had planned are still moving forward because a lot of our \nproducts that we actually manufacture ourselves are higher end OR type of, you know, surgical types \nof products and so we're continuing down that line.  \n \n ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7768564ef5b0aa0753833fb148d79b3c7162d6ae933951a83ca03876322f87b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cfa299f9-f3f4-45af-9714-1a60558fb22e", "node_type": "1", "metadata": {"window": "It clearly has changed our thinking a little bit our global \nfootprint.  Many of the plans that we had planned are still moving forward because a lot of our \nproducts that we actually manufacture ourselves are higher end OR type of, you know, surgical types \nof products and so we're continuing down that line.  \n \n  But as far as our PPE production I would say we're looking at a couple different things.  One is \nwe're evaluating the countries from which we're sourcing to make sure  that we're not overly \ndependent on any single company or product type.  And so that we will look at that because for \nexample a lot of gowns were produced in China.  And going forward we want to make sure that we \nhave a more diverse supply chain not only ove rall, but for individual items.  So that\u2019s one.  \n \n ", "original_text": "One is \nwe're evaluating the countries from which we're sourcing to make sure  that we're not overly \ndependent on any single company or product type. "}, "hash": "91bbbe48f55694db9eb8edd262f1fcb8561382b514043d9c5548fedd0e9f95aa", "class_name": "RelatedNodeInfo"}}, "text": "But as far as our PPE production I would say we're looking at a couple different things. ", "start_char_idx": 1000, "end_char_idx": 1089, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cfa299f9-f3f4-45af-9714-1a60558fb22e": {"__data__": {"id_": "cfa299f9-f3f4-45af-9714-1a60558fb22e", "embedding": null, "metadata": {"window": "It clearly has changed our thinking a little bit our global \nfootprint.  Many of the plans that we had planned are still moving forward because a lot of our \nproducts that we actually manufacture ourselves are higher end OR type of, you know, surgical types \nof products and so we're continuing down that line.  \n \n  But as far as our PPE production I would say we're looking at a couple different things.  One is \nwe're evaluating the countries from which we're sourcing to make sure  that we're not overly \ndependent on any single company or product type.  And so that we will look at that because for \nexample a lot of gowns were produced in China.  And going forward we want to make sure that we \nhave a more diverse supply chain not only ove rall, but for individual items.  So that\u2019s one.  \n \n ", "original_text": "One is \nwe're evaluating the countries from which we're sourcing to make sure  that we're not overly \ndependent on any single company or product type. ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8402db9403696f1e9678026f6e69655c1c920e312c73df8b6b0efd53ec34fa62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aca17415-74c0-4e3a-bed8-567c3263bfed", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes it\u2019s a great question.  It clearly has changed our thinking a little bit our global \nfootprint.  Many of the plans that we had planned are still moving forward because a lot of our \nproducts that we actually manufacture ourselves are higher end OR type of, you know, surgical types \nof products and so we're continuing down that line.  \n \n  But as far as our PPE production I would say we're looking at a couple different things.  One is \nwe're evaluating the countries from which we're sourcing to make sure  that we're not overly \ndependent on any single company or product type.  And so that we will look at that because for \nexample a lot of gowns were produced in China.  And going forward we want to make sure that we \nhave a more diverse supply chain not only ove rall, but for individual items. ", "original_text": "But as far as our PPE production I would say we're looking at a couple different things. ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eed87aa19e079657119579329b5012c54a1984dc747bf1b2663ed704d3ebd529", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ec7ad64-0fea-41c0-8ae2-ae0abb66f56a", "node_type": "1", "metadata": {"window": "Many of the plans that we had planned are still moving forward because a lot of our \nproducts that we actually manufacture ourselves are higher end OR type of, you know, surgical types \nof products and so we're continuing down that line.  \n \n  But as far as our PPE production I would say we're looking at a couple different things.  One is \nwe're evaluating the countries from which we're sourcing to make sure  that we're not overly \ndependent on any single company or product type.  And so that we will look at that because for \nexample a lot of gowns were produced in China.  And going forward we want to make sure that we \nhave a more diverse supply chain not only ove rall, but for individual items.  So that\u2019s one.  \n \n  Two is we've been - have been and will continue to increase our own capacity for the \nproduction of certain products like masks which is an area where we made investments and have \nincreased our productivity. ", "original_text": "And so that we will look at that because for \nexample a lot of gowns were produced in China. "}, "hash": "2fb231b9d0810e7ee6ccab44c85fc80f089dda13d1784e34c93b2d0f87390efb", "class_name": "RelatedNodeInfo"}}, "text": "One is \nwe're evaluating the countries from which we're sourcing to make sure  that we're not overly \ndependent on any single company or product type. ", "start_char_idx": 1089, "end_char_idx": 1240, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ec7ad64-0fea-41c0-8ae2-ae0abb66f56a": {"__data__": {"id_": "9ec7ad64-0fea-41c0-8ae2-ae0abb66f56a", "embedding": null, "metadata": {"window": "Many of the plans that we had planned are still moving forward because a lot of our \nproducts that we actually manufacture ourselves are higher end OR type of, you know, surgical types \nof products and so we're continuing down that line.  \n \n  But as far as our PPE production I would say we're looking at a couple different things.  One is \nwe're evaluating the countries from which we're sourcing to make sure  that we're not overly \ndependent on any single company or product type.  And so that we will look at that because for \nexample a lot of gowns were produced in China.  And going forward we want to make sure that we \nhave a more diverse supply chain not only ove rall, but for individual items.  So that\u2019s one.  \n \n  Two is we've been - have been and will continue to increase our own capacity for the \nproduction of certain products like masks which is an area where we made investments and have \nincreased our productivity. ", "original_text": "And so that we will look at that because for \nexample a lot of gowns were produced in China. ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8402db9403696f1e9678026f6e69655c1c920e312c73df8b6b0efd53ec34fa62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cfa299f9-f3f4-45af-9714-1a60558fb22e", "node_type": "1", "metadata": {"window": "It clearly has changed our thinking a little bit our global \nfootprint.  Many of the plans that we had planned are still moving forward because a lot of our \nproducts that we actually manufacture ourselves are higher end OR type of, you know, surgical types \nof products and so we're continuing down that line.  \n \n  But as far as our PPE production I would say we're looking at a couple different things.  One is \nwe're evaluating the countries from which we're sourcing to make sure  that we're not overly \ndependent on any single company or product type.  And so that we will look at that because for \nexample a lot of gowns were produced in China.  And going forward we want to make sure that we \nhave a more diverse supply chain not only ove rall, but for individual items.  So that\u2019s one.  \n \n ", "original_text": "One is \nwe're evaluating the countries from which we're sourcing to make sure  that we're not overly \ndependent on any single company or product type. ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb2b502b5b9654d6d8f7594045aa2f7a149ed98868f46bea16e32f5ddd117388", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6f88bf7-fa77-4d42-9cfd-90d3fbf571bb", "node_type": "1", "metadata": {"window": "But as far as our PPE production I would say we're looking at a couple different things.  One is \nwe're evaluating the countries from which we're sourcing to make sure  that we're not overly \ndependent on any single company or product type.  And so that we will look at that because for \nexample a lot of gowns were produced in China.  And going forward we want to make sure that we \nhave a more diverse supply chain not only ove rall, but for individual items.  So that\u2019s one.  \n \n  Two is we've been - have been and will continue to increase our own capacity for the \nproduction of certain products like masks which is an area where we made investments and have \nincreased our productivity.  And then we will take a hard look at the US. ", "original_text": "And going forward we want to make sure that we \nhave a more diverse supply chain not only ove rall, but for individual items. "}, "hash": "5298735a05be505dcadf2a23b8d05798bee71829f50a9183a5f76e22c2daaca4", "class_name": "RelatedNodeInfo"}}, "text": "And so that we will look at that because for \nexample a lot of gowns were produced in China. ", "start_char_idx": 1240, "end_char_idx": 1333, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6f88bf7-fa77-4d42-9cfd-90d3fbf571bb": {"__data__": {"id_": "c6f88bf7-fa77-4d42-9cfd-90d3fbf571bb", "embedding": null, "metadata": {"window": "But as far as our PPE production I would say we're looking at a couple different things.  One is \nwe're evaluating the countries from which we're sourcing to make sure  that we're not overly \ndependent on any single company or product type.  And so that we will look at that because for \nexample a lot of gowns were produced in China.  And going forward we want to make sure that we \nhave a more diverse supply chain not only ove rall, but for individual items.  So that\u2019s one.  \n \n  Two is we've been - have been and will continue to increase our own capacity for the \nproduction of certain products like masks which is an area where we made investments and have \nincreased our productivity.  And then we will take a hard look at the US. ", "original_text": "And going forward we want to make sure that we \nhave a more diverse supply chain not only ove rall, but for individual items. ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8402db9403696f1e9678026f6e69655c1c920e312c73df8b6b0efd53ec34fa62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ec7ad64-0fea-41c0-8ae2-ae0abb66f56a", "node_type": "1", "metadata": {"window": "Many of the plans that we had planned are still moving forward because a lot of our \nproducts that we actually manufacture ourselves are higher end OR type of, you know, surgical types \nof products and so we're continuing down that line.  \n \n  But as far as our PPE production I would say we're looking at a couple different things.  One is \nwe're evaluating the countries from which we're sourcing to make sure  that we're not overly \ndependent on any single company or product type.  And so that we will look at that because for \nexample a lot of gowns were produced in China.  And going forward we want to make sure that we \nhave a more diverse supply chain not only ove rall, but for individual items.  So that\u2019s one.  \n \n  Two is we've been - have been and will continue to increase our own capacity for the \nproduction of certain products like masks which is an area where we made investments and have \nincreased our productivity. ", "original_text": "And so that we will look at that because for \nexample a lot of gowns were produced in China. ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12fd486709bb6aeec733bf98fbec775b7612cecfa2049f993fe4cf9bb2cc48d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "304942b4-08ea-4f8a-9fda-9bbdfb23c3cb", "node_type": "1", "metadata": {"window": "One is \nwe're evaluating the countries from which we're sourcing to make sure  that we're not overly \ndependent on any single company or product type.  And so that we will look at that because for \nexample a lot of gowns were produced in China.  And going forward we want to make sure that we \nhave a more diverse supply chain not only ove rall, but for individual items.  So that\u2019s one.  \n \n  Two is we've been - have been and will continue to increase our own capacity for the \nproduction of certain products like masks which is an area where we made investments and have \nincreased our productivity.  And then we will take a hard look at the US.  We would love to be able to \ndo more production in the US. ", "original_text": "So that\u2019s one.  \n \n "}, "hash": "f592aea32ffbd446537e50a01fcd5501ca6da76cbdafe3f700ef5840e965af30", "class_name": "RelatedNodeInfo"}}, "text": "And going forward we want to make sure that we \nhave a more diverse supply chain not only ove rall, but for individual items. ", "start_char_idx": 1333, "end_char_idx": 1459, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "304942b4-08ea-4f8a-9fda-9bbdfb23c3cb": {"__data__": {"id_": "304942b4-08ea-4f8a-9fda-9bbdfb23c3cb", "embedding": null, "metadata": {"window": "One is \nwe're evaluating the countries from which we're sourcing to make sure  that we're not overly \ndependent on any single company or product type.  And so that we will look at that because for \nexample a lot of gowns were produced in China.  And going forward we want to make sure that we \nhave a more diverse supply chain not only ove rall, but for individual items.  So that\u2019s one.  \n \n  Two is we've been - have been and will continue to increase our own capacity for the \nproduction of certain products like masks which is an area where we made investments and have \nincreased our productivity.  And then we will take a hard look at the US.  We would love to be able to \ndo more production in the US. ", "original_text": "So that\u2019s one.  \n \n ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8402db9403696f1e9678026f6e69655c1c920e312c73df8b6b0efd53ec34fa62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6f88bf7-fa77-4d42-9cfd-90d3fbf571bb", "node_type": "1", "metadata": {"window": "But as far as our PPE production I would say we're looking at a couple different things.  One is \nwe're evaluating the countries from which we're sourcing to make sure  that we're not overly \ndependent on any single company or product type.  And so that we will look at that because for \nexample a lot of gowns were produced in China.  And going forward we want to make sure that we \nhave a more diverse supply chain not only ove rall, but for individual items.  So that\u2019s one.  \n \n  Two is we've been - have been and will continue to increase our own capacity for the \nproduction of certain products like masks which is an area where we made investments and have \nincreased our productivity.  And then we will take a hard look at the US. ", "original_text": "And going forward we want to make sure that we \nhave a more diverse supply chain not only ove rall, but for individual items. ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5c2fc0a754904ca4788153068767252cfdefc812b80b409c1f031418863df18e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7f4f668-ca9e-4634-a258-2c71ab7c5731", "node_type": "1", "metadata": {"window": "And so that we will look at that because for \nexample a lot of gowns were produced in China.  And going forward we want to make sure that we \nhave a more diverse supply chain not only ove rall, but for individual items.  So that\u2019s one.  \n \n  Two is we've been - have been and will continue to increase our own capacity for the \nproduction of certain products like masks which is an area where we made investments and have \nincreased our productivity.  And then we will take a hard look at the US.  We would love to be able to \ndo more production in the US.  However we need to make sure that we're listening to our customers ", "original_text": "Two is we've been - have been and will continue to increase our own capacity for the \nproduction of certain products like masks which is an area where we made investments and have \nincreased our productivity. "}, "hash": "ccdc4162ca33e1c54a3cea048eb4acc78ed062340b6658c44243535ed5aa5437", "class_name": "RelatedNodeInfo"}}, "text": "So that\u2019s one.  \n \n ", "start_char_idx": 1459, "end_char_idx": 1479, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7f4f668-ca9e-4634-a258-2c71ab7c5731": {"__data__": {"id_": "f7f4f668-ca9e-4634-a258-2c71ab7c5731", "embedding": null, "metadata": {"window": "And so that we will look at that because for \nexample a lot of gowns were produced in China.  And going forward we want to make sure that we \nhave a more diverse supply chain not only ove rall, but for individual items.  So that\u2019s one.  \n \n  Two is we've been - have been and will continue to increase our own capacity for the \nproduction of certain products like masks which is an area where we made investments and have \nincreased our productivity.  And then we will take a hard look at the US.  We would love to be able to \ndo more production in the US.  However we need to make sure that we're listening to our customers ", "original_text": "Two is we've been - have been and will continue to increase our own capacity for the \nproduction of certain products like masks which is an area where we made investments and have \nincreased our productivity. ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8402db9403696f1e9678026f6e69655c1c920e312c73df8b6b0efd53ec34fa62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "304942b4-08ea-4f8a-9fda-9bbdfb23c3cb", "node_type": "1", "metadata": {"window": "One is \nwe're evaluating the countries from which we're sourcing to make sure  that we're not overly \ndependent on any single company or product type.  And so that we will look at that because for \nexample a lot of gowns were produced in China.  And going forward we want to make sure that we \nhave a more diverse supply chain not only ove rall, but for individual items.  So that\u2019s one.  \n \n  Two is we've been - have been and will continue to increase our own capacity for the \nproduction of certain products like masks which is an area where we made investments and have \nincreased our productivity.  And then we will take a hard look at the US.  We would love to be able to \ndo more production in the US. ", "original_text": "So that\u2019s one.  \n \n ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4c15bb65c9974eb94cad96c252c0a4821cdace69e78c39f4a2cdf78cb62feb9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f1b0e14-8256-40bd-8346-292d601c5078", "node_type": "1", "metadata": {"window": "And going forward we want to make sure that we \nhave a more diverse supply chain not only ove rall, but for individual items.  So that\u2019s one.  \n \n  Two is we've been - have been and will continue to increase our own capacity for the \nproduction of certain products like masks which is an area where we made investments and have \nincreased our productivity.  And then we will take a hard look at the US.  We would love to be able to \ndo more production in the US.  However we need to make sure that we're listening to our customers ", "original_text": "And then we will take a hard look at the US. "}, "hash": "5df55a0c9d8ab4e6378e737738f8e4d0c8efd450fdb92ba67f774f08e85c5013", "class_name": "RelatedNodeInfo"}}, "text": "Two is we've been - have been and will continue to increase our own capacity for the \nproduction of certain products like masks which is an area where we made investments and have \nincreased our productivity. ", "start_char_idx": 1479, "end_char_idx": 1688, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f1b0e14-8256-40bd-8346-292d601c5078": {"__data__": {"id_": "2f1b0e14-8256-40bd-8346-292d601c5078", "embedding": null, "metadata": {"window": "And going forward we want to make sure that we \nhave a more diverse supply chain not only ove rall, but for individual items.  So that\u2019s one.  \n \n  Two is we've been - have been and will continue to increase our own capacity for the \nproduction of certain products like masks which is an area where we made investments and have \nincreased our productivity.  And then we will take a hard look at the US.  We would love to be able to \ndo more production in the US.  However we need to make sure that we're listening to our customers ", "original_text": "And then we will take a hard look at the US. ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8402db9403696f1e9678026f6e69655c1c920e312c73df8b6b0efd53ec34fa62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7f4f668-ca9e-4634-a258-2c71ab7c5731", "node_type": "1", "metadata": {"window": "And so that we will look at that because for \nexample a lot of gowns were produced in China.  And going forward we want to make sure that we \nhave a more diverse supply chain not only ove rall, but for individual items.  So that\u2019s one.  \n \n  Two is we've been - have been and will continue to increase our own capacity for the \nproduction of certain products like masks which is an area where we made investments and have \nincreased our productivity.  And then we will take a hard look at the US.  We would love to be able to \ndo more production in the US.  However we need to make sure that we're listening to our customers ", "original_text": "Two is we've been - have been and will continue to increase our own capacity for the \nproduction of certain products like masks which is an area where we made investments and have \nincreased our productivity. ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "39262e4e3dc6d7c1cfe90726afc386ee511255608e3cc23b5deb1e8f772237ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de520e6a-8576-47e6-95f4-4088f07ee95d", "node_type": "1", "metadata": {"window": "So that\u2019s one.  \n \n  Two is we've been - have been and will continue to increase our own capacity for the \nproduction of certain products like masks which is an area where we made investments and have \nincreased our productivity.  And then we will take a hard look at the US.  We would love to be able to \ndo more production in the US.  However we need to make sure that we're listening to our customers ", "original_text": "We would love to be able to \ndo more production in the US. "}, "hash": "3f2a46d36262b917b9ca015aaa4ccf5661c2dd3ea96119235fd2797063dee2f4", "class_name": "RelatedNodeInfo"}}, "text": "And then we will take a hard look at the US. ", "start_char_idx": 1688, "end_char_idx": 1733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de520e6a-8576-47e6-95f4-4088f07ee95d": {"__data__": {"id_": "de520e6a-8576-47e6-95f4-4088f07ee95d", "embedding": null, "metadata": {"window": "So that\u2019s one.  \n \n  Two is we've been - have been and will continue to increase our own capacity for the \nproduction of certain products like masks which is an area where we made investments and have \nincreased our productivity.  And then we will take a hard look at the US.  We would love to be able to \ndo more production in the US.  However we need to make sure that we're listening to our customers ", "original_text": "We would love to be able to \ndo more production in the US. ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8402db9403696f1e9678026f6e69655c1c920e312c73df8b6b0efd53ec34fa62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f1b0e14-8256-40bd-8346-292d601c5078", "node_type": "1", "metadata": {"window": "And going forward we want to make sure that we \nhave a more diverse supply chain not only ove rall, but for individual items.  So that\u2019s one.  \n \n  Two is we've been - have been and will continue to increase our own capacity for the \nproduction of certain products like masks which is an area where we made investments and have \nincreased our productivity.  And then we will take a hard look at the US.  We would love to be able to \ndo more production in the US.  However we need to make sure that we're listening to our customers ", "original_text": "And then we will take a hard look at the US. ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3154907955610bcf824dddd8f485c1061b7a6e27d92d2e5f0de4366dd05d2896", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "928163d1-cac6-48ad-af3c-1304d88f1d67", "node_type": "1", "metadata": {"window": "Two is we've been - have been and will continue to increase our own capacity for the \nproduction of certain products like masks which is an area where we made investments and have \nincreased our productivity.  And then we will take a hard look at the US.  We would love to be able to \ndo more production in the US.  However we need to make sure that we're listening to our customers ", "original_text": "However we need to make sure that we're listening to our customers "}, "hash": "db0cd9916deed570390acbe09986b4d17804c201431796cadd0b56926d822f49", "class_name": "RelatedNodeInfo"}}, "text": "We would love to be able to \ndo more production in the US. ", "start_char_idx": 1733, "end_char_idx": 1792, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "928163d1-cac6-48ad-af3c-1304d88f1d67": {"__data__": {"id_": "928163d1-cac6-48ad-af3c-1304d88f1d67", "embedding": null, "metadata": {"window": "Two is we've been - have been and will continue to increase our own capacity for the \nproduction of certain products like masks which is an area where we made investments and have \nincreased our productivity.  And then we will take a hard look at the US.  We would love to be able to \ndo more production in the US.  However we need to make sure that we're listening to our customers ", "original_text": "However we need to make sure that we're listening to our customers ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8402db9403696f1e9678026f6e69655c1c920e312c73df8b6b0efd53ec34fa62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de520e6a-8576-47e6-95f4-4088f07ee95d", "node_type": "1", "metadata": {"window": "So that\u2019s one.  \n \n  Two is we've been - have been and will continue to increase our own capacity for the \nproduction of certain products like masks which is an area where we made investments and have \nincreased our productivity.  And then we will take a hard look at the US.  We would love to be able to \ndo more production in the US.  However we need to make sure that we're listening to our customers ", "original_text": "We would love to be able to \ndo more production in the US. ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd87eb0c523849eb237014d331b617d76ddf40ad38049cc5a82a425ee286bcb7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c601b03-6d50-454f-870f-efe0294517b5", "node_type": "1", "metadata": {"window": " \nPage 31 of 31 \n \nand balancing, you know, their need to have lower cost with where we're manufacturing product and \nwhat\u2019s going on there.  So we're going to continue to evaluate that but continue to ramp up.  \n \n  And then also we're going to evaluate the inventory levels that we carry so that we can work \nwith customers going forward around levels of safety stoc k. So those are some of the different things \nthat we're looking at in our supply chain and we'll continue to make some tweaks as we move along.  \n \n Jailendra Singh:  Great.  \n \n", "original_text": " \nPage 31 of 31 \n \nand balancing, you know, their need to have lower cost with where we're manufacturing product and \nwhat\u2019s going on there. "}, "hash": "59c4ffba250ef3af6824eb9a7fee659f463f3009210471d2d980247c5b94e093", "class_name": "RelatedNodeInfo"}}, "text": "However we need to make sure that we're listening to our customers ", "start_char_idx": 1792, "end_char_idx": 1859, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c601b03-6d50-454f-870f-efe0294517b5": {"__data__": {"id_": "1c601b03-6d50-454f-870f-efe0294517b5", "embedding": null, "metadata": {"window": " \nPage 31 of 31 \n \nand balancing, you know, their need to have lower cost with where we're manufacturing product and \nwhat\u2019s going on there.  So we're going to continue to evaluate that but continue to ramp up.  \n \n  And then also we're going to evaluate the inventory levels that we carry so that we can work \nwith customers going forward around levels of safety stoc k. So those are some of the different things \nthat we're looking at in our supply chain and we'll continue to make some tweaks as we move along.  \n \n Jailendra Singh:  Great.  \n \n", "original_text": " \nPage 31 of 31 \n \nand balancing, you know, their need to have lower cost with where we're manufacturing product and \nwhat\u2019s going on there. ", "page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a27c321-3a7b-402a-abb8-9964cef9499a", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23a929a286262ab5594fcb0134f2da358b147a62a9d92fe33378127a92a97f9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "928163d1-cac6-48ad-af3c-1304d88f1d67", "node_type": "1", "metadata": {"window": "Two is we've been - have been and will continue to increase our own capacity for the \nproduction of certain products like masks which is an area where we made investments and have \nincreased our productivity.  And then we will take a hard look at the US.  We would love to be able to \ndo more production in the US.  However we need to make sure that we're listening to our customers ", "original_text": "However we need to make sure that we're listening to our customers ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f5792e7f7ee85ffc7d0dce0fdbca29ac2cc8be98684a880b1d76b137bff4973", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9a42ba7-192c-463a-abfe-017ba5d1c31e", "node_type": "1", "metadata": {"window": " \nPage 31 of 31 \n \nand balancing, you know, their need to have lower cost with where we're manufacturing product and \nwhat\u2019s going on there.  So we're going to continue to evaluate that but continue to ramp up.  \n \n  And then also we're going to evaluate the inventory levels that we carry so that we can work \nwith customers going forward around levels of safety stoc k. So those are some of the different things \nthat we're looking at in our supply chain and we'll continue to make some tweaks as we move along.  \n \n Jailendra Singh:  Great.  \n \n Mike Kaufmann:  Great. ", "original_text": "So we're going to continue to evaluate that but continue to ramp up.  \n \n "}, "hash": "4bc85f4d41b1a29f99c9dbf426a9d80d32a73115a6f57433a1d198f41cf28e07", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 31 of 31 \n \nand balancing, you know, their need to have lower cost with where we're manufacturing product and \nwhat\u2019s going on there. ", "start_char_idx": 0, "end_char_idx": 141, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9a42ba7-192c-463a-abfe-017ba5d1c31e": {"__data__": {"id_": "e9a42ba7-192c-463a-abfe-017ba5d1c31e", "embedding": null, "metadata": {"window": " \nPage 31 of 31 \n \nand balancing, you know, their need to have lower cost with where we're manufacturing product and \nwhat\u2019s going on there.  So we're going to continue to evaluate that but continue to ramp up.  \n \n  And then also we're going to evaluate the inventory levels that we carry so that we can work \nwith customers going forward around levels of safety stoc k. So those are some of the different things \nthat we're looking at in our supply chain and we'll continue to make some tweaks as we move along.  \n \n Jailendra Singh:  Great.  \n \n Mike Kaufmann:  Great. ", "original_text": "So we're going to continue to evaluate that but continue to ramp up.  \n \n ", "page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a27c321-3a7b-402a-abb8-9964cef9499a", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23a929a286262ab5594fcb0134f2da358b147a62a9d92fe33378127a92a97f9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c601b03-6d50-454f-870f-efe0294517b5", "node_type": "1", "metadata": {"window": " \nPage 31 of 31 \n \nand balancing, you know, their need to have lower cost with where we're manufacturing product and \nwhat\u2019s going on there.  So we're going to continue to evaluate that but continue to ramp up.  \n \n  And then also we're going to evaluate the inventory levels that we carry so that we can work \nwith customers going forward around levels of safety stoc k. So those are some of the different things \nthat we're looking at in our supply chain and we'll continue to make some tweaks as we move along.  \n \n Jailendra Singh:  Great.  \n \n", "original_text": " \nPage 31 of 31 \n \nand balancing, you know, their need to have lower cost with where we're manufacturing product and \nwhat\u2019s going on there. ", "page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "17c0b12aee57163b321b2b457e9ba510e9058b30c27792ccab00ea93c73d142e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e2c7187-2320-4503-ad73-4c9753bd069b", "node_type": "1", "metadata": {"window": " \nPage 31 of 31 \n \nand balancing, you know, their need to have lower cost with where we're manufacturing product and \nwhat\u2019s going on there.  So we're going to continue to evaluate that but continue to ramp up.  \n \n  And then also we're going to evaluate the inventory levels that we carry so that we can work \nwith customers going forward around levels of safety stoc k. So those are some of the different things \nthat we're looking at in our supply chain and we'll continue to make some tweaks as we move along.  \n \n Jailendra Singh:  Great.  \n \n Mike Kaufmann:  Great.  Well, first of all, thanks for all the questions and we really  appreciate all of \nyou joining us this morning. ", "original_text": "And then also we're going to evaluate the inventory levels that we carry so that we can work \nwith customers going forward around levels of safety stoc k. So those are some of the different things \nthat we're looking at in our supply chain and we'll continue to make some tweaks as we move along.  \n \n"}, "hash": "96d20f4b7168bc40fe88f82a68331ed3d0ff873bbdec4e9e15e256bad45c8082", "class_name": "RelatedNodeInfo"}}, "text": "So we're going to continue to evaluate that but continue to ramp up.  \n \n ", "start_char_idx": 141, "end_char_idx": 215, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e2c7187-2320-4503-ad73-4c9753bd069b": {"__data__": {"id_": "5e2c7187-2320-4503-ad73-4c9753bd069b", "embedding": null, "metadata": {"window": " \nPage 31 of 31 \n \nand balancing, you know, their need to have lower cost with where we're manufacturing product and \nwhat\u2019s going on there.  So we're going to continue to evaluate that but continue to ramp up.  \n \n  And then also we're going to evaluate the inventory levels that we carry so that we can work \nwith customers going forward around levels of safety stoc k. So those are some of the different things \nthat we're looking at in our supply chain and we'll continue to make some tweaks as we move along.  \n \n Jailendra Singh:  Great.  \n \n Mike Kaufmann:  Great.  Well, first of all, thanks for all the questions and we really  appreciate all of \nyou joining us this morning. ", "original_text": "And then also we're going to evaluate the inventory levels that we carry so that we can work \nwith customers going forward around levels of safety stoc k. So those are some of the different things \nthat we're looking at in our supply chain and we'll continue to make some tweaks as we move along.  \n \n", "page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a27c321-3a7b-402a-abb8-9964cef9499a", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23a929a286262ab5594fcb0134f2da358b147a62a9d92fe33378127a92a97f9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9a42ba7-192c-463a-abfe-017ba5d1c31e", "node_type": "1", "metadata": {"window": " \nPage 31 of 31 \n \nand balancing, you know, their need to have lower cost with where we're manufacturing product and \nwhat\u2019s going on there.  So we're going to continue to evaluate that but continue to ramp up.  \n \n  And then also we're going to evaluate the inventory levels that we carry so that we can work \nwith customers going forward around levels of safety stoc k. So those are some of the different things \nthat we're looking at in our supply chain and we'll continue to make some tweaks as we move along.  \n \n Jailendra Singh:  Great.  \n \n Mike Kaufmann:  Great. ", "original_text": "So we're going to continue to evaluate that but continue to ramp up.  \n \n ", "page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7ef0c7cebe40d6e1f5d2af354ce667623dedc91f1e636f7fbc96a6602e1cdfb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c7177ec-7337-4bf1-be51-7e92c559a262", "node_type": "1", "metadata": {"window": " \nPage 31 of 31 \n \nand balancing, you know, their need to have lower cost with where we're manufacturing product and \nwhat\u2019s going on there.  So we're going to continue to evaluate that but continue to ramp up.  \n \n  And then also we're going to evaluate the inventory levels that we carry so that we can work \nwith customers going forward around levels of safety stoc k. So those are some of the different things \nthat we're looking at in our supply chain and we'll continue to make some tweaks as we move along.  \n \n Jailendra Singh:  Great.  \n \n Mike Kaufmann:  Great.  Well, first of all, thanks for all the questions and we really  appreciate all of \nyou joining us this morning.  And on behalf of the entire Cardinal Health family, we hope you and your \nfamilies stay safe and well. ", "original_text": "Jailendra Singh:  Great.  \n \n"}, "hash": "a9be7fa2897f19c04f683e5448e29e8562ce15899342097179b8cbaafac388b5", "class_name": "RelatedNodeInfo"}}, "text": "And then also we're going to evaluate the inventory levels that we carry so that we can work \nwith customers going forward around levels of safety stoc k. So those are some of the different things \nthat we're looking at in our supply chain and we'll continue to make some tweaks as we move along.  \n \n", "start_char_idx": 215, "end_char_idx": 516, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c7177ec-7337-4bf1-be51-7e92c559a262": {"__data__": {"id_": "5c7177ec-7337-4bf1-be51-7e92c559a262", "embedding": null, "metadata": {"window": " \nPage 31 of 31 \n \nand balancing, you know, their need to have lower cost with where we're manufacturing product and \nwhat\u2019s going on there.  So we're going to continue to evaluate that but continue to ramp up.  \n \n  And then also we're going to evaluate the inventory levels that we carry so that we can work \nwith customers going forward around levels of safety stoc k. So those are some of the different things \nthat we're looking at in our supply chain and we'll continue to make some tweaks as we move along.  \n \n Jailendra Singh:  Great.  \n \n Mike Kaufmann:  Great.  Well, first of all, thanks for all the questions and we really  appreciate all of \nyou joining us this morning.  And on behalf of the entire Cardinal Health family, we hope you and your \nfamilies stay safe and well. ", "original_text": "Jailendra Singh:  Great.  \n \n", "page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a27c321-3a7b-402a-abb8-9964cef9499a", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23a929a286262ab5594fcb0134f2da358b147a62a9d92fe33378127a92a97f9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e2c7187-2320-4503-ad73-4c9753bd069b", "node_type": "1", "metadata": {"window": " \nPage 31 of 31 \n \nand balancing, you know, their need to have lower cost with where we're manufacturing product and \nwhat\u2019s going on there.  So we're going to continue to evaluate that but continue to ramp up.  \n \n  And then also we're going to evaluate the inventory levels that we carry so that we can work \nwith customers going forward around levels of safety stoc k. So those are some of the different things \nthat we're looking at in our supply chain and we'll continue to make some tweaks as we move along.  \n \n Jailendra Singh:  Great.  \n \n Mike Kaufmann:  Great.  Well, first of all, thanks for all the questions and we really  appreciate all of \nyou joining us this morning. ", "original_text": "And then also we're going to evaluate the inventory levels that we carry so that we can work \nwith customers going forward around levels of safety stoc k. So those are some of the different things \nthat we're looking at in our supply chain and we'll continue to make some tweaks as we move along.  \n \n", "page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49dfe7bdae979dbbacd1ae9f0ca9db1c3fd2bb1d27c4338fc2a74e3421767056", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4013577-1761-4bee-88e2-0b07638f972f", "node_type": "1", "metadata": {"window": "So we're going to continue to evaluate that but continue to ramp up.  \n \n  And then also we're going to evaluate the inventory levels that we carry so that we can work \nwith customers going forward around levels of safety stoc k. So those are some of the different things \nthat we're looking at in our supply chain and we'll continue to make some tweaks as we move along.  \n \n Jailendra Singh:  Great.  \n \n Mike Kaufmann:  Great.  Well, first of all, thanks for all the questions and we really  appreciate all of \nyou joining us this morning.  And on behalf of the entire Cardinal Health family, we hope you and your \nfamilies stay safe and well.  And we look forward to speaking again to you sometime soon.  \n \n", "original_text": "Mike Kaufmann:  Great. "}, "hash": "bc0f48a9a9c9ba88a2a2c928c1abe74fc0a3016a41c9fdefc04276ac9d72922d", "class_name": "RelatedNodeInfo"}}, "text": "Jailendra Singh:  Great.  \n \n", "start_char_idx": 516, "end_char_idx": 545, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4013577-1761-4bee-88e2-0b07638f972f": {"__data__": {"id_": "a4013577-1761-4bee-88e2-0b07638f972f", "embedding": null, "metadata": {"window": "So we're going to continue to evaluate that but continue to ramp up.  \n \n  And then also we're going to evaluate the inventory levels that we carry so that we can work \nwith customers going forward around levels of safety stoc k. So those are some of the different things \nthat we're looking at in our supply chain and we'll continue to make some tweaks as we move along.  \n \n Jailendra Singh:  Great.  \n \n Mike Kaufmann:  Great.  Well, first of all, thanks for all the questions and we really  appreciate all of \nyou joining us this morning.  And on behalf of the entire Cardinal Health family, we hope you and your \nfamilies stay safe and well.  And we look forward to speaking again to you sometime soon.  \n \n", "original_text": "Mike Kaufmann:  Great. ", "page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a27c321-3a7b-402a-abb8-9964cef9499a", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23a929a286262ab5594fcb0134f2da358b147a62a9d92fe33378127a92a97f9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c7177ec-7337-4bf1-be51-7e92c559a262", "node_type": "1", "metadata": {"window": " \nPage 31 of 31 \n \nand balancing, you know, their need to have lower cost with where we're manufacturing product and \nwhat\u2019s going on there.  So we're going to continue to evaluate that but continue to ramp up.  \n \n  And then also we're going to evaluate the inventory levels that we carry so that we can work \nwith customers going forward around levels of safety stoc k. So those are some of the different things \nthat we're looking at in our supply chain and we'll continue to make some tweaks as we move along.  \n \n Jailendra Singh:  Great.  \n \n Mike Kaufmann:  Great.  Well, first of all, thanks for all the questions and we really  appreciate all of \nyou joining us this morning.  And on behalf of the entire Cardinal Health family, we hope you and your \nfamilies stay safe and well. ", "original_text": "Jailendra Singh:  Great.  \n \n", "page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29f299e4f409ddd32607e8e459fd3387d3364dc9aa15d1b104ecd70751ff5899", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f1bfafa-1d49-4e14-b34f-975a29e17647", "node_type": "1", "metadata": {"window": "And then also we're going to evaluate the inventory levels that we carry so that we can work \nwith customers going forward around levels of safety stoc k. So those are some of the different things \nthat we're looking at in our supply chain and we'll continue to make some tweaks as we move along.  \n \n Jailendra Singh:  Great.  \n \n Mike Kaufmann:  Great.  Well, first of all, thanks for all the questions and we really  appreciate all of \nyou joining us this morning.  And on behalf of the entire Cardinal Health family, we hope you and your \nfamilies stay safe and well.  And we look forward to speaking again to you sometime soon.  \n \n Operator:  Thank you. ", "original_text": "Well, first of all, thanks for all the questions and we really  appreciate all of \nyou joining us this morning. "}, "hash": "5cb6bb106a05d3e8543b4740a89650e9c9d5334d56ec3d68a2b123af8620d8ba", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Great. ", "start_char_idx": 545, "end_char_idx": 568, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f1bfafa-1d49-4e14-b34f-975a29e17647": {"__data__": {"id_": "1f1bfafa-1d49-4e14-b34f-975a29e17647", "embedding": null, "metadata": {"window": "And then also we're going to evaluate the inventory levels that we carry so that we can work \nwith customers going forward around levels of safety stoc k. So those are some of the different things \nthat we're looking at in our supply chain and we'll continue to make some tweaks as we move along.  \n \n Jailendra Singh:  Great.  \n \n Mike Kaufmann:  Great.  Well, first of all, thanks for all the questions and we really  appreciate all of \nyou joining us this morning.  And on behalf of the entire Cardinal Health family, we hope you and your \nfamilies stay safe and well.  And we look forward to speaking again to you sometime soon.  \n \n Operator:  Thank you. ", "original_text": "Well, first of all, thanks for all the questions and we really  appreciate all of \nyou joining us this morning. ", "page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a27c321-3a7b-402a-abb8-9964cef9499a", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23a929a286262ab5594fcb0134f2da358b147a62a9d92fe33378127a92a97f9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4013577-1761-4bee-88e2-0b07638f972f", "node_type": "1", "metadata": {"window": "So we're going to continue to evaluate that but continue to ramp up.  \n \n  And then also we're going to evaluate the inventory levels that we carry so that we can work \nwith customers going forward around levels of safety stoc k. So those are some of the different things \nthat we're looking at in our supply chain and we'll continue to make some tweaks as we move along.  \n \n Jailendra Singh:  Great.  \n \n Mike Kaufmann:  Great.  Well, first of all, thanks for all the questions and we really  appreciate all of \nyou joining us this morning.  And on behalf of the entire Cardinal Health family, we hope you and your \nfamilies stay safe and well.  And we look forward to speaking again to you sometime soon.  \n \n", "original_text": "Mike Kaufmann:  Great. ", "page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67f50aee3efd24b6b344b714c0dc07b19de9bbde9dd72796802e9f750d4892dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9faa7a44-ff93-4d5a-b61d-e650087c6a39", "node_type": "1", "metadata": {"window": "Jailendra Singh:  Great.  \n \n Mike Kaufmann:  Great.  Well, first of all, thanks for all the questions and we really  appreciate all of \nyou joining us this morning.  And on behalf of the entire Cardinal Health family, we hope you and your \nfamilies stay safe and well.  And we look forward to speaking again to you sometime soon.  \n \n Operator:  Thank you.  Ladies and gentlemen, t hat does conclude today's call. ", "original_text": "And on behalf of the entire Cardinal Health family, we hope you and your \nfamilies stay safe and well. "}, "hash": "262e85ef71f89b9a038e3e00d8a1cb26a77a7512d58d0ab66bee094a3feb4404", "class_name": "RelatedNodeInfo"}}, "text": "Well, first of all, thanks for all the questions and we really  appreciate all of \nyou joining us this morning. ", "start_char_idx": 568, "end_char_idx": 680, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9faa7a44-ff93-4d5a-b61d-e650087c6a39": {"__data__": {"id_": "9faa7a44-ff93-4d5a-b61d-e650087c6a39", "embedding": null, "metadata": {"window": "Jailendra Singh:  Great.  \n \n Mike Kaufmann:  Great.  Well, first of all, thanks for all the questions and we really  appreciate all of \nyou joining us this morning.  And on behalf of the entire Cardinal Health family, we hope you and your \nfamilies stay safe and well.  And we look forward to speaking again to you sometime soon.  \n \n Operator:  Thank you.  Ladies and gentlemen, t hat does conclude today's call. ", "original_text": "And on behalf of the entire Cardinal Health family, we hope you and your \nfamilies stay safe and well. ", "page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a27c321-3a7b-402a-abb8-9964cef9499a", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23a929a286262ab5594fcb0134f2da358b147a62a9d92fe33378127a92a97f9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f1bfafa-1d49-4e14-b34f-975a29e17647", "node_type": "1", "metadata": {"window": "And then also we're going to evaluate the inventory levels that we carry so that we can work \nwith customers going forward around levels of safety stoc k. So those are some of the different things \nthat we're looking at in our supply chain and we'll continue to make some tweaks as we move along.  \n \n Jailendra Singh:  Great.  \n \n Mike Kaufmann:  Great.  Well, first of all, thanks for all the questions and we really  appreciate all of \nyou joining us this morning.  And on behalf of the entire Cardinal Health family, we hope you and your \nfamilies stay safe and well.  And we look forward to speaking again to you sometime soon.  \n \n Operator:  Thank you. ", "original_text": "Well, first of all, thanks for all the questions and we really  appreciate all of \nyou joining us this morning. ", "page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a58dfca0953198c059060a14947eae32e31bf97b5c0a69303537330d702d1d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c5dc2f7-2af7-4942-80b8-d9a4863458df", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Great.  Well, first of all, thanks for all the questions and we really  appreciate all of \nyou joining us this morning.  And on behalf of the entire Cardinal Health family, we hope you and your \nfamilies stay safe and well.  And we look forward to speaking again to you sometime soon.  \n \n Operator:  Thank you.  Ladies and gentlemen, t hat does conclude today's call.  We do thank you for \nyour participation. ", "original_text": "And we look forward to speaking again to you sometime soon.  \n \n"}, "hash": "1e2dea16b9fbe2d2c50f8612e92541973a87384659a88c67de35ac54c476b575", "class_name": "RelatedNodeInfo"}}, "text": "And on behalf of the entire Cardinal Health family, we hope you and your \nfamilies stay safe and well. ", "start_char_idx": 680, "end_char_idx": 783, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c5dc2f7-2af7-4942-80b8-d9a4863458df": {"__data__": {"id_": "4c5dc2f7-2af7-4942-80b8-d9a4863458df", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Great.  Well, first of all, thanks for all the questions and we really  appreciate all of \nyou joining us this morning.  And on behalf of the entire Cardinal Health family, we hope you and your \nfamilies stay safe and well.  And we look forward to speaking again to you sometime soon.  \n \n Operator:  Thank you.  Ladies and gentlemen, t hat does conclude today's call.  We do thank you for \nyour participation. ", "original_text": "And we look forward to speaking again to you sometime soon.  \n \n", "page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a27c321-3a7b-402a-abb8-9964cef9499a", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23a929a286262ab5594fcb0134f2da358b147a62a9d92fe33378127a92a97f9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9faa7a44-ff93-4d5a-b61d-e650087c6a39", "node_type": "1", "metadata": {"window": "Jailendra Singh:  Great.  \n \n Mike Kaufmann:  Great.  Well, first of all, thanks for all the questions and we really  appreciate all of \nyou joining us this morning.  And on behalf of the entire Cardinal Health family, we hope you and your \nfamilies stay safe and well.  And we look forward to speaking again to you sometime soon.  \n \n Operator:  Thank you.  Ladies and gentlemen, t hat does conclude today's call. ", "original_text": "And on behalf of the entire Cardinal Health family, we hope you and your \nfamilies stay safe and well. ", "page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "322752abd7a5c8ce9a44e959351d98106735c09ae634c8ceb9293fa9bf316807", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "399ec58d-443b-4ff8-b4e9-424c0a2f0ade", "node_type": "1", "metadata": {"window": "Well, first of all, thanks for all the questions and we really  appreciate all of \nyou joining us this morning.  And on behalf of the entire Cardinal Health family, we hope you and your \nfamilies stay safe and well.  And we look forward to speaking again to you sometime soon.  \n \n Operator:  Thank you.  Ladies and gentlemen, t hat does conclude today's call.  We do thank you for \nyour participation.  You may now disconnect.  \n \n  \n \n \n ", "original_text": "Operator:  Thank you. "}, "hash": "cab120282bf5da3b8166cf2f80cc9fd40a3c5671918d58235d80d366d5ce0a1a", "class_name": "RelatedNodeInfo"}}, "text": "And we look forward to speaking again to you sometime soon.  \n \n", "start_char_idx": 783, "end_char_idx": 847, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "399ec58d-443b-4ff8-b4e9-424c0a2f0ade": {"__data__": {"id_": "399ec58d-443b-4ff8-b4e9-424c0a2f0ade", "embedding": null, "metadata": {"window": "Well, first of all, thanks for all the questions and we really  appreciate all of \nyou joining us this morning.  And on behalf of the entire Cardinal Health family, we hope you and your \nfamilies stay safe and well.  And we look forward to speaking again to you sometime soon.  \n \n Operator:  Thank you.  Ladies and gentlemen, t hat does conclude today's call.  We do thank you for \nyour participation.  You may now disconnect.  \n \n  \n \n \n ", "original_text": "Operator:  Thank you. ", "page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a27c321-3a7b-402a-abb8-9964cef9499a", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23a929a286262ab5594fcb0134f2da358b147a62a9d92fe33378127a92a97f9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c5dc2f7-2af7-4942-80b8-d9a4863458df", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Great.  Well, first of all, thanks for all the questions and we really  appreciate all of \nyou joining us this morning.  And on behalf of the entire Cardinal Health family, we hope you and your \nfamilies stay safe and well.  And we look forward to speaking again to you sometime soon.  \n \n Operator:  Thank you.  Ladies and gentlemen, t hat does conclude today's call.  We do thank you for \nyour participation. ", "original_text": "And we look forward to speaking again to you sometime soon.  \n \n", "page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f055020cad23000d4a598b44f4e2f1f16b43be19e11bf91f1789186bdcf991f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a2493cf-3f25-4d5f-84c9-d8b89ab53572", "node_type": "1", "metadata": {"window": "And on behalf of the entire Cardinal Health family, we hope you and your \nfamilies stay safe and well.  And we look forward to speaking again to you sometime soon.  \n \n Operator:  Thank you.  Ladies and gentlemen, t hat does conclude today's call.  We do thank you for \nyour participation.  You may now disconnect.  \n \n  \n \n \n ", "original_text": "Ladies and gentlemen, t hat does conclude today's call. "}, "hash": "d12ced327a4ed30a29d7bbebdee6810d1acd079dd6b4232eb4b74d09259b7418", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you. ", "start_char_idx": 847, "end_char_idx": 869, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a2493cf-3f25-4d5f-84c9-d8b89ab53572": {"__data__": {"id_": "9a2493cf-3f25-4d5f-84c9-d8b89ab53572", "embedding": null, "metadata": {"window": "And on behalf of the entire Cardinal Health family, we hope you and your \nfamilies stay safe and well.  And we look forward to speaking again to you sometime soon.  \n \n Operator:  Thank you.  Ladies and gentlemen, t hat does conclude today's call.  We do thank you for \nyour participation.  You may now disconnect.  \n \n  \n \n \n ", "original_text": "Ladies and gentlemen, t hat does conclude today's call. ", "page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a27c321-3a7b-402a-abb8-9964cef9499a", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23a929a286262ab5594fcb0134f2da358b147a62a9d92fe33378127a92a97f9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "399ec58d-443b-4ff8-b4e9-424c0a2f0ade", "node_type": "1", "metadata": {"window": "Well, first of all, thanks for all the questions and we really  appreciate all of \nyou joining us this morning.  And on behalf of the entire Cardinal Health family, we hope you and your \nfamilies stay safe and well.  And we look forward to speaking again to you sometime soon.  \n \n Operator:  Thank you.  Ladies and gentlemen, t hat does conclude today's call.  We do thank you for \nyour participation.  You may now disconnect.  \n \n  \n \n \n ", "original_text": "Operator:  Thank you. ", "page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9fafae06d83eb416828bda5d142e77d319c6bf4dfd8a2e652ae6724c96dca347", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8766cfde-ec8d-4a6d-86d1-8fc768b8dda0", "node_type": "1", "metadata": {"window": "And we look forward to speaking again to you sometime soon.  \n \n Operator:  Thank you.  Ladies and gentlemen, t hat does conclude today's call.  We do thank you for \nyour participation.  You may now disconnect.  \n \n  \n \n \n ", "original_text": "We do thank you for \nyour participation. "}, "hash": "c55322ffdb6900e8a899223ec5111289bb823c496223d1d83369a9ce3a063c48", "class_name": "RelatedNodeInfo"}}, "text": "Ladies and gentlemen, t hat does conclude today's call. ", "start_char_idx": 869, "end_char_idx": 925, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8766cfde-ec8d-4a6d-86d1-8fc768b8dda0": {"__data__": {"id_": "8766cfde-ec8d-4a6d-86d1-8fc768b8dda0", "embedding": null, "metadata": {"window": "And we look forward to speaking again to you sometime soon.  \n \n Operator:  Thank you.  Ladies and gentlemen, t hat does conclude today's call.  We do thank you for \nyour participation.  You may now disconnect.  \n \n  \n \n \n ", "original_text": "We do thank you for \nyour participation. ", "page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a27c321-3a7b-402a-abb8-9964cef9499a", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23a929a286262ab5594fcb0134f2da358b147a62a9d92fe33378127a92a97f9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a2493cf-3f25-4d5f-84c9-d8b89ab53572", "node_type": "1", "metadata": {"window": "And on behalf of the entire Cardinal Health family, we hope you and your \nfamilies stay safe and well.  And we look forward to speaking again to you sometime soon.  \n \n Operator:  Thank you.  Ladies and gentlemen, t hat does conclude today's call.  We do thank you for \nyour participation.  You may now disconnect.  \n \n  \n \n \n ", "original_text": "Ladies and gentlemen, t hat does conclude today's call. ", "page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "003c6eedbdce256fe27180a534b8ec51be6b38d88c0748345685fdb7f0d0b9d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c38b631-743e-4e65-bed3-ed09cd34544d", "node_type": "1", "metadata": {"window": "Operator:  Thank you.  Ladies and gentlemen, t hat does conclude today's call.  We do thank you for \nyour participation.  You may now disconnect.  \n \n  \n \n \n ", "original_text": "You may now disconnect.  \n \n  \n \n \n "}, "hash": "b20341479bf790aafb2f47d9c4023326a03e478dd7726c9d162383e36583d6fa", "class_name": "RelatedNodeInfo"}}, "text": "We do thank you for \nyour participation. ", "start_char_idx": 925, "end_char_idx": 966, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c38b631-743e-4e65-bed3-ed09cd34544d": {"__data__": {"id_": "8c38b631-743e-4e65-bed3-ed09cd34544d", "embedding": null, "metadata": {"window": "Operator:  Thank you.  Ladies and gentlemen, t hat does conclude today's call.  We do thank you for \nyour participation.  You may now disconnect.  \n \n  \n \n \n ", "original_text": "You may now disconnect.  \n \n  \n \n \n ", "page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a27c321-3a7b-402a-abb8-9964cef9499a", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23a929a286262ab5594fcb0134f2da358b147a62a9d92fe33378127a92a97f9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8766cfde-ec8d-4a6d-86d1-8fc768b8dda0", "node_type": "1", "metadata": {"window": "And we look forward to speaking again to you sometime soon.  \n \n Operator:  Thank you.  Ladies and gentlemen, t hat does conclude today's call.  We do thank you for \nyour participation.  You may now disconnect.  \n \n  \n \n \n ", "original_text": "We do thank you for \nyour participation. ", "page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dbdbfbbd323ee95c982675618a66e33db63f67beb12069e09ddc198725dbbd8c", "class_name": "RelatedNodeInfo"}}, "text": "You may now disconnect.  \n \n  \n \n \n ", "start_char_idx": 966, "end_char_idx": 1002, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"19f55e17-8d97-4090-a7f3-6fb80fd650e5": {"doc_hash": "c905390cfc23bd28d6fd7947b5d5e62d9913e149e6319c78a78d6eaa6b1c5446", "ref_doc_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d"}, "73c38dfc-475e-4b3a-97f5-631e8dc13d6d": {"doc_hash": "292f141ae1fde93281fb8d3dae9912096f8d835f60d6a90d5112eccd73adc41e", "ref_doc_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d"}, "0e559be4-935b-41e6-bf07-032759fef578": {"doc_hash": "ce62ccb5eb3db55368dc1f4cda1f474828bf03bb6d9aed114f52a1c6f3163fef", "ref_doc_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d"}, "ca094ce4-bddf-423d-91dc-62af0696fe5a": {"doc_hash": "e821f4fe978b259a90ac1cf2a4844bdee01ba4c20635d9b9acc948ed657aff0d", "ref_doc_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d"}, "9f4af5d4-3890-4c10-bbac-73ee8b8c291a": {"doc_hash": "a59ffffb5515f253399019d7c7c2310aa7887acf4fa4d97f8f025aa451b6e495", "ref_doc_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d"}, "8a728ce5-9960-47ec-b0f0-d0e48f440e79": {"doc_hash": "7c96c2163dcb9d2ac3944fc4b63d21ddc91c510d0acf97b5bfdee446c5674f75", "ref_doc_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d"}, "3d1c53c7-aa34-4ebf-b6d0-1928c8ad41b4": {"doc_hash": "412b22965db08eac3d62ffe640995ff563ce7eefd289ea71ae46acfdb10da0e0", "ref_doc_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d"}, "2d561b67-c87f-4314-b6c7-b3d4ca36b6c7": {"doc_hash": "e60f55c07dbb81cdb181d170ca0a5eacd8ae74237cdb557695455c5fe0f9b3f3", "ref_doc_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d"}, "50ba95e0-b4a4-4494-b3c6-cfcb819a160b": {"doc_hash": "3854a6a323c33b8ddc487b0365389f3e31c0f873341d4e9ab442f6b7a6c6a10b", "ref_doc_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d"}, "11a3dc75-2147-4e3e-ad03-4ae36ef0ee26": {"doc_hash": "e718dedaf1d401e10e02a244bf216599482c73596ebc15fd01ff22d95785e2b7", "ref_doc_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d"}, "40019dd5-4273-4402-9edb-7c00e88eaad6": {"doc_hash": "06f6f6c2d498a6a307bf0548d7ff735eccc3bb8ef7efb388c527a7c1f95ce3a0", "ref_doc_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d"}, "518bc030-5f87-409e-9290-8fdb3b4b49c0": {"doc_hash": "48c258dce4b2f800e11852d2091d28f6da4ff35cab57ea53b7fac6abf2e29c37", "ref_doc_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d"}, "ca646f7c-fb85-4e14-b9f1-a63f7bbdde5a": {"doc_hash": "a65c2357e1a85e08d433ccaf3e699dd2990d7347c471465ab64fd5c7394b5787", "ref_doc_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d"}, "666e084e-6941-4f68-8e39-96545a6f2236": {"doc_hash": "07ae10a6686d063a7a1185b647e9b648d68795bf2f059f685ee503021c4b7eaa", "ref_doc_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d"}, "52a575a2-d405-4736-9876-286be08f836a": {"doc_hash": "c4b53b90c1da6a89e48c41e3adbe08b87d57c95e7a620f766d1087bc1c04811c", "ref_doc_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d"}, "6d680f8b-bfc2-464d-b5b6-aa1d9b8120a1": {"doc_hash": "926781c929404837c5f4f0f7d981515f30cc89210b4eb70261ddf557cb3c03ed", "ref_doc_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d"}, "5238ae64-9827-4595-bbf4-4f136bdbe20a": {"doc_hash": "46211e0aa63f1f56a1eddd791b84d2b9f51e474fbe6a318c4abddbe15cad235c", "ref_doc_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d"}, "dd3b245e-c22b-4fd8-a291-da486e07fceb": {"doc_hash": "08c3d390247660202912a85b8850f7d465f3eec84b41511c66e84e7674b19019", "ref_doc_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d"}, "8b62bede-39f9-4e4e-acd7-73a13a2199cc": {"doc_hash": "a21702e706839462c51e1e2b365192e07a657827263ed22040455f9e056a705b", "ref_doc_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d"}, "1b86d48e-d582-4fc3-82f1-6d2931eb22bf": {"doc_hash": "25d5afd65a1bf942fe3982f8b05bc28c021b66704d4984ccf6334a0e325a33d0", "ref_doc_id": "189eda67-ddcf-494c-bfdd-8e912ff3f49d"}, "24e03b24-6abd-4f09-afc5-1896a54cff29": {"doc_hash": "3aa759e51196b02a0d58a687d64c14474d82a8e1ae3f6364e443bba0180edc0b", "ref_doc_id": "c8a6b818-b294-4b3d-ae18-fbb665a79bdd"}, "11bdb025-1ff1-48c1-af94-e3991b3969d8": {"doc_hash": "a1ece334099a0707c01bf4e0e201a8c0660fe7bebb9450b80e5afa825cdf88a4", "ref_doc_id": "c8a6b818-b294-4b3d-ae18-fbb665a79bdd"}, "22ac2b64-e4a1-411c-a4d4-03fdb32f4219": {"doc_hash": "3beb4853a177a20d6f32bb29201bb6997be671c010c5a7c577b3119843c8bc25", "ref_doc_id": "c8a6b818-b294-4b3d-ae18-fbb665a79bdd"}, "f103894b-944d-4785-981d-b69b247ff497": {"doc_hash": "1d9a2169b19ec822b8652eb3ff2b45d3e84c743c7fd09067ca3a9718fa939a9c", "ref_doc_id": "c8a6b818-b294-4b3d-ae18-fbb665a79bdd"}, "dcb11cb0-f96c-44cb-b951-c59ba1eacbb3": {"doc_hash": "a0d4297928b6301c6be66811e1301de9549d4695ba34df72a1e0c94e28843a61", "ref_doc_id": "c8a6b818-b294-4b3d-ae18-fbb665a79bdd"}, "973cb6dd-ab58-45d6-b9e0-c2f135151533": {"doc_hash": "6357d738f2d823d6e138ee7fbb2501adf578d869cff6a8fab54a0dfc9991d854", "ref_doc_id": "c8a6b818-b294-4b3d-ae18-fbb665a79bdd"}, "da4b35a0-4b3d-4f71-94b5-c3bbdbc72f03": {"doc_hash": "b608f981995d1aebafe83ef92a26a67acb18ccd00ba9e51084a0c266dc4ae169", "ref_doc_id": "c8a6b818-b294-4b3d-ae18-fbb665a79bdd"}, "376921ea-0913-4cc4-9b00-eb72ae78246c": {"doc_hash": "bc0ba7fede9cd4d12e9cb5faebbf576896dad3de316b4ed28db10a117446ec6f", "ref_doc_id": "c8a6b818-b294-4b3d-ae18-fbb665a79bdd"}, "010ec09f-6a66-431e-b60c-2144632c56ec": {"doc_hash": "f9f63fb2dd43e0c2966f1200b3996259210c5c8656c0fc1b1b5d7c8d109c2f3b", "ref_doc_id": "c8a6b818-b294-4b3d-ae18-fbb665a79bdd"}, "fcbc7966-1b00-4883-b3c3-0b439af1cf4a": {"doc_hash": "93f6cbd97ab9b1c90e14a38c5d6387e83dcab972483e17fc34c3f920bea8c1eb", "ref_doc_id": "c8a6b818-b294-4b3d-ae18-fbb665a79bdd"}, "c7e75312-9637-48e4-8690-1a13dca3e149": {"doc_hash": "42f455ae4cf478337fee928caf7ef41f489d0ab2ae41cae9786716da480887e8", "ref_doc_id": "c8a6b818-b294-4b3d-ae18-fbb665a79bdd"}, "903607c5-7e2c-497f-a1f5-55848f59e898": {"doc_hash": "b78253315203690385113b92fa3c7ec4e7c09b414df156f04754eefc3ce5e65e", "ref_doc_id": "c7e7a17a-8d74-4fa1-8a13-fb462afeb8b4"}, "6d4e84ad-5901-4d9e-a39b-37849537a7ce": {"doc_hash": "3836aad33d4afd0f279fa55dbb7128cf7afd84b011015123db43b7dfa155cb91", "ref_doc_id": "c7e7a17a-8d74-4fa1-8a13-fb462afeb8b4"}, "1e675ee0-8f3c-4ede-8fb7-07b89a76730a": {"doc_hash": "b306506313d26b8b6415b28ab62d337895c187a021542c25d69ebe1b30254911", "ref_doc_id": "c7e7a17a-8d74-4fa1-8a13-fb462afeb8b4"}, "790a4a87-6d47-4b66-a6a1-762e84c73d48": {"doc_hash": "f689c1ec35bf6d4139cc283e0480cff600c486c625d6720ff337a19af471a68e", "ref_doc_id": "c7e7a17a-8d74-4fa1-8a13-fb462afeb8b4"}, "a48bd4a6-93d9-4b21-aa72-927cf414607f": {"doc_hash": "34e503c0d57e38f3e19f697de6fe148727039822818226d12f0cfe6d96d5317c", "ref_doc_id": "c7e7a17a-8d74-4fa1-8a13-fb462afeb8b4"}, "b6a4423f-a20d-48a9-87a2-78f0cab7f743": {"doc_hash": "128c61c30042365d3d39a8dac3160c2cefc289748eb89b0cd87c89d25607b60b", "ref_doc_id": "c7e7a17a-8d74-4fa1-8a13-fb462afeb8b4"}, "29423008-e546-423b-ab49-b37d78004ebe": {"doc_hash": "5bd02d628490a3728675a322b11b67aaccdb74bcfe4d63d9854f2e720a435f2d", "ref_doc_id": "c7e7a17a-8d74-4fa1-8a13-fb462afeb8b4"}, "b69e81f1-7fb4-48ea-bef5-5fc4a8792aba": {"doc_hash": "ade64349fad204de49df4f567e7d0bd7c7055bad1611acbb60d2ce57fe61583a", "ref_doc_id": "c7e7a17a-8d74-4fa1-8a13-fb462afeb8b4"}, "97031aea-85e3-4c3d-aa67-b8f32103148e": {"doc_hash": "4aac1b5cfa312dc39c743f48437e0072675048364960773e14879f250d5d74c0", "ref_doc_id": "c7e7a17a-8d74-4fa1-8a13-fb462afeb8b4"}, "5f516ff6-f510-417f-ad2c-b932ec840fc1": {"doc_hash": "4b9ae6d24f8b0899036387960961028ee5bcfc06e447bd81d1521e2c1107ae07", "ref_doc_id": "3fe6ce10-fe5e-4d94-b32d-9477a82f8e03"}, "ad581678-9160-419d-8f23-1f035ff78104": {"doc_hash": "c06f3c260033baa4e4c306b56e3c1b3b536ff7faebd6851008191a1c3c393cad", "ref_doc_id": "3fe6ce10-fe5e-4d94-b32d-9477a82f8e03"}, "4bfe0848-d577-4158-9c5b-c59058f75165": {"doc_hash": "37fdf68f0a153a7aac6c9bd42c891a22ccc4b454672c3608c690c2b30ed9187b", "ref_doc_id": "3fe6ce10-fe5e-4d94-b32d-9477a82f8e03"}, "df84a6d8-e359-4e82-8784-5b863ac6691d": {"doc_hash": "de2f9aa8942ff4900519f2d0fc2359bf391e12d2f8ef8526b738e371787454c2", "ref_doc_id": "3fe6ce10-fe5e-4d94-b32d-9477a82f8e03"}, "a3938704-1db9-4495-9aec-0102dc1ee48c": {"doc_hash": "bc452babd9f7ba614a43b7d9402268bcde09fc481020a3b5e410e80f45092535", "ref_doc_id": "3fe6ce10-fe5e-4d94-b32d-9477a82f8e03"}, "c4f308ff-4b77-47a0-b1b0-496510ff6554": {"doc_hash": "e1749885037ef4600a7557d7c5cce4eb05f8818360950bfd58dd488e624a518f", "ref_doc_id": "3fe6ce10-fe5e-4d94-b32d-9477a82f8e03"}, "465ff21e-edb4-4dae-ac42-7d00c646c2a2": {"doc_hash": "39bc76de312e4137fb55d52a5a77f260eec22c7fe3d5ef90bf1b0d57c1c6f097", "ref_doc_id": "3fe6ce10-fe5e-4d94-b32d-9477a82f8e03"}, "239aac79-9dae-49ab-9c7b-1d530cc3076f": {"doc_hash": "3432c67ae2487082fdd41684cd95e9650f970c59c5d4558b86fc26942a7e600d", "ref_doc_id": "3fe6ce10-fe5e-4d94-b32d-9477a82f8e03"}, "098d02ee-7b4f-40ae-8653-445a4730fc14": {"doc_hash": "b9f1b62cfc87b330ed277525c27d321d7ddae45a90dab0b5262f664db26795f2", "ref_doc_id": "3fe6ce10-fe5e-4d94-b32d-9477a82f8e03"}, "3437bc37-3389-463e-8e3d-eb6c0a1a5958": {"doc_hash": "6e7e3135f5249381747e191861c20caed7a437d7943c7c83246d1a473b4be750", "ref_doc_id": "3fe6ce10-fe5e-4d94-b32d-9477a82f8e03"}, "e44d6bb0-370e-4e7f-8c62-20f794ad80ad": {"doc_hash": "621dda8133f3ed8e5390ab2f3d577c157e9dea23af3c050aaf2792906d47ab33", "ref_doc_id": "3fe6ce10-fe5e-4d94-b32d-9477a82f8e03"}, "6ab2020d-e408-4ea9-8591-5e577a60dd31": {"doc_hash": "f789db7d0c0381a71f289ed4c55befd2193dfedbb88ff0f673b9dc9bcb9d15ec", "ref_doc_id": "3fe6ce10-fe5e-4d94-b32d-9477a82f8e03"}, "7b2d9524-2acb-4242-9aac-9b00d4a2d0dc": {"doc_hash": "a9953e83668a752bbc84051bf91fda74d886205ca9308b5169567105339aec1d", "ref_doc_id": "776af277-817b-4ec3-bb54-b0c50d9f341b"}, "b2e02f5f-3c27-4622-9557-da7fce123ba3": {"doc_hash": "1146be0ccda66e9ed4db72ceee5748afdb68805f08ffa19175e8ac1d860266f0", "ref_doc_id": "776af277-817b-4ec3-bb54-b0c50d9f341b"}, "ee3eee87-e200-4f9f-acef-dabd0f46f229": {"doc_hash": "62ce38e993bc37de5afaf86ed6d8199abdc41f658ff796d5957f76ae6cd1a63d", "ref_doc_id": "776af277-817b-4ec3-bb54-b0c50d9f341b"}, "c690610c-1ee5-4698-b33b-9c4350ca8fea": {"doc_hash": "09d7226231592a8677828bc90e316036de78910d7336c3d1185d0b3c2b1003c9", "ref_doc_id": "776af277-817b-4ec3-bb54-b0c50d9f341b"}, "6b27d47a-f281-473e-aa0d-985399cea5a4": {"doc_hash": "2eb74857a486cfb68eefe184d16437d62af60c39f99af0908bc0174c18ad30de", "ref_doc_id": "776af277-817b-4ec3-bb54-b0c50d9f341b"}, "3860c263-0a3c-40ec-b3ac-b729b9ff225d": {"doc_hash": "0110b1c8ec15fdd7e316f786c710528299c4eeead72cf49babf8d164dc91adba", "ref_doc_id": "776af277-817b-4ec3-bb54-b0c50d9f341b"}, "8f8c379f-ce6f-4ca3-b573-53ec91a81e7c": {"doc_hash": "9d89658cc50460687faa1d3d491f763ce773cb9db9c3d2599b6b78900dbafb7b", "ref_doc_id": "776af277-817b-4ec3-bb54-b0c50d9f341b"}, "eb48c738-22d3-4f73-bff9-fce3276da250": {"doc_hash": "a59eaee6fe223903526fbf1e339c197941cd842aa69d6b679956e599334dd7e5", "ref_doc_id": "776af277-817b-4ec3-bb54-b0c50d9f341b"}, "988003d2-f3c5-4460-ad37-be1a4e671626": {"doc_hash": "f302b62d7c23724acb4052d0b955b46f1f4607e32073d540a9d037bd3d9505c0", "ref_doc_id": "776af277-817b-4ec3-bb54-b0c50d9f341b"}, "92932204-b327-4b44-bbc5-036aa0941f42": {"doc_hash": "097b38711973858591307c0ac3a5088fac3847b45d0424b44a6bcf7b9793f0ee", "ref_doc_id": "776af277-817b-4ec3-bb54-b0c50d9f341b"}, "89ae58e9-125e-45f2-bc4d-6e7f317cac5a": {"doc_hash": "774408fc81cecbac47f23fc105f4118146893c760dc205f03d156a3b8a0065e7", "ref_doc_id": "776af277-817b-4ec3-bb54-b0c50d9f341b"}, "61098b3f-06ed-400e-8ffd-44b0c7c4fb38": {"doc_hash": "c5ac16944bb01ec95f64fc6ca976c9b598ad6caa3226d080e5c0a838c3635884", "ref_doc_id": "91d90699-bd7b-4281-a21c-c28f6658f0be"}, "71a956af-3359-4bf2-b858-f45b2cb40d99": {"doc_hash": "76d122413c41139b69a833d0ff8d6b740ab62cad4322cbf3e43bd5f99bb321ac", "ref_doc_id": "91d90699-bd7b-4281-a21c-c28f6658f0be"}, "8a0bfb30-2cab-4586-b944-0c2bcba769d0": {"doc_hash": "b53491953f6267fb21bc415195ec77b001f712588bb3428f4dc90ab28faea657", "ref_doc_id": "91d90699-bd7b-4281-a21c-c28f6658f0be"}, "fb55a3f6-523b-4acb-9a1f-77c83685f062": {"doc_hash": "ef0561a363cef322a8c91aab18b60a56f7c0557a332416c2725bc958ca7a6809", "ref_doc_id": "91d90699-bd7b-4281-a21c-c28f6658f0be"}, "f99d7e92-9a38-40a4-b071-9ae8c81277b2": {"doc_hash": "27795cad4ebf3304eb858aa67c5f6468602becfad48c73e9196a1082ea336684", "ref_doc_id": "91d90699-bd7b-4281-a21c-c28f6658f0be"}, "77c5c322-efc7-44d9-a687-f457ab4149d3": {"doc_hash": "7a0313f6e16b6a8bb7c96ce6025c758cc5b890336f046920d510507f9d20b85d", "ref_doc_id": "91d90699-bd7b-4281-a21c-c28f6658f0be"}, "25e88350-3498-47a5-acf0-6ca59964a255": {"doc_hash": "bd1c66620bc99e7c354412b6ed9486cec849854512f1ce540e986d91a5d74bc4", "ref_doc_id": "91d90699-bd7b-4281-a21c-c28f6658f0be"}, "44f815de-eb18-443c-99ee-a6718d1c7135": {"doc_hash": "47061143a6cb5409f9ac8f95d369c093ce43806b5599246f2040f4f5135535fc", "ref_doc_id": "91d90699-bd7b-4281-a21c-c28f6658f0be"}, "ed9831fe-8ef3-4b56-a238-6e59a8e8270f": {"doc_hash": "bbe3741cb1d7e3037d7db4aa784cc46b37eccfa12660b64f80841f1e88f27cc7", "ref_doc_id": "91d90699-bd7b-4281-a21c-c28f6658f0be"}, "29bd0de8-a244-44b3-8dcf-eb82f425f522": {"doc_hash": "006a7f5784afaa179a9b14bac37d8f3a9b75a78813c44842fe59b92a9b78932a", "ref_doc_id": "91d90699-bd7b-4281-a21c-c28f6658f0be"}, "c733ec25-46d9-4bd9-9e3a-eae5e86205e0": {"doc_hash": "fa49e5d02891b64d199fc46c07b6e43bfa6ea8167d57731845a22a736cba30fd", "ref_doc_id": "91d90699-bd7b-4281-a21c-c28f6658f0be"}, "c979cb4d-50a7-4a61-a741-5057e7ec2ff1": {"doc_hash": "2d4700c85d276b26370eb9e08aa06ce32b3b3f72f2126bc3212dddeada329dd6", "ref_doc_id": "91d90699-bd7b-4281-a21c-c28f6658f0be"}, "3f58158c-b83e-4781-98e4-9306d205f347": {"doc_hash": "d4d5cd00357819c67ab29673e413505af65a6bbb664ab2d7cb15caa571865249", "ref_doc_id": "3cb67424-de13-43db-b082-558d37f75ec2"}, "24134567-87a3-4524-95e3-eefdb4c51361": {"doc_hash": "9e8420bc423f8ad70744386b3caf60f31b651c7073a3428509d75ad55b78400c", "ref_doc_id": "3cb67424-de13-43db-b082-558d37f75ec2"}, "6639e552-b50e-4c85-a10d-bc71ee227887": {"doc_hash": "964d343288807aa909f04aa6c1599499c4a666651c6ebe8273b06d3adf4a815c", "ref_doc_id": "3cb67424-de13-43db-b082-558d37f75ec2"}, "b4368969-aa9c-4567-bee5-51b78b66ade4": {"doc_hash": "498c3137f75d6c776172dd497b843b3442609b508d66384dafe0de13af4dc84d", "ref_doc_id": "3cb67424-de13-43db-b082-558d37f75ec2"}, "93e55058-6cbb-48a0-bc95-3ae8d6411b67": {"doc_hash": "4bee5dfc0e8ce20c8235527b1dcb39617cbe2b72b3d6702641b590803ee45793", "ref_doc_id": "3cb67424-de13-43db-b082-558d37f75ec2"}, "f1cbd26c-add5-4709-93c4-a5f1167202de": {"doc_hash": "69a2c1effe1358024a094e815a7db07a1fc80c86b926b3bf628a543143ae24a4", "ref_doc_id": "3cb67424-de13-43db-b082-558d37f75ec2"}, "56a56827-ded7-445a-ad49-0ede13e4209e": {"doc_hash": "db87044ccbbdb9ede276c309d4c69aca1567a56494c44ad49b5f7f8490be80cc", "ref_doc_id": "3cb67424-de13-43db-b082-558d37f75ec2"}, "a49809cc-0f98-4b68-95f7-2d7c2886a8a4": {"doc_hash": "b1371e15d2487a793885609ff91c718a8bd5bedbcf467b81315e1832693c25fc", "ref_doc_id": "3cb67424-de13-43db-b082-558d37f75ec2"}, "871ac8d4-d387-4e60-9bb8-fc11f683bac8": {"doc_hash": "16b60f48121f0faf9cc3c6ed44e7252a6eeb0b006ec8c9defcf6999f6c4226c3", "ref_doc_id": "3cb67424-de13-43db-b082-558d37f75ec2"}, "cbd7a769-5861-4493-9822-32d73cad7800": {"doc_hash": "926a47f19b3b74116addf6a231d64fa6dcbef9e6517456418bd86ac51aee7cc7", "ref_doc_id": "b55f1c03-037f-4ed6-b32c-0f51cdce7cf3"}, "6bb30662-ef72-4c81-b429-799a163664a7": {"doc_hash": "b1bd42458b87a9b05d5a22194f9debbc014821cef39ba52e4d46c0315c52f116", "ref_doc_id": "b55f1c03-037f-4ed6-b32c-0f51cdce7cf3"}, "e84e8799-b0d1-4cc5-a861-8a6b20ab8740": {"doc_hash": "b1d3d41327f1dd75801035dcb293dbda2c06f89add3975319e33b01353167976", "ref_doc_id": "b55f1c03-037f-4ed6-b32c-0f51cdce7cf3"}, "3dde167d-9554-4b30-8b54-058aa0d9027d": {"doc_hash": "1e98fa26a67aab2e1432d5960a2bc092f9bfb3371781b2468d0679856ca2443c", "ref_doc_id": "b55f1c03-037f-4ed6-b32c-0f51cdce7cf3"}, "42814d00-34b6-4e4e-bd11-63125562b94b": {"doc_hash": "4a072342558b86b09714d3894517dc278239d8d344b8591d2da59bcdd4e2da6d", "ref_doc_id": "b55f1c03-037f-4ed6-b32c-0f51cdce7cf3"}, "88da3a2e-7618-48ad-aab8-91d4cc40a479": {"doc_hash": "1f65cce9924bd961b096987766d02560208f7f7ba94d4b69d1cffef84c410f5c", "ref_doc_id": "b55f1c03-037f-4ed6-b32c-0f51cdce7cf3"}, "6cb7ff4d-bab8-40a9-9572-7e642c0ef388": {"doc_hash": "56e7bcb4a16474ccba0971264e541258da38fcccb7d7ed09275c19db0a8b8b4e", "ref_doc_id": "b55f1c03-037f-4ed6-b32c-0f51cdce7cf3"}, "cc326d9d-2b3b-4a73-a271-d0ee1dfaad24": {"doc_hash": "e6e3e53f30fcb7f9d40f679b4f5281b18c339a965539857f32623aee59ace1d5", "ref_doc_id": "b55f1c03-037f-4ed6-b32c-0f51cdce7cf3"}, "c2e34d1c-1fd5-4f8c-97de-41a8b5bf194f": {"doc_hash": "71843370ccfc1b1bebd1319c40f0d6b97fb7469526757bf5669ddacda38c04d5", "ref_doc_id": "b55f1c03-037f-4ed6-b32c-0f51cdce7cf3"}, "aad782db-0ade-4ede-a289-5bfc6b0f1934": {"doc_hash": "17e605818d6f77e4c8f9123f7aa59e4c986635c3366f43d72a1c5b1b7d7f5821", "ref_doc_id": "b55f1c03-037f-4ed6-b32c-0f51cdce7cf3"}, "913b95ef-6264-4484-9c7a-6694d1b28d64": {"doc_hash": "134ae2832ea79814bd054d9606b91af9e4898044b262208734b5947847516ca3", "ref_doc_id": "43360e11-0ef7-4bb3-9af2-c2b08bba0418"}, "9014ceb6-b9c1-43cd-baa1-a3c1f1efac57": {"doc_hash": "d8aa208117ed1fbd4e4f551b5fc0f7de6a65336fdf262f7b8389242cce73442a", "ref_doc_id": "43360e11-0ef7-4bb3-9af2-c2b08bba0418"}, "f92afadd-0c9d-4c73-adf7-772a5509765a": {"doc_hash": "da38b9d73e771674c7984863da72e089b341c8a2fad3f5f2748162efb2e4ece7", "ref_doc_id": "43360e11-0ef7-4bb3-9af2-c2b08bba0418"}, "c4fab729-fcf4-4396-aec2-6d6b160b9f98": {"doc_hash": "f265e6009a134af07751a149b02b215958702bb506108fa269b38fa0abccc026", "ref_doc_id": "43360e11-0ef7-4bb3-9af2-c2b08bba0418"}, "8c2952e7-4338-4482-848b-34a7447ae710": {"doc_hash": "622a3117fdc1c41d4655748b6dd50c156ec39854cf6364b8f3fbcd86986835ab", "ref_doc_id": "43360e11-0ef7-4bb3-9af2-c2b08bba0418"}, "a1992716-3dd4-4e33-a914-63226daba0cf": {"doc_hash": "61806bbe68ea9fde9a3530beb94887060a637114d31321c6c2c673ca3417b71b", "ref_doc_id": "43360e11-0ef7-4bb3-9af2-c2b08bba0418"}, "57c4a5ba-6292-4b07-b53e-6b96514d6c8c": {"doc_hash": "9881c7c3e42a08e58a0e57adc95eb5695fb64b491a1cc00b7c93d5b43353f13e", "ref_doc_id": "43360e11-0ef7-4bb3-9af2-c2b08bba0418"}, "36b72c4d-ba05-4809-9e39-2094da70e421": {"doc_hash": "3bce7111ec805b25f2409004d00b0d266cc31d280132c2635effc2f791f57827", "ref_doc_id": "43360e11-0ef7-4bb3-9af2-c2b08bba0418"}, "9e1f4c5f-5310-46ee-9b14-8bf762677c07": {"doc_hash": "122a8191327ae56fbbdb70d15692ecab5f696166953e197921b7ae56cade8100", "ref_doc_id": "43360e11-0ef7-4bb3-9af2-c2b08bba0418"}, "c788baed-0daa-40ab-ae74-05e24461a9ed": {"doc_hash": "6a3762ddc82a682fb115b020877e4859f6272d706368339ef7c4b8c684ed0a68", "ref_doc_id": "f206d3e4-a985-4e1c-9a04-4bbaf8aaebb1"}, "0a14d0ee-c0c0-4852-9334-8dba8e682646": {"doc_hash": "80ad174c414b33ea00563031e66e69e369423fa168059842c6b37026bc418dd9", "ref_doc_id": "f206d3e4-a985-4e1c-9a04-4bbaf8aaebb1"}, "922d9bcb-193f-421e-b7de-efc61a836cac": {"doc_hash": "ee516a46c318eb02381dbeb6281721cee07160119b6c267800324994c7c314a0", "ref_doc_id": "f206d3e4-a985-4e1c-9a04-4bbaf8aaebb1"}, "316f9175-08d1-4ea2-b4ce-6cf248416e66": {"doc_hash": "e7d02ea02c7360a2c3f7c4db194a28fb1c1770c998076c55b4b0222c697a3e61", "ref_doc_id": "f206d3e4-a985-4e1c-9a04-4bbaf8aaebb1"}, "0bad7abd-a093-4392-b598-233440078953": {"doc_hash": "88e5d475af2afa0a1ceedb224d2cd42137074efb55e91f6c24e6096743e6db48", "ref_doc_id": "f206d3e4-a985-4e1c-9a04-4bbaf8aaebb1"}, "d7a752f3-33ad-4608-8d18-7ed803874077": {"doc_hash": "cac0129c6666d4a6f2d47ba191ab5ba3b75b755be5a84181cb23caf780943eec", "ref_doc_id": "f206d3e4-a985-4e1c-9a04-4bbaf8aaebb1"}, "a9d5ffa4-6af6-47c4-a647-aa044d79366d": {"doc_hash": "dd636cc1ee7b04a22f1689927ad1adc674980cd840f9aec4c4cd684daa8fd2c3", "ref_doc_id": "f206d3e4-a985-4e1c-9a04-4bbaf8aaebb1"}, "473821da-71e0-4e9f-9eee-c4837d779214": {"doc_hash": "eecdf12ead114b44f88079876d752e1c72a940cdb35073c1e323bdc852120a1d", "ref_doc_id": "f206d3e4-a985-4e1c-9a04-4bbaf8aaebb1"}, "3eab3dcb-5b2f-496b-a4ff-9d555144bbc7": {"doc_hash": "a044c2768b96f60be80bfbf851e32120d5bbdd4c040e452fde69e1d0ef69e80a", "ref_doc_id": "f206d3e4-a985-4e1c-9a04-4bbaf8aaebb1"}, "b892c5c1-2378-4d71-a656-527e241159a2": {"doc_hash": "558fe7224df7db68cb5d035e8abd6f1b6f6325c0088e3366df71eb14cbe55355", "ref_doc_id": "f206d3e4-a985-4e1c-9a04-4bbaf8aaebb1"}, "e872649b-5634-476c-b818-ca6605cd04e2": {"doc_hash": "cdf2381ec4bb8629d2ca86a97c51ec674afbcd40396c045ea6abbd6414843203", "ref_doc_id": "0f6fea48-a7c1-4810-bfee-5e9fbc802a26"}, "25713efc-5b14-42a7-8fe6-3d601d8c846e": {"doc_hash": "66ad1cbdae985df17a335e483cfe4ae7cadfbd36b89c27a96cd9bfdd2e6475c4", "ref_doc_id": "0f6fea48-a7c1-4810-bfee-5e9fbc802a26"}, "82c99bf1-5d29-4938-9296-e0e878bbba5b": {"doc_hash": "efdb60e5184324970f80fd1ccd58bfe34e1658168481b06780796b01ee3af07e", "ref_doc_id": "0f6fea48-a7c1-4810-bfee-5e9fbc802a26"}, "2897a40d-2757-466c-8f68-5a8d642603ed": {"doc_hash": "eeee0bddaabdfbc91146af2f1568e7274fed3a637e67d6241322bfcda5d1b218", "ref_doc_id": "0f6fea48-a7c1-4810-bfee-5e9fbc802a26"}, "90ee906f-3628-4f75-9c42-05eb784da364": {"doc_hash": "0961205e10b01ed6c898dcd999f421792acae9e9a11278f877f00ab8b9559a1d", "ref_doc_id": "0f6fea48-a7c1-4810-bfee-5e9fbc802a26"}, "2475a12d-06b7-4150-bdeb-810ca20ec9ee": {"doc_hash": "5e0cc9aa412a695811e1041f374d6b5cf981229c15b0735680bf6bb43f4400d0", "ref_doc_id": "0f6fea48-a7c1-4810-bfee-5e9fbc802a26"}, "e09e745f-8297-43d0-9d76-ba995c39f1e9": {"doc_hash": "f187028fe3daf4de13227c1b7a873fc2f969ff9a3be5976c58690cf2c8747e43", "ref_doc_id": "0f6fea48-a7c1-4810-bfee-5e9fbc802a26"}, "2789efde-d324-4660-8758-4615a35dd864": {"doc_hash": "dca256ac31fdbba15f5fc05f0626a16479f8e400c1e05412b2b7f1f15695cd76", "ref_doc_id": "0f6fea48-a7c1-4810-bfee-5e9fbc802a26"}, "e48181b5-2b1a-41e4-a612-78d1ccccc38e": {"doc_hash": "74048eda51c6fda2c21a3f0eefb5b5a14c61d7439e09fae1f444aaf77b5bd9fd", "ref_doc_id": "0f6fea48-a7c1-4810-bfee-5e9fbc802a26"}, "da92bdab-2f8c-4e85-ab11-29988a60d370": {"doc_hash": "f44b78c0a83adcd537a99116ca0b676bd88ca33f631dc6760b1591dd78fd813f", "ref_doc_id": "0f6fea48-a7c1-4810-bfee-5e9fbc802a26"}, "65bebd47-205f-467e-9609-83982046f48b": {"doc_hash": "ae9c95c5e6b88222cb05b55ae6f5cb588c7ed53ea6deb20424e451655573018f", "ref_doc_id": "b803411d-7757-4a56-8ae1-333719409f76"}, "b9526225-f598-4ae9-8d09-aedf27fc8bab": {"doc_hash": "4fca108057d63c63719c9751082038da612de58f1eb491abf2f249fd12fabdae", "ref_doc_id": "b803411d-7757-4a56-8ae1-333719409f76"}, "75679fe9-0c65-4075-87cf-aa27715f428b": {"doc_hash": "615795e3f52d851f443121c9dabbc9bd0abf73a1342418e73153bff4f8220f8e", "ref_doc_id": "b803411d-7757-4a56-8ae1-333719409f76"}, "5b140aca-ed69-4412-9c38-73972ce1cac1": {"doc_hash": "d12f1089c1876c48473bc2cc9bdc43e9c2f1ce0d1a9b5a6f5ebc9a259fd7d089", "ref_doc_id": "b803411d-7757-4a56-8ae1-333719409f76"}, "eaa128fb-ce58-4457-bc51-e08ad83b3a2e": {"doc_hash": "cf43bc23681554722e37f73ccc1ada8c789d0ebf382b58dbfb865e384900c115", "ref_doc_id": "b803411d-7757-4a56-8ae1-333719409f76"}, "a826c9d3-e2d3-4999-97e4-bcf7d917f83e": {"doc_hash": "ceb904c276a84e920ede6b0acc68f3115667c232a2d5e5d5614719fbedc32bbc", "ref_doc_id": "b803411d-7757-4a56-8ae1-333719409f76"}, "f35a1739-ea3c-41a2-a6b3-5ca2e83b75da": {"doc_hash": "a8c18d68ffdf36054058688159b6f5b7ed83870500458eb3f7908552c0954f63", "ref_doc_id": "b803411d-7757-4a56-8ae1-333719409f76"}, "c946f4c1-c54e-44f5-8ed0-2126adea8b8f": {"doc_hash": "2b168035053420397acdaf0919e5254e52c65a1955aeab5e78cd80f1c10f4aa0", "ref_doc_id": "b803411d-7757-4a56-8ae1-333719409f76"}, "db57f8ba-7fcf-494a-a91e-249e711f3bb4": {"doc_hash": "5250727a0b11dd8f6492d43ae26ee3ae37e6301a4f51c98e15abfa6d973d17a8", "ref_doc_id": "b803411d-7757-4a56-8ae1-333719409f76"}, "af5b9ed0-fcc2-4eb8-868b-4d5c0c46ccd5": {"doc_hash": "8953683d7a31ebda538e8bc20a02231d60a83a5cc4dc10ebd7c14f7a3a5b3cb8", "ref_doc_id": "b803411d-7757-4a56-8ae1-333719409f76"}, "839e2d38-bded-4834-8d4a-fb14672698b8": {"doc_hash": "035deda1ddac2276d40a6758da4efb29b06313566d453c16917cce1d22236dae", "ref_doc_id": "86caa692-41f3-414c-9fbc-154c8c6d5001"}, "1ab00943-3cc9-4e74-8e64-6a9935c1fcf4": {"doc_hash": "a5c81d9aa5c94b104551020ea1196949d4ce07ab8a6c3f2d696b51eeb4407f31", "ref_doc_id": "86caa692-41f3-414c-9fbc-154c8c6d5001"}, "bc4db64f-9476-4318-9ef3-8fc70164b3a6": {"doc_hash": "6f1c382da8b5e9000d7e660e802f6f40782cf57523cacc933ba89dc6d5f43933", "ref_doc_id": "86caa692-41f3-414c-9fbc-154c8c6d5001"}, "8f68b0e7-876d-43b1-ac19-0ce8b550111e": {"doc_hash": "e3c88f503c3e5bac6e6ef112dd7c417e19d9317b9127ba6180d8293fbba53420", "ref_doc_id": "86caa692-41f3-414c-9fbc-154c8c6d5001"}, "0abc12cc-d8ce-4e7c-9909-62d77afb41bc": {"doc_hash": "16c1f46a663ed12101796571dcae07b3a7982b35bde04e46269cb8413c07af59", "ref_doc_id": "86caa692-41f3-414c-9fbc-154c8c6d5001"}, "fb264bb1-c94e-45dc-9934-17d46f0d0c46": {"doc_hash": "a4b4eb5a8a689d2ba74545ae11a67ba866965af1194f4c7741cc121a630b19dd", "ref_doc_id": "86caa692-41f3-414c-9fbc-154c8c6d5001"}, "2334ca60-2c04-4be1-a1fb-7fa7b414b2db": {"doc_hash": "1f11d9db5775714d7208378d855ef71fd0b38d76221d645d53a558c3c0410a14", "ref_doc_id": "86caa692-41f3-414c-9fbc-154c8c6d5001"}, "997e480c-27da-4c4f-bab5-2ea0b973f755": {"doc_hash": "d07cf5459a3c39bf77feb10a5bb1c8339f4204ee28ada0534dee9b8e085fe84d", "ref_doc_id": "86caa692-41f3-414c-9fbc-154c8c6d5001"}, "8d8c6e06-5c13-4f38-880f-83322485fdfb": {"doc_hash": "75ec1bcabf2feaf01962115a53024fc5d67825b231c38512c5921c9ef6251bc3", "ref_doc_id": "86caa692-41f3-414c-9fbc-154c8c6d5001"}, "46268da2-1da7-41d9-83ee-1692439ea447": {"doc_hash": "13f79057c5a182716bac63318907caeb084e9bd558c7b906e313dea59ca4628f", "ref_doc_id": "bda01840-44a8-4a6f-9d92-3b10e2b59e06"}, "fca19427-fae5-46de-8fe8-2f0e64ed383d": {"doc_hash": "7678a1eb40d8e6ffddf421826297834d93b62b87f5ee8e5a96c44f0b50f8e0a8", "ref_doc_id": "bda01840-44a8-4a6f-9d92-3b10e2b59e06"}, "be9feac5-b2b3-4c98-b034-92309d23b1ce": {"doc_hash": "4612567c8312ce7c77d2bf931f309e957ba04bf98ae0f479504bcb2a1f6dc46a", "ref_doc_id": "bda01840-44a8-4a6f-9d92-3b10e2b59e06"}, "a6dd2b8f-e169-4a5f-829a-355ffcaaee94": {"doc_hash": "de5ce472f8789f3a3fbf76e551a557580b3546f1ced0a4729e558409bae3965f", "ref_doc_id": "bda01840-44a8-4a6f-9d92-3b10e2b59e06"}, "4a8fb50e-7b86-42db-b813-190b599fa853": {"doc_hash": "1bdfee2e68acd27e73d9efc8f653c9d93774e300e8e2b24d27b96429afd891ae", "ref_doc_id": "bda01840-44a8-4a6f-9d92-3b10e2b59e06"}, "16bb59f2-fa6d-4444-9803-60907e0a798d": {"doc_hash": "0a990786d1334aef0745270a5fc71c4957446dac4d0a5214a3fdc27ec55157bc", "ref_doc_id": "bda01840-44a8-4a6f-9d92-3b10e2b59e06"}, "a51de891-dd53-45b9-8151-52a4beb4b7ba": {"doc_hash": "673580984691d1ed1ea20ecffa4728f18429a9198d8d1837ae1a992d53c13911", "ref_doc_id": "bda01840-44a8-4a6f-9d92-3b10e2b59e06"}, "8bf371a7-a762-48d8-a7a2-93bc7e8998e4": {"doc_hash": "5176f55dbfbf3fdb6b4cecfc85b0354fd20fa02d80a798fb8891ced039058e67", "ref_doc_id": "bda01840-44a8-4a6f-9d92-3b10e2b59e06"}, "d0eefee8-7c90-4bd0-ba4f-91a588d1a4e1": {"doc_hash": "5ab4c82e78c8bdd0536ec39eb2136da5041a3f55eb2d77407c89dc6b7e51ff82", "ref_doc_id": "bda01840-44a8-4a6f-9d92-3b10e2b59e06"}, "f83eb034-6e57-42cf-b25b-0d6ebfa5d161": {"doc_hash": "ff6ce744da9d1cb95aa2617161321fdef793843a1ffef4a1f1e2acead891a51f", "ref_doc_id": "bda01840-44a8-4a6f-9d92-3b10e2b59e06"}, "17fb75e0-2dee-4de1-994b-eb9bf36af7a0": {"doc_hash": "b7efa34076f185fe90b3e6c10a04fcb91145c105f9e2968fce4bc03a33bfd99a", "ref_doc_id": "bda01840-44a8-4a6f-9d92-3b10e2b59e06"}, "8133afb5-82b2-4e3c-b6c8-19846d06ff42": {"doc_hash": "b2ebcd97dda379a4cebb085cb60a718257a85778e8d47be17355d53fbbe1d79c", "ref_doc_id": "bda01840-44a8-4a6f-9d92-3b10e2b59e06"}, "7293f0f6-006f-456f-a2fe-13bbaf27c2c6": {"doc_hash": "277f58740711d21fa1c12ea79b257cdbf3a4e82d11402f76a35dd0d8e92946cb", "ref_doc_id": "8d48d411-660e-4844-a192-428ac1781c55"}, "e635cb31-d972-4124-8895-eef0a38f1a01": {"doc_hash": "9d0d57a5a202b37d67bcc7eb854f30dcf555925a280d383acf045e4d7a9f2325", "ref_doc_id": "8d48d411-660e-4844-a192-428ac1781c55"}, "cc2b2b37-c369-4f91-a4b3-082f3b435d25": {"doc_hash": "a9b4ade20039a3ae5fa987a379ee08d46795634cace5e9a00c60f159977815e2", "ref_doc_id": "8d48d411-660e-4844-a192-428ac1781c55"}, "62ae12e5-b03e-4ac2-8a6f-9ab16d4c3fba": {"doc_hash": "75199e262e478c33a37fb9e6154ef9e433a4f60132befe7944e374312e11bb0c", "ref_doc_id": "8d48d411-660e-4844-a192-428ac1781c55"}, "0d2f3e57-844b-4219-a1d0-ace80908d2b2": {"doc_hash": "8815510daf75fd785adcd2d9f955bc78ebf472a822d3d6710ccb8cf47fcfe7ac", "ref_doc_id": "8d48d411-660e-4844-a192-428ac1781c55"}, "61c31698-c2ff-41fa-a007-a94466bbd5bb": {"doc_hash": "dac719c8c1968910b177e6285b46104f670048ff0c0bdfee53735e36fd905fce", "ref_doc_id": "8d48d411-660e-4844-a192-428ac1781c55"}, "07260682-3a82-4e2c-b8a5-44d3abf6b89b": {"doc_hash": "1ed5dc12092afdaf185789fd7a5bbb184cf234c35d9418f59d04b9049b9ff4e0", "ref_doc_id": "8d48d411-660e-4844-a192-428ac1781c55"}, "675ef5c2-b707-4828-9c71-d5fc0e5eaac9": {"doc_hash": "a856e10c2912b9765ee6bfa1c72371276adc61406c3efe4c3c04f066e36faf24", "ref_doc_id": "8d48d411-660e-4844-a192-428ac1781c55"}, "5231930f-c1bf-4238-80bc-e918e52ffb7b": {"doc_hash": "d0e3a895ddd23a21068bd715ddbb991a0232c74ed418146746be427ae2ce174b", "ref_doc_id": "8d48d411-660e-4844-a192-428ac1781c55"}, "e4b022a5-fa77-42c3-a35b-74630777daea": {"doc_hash": "ceb4eaafe375d66ba3cccbfa9c273480cdd4e85209922b464b4f57f9240fbc85", "ref_doc_id": "8d48d411-660e-4844-a192-428ac1781c55"}, "24e149cf-2cb5-49c5-9032-8a64b287efdd": {"doc_hash": "ee44dbcf29d90776c4e532c0e5113e98405a6176dc5c7f9ae8f7dc6b3f137527", "ref_doc_id": "8d48d411-660e-4844-a192-428ac1781c55"}, "2e92ccb7-3c96-4930-98d8-7b3ec07308d7": {"doc_hash": "6ff2a396c8c8c7c1eac4bda097790dbdc30a91e27dee899d776965ea395da841", "ref_doc_id": "8d48d411-660e-4844-a192-428ac1781c55"}, "907b1ef8-2ee4-4e6c-899b-158f63a19e2e": {"doc_hash": "acc69a4903d72a32811fb1e263b4bd8aab4898e0b333b257b3fb3bf380c892df", "ref_doc_id": "8d48d411-660e-4844-a192-428ac1781c55"}, "e03567a3-26ba-4130-bf32-01f16c46528f": {"doc_hash": "ca0006cc8d086628350b0a51ba130626011ca851aaae142755a65dbfb4d02e83", "ref_doc_id": "8d48d411-660e-4844-a192-428ac1781c55"}, "bdfa4baa-65ea-4e8f-bc84-7e4faac40cf5": {"doc_hash": "08c3e04a5e40a57c35b4f46c0300c4c3b2f410373d65bac814bc3d8d7921c75a", "ref_doc_id": "8d48d411-660e-4844-a192-428ac1781c55"}, "006ba99f-645b-44be-8fd1-db2e4117b617": {"doc_hash": "5430aa535058e9739f12eec716418766fa2d1ab6287dca799d4f7ba84414ab51", "ref_doc_id": "8d48d411-660e-4844-a192-428ac1781c55"}, "63135c5b-aece-4b14-b625-49f80fedd5e2": {"doc_hash": "e0932c543856ed97b651a65f9df154f3341a06be53726e8d4ba64b6229af45e1", "ref_doc_id": "8d48d411-660e-4844-a192-428ac1781c55"}, "961ff273-9706-4913-af13-309cfacedb2d": {"doc_hash": "cbdf72611da604b17d2efc64c477420e2abb094fbbfb2addb6305d318b7214c4", "ref_doc_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233"}, "810ec6fb-4482-443c-875e-7e0158325da9": {"doc_hash": "7d1225a0ccc03f874e2347b23a268fd523e4334536c613a7f854fc11c8eb3051", "ref_doc_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233"}, "b79b9ef2-d8b4-4891-b6c5-60c22598f751": {"doc_hash": "8e5d9e8cc935c30354d71a4c3659014b914b685eb733acce063de2dcec4a0105", "ref_doc_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233"}, "f2ab5e62-852c-4f83-94f0-29661f6c1e7c": {"doc_hash": "a655ec1554e9e293040426a585d25b2b954e3d265aabe0383fd624266886e28d", "ref_doc_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233"}, "fdf7b348-96e9-4915-8fea-4e9db5febf8a": {"doc_hash": "391b10b27c65fce218cd5d8f246544ef2213515eac771d90395e7bdef404b74f", "ref_doc_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233"}, "8a62aa45-38b3-4ae1-b681-23006967f893": {"doc_hash": "0fc1db9203c07782bdd30990fa5113a2a3abe96de07ab0e1dc1d148c284dbe1d", "ref_doc_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233"}, "57b93a0b-bf70-42d9-998d-1a5c2e3ee73b": {"doc_hash": "c751294cdd2ba9d9ee870b431c50bcb2e71181d04ad2180b3ef5211e2ff0cca0", "ref_doc_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233"}, "1c7ad0f7-33e0-4da6-be43-87d32cd4276e": {"doc_hash": "0de0c21578f31df6ec0a7fb872f15cd41d29ea197a45bec38d7bb25dd0d49d56", "ref_doc_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233"}, "9e4f140f-d5f9-45a3-960b-f04569cda6f5": {"doc_hash": "be3b1a3283ac0a0878ef1c37c2ce809e5d4b3e592167cac30f731208a61e9acc", "ref_doc_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233"}, "8a13ed5c-7224-43ed-a7cb-d467fde8cc02": {"doc_hash": "3258b11be73a0a0bbb1add741d187459398bb3ff63881bcc77f6f948381b40f4", "ref_doc_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233"}, "4bc29345-26de-4925-a3c0-6cc56ed81b94": {"doc_hash": "5367c4b83a6508bf1f880fa0cd3a91de5ba0afb292d60ad995727851ce567a0a", "ref_doc_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233"}, "081b2a83-b4a9-4037-b579-e7ea6e25c542": {"doc_hash": "19929d0e034c8112097d40df8196e4962ddb8e3f13b1dd29d1c9cbbcfe369074", "ref_doc_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233"}, "dd6e5011-44bf-49b0-90f4-ec43c4346d4d": {"doc_hash": "80c53e7ef1b4b1b4d30ca1408c46e230417d0bc944559612cd36458c8ac713cc", "ref_doc_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233"}, "5a1f8b23-176a-476b-ae8a-35aa4e226ffa": {"doc_hash": "0567e724b7b1097911b42e2f326025efe1e3dfba419301a31ea4eeb2fae63dff", "ref_doc_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233"}, "26a8b431-d646-4478-b0cd-2d70eec3dbd6": {"doc_hash": "9777715c64f643966de1fc1bdc3568e90c249c8f52b0cf9f087482a55287f613", "ref_doc_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233"}, "5795ee25-5eed-4e9b-8cec-0d751be37457": {"doc_hash": "00286e44e788bf402f440286b8c98cc5dc71ab6f6cee83fd71f6434aa2474b6b", "ref_doc_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233"}, "b9e92c66-2cc3-43dc-917c-5d3653ce395b": {"doc_hash": "1010938e5b5ae65993f37d16cc4644ad1ebac9bc536ccf757ee162c49808d02a", "ref_doc_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233"}, "132b0ee1-e439-4344-b578-3edbf27605d5": {"doc_hash": "6452ab6816f6d07f227af224439a146a316ef911aef43185360c8821fdd6a001", "ref_doc_id": "177848d0-8d8a-4b5b-8f24-ab1dff41d233"}, "38f202d9-ad37-40fe-80c8-d775c10fee49": {"doc_hash": "31d4cd78fe7c8dc2bdbd505f6ed636932f2768ba73e44e33fae6a731bf066cbe", "ref_doc_id": "1203bfd5-ad97-415c-8620-a142c7e42944"}, "e003587a-9f6e-4752-991d-2bb0b84f6705": {"doc_hash": "4cae385cee31065f1ad618f4c1a28103a0e614ca9ba9a749b5e3ed3dfea40d5a", "ref_doc_id": "1203bfd5-ad97-415c-8620-a142c7e42944"}, "391edb10-ea92-4d7d-8f53-d38100392265": {"doc_hash": "317c60bf8a430df8f400389164a649af54dcd0886d677191eec7339680ddaadf", "ref_doc_id": "1203bfd5-ad97-415c-8620-a142c7e42944"}, "fc3f9e25-66fa-4cdc-93be-c1fcf34f6450": {"doc_hash": "fe1961bf26e6936a89029a9e00f27300cb21a98ffcb80ffa4b90641786bebcec", "ref_doc_id": "1203bfd5-ad97-415c-8620-a142c7e42944"}, "524d566d-d76c-485b-a6a6-782c2a5311a2": {"doc_hash": "6469194da030cd6426a7a9e8a6de9f911ecf3088270d21234d12390e92bd3cca", "ref_doc_id": "1203bfd5-ad97-415c-8620-a142c7e42944"}, "5c8deb33-82e5-4117-98fb-b59c3f8aeccf": {"doc_hash": "34d96010959501355533c31d7e2189194e757e24695049d5bcbaffcef8f1ea71", "ref_doc_id": "1203bfd5-ad97-415c-8620-a142c7e42944"}, "69ba23d2-0dc2-4836-a49c-76d1dd4e4cc7": {"doc_hash": "47f2304de9bb730c17acf4f45b318bbbcdb047f478e0aca723b9c566bb09d1cc", "ref_doc_id": "1203bfd5-ad97-415c-8620-a142c7e42944"}, "d88e425a-eedf-448e-a34d-fcc663cab646": {"doc_hash": "fe2f81028b8513689e365e710b2d3cbe495548a9268df930efd9919178030742", "ref_doc_id": "1203bfd5-ad97-415c-8620-a142c7e42944"}, "5e106f78-491c-4f18-8e0a-b143d6d2ca5c": {"doc_hash": "fe013ac671ecf85c74227412bc771049d93df9f24301dece19465998a5f0c547", "ref_doc_id": "1203bfd5-ad97-415c-8620-a142c7e42944"}, "71c950e8-6cff-445b-89dc-a309b7a69cbd": {"doc_hash": "ce010191bfca03523fd01fa2ffdf502a71f32ca0b71933b8dbe1cba641af04b1", "ref_doc_id": "1203bfd5-ad97-415c-8620-a142c7e42944"}, "eb194900-2bc0-48b0-b875-640ffaab0ee5": {"doc_hash": "a2857064f8439e128cf5d9e221092a46cadf58062178e70eb2ba6df3c64b18d9", "ref_doc_id": "1203bfd5-ad97-415c-8620-a142c7e42944"}, "c2bb43c3-06c3-44e7-b105-b1035c9c15f4": {"doc_hash": "cc9f18ef0617d9d28fc84d66a6fcd96170b666d36a994ae15df7714b39b8c4ee", "ref_doc_id": "5c854892-2d3f-4fb8-9537-8c1dc858f5cf"}, "dbcb9245-c4a4-4d2c-852f-89e6d9903875": {"doc_hash": "9fa2a5f813ba35007b0a7c1e576cb95884ac2dfd9ba97549e0131339d7913deb", "ref_doc_id": "5c854892-2d3f-4fb8-9537-8c1dc858f5cf"}, "a58f672b-65de-4694-8619-18fbfda68c0c": {"doc_hash": "663e44031c8420e42d509b217746c50b824888f59144e7950ddeb3eab6c84f67", "ref_doc_id": "5c854892-2d3f-4fb8-9537-8c1dc858f5cf"}, "73a15440-c6b6-4d63-a9c7-ab6a08483d7c": {"doc_hash": "5616782cef8a9747fd64d0d213d488b41e3bff1ed748992d08b943a66be2513c", "ref_doc_id": "5c854892-2d3f-4fb8-9537-8c1dc858f5cf"}, "80af2dc2-32d1-44e8-8f77-d2474808c035": {"doc_hash": "98e736bdf6b96ed0ce64897cb7b13ece298061a598d79328cfb53094b97a03a4", "ref_doc_id": "5c854892-2d3f-4fb8-9537-8c1dc858f5cf"}, "4e7f6b3b-015d-4e7e-b0a5-8d076e2b55ee": {"doc_hash": "aeee3aeef1d6e96e4c07fdb4d22488d666abb90c416fc421a095a646fe48d5ce", "ref_doc_id": "5c854892-2d3f-4fb8-9537-8c1dc858f5cf"}, "853c1a37-60a4-497e-95af-069473f24ec3": {"doc_hash": "5093478241ad658366bd89b9f8036eb37f32f6df49191c4eab8ab2ec495a1ce9", "ref_doc_id": "5c854892-2d3f-4fb8-9537-8c1dc858f5cf"}, "8b52ca8b-f39a-464a-a428-ae8e1ddcb941": {"doc_hash": "8902706c10e25047d16101c0aeeefeb63dd17f0c23a4eaeeeadefd6b238b2333", "ref_doc_id": "5c854892-2d3f-4fb8-9537-8c1dc858f5cf"}, "fbf4d4c0-cf07-4d21-8cbe-4694658971ea": {"doc_hash": "df5f9b3c6622246901691a2c6b07ad1e3b1419f25a10c6000155ef4ff62f1226", "ref_doc_id": "5c854892-2d3f-4fb8-9537-8c1dc858f5cf"}, "d6d90fc0-ba96-4822-b279-0eddc51e45a2": {"doc_hash": "e014e2153b09c7de904d66e4f59387b359132bd9ac70b4e8aef0e96c52eb74e1", "ref_doc_id": "5c854892-2d3f-4fb8-9537-8c1dc858f5cf"}, "687fc24a-7e68-46a4-8213-ff41a9684267": {"doc_hash": "0db72e2079211d04ac1ba3da6a42c8a5940dcad4fffec71ef0966702d99c66e7", "ref_doc_id": "5c854892-2d3f-4fb8-9537-8c1dc858f5cf"}, "10e586bd-10c2-4b5e-b7f8-abc07dbba3dd": {"doc_hash": "ffa8a64e2f84e4e1b1b05c09ba1e0becb6334fbf4ec6871415e30624bb827ad4", "ref_doc_id": "5c854892-2d3f-4fb8-9537-8c1dc858f5cf"}, "ff3a7f64-af73-4b34-86e4-a356dab49917": {"doc_hash": "49a2e7495cd97c67dabaf45b3ee716231d1516505b5328e9c1043ce7380d5f68", "ref_doc_id": "5c854892-2d3f-4fb8-9537-8c1dc858f5cf"}, "9649b482-475b-42d8-886f-7d85e663108e": {"doc_hash": "13d8eccb605f9a575f57ac97d2b81143754c1bcfa6fc5042942f8e26d05f3114", "ref_doc_id": "5c854892-2d3f-4fb8-9537-8c1dc858f5cf"}, "8ac25cc4-5f11-4965-aa21-8e0d8bd0051c": {"doc_hash": "091a6b581335ecdb26bd491932a9ec0b69d77fbec70554fa3ea549e5fb36c329", "ref_doc_id": "5c854892-2d3f-4fb8-9537-8c1dc858f5cf"}, "dd922fc6-f078-414a-a3cf-4600ae9d3a03": {"doc_hash": "4b3c70da160b81ac481b51430ecf6258f258fd8a573d64738d60b15db4046ed1", "ref_doc_id": "338c4ec9-a1cf-40ca-a930-96ab8b67eb44"}, "aee34d0e-165e-4947-8be1-1ac884430560": {"doc_hash": "9aa7ee71fa06aa83969e7dacbe231360f566ebd91295ef5dbd9c6b848d66c5bb", "ref_doc_id": "338c4ec9-a1cf-40ca-a930-96ab8b67eb44"}, "f700e947-0fb3-46be-92df-ed7b9bae9666": {"doc_hash": "3e2ab4df58beaf8db26baae755d7ecaff8e2e72ed8459c68f08c9b5d0cd6993c", "ref_doc_id": "338c4ec9-a1cf-40ca-a930-96ab8b67eb44"}, "4add8834-82a8-4a4a-8128-ab29dff7c8a6": {"doc_hash": "cc3f558bc9633d88196c1523d73e59f744a45118862fc91585ff6d4cddd18422", "ref_doc_id": "338c4ec9-a1cf-40ca-a930-96ab8b67eb44"}, "8890c6d2-58f0-4016-bac9-d7baf0148963": {"doc_hash": "0eea704e2cdb6679021794ceb26ea78ce2a6f2f400474a1c2917cd76ff93455c", "ref_doc_id": "338c4ec9-a1cf-40ca-a930-96ab8b67eb44"}, "8c716b3c-8b13-4905-825c-e1d0b817c7e2": {"doc_hash": "69d69e40eda5725f0a124f85326197e85b38ae66febf30d4bf5b0da91f4dcde5", "ref_doc_id": "338c4ec9-a1cf-40ca-a930-96ab8b67eb44"}, "4fc98ee4-baf9-4208-9de8-7011f2c8e375": {"doc_hash": "e6067a685679eb98cd0e1681c1302830c6a53db6303f5d443e88916a657e5d20", "ref_doc_id": "338c4ec9-a1cf-40ca-a930-96ab8b67eb44"}, "d6a9e078-48d4-47a8-8d36-499224853e17": {"doc_hash": "48d79854c28a88a10c8ecc69fecf8ec64e53ed5c34d3ed11db14c88e1e1e1636", "ref_doc_id": "338c4ec9-a1cf-40ca-a930-96ab8b67eb44"}, "9b4f728d-0881-4d9d-9028-bafa921ba161": {"doc_hash": "5cfb876aad67dbd15ef54d738ebdc8f06943648ed84415e22ed1667667c9871d", "ref_doc_id": "338c4ec9-a1cf-40ca-a930-96ab8b67eb44"}, "8712c1b9-6317-497b-8cd9-6772a29c3c02": {"doc_hash": "4cebc6fdbf4cb6648ea73418d5ba7e969459207b9096e40314f2f55c3860cb25", "ref_doc_id": "338c4ec9-a1cf-40ca-a930-96ab8b67eb44"}, "e06c071b-aa27-4cf8-89d2-a9636a170145": {"doc_hash": "40c64f340bb9423529e626746f8e3a009aa985d3f55da9123b3c10f732944c76", "ref_doc_id": "338c4ec9-a1cf-40ca-a930-96ab8b67eb44"}, "0d4fe1df-5e59-4310-9fa7-add3ca1bf32e": {"doc_hash": "c61d894d6b8d8940245a9da9a700666b4686cca5e50d917478eb50489f2d7e56", "ref_doc_id": "338c4ec9-a1cf-40ca-a930-96ab8b67eb44"}, "13b7bdaa-6e08-4b14-b3ad-391dd3948f8d": {"doc_hash": "48bc0ea8cce79c395bcd57bc975c0b3d046ba3869d1ffaba08e5e078fbcdb581", "ref_doc_id": "338c4ec9-a1cf-40ca-a930-96ab8b67eb44"}, "77c6135b-2441-4074-b94d-2ce4561fa250": {"doc_hash": "d6a76b68f672aa4baa611ca9bcb41764273c4bb45cb81d8f7b79a5a1e99e972a", "ref_doc_id": "338c4ec9-a1cf-40ca-a930-96ab8b67eb44"}, "edc49521-ab8a-483a-b8eb-bab245be0f72": {"doc_hash": "154b5ae8d829c6a6120ac3abebffeb84c5b8d0720fbdc09918d813385cdd4cc6", "ref_doc_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab"}, "39e265d6-6aee-4142-b7a4-653fe8b30b2e": {"doc_hash": "a5653a5960c05cfa6fccc5e0efd8f10e674604fb35ed52ce36aac8b070158d42", "ref_doc_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab"}, "fe2563c3-67e0-4e9d-aa14-210e68a5f958": {"doc_hash": "9f6d6617bd76fa4ebdf8708bb79c03fdd1e62a2dd94da8278b0a54267773019e", "ref_doc_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab"}, "d8fada0e-6df6-4489-a744-f02769fe79ef": {"doc_hash": "543c6d02f0923b0d42e9c016172218c181731da80bcf65da2be4b6ee5013ccae", "ref_doc_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab"}, "61d80c5f-5f1e-4389-961e-fe53d22f98a7": {"doc_hash": "591ab4a8b41eaecee2ac07934eb8fdaebd0ff1564ef4d26e7cb9d38c3656637b", "ref_doc_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab"}, "2d457991-93e9-458c-840f-d343381cf1e0": {"doc_hash": "8c6889a990437e80d25f1b87883e43f7e86c770b1cdc7d136d1fdd4fe2240c92", "ref_doc_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab"}, "384ac847-5d4b-42c9-be89-6085ce5271fd": {"doc_hash": "3258a5ad4555cadc4377b88ff629d5dfde96ce9507504747dfd1ef8232aaf4d7", "ref_doc_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab"}, "a15c7f31-adf2-4197-b949-02f48c6e5b93": {"doc_hash": "425dedf4a6b20ab756fda08d793f32bed29ea91717dbd2e69729796796c130f1", "ref_doc_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab"}, "823b3a00-03fd-4312-b648-dc99143ef1fe": {"doc_hash": "064de4323bafb053d91678051b6dc893faa9013b16255c5a1cd5c4f8bdbb1cd4", "ref_doc_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab"}, "5ba21d56-67b8-48a9-93be-4cabc945c660": {"doc_hash": "9262cfe544f3b18c75719a3460647b9d2ca90a3d2fa26eb5af5f8b6bba0b43eb", "ref_doc_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab"}, "6e8d98a7-c730-4fe1-9c70-0706267eacb7": {"doc_hash": "145cf9ab726af6ad06aed6e15307b49c8c4b0b5e6933228babad3555dc95c7f0", "ref_doc_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab"}, "c524bc8f-c6ab-46e8-bd70-78647ab39e13": {"doc_hash": "5903385520ad6a868afed14b9e1b5923787fd8be3030a4eb4014458c0a2f5eab", "ref_doc_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab"}, "23d26b13-ace6-46cd-a74c-54a129bbc687": {"doc_hash": "b9157f2183bcb7e13e2902fe825f002a029f8e1c9d0a359d65e7f780c92164d6", "ref_doc_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab"}, "58608f97-6a32-4d68-8af9-dd4b2469066b": {"doc_hash": "4eddebc3aa7807cc5f475ba8a0906c04900f3eeee3081c2e0c4a57135165dc4f", "ref_doc_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab"}, "8a2c6d55-36cd-4fed-8efa-752a01a607c7": {"doc_hash": "1c8e058fea06130bfb1680b79458903ef474a3fc01695905798da541bceb0850", "ref_doc_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab"}, "a925d074-75f5-4e2a-b172-b3adb2dbcaec": {"doc_hash": "521b488a6e99f34046514acaf5c8fa01c6f3ba810c7ec2ca1bb80ea8aeb22e67", "ref_doc_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab"}, "e9575c02-153b-45b4-9737-bc7b72370f36": {"doc_hash": "180f69215c39aeb412f15a24ede5a6b205f1a01de7a6b5ba3e01b3634281c588", "ref_doc_id": "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab"}, "e71652ab-6337-416c-b9c9-64235b85c145": {"doc_hash": "f777988b885278ee84def3fb487a05995f8d18eee7ca7e1abce236d7a01e1871", "ref_doc_id": "44979e2c-e074-4f22-a939-50ea3bd188dd"}, "60160942-3fb9-4ca5-9630-5ecb80bf59fb": {"doc_hash": "ab2a31999aaacd1dba1138070d32ab2a75f651fc664bf7f4760c82429cb2bf33", "ref_doc_id": "44979e2c-e074-4f22-a939-50ea3bd188dd"}, "2f1a4a76-f275-470e-be10-9dadb5608bc0": {"doc_hash": "55ac8d89f3ba804d5f7018b0abd3cd46a58da93cbca24eb3cc4c9ab024d682a6", "ref_doc_id": "44979e2c-e074-4f22-a939-50ea3bd188dd"}, "29b018f3-7f81-4b84-994a-e9e557158649": {"doc_hash": "53f345192c888ac453d6dbc15117c013ace67a86ce5f070ac5906178ca314b0a", "ref_doc_id": "44979e2c-e074-4f22-a939-50ea3bd188dd"}, "c24a432e-33fb-44ef-88ba-0d4653268fd5": {"doc_hash": "ffbd1020371bdb172ed9dcb8ccf49c46099aecd5c60a1f8807a7a01a54416434", "ref_doc_id": "44979e2c-e074-4f22-a939-50ea3bd188dd"}, "4cf2eff0-468f-4ed1-aca6-155c844c4241": {"doc_hash": "5fe8d1fdd31535400f00240e5895a0456be77de6eb775dd63a328d7de665c380", "ref_doc_id": "44979e2c-e074-4f22-a939-50ea3bd188dd"}, "70516d1f-0fa6-4d3f-8090-2dcaed2c8378": {"doc_hash": "578c13ba830cb41b4f5957a3f947d68183af4cfeaa88f114521ee37005f04287", "ref_doc_id": "44979e2c-e074-4f22-a939-50ea3bd188dd"}, "103fac21-6791-424c-b681-fa7717557bec": {"doc_hash": "fdf580f6c3909d57e174830a6059a0ee95eceb1094afe78076a01d6846185989", "ref_doc_id": "44979e2c-e074-4f22-a939-50ea3bd188dd"}, "71700b78-f7c9-41ab-a3d5-1f08c96b64d5": {"doc_hash": "eb681626581434374cc00b819e82ea7cb6a42295d910fb28d4e98a5d7c44b8eb", "ref_doc_id": "44979e2c-e074-4f22-a939-50ea3bd188dd"}, "bb1bc6fb-2b94-4e4f-9707-86adcb8c3b6a": {"doc_hash": "def259b44c5567acda7fa28464c51d3a8f50bc252dffe25b682e3eade4a162b3", "ref_doc_id": "44979e2c-e074-4f22-a939-50ea3bd188dd"}, "a40a6b08-e640-4683-9649-2e60308a6a2d": {"doc_hash": "fe2bc3c29846d8d08ac2b9e287873eeefb59d2ca9324fd51281740276bb2fa85", "ref_doc_id": "44979e2c-e074-4f22-a939-50ea3bd188dd"}, "823b47cb-c3a1-4fe6-8fcc-a98c53e5652f": {"doc_hash": "1b4f5d7d82d7483f7eb7ba9ea81a38e7e58b6548039032cd81da6012981fffa6", "ref_doc_id": "44979e2c-e074-4f22-a939-50ea3bd188dd"}, "8d31d1af-9119-4c1d-ab65-b8f76a30c7c8": {"doc_hash": "d632db484fc83ff2de2f1bc2e607f419de79e9521146877cb7ab4bbf540b6cb4", "ref_doc_id": "44979e2c-e074-4f22-a939-50ea3bd188dd"}, "4d9431f7-6601-4bdd-9073-4a1c48f864b2": {"doc_hash": "641f0d872dd954dd628d4085d27752e4f126a93e0e45873b8a5715e7a0de87c9", "ref_doc_id": "8291a5de-e14a-4b76-a285-09a126f85d3f"}, "3bff864b-8300-41f4-a756-b38a88bb3c8d": {"doc_hash": "84fc208d44af06d948ec9e2a41978dfc4b51c796e9ca8baab7b7c2c29a2ebf13", "ref_doc_id": "8291a5de-e14a-4b76-a285-09a126f85d3f"}, "0e085180-a8f1-4823-aa6f-f9f468ba48e9": {"doc_hash": "a08ccb43770bfd30132cc09918e50f8d41730d32abbc180d3a2b38d3ba014145", "ref_doc_id": "8291a5de-e14a-4b76-a285-09a126f85d3f"}, "32dea304-bf5d-47ea-ba70-82a2d04d53a2": {"doc_hash": "84eb24151d6e2c942f1450e550f423d508cf1304283f310fbc71d9658a4a4be0", "ref_doc_id": "8291a5de-e14a-4b76-a285-09a126f85d3f"}, "bcaa7e55-c7b7-4481-907d-dd7f77f70ef7": {"doc_hash": "2312b9c5a2340ac426a85abab749fc7724872a2f5a3166f1ec12b1b790044a31", "ref_doc_id": "8291a5de-e14a-4b76-a285-09a126f85d3f"}, "3cd633bc-cf92-4f6b-bd82-294e04921c05": {"doc_hash": "454d5ce4ecd055e8151b5a8fd2d1790f89887019d344e1d88d4cd1592f3d757c", "ref_doc_id": "8291a5de-e14a-4b76-a285-09a126f85d3f"}, "68510a7b-9816-451e-bfb2-b10bc6b22dc5": {"doc_hash": "58a7ef4d0ad5de4ee09327ef9a891a9e8733d34017014f76534079ad8b6afea1", "ref_doc_id": "8291a5de-e14a-4b76-a285-09a126f85d3f"}, "455244ab-548b-4ddd-ae87-103bd4b7de2d": {"doc_hash": "d3c28047029c776c6a23ebbc5d13c7e5d393ee96d5a99b01b1a6e617c64af9fc", "ref_doc_id": "8291a5de-e14a-4b76-a285-09a126f85d3f"}, "841dc174-3876-465c-9c5f-dc17ca7ad0a0": {"doc_hash": "217a78f414973ba77c45b3364928364ec85a30b5ddab1901dc0847d385f1c1fc", "ref_doc_id": "8291a5de-e14a-4b76-a285-09a126f85d3f"}, "601ffe31-18de-42f2-b0d9-cc1bda8128f5": {"doc_hash": "c1c01eed9a85f0107cc8d7a6266a090f8beff90888e9a675439ee54b91eb4311", "ref_doc_id": "8291a5de-e14a-4b76-a285-09a126f85d3f"}, "04d34d83-93e5-4fec-a6b5-57fe504821f6": {"doc_hash": "1f803965c5f06521f171aa078c151c03104db6f9e7e14e730b703923d5c3dcfb", "ref_doc_id": "8291a5de-e14a-4b76-a285-09a126f85d3f"}, "c0ae42bd-612d-475a-8847-8c4b24e1666e": {"doc_hash": "620f7a728df3ae3259839249e7805d10f1359f80e02809c5aed5754537937381", "ref_doc_id": "8291a5de-e14a-4b76-a285-09a126f85d3f"}, "95b698c0-f15e-4226-a1c8-b3ca805f41d9": {"doc_hash": "b94b7d45e53f1eaee10715d1530dc4fa58b7f2183d826c5b6ae670cda5d41980", "ref_doc_id": "8291a5de-e14a-4b76-a285-09a126f85d3f"}, "4b61404a-bbcb-40c3-a5a8-5483fcdac7f9": {"doc_hash": "de1adc1e091fa9e4fea21eb956b18c04b4e9a23712170ca944f06f2118887c80", "ref_doc_id": "8291a5de-e14a-4b76-a285-09a126f85d3f"}, "0f47e7b3-6f25-40dc-8e34-534e632586f7": {"doc_hash": "181a96a1206ea29f44e2ecaf4dd3a24a3c5d9f3b773b150ce32a58da81f06d22", "ref_doc_id": "8291a5de-e14a-4b76-a285-09a126f85d3f"}, "341707fb-0c18-4a2a-9026-9777d22f5dcd": {"doc_hash": "fa39a203b4ed88b3d2a24d07a855a0af7fc7f85e61b29082d1df46ed36af2d9b", "ref_doc_id": "8291a5de-e14a-4b76-a285-09a126f85d3f"}, "c142b3e8-cffa-445d-ad34-eee6ae233e8f": {"doc_hash": "2b31f759ebe42b4f4dc567835396c4c42781b0c2b7f3036f4b343772a7321568", "ref_doc_id": "8291a5de-e14a-4b76-a285-09a126f85d3f"}, "0280c184-bc0c-4fbb-a4d3-20dea8e44be5": {"doc_hash": "ebd515a9f98fe7c292a2c9065c16f10ef1296e611c410df4b5d34109398eb019", "ref_doc_id": "8291a5de-e14a-4b76-a285-09a126f85d3f"}, "cb3e29e3-0fdb-49fb-9fbe-e4aaad1ce60a": {"doc_hash": "5771a91781afc896749abb4408f081dfa5cd122b47b361e8a1da04fa3a4f5567", "ref_doc_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b"}, "6da41465-5555-4295-9f1d-4fdeb06c66f5": {"doc_hash": "339d2c388e33a1eae320c0cbd1373a6eec49f0daa7279ad36e6a7c3fbfeac287", "ref_doc_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b"}, "a98888b8-d7aa-4ecb-967e-a6c3c5de7bf9": {"doc_hash": "ee1f62c15d835ab0474822802e087982b338705861138c5d88f56d2e1962030c", "ref_doc_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b"}, "e90515a0-b9ea-4271-8a86-73a85e0559d5": {"doc_hash": "01f6e8139a69b71bbb9c6fa94ae6a1773ac12a4c36a0b62012a55e3cb2dc5d45", "ref_doc_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b"}, "18b74887-07dd-4af0-9a46-2b5a7aab2d05": {"doc_hash": "312b144b816b2bda62eb2eefdfdbfd8de54c8e39d70d0f6b70b86f8098fee25b", "ref_doc_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b"}, "06d11cd1-da0d-46f7-a2b0-ecd9829d5e37": {"doc_hash": "8ab94bed788892f724b7c72bbfedacb711a291ec2a151c8b6a875d1e55711246", "ref_doc_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b"}, "67977b1d-b92b-4600-9a8d-c44e71b600fe": {"doc_hash": "25a8d0303908cf95e81b49523b5e3c7532fa05f7c37554544f24481bdb5f38e3", "ref_doc_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b"}, "95edb33f-85c7-4d2b-8a65-165163080947": {"doc_hash": "f073e802f0a814085868e9efa461586443a627b4a5d4e0d003ba205233d8b6f0", "ref_doc_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b"}, "d1abb3c0-9980-4451-a15d-dd9f997f5843": {"doc_hash": "cc5a444e720a0490edab0cbc987f2d2cf689e843d87470a3a60c2cd9e7f42b09", "ref_doc_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b"}, "dbb9c025-1bf6-4323-aade-905b2533c43e": {"doc_hash": "df9a829fdc392d711a27a3d5dbb2abe023a5a40fba07f51efb14b1a41442fca2", "ref_doc_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b"}, "cc8478fd-705f-4e7b-855e-62d2fd7d8de3": {"doc_hash": "88e9522786d6d83b3e858cacf7b923249416b2dbdd57687c05a3b0f4bb8133c1", "ref_doc_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b"}, "14e3f531-5ac1-4619-b67e-fdb531dc9b35": {"doc_hash": "81dd54fbc25969c09b115cf80d50b15cec582f112012e5c94b76a7747b6631eb", "ref_doc_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b"}, "25d3c256-7f64-4c6b-b506-6431c459c111": {"doc_hash": "903dfea4a12554a26146969c3321f55eb8551a746e1f2e5c0fd999e4b1b4984d", "ref_doc_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b"}, "36aeb147-8704-4f75-96e7-c1a0d00020cd": {"doc_hash": "8bba90f9edfea7566ba93c751ea031d687909a498dd54391138dbfb3fc20dd45", "ref_doc_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b"}, "d2c9724a-78ef-4c6b-9f01-8ac4f64e481d": {"doc_hash": "b72f13125bbe5ac8a54ba8e41e71e377e4fe6a5f3a8da60fbe8a527591c42a4e", "ref_doc_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b"}, "f728fa75-c160-46c2-a84b-98f0ee696546": {"doc_hash": "bac6940f225e1dca0edaadb6e734d97ef9a9a752523de04bd99a86bb1f7d1ee1", "ref_doc_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b"}, "bf24ed21-9a1b-4095-b8e6-3cfb494f6863": {"doc_hash": "6b1d4274b9f8ea490c3277a61dcac47b5288e8afb52a8b58a3150c9ede0f0965", "ref_doc_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b"}, "28b68abc-0012-48ca-a567-13c38848ac1c": {"doc_hash": "86c689cc4c068461c91f3e57b3b759d5cec3d31c27e33c0c83247c648aae6a9e", "ref_doc_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b"}, "5d24d938-caaf-4b22-a40f-2608b5e4be55": {"doc_hash": "86e56d874a513defad67d5bc0055f6c6df6920d5162b6ae3a9f75a71271051d5", "ref_doc_id": "42b13386-98f0-436c-8bb1-96cdcbedf48b"}, "4b517694-3be0-4813-afdb-be2a48120ccf": {"doc_hash": "7444a1d2cfe748f7653b74a28af4aec6940f39b5b014d4cec921595fd8086ff0", "ref_doc_id": "bf26c2cb-b152-4f3c-a15e-c9296bf73bad"}, "6be5b1fa-d6b8-43c3-a30e-6c4a5da1107c": {"doc_hash": "23609c65ed4dfbbbd333f20cad774264603511b624d3454f4aaa9f341d7013e6", "ref_doc_id": "bf26c2cb-b152-4f3c-a15e-c9296bf73bad"}, "97bb9dd3-8eef-4427-827e-9578716c71d7": {"doc_hash": "0955e5724fb3b4b2d2109f42fbc924561dcce13a66b63d997717b568ee71c4e6", "ref_doc_id": "bf26c2cb-b152-4f3c-a15e-c9296bf73bad"}, "296597f7-3cfd-4117-b603-d01e9a923cf2": {"doc_hash": "4882805e9927020c5ccd6744da52896ef6be6363e1a4fd91c0d3f7a454b6dbf7", "ref_doc_id": "bf26c2cb-b152-4f3c-a15e-c9296bf73bad"}, "004c201d-dc1d-4d40-864a-aaccf997730d": {"doc_hash": "7011405b9f6384854c4dbcc4fe028f7061487227d94ec476f084bad25794633b", "ref_doc_id": "bf26c2cb-b152-4f3c-a15e-c9296bf73bad"}, "113cae38-ff65-4ae9-8ba8-d9e77ca6d479": {"doc_hash": "3993b212cf5ef50def17bb06e15302e8be8f0464722bf5d97ddf4c2d1a43f8fd", "ref_doc_id": "bf26c2cb-b152-4f3c-a15e-c9296bf73bad"}, "a13e7c19-e489-4271-9094-d81add8e4530": {"doc_hash": "f06fba10d1758aecf1515630e0e50d4d1a859c6c5ca408f55a12d2ccc8958af7", "ref_doc_id": "bf26c2cb-b152-4f3c-a15e-c9296bf73bad"}, "3f92a8c2-2c8c-4e8c-af98-217a224e5539": {"doc_hash": "804443e9fcf62e85571c80f4eda151e1765a305f0ee6fa80e393ef8e61530e53", "ref_doc_id": "bf26c2cb-b152-4f3c-a15e-c9296bf73bad"}, "6bd4861e-04aa-45f6-8eb1-dbc8edb4b3a2": {"doc_hash": "87b009fdf4dd39e0d7b899f791bfc20da09cf67fb0c4529819a71393729c0a95", "ref_doc_id": "bf26c2cb-b152-4f3c-a15e-c9296bf73bad"}, "a5ece1f9-f967-480a-83a5-fdfc29e204f0": {"doc_hash": "be17861a74f38ccaa43f395f21cf441b4b3f8a68be5e9020071d67a9e7472e66", "ref_doc_id": "bf26c2cb-b152-4f3c-a15e-c9296bf73bad"}, "0579de0b-9138-49e3-ac58-3c28ae3625d5": {"doc_hash": "5294afd1c1a9e4744dbe3ae4a8ba4ee04b22c2422f56e2685ff31642a1da1a4f", "ref_doc_id": "bf26c2cb-b152-4f3c-a15e-c9296bf73bad"}, "181662ac-a270-4592-96d0-848d3bd32013": {"doc_hash": "ea5c9ae0cee5066d53fea58cca6a0dc60ca97c8476709370a9fa8b0aac928d6f", "ref_doc_id": "bf26c2cb-b152-4f3c-a15e-c9296bf73bad"}, "677a0ba6-420e-4573-b34b-7ee01081aae0": {"doc_hash": "dc4355430a415a84aeb552461b88a2619429e974cc010d2f8fb00e7da7d4adc9", "ref_doc_id": "bf26c2cb-b152-4f3c-a15e-c9296bf73bad"}, "16f03256-9f99-4d19-acce-6ecb6ad6298c": {"doc_hash": "91cac2bb79b9ad185a1e0f6731d455040f2b5c005cd7b9c2fd7be64a818184c9", "ref_doc_id": "bf26c2cb-b152-4f3c-a15e-c9296bf73bad"}, "fddc61da-f54a-4317-ab00-bba6c9d5c796": {"doc_hash": "e1f077cfc1354ae56a923f0acb0339941f80612614ecef915675f7ed4fcc7738", "ref_doc_id": "bf26c2cb-b152-4f3c-a15e-c9296bf73bad"}, "87adc9b4-47f6-4962-929f-16a24d882479": {"doc_hash": "8509e51f16b4246c714cd31f35eece6fb64468aaf456d3000a9f20c3f0e05be5", "ref_doc_id": "bf26c2cb-b152-4f3c-a15e-c9296bf73bad"}, "259777eb-a771-4cf7-ab66-2593b6b42af2": {"doc_hash": "37853e5dc438aa97eb2e433a04f58b3d65ac87d70803bca3dc807f22b1cc6e46", "ref_doc_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7"}, "22d75d1a-4af8-4afc-be3a-72dc20cf8abc": {"doc_hash": "d2461c1411aebf34c6d4cfec726fbad7c55d705fa1aea71a1a2ce7b0f70b5c8e", "ref_doc_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7"}, "76b4577a-f25d-4f82-a832-2e0e010f8ec6": {"doc_hash": "bb605b4038081bf9a4cc16ea81d89367ff5b02865257c05962ffdde36d312ad2", "ref_doc_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7"}, "d2e580bf-a1b5-4f44-ac0d-a70ea4782367": {"doc_hash": "d29cbcc29e6cc22459e539383a7a2e067937b12912c24718ffc2372b338a7c27", "ref_doc_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7"}, "30bdea05-494b-475d-adee-1eacfeeb8065": {"doc_hash": "20efa70a9c89daf8273782daad799e0f2f4d3feff25148bf7a7c462cef458a25", "ref_doc_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7"}, "0722405a-aa5e-4bab-bc08-5867bed364de": {"doc_hash": "bd8ae5130a6e99c54cc63f4d567001ade31b72c7df4a68c14b9394c92c6db94f", "ref_doc_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7"}, "04e4b335-ecc3-4441-99ba-47b8d8d44ce5": {"doc_hash": "f878d84d35c4b7d00aa30fb8e8bb125c4590b3fa66e8c0f592cad0a831860f52", "ref_doc_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7"}, "a2fe3836-f5f6-4eff-9320-accf7c5a5efb": {"doc_hash": "8cca7d86f285669672ebd3686eda99d8ea23d428eb431ad1635d114670420085", "ref_doc_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7"}, "40aa2f2a-0191-443f-ad4b-270b723f70bc": {"doc_hash": "0305c78a5ce4c51e8e42d67764bb94d85222a810e748a4c589f4b6d301f4c352", "ref_doc_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7"}, "34a4504d-7b73-42b1-bfb6-7dd6df339ca0": {"doc_hash": "8237d5f254d53e5d273093b030f864e9e2514a67582344c33d96f73e8c2d6326", "ref_doc_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7"}, "926158d7-923c-48d6-88be-bb64a0395b83": {"doc_hash": "4f90c545e307a26e1b920548f38a1d2956882470df82792005eaa7434c698188", "ref_doc_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7"}, "25b050b0-1fad-417c-8809-21d8a4b9f002": {"doc_hash": "3437c7454b9cf56814780f2f0c1b23e2196539289ecc9088eb29961fae224fa7", "ref_doc_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7"}, "c7903286-aa50-466d-95a7-0422353bb9d3": {"doc_hash": "87e52b8e4387361d40443690b69678cfea0f4bf6a7f3ab34461f3ba24b9a9af6", "ref_doc_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7"}, "93b31103-4785-43a8-9e58-7e4f408c77ea": {"doc_hash": "f91f1f8f53f736439291b423c578972e640effc1f1b50fc0f46f94022aa24dec", "ref_doc_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7"}, "bc66c50e-b9f6-43ae-91c1-29fc15343783": {"doc_hash": "d5f910dd1b1e34de21668c2a0d12676a22312cbe9fe2442992bcf07043e34bf4", "ref_doc_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7"}, "93fca1f5-3039-4a9e-bad6-5c2441c1e9f1": {"doc_hash": "d7fc88672dcfada8ff172f63df516cd84dc6a320f34628126299ffa2afc78436", "ref_doc_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7"}, "bb8c1be0-3c54-4171-97de-1a0345ad0335": {"doc_hash": "5a97a15199ba876ed2a956d5235e70a091f1c5a576bff2c1156ede093db266df", "ref_doc_id": "d70d88bd-6a28-49e7-898c-6c8fce2261a7"}, "510241fd-2d89-4fa3-999e-23248c5cb265": {"doc_hash": "4f2342f517e3bb0efe518b365a77146db7d7583d0c34c16aa63d020b56bfa16d", "ref_doc_id": "8350e855-9008-407e-8b5d-0c99fd0658e2"}, "3ed6a480-b637-4fcd-85ac-a1cf1d46100b": {"doc_hash": "78241e9b5eb021b9750e7db78528706c3c6dcf9c08d06e5a062e9922731a29ee", "ref_doc_id": "8350e855-9008-407e-8b5d-0c99fd0658e2"}, "4dbd95dd-2d29-4e15-a7aa-3d449d631da4": {"doc_hash": "02c54430d430639ffc563c0868567ae67397e5207c6f5bc231cb3132c9a4106c", "ref_doc_id": "8350e855-9008-407e-8b5d-0c99fd0658e2"}, "11d433d0-f003-4d4d-80db-1350fbcac224": {"doc_hash": "25550f7a5fb39870b79a5dd54cf76e5917e3eba3edbaa72af9d9948e4d85649a", "ref_doc_id": "8350e855-9008-407e-8b5d-0c99fd0658e2"}, "31943cf9-752d-4977-ab92-d761302a38d8": {"doc_hash": "52cdd4c0dd000384bc831a17388e63f77b824f11478cc57c31c9b73ba040653c", "ref_doc_id": "8350e855-9008-407e-8b5d-0c99fd0658e2"}, "ff1d27c4-e505-42e0-83d7-99c439bc1777": {"doc_hash": "94feb03c45e1deea4dfd7a07c39cc43bbe740ff9dfc9af5dc155bc780189c5d4", "ref_doc_id": "8350e855-9008-407e-8b5d-0c99fd0658e2"}, "5d1c772e-c9b2-4ede-ade2-c6757e890006": {"doc_hash": "40e827036c59b3539be46c559e5fbf08d72ffd6557e8e8c6b00b397a1373e39e", "ref_doc_id": "8350e855-9008-407e-8b5d-0c99fd0658e2"}, "daae7d2d-f18d-430f-9f71-6ec0e4cfc582": {"doc_hash": "2db00c8891e852a5861f00011303b88cff509aa249687fdd5facad5ff9c75dba", "ref_doc_id": "8350e855-9008-407e-8b5d-0c99fd0658e2"}, "0e4c3603-e33c-4034-a9fb-3f7f0213e2a1": {"doc_hash": "5e43037b4ad92f74e787f11664888d8b27e75e91cd4a4449d6f3d138f891f7ef", "ref_doc_id": "8350e855-9008-407e-8b5d-0c99fd0658e2"}, "9c472a46-62d9-409f-88d9-43f0124843c6": {"doc_hash": "3e5f62a4936fd09ed16bd7225cfcb28c645b573c5ae51c1f63dcb6e6c6719ae3", "ref_doc_id": "8350e855-9008-407e-8b5d-0c99fd0658e2"}, "e670dec1-7c6b-4f5c-94d9-1bb85a8765c6": {"doc_hash": "f641d4426397c53d8f84a3aaaef9e57b7e10f6767ebddb4ff6055d84c16fdd83", "ref_doc_id": "8350e855-9008-407e-8b5d-0c99fd0658e2"}, "a299591a-97f5-42b0-b46d-1cae35cdd22a": {"doc_hash": "18336b89ce41c6d4ef418a99f3652dc52a989c350b9bca6b452d05e4d714e08b", "ref_doc_id": "8350e855-9008-407e-8b5d-0c99fd0658e2"}, "88bd6670-7499-4a3c-9fa0-04b9b0ead76e": {"doc_hash": "14209929bb4f8380e05cb40bd2d32040a3bb75732bd71d50c7fb504cc70a98a2", "ref_doc_id": "8350e855-9008-407e-8b5d-0c99fd0658e2"}, "fb96adff-f751-4aa5-9618-74badfc0e6ad": {"doc_hash": "a35428a1a275487c561af747d3efb7be2874d7acce9f06091b904edc3625a8a4", "ref_doc_id": "8350e855-9008-407e-8b5d-0c99fd0658e2"}, "2092668c-882f-4476-a84d-d6fd9f1c4243": {"doc_hash": "d4786f015e8d306106ddb27fe9fca1de7326eb8036a37aae9e9d3f24de8e7fd2", "ref_doc_id": "8350e855-9008-407e-8b5d-0c99fd0658e2"}, "c70c576b-1fb6-401d-83a7-411d8e10f7aa": {"doc_hash": "93d52017800d9021aa63619f73cd9833ce1aa8daac70b1dd2fc4fd1714f9b385", "ref_doc_id": "8350e855-9008-407e-8b5d-0c99fd0658e2"}, "127918cc-009f-4ebe-bd57-f685ed4a6380": {"doc_hash": "9c28cb2433ec35b69f2097079e9855ea3e1c7fe024615bfb7a6a0a20deac9dab", "ref_doc_id": "8350e855-9008-407e-8b5d-0c99fd0658e2"}, "2908dbc6-d79f-4cb0-8b30-82d8edce6893": {"doc_hash": "635b9484e7b6b42a0b37791535825300e054ad1840ca474fc81244b8e2cbe969", "ref_doc_id": "8350e855-9008-407e-8b5d-0c99fd0658e2"}, "a4aaa0b4-c079-4977-9d27-5cd7d6a76a1e": {"doc_hash": "becc05662ff4c8eedcd7249b333327201c52da01c98bb7fd63459cb89c9a7188", "ref_doc_id": "1d5ca99a-62c2-481c-bc71-e592b11cf6c6"}, "ea92ec35-be24-4d74-ba05-b68598d718e5": {"doc_hash": "256f5466fd88cbb850b5b6d718e9a4e751e43f5270cdcdedbad97a5336888ea6", "ref_doc_id": "1d5ca99a-62c2-481c-bc71-e592b11cf6c6"}, "bcf0b12c-e095-445c-8316-cff7f1be32c3": {"doc_hash": "847ce47b3913271430f523634f3e8da8be65ccc0955601fb22e49a901fd0461d", "ref_doc_id": "1d5ca99a-62c2-481c-bc71-e592b11cf6c6"}, "e37e9811-3e7e-4e1d-abd6-3e947a429e0a": {"doc_hash": "74711ca769b909009597207ab6508967a88011aa2f6cd642377e8c48758bf3d5", "ref_doc_id": "1d5ca99a-62c2-481c-bc71-e592b11cf6c6"}, "df3d167a-ae8c-4048-bd41-1e2dcebc16e6": {"doc_hash": "64be2d9b7f23947c72981027fb929fea86f3495135a09bda8de829cc708d3a40", "ref_doc_id": "1d5ca99a-62c2-481c-bc71-e592b11cf6c6"}, "891d70ff-e497-4562-9f56-cc85cfa81270": {"doc_hash": "6993c19774be87377411a7f37a35d91d38c24eabf078df721bf4365a501d47ea", "ref_doc_id": "1d5ca99a-62c2-481c-bc71-e592b11cf6c6"}, "9e8a1de4-0a2b-4ef2-b80d-e1c2e07f504d": {"doc_hash": "14d84d6f2c0c2e2a54b59a8eb3a77e92545cf2600abd92d70a2ae790b500112b", "ref_doc_id": "1d5ca99a-62c2-481c-bc71-e592b11cf6c6"}, "18638624-ec2b-4b2c-b012-72ec8bcb097c": {"doc_hash": "ca6eaa315d0c29b2708e662cc17b179baf6842f985db7d92bd89d11f9f5d865b", "ref_doc_id": "1d5ca99a-62c2-481c-bc71-e592b11cf6c6"}, "19293be8-a574-47ba-b277-16ca4eaedbf4": {"doc_hash": "802e38bcd52cb86989718c893ca1fd0fdcf2314bd9f3cff48e12ccbef4e3af05", "ref_doc_id": "1d5ca99a-62c2-481c-bc71-e592b11cf6c6"}, "d9cb2bc8-8132-4c8b-9b7c-8f4d114d2f00": {"doc_hash": "74fd18558af631d777b3a094ebbaf7f102c0bf97e52fff256e12f10eff94512c", "ref_doc_id": "1d5ca99a-62c2-481c-bc71-e592b11cf6c6"}, "90a09c99-07a2-4301-a464-453cdeefedbd": {"doc_hash": "ef311214cc743822721b85fc6b8fe86f9e3d3c34dcdf291ed4e0f187b6ccbc61", "ref_doc_id": "1d5ca99a-62c2-481c-bc71-e592b11cf6c6"}, "5950fa1f-feba-4980-98fa-d0a4caac1c03": {"doc_hash": "5050bf300cf021cd1a056d29e3dc09b022e8593c99c63919b376795880d5da66", "ref_doc_id": "1d5ca99a-62c2-481c-bc71-e592b11cf6c6"}, "09372fc5-0656-4432-8eb2-30b4a24b2f49": {"doc_hash": "ee7c9a07c0e1aa5903ac7d0b3d73c445a26442bbbd7a7a86d03e08b6b5e7e5aa", "ref_doc_id": "1d5ca99a-62c2-481c-bc71-e592b11cf6c6"}, "c4e3a009-f1c2-4b88-b940-a379006cf300": {"doc_hash": "1682402a25f8ca7248683f715e8b9407dad7c4cec38e5f5acf469a0e21c380c9", "ref_doc_id": "1d5ca99a-62c2-481c-bc71-e592b11cf6c6"}, "e8a66a33-be7b-4846-b8f5-68e52505864f": {"doc_hash": "a8d8c0f26f9c9b8cf313d5ba107010965ce73e7e82c6c56ebfec5420371ef355", "ref_doc_id": "1d5ca99a-62c2-481c-bc71-e592b11cf6c6"}, "3bc5bd06-0eb7-476b-9a85-c97049671882": {"doc_hash": "4e9bf8b5a1baa97bdfc42a0e548c139a4f872f05b400d1aa222b31a1164e5e91", "ref_doc_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb"}, "a99c3054-fd26-4a00-bde6-dff7d72b8340": {"doc_hash": "9ae02f1ddad00ad23bb35f7e1ef177a83b814d3059945657e05d230395690d27", "ref_doc_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb"}, "c175e8b0-4170-4672-b564-a037f131f198": {"doc_hash": "fd2b3098e9eb41470750992aed8eb66b7340e16a5850af0618b1655c410b02b0", "ref_doc_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb"}, "ee0d6bf3-5a41-45b9-b9ed-d6c9e5f39c6e": {"doc_hash": "594e6c2c546c02682d722fba5f7602afe2e46ba1f86d76893db5c1c4deab0c81", "ref_doc_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb"}, "50048eff-c9d9-4a3e-85b0-07e4f9073315": {"doc_hash": "6a26396015240da5dae4580289cc9c3dbba63d5573857bf5c2d8535306cbef44", "ref_doc_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb"}, "b96c112f-5b4a-42e4-aacb-23279e00cdc1": {"doc_hash": "fb4761c32ad66f7d698b57311362dd919e8e5807c3b7d84fa86679c1884a606d", "ref_doc_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb"}, "9ae2d983-1e6a-448a-b7ec-530088519d8f": {"doc_hash": "2bd6f9b315acf56946ae74d14f274278b1f193acb9b15a72c4f1d6ad957ea3f2", "ref_doc_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb"}, "2ec2a23c-6e82-49c5-b246-e982b8b9643e": {"doc_hash": "29ba67e2efd1c3713a980bebf69d763cb8d86a08f482e12f59a6f67411ae948d", "ref_doc_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb"}, "23f5bddd-7269-4180-bea3-1832b38ea3af": {"doc_hash": "e2570019637cd7d297c0f1e8e39a3adb4c84481fb09541bea2fcd7b865cf201a", "ref_doc_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb"}, "afe537ad-3d14-43d1-9336-792023d809b4": {"doc_hash": "b0e2d7b006c1fe9fcaae2f280f5b58b859c275141844a5577a64dd2958b82dd3", "ref_doc_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb"}, "87a0dc2f-4b14-40c2-8606-afe2bde6d6e4": {"doc_hash": "2da908e30c73a47f4daf821e235f2358de4c1d1721529e2b68ed93870158dcac", "ref_doc_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb"}, "3cfdd5f5-516b-474c-90ac-97cf3c392ce1": {"doc_hash": "bdf0501ef3a33238c5ff4ad9e00272f661db9f19aa8441da6eb6abe89a5b2a33", "ref_doc_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb"}, "405d8c48-9242-481b-a352-69f635b0177d": {"doc_hash": "6ba55f2236f8c5e306bd6bea55e5de9d61f35c34f5f515ffc689e54e8cd61846", "ref_doc_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb"}, "fe31cd10-ed02-497a-b25d-e8c17ab05a6f": {"doc_hash": "702de5731a509d1b8eb74a4d46027b9f701ffdacc3a0ef7c7fa222845aa73e66", "ref_doc_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb"}, "0ce2b79a-6584-4960-b0a1-82eb9d8d67e7": {"doc_hash": "79e5b45d7bfc0da96cc56a80d413462534f85d63b0bb4f169668e2507b3c59b0", "ref_doc_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb"}, "8fa59a78-ee3b-47d0-8ac0-5123b34a4798": {"doc_hash": "38a776f98997367859788a3d8b8f003db96875c74fc20922f2b8c7ace2103152", "ref_doc_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb"}, "d288e05b-31df-414c-9464-938eaca7096f": {"doc_hash": "5d3ac42950a25d90a14ef9ebc330f89c178defe7da98bbd72049758e2cbc620e", "ref_doc_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb"}, "96bcc8d1-f48a-4fdb-9d5c-3043b694d671": {"doc_hash": "17ee85da2dbbb9e623b9946d32497c6443934a81fec7c00bd5b19e8bd70cd936", "ref_doc_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb"}, "b8605552-cf4d-4038-bd62-dedb13114691": {"doc_hash": "6b5d77b3e1542576a4d28bd0899799986440f25644da21d0cd462c68f875292b", "ref_doc_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb"}, "a88fccaa-697c-45ff-beeb-2b408068b3fb": {"doc_hash": "03a8f8faeffaafbd1e521735f12556b6c592a657e67f7ad41affe89b3d64ed74", "ref_doc_id": "2964d91f-fe41-4867-9e55-6dab334ecbfb"}, "a894a97b-1c05-4e6d-af5f-4c3f6964bf78": {"doc_hash": "4ea6b3f6e3e553345ea9f468a0cefcad12a5984d606467c47281cb5b792aab4f", "ref_doc_id": "8902963b-6af6-4797-9436-bd1772a8635d"}, "5e0b8ffd-6d0d-497e-9991-e3bda1742094": {"doc_hash": "bfa44579b3c07d2b4fceddf0a937f81c28bfcf7710d5146ef391ab844c5a4008", "ref_doc_id": "8902963b-6af6-4797-9436-bd1772a8635d"}, "371fc9e2-b852-4118-916d-ae2183b77f61": {"doc_hash": "e91fc6a9beec81b0bb16f82e5512261a99b974a95c671a76caa5f52747ed367a", "ref_doc_id": "8902963b-6af6-4797-9436-bd1772a8635d"}, "b4251048-745d-48fb-9cdc-5d0ee7c18edf": {"doc_hash": "2ddb32adc4fab874fedaaf0091748769e1c5ae0550f32a5359126ef17517af2d", "ref_doc_id": "8902963b-6af6-4797-9436-bd1772a8635d"}, "0d159b10-dfd0-4263-9eaf-a9d388c48d73": {"doc_hash": "3d98a01aa7b9b97eecc025911f4cee7b4f3197653460cc32b16319ab872278d2", "ref_doc_id": "8902963b-6af6-4797-9436-bd1772a8635d"}, "504671ac-4822-4cd1-a074-e97084c039b1": {"doc_hash": "7fba935dfdd785b0feeab9e55c61d8267e8416a843df7b773ebe2f43936dcfd2", "ref_doc_id": "8902963b-6af6-4797-9436-bd1772a8635d"}, "d15db728-d44b-4eb2-8ec1-1dfc30ab24ac": {"doc_hash": "79a58e0cb7f1b89ea5d30db7d1b0d6701dda96e15764e7bc446316382681ca25", "ref_doc_id": "8902963b-6af6-4797-9436-bd1772a8635d"}, "44b10553-b90a-4519-885e-ebb443337528": {"doc_hash": "6390363addc4619a1bd499ad7d9d84deb6f4647b51cd9b1a8dbfcca08f3be011", "ref_doc_id": "8902963b-6af6-4797-9436-bd1772a8635d"}, "17cfba9d-a0fc-4bbe-ac9d-5de48173ab5a": {"doc_hash": "c9ab6bfe9611fd1ffef931f8a10c22a94d5aea7311c9d27d8bd43d899d5ec318", "ref_doc_id": "8902963b-6af6-4797-9436-bd1772a8635d"}, "e34e4692-5d33-4577-9392-e80cc2e71c70": {"doc_hash": "8eddc9904cfee40ad9f04ca86f6ff298ce13b8ac4d3a5542298c8fbf037d0af8", "ref_doc_id": "8902963b-6af6-4797-9436-bd1772a8635d"}, "3c5f00a4-521b-48cd-b828-38e81f5ef2cc": {"doc_hash": "b3edc8ba8cf2474e76909dc1d8d5a644397359d16e0b02cb8dd366ea81b23972", "ref_doc_id": "8902963b-6af6-4797-9436-bd1772a8635d"}, "b91842ca-f695-45f1-81b8-bc145814af2c": {"doc_hash": "b96cd150ca17f7c1f2f3ff4b9d40d32aac974e01abe3a000c3c8142b3c49238e", "ref_doc_id": "8902963b-6af6-4797-9436-bd1772a8635d"}, "7ae30aaf-3fba-4426-aac9-795b900643cb": {"doc_hash": "6e86595921cc313dd30fdc1cc0492e41f9b2c907085003b6e5d1600dc90a93b7", "ref_doc_id": "8902963b-6af6-4797-9436-bd1772a8635d"}, "c476f603-0426-4280-86c1-2085ce8f8d76": {"doc_hash": "00899ba3f1423bdc32de58fec2f501e70ae32b21a5c1c391fecdbd4d4d453b49", "ref_doc_id": "8902963b-6af6-4797-9436-bd1772a8635d"}, "0be8ef39-4145-43c3-a490-6fc14f0bb1c4": {"doc_hash": "54beb2ca827fe1f1657e3ccf16f9391f3ca5c1d42f0bdf8da26e059bcc90464d", "ref_doc_id": "8902963b-6af6-4797-9436-bd1772a8635d"}, "a4afddbb-67ce-434c-a7a2-a5722be5a457": {"doc_hash": "8903aaf0bf53012cd9c86f595baf902d97bde15ecea8c3492552990dc6e55151", "ref_doc_id": "8902963b-6af6-4797-9436-bd1772a8635d"}, "4524ee8a-2f40-4996-8692-8453e7a2c0bb": {"doc_hash": "735678a0a8df2abb3c9ea6e647fbaf04b9a82dc7ef1257ebc3ff023b3f52eb89", "ref_doc_id": "8902963b-6af6-4797-9436-bd1772a8635d"}, "5141a33b-12b5-4388-8df6-288c1d4f62be": {"doc_hash": "047949b2b2089ee9b1ae5ba6e84592579437cb2e1c89c152fecb747a823e5141", "ref_doc_id": "8902963b-6af6-4797-9436-bd1772a8635d"}, "8caf2268-5302-41ee-9838-9081c77a168b": {"doc_hash": "28392575b744f99e0928be730e5bd12676976d2d96ea5765d99f2baed5dcd1af", "ref_doc_id": "8902963b-6af6-4797-9436-bd1772a8635d"}, "e300c023-f6cf-4f4e-8158-47ec8033e82a": {"doc_hash": "c516ebfbeb20e774bd3ad903536721d4c7c946a0fc616af0ddb7d12a3640b8ef", "ref_doc_id": "8902963b-6af6-4797-9436-bd1772a8635d"}, "9d492b02-bafb-4e69-8f64-6c1bcb2a2ffa": {"doc_hash": "0cbe2138cf046f86d46baddcb474db945c5f533bb5a073fea66adf1bafe7c880", "ref_doc_id": "8902963b-6af6-4797-9436-bd1772a8635d"}, "6f91eab8-21bc-4738-a648-ae357804a8be": {"doc_hash": "7fee30ed2aba351f6dd8eb2a7388e3ede422ffac21ed8c0bf27b5acf1face73a", "ref_doc_id": "8902963b-6af6-4797-9436-bd1772a8635d"}, "9230ce05-6d99-402b-b9b0-d77413b575b3": {"doc_hash": "5c32b21f33d830607350df79c93f33414371172aa0ea3ca3d6f8c3808a354626", "ref_doc_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5"}, "2318968a-340a-4646-8a4a-7667dc30f096": {"doc_hash": "f999a46f37a6e5c4cc391012e617ca5cc65f245d08d6e0df29400612e3c5266f", "ref_doc_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5"}, "be652523-47ff-4eaa-978b-bcc6ced42850": {"doc_hash": "fb5e89a1e4c74c9caaf2a9e66325f9956f226065b616768a439b86dbdd4b9a4d", "ref_doc_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5"}, "ac8d3b08-a322-489c-82fe-5ca58e4fb7f1": {"doc_hash": "6f01676299f5a9b7313e3e499d888e04acdf267b7baf371bc182df16512138d0", "ref_doc_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5"}, "d72dd814-c3a8-4d29-9998-b2d8836f10d2": {"doc_hash": "cf7f6ffb56cbea0b3fc195984943d75d86c23cb98da1a048d678a9f77272f623", "ref_doc_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5"}, "182344c3-c7c3-4265-907f-b27bcbe65c19": {"doc_hash": "5d4c6799374c3befad5b501871b2b762cac54f756104db9ccc28b2370c7f7df7", "ref_doc_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5"}, "2a7cb92d-0884-4881-8518-e7ae8c9e02cb": {"doc_hash": "e1fcea3b37bd7a5f7ab7b96e8418940958a08d54ed7b7530aa490bbd632a8c83", "ref_doc_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5"}, "3bedbe59-fe79-4bab-9162-b0a539bc95a4": {"doc_hash": "cd7497a893b6c8cef83c2ee49fcac2e10a1bda032f81d470171bd3f32d00a037", "ref_doc_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5"}, "a791aea3-448f-48aa-8b47-e27d69e463f8": {"doc_hash": "14a6ac7f5f811523bd2867424a99a9e75c2bb00c6d70a47acb75d456173eed98", "ref_doc_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5"}, "7323e892-f853-41db-afec-692ccdd6198c": {"doc_hash": "c0ccc9fa734e32b13d95e6dfb441f8079adb03d54554e92bff7010ab7dec9ada", "ref_doc_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5"}, "b50d2550-a23c-4e3b-8dfd-51ae42dcaeb5": {"doc_hash": "1f7be061ffc956c83a38ea57348de1f2cfccf43ad4ae22b3e69837aad9d8d37a", "ref_doc_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5"}, "8cc57c54-fc60-4ce6-8094-b2dc01ca9ab9": {"doc_hash": "fa53e52431650d8ba3307dd66a1be88a70462dd874d1ff1c61493959993cfaf6", "ref_doc_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5"}, "1c80e944-94b4-468c-a14e-285c823c5fb5": {"doc_hash": "7768564ef5b0aa0753833fb148d79b3c7162d6ae933951a83ca03876322f87b9", "ref_doc_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5"}, "aca17415-74c0-4e3a-bed8-567c3263bfed": {"doc_hash": "eed87aa19e079657119579329b5012c54a1984dc747bf1b2663ed704d3ebd529", "ref_doc_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5"}, "cfa299f9-f3f4-45af-9714-1a60558fb22e": {"doc_hash": "fb2b502b5b9654d6d8f7594045aa2f7a149ed98868f46bea16e32f5ddd117388", "ref_doc_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5"}, "9ec7ad64-0fea-41c0-8ae2-ae0abb66f56a": {"doc_hash": "12fd486709bb6aeec733bf98fbec775b7612cecfa2049f993fe4cf9bb2cc48d2", "ref_doc_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5"}, "c6f88bf7-fa77-4d42-9cfd-90d3fbf571bb": {"doc_hash": "5c2fc0a754904ca4788153068767252cfdefc812b80b409c1f031418863df18e", "ref_doc_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5"}, "304942b4-08ea-4f8a-9fda-9bbdfb23c3cb": {"doc_hash": "4c15bb65c9974eb94cad96c252c0a4821cdace69e78c39f4a2cdf78cb62feb9f", "ref_doc_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5"}, "f7f4f668-ca9e-4634-a258-2c71ab7c5731": {"doc_hash": "39262e4e3dc6d7c1cfe90726afc386ee511255608e3cc23b5deb1e8f772237ab", "ref_doc_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5"}, "2f1b0e14-8256-40bd-8346-292d601c5078": {"doc_hash": "3154907955610bcf824dddd8f485c1061b7a6e27d92d2e5f0de4366dd05d2896", "ref_doc_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5"}, "de520e6a-8576-47e6-95f4-4088f07ee95d": {"doc_hash": "cd87eb0c523849eb237014d331b617d76ddf40ad38049cc5a82a425ee286bcb7", "ref_doc_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5"}, "928163d1-cac6-48ad-af3c-1304d88f1d67": {"doc_hash": "7f5792e7f7ee85ffc7d0dce0fdbca29ac2cc8be98684a880b1d76b137bff4973", "ref_doc_id": "ba87a0de-7599-4670-901a-ba9ec3a247c5"}, "1c601b03-6d50-454f-870f-efe0294517b5": {"doc_hash": "17c0b12aee57163b321b2b457e9ba510e9058b30c27792ccab00ea93c73d142e", "ref_doc_id": "8a27c321-3a7b-402a-abb8-9964cef9499a"}, "e9a42ba7-192c-463a-abfe-017ba5d1c31e": {"doc_hash": "b7ef0c7cebe40d6e1f5d2af354ce667623dedc91f1e636f7fbc96a6602e1cdfb", "ref_doc_id": "8a27c321-3a7b-402a-abb8-9964cef9499a"}, "5e2c7187-2320-4503-ad73-4c9753bd069b": {"doc_hash": "49dfe7bdae979dbbacd1ae9f0ca9db1c3fd2bb1d27c4338fc2a74e3421767056", "ref_doc_id": "8a27c321-3a7b-402a-abb8-9964cef9499a"}, "5c7177ec-7337-4bf1-be51-7e92c559a262": {"doc_hash": "29f299e4f409ddd32607e8e459fd3387d3364dc9aa15d1b104ecd70751ff5899", "ref_doc_id": "8a27c321-3a7b-402a-abb8-9964cef9499a"}, "a4013577-1761-4bee-88e2-0b07638f972f": {"doc_hash": "67f50aee3efd24b6b344b714c0dc07b19de9bbde9dd72796802e9f750d4892dc", "ref_doc_id": "8a27c321-3a7b-402a-abb8-9964cef9499a"}, "1f1bfafa-1d49-4e14-b34f-975a29e17647": {"doc_hash": "7a58dfca0953198c059060a14947eae32e31bf97b5c0a69303537330d702d1d8", "ref_doc_id": "8a27c321-3a7b-402a-abb8-9964cef9499a"}, "9faa7a44-ff93-4d5a-b61d-e650087c6a39": {"doc_hash": "322752abd7a5c8ce9a44e959351d98106735c09ae634c8ceb9293fa9bf316807", "ref_doc_id": "8a27c321-3a7b-402a-abb8-9964cef9499a"}, "4c5dc2f7-2af7-4942-80b8-d9a4863458df": {"doc_hash": "7f055020cad23000d4a598b44f4e2f1f16b43be19e11bf91f1789186bdcf991f", "ref_doc_id": "8a27c321-3a7b-402a-abb8-9964cef9499a"}, "399ec58d-443b-4ff8-b4e9-424c0a2f0ade": {"doc_hash": "9fafae06d83eb416828bda5d142e77d319c6bf4dfd8a2e652ae6724c96dca347", "ref_doc_id": "8a27c321-3a7b-402a-abb8-9964cef9499a"}, "9a2493cf-3f25-4d5f-84c9-d8b89ab53572": {"doc_hash": "003c6eedbdce256fe27180a534b8ec51be6b38d88c0748345685fdb7f0d0b9d8", "ref_doc_id": "8a27c321-3a7b-402a-abb8-9964cef9499a"}, "8766cfde-ec8d-4a6d-86d1-8fc768b8dda0": {"doc_hash": "dbdbfbbd323ee95c982675618a66e33db63f67beb12069e09ddc198725dbbd8c", "ref_doc_id": "8a27c321-3a7b-402a-abb8-9964cef9499a"}, "8c38b631-743e-4e65-bed3-ed09cd34544d": {"doc_hash": "2e86857251256df091b399b8f429290f218c0475b22d2d40b354024e55f818b6", "ref_doc_id": "8a27c321-3a7b-402a-abb8-9964cef9499a"}}, "docstore/ref_doc_info": {"189eda67-ddcf-494c-bfdd-8e912ff3f49d": {"node_ids": ["19f55e17-8d97-4090-a7f3-6fb80fd650e5", "73c38dfc-475e-4b3a-97f5-631e8dc13d6d", "0e559be4-935b-41e6-bf07-032759fef578", "ca094ce4-bddf-423d-91dc-62af0696fe5a", "9f4af5d4-3890-4c10-bbac-73ee8b8c291a", "8a728ce5-9960-47ec-b0f0-d0e48f440e79", "3d1c53c7-aa34-4ebf-b6d0-1928c8ad41b4", "2d561b67-c87f-4314-b6c7-b3d4ca36b6c7", "50ba95e0-b4a4-4494-b3c6-cfcb819a160b", "11a3dc75-2147-4e3e-ad03-4ae36ef0ee26", "40019dd5-4273-4402-9edb-7c00e88eaad6", "518bc030-5f87-409e-9290-8fdb3b4b49c0", "ca646f7c-fb85-4e14-b9f1-a63f7bbdde5a", "666e084e-6941-4f68-8e39-96545a6f2236", "52a575a2-d405-4736-9876-286be08f836a", "6d680f8b-bfc2-464d-b5b6-aa1d9b8120a1", "5238ae64-9827-4595-bbf4-4f136bdbe20a", "dd3b245e-c22b-4fd8-a291-da486e07fceb", "8b62bede-39f9-4e4e-acd7-73a13a2199cc", "1b86d48e-d582-4fc3-82f1-6d2931eb22bf"], "metadata": {"window": " \nPage 1 of 31 \n \nQ4 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust  6th, 2020 8:30AM Eastern  \n \nOperator:  Good day and welcome to the Cardinal Health Incorporated Fourth Quarter Fiscal Year \n2020 Earnings Conference Call.  Today's conference is being recorded.  And at this time I'd like to turn \nthe conference over to Mr. ", "original_text": " \nPage 1 of 31 \n \nQ4 FY20 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c8a6b818-b294-4b3d-ae18-fbb665a79bdd": {"node_ids": ["24e03b24-6abd-4f09-afc5-1896a54cff29", "11bdb025-1ff1-48c1-af94-e3991b3969d8", "22ac2b64-e4a1-411c-a4d4-03fdb32f4219", "f103894b-944d-4785-981d-b69b247ff497", "dcb11cb0-f96c-44cb-b951-c59ba1eacbb3", "973cb6dd-ab58-45d6-b9e0-c2f135151533", "da4b35a0-4b3d-4f71-94b5-c3bbdbc72f03", "376921ea-0913-4cc4-9b00-eb72ae78246c", "010ec09f-6a66-431e-b60c-2144632c56ec", "fcbc7966-1b00-4883-b3c3-0b439af1cf4a", "c7e75312-9637-48e4-8690-1a13dca3e149"], "metadata": {"window": " \nPage 2 of 31 \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion, so that we can try and give everyone an opportunity.  With that, I will now turn the call over \nto Mike.  \n \n Mike Kauffman:  Thanks, Kevin.  And good morning to everyone joining us.  \n \n ", "original_text": " \nPage 2 of 31 \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one \nquestion, so that we can try and give everyone an opportunity. ", "page_label": "2", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c7e7a17a-8d74-4fa1-8a13-fb462afeb8b4": {"node_ids": ["903607c5-7e2c-497f-a1f5-55848f59e898", "6d4e84ad-5901-4d9e-a39b-37849537a7ce", "1e675ee0-8f3c-4ede-8fb7-07b89a76730a", "790a4a87-6d47-4b66-a6a1-762e84c73d48", "a48bd4a6-93d9-4b21-aa72-927cf414607f", "b6a4423f-a20d-48a9-87a2-78f0cab7f743", "29423008-e546-423b-ab49-b37d78004ebe", "b69e81f1-7fb4-48ea-bef5-5fc4a8792aba", "97031aea-85e3-4c3d-aa67-b8f32103148e"], "metadata": {"window": " \nPage 3 of 31 \n \n We achieved these results as we adapted our operations to address the unique challenges \npresented by COVID -19.  We successfully transitioned our office employees to a remote work model, \nand we continuously maintained operations in all of our distribution facilities, nuclear pharmacies, and \nglobal manufacturing plants.  \n \n  Through all of this, we kept our primary focus:  delivering critical products and services to our \ncustomers , and at the same time prioritizing the safety of our employees.  \n \n  As I look toward the coming year, I recognize that the global and industry dynamics, resulting \nfrom the pandemic will continue to challenge areas of our business. ", "original_text": " \nPage 3 of 31 \n \n We achieved these results as we adapted our operations to address the unique challenges \npresented by COVID -19. ", "page_label": "3", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "3fe6ce10-fe5e-4d94-b32d-9477a82f8e03": {"node_ids": ["5f516ff6-f510-417f-ad2c-b932ec840fc1", "ad581678-9160-419d-8f23-1f035ff78104", "4bfe0848-d577-4158-9c5b-c59058f75165", "df84a6d8-e359-4e82-8784-5b863ac6691d", "a3938704-1db9-4495-9aec-0102dc1ee48c", "c4f308ff-4b77-47a0-b1b0-496510ff6554", "465ff21e-edb4-4dae-ac42-7d00c646c2a2", "239aac79-9dae-49ab-9c7b-1d530cc3076f", "098d02ee-7b4f-40ae-8653-445a4730fc14", "3437bc37-3389-463e-8e3d-eb6c0a1a5958", "e44d6bb0-370e-4e7f-8c62-20f794ad80ad", "6ab2020d-e408-4ea9-8591-5e577a60dd31"], "metadata": {"window": " \nPage 4 of 31 \n \n Starting with the quarter, we delivered better than expected EPS of $1.04, driven by improved \noperating performance , as well as lower interest and other expense.  \n \n  Turning to the segments.  Beginning with pharma on slide six , revenue was flat for the quarter. \n As expected, in Q4 we saw reduced pharmaceutical demand as a result of the accelerated Q3 sales \nrelated to COVID -19. ", "original_text": " \nPage 4 of 31 \n \n Starting with the quarter, we delivered better than expected EPS of $1.04, driven by improved \noperating performance , as well as lower interest and other expense.  \n \n ", "page_label": "4", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "776af277-817b-4ec3-bb54-b0c50d9f341b": {"node_ids": ["7b2d9524-2acb-4242-9aac-9b00d4a2d0dc", "b2e02f5f-3c27-4622-9557-da7fce123ba3", "ee3eee87-e200-4f9f-acef-dabd0f46f229", "c690610c-1ee5-4698-b33b-9c4350ca8fea", "6b27d47a-f281-473e-aa0d-985399cea5a4", "3860c263-0a3c-40ec-b3ac-b729b9ff225d", "8f8c379f-ce6f-4ca3-b573-53ec91a81e7c", "eb48c738-22d3-4f73-bff9-fce3276da250", "988003d2-f3c5-4460-ad37-be1a4e671626", "92932204-b327-4b44-bbc5-036aa0941f42", "89ae58e9-125e-45f2-bc4d-6e7f317cac5a"], "metadata": {"window": " \nPage 5 of 31 \n \n \n Across both segments, COVID -19 was a significant headwind to our business in the fourth \nquarter.  \n \n  Although it's always difficult to approximate the impact of lost sales, we estimate COVID -19 \nnegatively affected operating earnings by approximately $130 million despite some improvement in \nelective procedures and physician office visits over the course of the quarter.  \n \n  In Q4 we generated $240 million of operating cash flow.  Reflecting our continued  commitment \nto maintaining a strong balance sheet, in June we redeemed $500 million of notes with December \n2020 maturities. ", "original_text": " \nPage 5 of 31 \n \n \n Across both segments, COVID -19 was a significant headwind to our business in the fourth \nquarter.  \n \n ", "page_label": "5", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "91d90699-bd7b-4281-a21c-c28f6658f0be": {"node_ids": ["61098b3f-06ed-400e-8ffd-44b0c7c4fb38", "71a956af-3359-4bf2-b858-f45b2cb40d99", "8a0bfb30-2cab-4586-b944-0c2bcba769d0", "fb55a3f6-523b-4acb-9a1f-77c83685f062", "f99d7e92-9a38-40a4-b071-9ae8c81277b2", "77c5c322-efc7-44d9-a687-f457ab4149d3", "25e88350-3498-47a5-acf0-6ca59964a255", "44f815de-eb18-443c-99ee-a6718d1c7135", "ed9831fe-8ef3-4b56-a238-6e59a8e8270f", "29bd0de8-a244-44b3-8dcf-eb82f425f522", "c733ec25-46d9-4bd9-9e3a-eae5e86205e0", "c979cb4d-50a7-4a61-a741-5057e7ec2ff1"], "metadata": {"window": " \nPage 6 of 31 \n \n \n We finished the year with $2 billion of operating cash flow.  As a reminder , the day of the week \nin which the quarter ends affects point -in-time of cash flows.  \n \n  We ended the year with a $2.8 billion cash balance, with roughly half a billion dollars held \noutside the US and nothing outstanding under our $3 billion credit facilities.  \n \n  From a capital allocation perspective, we took additional actions in fiscal 20 to strengthen our \nposition for long -term growt h. We invested $37 5 million of capex  back into the business, focusing on \nenhancing our IT infrastructure and fueling strategic growth opportunities. ", "original_text": " \nPage 6 of 31 \n \n \n We finished the year with $2 billion of operating cash flow. ", "page_label": "6", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "3cb67424-de13-43db-b082-558d37f75ec2": {"node_ids": ["3f58158c-b83e-4781-98e4-9306d205f347", "24134567-87a3-4524-95e3-eefdb4c51361", "6639e552-b50e-4c85-a10d-bc71ee227887", "b4368969-aa9c-4567-bee5-51b78b66ade4", "93e55058-6cbb-48a0-bc95-3ae8d6411b67", "f1cbd26c-add5-4709-93c4-a5f1167202de", "56a56827-ded7-445a-ad49-0ede13e4209e", "a49809cc-0f98-4b68-95f7-2d7c2886a8a4", "871ac8d4-d387-4e60-9bb8-fc11f683bac8"], "metadata": {"window": " \nPage 7 of 31 \n \n \n In Medical, performance was strong.  Although revenue decreased 1% to $15.4 billion due to \nthe adverse impact from COVID -19, segment profit increased 15% to $663 million.  T his was driven by \ncost savings initiatives, particularly within our global manufacturing and supply chain , and the \nbeneficial comparison to a supplier -related charge in the prior year, partially offset by the impact of \nCOVID -19. \n \n  Across the company in fis cal 20 we demonstrated positive performance despite significant \nglobal challenges. ", "original_text": " \nPage 7 of 31 \n \n \n In Medical, performance was strong. ", "page_label": "7", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "b55f1c03-037f-4ed6-b32c-0f51cdce7cf3": {"node_ids": ["cbd7a769-5861-4493-9822-32d73cad7800", "6bb30662-ef72-4c81-b429-799a163664a7", "e84e8799-b0d1-4cc5-a861-8a6b20ab8740", "3dde167d-9554-4b30-8b54-058aa0d9027d", "42814d00-34b6-4e4e-bd11-63125562b94b", "88da3a2e-7618-48ad-aab8-91d4cc40a479", "6cb7ff4d-bab8-40a9-9572-7e642c0ef388", "cc326d9d-2b3b-4a73-a271-d0ee1dfaad24", "c2e34d1c-1fd5-4f8c-97de-41a8b5bf194f", "aad782db-0ade-4ede-a289-5bfc6b0f1934"], "metadata": {"window": " \nPage 8 of 31 \n \n On average, we believe elective procedures will be down relative to pre -pandemic levels in the \nhigh-single digit range, and physician office visits will be down in the mid -single digit range for the full \nyear.  \n \n  Additionally, while we are working diligently to address global PPE supply challenges, we are \nassuming demand will continue to outpace available sup ply for the balance of fiscal 21.   We are \nincurring higher cost procuring certain PPE products for our customers during the pandemic , and this \nwill be a headwind for us in fiscal 21, especially in the first half of the year.  Keep in mind, our outlook \nis sub ject to considerable uncertainty and at this time does not assume additional widespread \nshutdowns like we saw in the spring.  \n \n ", "original_text": " \nPage 8 of 31 \n \n On average, we believe elective procedures will be down relative to pre -pandemic levels in the \nhigh-single digit range, and physician office visits will be down in the mid -single digit range for the full \nyear.  \n \n ", "page_label": "8", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "43360e11-0ef7-4bb3-9af2-c2b08bba0418": {"node_ids": ["913b95ef-6264-4484-9c7a-6694d1b28d64", "9014ceb6-b9c1-43cd-baa1-a3c1f1efac57", "f92afadd-0c9d-4c73-adf7-772a5509765a", "c4fab729-fcf4-4396-aec2-6d6b160b9f98", "8c2952e7-4338-4482-848b-34a7447ae710", "a1992716-3dd4-4e33-a914-63226daba0cf", "57c4a5ba-6292-4b07-b53e-6b96514d6c8c", "36b72c4d-ba05-4809-9e39-2094da70e421", "9e1f4c5f-5310-46ee-9b14-8bf762677c07"], "metadata": {"window": " \nPage 9 of 31 \n \n Given we have multiple years of US tax audits open, we could expect greater than usual \nvariability in our effective tax rate in the near to medium term.  \n \n  We anticipate dilut ive shares in the range of 292 to 296 million , and finally , we expect capital \nexpenditures of 400 to $450 million.  \n \n  For the segments, beginning with Pharma on slide 15, we expect mid -single digits segment \nrevenue growth, and segment profit  growth in the low single digits.  We are anticipating consistent \nmarket dynamics within our generics program and a similar contingent brand inflation rate in fiscal 21 \nas in fiscal 20.  \n \n ", "original_text": " \nPage 9 of 31 \n \n Given we have multiple years of US tax audits open, we could expect greater than usual \nvariability in our effective tax rate in the near to medium term.  \n \n ", "page_label": "9", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "f206d3e4-a985-4e1c-9a04-4bbaf8aaebb1": {"node_ids": ["c788baed-0daa-40ab-ae74-05e24461a9ed", "0a14d0ee-c0c0-4852-9334-8dba8e682646", "922d9bcb-193f-421e-b7de-efc61a836cac", "316f9175-08d1-4ea2-b4ce-6cf248416e66", "0bad7abd-a093-4392-b598-233440078953", "d7a752f3-33ad-4608-8d18-7ed803874077", "a9d5ffa4-6af6-47c4-a647-aa044d79366d", "473821da-71e0-4e9f-9eee-c4837d779214", "3eab3dcb-5b2f-496b-a4ff-9d555144bbc7", "b892c5c1-2378-4d71-a656-527e241159a2"], "metadata": {"window": " \nPage 10 of 31 \n \n Those initial impressions have be en further confirmed in my first few months.  I am confident \nwe can collectively navigate current and future complexities to perform our essential role in \nhealthcare and realize our future opportunities.  \n \n  With that, let me turn it back over to Mike.  \n \n Mike Kaufmann:  Jason has quickly learned our business, our strategy, and our ongoing \ntransformations across the enterprise and on behalf of our full leadership team, we are grateful for his \nearly contributions and partnership.  \n \n ", "original_text": " \nPage 10 of 31 \n \n Those initial impressions have be en further confirmed in my first few months. ", "page_label": "10", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "0f6fea48-a7c1-4810-bfee-5e9fbc802a26": {"node_ids": ["e872649b-5634-476c-b818-ca6605cd04e2", "25713efc-5b14-42a7-8fe6-3d601d8c846e", "82c99bf1-5d29-4938-9296-e0e878bbba5b", "2897a40d-2757-466c-8f68-5a8d642603ed", "90ee906f-3628-4f75-9c42-05eb784da364", "2475a12d-06b7-4150-bdeb-810ca20ec9ee", "e09e745f-8297-43d0-9d76-ba995c39f1e9", "2789efde-d324-4660-8758-4615a35dd864", "e48181b5-2b1a-41e4-a612-78d1ccccc38e", "da92bdab-2f8c-4e85-ab11-29988a60d370"], "metadata": {"window": " \nPage 11 of 31 \n \n In Specialty, we are beginning to operationalize the investment we mentioned in Q1 to \nestablish a new distribution center outside of Nashville, Tennessee.  \n \n  This facility includes a state -of-the-art cold chain complex with deep -frozen technology, and it \nenables us to drive operational efficiencies , as well as support further growth in this area of the \nindustry.  \n \n  In Connected Care, we're identifying and investing in innovative digital capabilities that will \nimprove interactions with patients, payers, p harmacies, and providers.  \n \n  We are also investing in an expanded innovations center for theranostics opportunities in our \nNuclear business, which will drive longer -term profitable growth.  \n \n ", "original_text": " \nPage 11 of 31 \n \n In Specialty, we are beginning to operationalize the investment we mentioned in Q1 to \nestablish a new distribution center outside of Nashville, Tennessee.  \n \n ", "page_label": "11", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "b803411d-7757-4a56-8ae1-333719409f76": {"node_ids": ["65bebd47-205f-467e-9609-83982046f48b", "b9526225-f598-4ae9-8d09-aedf27fc8bab", "75679fe9-0c65-4075-87cf-aa27715f428b", "5b140aca-ed69-4412-9c38-73972ce1cac1", "eaa128fb-ce58-4457-bc51-e08ad83b3a2e", "a826c9d3-e2d3-4999-97e4-bcf7d917f83e", "f35a1739-ea3c-41a2-a6b3-5ca2e83b75da", "c946f4c1-c54e-44f5-8ed0-2126adea8b8f", "db57f8ba-7fcf-494a-a91e-249e711f3bb4", "af5b9ed0-fcc2-4eb8-868b-4d5c0c46ccd5"], "metadata": {"window": " \nPage 12 of 31 \n \n \n In addition to short -term pricing actions to mitigate increasing costs, our teams are also \nbuilding a longer -term strategy for supply assurance.  \n \n  Regarding our commercial strategy, although our pace has been and will continue to be \naffected by COVID -19, we are confident in our talent and ability to execute this important workstream.  \n We are moving forward with an enhanced focus on supporting the needs of our diverse customer \nbase.   We believe this workstream will ramp up with the gradual increase in elective p rocedures , as its \nprogress is dependent upon our customers \u2019 readiness to engage in incremental product and services \ndiscussions.  \n \n ", "original_text": " \nPage 12 of 31 \n \n \n In addition to short -term pricing actions to mitigate increasing costs, our teams are also \nbuilding a longer -term strategy for supply assurance.  \n \n ", "page_label": "12", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "86caa692-41f3-414c-9fbc-154c8c6d5001": {"node_ids": ["839e2d38-bded-4834-8d4a-fb14672698b8", "1ab00943-3cc9-4e74-8e64-6a9935c1fcf4", "bc4db64f-9476-4318-9ef3-8fc70164b3a6", "8f68b0e7-876d-43b1-ac19-0ce8b550111e", "0abc12cc-d8ce-4e7c-9909-62d77afb41bc", "fb264bb1-c94e-45dc-9934-17d46f0d0c46", "2334ca60-2c04-4be1-a1fb-7fa7b414b2db", "997e480c-27da-4c4f-bab5-2ea0b973f755", "8d8c6e06-5c13-4f38-880f-83322485fdfb"], "metadata": {"window": " \nPage 13 of 31 \n \n Our commitment to efficient operations will enable us to optimize and invest.  To that end, we \nhave multiple initiatives in flight that will deliver savings in excess of our multi -year, $500 million target \nas well as technology and process improvements that drive future growth.  \n \n  Turning briefly to capital allocation , our priorities of investing in the business, strengthening our \nbalance s heet through debt pay down, and returning cash to shareholders through our differentiated \ndividend remain unchanged.  \n \n  To close, al though  fiscal 20 presented significant global and industry challenges, we delivered \non our commitments, and our team responde d with the grit that I've seen time and time again at \nCardinal Health.  \n \n ", "original_text": " \nPage 13 of 31 \n \n Our commitment to efficient operations will enable us to optimize and invest. ", "page_label": "13", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "bda01840-44a8-4a6f-9d92-3b10e2b59e06": {"node_ids": ["46268da2-1da7-41d9-83ee-1692439ea447", "fca19427-fae5-46de-8fe8-2f0e64ed383d", "be9feac5-b2b3-4c98-b034-92309d23b1ce", "a6dd2b8f-e169-4a5f-829a-355ffcaaee94", "4a8fb50e-7b86-42db-b813-190b599fa853", "16bb59f2-fa6d-4444-9803-60907e0a798d", "a51de891-dd53-45b9-8151-52a4beb4b7ba", "8bf371a7-a762-48d8-a7a2-93bc7e8998e4", "d0eefee8-7c90-4bd0-ba4f-91a588d1a4e1", "f83eb034-6e57-42cf-b25b-0d6ebfa5d161", "17fb75e0-2dee-4de1-994b-eb9bf36af7a0", "8133afb5-82b2-4e3c-b6c8-19846d06ff42"], "metadata": {"window": " \nPage 14 of 31 \n \n \n How do you think about the swing factors that would lead to upside or downside in terms of \nyour current outlook and how this could factor through  into the potential for upside downsides to the \nprofit growth outlook that you have?  \n \n Mike Kaufmann:  Yes, thanks for the question Michael.  First of all we're really excited that we were \nable to see Med grow this year and if you, you know, you adjust for C OVID next year we're excited \nthat we have Med growing in the mid -single digits next year, too.  So we feel really good about the \ntrajectory.  \n \n ", "original_text": " \nPage 14 of 31 \n \n \n How do you think about the swing factors that would lead to upside or downside in terms of \nyour current outlook and how this could factor through  into the potential for upside downsides to the \nprofit growth outlook that you have?  \n \n", "page_label": "14", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "8d48d411-660e-4844-a192-428ac1781c55": {"node_ids": ["7293f0f6-006f-456f-a2fe-13bbaf27c2c6", "e635cb31-d972-4124-8895-eef0a38f1a01", "cc2b2b37-c369-4f91-a4b3-082f3b435d25", "62ae12e5-b03e-4ac2-8a6f-9ab16d4c3fba", "0d2f3e57-844b-4219-a1d0-ace80908d2b2", "61c31698-c2ff-41fa-a007-a94466bbd5bb", "07260682-3a82-4e2c-b8a5-44d3abf6b89b", "675ef5c2-b707-4828-9c71-d5fc0e5eaac9", "5231930f-c1bf-4238-80bc-e918e52ffb7b", "e4b022a5-fa77-42c3-a35b-74630777daea", "24e149cf-2cb5-49c5-9032-8a64b287efdd", "2e92ccb7-3c96-4930-98d8-7b3ec07308d7", "907b1ef8-2ee4-4e6c-899b-158f63a19e2e", "e03567a3-26ba-4130-bf32-01f16c46528f", "bdfa4baa-65ea-4e8f-bc84-7e4faac40cf5", "006ba99f-645b-44be-8fd1-db2e4117b617", "63135c5b-aece-4b14-b625-49f80fedd5e2"], "metadata": {"window": " \nPage 15 of 31 \n \nbeing down and so we would expect to enter this year that way  and then exit FY21 at close to pre -\nCOVID levels.  \n \n  So that's kind of the trajectory that we see.  But again, different than that.  That would be the \nbiggest potential driver.  \n \n ", "original_text": " \nPage 15 of 31 \n \nbeing down and so we would expect to enter this year that way  and then exit FY21 at close to pre -\nCOVID levels.  \n \n ", "page_label": "15", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "177848d0-8d8a-4b5b-8f24-ab1dff41d233": {"node_ids": ["961ff273-9706-4913-af13-309cfacedb2d", "810ec6fb-4482-443c-875e-7e0158325da9", "b79b9ef2-d8b4-4891-b6c5-60c22598f751", "f2ab5e62-852c-4f83-94f0-29661f6c1e7c", "fdf7b348-96e9-4915-8fea-4e9db5febf8a", "8a62aa45-38b3-4ae1-b681-23006967f893", "57b93a0b-bf70-42d9-998d-1a5c2e3ee73b", "1c7ad0f7-33e0-4da6-be43-87d32cd4276e", "9e4f140f-d5f9-45a3-960b-f04569cda6f5", "8a13ed5c-7224-43ed-a7cb-d467fde8cc02", "4bc29345-26de-4925-a3c0-6cc56ed81b94", "081b2a83-b4a9-4037-b579-e7ea6e25c542", "dd6e5011-44bf-49b0-90f4-ec43c4346d4d", "5a1f8b23-176a-476b-ae8a-35aa4e226ffa", "26a8b431-d646-4478-b0cd-2d70eec3dbd6", "5795ee25-5eed-4e9b-8cec-0d751be37457", "b9e92c66-2cc3-43dc-917c-5d3653ce395b", "132b0ee1-e439-4344-b578-3edbf27605d5"], "metadata": {"window": " \nPage 16 of 31 \n \nJason Hollar:  Yes, it's an - yes, thank you for the question.  It is an additional incremental headwind of \na similar magnitude of what we saw in 20.  \n \n  And just to give you a little bit more perspective, in 20 we saw that fairly well -balanced \nbetween the two different segments, between Med and Pharma, in 21, because of some of the \nreasons Mike just talked about that were a little bit more impactful for Medical.  We would expect there \nto be a bit of an overweighting of the impact on Medical vs. ", "original_text": " \nPage 16 of 31 \n \nJason Hollar:  Yes, it's an - yes, thank you for the question. ", "page_label": "16", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "1203bfd5-ad97-415c-8620-a142c7e42944": {"node_ids": ["38f202d9-ad37-40fe-80c8-d775c10fee49", "e003587a-9f6e-4752-991d-2bb0b84f6705", "391edb10-ea92-4d7d-8f53-d38100392265", "fc3f9e25-66fa-4cdc-93be-c1fcf34f6450", "524d566d-d76c-485b-a6a6-782c2a5311a2", "5c8deb33-82e5-4117-98fb-b59c3f8aeccf", "69ba23d2-0dc2-4836-a49c-76d1dd4e4cc7", "d88e425a-eedf-448e-a34d-fcc663cab646", "5e106f78-491c-4f18-8e0a-b143d6d2ca5c", "71c950e8-6cff-445b-89dc-a309b7a69cbd", "eb194900-2bc0-48b0-b875-640ffaab0ee5"], "metadata": {"window": " \nPage 17 of 31 \n \nexpect to enter somewhere in that mid to high teens, negative v s. prior year, but exit the year at pre -\nCOVID levels with it obviously then improving during the year.  \n \n Kevin Moran:  Next question, please?  \n \n Operator:  Thank you, we'll next go to Charles R hyee with Cowen.  Please go ahead.  \n \n", "original_text": " \nPage 17 of 31 \n \nexpect to enter somewhere in that mid to high teens, negative v s. prior year, but exit the year at pre -\nCOVID levels with it obviously then improving during the year.  \n \n", "page_label": "17", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "5c854892-2d3f-4fb8-9537-8c1dc858f5cf": {"node_ids": ["c2bb43c3-06c3-44e7-b105-b1035c9c15f4", "dbcb9245-c4a4-4d2c-852f-89e6d9903875", "a58f672b-65de-4694-8619-18fbfda68c0c", "73a15440-c6b6-4d63-a9c7-ab6a08483d7c", "80af2dc2-32d1-44e8-8f77-d2474808c035", "4e7f6b3b-015d-4e7e-b0a5-8d076e2b55ee", "853c1a37-60a4-497e-95af-069473f24ec3", "8b52ca8b-f39a-464a-a428-ae8e1ddcb941", "fbf4d4c0-cf07-4d21-8cbe-4694658971ea", "d6d90fc0-ba96-4822-b279-0eddc51e45a2", "687fc24a-7e68-46a4-8213-ff41a9684267", "10e586bd-10c2-4b5e-b7f8-abc07dbba3dd", "ff3a7f64-af73-4b34-86e4-a356dab49917", "9649b482-475b-42d8-886f-7d85e663108e", "8ac25cc4-5f11-4965-aa21-8e0d8bd0051c"], "metadata": {"window": " \nPage 18 of 31 \n \n You know, it's interesting.  We did take a look at that business.  We really haven't seen much \nimpact on that business from the pandemic.  Because if you think about it it's people that are at home.  \n \n ", "original_text": " \nPage 18 of 31 \n \n You know, it's interesting. ", "page_label": "18", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "338c4ec9-a1cf-40ca-a930-96ab8b67eb44": {"node_ids": ["dd922fc6-f078-414a-a3cf-4600ae9d3a03", "aee34d0e-165e-4947-8be1-1ac884430560", "f700e947-0fb3-46be-92df-ed7b9bae9666", "4add8834-82a8-4a4a-8128-ab29dff7c8a6", "8890c6d2-58f0-4016-bac9-d7baf0148963", "8c716b3c-8b13-4905-825c-e1d0b817c7e2", "4fc98ee4-baf9-4208-9de8-7011f2c8e375", "d6a9e078-48d4-47a8-8d36-499224853e17", "9b4f728d-0881-4d9d-9028-bafa921ba161", "8712c1b9-6317-497b-8cd9-6772a29c3c02", "e06c071b-aa27-4cf8-89d2-a9636a170145", "0d4fe1df-5e59-4310-9fa7-add3ca1bf32e", "13b7bdaa-6e08-4b14-b3ad-391dd3948f8d", "77c6135b-2441-4074-b94d-2ce4561fa250"], "metadata": {"window": " \nPage 19 of 31 \n \n \nOperator:  Thank you, and we'll next go to Lisa Gill with JP Morgan.  Please go ahead.  \n \n Lisa Gill:  Thanks very much.  Good morning.  \n \n ", "original_text": " \nPage 19 of 31 \n \n \nOperator:  Thank you, and we'll next go to Lisa Gill with JP Morgan. ", "page_label": "19", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "9ec915a5-ab70-4b60-87e0-4fa2d4e356ab": {"node_ids": ["edc49521-ab8a-483a-b8eb-bab245be0f72", "39e265d6-6aee-4142-b7a4-653fe8b30b2e", "fe2563c3-67e0-4e9d-aa14-210e68a5f958", "d8fada0e-6df6-4489-a744-f02769fe79ef", "61d80c5f-5f1e-4389-961e-fe53d22f98a7", "2d457991-93e9-458c-840f-d343381cf1e0", "384ac847-5d4b-42c9-be89-6085ce5271fd", "a15c7f31-adf2-4197-b949-02f48c6e5b93", "823b3a00-03fd-4312-b648-dc99143ef1fe", "5ba21d56-67b8-48a9-93be-4cabc945c660", "6e8d98a7-c730-4fe1-9c70-0706267eacb7", "c524bc8f-c6ab-46e8-bd70-78647ab39e13", "23d26b13-ace6-46cd-a74c-54a129bbc687", "58608f97-6a32-4d68-8af9-dd4b2469066b", "8a2c6d55-36cd-4fed-8efa-752a01a607c7", "a925d074-75f5-4e2a-b172-b3adb2dbcaec", "e9575c02-153b-45b4-9737-bc7b72370f36"], "metadata": {"window": " \nPage 20 of 31 \n \nRicky Goldwasser:  Ah, yes.  Hi, good morning.  A couple of questions here on the Pharma segment \noutlook.  \n \n  So when you think about the variables of the impact coming in - last quarter you talked a lot \nabout nuclear - how is nuclear progressed in the quarter and importantly how do you think about the \nprogression in the - bits and better than your guidance? ", "original_text": " \nPage 20 of 31 \n \nRicky Goldwasser:  Ah, yes. ", "page_label": "20", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "44979e2c-e074-4f22-a939-50ea3bd188dd": {"node_ids": ["e71652ab-6337-416c-b9c9-64235b85c145", "60160942-3fb9-4ca5-9630-5ecb80bf59fb", "2f1a4a76-f275-470e-be10-9dadb5608bc0", "29b018f3-7f81-4b84-994a-e9e557158649", "c24a432e-33fb-44ef-88ba-0d4653268fd5", "4cf2eff0-468f-4ed1-aca6-155c844c4241", "70516d1f-0fa6-4d3f-8090-2dcaed2c8378", "103fac21-6791-424c-b681-fa7717557bec", "71700b78-f7c9-41ab-a3d5-1f08c96b64d5", "bb1bc6fb-2b94-4e4f-9707-86adcb8c3b6a", "a40a6b08-e640-4683-9649-2e60308a6a2d", "823b47cb-c3a1-4fe6-8fcc-a98c53e5652f", "8d31d1af-9119-4c1d-ab65-b8f76a30c7c8"], "metadata": {"window": " \nPage 21 of 31 \n \nAs far as the brand component goes really what we\u2019re saying there is we expect inflation to be \nthe same as it was this year roughly.  But because some of the fee for service arrangements and mix \nhas changed a little bit there'll be less of the brand margin that is contingent to inflation this year than \nwe\u2019ve - in FY21 than in FY20 which it\u2019s already at 95% or so is at already non -contingent.  So we see \nthat gett ing even a little bit higher in next year.  The \u2013 so I\u2019ll end it there.  \n \n", "original_text": " \nPage 21 of 31 \n \nAs far as the brand component goes really what we\u2019re saying there is we expect inflation to be \nthe same as it was this year roughly. ", "page_label": "21", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "8291a5de-e14a-4b76-a285-09a126f85d3f": {"node_ids": ["4d9431f7-6601-4bdd-9073-4a1c48f864b2", "3bff864b-8300-41f4-a756-b38a88bb3c8d", "0e085180-a8f1-4823-aa6f-f9f468ba48e9", "32dea304-bf5d-47ea-ba70-82a2d04d53a2", "bcaa7e55-c7b7-4481-907d-dd7f77f70ef7", "3cd633bc-cf92-4f6b-bd82-294e04921c05", "68510a7b-9816-451e-bfb2-b10bc6b22dc5", "455244ab-548b-4ddd-ae87-103bd4b7de2d", "841dc174-3876-465c-9c5f-dc17ca7ad0a0", "601ffe31-18de-42f2-b0d9-cc1bda8128f5", "04d34d83-93e5-4fec-a6b5-57fe504821f6", "c0ae42bd-612d-475a-8847-8c4b24e1666e", "95b698c0-f15e-4226-a1c8-b3ca805f41d9", "4b61404a-bbcb-40c3-a5a8-5483fcdac7f9", "0f47e7b3-6f25-40dc-8e34-534e632586f7", "341707fb-0c18-4a2a-9026-9777d22f5dcd", "c142b3e8-cffa-445d-ad34-eee6ae233e8f", "0280c184-bc0c-4fbb-a4d3-20dea8e44be5"], "metadata": {"window": " \nPage 22 of 31 \n \n \nMike Kaufmann:  Yes.  \n \n Ricky Goldwasser:  ...what type of - of course just because I'm trying to quantify it and adjust for it?  \n \n Mike Kaufmann:  Yes the - we would see the Pharma  segment more tightly aligned to physician office \nvisits are probably going to be the biggest driver.  I would say that what we\u2019ve been seeing in some of \nthe IQVIA data and various sources like that we feel like that that\u2019s a business that we expect to be \naveraging down in the mid -single digits for the year. ", "original_text": " \nPage 22 of 31 \n \n \nMike Kaufmann:  Yes.  \n \n", "page_label": "22", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "42b13386-98f0-436c-8bb1-96cdcbedf48b": {"node_ids": ["cb3e29e3-0fdb-49fb-9fbe-e4aaad1ce60a", "6da41465-5555-4295-9f1d-4fdeb06c66f5", "a98888b8-d7aa-4ecb-967e-a6c3c5de7bf9", "e90515a0-b9ea-4271-8a86-73a85e0559d5", "18b74887-07dd-4af0-9a46-2b5a7aab2d05", "06d11cd1-da0d-46f7-a2b0-ecd9829d5e37", "67977b1d-b92b-4600-9a8d-c44e71b600fe", "95edb33f-85c7-4d2b-8a65-165163080947", "d1abb3c0-9980-4451-a15d-dd9f997f5843", "dbb9c025-1bf6-4323-aade-905b2533c43e", "cc8478fd-705f-4e7b-855e-62d2fd7d8de3", "14e3f531-5ac1-4619-b67e-fdb531dc9b35", "25d3c256-7f64-4c6b-b506-6431c459c111", "36aeb147-8704-4f75-96e7-c1a0d00020cd", "d2c9724a-78ef-4c6b-9f01-8ac4f64e481d", "f728fa75-c160-46c2-a84b-98f0ee696546", "bf24ed21-9a1b-4095-b8e6-3cfb494f6863", "28b68abc-0012-48ca-a567-13c38848ac1c", "5d24d938-caaf-4b22-a40f-2608b5e4be55"], "metadata": {"window": " \nPage 23 of 31 \n \nbeen kind of hard to figure out.  But overall our - the generics piece being down a little bit more in Q4 \nis really just related to COVID volumes.  \n \n Eric Coldwell:  And Mike can you give us a sense about what you\u2019re se eing about deflation dynamics \nin that market buy side, sell side pricing, et cetera?  \n \n Mike Kaufmann:  Yes, what we saw, you know, was really pretty consistent dynamics throughout the \nwhole year. ", "original_text": " \nPage 23 of 31 \n \nbeen kind of hard to figure out. ", "page_label": "23", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "bf26c2cb-b152-4f3c-a15e-c9296bf73bad": {"node_ids": ["4b517694-3be0-4813-afdb-be2a48120ccf", "6be5b1fa-d6b8-43c3-a30e-6c4a5da1107c", "97bb9dd3-8eef-4427-827e-9578716c71d7", "296597f7-3cfd-4117-b603-d01e9a923cf2", "004c201d-dc1d-4d40-864a-aaccf997730d", "113cae38-ff65-4ae9-8ba8-d9e77ca6d479", "a13e7c19-e489-4271-9094-d81add8e4530", "3f92a8c2-2c8c-4e8c-af98-217a224e5539", "6bd4861e-04aa-45f6-8eb1-dbc8edb4b3a2", "a5ece1f9-f967-480a-83a5-fdfc29e204f0", "0579de0b-9138-49e3-ac58-3c28ae3625d5", "181662ac-a270-4592-96d0-848d3bd32013", "677a0ba6-420e-4573-b34b-7ee01081aae0", "16f03256-9f99-4d19-acce-6ecb6ad6298c", "fddc61da-f54a-4317-ab00-bba6c9d5c796", "87adc9b4-47f6-4962-929f-16a24d882479"], "metadata": {"window": " \nPage 24 of 31 \n \nyear\u2019s numbers versus this year\u2019s as we think about nuclear, you know, lower utilization, the PPE \nprocurement.   Just anything around the buckets would be helpful.  \n \n Jason Hollar:  Yes this is Jason.  Let me start here. ", "original_text": " \nPage 24 of 31 \n \nyear\u2019s numbers versus this year\u2019s as we think about nuclear, you know, lower utilization, the PPE \nprocurement.  ", "page_label": "24", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "d70d88bd-6a28-49e7-898c-6c8fce2261a7": {"node_ids": ["259777eb-a771-4cf7-ab66-2593b6b42af2", "22d75d1a-4af8-4afc-be3a-72dc20cf8abc", "76b4577a-f25d-4f82-a832-2e0e010f8ec6", "d2e580bf-a1b5-4f44-ac0d-a70ea4782367", "30bdea05-494b-475d-adee-1eacfeeb8065", "0722405a-aa5e-4bab-bc08-5867bed364de", "04e4b335-ecc3-4441-99ba-47b8d8d44ce5", "a2fe3836-f5f6-4eff-9320-accf7c5a5efb", "40aa2f2a-0191-443f-ad4b-270b723f70bc", "34a4504d-7b73-42b1-bfb6-7dd6df339ca0", "926158d7-923c-48d6-88be-bb64a0395b83", "25b050b0-1fad-417c-8809-21d8a4b9f002", "c7903286-aa50-466d-95a7-0422353bb9d3", "93b31103-4785-43a8-9e58-7e4f408c77ea", "bc66c50e-b9f6-43ae-91c1-29fc15343783", "93fca1f5-3039-4a9e-bad6-5c2441c1e9f1", "bb8c1be0-3c54-4171-97de-1a0345ad0335"], "metadata": {"window": " \nPage 25 of 31 \n \nOperator:  Thank you.  And we'll next go to George Hill with Deutsche Bank.  Please g o ahead.  \n \n George Hill:  Hey good morning guys and thanks for taking the question. ", "original_text": " \nPage 25 of 31 \n \nOperator:  Thank you. ", "page_label": "25", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "8350e855-9008-407e-8b5d-0c99fd0658e2": {"node_ids": ["510241fd-2d89-4fa3-999e-23248c5cb265", "3ed6a480-b637-4fcd-85ac-a1cf1d46100b", "4dbd95dd-2d29-4e15-a7aa-3d449d631da4", "11d433d0-f003-4d4d-80db-1350fbcac224", "31943cf9-752d-4977-ab92-d761302a38d8", "ff1d27c4-e505-42e0-83d7-99c439bc1777", "5d1c772e-c9b2-4ede-ade2-c6757e890006", "daae7d2d-f18d-430f-9f71-6ec0e4cfc582", "0e4c3603-e33c-4034-a9fb-3f7f0213e2a1", "9c472a46-62d9-409f-88d9-43f0124843c6", "e670dec1-7c6b-4f5c-94d9-1bb85a8765c6", "a299591a-97f5-42b0-b46d-1cae35cdd22a", "88bd6670-7499-4a3c-9fa0-04b9b0ead76e", "fb96adff-f751-4aa5-9618-74badfc0e6ad", "2092668c-882f-4476-a84d-d6fd9f1c4243", "c70c576b-1fb6-401d-83a7-411d8e10f7aa", "127918cc-009f-4ebe-bd57-f685ed4a6380", "2908dbc6-d79f-4cb0-8b30-82d8edce6893"], "metadata": {"window": " \nPage 26 of 31 \n \nOperator:  Thank you.  We'll next go to Eric Percher with Nephron Research.  Please go ahead.  \n \n Eric Percher:  Thank you. ", "original_text": " \nPage 26 of 31 \n \nOperator:  Thank you. ", "page_label": "26", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "1d5ca99a-62c2-481c-bc71-e592b11cf6c6": {"node_ids": ["a4aaa0b4-c079-4977-9d27-5cd7d6a76a1e", "ea92ec35-be24-4d74-ba05-b68598d718e5", "bcf0b12c-e095-445c-8316-cff7f1be32c3", "e37e9811-3e7e-4e1d-abd6-3e947a429e0a", "df3d167a-ae8c-4048-bd41-1e2dcebc16e6", "891d70ff-e497-4562-9f56-cc85cfa81270", "9e8a1de4-0a2b-4ef2-b80d-e1c2e07f504d", "18638624-ec2b-4b2c-b012-72ec8bcb097c", "19293be8-a574-47ba-b277-16ca4eaedbf4", "d9cb2bc8-8132-4c8b-9b7c-8f4d114d2f00", "90a09c99-07a2-4301-a464-453cdeefedbd", "5950fa1f-feba-4980-98fa-d0a4caac1c03", "09372fc5-0656-4432-8eb2-30b4a24b2f49", "c4e3a009-f1c2-4b88-b940-a379006cf300", "e8a66a33-be7b-4846-b8f5-68e52505864f"], "metadata": {"window": " \nPage 27 of 31 \n \n \nOperator:  Thank you.  We'll next go to Stephen Baxter with Wolfe Research.  Please go ahead.  \n \n Stephen Baxter:  Hey thanks for the question. ", "original_text": " \nPage 27 of 31 \n \n \nOperator:  Thank you. ", "page_label": "27", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "2964d91f-fe41-4867-9e55-6dab334ecbfb": {"node_ids": ["3bc5bd06-0eb7-476b-9a85-c97049671882", "a99c3054-fd26-4a00-bde6-dff7d72b8340", "c175e8b0-4170-4672-b564-a037f131f198", "ee0d6bf3-5a41-45b9-b9ed-d6c9e5f39c6e", "50048eff-c9d9-4a3e-85b0-07e4f9073315", "b96c112f-5b4a-42e4-aacb-23279e00cdc1", "9ae2d983-1e6a-448a-b7ec-530088519d8f", "2ec2a23c-6e82-49c5-b246-e982b8b9643e", "23f5bddd-7269-4180-bea3-1832b38ea3af", "afe537ad-3d14-43d1-9336-792023d809b4", "87a0dc2f-4b14-40c2-8606-afe2bde6d6e4", "3cfdd5f5-516b-474c-90ac-97cf3c392ce1", "405d8c48-9242-481b-a352-69f635b0177d", "fe31cd10-ed02-497a-b25d-e8c17ab05a6f", "0ce2b79a-6584-4960-b0a1-82eb9d8d67e7", "8fa59a78-ee3b-47d0-8ac0-5123b34a4798", "d288e05b-31df-414c-9464-938eaca7096f", "96bcc8d1-f48a-4fdb-9d5c-3043b694d671", "b8605552-cf4d-4038-bd62-dedb13114691", "a88fccaa-697c-45ff-beeb-2b408068b3fb"], "metadata": {"window": " \nPage 28 of 31 \n \nKevin Moran:  Next question please.  \n \n Operator:  Thank you.  We'll next go to Steve Valliquette with Barclays.  Please go ahead.  \n \n", "original_text": " \nPage 28 of 31 \n \nKevin Moran:  Next question please.  \n \n", "page_label": "28", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "8902963b-6af6-4797-9436-bd1772a8635d": {"node_ids": ["a894a97b-1c05-4e6d-af5f-4c3f6964bf78", "5e0b8ffd-6d0d-497e-9991-e3bda1742094", "371fc9e2-b852-4118-916d-ae2183b77f61", "b4251048-745d-48fb-9cdc-5d0ee7c18edf", "0d159b10-dfd0-4263-9eaf-a9d388c48d73", "504671ac-4822-4cd1-a074-e97084c039b1", "d15db728-d44b-4eb2-8ec1-1dfc30ab24ac", "44b10553-b90a-4519-885e-ebb443337528", "17cfba9d-a0fc-4bbe-ac9d-5de48173ab5a", "e34e4692-5d33-4577-9392-e80cc2e71c70", "3c5f00a4-521b-48cd-b828-38e81f5ef2cc", "b91842ca-f695-45f1-81b8-bc145814af2c", "7ae30aaf-3fba-4426-aac9-795b900643cb", "c476f603-0426-4280-86c1-2085ce8f8d76", "0be8ef39-4145-43c3-a490-6fc14f0bb1c4", "a4afddbb-67ce-434c-a7a2-a5722be5a457", "4524ee8a-2f40-4996-8692-8453e7a2c0bb", "5141a33b-12b5-4388-8df6-288c1d4f62be", "8caf2268-5302-41ee-9838-9081c77a168b", "e300c023-f6cf-4f4e-8158-47ec8033e82a", "9d492b02-bafb-4e69-8f64-6c1bcb2a2ffa", "6f91eab8-21bc-4738-a648-ae357804a8be"], "metadata": {"window": " \nPage 29 of 31 \n \n \nOperator:  Thank you.  We'll next go to Kevin Caliendo with UBS.  \n \n Kevin Caliendo:  Hi.  Thanks for taking my call. ", "original_text": " \nPage 29 of 31 \n \n \nOperator:  Thank you. ", "page_label": "29", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ba87a0de-7599-4670-901a-ba9ec3a247c5": {"node_ids": ["9230ce05-6d99-402b-b9b0-d77413b575b3", "2318968a-340a-4646-8a4a-7667dc30f096", "be652523-47ff-4eaa-978b-bcc6ced42850", "ac8d3b08-a322-489c-82fe-5ca58e4fb7f1", "d72dd814-c3a8-4d29-9998-b2d8836f10d2", "182344c3-c7c3-4265-907f-b27bcbe65c19", "2a7cb92d-0884-4881-8518-e7ae8c9e02cb", "3bedbe59-fe79-4bab-9162-b0a539bc95a4", "a791aea3-448f-48aa-8b47-e27d69e463f8", "7323e892-f853-41db-afec-692ccdd6198c", "b50d2550-a23c-4e3b-8dfd-51ae42dcaeb5", "8cc57c54-fc60-4ce6-8094-b2dc01ca9ab9", "1c80e944-94b4-468c-a14e-285c823c5fb5", "aca17415-74c0-4e3a-bed8-567c3263bfed", "cfa299f9-f3f4-45af-9714-1a60558fb22e", "9ec7ad64-0fea-41c0-8ae2-ae0abb66f56a", "c6f88bf7-fa77-4d42-9cfd-90d3fbf571bb", "304942b4-08ea-4f8a-9fda-9bbdfb23c3cb", "f7f4f668-ca9e-4634-a258-2c71ab7c5731", "2f1b0e14-8256-40bd-8346-292d601c5078", "de520e6a-8576-47e6-95f4-4088f07ee95d", "928163d1-cac6-48ad-af3c-1304d88f1d67"], "metadata": {"window": " \nPage 30 of 31 \n \ninto our share guidance.  And the exact timing and amount of that is something that we will continue to \nevaluate  based upon all the other factors.  So and yes so next question?  \n \n Operator:  Thank you. ", "original_text": " \nPage 30 of 31 \n \ninto our share guidance. ", "page_label": "30", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "8a27c321-3a7b-402a-abb8-9964cef9499a": {"node_ids": ["1c601b03-6d50-454f-870f-efe0294517b5", "e9a42ba7-192c-463a-abfe-017ba5d1c31e", "5e2c7187-2320-4503-ad73-4c9753bd069b", "5c7177ec-7337-4bf1-be51-7e92c559a262", "a4013577-1761-4bee-88e2-0b07638f972f", "1f1bfafa-1d49-4e14-b34f-975a29e17647", "9faa7a44-ff93-4d5a-b61d-e650087c6a39", "4c5dc2f7-2af7-4942-80b8-d9a4863458df", "399ec58d-443b-4ff8-b4e9-424c0a2f0ade", "9a2493cf-3f25-4d5f-84c9-d8b89ab53572", "8766cfde-ec8d-4a6d-86d1-8fc768b8dda0", "8c38b631-743e-4e65-bed3-ed09cd34544d"], "metadata": {"window": " \nPage 31 of 31 \n \nand balancing, you know, their need to have lower cost with where we're manufacturing product and \nwhat\u2019s going on there.  So we're going to continue to evaluate that but continue to ramp up.  \n \n  And then also we're going to evaluate the inventory levels that we carry so that we can work \nwith customers going forward around levels of safety stoc k. So those are some of the different things \nthat we're looking at in our supply chain and we'll continue to make some tweaks as we move along.  \n \n Jailendra Singh:  Great.  \n \n", "original_text": " \nPage 31 of 31 \n \nand balancing, you know, their need to have lower cost with where we're manufacturing product and \nwhat\u2019s going on there. ", "page_label": "31", "file_name": "CAH-Q4-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 220849, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}